PROTEIN DATA BANK LIST OF IDCODE, RESOLUTION, AND COMPOUND NAMES Fri May 24 13:28:48 EDT 2013 IDCODE RESOLUTION COMPOUND ------ - ---------- - -------------------------------------- 1U98 ; 2 ; ""Crystal Structure of E. coli RecA in a Compressed Helical Filament Form3"" 1U99 ; 2.6 ; ""Crystal Structures of E. coli RecA in a Compressed Helical Filament Form 4"" 1XP8 ; 2.5 ; ""Deinococcus radiodurans RecA in complex with ATP-gamma-S"" 3CZJ ; 2.05 ; ""E. COLI (lacZ) BETA-GALACTOSIDASE (N460T) IN COMPLEX WITH D-GALCTOPYRANOSYL-1-ONE"" 1XMV ; 1.9 ; ""E. Coli RecA in complex with MgADP"" 1XMS ; 2.1 ; ""E. Coli RecA in complex with MnAMP-PNP"" 1NM2 ; 2 ; ""Malonyl-CoA:ACP Transacylase"" 2QPS ; 2.2 ; ""Sugar tongs"" mutant Y380A in complex with acarbose 2HCJ ; 2.12 ; ""Trypsin-modified Elongation Factor Tu in complex with tetracycline"" 3CRW ; 4 ; ""XPD_APO"" 3CRV ; 2 ; ""XPD_Helicase"" 2E5O ; ; 'Solution structure of the TRIP_4C domain of target of activating signal cointegrator 1 3RK1 ; 2.3 ; 'X-ray crystal Structure of the putative N-type ATP pyrophosphatase (PF0828) in complex with ATP from Pyrococcus furiosus, Northeast Structural Genomics Consortium Target PfR23 1N21 ; 3.1 ; (+)-Bornyl Diphosphate Synthase: Cocrystal with Mg and 3-aza-2,3-dihydrogeranyl diphosphate 1N20 ; 2.3 ; (+)-Bornyl Diphosphate Synthase: Complex with Mg and 3-aza-2,3-dihydrogeranyl diphosphate 1N24 ; 2.3 ; (+)-Bornyl diphosphate synthase: Complex with Mg and product 1N1Z ; 2.3 ; (+)-Bornyl Diphosphate Synthase: Complex with Mg and pyrophosphate 1N23 ; 2.4 ; (+)-Bornyl diphosphate synthase: Complex with Mg, pyrophosphate, and (1R,4S)-2-azabornane 1N22 ; 2.4 ; (+)-Bornyl Diphosphate Synthase: Complex with Mg, pyrophosphate, and (4R)-7-aza-7,8-dihydrolimonene 1DSA ; ; (+)-DUOCARMYCIN SA COVALENTLY LINKED TO DUPLEX DNA, NMR, 20 STRUCTURES 1DSM ; ; (-)-duocarmycin SA covalently linked to duplex DNA 2AQY ; ; (3+1) assembly of three human telomeric DNA repeats into an asymmetrical dimeric G-quadruplex 2ET6 ; 2.22 ; (3R)-Hydroxyacyl-CoA Dehydrogenase Domain of Candida tropicalis Peroxisomal Multifunctional Enzyme Type 2 1GZ6 ; 2.38 ; (3R)-HYDROXYACYL-COA DEHYDROGENASE FRAGMENT OF RAT PEROXISOMAL MULTIFUNCTIONAL ENZYME TYPE 2 3FY4 ; 2.7 ; (6-4) Photolyase Crystal Structure 1H8E ; 2 ; (ADP.ALF4)2(ADP.SO4) BOVINE F1-ATPASE (ALL THREE CATALYTIC SITES OCCUPIED) 1GBV ; 2 ; (ALPHA-OXY, BETA-(C112G)DEOXY) T-STATE HUMAN HEMOGLOBIN 2LJQ ; ; (C9S, C14S)-leucocin A 1NP5 ; ; (GAC)3 parallel duplex 4IN6 ; 2.7 ; (M)L214A mutant of the Rhodobacter sphaeroides Reaction Center 4IN5 ; 2.2 ; (M)L214G mutant of the Rhodobacter sphaeroides Reaction Center 2RBS ; 1.557 ; (r)(+)-3-chloro-1-phenyl-1-propanol in complex with T4 lysozyme L99A/M102Q 3O3M ; 1.82 ; (R)-2-Hydroxyisocaproyl-CoA Dehydratase 3O3O ; 2 ; (R)-2-hydroxyisocaproyl-CoA dehydratase in complex with (R)-2-hydroxyisocaproate 3O3N ; 2.3 ; (R)-2-hydroxyisocaproyl-CoA dehydratase in complex with its substrate (R)-2-hydroxyisocaproyl-CoA 3UKB ; 1.42 ; (R)-cEt-BNA decamer structure 1IQ6 ; 1.5 ; (R)-HYDRATASE FROM A. CAVIAE INVOLVED IN PHA BIOSYNTHESIS 2LBN ; ; (Revised) Solution structure of the monomeric form of a mutant unliganded bovine neurophysin, 20 structures 3F80 ; 1.6 ; (S)-2-amino-6-nitrohexanoic acid binds to human arginase I through multiple nitro-metal coordination interactions in the binuclear manganese cluster. Resolution 1.60 A. 3UKC ; 1.54 ; (S)-cEt-BNA decamer structure 3UKE ; 1.68 ; (S)-cMOE-BNA decamer structure 3HTD ; 1.4 ; (Z)-Thiophene-2-carboxaldoxime in complex with T4 lysozyme L99A/M102Q 3PSM ; 0.98 ; .98A crystal structure of a dimeric plant defensin SPE10 1HSS ; 2.06 ; 0.19 ALPHA-AMYLASE INHIBITOR FROM WHEAT 1I0T ; 0.6 ; 0.6 A STRUCTURE OF Z-DNA CGCGCG 3UI4 ; 0.8 ; 0.8 A resolution crystal structure of human Parvulin 14 2H5C ; 0.82 ; 0.82A resolution crystal structure of alpha-lytic protease at pH 5 1SSX ; 0.83 ; 0.83A resolution crystal structure of alpha-lytic protease at pH 8 1N55 ; 0.83 ; 0.83A resolution structure of the E65Q mutant of Leishmania mexicana triosephosphate isomerase complexed with 2-phosphoglycolate 1X8P ; 0.85 ; 0.85 A Crystal Structure Of Nitrophorin 4 From Rhodnius Prolixus Complexed With Ammonia at pH 7.4 1X8Q ; 0.85 ; 0.85 A Crystal Structure Of Nitrophorin 4 From Rhodnius Prolixus in Complex with Water at pH 5.6 1PJX ; 0.85 ; 0.85 ANGSTROM STRUCTURE OF SQUID GANGLION DFPASE 3UI6 ; 0.89 ; 0.89 A resolution crystal structure of human Parvulin 14 in complex with oxidized DTT 1I1W ; 0.89 ; 0.89A Ultra high resolution structure of a Thermostable Xylanase from Thermoascus Aurantiacus 1YWA ; 0.89 ; 0.9 A Structure of NP4 from Rhodnius Prolixus complexed with CO at pH 5.6 1YWB ; 0.97 ; 0.9 A Structure of NP4 from Rhodnius Prolixus complexed with NO at pH 5.6 3M5Q ; 0.93 ; 0.93 A Structure of Manganese-Bound Manganese Peroxidase 3NJ6 ; 0.95 ; 0.95 A resolution X-ray structure of (GGCAGCAGCC)2 4EGU ; 0.95 ; 0.95A Resolution Structure of a Histidine Triad Protein from Clostridium difficile 2AT8 ; 1 ; 0.96 A Crystal Structure Of Nitrophorin 4 From Rhodnius Prolixus Containing Fe(III) 2,4 Dimethyl Deuteroporphyrin IX Complexed With Nitric Oxide at pH 5.6 1C75 ; 0.97 ; 0.97 A ""AB INITIO"" CRYSTAL STRUCTURE OF CYTOCHROME C-553 FROM BACILLUS PASTEURII 1TG0 ; 0.97 ; 0.97-A structure of the SH3 domain of bbc1 3C78 ; 0.98 ; 0.98 A crystal structure of nitrophorin 4 from Rhodnius prolixus containing FE(III) 2,4 dimethyl deuteroporphyrin ix complexed with ammonia at ph 7.5 2H5D ; 0.9 ; 0.9A resolution crystal structure of alpha-lytic protease complexed with a transition state analogue, MeOSuc-Ala-Ala-Pro-Val boronic acid 4PRG ; 2.9 ; 0072 PARTIAL AGONIST PPAR GAMMA COCRYSTAL 1EN8 ; 0.985 ; 1 A CRYSTAL STRUCTURES OF B-DNA REVEAL SEQUENCE-SPECIFIC BINDING AND GROOVE-SPECIFIC BENDING OF DNA BY MAGNESIUM AND CALCIUM 2OTY ; 1.83 ; 1,2-dichlorobenzene in complex with T4 Lysozyme L99A 3DN6 ; 1.8 ; 1,3,5-trifluoro-2,4,6-trichlorobenzene binding in the hydrophobic cavity of T4 lysozyme L99A mutant 1DYP ; 1.54 ; 1,3-ALPHA-1,4-BETA-D-GALACTOSE-4-SULFATE-3,6-ANHYDRO-D-GALACTOSE 4 GALACTOHYDROLASE 1H80 ; 1.6 ; 1,3-ALPHA-1,4-BETA-D-GALACTOSE-4-SULFATE-3,6-ANHYDRO-D-GALACTOSE-2-SULFATE 4 GALACTOHYDROLASE 1F2D ; 2 ; 1-AMINOCYCLOPROPANE-1-CARBOXYLATE DEAMINASE 1B8G ; 2.37 ; 1-AMINOCYCLOPROPANE-1-CARBOXYLATE SYNTHASE 1CP6 ; 1.9 ; 1-BUTANEBORONIC ACID BINDING TO AEROMONAS PROTEOLYTICA AMINOPEPTIDASE 1XCC ; 2.3 ; 1-Cys peroxidoxin from Plasmodium Yoelli 3TB2 ; 2.3 ; 1-Cys peroxidoxin from Plasmodium Yoelli 3IIE ; 2.21 ; 1-deoxy-D-xylulose 5-phosphate reductoisomerase from Yersinia pestis. 1R0L ; 2.7 ; 1-deoxy-D-xylulose 5-phosphate reductoisomerase from zymomonas mobilis in complex with NADPH 2O1X ; 2.9 ; 1-deoxy-D-xylulose 5-phosphate synthase (DXS) from Deinococcus radiodurans 2O1S ; 2.4 ; 1-deoxy-D-xylulose 5-phosphate synthase (DXS) from Escherichia coli 1K5H ; 2.5 ; 1-deoxy-D-xylulose-5-phosphate reductoisomerase 2RBY ; 1.5 ; 1-methyl-5-imidazolecarboxaldehyde in complex with Cytochrome C Peroxidase W191G 2OU0 ; 1.94 ; 1-methylpyrrole in complex with T4 Lysozyme L99A 1QAS ; 2.4 ; 1-PHOSPHATIDYLINOSITOL-4,5-BISPHOSPHATE PHOSPHODIESTERASE DELTA 1 1QAT ; 3 ; 1-PHOSPHATIDYLINOSITOL-4,5-BISPHOSPHATE PHOSPHODIESTERASE DELTA COMPLEX WITH SAMARIUM (III) CHLORIDE 1UZB ; 1.4 ; 1-PYRROLINE-5-CARBOXYLATE DEHYDROGENASE 2J40 ; 2.1 ; 1-PYRROLINE-5-CARBOXYLATE DEHYDROGENASE FROM THERMUS THERMOPHILUS WITH BOUND INHIBITOR L-PROLINE AND NAD. 2J5N ; 1.63 ; 1-PYRROLINE-5-CARBOXYLATE DEHYDROGENASE FROM THERMUS THERMOPHIRUS WITH BOUND INHIBITOR GLYCINE AND NAD. 2IY6 ; 1.8 ; 1-PYRROLINE-5-CARBOXYLATE DEHYDROGENASE FROM THERMUS WITH BOUND CITRATE 1SY2 ; 1 ; 1.0 A Crystal Structure of D129A/L130A Mutant of Nitrophorin 4 1SXX ; 1.01 ; 1.0 A Crystal Structure of D129A/L130A Mutant of Nitrophorin 4 Complexed with Nitric Oxide 1SY1 ; 1.01 ; 1.0 A Crystal Structure of T121V Mutant of Nitrophorin 4 Complexed with Nitric Oxide 2WYT ; 1 ; 1.0 A RESOLUTION STRUCTURE OF L38V SOD1 MUTANT 2QCP ; 1 ; 1.0 A Structure of CusF-Ag(I) residues 10-88 from Escherichia coli 3E6Z ; 1 ; 1.0 A Structure of CusF-W44A-Cu(II) residues 10-88 from Escherichia coli 3CCD ; 1 ; 1.0 A Structure of Post-Succinimide His15Asp HPr 4GNR ; 1 ; 1.0 Angstrom resolution crystal structure of the branched-chain amino acid transporter substrate binding protein LivJ from Streptococcus pneumoniae str. Canada MDR_19A in complex with Isoleucine 1SY3 ; 1 ; 1.00 A Crystal Structure of D30N Mutant of Nitrophorin 4 from Rhodnius Prolixus Complexed with Nitric Oxide 2AT3 ; 1 ; 1.00 A Crystal Structure Of L123V/L133V Mutant of Nitrophorin 4 From Rhodnius Prolixus Complexed With Imidazole at pH 5.6 2AT0 ; 1 ; 1.00 A Crystal Structure Of L133V Mutant of Nitrophorin 4 From Rhodnius Prolixus Complexed With Nitric Oxide at pH 5.6 2OFR ; 1 ; 1.00 A Crystal Structure Of V36A/D129A/L130A Mutant of Nitrophorin 4 From Rhodnius Prolixus Complexed With Nitric Oxide at pH 5.6 4B4E ; 1 ; 1.00 A Structure of Lysozyme Crystallized with (R)-2-methyl-2,4- pentanediol 1HJ8 ; 1 ; 1.00 AA TRYPSIN FROM ATLANTIC SALMON 1X8O ; 1.01 ; 1.01 A Crystal Structure Of Nitrophorin 4 From Rhodnius Prolixus Complexed With Nitric Oxide at pH 5.6 3NVS ; 1.021 ; 1.02 Angstrom resolution crystal structure of 3-phosphoshikimate 1-carboxyvinyltransferase from Vibrio cholerae in complex with shikimate-3-phosphate (partially photolyzed) and glyphosate 1NH0 ; 1.03 ; 1.03 A structure of HIV-1 protease: inhibitor binding inside and outside the active site 3O1N ; 1.03 ; 1.03 Angstrom Crystal Structure of Q236A Mutant Type I Dehydroquinate Dehydratase (aroD) from Salmonella typhimurium 1SXW ; 1.05 ; 1.05 A Crystal Structure of D30A Mutant of Nitrophorin 4 from Rhodnius Prolixus Complexed with Nitric Oxide 3M8M ; 1.05 ; 1.05 A Structure of Manganese-free Manganese Peroxidase 1I0M ; 1.05 ; 1.05 A STRUCTURE OF THE A-DECAMER GCGTATACGC WITH A SINGLE 2'-O-FLUOROETHYL THYMINE IN PLACE OF T6, HIGH RB-SALT 1I0K ; 1.05 ; 1.05 A STRUCTURE OF THE A-DECAMER GCGTATACGC WITH A SINGLE 2'-O-METHYL-[TRI(OXYETHYL)] THYMINE IN PLACE OF T6, MEDIUM CS-SALT 4I62 ; 1.05 ; 1.05 Angstrom crystal structure of an amino acid ABC transporter substrate-binding protein AbpA from Streptococcus pneumoniae Canada MDR_19A bound to L-arginine 1I0J ; 1.06 ; 1.06 A STRUCTURE OF THE A-DECAMER GCGTATACGC WITH A SINGLE 2'-O-METHYL-3'-METHYLENEPHOSPHONATE (T23) THYMINE IN PLACE OF T6, HIGH CS-SALT 1SFS ; 1.07 ; 1.07 A crystal structure of an uncharacterized B. stearothermophilus protein 1SXY ; 1.07 ; 1.07 A Crystal Structure of D30N Mutant of Nitrophorin 4 from Rhodnius Prolixus 3C76 ; 1.07 ; 1.07 A crystal structure of L133V mutant of nitrophorin 4 from Rhodnius prolixus complexed with ammonia at PH 7.5 1X8N ; 1.08 ; 1.08 A Crystal Structure Of Nitrophorin 4 From Rhodnius Prolixus Complexed With Nitric Oxide at pH 7.4 3C77 ; 1.08 ; 1.08 A crystal structure of nitrophorin 4 from Rhodnius prolixus containing FE(III) deuteroporphyrin ix complexed with ammonia at ph 7.5 1JBE ; 1.08 ; 1.08 A Structure of apo-Chey reveals meta-active conformation 1YWD ; 1.08 ; 1.08 A Structure of Ferrous NP4 (aquo complex) 2BV4 ; 1 ; 1.0A STRUCTURE OF CHROMOBACTERIUM VIOLACEUM LECTIN IN COMPLEX WITH ALPHA-METHYL-MANNOSIDE 1A0M ; 1.1 ; 1.1 ANGSTROM CRYSTAL STRUCTURE OF A-CONOTOXIN [TYR15]-EPI 4H4N ; 1.1 ; 1.1 Angstrom Crystal Structure of Hypothetical Protein BA_2335 from Bacillus anthracis 3RPE ; 1.1 ; 1.1 Angstrom Crystal Structure of Putative Modulator of Drug Activity (MdaB) from Yersinia pestis CO92. 1LU4 ; 1.12 ; 1.1 ANGSTROM RESOLUTION CRYSTAL STRUCTURE OF A SECRETED MYCOBACTERIUM TUBERCULOSIS DISULFIDE OXIDOREDUCTASE HOMOLOGOUS TO E. COLI DSBE: IMPLICATIONS FOR FUNCTIONS 1R0R ; 1.1 ; 1.1 Angstrom Resolution Structure of the Complex Between the Protein Inhibitor, OMTKY3, and the Serine Protease, Subtilisin Carlsberg 3U97 ; 1.102 ; 1.1 Angstrom-resolution crystal structure of the Brucella abortus ribonuclease toxin, BrnT 3BF7 ; 1.1 ; 1.1 resolution structure of ybfF, a new esterase from Escherichia coli: a unique substrate-binding crevice generated by domain arrangement 3BF8 ; 1.68 ; 1.1 resolution structure of ybfF, a new esterase from Escherichia coli: a unique substrate-binding crevice generated by domain arrangement 1I1X ; 1.11 ; 1.11 A ATOMIC RESOLUTION STRUCTURE OF A THERMOSTABLE XYLANASE FROM THERMOASCUS AURANTIACUS 2OFM ; 1.11 ; 1.11 A Crystal Structure of Apo Nitrophorin 4 From Rhodnius Prolixus 1D2U ; 1.15 ; 1.15 A CRYSTAL STRUCTURE OF NITROPHORIN 4 FROM RHODNIUS PROLIXUS 1SY0 ; 1.15 ; 1.15 A Crystal Structure of T121V Mutant of Nitrophorin 4 from Rhodnius Prolixus 3T3L ; 1.15 ; 1.15 A structure of human frataxin variant Q153A 4B49 ; 1.15 ; 1.15 A Structure of Lysozyme Crystallized without 2-methyl-2,4- pentanediol 2W2E ; 1.15 ; 1.15 Angstrom crystal structure of P.pastoris aquaporin, Aqy1, in a closed conformation at pH 3.5 2NSZ ; 1.15 ; 1.15 Angstrom Crystal Structure of the MA3 domain of Pdcd4 1Z70 ; 1.15 ; 1.15A resolution structure of the formylglycine generating enzyme FGE 1R3G ; 1.16 ; 1.16A X-ray structure of the synthetic DNA fragment with the incorporated 2'-O-[(2-Guanidinium)ethyl]-5-methyluridine residues 4JER ; 1.1 ; 1.1A resolution Apo structure of the hemophore HasA from Yersinia pestis (Tetragonal Form) 2BOI ; 1.1 ; 1.1A STRUCTURE OF CHROMOBACTERIUM VIOLACEUM LECTIN CV2L IN COMPLEX WITH ALPHA-METHYL-FUCOSIDE 2CS7 ; 1.2 ; 1.2 A Crystal structure of the S. pneumoniae PhtA histidine triad domain a novel zinc binding fold 1QU9 ; 1.2 ; 1.2 A CRYSTAL STRUCTURE OF YJGF GENE PRODUCT FROM E. COLI 367D ; 1.2 ; 1.2 A STRUCTURE DETERMINATION OF THE D(CG(5-BRU)ACG)2/5-BROMO-9-AMINO-DACA COMPLEX 1G7A ; 1.2 ; 1.2 A structure of T3R3 human insulin at 100 K 1KWN ; 1.2 ; 1.2 A Structure of Thaumatin Crystallized in Gel 3IR4 ; 1.2 ; 1.2 Angstrom Crystal Structure of the Glutaredoxin 2 (grxB) from Salmonella typhimurium in complex with Glutathione 1AMM ; 1.2 ; 1.2 ANGSTROM STRUCTURE OF GAMMA-B CRYSTALLIN AT 150K 3G91 ; 1.23 ; 1.2 Angstrom structure of the exonuclease III homologue Mth0212 4B4I ; 1.2 ; 1.20 A Structure of Lysozyme Crystallized with (S)-2-methyl-2,4- pentanediol 2AT5 ; 1.22 ; 1.22 A Crystal Structure Of Nitrophorin 4 From Rhodnius Prolixus Containing Fe(III) Deuteroporphyrin IX Complexed With Nitric Oxide at pH 5.6 2AT6 ; 1.22 ; 1.22 A Crystal Structure Of Nitrophorin 4 From Rhodnius Prolixus Containing Fe(III) Deuteroporphyrin IX Complexed With Water at pH 5.6 1MJU ; 1.22 ; 1.22 ANGSTROM RESOLUTION CRYSTAL STRUCTURE OF THE FAB FRAGMENT OF ESTEROLYTIC ANTIBODY MS6-12 3GLP ; 1.23 ; 1.23 A resolution X-ray structure of (GCUGCUGC)2 3T3K ; 1.24 ; 1.24 A Structure of Friedreich's ataxia frataxin variant Q148R 3RM1 ; 1.24 ; 1.24 Angstrom X-ray structure of bovine TRTK12-Ca(2+)-S100B D63N 2C9U ; 1.24 ; 1.24 ANGSTROMS RESOLUTION STRUCTURE OF AS-ISOLATED CU-ZN HUMAN SUPEROXIDE DISMUTASE 2C9S ; 1.24 ; 1.24 ANGSTROMS RESOLUTION STRUCTURE OF ZN-ZN HUMAN SUPEROXIDE DISMUTASE 4B4J ; 1.25 ; 1.25 A Structure of Lysozyme Crystallized with (RS)-2-methyl-2,4- pentanediol 3GIU ; 1.25 ; 1.25 Angstrom Crystal Structure of Pyrrolidone-Carboxylate Peptidase (pcp) from Staphylococcus aureus 2DN3 ; 1.25 ; 1.25A resolution crystal structure of human hemoglobin in the carbonmonoxy form 2DN2 ; 1.25 ; 1.25A resolution crystal structure of human hemoglobin in the deoxy form 2DN1 ; 1.25 ; 1.25A resolution crystal structure of human hemoglobin in the oxy form 1IKJ ; 1.27 ; 1.27 A CRYSTAL STRUCTURE OF NITROPHORIN 4 FROM RHODNIUS PROLIXUS COMPLEXED WITH IMIDAZOLE 2CAK ; 1.27 ; 1.27ANGSTROM STRUCTURE OF RUSTICYANIN FROM THIOBACILLUS FERROOXIDANS 2F91 ; 1.2 ; 1.2A resolution structure of a crayfish trypsin complexed with a peptide inhibitor, SGTI 3HT1 ; 1.2 ; 1.2A structure of the polyketide cyclase RemF from Streptomyces resistomycificus 366D ; 1.3 ; 1.3 A STRUCTURE DETERMINATION OF THE D(CG(5-BRU)ACG)2/6-BROMO-9-AMINO-DACA COMPLEX 1G7B ; 1.3 ; 1.3 A STRUCTURE OF T3R3 HUMAN INSULIN AT 100 K 1I0Q ; 1.3 ; 1.3 A STRUCTURE OF THE A-DECAMER GCGTATACGC WITH A SINGLE 2'-O-METHYL-[TRI(OXYETHYL)] THYMINE IN PLACE OF T6, MEDIUM NA-SALT 1I0N ; 1.3 ; 1.3 A STRUCTURE OF THE A-DECAMER GCGTATACGC WITH A SINGLE 2'-O-METHYL-[TRI(OXYETHYL)] THYMINE IN PLACE OF T6, MEDIUM RB-SALT 1I0P ; 1.3 ; 1.3 A STRUCTURE OF THE A-DECAMER GCGTATACGC WITH A SINGLE 2'-O-METHYL-[TRI(OXYETHYL)], MEDIUM K-SALT 1JW8 ; 1.3 ; 1.3 ANGSTROM RESOLUTION CRYSTAL STRUCTURE OF P6 FORM OF MYOGLOBIN 3DHC ; 1.3 ; 1.3 Angstrom Structure of N-Acyl Homoserine Lactone Hydrolase with the Product N-Hexanoyl-L-Homocysteine Bound to The catalytic Metal Center 4DJC ; 1.35 ; 1.35 A crystal structure of the NaV1.5 DIII-IV-Ca/CaM complex 1ZGK ; 1.35 ; 1.35 angstrom structure of the Kelch domain of Keap1 1LK2 ; 1.35 ; 1.35A crystal structure of H-2Kb complexed with the GNYSFYAL peptide 4EIV ; 1.37 ; 1.37 Angstrom resolution crystal structure of apo-form of a putative deoxyribose-phosphate aldolase from Toxoplasma gondii ME49 3T3T ; 1.38 ; 1.38 A structure of human frataxin variant Q148G 3C8Y ; 1.39 ; 1.39 Angstrom crystal structure of Fe-only hydrogenase 1SXV ; 1.3 ; 1.3A Crystal structure of rv3628, Mycobacterium tuberculosis inorganic pyrophosphatase (PPase) at pH5.0 3QGJ ; 1.3 ; 1.3A Structure of alpha-Lytic Protease Bound to Ac-AlaAlaPro-Alanal 1SXU ; 1.4 ; 1.4 A Crystal Structure of D30N Mutant of Nitrophorin 4 from Rhodnius Prolixus Complexed with Imidazole 1D3S ; 1.4 ; 1.4 A crystal structure of nitrophorin 4 from Rhodnius prolixis at pH=5.6. 2TNF ; 1.4 ; 1.4 A RESOLUTION STRUCTURE OF MOUSE TUMOR NECROSIS FACTOR, TOWARDS MODULATION OF ITS SELCTIVITY AND TRIMERISATION 4EQ9 ; 1.4 ; 1.4 Angstrom Crystal Structure of ABC Transporter Glutathione-Binding Protein GshT from Streptococcus pneumoniae strain Canada MDR_19A in Complex with Glutathione 3I19 ; 1.36 ; 1.4 Angstrom Crystal Structure of Fluorescent Protein Cypet 2W1P ; 1.4 ; 1.4 Angstrom crystal structure of P.pastoris aquaporin, Aqy1, in a closed conformation at pH 8.0 3M07 ; 1.4 ; 1.4 Angstrom Resolution Crystal Structure of Putative alpha Amylase from Salmonella typhimurium. 4GUC ; 1.4 ; 1.4 Angstrom resolution crystal structure of uncharacterized protein BA_2500 from Bacillus anthracis str. Ames 3DHB ; 1.4 ; 1.4 Angstrom Structure of N-Acyl Homoserine Lactone Hydrolase with the Product N-Hexanoyl-L-Homoserine Bound at The Catalytic Metal Center 1HMR ; 1.4 ; 1.4 ANGSTROMS STRUCTURAL STUDIES ON HUMAN MUSCLE FATTY ACID BINDING PROTEIN: BINDING INTERACTIONS WITH THREE SATURATED AND UNSATURATED C18 FATTY ACIDS 1HMS ; 1.4 ; 1.4 ANGSTROMS STRUCTURAL STUDIES ON HUMAN MUSCLE FATTY ACID BINDING PROTEIN: BINDING INTERACTIONS WITH THREE SATURATED AND UNSATURATED C18 FATTY ACIDS 1HMT ; 1.4 ; 1.4 ANGSTROMS STRUCTURAL STUDIES ON HUMAN MUSCLE FATTY ACID BINDING PROTEIN: BINDING INTERACTIONS WITH THREE SATURATED AND UNSATURATED C18 FATTY ACIDS 4JB7 ; 1.42 ; 1.42 Angstrom resolution crystal structure of accessory colonization factor AcfC (acfC) in complex with D-aspartic acid 1CXU ; 1.42 ; 1.42A RESOLUTION ASV INTEGRASE CORE DOMAIN FROM CITRATE 1DI6 ; 1.45 ; 1.45 A CRYSTAL STRUCTURE OF THE MOLYBDENUMM COFACTOR BIOSYNTHESIS PROTEIN MOGA FROM ESCHERICHIA COLI 1I0G ; 1.45 ; 1.45 A STRUCTURE OF THE A-DECAMER GCGTATACGC WITH A SINGLE 2'-O-FLUOROETHYL THYMINE IN PLACE OF T6, MEDIUM NA-SALT 3TNL ; 1.45 ; 1.45 Angstrom Crystal Structure of Shikimate 5-dehydrogenase from Listeria monocytogenes in Complex with Shikimate and NAD. 3O8Q ; 1.45 ; 1.45 Angstrom Resolution Crystal Structure of Shikimate 5-Dehydrogenase (aroE) from Vibrio cholerae 3RQV ; 1.45 ; 1.45 Angstrom Structure of STNV coat protein (half of the capsid, the other half in PDB 1VTZ) 1VTZ ; 1.45 ; 1.45 Angstrom Structure of STNV coat protein (half of the capsid, the other half in PDB 3RQV) 3LG3 ; 1.4 ; 1.4A Crystal Structure of Isocitrate Lyase from Yersinia pestis CO92 1O98 ; 1.4 ; 1.4A CRYSTAL STRUCTURE OF PHOSPHOGLYCERATE MUTASE FROM BACILLUS STEAROTHERMOPHILUS COMPLEXED WITH 2-PHOSPHOGLYCERATE 1QTO ; 1.5 ; 1.5 A CRYSTAL STRUCTURE OF A BLEOMYCIN RESISTANCE DETERMINANT FROM BLEOMYCIN-PRODUCING STREPTOMYCES VERTICILLUS 2GS5 ; 1.5 ; 1.5 A Crystal Structure of a Conserved Protein of Unknown Function from Corvnebacterium diphtheriae 1TP6 ; 1.5 ; 1.5 A Crystal Structure of a NTF-2 Like Protein of Unknown Function PA1314 from Pseudomonas aeruginosa 1TUA ; 1.5 ; 1.5 A Crystal Structure of a Protein of Unknown Function APE0754 from Aeropyrum pernix 2GZ4 ; 1.5 ; 1.5 A Crystal Structure of a Protein of Unknown Function ATU1052 from Agrobacterium tumefaciens 1Z6N ; 1.5 ; 1.5 A Crystal Structure of a Protein of Unknown Function PA1234 from Pseudomonas aeruginosa 2A35 ; 1.5 ; 1.5 A Crystal Structure of a Protein of Unknown Function PA4017 from Pseudomonas aeruginosa PAO1, Possible Epimerase 1SH8 ; 1.5 ; 1.5 A Crystal Structure of a Protein of Unknown Function PA5026 from Pseudomonas aeruginosa, Probable Thioesterase 2B5H ; 1.5 ; 1.5 A Resolution Crystal Structure of Recombinant R. Norvegicus Cysteine Dioxygenase 2GH2 ; 1.5 ; 1.5 A Resolution R. Norvegicus Cysteine Dioxygenase Structure Crystallized in the Presence of Cysteine 1PUY ; 1.5 ; 1.5 A resolution structure of a synthetic DNA hairpin with a stilbenediether linker 1ZEQ ; 1.5 ; 1.5 A Structure of apo-CusF residues 6-88 from Escherichia coli 2GRC ; 1.5 ; 1.5 A structure of bromodomain from human BRG1 protein, a central ATPase of SWI/SNF remodeling complex 2OE5 ; 1.51 ; 1.5 A X-ray crystal structure of Apramycin complex with RNA fragment GGCGUCGCUAGUACCG/GGUACUAAAAGUCGCCC containing the human ribosomal decoding A site: RNA construct with 3'-overhang 3HJB ; 1.5 ; 1.5 Angstrom Crystal Structure of Glucose-6-phosphate Isomerase from Vibrio cholerae. 1WPA ; 1.5 ; 1.5 Angstrom crystal structure of human occludin fragment 413-522 4EVM ; 1.506 ; 1.5 Angstrom crystal structure of soluble domain of membrane-anchored thioredoxin family protein from Streptococcus pneumoniae strain Canada MDR_19A 4EQB ; 1.5 ; 1.5 Angstrom Crystal Structure of Spermidine/Putrescine ABC Transporter Substrate-Binding Protein PotD from Streptococcus pneumoniae strain Canada MDR_19A in Complex with Calcium and HEPES 3RQT ; 1.5 ; 1.5 Angstrom Crystal Structure of the Complex of Ligand Binding Component of ABC-type Import System from Staphylococcus aureus with Nickel and two Histidines 4GUF ; 1.5 ; 1.5 Angstrom Crystal Structure of the Salmonella enterica 3-Dehydroquinate Dehydratase (aroD) E86A Mutant 1LMI ; 1.5 ; 1.5 ANGSTROM RESOLUTION CRYSTAL STRUCTURE OF A SECRETED PROTEIN FROM MYCOBACTERIUM TUBERCULOSIS-MPT63 4IFA ; 1.5 ; 1.5 Angstrom resolution crystal structure of an extracellular protein containing a SCP domain from Bacillus anthracis str. Ames 3TKF ; 1.5 ; 1.5 Angstrom Resolution Crystal Structure of K135M Mutant of Transaldolase B (TalA) from Francisella tularensis in Complex with Sedoheptulose 7-phosphate. 3UPB ; 1.5 ; 1.5 Angstrom Resolution Crystal Structure of Transaldolase from Francisella tularensis in Covalent Complex with Arabinose-5-Phosphate 3RY4 ; 1.5 ; 1.5 Angstrom resolution structure of glycosylated fcgammariia (low-responder polymorphism) 3IQO ; 1.5 ; 1.5 angstrom X-ray structure of bovine Ca(2+)-S100B 4GUJ ; 1.5 ; 1.50 Angstrom Crystal Structure of the Salmonella enterica 3-Dehydroquinate Dehydratase (aroD) in Complex with Shikimate 1K4V ; 1.53 ; 1.53 A Crystal Structure of the Beta-Galactoside-alpha-1,3-galactosyltransferase in Complex with UDP 1WCF ; 1.54 ; 1.54 A CRYSTAL STRUCTURE OF RV3628, MYCOBACTERIUM TUBERCULOSIS INORGANIC PYROPHOSPHATASE (PPASE) AT PH7.0 3QY1 ; 1.54 ; 1.54A Resolution Crystal Structure of a Beta-Carbonic Anhydrase from Salmonella enterica subsp. enterica serovar Typhimurium str. LT2 1MV8 ; 1.55 ; 1.55 A crystal structure of a ternary complex of GDP-mannose dehydrogenase from Psuedomonas aeruginosa 1KQ1 ; 1.55 ; 1.55 A Crystal structure of the pleiotropic translational regulator, Hfq 4FOJ ; 1.55 ; 1.55 A Crystal Structure of Xanthomonas citri FimX EAL domain in complex with c-diGMP 3GA7 ; 1.55 ; 1.55 Angstrom Crystal Structure of an Acetyl Esterase from Salmonella typhimurium 4ERR ; 1.55 ; 1.55 Angstrom Crystal Structure of the Four Helical Bundle Membrane Localization Domain (4HBM) of the Vibrio vulnificus MARTX Effector Domain DUF5 1F0L ; 1.55 ; 1.55 ANGSTROM CRYSTAL STRUCTURE OF WILD TYPE DIPHTHERIA TOXIN 3IFE ; 1.55 ; 1.55 Angstrom Resolution Crystal Structure of Peptidase T (pepT-1) from Bacillus anthracis str. 'Ames Ancestor'. 3R2K ; 1.55 ; 1.55A resolution structure of As-Isolated FtnA from Pseudomonas aeruginosa (pH 7.5) 3NEP ; 1.551 ; 1.55A resolution structure of malate dehydrogenase from Salinibacter ruber 2Y3Q ; 1.55 ; 1.55A STRUCTURE OF APO BACTERIOFERRITIN FROM E. COLI 1HFC ; 1.5 ; 1.56 ANGSTROM STRUCTURE OF MATURE TRUNCATED HUMAN FIBROBLAST COLLAGENASE 3T3X ; 1.57 ; 1.57 A structure of Friedreich's ataxia frataxin variant R165C 3GM7 ; 1.58 ; 1.58 A resolution X-ray structure of (CUG)6 3L4E ; 1.5 ; 1.5A Crystal Structure of a Putative Peptidase E Protein from Listeria monocytogenes EGD-e 1OZN ; 1.52 ; 1.5A Crystal Structure of the Nogo Receptor Ligand Binding Domain Reveals a Convergent Recognition Scaffold Mediating Inhibition of Myelination 1SQE ; 1.5 ; 1.5A Crystal Structure Of the protein PG130 from Staphylococcus aureus, Structural genomics 1ZKP ; 1.502 ; 1.5A Resolution Crystal Structure of a Metallo Beta Lactamase Family Protein, the ELAC Homolgue of Bacillus anthracis, a Putative Ribonuclease 3UR6 ; 1.5 ; 1.5A resolution structure of apo Norwalk Virus Protease 1JKS ; 1.5 ; 1.5A X-RAY STRUCTURE OF APO FORM OF A CATALYTIC DOMAIN OF DEATH-ASSOCIATED PROTEIN KINASE 2AP3 ; 1.6 ; 1.6 A Crystal Structure of a Conserved Protein of Unknown Function from Staphylococcus aureus 1ZKE ; 1.6 ; 1.6 A Crystal Structure of a Protein HP1531 of Unknown Function from Helicobacter pylori 3DMO ; 1.6 ; 1.6 A crystal structure of cytidine deaminase from Burkholderia pseudomallei 3OE2 ; 1.6 ; 1.6 A crystal structure of peptidyl-prolyl cis-trans isomerase PPIase from Pseudomonas syringae pv. tomato str. DC3000 (PSPTO DC3000) 1HFE ; 1.6 ; 1.6 A RESOLUTION STRUCTURE OF THE FE-ONLY HYDROGENASE FROM DESULFOVIBRIO DESULFURICANS 2WBZ ; 1.6 ; 1.6 A STRUCTURE OF THAUMATIN CRYSTALLIZED WITHOUT TARTRATE AT 4 C 1I0F ; 1.6 ; 1.6 A STRUCTURE OF THE A-DECAMER GCGTATACGC WITH A SINGLE 2'-O-AMINOOXYETHYL THYMINE IN PLACE OF T6, BA-FORM 1I0O ; 2 ; 1.6 A STRUCTURE OF THE A-DECAMER GCGTATACGC WITH A SINGLE 2'-O-METHYL-3'-METHYLENEPHOSPHONATE THYMINE IN PLACE OF T6, HIGH K-SALT 3B9F ; 1.6 ; 1.6 A structure of the PCI-thrombin-heparin complex 3GWA ; 1.6 ; 1.6 Angstrom crystal structure of 3-oxoacyl-(acyl-carrier-protein) synthase III 2BL7 ; 2.2 ; 1.6 ANGSTROM CRYSTAL STRUCTURE OF ENTA-IM: A BACTERIAL IMMUNITY PROTEIN CONFERRING IMMUNITY TO THE ANTIMICROBIAL ACTIVITY OF THE PEDIOCIN-LIKE BACTERIOCIN, ENTEROCIN A 2BL8 ; 1.6 ; 1.6 ANGSTROM CRYSTAL STRUCTURE OF ENTA-IM: A BACTERIAL IMMUNITY PROTEIN CONFERRING IMMUNITY TO THE ANTIMICROBIAL ACTIVITY OF THE PEDIOCIN-LIKE BACTERIOCIN, ENTEROCIN A 3GEX ; 1.6 ; 1.6 angstrom crystal structure of fluorescent protein Cypet 3LKM ; 1.6 ; 1.6 Angstrom Crystal Structure of the Alpha-kinase Domain of Myosin Heavy Chain Kinase A Complex with AMP 1JLJ ; 1.6 ; 1.6 Angstrom crystal structure of the human neuroreceptor anchoring and molybdenum cofactor biosynthesis protein gephyrin 3PP9 ; 1.6 ; 1.6 Angstrom resolution crystal structure of putative streptothricin acetyltransferase from Bacillus anthracis str. Ames in complex with acetyl coenzyme A 2A7M ; 1.6 ; 1.6 Angstrom Resolution Structure of the Quorum-Quenching N-Acyl Homoserine Lactone Hydrolase of Bacillus thuringiensis 1T4B ; 1.6 ; 1.6 Angstrom structure of Esherichia coli aspartate-semialdehyde dehydrogenase. 2GIM ; 1.6 ; 1.6 Angstrom structure of plastocyanin from Anabaena variabilis 1G4Y ; 1.6 ; 1.60 A CRYSTAL STRUCTURE OF THE GATING DOMAIN FROM SMALL CONDUCTANCE POTASSIUM CHANNEL COMPLEXED WITH CALCIUM-CALMODULIN 1DI7 ; 1.6 ; 1.60 ANGSTROM CRYSTAL STRUCTURE OF THE MOLYBDENUM COFACTOR BIOSYNTHESIS PROTEIN MOGA FROM ESCHERICHIA COLI 3U80 ; 1.6 ; 1.60 Angstrom Resolution Crystal Structure of a 3-Dehydroquinate Dehydratase-like Protein from Bifidobacterium longum 3V4G ; 1.6 ; 1.60 Angstrom resolution crystal structure of an arginine repressor from Vibrio vulnificus CMCP6 4GUG ; 1.62 ; 1.62 Angstrom Crystal Structure of the Salmonella enterica 3-Dehydroquinate Dehydratase (aroD) E86A Mutant in Complex with Dehydroshikimate (Crystal Form #1) 3UUW ; 1.63 ; 1.63 Angstrom Resolution Crystal Structure of Dehydrogenase (MviM) from Clostridium difficile. 3RYK ; 1.631 ; 1.63 Angstrom resolution crystal structure of dTDP-4-dehydrorhamnose 3,5-epimerase (rfbC) from Bacillus anthracis str. Ames with TDP and PPi bound 1M93 ; 1.65 ; 1.65 A Structure of Cleaved Viral Serpin CRMA 1SDI ; 1.65 ; 1.65 A structure of Escherichia coli ycfC gene product 3D72 ; 1.65 ; 1.65 Angstrom crystal structure of the Cys71Val variant in the fungal photoreceptor VVD 3TNO ; 1.65 ; 1.65 Angstrom Resolution Crystal Structure of Transaldolase B (TalA) from Francisella tularensis in Covalent Complex with Sedoheptulose-7-Phosphate 3LWZ ; 1.65 ; 1.65 Angstrom Resolution Crystal Structure of Type II 3-Dehydroquinate Dehydratase (aroQ) from Yersinia pestis 1DHN ; 1.65 ; 1.65 ANGSTROM RESOLUTION STRUCTURE OF 7,8-DIHYDRONEOPTERIN ALDOLASE FROM STAPHYLOCOCCUS AUREUS 2UZ1 ; 1.65 ; 1.65 ANGSTROM STRUCTURE OF BENZALDEHYDE LYASE COMPLEXED WITH 2-METHYL-2,4-PENTANEDIOL 1YO3 ; 1.65 ; 1.65 Angstrom Structure of the Dynein Light Chain 1 from Plasmodium falciparum 3DMS ; 1.65 ; 1.65A crystal structure of isocitrate dehydrogenase from Burkholderia pseudomallei 3R2R ; 1.65 ; 1.65A resolution structure of Iron Soaked FtnA from Pseudomonas aeruginosa (pH 6.0) 3UR9 ; 1.65 ; 1.65A resolution structure of Norwalk Virus Protease Containing a covalently bound dipeptidyl inhibitor 4JBU ; 1.65 ; 1.65A structure of the T3SS tip protein LcrV (G28-D322, C273S) from Yersinia pestis 1I2Y ; 1.66 ; 1.66 A STRUCTURE OF A-DUPLEX WITH BULGED ADENOSINE, SPERMINE FORM 1LLN ; 1.6 ; 1.6A CRYSTAL STRUCTURE OF POKEWEED ANTIVIRAL PROTEIN-III (PAP-III) WITH METHYLATED LYSINES 1YD9 ; 1.6 ; 1.6A Crystal Structure of the Non-Histone Domain of the Histone Variant MacroH2A1.1. 1RZ2 ; 1.6 ; 1.6A crystal structure of the protein BA4783/Q81L49 (similar to sortase B) from Bacillus anthracis. 4JES ; 1.6 ; 1.6A resolution Apo structure of the hemophore HasA from Yersinia pestis (Hexagonal Form) 1JUX ; 1.6 ; 1.6A Resolution Crystal Structures of the DNA Octamers d(IUATATAC) and d(ITITACAC):Binding of Two Distamycin Drugs Side-by-Side 2WCW ; 1.58 ; 1.6A RESOLUTION STRUCTURE OF ARCHAEOGLOBUS FULGIDUS HJC, A HOLLIDAY JUNCTION RESOLVASE FROM AN ARCHAEAL HYPERTHERMOPHILE 2WCZ ; 1.65 ; 1.6A RESOLUTION STRUCTURE OF ARCHAEOGLOBUS FULGIDUS HJC, A HOLLIDAY JUNCTION RESOLVASE FROM AN ARCHAEAL HYPERTHERMOPHILE 4DCD ; 1.69 ; 1.6A resolution structure of PolioVirus 3C Protease Containing a covalently bound dipeptidyl inhibitor 3Q7R ; 1.6 ; 1.6A resolution structure of the ChxR receiver domain from Chlamydia trachomatis 1JKL ; 1.62 ; 1.6A X-RAY STRUCTURE OF BINARY COMPLEX OF A CATALYTIC DOMAIN OF DEATH-ASSOCIATED PROTEIN KINASE WITH ATP ANALOGUE 1U17 ; 1.7 ; 1.7 A Crystal structure of H60C mutant of Nitrophorin I. Heme complexed with two molecules imidazole 3CXK ; 1.7 ; 1.7 A Crystal structure of methionine-R-sulfoxide reductase from Burkholderia pseudomallei: crystallization in a microfluidic crystal card. 1Y7R ; 1.7 ; 1.7 A Crystal Structure of Protein of Unknown Function SA2161 from Meticillin-Resistant Staphylococcus aureus, Probable Acetyltransferase 3R2H ; 1.7 ; 1.7 A resolution structure of As-Isolated FtnA from Pseudomonas aeruginosa (pH 10.5) 1UWF ; 1.69 ; 1.7 A RESOLUTION STRUCTURE OF THE RECEPTOR BINDING DOMAIN OF THE FIMH ADHESIN FROM UROPATHOGENIC E. COLI 1QUS ; 1.7 ; 1.7 A RESOLUTION STRUCTURE OF THE SOLUBLE LYTIC TRANSGLYCOSYLASE SLT35 FROM ESCHERICHIA COLI 4JCO ; 1.7 ; 1.7 A resolution structure of wild type malate dehydrogenase from haloarcula marismortui 3GVF ; 1.75 ; 1.7 Angstrom crystal structure of inorganic pyrophosphatase from burkholderia pseudomallei bound with phosphate 1PXZ ; 1.7 ; 1.7 Angstrom Crystal Structure of jun a 1, the major allergen from cedar pollen 1ZD7 ; 1.7 ; 1.7 Angstrom Crystal Structure Of Post-Splicing Form of a dnaE Intein from Synechocystis Sp. Pcc 6803 2PDR ; 1.7 ; 1.7 Angstrom Crystal Structure of the Photo-excited Blue-light Photoreceptor Vivid 1Z9L ; 1.7 ; 1.7 Angstrom Crystal Structure of the Rat VAP-A MSP Homology Domain 1EYE ; 1.7 ; 1.7 ANGSTROM RESOLUTION CRYSTAL STRUCTURE OF 6-HYDROXYMETHYL-7,8-DIHYDROPTEROATE SYNTHASE (DHPS) FROM MYCOBACTERIUM TUBERCULOSIS IN COMPLEX WITH 6-HYDROXYMETHYLPTERIN MONOPHOSPHATE 3HJV ; 1.7 ; 1.7 Angstrom resolution crystal structure of an acyl carrier protein S-malonyltransferase from Vibrio cholerae O1 biovar eltor str. N16961 3ED6 ; 1.7 ; 1.7 Angstrom resolution crystal structure of betaine aldehyde dehydrogenase (betB) from Staphylococcus aureus 3SD7 ; 1.7 ; 1.7 Angstrom Resolution Crystal Structure of Putative Phosphatase from Clostridium difficile 3VAA ; 1.7 ; 1.7 Angstrom Resolution Crystal Structure of Shikimate Kinase from Bacteroides thetaiotaomicron 2HRC ; 1.7 ; 1.7 angstrom structure of human ferrochelatase variant R115L 1SBP ; 1.7 ; 1.7 ANGSTROMS REFINED STRUCTURE OF SULFATE-BINDING PROTEIN INVOLVED IN ACTIVE TRANSPORT AND NOVEL MODE OF SULFATE BINDING 1I6K ; 1.72 ; 1.7 HIGH RESOLUTION EXPERIMENTAL PHASES FOR TRYPTOPHANYL-TRNA SYNTHETASE COMPLEXED WITH TRYPTOPHANYL-5'AMP 1I6L ; 1.72 ; 1.7 HIGH RESOLUTION EXPERIMENTAL PHASES FOR TRYPTOPHANYL-TRNA SYNTHETASE COMPLEXED WITH TRYPTOPHANYL-5'AMP 1I6M ; 1.72 ; 1.7 HIGH RESOLUTION EXPERIMENTAL PHASES FOR TRYPTOPHANYL-TRNA SYNTHETASE COMPLEXED WITH TRYPTOPHANYL-5'AMP 1YR5 ; 1.7 ; 1.7-A structure of calmodulin bound to a peptide from DAP kinase 2KIM ; ; 1.7-mm microcryoprobe solution NMR structure of an O6-methylguanine DNA methyltransferase family protein from Vibrio parahaemolyticus. Northeast Structural Genomics Consortium target VpR247. 4BGT ; 1.699 ; 1.70 A resolution structure of the malate dehydrogenase from Chloroflexus aurantiacus 3T3J ; 1.7 ; 1.70 A structure of Friedreich's ataxia frataxin variant N146K 4KI3 ; 1.7 ; 1.70 Angstrom resolution crystal structure of outer-membrane lipoprotein carrier protein (lolA) from Yersinia pestis CO92 3SLH ; 1.7 ; 1.70 Angstrom resolution structure of 3-phosphoshikimate 1-carboxyvinyltransferase (AroA) from Coxiella burnetii in complex with shikimate-3-phosphate and glyphosate 4EAM ; 1.7 ; 1.70A resolution structure of apo beta-glycosidase (W33G) from sulfolobus solfataricus 2ID7 ; 1.75 ; 1.75 A Structure of T87I Phosphono-CheY 4GHJ ; 1.75 ; 1.75 Angstrom Crystal Structure of Transcriptional Regulator ftom Vibrio vulnificus. 3OGA ; 1.75 ; 1.75 Angstrom resolution crystal structure of a putative NTP pyrophosphohydrolase (yfaO) from Salmonella typhimurium LT2 3M3H ; 1.75 ; 1.75 Angstrom resolution crystal structure of an orotate phosphoribosyltransferase from Bacillus anthracis str. 'Ames Ancestor' 4EAN ; 1.75 ; 1.75A resolution structure of indole bound beta-glycosidase (W33G) from sulfolobus solfataricus 3PZF ; 1.75 ; 1.75A resolution structure of Serpin-2 from Anopheles gambiae 1UWL ; 1.76 ; 1.76A STRUCTURE OF UROCANATE HYDRATASE FROM PSEUDOMONAS PUTIDA 4DUN ; 1.76 ; 1.76A X-ray Crystal Structure of a Putative Phenazine Biosynthesis PhzC/PhzF Protein from Clostridium difficile (strain 630) 3LDV ; 1.77 ; 1.77 Angstrom resolution crystal structure of orotidine 5'-phosphate decarboxylase from Vibrio cholerae O1 biovar eltor str. N16961 4GUI ; 1.78 ; 1.78 Angstrom Crystal Structure of the Salmonella enterica 3-Dehydroquinate Dehydratase (aroD) in Complex with Quinate 1P99 ; 1.7 ; 1.7A crystal structure of protein PG110 from Staphylococcus aureus 3RIX ; 1.7 ; 1.7A resolution structure of a firefly luciferase-Aspulvinone J inhibitor complex 3MHZ ; 1.7 ; 1.7A structure of 2-fluorohistidine labeled Protective Antigen 3DGL ; 1.8 ; 1.8 A Crystal Structure of a Non-biological Protein with Bound ATP in a Novel Bent Conformation 1S7I ; 1.8 ; 1.8 A Crystal Structure of a Protein of Unknown Function PA1349 from Pseudomonas aeruginosa 1T8H ; 1.8 ; 1.8 A CRYSTAL STRUCTURE OF AN UNCHARACTERIZED B. STEAROTHERMOPHILUS PROTEIN 1I6N ; 1.8 ; 1.8 A Crystal structure of IOLI protein with a binding zinc atom 3FC0 ; 1.76 ; 1.8 A crystal structure of murine GITR ligand dimer expressed in Drosophila melanogaster S2 cells 4FOK ; 1.8 ; 1.8 A Crystal structure of the FimX EAL domain in complex with c-diGMP 2Q3B ; 1.8 ; 1.8 A Resolution Crystal Structure of O-Acetylserine Sulfhydrylase (OASS) Holoenzyme From MYCOBACTERIUM TUBERCULOSIS 1JUE ; 1.8 ; 1.8 A resolution structure of native lactococcus lactis dihydroorotate dehydrogenase A 3S8F ; 1.8 ; 1.8 A structure of ba3 cytochrome c oxidase from Thermus thermophilus in lipid environment 3S8G ; 1.8 ; 1.8 A structure of ba3 cytochrome c oxidase mutant (A120F) from Thermus thermophilus in lipid environment 2OE8 ; 1.8 ; 1.8 A X-ray crystal structure of Apramycin complex with RNA fragment GGGCGUCGCUAGUACC/CGGUACUAAAAGUCGCC containing the human ribosomal decoding A site: RNA construct with 5'-overhang 1IMX ; 1.82 ; 1.8 Angstrom crystal structure of IGF-1 4GFS ; 1.8 ; 1.8 Angstrom Crystal Structure of the 3-Dehydroquinate Dehydratase (aroD) from Salmonella typhimurium LT2 with Nickel Bound at Active Site 2PD8 ; 1.8 ; 1.8 Angstrom Crystal Structure of the Cys71Ser mutant of Vivid 3HJI ; 1.8 ; 1.8 Angstrom Crystal Structure of the I74V:I85V Variant of Vivid (VVD). 3BS6 ; 1.8 ; 1.8 Angstrom crystal structure of the periplasmic domain of the membrane insertase YidC 4IUO ; 1.8 ; 1.8 Angstrom Crystal Structure of the Salmonella enterica 3-Dehydroquinate Dehydratase (aroD) K170M Mutant in Complex with Quinate 3LLP ; 1.8 ; 1.8 Angstrom human fascin 1 crystal structure 3QYQ ; 1.8 ; 1.8 Angstrom resolution crystal structure of a putative deoxyribose-phosphate aldolase from Toxoplasma gondii ME49 3LV8 ; 1.8 ; 1.8 Angstrom resolution crystal structure of a thymidylate kinase (tmk) from Vibrio cholerae O1 biovar eltor str. N16961 in complex with TMP, thymidine-5'-diphosphate and ADP 3IJ3 ; 1.8 ; 1.8 Angstrom Resolution Crystal Structure of Cytosol Aminopeptidase from Coxiella burnetii 3N2B ; 1.8 ; 1.8 Angstrom Resolution Crystal Structure of Diaminopimelate Decarboxylase (lysA) from Vibrio cholerae. 3JZE ; 1.8 ; 1.8 Angstrom resolution crystal structure of dihydroorotase (pyrC) from Salmonella enterica subsp. enterica serovar Typhimurium str. LT2 3KQF ; 1.8 ; 1.8 Angstrom Resolution Crystal Structure of Enoyl-CoA Hydratase from Bacillus anthracis. 3TE9 ; 1.8 ; 1.8 Angstrom Resolution Crystal Structure of K135M Mutant of Transaldolase B (TalA) from Francisella tularensis in Complex with Fructose 6-phosphate 3RU6 ; 1.8 ; 1.8 Angstrom resolution crystal structure of orotidine 5'-phosphate decarboxylase (pyrF) from Campylobacter jejuni subsp. jejuni NCTC 11168 4E0C ; 1.8 ; 1.8 Angstrom Resolution Crystal Structure of Transaldolase from Francisella tularensis (phosphate-free) 3NE4 ; 1.81 ; 1.8 Angstrom structure of intact native wild-type alpha-1-antitrypsin 1MI3 ; 1.8 ; 1.8 Angstrom structure of xylose reductase from Candida tenuis in complex with NADH 1HXN ; 1.8 ; 1.8 ANGSTROMS CRYSTAL STRUCTURE OF THE C-TERMINAL DOMAIN OF RABBIT SERUM HEMOPEXIN 1TPH ; 1.8 ; 1.8 ANGSTROMS CRYSTAL STRUCTURE OF WILD TYPE CHICKEN TRIOSEPHOSPHATE ISOMERASE-PHOSPHOGLYCOLOHYDROXAMATE COMPLEX 1GLP ; 1.9 ; 1.8 ANGSTROMS MOLECULAR STRUCTURE OF MOUSE LIVER CLASS PI GLUTATHIONE S-TRANSFERASE COMPLEXED WITH S-(P-NITROBENZYL)GLUTATHIONE AND OTHER INHIBITORS 1GLQ ; 1.8 ; 1.8 ANGSTROMS MOLECULAR STRUCTURE OF MOUSE LIVER CLASS PI GLUTATHIONE S-TRANSFERASE COMPLEXED WITH S-(P-NITROBENZYL)GLUTATHIONE AND OTHER INHIBITORS 3O76 ; 1.77 ; 1.8 Angstroms molecular structure of mouse liver glutathione S-transferase mutant C47A complexed with S-(P-nitrobenzyl)glutathione 1THG ; 1.8 ; 1.8 ANGSTROMS REFINED STRUCTURE OF THE LIPASE FROM GEOTRICHUM CANDIDUM 3VCZ ; 1.8 ; 1.80 Angstrom resolution crystal structure of a putative translation initiation inhibitor from Vibrio vulnificus CMCP6 3UWQ ; 1.8 ; 1.80 Angstrom resolution crystal structure of orotidine 5'-phosphate decarboxylase from Vibrio cholerae O1 biovar eltor str. N16961 in complex with uridine-5'-monophosphate (UMP) 4JM7 ; 1.824 ; 1.82 Angstrom resolution crystal structure of holo-(acyl-carrier-protein) synthase (acpS) from Staphylococcus aureus 3OYT ; 1.84 ; 1.84 Angstrom resolution crystal structure of 3-oxoacyl-(acyl carrier protein) synthase I (fabB) from Yersinia pestis CO92 1ODO ; 1.85 ; 1.85 A STRUCTURE OF CYP154A1 FROM STREPTOMYCES COELICOLOR A3(2) 2ID9 ; 1.75 ; 1.85 A Structure of T87I/Y106W Phosphono-CheY 4EGD ; 1.85 ; 1.85 Angstrom crystal structure of native hypothetical protein SAOUHSC_02783 from Staphylococcus aureus 3GC2 ; 1.85 ; 1.85 Angstrom Crystal Structure of O-succinylbenzoate Synthase from Salmonella typhimurium in Complex with Succinic Acid 4IR8 ; 1.85 ; 1.85 Angstrom Crystal Structure of Putative Sedoheptulose-1,7 bisphosphatase from Toxoplasma gondii 3L2I ; 1.85 ; 1.85 Angstrom Crystal Structure of the 3-Dehydroquinate Dehydratase (aroD) from Salmonella typhimurium LT2. 1U6E ; 1.85 ; 1.85 Angstrom Crystal Structure of the C112A Mutant of Mycobacterium Tuberculosis Beta-Ketoacyl-Acyl Carrier Protein Synthase III (FabH) 4EDP ; 1.85 ; 1.85 Angstrom resolution crystal structure of an ABC transporter from Clostridium perfringens ATCC 13124 3FG0 ; 1.85 ; 1.85 Angstrom resolution crystal structure of betaine aldehyde dehydrogenase (betB) from Staphylococcus aureus (idp00699) in complex with NAD+ 3QM3 ; 1.85 ; 1.85 Angstrom Resolution Crystal Structure of Fructose-bisphosphate Aldolase (Fba) from Campylobacter jejuni 3IGX ; 1.85 ; 1.85 Angstrom Resolution Crystal Structure of Transaldolase B (talA) from Francisella tularensis. 3R2L ; 1.85 ; 1.85A resolution structure of Iron Soaked FtnA from Pseudomonas aeruginosa (pH 7.5) 1XFK ; 1.8 ; 1.8A crsytal strucutre of formiminoglutamase from Vibrio cholerae O1 biovar eltor str. N16961 3T5N ; 1.787 ; 1.8A crystal structure of Lassa virus nucleoprotein in complex with ssRNA 2BWM ; 1.8 ; 1.8A CRYSTAL STRUCTURE OF OF PSATHYRELLA VELUTINA LECTIN IN COMPLEX WITH METHYL 2-ACETAMIDO-1,2-DIDEOXY-1-SELENO-BETA-D-GLUCOPYRANOSIDE 2C25 ; 1.8 ; 1.8A CRYSTAL STRUCTURE OF PSATHYRELLA VELUTINA LECTIN IN COMPLEX WITH N-ACETYLNEURAMINIC ACID 1HUQ ; 1.8 ; 1.8A CRYSTAL STRUCTURE OF THE MONOMERIC GTPASE RAB5C (MOUSE) 2PST ; 1.8 ; 1.8A Crystal Structure of the PA2412 protein from Pseudomonas aeruginosa 3QH6 ; 1.8 ; 1.8A resolution structure of CT296 from Chlamydia trachomatis 3R2M ; 1.8 ; 1.8A resolution structure of Doubly Soaked FtnA from Pseudomonas aeruginosa (pH 7.5) 1LJ5 ; 1.8 ; 1.8A Resolution Structure of Latent Plasminogen Activator Inhibitor-1(PAI-1) 1IG1 ; 1.8 ; 1.8A X-Ray structure of ternary complex of a catalytic domain of death-associated protein kinase with ATP analogue and Mn. 1Y7P ; 1.9 ; 1.9 A Crystal Structure of a Protein of Unknown Function AF1403 from Archaeoglobus fulgidus, Probable Metabolic Regulator 1T06 ; 1.9 ; 1.9 A Crystal Structure of a Protein of Unknown Function from Bacillus cereus ATCC 14579 4HJZ ; 1.9 ; 1.9 A Crystal structure of E. coli MltE-E64Q with bound chitopentaose 1VTO ; 1.9 ; 1.9 A RESOLUTION REFINED STRUCTURE OF TBP RECOGNIZING THE MINOR GROOVE OF TATAAAAG 3NJ7 ; 1.904 ; 1.9 A resolution X-ray structure of (GGCAGCAGCC)2 1C4W ; 1.84 ; 1.9 A STRUCTURE OF A-THIOPHOSPHONATE MODIFIED CHEY D57C 4FCU ; 1.9 ; 1.9 Angstrom Crystal Structure of 3-deoxy-manno-octulosonate Cytidylyltransferase (kdsB) from Acinetobacter baumannii without His-Tag Bound to the Active Site 1O0E ; 1.9 ; 1.9 Angstrom Crystal Structure of a plant cysteine protease Ervatamin C 2YHF ; 1.9 ; 1.9 ANGSTROM CRYSTAL STRUCTURE OF CLEC5A 3G25 ; 1.9 ; 1.9 Angstrom Crystal Structure of Glycerol Kinase (glpK) from Staphylococcus aureus in Complex with Glycerol. 3MJD ; 1.9 ; 1.9 Angstrom Crystal Structure of Orotate Phosphoribosyltransferase (pyrE) Francisella tularensis. 3EIF ; 1.9 ; 1.9 angstrom crystal structure of the active form of the C5a peptidase from Streptococcus pyogenes (ScpA) 1Z9O ; 1.9 ; 1.9 Angstrom Crystal Structure of the Rat VAP-A MSP Homology Domain in Complex with the Rat ORP1 FFAT Motif 2AFQ ; 1.93 ; 1.9 angstrom crytal structure of wild-type human thrombin in the sodium free state 3HMQ ; 1.9 ; 1.9 Angstrom resolution crystal structure of a NAD synthetase (nadE) from Salmonella typhimurium LT2 in complex with NAD(+) 2PNS ; 1.9 ; 1.9 Angstrom resolution crystal structure of a plant cysteine protease Ervatamin-C refinement with cDNA derived amino acid sequence 4EG9 ; 1.9 ; 1.9 Angstrom resolution crystal structure of Se-methionine hypothetical protein SAOUHSC_02783 from Staphylococcus aureus 3V85 ; 1.9 ; 1.9 Angstrom resolution crystal structure of the protein Q9SIY3 from Arabidopsis thaliana 1EQ6 ; 1.9 ; 1.9 ANGSTROM RESOLUTION CRYSTAL STRUCTURE OF THE SACCHAROMYCES CEREVISIAE RAN-BINDING PROTEIN MOG1P 4KMQ ; 1.9 ; 1.9 Angstrom resolution crystal structure of uncharacterized protein lmo2446 from Listeria monocytogenes EGD-e 1FAS ; 1.8 ; 1.9 ANGSTROM RESOLUTION STRUCTURE OF FASCICULIN 1, AN ANTI-ACETYLCHOLINESTERASE TOXIN FROM GREEN MAMBA SNAKE VENOM 1XW6 ; 1.9 ; 1.9 angstrom resolution structure of human glutathione S-transferase M1A-1A complexed with glutathione 3FZI ; 1.9 ; 1.9 Angstrom structure of the thermophilic exonuclease III homologue Mth0212 3TI2 ; 1.9 ; 1.90 Angstrom resolution crystal structure of N-terminal domain 3-phosphoshikimate 1-carboxyvinyltransferase from Vibrio cholerae 3TU3 ; 1.92 ; 1.92 Angstrom resolution crystal structure of the full-length SpcU in complex with full-length ExoU from the type III secretion system of Pseudomonas aeruginosa 1O6Z ; 1.95 ; 1.95 A RESOLUTION STRUCTURE OF (R207S,R292S) MUTANT OF MALATE DEHYDROGENASE FROM THE HALOPHILIC ARCHAEON HALOARCULA MARISMORTUI (HOLO FORM) 3R2O ; 1.95 ; 1.95 A resolution structure of As-Isolated FtnA from Pseudomonas aeruginosa (pH 6.0) 1SUG ; 1.95 ; 1.95 A structure of apo protein tyrosine phosphatase 1B 3NVT ; 1.95 ; 1.95 Angstrom crystal structure of a bifunctional 3-deoxy-7-phosphoheptulonate synthase/chorismate mutase (aroA) from Listeria monocytogenes EGD-e 3TFC ; 1.95 ; 1.95 Angstrom crystal structure of a bifunctional 3-deoxy-7-phosphoheptulonate synthase/chorismate mutase (aroA) from Listeria monocytogenes EGD-e in complex with phosphoenolpyruvate 1ZDE ; 1.95 ; 1.95 Angstrom Crystal Structure of a dnaE Intein Precursor from Synechocystis Sp. Pcc 6803 3III ; 1.95 ; 1.95 Angstrom Crystal Structure of CocE/NonD family hydrolase (SACOL2612) from Staphylococcus aureus 3HVU ; 1.95 ; 1.95 Angstrom Crystal Structure of Complex of Hypoxanthine-Guanine Phosphoribosyltransferase from Bacillus anthracis with 2-(N-morpholino)ethanesulfonic acid (MES) 4JBE ; 1.95 ; 1.95 Angstrom Crystal Structure of Gamma-glutamyl phosphate Reductase from Saccharomonospora viridis. 4H3D ; 1.95 ; 1.95 Angstrom Crystal Structure of of Type I 3-Dehydroquinate Dehydratase (aroD) from Clostridium difficile with Covalent Modified Comenic Acid. 3T4E ; 1.95 ; 1.95 Angstrom Crystal Structure of Shikimate 5-dehydrogenase (AroE) from Salmonella enterica subsp. enterica serovar Typhimurium in Complex with NAD 4GUH ; 1.95 ; 1.95 Angstrom Crystal Structure of the Salmonella enterica 3-Dehydroquinate Dehydratase (aroD) E86A Mutant in Complex with Dehydroshikimate (Crystal Form #2) 3IJ5 ; 1.95 ; 1.95 Angstrom Resolution Crystal Structure of 3-deoxy-D-manno-octulosonate 8-phosphate phosphatase from Yersinia pestis 3T41 ; 1.95 ; 1.95 Angstrom Resolution Crystal Structure of Epidermin Leader Peptide Processing Serine Protease (EpiP) S393A Mutant from Staphylococcus aureus 4DB3 ; 1.95 ; 1.95 Angstrom Resolution Crystal Structure of N-acetyl-D-glucosamine kinase from Vibrio vulnificus. 3INO ; 1.95 ; 1.95A Resolution Structure of Protective Antigen Domain 4 1U18 ; 1.96 ; 1.96 A Crystal structure of H60C mutant of nitrophorin complexed with histamine 1M5W ; 1.96 ; 1.96 A Crystal Structure of Pyridoxine 5'-Phosphate Synthase in Complex with 1-deoxy-D-xylulose phosphate 2I5N ; 1.96 ; 1.96 A X-ray structure of photosynthetic reaction center from Rhodopseudomonas viridis:Crystals grown by microfluidic technique 3O7M ; 1.98 ; 1.98 Angstrom resolution crystal structure of a hypoxanthine-guanine phosphoribosyltransferase (hpt-2) from Bacillus anthracis str. 'Ames Ancestor' 3IMF ; 1.99 ; 1.99 Angstrom resolution crystal structure of a short chain dehydrogenase from Bacillus anthracis str. 'Ames Ancestor' 1YDP ; 1.9 ; 1.9A crystal structure of HLA-G 1R4V ; 1.9 ; 1.9A crystal structure of protein AQ328 from Aquifex aeolicus 1SFL ; 1.9 ; 1.9A Crystal structure of Staphylococcus aureus type I 3-dehydroquinase, apo form 1G6L ; 1.9 ; 1.9A CRYSTAL STRUCTURE OF TETHERED HIV-1 PROTEASE 1XBW ; 1.9 ; 1.9A Crystal Structure of the protein isdG from Staphylococcus aureus aureus, Structural genomics, MCSG 3ENK ; 1.9 ; 1.9A crystal structure of udp-glucose 4-epimerase from burkholderia pseudomallei 3D03 ; 1.9 ; 1.9A structure of Glycerophoshphodiesterase (GpdQ) from Enterobacter aerogenes 1CE1 ; 1.9 ; 1.9A STRUCTURE OF THE THERAPEUTIC ANTIBODY CAMPATH-1H FAB IN COMPLEX WITH A SYNTHETIC PEPTIDE ANTIGEN 2P1Y ; 2.42 ; 1.B2.D9, a bispecific alpha/beta TCR 1K43 ; ; 10 Structure Ensemble of the 14-residue peptide RG-KWTY-NG-ITYE-GR (MBH12) 2GPN ; 1.99 ; 100 K STRUCTURE OF GLYCOGEN PHOSPHORYLASE AT 2.0 ANGSTROMS RESOLUTION 4GCB ; 1.8 ; 100K X-ray diffraction study of a 6-fold molar excess of a cisplatin/carboplatin mixture binding to HEWL 4G4H ; 2 ; 100K X-ray diffraction study of carboplatin binding to HEWL in DMSO media after 13 months of crystal storage 3BEW ; 2.6 ; 10mer Crystal Structure of chicken MHC class I haplotype B21 2JSI ; ; 11-23 obestatin fragment in DPC/SDS micellar solution 1FYI ; ; 11-MER DNA DUPLEX CONTAINING A 2'-DEOXYARISTEROMYCIN 8-OXO-GUANINE BASE PAIR; 3BEV ; 2.1 ; 11mer Structure of an MHC class I molecule from B21 chickens illustrate promiscuous peptide binding 1Q45 ; 2 ; 12-0xo-phytodienoate reductase isoform 3 1BSO ; 2.23 ; 12-BROMODODECANOIC ACID BINDS INSIDE THE CALYX OF BOVINE BETA-LACTOGLOBULIN 1RSX ; ; 12-mer from site II calbindin D9K (DKNGDGEVSFEE) coordinating Cd(II) 1RT0 ; ; 12-mer from site II calbindin D9K (DKNGDGEVSFEE) coordinating Zn(II) 1RSW ; ; 12-mer from site II calbindin D9K (DKNGDGEVSFEE) coordination Pb(II) 2B8K ; 4.15 ; 12-subunit RNA Polymerase II 3FKI ; 3.88 ; 12-Subunit RNA Polymerase II Refined with Zn-SAD data 3RYG ; 1.75 ; 128 hours neutron structure of perdeuterated rubredoxin 1ZJE ; 2.1 ; 12mer-spd 1ZJF ; 2.2 ; 12mer-spd-P4N 2IWP ; 2.15 ; 12TH PDZ DOMAIN OF MULTIPLE PDZ DOMAIN PROTEIN MPDZ (CASP TARGET) 2IWO ; 1.7 ; 12th PDZ domain of Multiple PDZ Domain Protein MPDZ (CASP Target) 2OTJ ; 2.9 ; 13-deoxytedanolide bound to the large subunit of Haloarcula marismortui 2HSS ; ; 13mer duplex DNA containg an abasic site with beta anomer, averaged structure 2HPX ; ; 13mer Duplex DNA containing a 4'-oxidized abasic site, averaged structure 2HSR ; ; 13mer duplex DNA containing an abasic site with beta anomer 1ZJG ; 3 ; 13mer-co 4BG6 ; 2.3 ; 14-3-3 interaction with Rnd3 prenyl-phosphorylation motif 4FJ3 ; 1.95 ; 14-3-3 isoform zeta in complex with a diphoyphorylated C-RAF peptide 2BQ0 ; 2.5 ; 14-3-3 PROTEIN BETA (HUMAN) 2C23 ; 2.65 ; 14-3-3 PROTEIN BETA (HUMAN) IN COMPLEX WITH EXOENZYME S PEPTIDE 2BR9 ; 1.75 ; 14-3-3 PROTEIN EPSILON (HUMAN) COMPLEXED TO PEPTIDE 2C63 ; 2.15 ; 14-3-3 PROTEIN ETA (HUMAN) COMPLEXED TO PEPTIDE 2C74 ; 2.7 ; 14-3-3 PROTEIN ETA (HUMAN) COMPLEXED TO PEPTIDE 4JC3 ; 2.05 ; 14-3-3 protein interaction with Estrogen Receptor Alpha provides a novel drug target interface 4JDD ; 2.1 ; 14-3-3 protein interaction with Estrogen Receptor Alpha provides a novel drug target interface 2BTP ; 2.8 ; 14-3-3 PROTEIN THETA (HUMAN) COMPLEXED TO PEPTIDE 1A37 ; 3.6 ; 14-3-3 PROTEIN ZETA BOUND TO PS-RAF259 PEPTIDE 1A38 ; 3.35 ; 14-3-3 PROTEIN ZETA BOUND TO R18 PEPTIDE 2V7D ; 2.5 ; 14-3-3 PROTEIN ZETA IN COMPLEX WITH THR758 PHOSPHORYLATED INTEGRIN BETA2 PEPTIDE 1A4O ; 2.8 ; 14-3-3 PROTEIN ZETA ISOFORM 3MHR ; 1.15 ; 14-3-3 sigma in complex with YAP pS127-peptide 1QJB ; 2 ; 14-3-3 ZETA/PHOSPHOPEPTIDE COMPLEX (MODE 1) 1QJA ; 2 ; 14-3-3 ZETA/PHOSPHOPEPTIDE COMPLEX (MODE 2) 1B4L ; 1.8 ; 15 ATMOSPHERE OXYGEN YEAST CU/ZN SUPEROXIDE DISMUTASE ROOM TEMPERATURE (298K) STRUCTURE 3BPP ; 2.3 ; 1510-N membrane protease K138A mutant specific for a stomatin homolog from Pyrococcus horikoshii 2DEO ; 3 ; 1510-N membrane protease specific for a stomatin homolog from Pyrococcus horikoshii 3VIV ; 2.25 ; 1510-N membrane-bound stomatin-specific protease K138A mutant in complex with a substrate peptide 1AT0 ; 1.9 ; 17-kDA fragment of hedgehog C-terminal autoprocessing domain 3KLP ; 2.5 ; 17beta-HSD1 in complex with A-diol 3KLM ; 1.7 ; 17beta-HSD1 in complex with DHT 3HB4 ; 2.21 ; 17beta-hydroxysteroid dehydrogenase type1 complexed with E2B 3KM0 ; 2.3 ; 17betaHSD1 in complex with 3beta-diol 1GV8 ; 1.95 ; 18 KDA FRAGMENT OF N-II DOMAIN OF DUCK OVOTRANSFERRIN 1ZNT ; ; 18 NMR structures of AcAMP2-Like Peptide with non Natural Fluoroaromatic Residue (AcAMP2F18Pff/Y20Pff) complex with N,N,N-triacetylchitotriose 1NP8 ; 2 ; 18-k C-terminally trunucated small subunit of calpain 1GVC ; 1.9 ; 18KDA N-II DOMAIN FRAGMENT OF DUCK OVOTRANSFERRIN + NTA 1RUZ ; 2.9 ; 1918 H1 Hemagglutinin 1RVT ; 2.5 ; 1930 H1 Hemagglutinin in complex with LSTC 1RUY ; 2.7 ; 1930 Swine H1 Hemagglutinin 1RV0 ; 2.5 ; 1930 Swine H1 Hemagglutinin complexed with LSTA 1RVX ; 2.2 ; 1934 H1 Hemagglutinin in complex with LSTA 1RVZ ; 2.25 ; 1934 H1 Hemagglutinin in complex with LSTC 1RU7 ; 2.3 ; 1934 Human H1 Hemagglutinin 1FYH ; 2.04 ; 1:1 COMPLEX BETWEEN AN INTERFERON GAMMA SINGLE-CHAIN VARIANT AND ITS RECEPTOR 1HWH ; 2.9 ; 1:1 COMPLEX OF HUMAN GROWTH HORMONE MUTANT G120R WITH ITS SOLUBLE BINDING PROTEIN 1HWG ; 2.5 ; 1:2 COMPLEX OF HUMAN GROWTH HORMONE WITH ITS SOLUBLE BINDING PROTEIN 1EN3 ; 0.985 ; 1A CRYSTAL STRUCTURES OF B-DNA REVEAL SEQUENCE-SPECIFIC BINDING AND GROOVE-SPECIFIC BENDING OF DNA BY MAGNESIUM AND CALCIUM 1EN9 ; 0.985 ; 1A CRYSTAL STRUCTURES OF B-DNA REVEAL SEQUENCE-SPECIFIC BINDING AND GROOVE-SPECIFIC BENDING OF DNA BY MAGNESIUM AND CALCIUM. 1ENE ; 0.985 ; 1A CRYSTAL STRUCTURES OF B-DNA REVEAL SEQUENCE-SPECIFIC BINDING AND GROOVE-SPECIFIC BENDING OF DNA BY MAGNESIUM AND CALCIUM. 2B5R ; 1.65 ; 1B Lactamase / B Lactamase Inhibitor 1S0W ; 2.3 ; 1b Lactamse/ b Lactamase Inhibitor 3UTP ; 2.574 ; 1E6 TCR specific for HLA-A*0201-ALWGPDPAAA 3UTS ; 2.712 ; 1E6-A*0201-ALWGPDPAAA Complex, Monoclinic 3UTT ; 2.6 ; 1E6-A*0201-ALWGPDPAAA Complex, Triclinic 3MFF ; 2 ; 1F1E8hu TCR 1SRL ; ; 1H AND 15N ASSIGNMENTS AND SECONDARY STRUCTURE OF THE SRC SH3 DOMAIN 1SRM ; ; 1H AND 15N ASSIGNMENTS AND SECONDARY STRUCTURE OF THE SRC SH3 DOMAIN 2LCN ; ; 1H and 15N assignments of WALP19-P10 peptide in SDS micelles 2LCO ; ; 1H and 15N assignments of WALP19-P8 peptide in SDS micelles 1DOX ; ; 1H AND 15N SEQUENTIAL ASSIGNMENT, SECONDARY STRUCTURE AND TERTIARY FOLD OF [2FE-2S] FERREDOXIN FROM SYNECHOCYSTIS SP. PCC 6803 1DOY ; ; 1H AND 15N SEQUENTIAL ASSIGNMENT, SECONDARY STRUCTURE AND TERTIARY FOLD OF [2FE-2S] FERREDOXIN FROM SYNECHOCYSTIS SP. PCC 6803 2L1J ; ; 1H assignments for ASIP(93-126, P103A, P105A, P111A, Q115Y, S124Y) 2LDJ ; ; 1H Chemical Shift Assignments and structure of Trp-Cage mini-protein with D-amino acid 2LR5 ; ; 1H chemical shift assignments for micasin 2LS2 ; ; 1H Chemical Shift Assignments for the first transmembrane domain from human copper transport 1 2LS3 ; ; 1H Chemical Shift Assignments for the secondary transmembrane domain from human copper transport 1 2LS4 ; ; 1H Chemical Shift Assignments for the third transmembrane domain from the human copper transport 1 1BJ6 ; ; 1H NMR OF (12-53) NCP7/D(ACGCC) COMPLEX, 10 STRUCTURES 1DF6 ; ; 1H NMR SOLUTION STRUCTURE OF CYCLOVIOLACIN O1 1Q3M ; ; 1H NMR structure bundle of bovine Ca2+-osteocalcin 1ORL ; ; 1H NMR structure determination of Viscotoxin C1 1Y9O ; ; 1H NMR Structure of Acylphosphatase from the hyperthermophile Sulfolobus Solfataricus 1MMC ; ; 1H NMR STUDY OF THE SOLUTION STRUCTURE OF AC-AMP2 2KWA ; ; 1H, 13C and 15N backbone and side chain resonance assignments of the N-terminal domain of the histidine kinase inhibitor KipI from Bacillus subtilis 2KXC ; ; 1H, 13C, and 15N Chemical Shift Assignments for IRTKS-SH3 and EspFu-R47 complex 2RS2 ; ; 1H, 13C, and 15N Chemical Shift Assignments for Musashi1 RBD1:r(GUAGU) complex 2LI6 ; ; 1H, 13C, and 15N Chemical Shift Assignments for yeast protein 2L07 ; ; 1H, 13C, and 15N chemical shifts and structure of brazzein-derived peptide CKR-PNG 2K0A ; ; 1H, 15N and 13C chemical shift assignments for Rds3 protein 1ESX ; ; 1H, 15N AND 13C STRUCTURE OF THE HIV-1 REGULATORY PROTEIN VPR : COMPARISON WITH THE N-AND C-TERMINAL DOMAIN STRUCTURE, (1-51)VPR AND (52-96)VPR 2KYQ ; ; 1H, 15N, 13C chemical shifts and structure of CKR-brazzein 2AIH ; ; 1H-NMR solution structure of a trypsin/chymotrypsin Bowman-Birk inhibitor from Lens culinaris. 1G47 ; ; 1ST LIM DOMAIN OF PINCH PROTEIN 2J9V ; 2 ; 2 ANGSTROM X-RAY STRUCTURE OF THE YEAST ESCRT-I VPS28 C-TERMINUS 2J9U ; 2 ; 2 ANGSTROM X-RAY STRUCTURE OF THE YEAST ESCRT-I VPS28 C-TERMINUS IN COMPLEX WITH THE NZF-N DOMAIN FROM ESCRT-II 3ETO ; 2 ; 2 Angstrom Xray structure of the NOTCH1 Negative Regulatory Region (NRR) 2W52 ; 1.56 ; 2 beta-glucans (6-O-glucosyl-laminaritriose) in both donor and acceptor sites of GH16 Laminarinase 16A from Phanerochaete chrysosporium. 4A3H ; 1.65 ; 2',4' DINITROPHENYL-2-DEOXY-2-FLURO-B-D-CELLOBIOSIDE COMPLEX OF THE ENDOGLUCANASE CEL5A FROM BACILLUS AGARADHAERENS AT 1.6 A RESOLUTION 1BHR ; ; 2'-DEOXY-ISOGUANOSINE BASE PAIRED TO THYMIDINE, NMR, MINIMIZED AVERAGE STRUCTURE 2DLJ ; 1.5 ; 2'-Me-Se and Br Derivitation of A-DNA Octamer G(UMS)G(BRU)ACAC 2GPX ; 1.6 ; 2'-Me-Se and Br Derivitation of A-DNA Octamer G(UMS)G(BRU)ACAC 1Z7I ; 1.28 ; 2'-Me-Se Derivitation of A-DNA Octamer G(UMSe)GTACAC 2HC7 ; 1.4 ; 2'-selenium-T A-DNA [G(TSe)GTACAC] 3IFF ; 1.75 ; 2'-SeMe-A modified DNA decamer 3IFI ; 1.2 ; 2'-SeMe-dG modified octamer DNA 3P4A ; 1.2 ; 2'Fluoro modified RNA octamer fA2U2 1EIL ; 2 ; 2,3-DIHYDROXYBIPHENYL-1,2-DIOXYGENASE 1EIQ ; 2 ; 2,3-DIHYDROXYBIPHENYL-1,2-DIOXYGENASE 1EIR ; 2 ; 2,3-DIHYDROXYBIPHENYL-1,2-DIOXYGENASE 4G5E ; 2.5 ; 2,4,6-Trichlorophenol 4-monooxygenase 4HUZ ; 2.6 ; 2,6-Dichloro-p-hydroquinone 1,2-Dioxygenase 2RB0 ; 1.84 ; 2,6-difluorobenzylbromide complex with T4 lysozyme L99A 4JPG ; 2.33 ; 2-((1H-benzo[d]imidazol-1-yl)methyl)-4H-pyrido[1,2-a]pyrimidin-4-ones as Novel PKM2 Activators 2R2M ; 2.1 ; 2-(2-Chloro-6-Fluorophenyl)Acetamides as Potent Thrombin Inhibitors 2RBP ; 1.467 ; 2-(n-propylthio)ethanol in complex with T4 lysozyme L99A/M102Q 3BYZ ; 2.69 ; 2-Amino-1,3-thiazol-4(5H)-ones as Potent and Selective 11-Hydroxysteroid Dehydrogenase Type 1 Inhibitors 1FC4 ; 2 ; 2-AMINO-3-KETOBUTYRATE COA LIGASE 2KUZ ; ; 2-Aminopurine incorporation perturbs the dynamics and structure of DNA 2KV0 ; ; 2-Aminopurine incorporation perturbs the dynamics and structure of DNA 3IO7 ; 2.6 ; 2-Aminopyrazolo[1,5-a]pyrimidines as potent and selective inhibitors of JAK2 3IOK ; 2.1 ; 2-Aminopyrazolo[1,5-a]pyrimidines as potent and selective inhibitors of JAK2 3GHZ ; 2.03 ; 2-C-methyl-D-erythritol 2,4-cyclodiphosphate synthase from Salmonella typhimurium 1DXE ; 1.8 ; 2-DEHYDRO-3-DEOXY-GALACTARATE ALDOLASE FROM ESCHERICHIA COLI 1DXF ; 2.6 ; 2-DEHYDRO-3-DEOXY-GALACTARATE ALDOLASE FROM ESCHERICHIA COLI IN COMPLEX WITH PYRUVATE 1E4I ; 2 ; 2-DEOXY-2-FLUORO-BETA-D-GLUCOSYL/ENZYME INTERMEDIATE COMPLEX OF THE BETA-GLUCOSIDASE FROM BACILLUS POLYMYXA 5A3H ; 1.82 ; 2-DEOXY-2-FLURO-B-D-CELLOBIOSYL/ENZYME INTERMEDIATE COMPLEX OF THE ENDOGLUCANASE CEL5A FROM BACILLUS AGARADHEARANS AT 1.8 ANGSTROMS RESOLUTION 1H11 ; 1.08 ; 2-DEOXY-2-FLURO-B-D-CELLOTRIOSYL/ENZYME INTERMEDIATE COMPLEX OF THE ENDOGLUCANASE CEL5A FROM BACILLUS AGARADHEARANS AT 1.08 ANGSTROM RESOLUTION 6A3H ; 1.68 ; 2-DEOXY-2-FLURO-B-D-CELLOTRIOSYL/ENZYME INTERMEDIATE COMPLEX OF THE ENDOGLUCANASE CEL5A FROM BACILLUS AGARADHEARANS AT 1.6 ANGSTROM RESOLUTION 1DUB ; 2.5 ; 2-ENOYL-COA HYDRATASE, DATA COLLECTED AT 100 K, PH 6.5 3HTG ; 1.26 ; 2-ethoxy-3,4-dihydro-2h-pyran in complex with T4 lysozyme L99A/M102Q 2RB1 ; 1.7 ; 2-ethoxyphenol in complex with T4 lysozyme L99A 3HU8 ; 1.8 ; 2-ethoxyphenol in complex with T4 lysozyme L99A/M102Q 3HT7 ; 1.7 ; 2-ethylphenol in complex with T4 lysozyme L99A/M102Q 1E70 ; 1.65 ; 2-F-GLUCOSYLATED MYROSINASE FROM SINAPIS ALBA 1E73 ; 1.5 ; 2-F-GLUCOSYLATED MYROSINASE FROM SINAPIS ALBA WITH BOUND L-ASCORBATE 1C4X ; 2.4 ; 2-HYDROXY-6-OXO-6-PHENYLHEXA-2,4-DIENOATE HYDROLASE (BPHD) FROM RHODOCOCCUS SP. STRAIN RHA1 2KH0 ; ; 2-Hydroxy-7-nitrofluorene covalently linked into a 13mer DNA duplex - solution structure of the face-down orientation 2KH1 ; ; 2-Hydroxy-7-nitrofluorene covalently linked into a 13mer DNA duplex - solution structure of the face-up orientation 2IME ; 1.7 ; 2-Hydroxychromene-2-carboxylate Isomerase: a Kappa Class Glutathione-S-Transferase from Pseudomonas putida 2IMF ; 1.3 ; 2-Hydroxychromene-2-carboxylate Isomerase: a Kappa Class Glutathione-S-Transferase from Pseudomonas putida 2Q18 ; 2.1 ; 2-keto-3-deoxy-D-arabinonate dehydratase 2Q19 ; 3 ; 2-keto-3-deoxy-D-arabinonate dehydratase apo form 2Q1C ; 2.8 ; 2-keto-3-deoxy-D-arabinonate dehydratase complexed with calcium and 2-oxobutyrate 2Q1D ; 2.7 ; 2-keto-3-deoxy-D-arabinonate dehydratase complexed with magnesium and 2,5-dioxopentanoate 2Q1A ; 2.5 ; 2-keto-3-deoxy-D-arabinonate dehydratase complexed with magnesium and 2-oxobutyrate 2NUY ; 2.5 ; 2-keto-3-deoxygluconate aldolase from Sulfolobus acidocaldarius in complex with pyruvate 2NUW ; 1.8 ; 2-keto-3-deoxygluconate aldolase from Sulfolobus acidocaldarius, native structure at 1.8 A resolution 2NUX ; 2.5 ; 2-keto-3-deoxygluconate aldolase from Sulfolobus acidocaldarius, native structure in p6522 at 2.5 A resolution 1V19 ; 2.3 ; 2-KETO-3-DEOXYGLUCONATE KINASE FROM THERMUS THERMOPHILUS 1V1S ; 3.2 ; 2-KETO-3-DEOXYGLUCONATE KINASE FROM THERMUS THERMOPHILUS (CRYSTAL FORM 2) 1V1A ; 2.1 ; 2-KETO-3-DEOXYGLUCONATE KINASE FROM THERMUS THERMOPHILUS WITH BOUND 2-KETO-3-DEOXYGLUCONATE AND ADP 1V1B ; 2.6 ; 2-KETO-3-DEOXYGLUCONATE KINASE FROM THERMUS THERMOPHILUS WITH BOUND ATP 1W37 ; 2 ; 2-KETO-3-DEOXYGLUCONATE(KDG) ALDOLASE OF SULFOLOBUS SOLFATARICUS 3HT9 ; 2.02 ; 2-methoxyphenol in complex with T4 lysozyme L99A/M102Q 3HT6 ; 1.59 ; 2-methylphenol in complex with T4 lysozyme L99A/M102Q 2RBO ; 1.29 ; 2-nitrothiophene in complex with T4 lysozyme L99A/M102Q 1Z01 ; 1.8 ; 2-Oxoquinoline 8-Monooxygenase Component: Active site Modulation by Rieske-[2fe-2S] Center Oxidation/Reduction 1Z02 ; 1.8 ; 2-Oxoquinoline 8-Monooxygenase Component: Active site Modulation by Rieske-[2fe-2S] Center Oxidation/Reduction 1Z03 ; 1.8 ; 2-Oxoquinoline 8-Monooxygenase Component: Active site Modulation by Rieske-[2fe-2S] Center Oxidation/Reduction 2RBR ; 1.433 ; 2-phenoxyethanol in complex with T4 lysozyme L99A/M102Q 3HTB ; 1.81 ; 2-propylphenol in complex with T4 lysozyme L99A/M102Q 1EE0 ; 2.05 ; 2-PYRONE SYNTHASE COMPLEXED WITH ACETOACETYL-COA 2ZL9 ; 1.9 ; 2-Substituted-16-ene-22-thia-1alpha,25-dihydroxy-26,27-dimethyl-19-norvitamin D3 analogs: Synthesis, biological evaluation and crystal structure 2ZLA ; 2 ; 2-Substituted-16-ene-22-thia-1alpha,25-dihydroxy-26,27-dimethyl-19-norvitamin D3 analogs: Synthesis, biological evaluation and crystal structure 2ZLC ; 2 ; 2-Substituted-16-ene-22-thia-1alpha,25-dihydroxy-26,27-dimethyl-19-norvitamin D3 analogs: Synthesis, biological evaluation and crystal structure 1R7L ; 2 ; 2.0 A Crystal Structure of a Phage Protein from Bacillus cereus ATCC 14579 1TWU ; 2 ; 2.0 A Crystal Structure of a YycE Protein of Unknown Function from Bacillus subtilis, Putative Glyoxalase/Fosfomycin Resistance Protein 1MUU ; 2.02 ; 2.0 A crystal structure of GDP-mannose dehydrogenase 1NG5 ; 2 ; 2.0 A crystal structure of Staphylococcus aureus Sortase B 2BE6 ; 2 ; 2.0 A crystal structure of the CaV1.2 IQ domain-Ca/CaM complex 1DM1 ; 1.99 ; 2.0 A CRYSTAL STRUCTURE OF THE DOUBLE MUTANT H(E7)V, T(E10)R OF MYOGLOBIN FROM APLYSIA LIMACINA 4E6K ; 2 ; 2.0 A resolution structure of Pseudomonas aeruginosa bacterioferritin (BfrB) in complex with bacterioferritin associated ferredoxin (Bfd) 2J5K ; 2 ; 2.0 A RESOLUTION STRUCTURE OF THE WILD TYPE MALATE DEHYDROGENASE FROM HALOARCULA MARISMORTUI (RADIATION DAMAGE SERIES) 1NI9 ; 2 ; 2.0 A structure of glycerol metabolism protein from E. coli 1NIG ; 2 ; 2.0 A Structure of Protein of Unknown Function from Thermoplasma acidophilum 1MI8 ; 2 ; 2.0 Angstrom crystal structure of a DnaB intein from Synechocystis sp. PCC 6803 3H0P ; 2 ; 2.0 Angstrom Crystal Structure of an Acyl Carrier Protein S-malonyltransferase from Salmonella typhimurium. 3NZT ; 2 ; 2.0 Angstrom Crystal structure of Glutamate--Cysteine Ligase (gshA) ftom Francisella tularensis in Complex with AMP 3UN6 ; 2.01 ; 2.0 Angstrom Crystal Structure of Ligand Binding Component of ABC-type Import System from Staphylococcus aureus with Zinc bound 2AYL ; 2 ; 2.0 Angstrom Crystal Structure of Manganese Protoporphyrin IX-reconstituted Ovine Prostaglandin H2 Synthase-1 Complexed With Flurbiprofen 1Q4G ; 2 ; 2.0 Angstrom Crystal Structure of Ovine Prostaglandin H2 Synthase-1, in complex with alpha-methyl-4-biphenylacetic acid 2PD7 ; 2 ; 2.0 Angstrom Crystal Structure of the Fungal Blue-Light Photoreceptor Vivid 1APM ; 2 ; 2.0 ANGSTROM REFINED CRYSTAL STRUCTURE OF THE CATALYTIC SUBUNIT OF CAMP-DEPENDENT PROTEIN KINASE COMPLEXED WITH A PEPTIDE INHIBITOR AND DETERGENT 3IFS ; 2.004 ; 2.0 Angstrom Resolution Crystal Structure of Glucose-6-phosphate Isomerase (pgi) from Bacillus anthracis. 3TK7 ; 2 ; 2.0 Angstrom Resolution Crystal Structure of Transaldolase B (TalA) from Francisella tularensis in Covalent Complex with Fructose 6-Phosphate 1N2Z ; 2 ; 2.0 Angstrom structure of BtuF, the vitamin B12 binding protein of E. coli 1QLP ; 2 ; 2.0 ANGSTROM STRUCTURE OF INTACT ALPHA-1-ANTITRYPSIN: A CANONICAL TEMPLATE FOR ACTIVE SERPINS 3HJK ; 2 ; 2.0 Angstrom Structure of the Ile74Val Variant of Vivid (VVD). 3RLZ ; 2.01 ; 2.0 Angstrom X-ray structure of bovine Ca(2+)-S100B D63N 2AFG ; 2 ; 2.0 ANGSTROM X-RAY STRUCTURE OF HUMAN ACIDIC FIBROBLAST GROWTH FACTOR 2IDM ; 2 ; 2.00 A Structure of T87I/Y106W Phosphono-CheY 3LXM ; 2 ; 2.00 Angstrom resolution crystal structure of a catalytic subunit of an aspartate carbamoyltransferase (pyrB) from Yersinia pestis CO92 3PAJ ; 2 ; 2.00 Angstrom resolution crystal structure of a quinolinate phosphoribosyltransferase from Vibrio cholerae O1 biovar eltor str. N16961 3IMI ; 2.01 ; 2.01 Angstrom resolution crystal structure of a HIT family protein from Bacillus anthracis str. 'Ames Ancestor' 2C3C ; 2.15 ; 2.01 ANGSTROM X-RAY CRYSTAL STRUCTURE OF A MIXED DISULFIDE BETWEEN COENZYME M AND NADPH-DEPENDENT OXIDOREDUCTASE 2-KETOPROPYL COENZYME M CARBOXYLASE 3FGP ; 2.05 ; 2.05 a Crystal Structure of CysM from Mycobacterium Tuberculosis - Open and Closed Conformations 3QFK ; 2.05 ; 2.05 Angstrom Crystal Structure of Putative 5'-Nucleotidase from Staphylococcus aureus in complex with alpha-ketoglutarate 3IJR ; 2.05 ; 2.05 Angstrom resolution crystal structure of a short chain dehydrogenase from Bacillus anthracis str. 'Ames Ancestor' in complex with NAD+ 3INP ; 2.05 ; 2.05 Angstrom Resolution Crystal Structure of D-ribulose-phosphate 3-epimerase from Francisella tularensis. 3QFH ; 2.05 ; 2.05 Angstrom Resolution Crystal Structure of Epidermin Leader Peptide Processing Serine Protease (EpiP) from Staphylococcus aureus. 3GSD ; 2.05 ; 2.05 Angstrom structure of a divalent-cation tolerance protein (CutA) from Yersinia pestis 2GEL ; 2.05 ; 2.05A crystal structure of Salmonella typhimurium YeaZ, form B 3I3O ; 2.06 ; 2.06 Angstrom resolution crystal structure of a short chain dehydrogenase from Bacillus anthracis str. 'Ames Ancestor' in complex with NAD-acetone 4JJP ; 2.056 ; 2.06 Angstrom resolution crystal structure of phosphomethylpyrimidine kinase (thiD)from Clostridium difficile 630 3H83 ; 2.06 ; 2.06 Angstrom resolution structure of a hypoxanthine-guanine phosphoribosyltransferase (hpt-1) from Bacillus anthracis str. 'Ames Ancestor' 3KB8 ; 2.09 ; 2.09 Angstrom resolution structure of a hypoxanthine-guanine phosphoribosyltransferase (hpt-1) from Bacillus anthracis str. 'Ames Ancestor' in complex with GMP 4E77 ; 2 ; 2.0A Crystal Structure of a Glutamate-1-Semialdehyde Aminotransferase from Yersinia pestis CO92 3S5J ; 2.02 ; 2.0A Crystal structure of human phosphoribosyl pyrophosphate synthetase 1 3EOL ; 2 ; 2.0A crystal structure of isocitrate lyase from Brucella melitensis (P43212) 2QR8 ; 2 ; 2.0A X-ray structure of C-terminal kinase domain of p90 ribosomal S6 kinase 2 (RSK2) 2QR7 ; 2 ; 2.0A X-ray structure of C-terminal kinase domain of p90 ribosomal S6 kinase 2: Se-Met derivative 2F96 ; 2.09 ; 2.1 A crystal structure of Pseudomonas aeruginosa rnase T (Ribonuclease T) 1QQH ; 2.1 ; 2.1 A CRYSTAL STRUCTURE OF THE HUMAN PAPILLOMAVIRUS TYPE 18 E2 ACTIVATION DOMAIN 2Q3C ; 2.1 ; 2.1 A Resolution Crystal Structure of O-Acetylserine Sulfhydrylase (OASS) Holoenzyme From MYCOBACTERIUM TUBERCULOSIS in Complex with the Inhibitory Peptide DFSI 1QDR ; 2.1 ; 2.1 A RESOLUTION STRUCTURE OF ESCHERICHIA COLI LYTIC TRANSGLYCOSYLASE SLT35 1QDT ; 2.1 ; 2.1 A RESOLUTION STRUCTURE OF ESCHERICHIA COLI LYTIC TRANSGLYCOYSLASE SLT35 IN COMPLEX WITH CALCIUM 3ETC ; 2.1 ; 2.1 A structure of acyl-adenylate synthetase from Methanosarcina acetivorans containing a link between Lys256 and Cys298 3DKI ; 2.1 ; 2.1 A X-ray structure of CysM (Rv1336) from Mycobacterium tuberculosis an O-phosphoserine dependent cysteine synthase 2P04 ; 2.11 ; 2.1 Ang structure of the dimerized PAS domain of signal transduction histidine kinase from Nostoc punctiforme PCC 73102 with homology to the H-NOXA/H-NOBA domain of the soluble guanylyl cyclase 3GRP ; 2.09 ; 2.1 Angstrom crystal structure of 3-ketoacyl-(acyl-carrier-protein) reductase from Bartonella henselae 3GWE ; 2.1 ; 2.1 Angstrom crystal structure of 3-oxoacyl-(acyl-carrier-protein) synthase III 1QYR ; 2.1 ; 2.1 Angstrom Crystal structure of KsgA: A Universally Conserved Adenosine Dimethyltransferase 3PP8 ; 2.1 ; 2.1 Angstrom Crystal Structure of Putative Oxidoreductase (ycdW) from Salmonella typhimurium 2A8T ; 2.1 ; 2.1 Angstrom Crystal Structure of the Complex Between the Nuclear U8 snoRNA Decapping Nudix Hydrolase X29, Manganese and m7G-PPP-A 3TPZ ; 2.1 ; 2.1 Angstrom crystal structure of the L114P mutant of E. Coli KsgA 1VF6 ; 2.1 ; 2.1 Angstrom crystal structure of the PALS-1-L27N and PATJ L27 heterodimer complex 3N2L ; 2.1 ; 2.1 Angstrom resolution crystal structure of an Orotate Phosphoribosyltransferase (pyrE) from Vibrio cholerae O1 biovar eltor str. N16961 3K96 ; 2.1 ; 2.1 Angstrom resolution crystal structure of glycerol-3-phosphate dehydrogenase (gpsA) from Coxiella burnetii 3R2U ; 2.1 ; 2.1 Angstrom Resolution Crystal Structure of Metallo-beta-lactamase from Staphylococcus aureus subsp. aureus COL 4GQO ; 2.1 ; 2.1 Angstrom resolution crystal structure of uncharacterized protein lmo0859 from Listeria monocytogenes EGD-e 2B5T ; 2.1 ; 2.1 Angstrom structure of a nonproductive complex between antithrombin, synthetic heparin mimetic SR123781 and two S195A thrombin molecules 1G6N ; 2.1 ; 2.1 ANGSTROM STRUCTURE OF CAP-CAMP 2A5H ; 2.1 ; 2.1 Angstrom X-ray crystal structure of lysine-2,3-aminomutase from Clostridium subterminale SB4, with Michaelis analog (L-alpha-lysine external aldimine form of pyridoxal-5'-phosphate). 2WB0 ; 1.95 ; 2.1 RESOLUTION STRUCTURE OF THE C-TERMINAL DOMAIN OF THE HUMAN ADENOVIRUS 5 SSDNA BINDING PROTEIN 4WBC ; 2.138 ; 2.13 A STRUCTURE OF A KUNITZ-TYPE WINGED BEAN CHYMOTRYPSIN INHIBITOR PROTEIN 3KBO ; 2.14 ; 2.14 Angstrom Crystal Structure of Putative Oxidoreductase (ycdW) from Salmonella typhimurium in Complex with NADP 2J5Q ; 2.15 ; 2.15 A RESOLUTION STRUCTURE OF THE WILD TYPE MALATE DEHYDROGENASE FROM HALOARCULA MARISMORTUI AFTER FIRST RADIATION BURN (RADIATION DAMAGE SERIES) 2C3D ; 2.15 ; 2.15 ANGSTROM CRYSTAL STRUCTURE OF 2-KETOPROPYL COENZYME M OXIDOREDUCTASE CARBOXYLASE WITH A COENZYME M DISULFIDE BOUND AT THE ACTIVE SITE 4K28 ; 2.15 ; 2.15 Angstrom resolution crystal structure of a shikimate dehydrogenase family protein from Pseudomonas putida KT2440 in complex with NAD+ 3H02 ; 2.15 ; 2.15 Angstrom Resolution Crystal Structure of Naphthoate Synthase from Salmonella typhimurium. 3Q7T ; 2.15 ; 2.15A resolution structure (I41 Form) of the ChxR receiver domain from Chlamydia trachomatis 4E0B ; 2.17 ; 2.17 Angstrom resolution crystal structure of malate dehydrogenase from Vibrio vulnificus CMCP6 1H5W ; 2.1 ; 2.1A BACTERIOPHAGE PHI-29 CONNECTOR 3ENN ; 2.1 ; 2.1A crystal structure of glucose/ribitol dehydrogenase from brucella melitensis (p43212) 2GEM ; 2.1 ; 2.1A crystal structure of Salmonella tyhpimurium YeaZ, a putative Gram-negative RPF, form-A 3SKY ; 2.1 ; 2.1A crystal structure of the phosphate bound ATP binding domain of Archaeoglobus fulgidus COPB 3R2S ; 2.1 ; 2.1A resolution structure of Doubly Soaked FtnA from Pseudomonas aeruginosa (pH 6.0) 3Q7S ; 2.1 ; 2.1A resolution structure of the ChxR receiver domain containing I3C from Chlamydia trachomatis 1EK9 ; 2.1 ; 2.1A X-RAY STRUCTURE OF TOLC: AN INTEGRAL OUTER MEMBRANE PROTEIN AND EFFLUX PUMP COMPONENT FROM ESCHERICHIA COLI 2DXI ; 2.2 ; 2.2 A crystal structure of glutamyl-tRNA synthetase from Thermus thermophilus complexed with tRNA(Glu), ATP, and L-glutamol 3D6B ; 2.21 ; 2.2 A crystal structure of glutaryl-CoA dehydrogenase from Burkholderia pseudomallei 3D53 ; 2.2 ; 2.2 A crystal structure of inorganic pyrophosphatase from Rickettsia prowazekii 3EMJ ; 2.2 ; 2.2 A crystal structure of inorganic pyrophosphatase from rickettsia prowazekii (p21 form) 2Q3D ; 2.2 ; 2.2 A Resolution Crystal Structure of O-Acetylserine Sulfhydrylase (OASS) From MYCOBACTERIUM TUBERCULOSIS in Complex with the Reaction Intermediate ALPHA-AMINOACRYLATE 2PZZ ; 2.2 ; 2.2 A resolution crystal structure of UPF0201 protein from Methanococcus jannaschii 3R2P ; 2.2045 ; 2.2 Angstrom Crystal Structure of C Terminal Truncated Human Apolipoprotein A-I Reveals the Assembly of HDL by Dimerization. 4EG2 ; 2.2 ; 2.2 Angstrom Crystal Structure of Cytidine deaminase from Vibrio cholerae in Complex with Zinc and Uridine 3IAC ; 2.22 ; 2.2 Angstrom Crystal Structure of Glucuronate Isomerase from Salmonella typhimurium. 3TOZ ; 2.2 ; 2.2 Angstrom Crystal Structure of Shikimate 5-dehydrogenase from Listeria monocytogenes in Complex with NAD. 3T6H ; 2.2 ; 2.2 Angstrom Crystal Structure of TagRFP-T 3PMA ; 2.2 ; 2.2 Angstrom crystal structure of the complex between Bovine Thrombin and Sucrose Octasulfate 3DRM ; 2.2 ; 2.2 Angstrom Crystal Structure of Thr114Phe Alpha1-Antitrypsin 1ATP ; 2.2 ; 2.2 angstrom refined crystal structure of the catalytic subunit of cAMP-dependent protein kinase complexed with MNATP and a peptide inhibitor 3N3W ; 2.205 ; 2.2 Angstrom Resolution Crystal Structure of Nuclease Domain of Ribonuclase III (rnc) from Campylobacter jejuni 3OT5 ; 2.2 ; 2.2 Angstrom Resolution Crystal Structure of putative UDP-N-acetylglucosamine 2-epimerase from Listeria monocytogenes 3R2T ; 2.21 ; 2.2 Angstrom Resolution Crystal Structure of Superantigen-like Protein from Staphylococcus aureus subsp. aureus NCTC 8325. 1DCC ; 2.2 ; 2.2 ANGSTROM STRUCTURE OF OXYPEROXIDASE: A MODEL FOR THE ENZYME:PEROXIDE COMPLEX 3NA7 ; 2.2 ; 2.2 Angstrom Structure of the HP0958 Protein from Helicobacter pylori CCUG 17874 2QD1 ; 2.2 ; 2.2 Angstrom Structure of the human ferrochelatase variant E343K with substrate bound 1DR1 ; 2.2 ; 2.2 ANGSTROMS CRYSTAL STRUCTURE OF CHICKEN LIVER DIHYDROFOLATE REDUCTASE COMPLEXED WITH NADP+ AND BIOPTERIN 1LTA ; 2.2 ; 2.2 ANGSTROMS CRYSTAL STRUCTURE OF E. COLI HEAT-LABILE ENTEROTOXIN (LT) WITH BOUND GALACTOSE 1WGC ; 2.2 ; 2.2 ANGSTROMS RESOLUTION STRUCTURE ANALYSIS OF TWO REFINED N-ACETYLNEURAMINYLLACTOSE-WHEAT GERM AGGLUTININ ISOLECTIN COMPLEXES 2WGC ; 2.2 ; 2.2 ANGSTROMS RESOLUTION STRUCTURE ANALYSIS OF TWO REFINED N-ACETYLNEURAMINYLLACTOSE-WHEAT GERM AGGLUTININ ISOLECTIN COMPLEXES 7WGA ; 2 ; 2.2 ANGSTROMS RESOLUTION STRUCTURE ANALYSIS OF TWO REFINED N-ACETYLNEURAMINYLLACTOSE-WHEAT GERM AGGLUTININ ISOLECTIN COMPLEXES 9WGA ; 1.8 ; 2.2 ANGSTROMS RESOLUTION STRUCTURE ANALYSIS OF TWO REFINED N-ACETYLNEURAMINYLLACTOSE-WHEAT GERM AGGLUTININ ISOLECTIN COMPLEXES 1HAR ; 2.2 ; 2.2 ANGSTROMS RESOLUTION STRUCTURE OF THE AMINO-TERMINAL HALF OF HIV-1 REVERSE TRANSCRIPTASE (FINGERS AND PALM SUBDOMAINS) 3ROI ; 2.2 ; 2.20 Angstrom resolution structure of 3-phosphoshikimate 1-carboxyvinyltransferase (AroA) from Coxiella burnetii 3R38 ; 2.23 ; 2.23 Angstrom resolution crystal structure of UDP-N-acetylglucosamine 1-carboxyvinyltransferase (murA) from Listeria monocytogenes EGD-e 2J5R ; 2.25 ; 2.25 A RESOLUTION STRUCTURE OF THE WILD TYPE MALATE DEHYDROGENASE FROM HALOARCULA MARISMORTUI AFTER SECOND RADIATION BURN (RADIATION DAMAGE SERIES) 3QM2 ; 2.25 ; 2.25 Angstrom Crystal Structure of Phosphoserine Aminotransferase (SerC) from Salmonella enterica subsp. enterica serovar Typhimurium 3N2I ; 2.25 ; 2.25 Angstrom resolution crystal structure of a thymidylate kinase (tmk) from Vibrio cholerae O1 biovar eltor str. N16961 in complex with thymidine 4HV4 ; 2.25 ; 2.25 Angstrom resolution crystal structure of UDP-N-acetylmuramate--L-alanine ligase (murC) from Yersinia pestis CO92 in complex with AMP 4HW8 ; 2.251 ; 2.25 Angstrom Structure of the Extracellular Solute-binding Protein from Staphylococcus aureus in complex with Maltose. 4F49 ; 2.25 ; 2.25A resolution structure of Transmissible Gastroenteritis Virus Protease containing a covalently bound Dipeptidyl Inhibitor 4GIB ; 2.27 ; 2.27 Angstrom Crystal Structure of beta-Phosphoglucomutase (pgmB) from Clostridium difficile 4DXB ; 2.29 ; 2.29A structure of the engineered MBP TEM-1 fusion protein RG13 in complex with zinc, P1 space group 3GAF ; 2.2 ; 2.2A Crystal Structure of 7-Alpha-Hydroxysteroid Dehydrogenase from Brucella Melitensis 4E5D ; 2.201 ; 2.2A resolution structure of a firefly luciferase-benzothiazole inhibitor complex 4JET ; 2.2 ; 2.2A resolution structure of Holo hemophore HasA from Yersinia pestis 4FP7 ; 2.2 ; 2.2A resolution structure of Proteasome Assembly Chaperone Hsm3 3DAH ; 2.3 ; 2.3 A crystal structure of ribose-phosphate pyrophosphokinase from Burkholderia pseudomallei 2G7U ; 2.3 ; 2.3 A structure of putative catechol degradative operon regulator from Rhodococcus sp. RHA1 3POL ; 2.3 ; 2.3 Angstrom Crystal Structure of 3-deoxy-manno-octulosonate Cytidylyltransferase (kdsB) from Acinetobacter baumannii. 3IS2 ; 2.3 ; 2.3 Angstrom Crystal Structure of a Cys71 Sulfenic Acid form of Vivid 4ECM ; 2.3 ; 2.3 Angstrom Crystal Structure of a Glucose-1-phosphate Thymidylyltransferase from Bacillus anthracis in Complex with Thymidine-5-diphospho-alpha-D-glucose and Pyrophosphate 1Z7H ; 2.3 ; 2.3 Angstrom crystal structure of tetanus neurotoxin light chain 4JID ; 2.3 ; 2.3 Angstrom Resolution Crystal Structure of D-alanyl-D-alanine carboxypeptidase from Bacillus anthracis. 1XWK ; 2.3 ; 2.3 angstrom resolution crystal structure of human glutathione S-transferase M1A-1A complexed with glutathionyl-S-dinitrobenzene 2PDT ; 2.2 ; 2.3 Angstrom Structure of Phosphodiesterase treated Vivid 1DR2 ; 2.3 ; 2.3 ANGSTROMS CRYSTAL STRUCTURE OF CHICKEN LIVER DIHYDROFOLATE REDUCTASE COMPLEXED WITH THIONADP+ AND BIOPTERIN 1DR3 ; 2.3 ; 2.3 ANGSTROMS CRYSTAL STRUCTURE OF CHICKEN LIVER DIHYDROFOLATE REDUCTASE COMPLEXED WITH THIONADP+ AND BIOPTERIN 1RPL ; 2.3 ; 2.3 ANGSTROMS CRYSTAL STRUCTURE OF THE CATALYTIC DOMAIN OF DNA POLYMERASE BETA 3HYK ; 2.31 ; 2.31 Angstrom resolution crystal structure of a holo-(acyl-carrier-protein) synthase from Bacillus anthracis str. Ames in complex with CoA (3',5'-ADP) 4FBD ; 2.35 ; 2.35 Angstrom Crystal Structure of Conserved Hypothetical Protein from Toxoplasma gondii ME49. 3KY7 ; 2.35 ; 2.35 Angstrom resolution crystal structure of a putative tRNA (guanine-7-)-methyltransferase (trmD) from Staphylococcus aureus subsp. aureus MRSA252 3DZC ; 2.35 ; 2.35 Angstrom resolution structure of WecB (VC0917), a UDP-N-acetylglucosamine 2-epimerase from Vibrio cholerae. 3OO2 ; 2.37 ; 2.37 Angstrom resolution crystal structure of an alanine racemase (alr) from Staphylococcus aureus subsp. aureus COL 1S6Y ; 2.31 ; 2.3A crystal structure of phospho-beta-glucosidase 4HJY ; 2.4 ; 2.4 A Crystal structure of E. coli MltE-E64Q with bound chitopentaose 3E5B ; 2.37 ; 2.4 A crystal structure of isocitrate lyase from brucella melitensis 3EOM ; 2.398 ; 2.4 A crystal structure of native glutaryl-coa dehydrogenase from Burkholderia pseudomallei 1EEP ; 2.4 ; 2.4 A RESOLUTION CRYSTAL STRUCTURE OF BORRELIA BURGDORFERI INOSINE 5'-MONPHOSPHATE DEHYDROGENASE IN COMPLEX WITH A SULFATE ION 3DGM ; 2.4 ; 2.4 A Structure of a Non-biological ATP binding protein with ADP bound 1I2X ; 2.4 ; 2.4 A STRUCTURE OF A-DUPLEX WITH BULGED ADENOSINE, SPERMIDINE FORM 1IHH ; 2.4 ; 2.4 ANGSTROM CRYSTAL STRUCTURE OF AN OXALIPLATIN 1,2-D(GPG) INTRASTRAND CROSS-LINK IN A DNA DODECAMER DUPLEX 3PNU ; 2.4 ; 2.4 Angstrom Crystal Structure of Dihydroorotase (pyrC) from Campylobacter jejuni. 3MGA ; 2.4 ; 2.4 Angstrom Crystal Structure of Ferric Enterobactin Esterase (fes) from Salmonella typhimurium 3GTD ; 2.4 ; 2.4 Angstrom crystal structure of fumarate hydratase from Rickettsia prowazekii 2Q6S ; 2.4 ; 2.4 angstrom crystal structure of PPAR gamma complexed to BVT.13 without co-activator peptides 3HZZ ; 2.4 ; 2.4 Angstrom Crystal Structure of Streptomyces collinus crotonyl CoA carboxylase/reductase 3V05 ; 2.4 ; 2.4 Angstrom Crystal Structure of Superantigen-like Protein from Staphylococcus aureus. 1LU5 ; 2.4 ; 2.4 Angstrom Crystal Structure of the Asymmetric Platinum Complex {Pt(ammine)(cyclohexylamine)}2+ Bound to a Dodecamer DNA Duplex 3SEF ; 2.4 ; 2.4 Angstrom resolution crystal structure of shikimate 5-dehydrogenase (aroE) from Vibrio cholerae O1 biovar eltor str. N16961 in complex with shikimate and NADPH 2A8R ; 2.45 ; 2.45 Angstrom Crystal Structure of the Complex Between the Nuclear SnoRNA Decapping Nudix Hydrolase X29 and Manganese in the Presence of 7-methyl-GTP 2A8S ; 2.45 ; 2.45 Angstrom Crystal Structure of the Complex Between the Nuclear SnoRNA Decapping Nudix Hydrolase X29, Manganese and GTP 3PGJ ; 2.49 ; 2.49 Angstrom resolution crystal structure of shikimate 5-dehydrogenase (aroE) from Vibrio cholerae O1 biovar eltor str. N16961 in complex with shikimate 1SFJ ; 2.4 ; 2.4A Crystal structure of Staphylococcus aureus type I 3-dehydroquinase, with 3-dehydroquinate bound 2OE6 ; 2.4 ; 2.4A X-ray crystal structure of unliganded RNA fragment GGGCGUCGCUAGUACC/CGGUACUAAAAGUCGCC containing the human ribosomal decoding A site: RNA construct with 5'-overhang 1JKK ; 2.4 ; 2.4A X-RAY STRUCTURE OF TERNARY COMPLEX OF A CATALYTIC DOMAIN OF DEATH-ASSOCIATED PROTEIN KINASE WITH ATP ANALOGUE AND MG. 1X87 ; 2.4 ; 2.4A X-ray structure of Urocanase protein complexed with NAD 3QH7 ; 2.497 ; 2.5 A resolution structure of Se-Met labeled CT296 from Chlamydia trachomatis 3REH ; 2.5 ; 2.5 Angstrom Crystal Structure of the Nucleosome Core Particle Assembled with a 145 bp Alpha-Satellite DNA (NCP145) 3OKF ; 2.5 ; 2.5 Angstrom Resolution Crystal Structure of 3-Dehydroquinate Synthase (aroB) from Vibrio cholerae 4ECD ; 2.5 ; 2.5 Angstrom Resolution Crystal Structure of Bifidobacterium longum Chorismate Synthase 2F9D ; 2.5 ; 2.5 angstrom resolution structure of the spliceosomal protein p14 bound to region of SF3b155 1RC2 ; 2.5 ; 2.5 Angstrom Resolution X-ray Structure of Aquaporin Z 4EGR ; 2.5 ; 2.50 angstrom resolution structure of 3-phosphoshikimate 1-carboxyvinyltransferase (AroA) from Coxiella burnetii in complex with phosphoenolpyruvate 4DXE ; 2.51 ; 2.52 Angstrom resolution crystal structure of the acyl-carrier-protein synthase (AcpS)-acyl carrier protein (ACP) protein-protein complex from Staphylococcus aureus subsp. aureus COL 3REJ ; 2.55 ; 2.55 Angstrom Crystal Structure of the Nucleosome Core Particle Assembled with a 146 bp Alpha-Satellite DNA (NCP146b) 3EON ; 2.55 ; 2.55A crystal structure of native glutaryl-coa dehydrogenase from Burkholderia pseudomallei in complex with a small molecule 3EMK ; 2.5 ; 2.5A crystal structure of glucose/ribitol dehydrogenase from brucella melitensis 1TB6 ; 2.5 ; 2.5A Crystal Structure of the Antithrombin-Thrombin-Heparin Ternary Complex 1RD3 ; 2.5 ; 2.5A Structure of Anticoagulant Thrombin Variant E217K 2AF5 ; 2.5 ; 2.5A X-ray Structure of Engineered OspA protein 1F66 ; 2.6 ; 2.6 A CRYSTAL STRUCTURE OF A NUCLEOSOME CORE PARTICLE CONTAINING THE VARIANT HISTONE H2A.Z 3DMP ; 2.6 ; 2.6 A crystal structure of uracil phosphoribosyltransferase from Burkholderia pseudomallei 4IIW ; 2.6 ; 2.6 Angstrom Crystal Structure of Putative yceG-like Protein lmo1499 from Listeria monocytogenes 2QO1 ; 2.6 ; 2.6 Angstrom Crystal Structure of the Complex Between 11-(decyldithiocarbonyloxy)-undecanoic acid and Mycobacterium Tuberculosis FabH. 2A8Q ; 2.6 ; 2.6 Angstrom Crystal Structure of the Complex Between the Nuclear SnoRNA Decapping Nudix Hydrolase X29 and Manganese in the Presence of 7-methyl-GDP 3REK ; 2.6 ; 2.6 Angstrom Crystal Structure of the Nucleosome Core Particle Assembled with a 146 bp Alpha-Satellite DNA (NCP146b) Derivatized with Oxaliplatin 3SG1 ; 2.6 ; 2.6 Angstrom Crystal Structure of UDP-N-acetylglucosamine 1-carboxyvinyltransferase 1 (MurA1) from Bacillus anthracis 4HS7 ; 2.6 ; 2.6 Angstrom Structure of the Extracellular Solute-binding Protein from Staphylococcus aureus in complex with PEG. 4DIR ; 2.6 ; 2.6 Angstrom X-ray structure of human CA(2+)-S100A5 1LTB ; 2.6 ; 2.6 ANGSTROMS CRYSTAL STRUCTURE OF PARTIALLY-ACTIVATED E. COLI HEAT-LABILE ENTEROTOXIN (LT) 3REI ; 2.65 ; 2.65 Angstrom Crystal Structure of the Nucleosome Core Particle Assembled with a 145 bp Alpha-Satellite DNA (NCP145) Derivatized with Triamminechloroplatinum(II) Chloride 3OSC ; 2.65 ; 2.65 Angstrom resolution crystal structure of an orotate phosphoribosyltransferase from Bacillus anthracis str. 'Ames Ancestor' in complex with 5-phospho-alpha-D-ribosyl diphosphate (PRPP) 3SC6 ; 2.65 ; 2.65 Angstrom resolution crystal structure of dTDP-4-dehydrorhamnose reductase (rfbD) from Bacillus anthracis str. Ames in complex with NADP 4GFQ ; 2.65 ; 2.65 Angstrom Resolution Crystal Structure of Ribosome Recycling Factor (frr) from Bacillus anthracis 2C4D ; 2.6 ; 2.6A CRYSTAL STRUCTURE OF PSATHYRELLA VELUTINA LECTIN IN COMPLEX WITH N-ACETYLGLUCOSAMINE 3R9I ; 2.6 ; 2.6A resolution structure of MinD complexed with MinE (12-31) peptide 2GYS ; 2.7 ; 2.7 A structure of the extracellular domains of the human beta common receptor involved in IL-3, IL-5, and GM-CSF signalling 3V0A ; 2.703 ; 2.7 angstrom crystal structure of BoNT/Ai in complex with NTNHA 3GE1 ; 2.7 ; 2.7 Angstrom Crystal Structure of Glycerol Kinase (glpK) from Staphylococcus aureus in Complex with ADP and Glycerol 2A8P ; 2.7 ; 2.7 Angstrom Crystal Structure of the Complex Between the Nuclear SnoRNA Decapping Nudix Hydrolase X29 and Manganese 3REL ; 2.7 ; 2.7 Angstrom Crystal Structure of the Nucleosome Core Particle Assembled with a 146 bp Alpha-Satellite DNA (NCP146b) Derivatized with Triamminechloroplatinum(II) Chloride 3PFI ; 2.695 ; 2.7 Angstrom resolution crystal structure of a probable holliday junction DNA helicase (ruvB) from Campylobacter jejuni subsp. jejuni NCTC 11168 in complex with adenosine-5'-diphosphate 4GFP ; 2.7 ; 2.7 Angstrom resolution structure of 3-phosphoshikimate 1-carboxyvinyltransferase (AroA) from Coxiella burnetii in a second conformational state 4H44 ; 2.7 ; 2.70 A Cytochrome b6f Complex Structure From Nostoc PCC 7120 3OTR ; 2.75 ; 2.75 Angstrom Crystal Structure of Enolase 1 from Toxoplasma gondii 4K15 ; 2.75 ; 2.75 Angstrom Crystal Structure of Hypothetical Protein lmo2686 from Listeria monocytogenes EGD-e 2UUW ; 2.76 ; 2.75 ANGSTROM STRUCTURE OF THE D347G D348G MUTANT STRUCTURE OF SAPPORO VIRUS RDRP POLYMERASE 3HL3 ; 2.76 ; 2.76 Angstrom Crystal Structure of a Putative Glucose-1-Phosphate Thymidylyltransferase from Bacillus anthracis in Complex with a Sucrose. 2UXS ; 2.7 ; 2.7A CRYSTAL STRUCTURE OF INORGANIC PYROPHOSPHATASE (RV3628) FROM MYCOBACTERIUM TUBERCULOSIS AT PH 7.5 2X0J ; 2.786 ; 2.8 A RESOLUTION STRUCTURE OF MALATE DEHYDROGENASE FROM ARCHAEOGLOBUS FULGIDUS IN COMPLEX WITH ETHENO-NAD 1YSC ; 2.8 ; 2.8 ANGSTROMS STRUCTURE OF YEAST SERINE CARBOXYPEPTIDASE 2AAT ; 2.8 ; 2.8-ANGSTROMS-RESOLUTION CRYSTAL STRUCTURE OF AN ACTIVE-SITE MUTANT OF ASPARTATE AMINOTRANSFERASE FROM ESCHERICHIA COLI 1IMV ; 2.85 ; 2.85 A crystal structure of PEDF 1D2R ; 2.9 ; 2.9 A CRYSTAL STRUCTURE OF LIGAND-FREE TRYPTOPHANYL-TRNA SYNTHETASE: DOMAIN MOVEMENTS FRAGMENT THE ADENINE NUCLEOTIDE BINDING SITE. 1NTA ; 2.9 ; 2.9 A crystal structure of Streptomycin RNA-aptamer 1NTB ; 2.9 ; 2.9 A crystal structure of Streptomycin RNA-aptamer complex 2X0I ; 2.91 ; 2.9 A RESOLUTION STRUCTURE OF MALATE DEHYDROGENASE FROM ARCHAEOGLOBUS FULGIDUS IN COMPLEX WITH NADH 1C8O ; 2.9 ; 2.9 A STRUCTURE OF CLEAVED VIRAL SERPIN CRMA 3PMB ; 2.9 ; 2.9 Angstrom crystal structure of bovine thrombin in tetragonal spacegroup 1F5O ; 2.9 ; 2.9 ANGSTROM CRYSTAL STRUCTURE OF DEOXYGENATED LAMPREY HEMOGLOBIN V IN THE SPACE GROUP P2(1)2(1)2(1) 1F5P ; 2.9 ; 2.9 ANGSTROM CRYSTAL STRUCTURE OF LAMPREY HEMOGLOBIN THAT HAS BEEN EXPOSED TO CARBON MONOXIDE. 3UPD ; 2.91 ; 2.9 Angstrom Crystal Structure of Ornithine Carbamoyltransferase (ArgF) from Vibrio vulnificus 2F8N ; 2.9 ; 2.9 Angstrom X-ray structure of hybrid macroH2A nucleosomes 1BAF ; 2.9 ; 2.9 ANGSTROMS RESOLUTION STRUCTURE OF AN ANTI-DINITROPHENYL-SPIN-LABEL MONOCLONAL ANTIBODY FAB FRAGMENT WITH BOUND HAPTEN 1VSG ; 2.9 ; 2.9 ANGSTROMS RESOLUTION STRUCTURE OF THE N-TERMINAL DOMAIN OF A VARIANT SURFACE GLYCOPROTEIN FROM TRYPANOSOMA BRUCEI 3EOO ; 2.9 ; 2.9A crystal structure of methyl-isocitrate lyase from Burkholderia pseudomallei 1J2Q ; 2.83 ; 20S proteasome in complex with calpain-Inhibitor I from archaeoglobus fulgidus 4FZC ; 2.8 ; 20S yeast proteasome in complex with cepafungin I 4FZG ; 3 ; 20S yeast proteasome in complex with glidobactin 2FMJ ; 1.65 ; 220-loop mutant of streptomyces griseus trypsin 1HCW ; ; 23-RESIDUE DESIGNED METAL-FREE PEPTIDE BASED ON THE ZINC FINGER DOMAINS, NMR, 35 STRUCTURES 1GZ0 ; 2.5 ; 23S RIBOSOMAL RNA G2251 2'O-METHYLTRANSFERASE RLMB 1C2W ; 7.5 ; 23S RRNA STRUCTURE FITTED TO A CRYO-ELECTRON MICROSCOPIC MAP AT 7.5 ANGSTROMS RESOLUTION 1ZUV ; ; 24 NMR structures of AcAMP2-Like Peptide with Phenylalanine 18 mutated to Tryptophan 1RHT ; ; 24-MER RNA HAIRPIN COAT PROTEIN BINDING SITE FOR BACTERIOPHAGE R17 (NMR, MINIMIZED AVERAGE STRUCTURE) 1T0W ; ; 25 NMR structures of Truncated Hevein of 32 aa (Hevein-32) complex with N,N,N-triacetylglucosamina 1IGI ; 2.7 ; 26-10 FAB:DIGOXIN COMPLEX-AFFINITY AND SPECIFICITY DUE TO SURFACE COMPLEMENTARITY 1IGJ ; 2.5 ; 26-10 FAB:DIGOXIN COMPLEX-AFFINITY AND SPECIFICITY DUE TO SURFACE COMPLEMENTARITY 1OE7 ; 1.8 ; 28KDA GLUTATHIONE S-TRANSFERASE FROM SCHISTOSOMA HAEMATOBIUM 1OE8 ; 1.65 ; 28KDA GLUTATHIONE S-TRANSFERASE FROM SCHISTOSOMA HAEMATOBIUM (GLUTATHIONE SATURATED) 1D4R ; 2 ; 29-mer fragment of human srp rna helix 6 1A0Q ; 2.3 ; 29G11 COMPLEXED WITH PHENYL [1-(1-N-SUCCINYLAMINO)PENTYL] PHOSPHONATE 1CD9 ; 2.8 ; 2:2 COMPLEX OF G-CSF WITH ITS RECEPTOR 1PGR ; 3.5 ; 2:2 COMPLEX OF G-CSF WITH ITS RECEPTOR 1Z8R ; ; 2A cysteine proteinase from human coxsackievirus B4 (strain JVB / Benschoten / New York / 51) 2HRV ; 1.95 ; 2A CYSTEINE PROTEINASE FROM HUMAN RHINOVIRUS 2 3MUS ; 2 ; 2A Resolution Structure of Rat Type B Cytochrome b5 4HEI ; 1.6 ; 2A X-RAY STRUCTURE OF HPF from VIBRIO CHOLERAE 1JY8 ; 2.5 ; 2C-methyl-D-erythritol 2,4-cyclodiphosphate synthase (IspF) 1W77 ; 2 ; 2C-METHYL-D-ERYTHRITOL 4-PHOSPHATE CYTIDYLYLTRANSFERASE (ISPD) FROM ARABIDOPSIS THALIANA 1MWA ; 2.4 ; 2C/H-2KBM3/DEV8 ALLOGENEIC COMPLEX 2DZI ; ; 2DZI/Solution Structure of the N-terminal Ubiquitin-like Domain in Human Ubiquitin-like Protein 4A (GDX) 2DZJ ; ; 2DZJ/Solution Structure of the N-terminal Ubiquitin-like Domain in Human Synaptic Glycoprotein SC2 12E8 ; 1.9 ; 2E8 FAB FRAGMENT 3LEX ; 1.97 ; 2F5 Epitope scaffold elicited anti-HIV-1 monoclonal antibody 11F10 in complex with HIV-1 GP41 3LEY ; 1.99 ; 2F5 Epitope scaffold elicited anti-HIV-1 monoclonal antibody 6a7 in complex with HIV-1 GP41 3LES ; 2.77 ; 2F5 Epitope scaffold ES2 1DOI ; 1.9 ; 2FE-2S FERREDOXIN FROM HALOARCULA MARISMORTUI 1OFF ; 1.8 ; 2FE-2S FERREDOXIN FROM SYNECHOCYSTIS SP. PCC 6803 3T5W ; 1.8 ; 2ME modified human SOD1 2F9S ; 1.401 ; 2nd Crystal Structure Of A Soluble Domain Of ResA In The Oxidised Form 2BYG ; 1.85 ; 2ND PDZ DOMAIN OF DISCS LARGE HOMOLOGUE 2 3MLG ; 2.29 ; 2ouf-2x, a designed knotted protein 3MLI ; 2.9 ; 2ouf-ds, a disulfide-linked dimer of Helicobacter pylori protein HP0242 2QB1 ; 2.61 ; 2TEL crystallization module 2FDN ; 0.94 ; 2[4FE-4S] FERREDOXIN FROM CLOSTRIDIUM ACIDI-URICI 1MFJ ; ; 3' Stem-Loop from Human U4 SNRNA 2JC4 ; 1.9 ; 3'-5' EXONUCLEASE (NEXO) FROM NEISSERIA MENINGITIDIS 398D ; 1.94 ; 3'-DNA-RNA-5' JUNCTION FORMED DURING INITIATION OF MINUS-STRAND SYNTHESIS OF HIV REPLICATION 1ZBH ; 3 ; 3'-end specific recognition of histone mRNA stem-loop by 3'-exonuclease 3Q61 ; 1.56 ; 3'-Fluoro Hexitol Nucleic Acid DNA Structure 1B99 ; 2.7 ; 3'-FLUORO-URIDINE DIPHOSPHATE BINDING TO NUCLEOSIDE DIPHOSPHATE KINASE 1BUX ; 2.8 ; 3'-PHOSPHORYLATED NUCLEOTIDES BINDING TO NUCLEOSIDE DIPHOSPHATE KINASE 2J14 ; 2.8 ; 3,4,5-TRISUBSTITUTED ISOXAZOLES AS NOVEL PPARDELTA AGONISTS: PART2 3H0E ; 1.997 ; 3,4-Dihydropyrimido(1,2-a)indol-10(2H)-ones as Potent Non-Peptidic Inhibitors of Caspase-3 1PVW ; 2.45 ; 3,4-dihydroxy-2-butanone 4-phosphate synthase from M. jannaschii 1PVY ; 1.7 ; 3,4-dihydroxy-2-butanone 4-phosphate synthase from M. jannaschii in complex with ribulose 5-phosphate 1SNN ; 1.55 ; 3,4-dihydroxy-2-butanone 4-phosphate synthase from Methanococcus jannaschii 1B6Y ; ; 3,N4-ETHENO-2'-DEOXYCYTIDINE OPPOSITE ADENINE IN AN 11-MER DUPLEX, SOLUTION STRUCTURE FROM NMR AND MOLECULAR DYNAMICS, 2 STRUCTURES 1B60 ; ; 3,N4-ETHENO-2'-DEOXYCYTIDINE OPPOSITE CYTIDINE IN AN 11-MER DUPLEX, SOLUTION STRUCTURE FROM NMR AND MOLECULAR DYNAMICS 1B6X ; ; 3,N4-ETHENO-2'-DEOXYCYTIDINE OPPOSITE GUANINE IN AN 11-MER DUPLEX, SOLUTION STRUCTURE FROM NMR AND MOLECULAR DYNAMICS, 4 STRUCTURES 1B5K ; ; 3,N4-ETHENO-2'-DEOXYCYTIDINE OPPOSITE THYMIDINE IN AN 11-MER DUPLEX, SOLUTION STRUCTURE FROM NMR AND MOLECULAR DYNAMICS 2BYH ; 1.9 ; 3-(5-CHLORO-2,4-DIHYDROXYPHENYL)-PYRAZOLE-4-CARBOXAMIDES AS INHIBITORS OF THE HSP90 MOLECULAR CHAPERONE 2BYI ; 1.6 ; 3-(5-CHLORO-2,4-DIHYDROXYPHENYL)-PYRAZOLE-4-CARBOXAMIDES AS INHIBITORS OF THE HSP90 MOLECULAR CHAPERONE 1LWI ; 2.7 ; 3-ALPHA-HYDROXYSTEROID/DIHYDRODIOL DEHYDROGENASE FROM RATTUS NORVEGICUS 3L1S ; 2.9 ; 3-Aryl-4-(arylhydrazono)-1H-pyrazol-5-ones: Highly ligand efficient and potent inhibitors of GSK3 2FEL ; 2.2 ; 3-carboxy-cis,cis-muconate lactonizing enzyme from Agrobacterium radiobacter S2 2FEN ; 2.6 ; 3-carboxy-cis,cis-muconate lactonizing enzyme from Agrobacterium radiobacter S2 1SYM ; ; 3-D SOLUTION STRUCTURE OF REDUCED APO-S100B FROM RAT, NMR, 20 STRUCTURES 1DZA ; 1.65 ; 3-D structure of a HP-RNase 1GM6 ; 2.13 ; 3-D STRUCTURE OF A SALIVARY LIPOCALIN FROM BOAR 2DFS ; 24 ; 3-D structure of Myosin-V inhibited state 2WYR ; 2.245 ; 3-D STRUCTURE OF PHTET1-12S, DODECAMER IN THE ASYMMETRIC UNIT 3HYX ; 2.9 ; 3-D X-Ray structure of the sulfide:quinone oxidoreductase from Aquifex aeolicus in complex with Aurachin C 3HYV ; 2.3 ; 3-D X-Ray structure of the sulfide:quinone oxidoreductase from the hyperthermophilic bacterium Aquifex aeolicus 3HYW ; 2 ; 3-D X-Ray structure of the sulfide:quinone oxidoreductase of the hyperthermophilic bacterium Aquifex aeolicus in complex with decylubiquinone 2DHQ ; 2 ; 3-DEHYDROQUINATE DEHYDRATASE FROM MYCOBACTERIUM TUBERCULOSIS 1H0S ; 1.7 ; 3-DEHYDROQUINATE DEHYDRATASE FROM MYCOBACTERIUM TUBERCULOSIS IN COMPLEX WITH 3-HYDROXYIMINO-QUINIC ACID 1H05 ; 1.5 ; 3-DEHYDROQUINATE DEHYDRATASE FROM MYCOBACTERIUM TUBERCULOSIS IN COMPLEX WITH SULPHATE 3QBD ; 2.47 ; 3-Dehydroquinate Synthase (aroB) from Mycobacterium tuberculosis in complex with NAD 2YPP ; 2.3 ; 3-deoxy-D-arabino-heptulosonate 7-phosphate synthase in complex with 3 tyrosine molecules 2YPO ; 2 ; 3-deoxy-D-arabino-heptulosonate 7-phosphate synthase with phenylalanine bound in only one site 2YPQ ; 2.76 ; 3-deoxy-D-arabino-heptulosonate 7-phosphate synthase with tryptophan and tyrosine bound 3JTJ ; 2.18 ; 3-deoxy-manno-octulosonate cytidylyltransferase from Yersinia pestis 1Q9H ; 2.35 ; 3-Dimensional structure of native Cel7A from Talaromyces emersonii 3UDL ; 2.174 ; 3-heterocyclyl quinolone bound to HCV NS5B 3QAU ; 2.3 ; 3-Hydroxy-3-MethylGlutaryl-Coenzyme A Reductase from Streptococcus pneumoniae 3QAE ; 2.3 ; 3-hydroxy-3-methylglutaryl-coenzyme A reductase of Streptococcus pneumoniae 1CNZ ; 1.76 ; 3-ISOPROPYLMALATE DEHYDROGENASE (IPMDH) FROM SALMONELLA TYPHIMURIUM 1WAL ; 2.27 ; 3-ISOPROPYLMALATE DEHYDROGENASE (IPMDH) MUTANT (M219A)FROM THERMUS THERMOPHILUS 1CM7 ; 2.06 ; 3-ISOPROPYLMALATE DEHYDROGENASE FROM ESCHERICHIA COLI 3VMK ; 1.48 ; 3-isopropylmalate dehydrogenase from Shewanella benthica DB21 MT-2 3VMJ ; 1.56 ; 3-isopropylmalate dehydrogenase from Shewanella oneidensis MR-1 3VL2 ; 2.06 ; 3-isopropylmalate dehydrogenase from Shewanella oneidensis MR-1 at 160 MPa 3VL3 ; 1.8 ; 3-isopropylmalate dehydrogenase from Shewanella oneidensis MR-1 at 340 MPa 3VL4 ; 1.88 ; 3-isopropylmalate dehydrogenase from Shewanella oneidensis MR-1 at 410 MPa 3VL6 ; 2.07 ; 3-isopropylmalate dehydrogenase from Shewanella oneidensis MR-1 at 580 MPa 3VL7 ; 2.2 ; 3-isopropylmalate dehydrogenase from Shewanella oneidensis MR-1 at 650 MPa 3VKZ ; 1.84 ; 3-isopropylmalate dehydrogenase from Shewanella oneidensis MR-1 at atmospheric pressure 2AYQ ; 3 ; 3-ISOPROPYLMALATE DEHYDROGENASE FROM THE MODERATE FACULTATIVE THERMOPHILE, BACILLUS COAGULANS 1IDM ; 2.2 ; 3-ISOPROPYLMALATE DEHYDROGENASE, LOOP-DELETED CHIMERA 1XAA ; 2.1 ; 3-ISOPROPYLMALATE DEHYDROGENASE, LOW TEMPERATURE (100K) STRUCTURE 1XAB ; 2.1 ; 3-ISOPROPYLMALATE DEHYDROGENASE, LOW TEMPERATURE (150K) STRUCTURE 1OKG ; 2.1 ; 3-MERCAPTOPYRUVATE SULFURTRANSFERASE FROM LEISHMANIA MAJOR 1MPG ; 1.8 ; 3-METHYLADENINE DNA GLYCOSYLASE II FROM ESCHERICHIA COLI 2JHJ ; 1.9 ; 3-METHYLADENINE DNA-GLYCOSYLASE FROM ARCHAEOGLOBUS FULGIDUS 2JHN ; 1.8 ; 3-METHYLADENINE DNA-GLYCOSYLASE FROM ARCHAEOGLOBUS FULGIDUS 1PVS ; 2.4 ; 3-methyladenine Glcosylase II(AlkA) Hypoxanthine complex 2RBQ ; 1.633 ; 3-methylbenzylazide in complex with T4 L99A/M102Q 2RB2 ; 1.463 ; 3-methylbenzylazide in complex with T4 lysozyme L99A 1ISK ; ; 3-OXO-DELTA5-STEROID ISOMERASE, NMR, 20 STRUCTURES 2A4K ; 2.301 ; 3-Oxoacyl-[acyl carrier protein] reductase from Thermus thermophilus TT0137 4DML ; 2.5 ; 3-oxoacyl-[acyl-carrier-protein] reductase from Synechococcus elongatus PCC 7942 4DMM ; 2.38 ; 3-oxoacyl-[acyl-carrier-protein] reductase from Synechococcus elongatus PCC 7942 in complex with NADP 1QPG ; 2.4 ; 3-PHOSPHOGLYCERATE KINASE, MUTATION R65Q 3QGA ; 3 ; 3.0 A Model of Iron Containing Urease UreA2B2 from Helicobacter mustelae 3QGK ; 3 ; 3.0 A Model of Iron Containing Urease UreA2B2 from Helicobacter mustelae (refined w/ no ordered solvent) 2X0S ; 2.997 ; 3.0 A RESOLUTION CRYSTAL STRUCTURE OF GLYCOSOMAL PYRUVATE PHOSPHATE DIKINASE FROM TRYPANOSOMA BRUCEI 364D ; 3 ; 3.0 A STRUCTURE OF FRAGMENT I FROM E. COLI 5S RRNA 3RED ; 3.03 ; 3.0 A structure of the Prunus mume hydroxynitrile lyase isozyme-1 2H1N ; 3 ; 3.0 A X-ray structure of putative oligoendopeptidase F: crystals grown by vapor diffusion technique 4EGB ; 3 ; 3.0 Angstrom resolution crystal structure of dTDP-glucose 4,6-dehydratase (rfbB) from Bacillus anthracis str. Ames in complex with NAD 2F9J ; 3 ; 3.0 angstrom resolution structure of a Y22M mutant of the spliceosomal protein p14 bound to a region of SF3b155 2H1J ; 3.1 ; 3.1 A X-ray structure of putative Oligoendopeptidase F: Crystals grown by microfluidic seeding 3IZX ; 3.1 ; 3.1 Angstrom cryoEM structure of cytoplasmic polyhedrosis virus 1XQJ ; 3.1 ; 3.10 A Crystal structure of maspin, space group I 4 2 2 1XQG ; 3.1 ; 3.10 A crystal structure of maspin, Space group P 4 21 2 357D ; 3.5 ; 3.5 A structure of fragment I from E. coli 5S RRNA 3IYN ; 3.6 ; 3.6-Angstrom cryoEM structure of human adenovirus type 5 3CNF ; 3.88 ; 3.88 Angstrom structure of cytoplasmic polyhedrosis virus by cryo-electron microscopy 3V0B ; 3.9 ; 3.9 angstrom crystal structure of BoNT/Ai in complex with NTNHA 1ZWU ; ; 30 NMR structures of AcAMP2-like peptide with non natural beta-(2-naphthyl)-alanine residue. 1L5I ; ; 30-CONFORMER NMR ENSEMBLE OF THE N-TERMINAL, DNA-BINDING DOMAIN OF THE REPLICATION INITIATION PROTEIN FROM A GEMINIVIRUS (TOMATO YELLOW LEAF CURL VIRUS-SARDINIA) 3NQ4 ; 3.5 ; 30mer structure of Lumazine synthase from Salmonella typhimurium LT2 4IYL ; 2.36 ; 30S ribosomal protein S15 from Campylobacter jejuni 2YKR ; 9.8 ; 30S ribosomal subunit with RsgA bound in the presence of GMPPNP 2B9O ; 6.46 ; 30S ribosomal subunit, tRNAs and mRNA from a crystal structure of the whole ribosomal complex with a stop codon in the A-site. This file contains the 30S subunit, tRNAs and mRNA from a crystal structure of the whole ribosomal complex with a stop codon in the A-site and is described in remark 400. 2B64 ; 5.9 ; 30S ribosomal subunit, tRNAs, mRNA and release factor RF1 from a crystal structure of the whole ribosomal complex. This file contains the 30S subunit, tRNAs, mRNA and release factor RF1 from a crystal structure of the whole ribosomal complex"". The entire crystal structure contains one 70S ribosome, tRNAs, mRNA and release factor RF1 and is described in remark 400. 2B9M ; 6.76 ; 30S ribosomal subunit, tRNAs, mRNA and release factor RF2 from a crystal structure of the whole ribosomal complex. This file contains the 30S ribosomal subunit, tRNAs, mRNA and release factor RF2 from a crystal structure of the whole ribosomal complex"". The entire crystal structure contains one 70S ribosome, tRNAs, mRNA and release factor RF2 and is described in remark 400. 2F4V ; 3.8 ; 30S ribosome + designer antibiotic 1U86 ; ; 321-TW-322 insertion mutant of the third zinc finger of BKLF 3I77 ; 2.1 ; 35/99/170-loops of FXa in SGT 3I78 ; 3 ; 35/99/170/186/220-loops of FXa in SGT 1FG9 ; 2.9 ; 3:1 COMPLEX OF INTERFERON-GAMMA RECEPTOR WITH INTERFERON-GAMMA DIMER 3T5Q ; 3 ; 3A structure of Lassa virus nucleoprotein in complex with ssRNA 1N0Q ; 1.26 ; 3ANK: A designed ankyrin repeat protein with three identical consensus repeats 2WNX ; 1.31 ; 3b' carbohydrate-binding module from the Cel9V glycoside hydrolase from Clostridium thermocellum 2WO4 ; 1.85 ; 3b' carbohydrate-binding module from the Cel9V glycoside hydrolase from Clostridium thermocellum, in-house data 2WOB ; 2 ; 3b' carbohydrate-binding module from the Cel9V glycoside hydrolase from Clostridium thermocellum. Orthorhombic structure 2BHG ; 1.9 ; 3C PROTEASE FROM TYPE A10(61) FOOT-AND-MOUTH DISEASE VIRUS 2J92 ; 2.2 ; 3C PROTEASE FROM TYPE A10(61) FOOT-AND-MOUTH DISEASE VIRUS-CRYSTAL PACKING MUTANT (K51Q) 3ZV9 ; 2.05 ; 3C protease of Enterovirus 68 complexed with Michael receptor inhibitor 74 3ZVA ; 2.2 ; 3C protease of Enterovirus 68 complexed with Michael receptor inhibitor 75 3ZVB ; 2.65 ; 3C protease of Enterovirus 68 complexed with Michael receptor inhibitor 81 3ZVC ; 2 ; 3C protease of Enterovirus 68 complexed with Michael receptor inhibitor 82 3ZVD ; 2.25 ; 3C protease of Enterovirus 68 complexed with Michael receptor inhibitor 83 3ZVE ; 1.8 ; 3C protease of Enterovirus 68 complexed with Michael receptor inhibitor 84 3ZVF ; 2.5 ; 3C protease of Enterovirus 68 complexed with Michael receptor inhibitor 85 3ZVG ; 2.1 ; 3C protease of Enterovirus 68 complexed with Michael receptor inhibitor 98 1TIJ ; 3.03 ; 3D Domain-swapped human cystatin C with amyloid-like intermolecular beta-sheets 2RMI ; ; 3D NMR structure of astressin 2K1M ; ; 3D NMR structure of domain cC0 of cardiac myosin binding protein C (MyBPC) 2JND ; ; 3D NMR structure of ECD1 of mCRF-R2b in complex with Astressin 1U34 ; ; 3D NMR structure of the first extracellular domain of CRFR-2beta, a type B1 G-protein coupled receptor 1J47 ; ; 3D Solution NMR Structure of the M9I Mutant of the HMG-Box Domain of the Human Male Sex Determining Factor SRY Complexed to DNA 1J46 ; ; 3D Solution NMR Structure of the Wild Type HMG-BOX Domain of the Human Male Sex Determining Factor Sry Complexed to DNA 2LG4 ; ; 3D solution structure of antimicrobial peptide aurelin 2L37 ; ; 3D solution structure of arginine/glutamate-rich polypeptide Luffin P1 from the seeds of sponge gourd (Luffa cylindrical) 2M6N ; ; 3D solution structure of EMI1 (Early Mitotic Inhibitor 1) 1AWZ ; ; 3D SOLUTION STRUCTURE OF HUMAN ANGIOGENIN DETERMINED BY 1H, 15N NMR SPECTROSCOPY, 30 STRUCTURES 2LJO ; ; 3D solution structure of lipid transfer protein Lc-LTP2 2LJ7 ; ; 3D solution structure of plant defensin Lc-def 2CXJ ; ; 3D Solution Structure of S100A13 1XJ1 ; ; 3D solution structure of the C-terminal cysteine-rich domain of the VHv1.1 polydnaviral gene product 1X3Q ; ; 3D Solution Structure of the Chromo-2 Domain of cpSRP43 2HUG ; ; 3D Solution Structure of the Chromo-2 Domain of cpSRP43 complexed with cpSRP54 peptide 1X3P ; ; 3D solution structure of the Chromo-3 domain of cpSRP43 1YL8 ; ; 3D Solution Structure of [Tyr3]Octreotate derivatives in DMSO 1YL9 ; ; 3D Solution Structure of [Tyr3]Octreotate derivatives in DMSO 2JTC ; ; 3D structure and backbone dynamics of SPE B 3ZSE ; 1.78 ; 3D Structure of a thermophilic family GH11 xylanase from Thermobifida fusca 2F9M ; 1.95 ; 3D structure of active human Rab11b GTPase 2BEG ; ; 3D Structure of Alzheimer's Abeta(1-42) fibrils 2E8D ; ; 3D Structure of amyloid protofilaments of beta2-microglobulin fragment probed by solid-state NMR 2M02 ; ; 3D structure of cap-gly domain of mammalian dynactin determined by magic angle spinning NMR spectroscopy 1W6L ; 2 ; 3D STRUCTURE OF COTA INCUBATED WITH CUCL2 1W8E ; 2.2 ; 3D STRUCTURE OF COTA INCUBATED WITH HYDROGEN PEROXIDE 1W6W ; 2.2 ; 3D STRUCTURE OF COTA INCUBATED WITH SODIUM AZIDE 4ACK ; 2.15 ; 3D Structure of DotU from Francisella novicida 4ACL ; 2.49 ; 3D Structure of DotU from Francisella novicida 4AJ3 ; 1.9 ; 3D structure of E. coli Isocitrate Dehydrogenase in complex with Isocitrate, calcium(II) and NADP - The pseudo-Michaelis complex 4AJA ; 1.799 ; 3D structure of E. coli Isocitrate Dehydrogenase in complex with Isocitrate, calcium(II) and thioNADP 4AJC ; 2.3 ; 3D structure of E. coli Isocitrate Dehydrogenase K100M mutant in complex with alpha-ketoglutarate, calcium(II) and adenine nucleotide phosphate 4AJR ; 2.687 ; 3D structure of E. coli Isocitrate Dehydrogenase K100M mutant in complex with alpha-ketoglutarate, magnesium(II) and NADPH - The product complex 4AJB ; 1.9 ; 3D structure of E. coli Isocitrate Dehydrogenase K100M mutant in complex with Isocitrate, calcium(II) and thioNADP 4AJS ; 1.802 ; 3D structure of E. coli Isocitrate Dehydrogenase K100M mutant in complex with isocitrate, magnesium(II), Adenosine 2',5'-biphosphate and ribosylnicotinamide-5'-phosphate 3R0G ; 2.2 ; 3D Structure of Ferric Methanosarcina Acetivorans Protoglobin I149F mutant in Aquomet form 3QZX ; 1.3 ; 3D Structure of ferric methanosarcina acetivorans protoglobin Y61A mutant with unknown ligand 3QZZ ; 2.4 ; 3D Structure of Ferric Methanosarcina Acetivorans Protoglobin Y61W mutant in Aquomet form 2F9L ; 1.55 ; 3D structure of inactive human Rab11b GTPase 1KCP ; ; 3D STRUCTURE OF K-CONOTOXIN PVIIA, A NOVEL POTASSIUM CHANNEL-BLOCKING TOXIN FROM CONE SNAILS, NMR, 22 STRUCTURES 2JFB ; 2.5 ; 3D STRUCTURE OF LUMAZINE SYNTHASE FROM CANDIDA ALBICANS 2RQS ; ; 3D structure of Pin from the psychrophilic archeon Cenarcheaum symbiosum (CsPin) 3RX9 ; 1.35 ; 3D structure of SciN from an Escherichia coli Patotype 2WZN ; 1.9 ; 3D STRUCTURE OF TET3 FROM PYROCOCCUS HORIKOSHII 1IK6 ; 2 ; 3D structure of the E1beta subunit of pyruvate dehydrogenase from the archeon Pyrobaculum aerophilum 2C9O ; 2.2 ; 3D STRUCTURE OF THE HUMAN RUVB-LIKE HELICASE RUVBL1 2V1V ; ; 3D STRUCTURE OF THE M8L MUTANT OF SQUASH TRYPSIN INHIBITOR CMTI-I 2BHF ; 2.5 ; 3D STRUCTURE OF THE REDUCED FORM OF COTA 2BAG ; 2.4 ; 3D Structure of Torpedo californica acetylcholinesterase complexed with Ganstigmine 3I6M ; 2.26 ; 3D Structure of Torpedo californica acetylcholinesterase complexed with N-piperidinopropyl-galanthamine 3I6Z ; 2.19 ; 3D Structure of Torpedo californica acetylcholinesterase complexed with N-saccharinohexyl-galanthamine 2WJ1 ; 1.84 ; 3D-CRYSTAL STRUCTURE OF HUMANIZED-RAT FATTY ACID AMIDE HYDROLASE (FAAH) CONJUGATED WITH 7-PHENYL-1-(4-(PYRIDIN-2-YL)OXAZOL-2-YL)HEPTAN-1-ONE, AN ALPHA-KETOOXAZOLE 2WJ2 ; 2.55 ; 3D-CRYSTAL STRUCTURE OF HUMANIZED-RAT FATTY ACID AMIDE HYDROLASE (FAAH) CONJUGATED WITH 7-PHENYL-1-(5-(PYRIDIN-2-YL)OXAZOL-2-YL)HEPTAN-1-ONE, AN ALPHA-KETOOXAZOLE 3LJ7 ; 2.3 ; 3D-crystal structure of humanized-rat fatty acid amide hydrolase (FAAH) conjugated with Carbamate inhibitor URB597 2WAP ; 2.8 ; 3D-CRYSTAL STRUCTURE OF HUMANIZED-RAT FATTY ACID AMIDE HYDROLASE (FAAH) CONJUGATED WITH THE DRUG-LIKE UREA INHIBITOR PF-3845 3LJ6 ; 2.42 ; 3D-CRYSTAL STRUCTURE OF HUMANIZED-RAT FATTY ACID AMIDE HYDROLASE (FAAH) CONJUGATED WITH THE DRUG-LIKE UREA INHIBITOR PF-3845 at 2.42A RESOLUTION 2WW5 ; 1.61 ; 3D-STRUCTURE OF THE MODULAR AUTOLYSIN LYTC FROM STREPTOCOCCUS PNEUMONIAE AT 1.6 A RESOLUTION 2WWD ; 2.25 ; 3D-structure of the modular autolysin LytC from Streptococcus pneumoniae in complex with pneummococcal peptidoglycan fragment 2WWC ; 1.75 ; 3D-structure of the modular autolysin LytC from Streptococcus pneumoniae in complex with synthetic peptidoglycan ligand 2VKR ; 2.01 ; 3FE-4S, 4FE-4S PLUS ZN ACIDIANUS AMBIVALENS FERREDOXIN 2RJM ; 2 ; 3Ig structure of titin domains I67-I69 E-to-A mutated variant 2IWN ; 1.35 ; 3RD PDZ DOMAIN OF MULTIPLE PDZ DOMAIN PROTEIN MPDZ (CASP TARGET) 1ZRC ; 2.8 ; 4 Crystal structures of CAP-DNA with all base-pair substitutions at position 6, CAP-ICAP38 DNA 1ZRD ; 2.8 ; 4 crystal structures of CAP-DNA with all base-pair substitutions at position 6, CAP-[6A;17T]ICAP38 DNA 1ZRF ; 2.1 ; 4 crystal structures of CAP-DNA with all base-pair substitutions at position 6, CAP-[6C;17G]ICAP38 DNA 1ZRE ; 2.8 ; 4 crystal structures of CAP-DNA with all base-pair substitutions at position 6, CAP-[6G;17C]ICAP38 DNA 2VKU ; 1.95 ; 4,4'-DIHYDROXYBENZOPHENONE MIMICS STEROL SUBSTRATE IN THE BINDING SITE OF STEROL 14ALPHA-DEMETHYLASE (CYP51) IN THE X-RAY STRUCTURE OF THE COMPLEX 2VCI ; 2 ; 4,5 DIARYL ISOXAZOLE HSP90 CHAPERONE INHIBITORS: POTENTIAL THERAPEUTIC AGENTS FOR THE TREATMENT OF CANCER 2VCJ ; 2.5 ; 4,5 DIARYL ISOXAZOLE HSP90 CHAPERONE INHIBITORS: POTENTIAL THERAPEUTIC AGENTS FOR THE TREATMENT OF CANCER 3HUA ; 1.4 ; 4,5,6,7-tetrahydroindole in complex with T4 lysozyme L99A/M102Q 3N3G ; 1.6 ; 4-(3-Trifluoromethylphenyl)-pyrimidine-2-carbonitrile as cathepsin S inhibitors: N3, not N1 is critically important 2GDO ; 3 ; 4-(Aminoalkylamino)-3-Benzimidazole-Quinolinones As Potent CHK1 Inhibitors 2RAZ ; 1.641 ; 4-(methylthio)nitrobenzene in complex with T4 lysozyme L99A 1FLR ; 1.85 ; 4-4-20 FAB FRAGMENT 1JXH ; 2.3 ; 4-Amino-5-hydroxymethyl-2-methylpyrimidine Phosphate Kinase from Salmonella typhimurium 1JXI ; 2.64 ; 4-Amino-5-hydroxymethyl-2-methylpyrimidine Phosphate Kinase from Salmonella typhimurium complexed with 4-Amino-5-hydroxymethyl-2-methylpyrimidine 1OHV ; 2.3 ; 4-AMINOBUTYRATE-AMINOTRANSFERASE FROM PIG 1OHY ; 2.8 ; 4-AMINOBUTYRATE-AMINOTRANSFERASE INACTIVATED BY GAMMA-ETHYNYL GABA 1OHW ; 2.3 ; 4-AMINOBUTYRATE-AMINOTRANSFERASE INACTIVATED BY GAMMA-VINYL GABA 2CLX ; 1.8 ; 4-ARYLAZO-3,5-DIAMINO-1H-PYRAZOLE CDK INHIBITORS: SAR STUDY, CRYSTAL STRUCTURE IN COMPLEX WITH CDK2, SELECTIVITY, AND CELLULAR EFFECTS 3HTF ; 1.85 ; 4-chloro-1h-pyrazole in complex with T4 lysozyme L99A/M102Q 1NZY ; 1.8 ; 4-CHLOROBENZOYL COENZYME A DEHALOGENASE FROM PSEUDOMONAS SP. STRAIN CBS-3 1T5D ; 2.206 ; 4-Chlorobenzoyl-CoA Ligase/Synthetase bound to 4-chlorobenzoate 3CW9 ; 2 ; 4-Chlorobenzoyl-CoA Ligase/Synthetase in the Thioester-forming Conformation, bound to 4-chlorophenacyl-CoA 1T5H ; 2.002 ; 4-Chlorobenzoyl-CoA Ligase/Synthetase unliganded, selenomethionine 3CW8 ; 2.25 ; 4-Chlorobenzoyl-CoA Ligase/Synthetase, bound to 4CBA-Adenylate 2QW0 ; 2.56 ; 4-Chlorobenzoyl-CoA Ligase/Synthetase, I303A mutation, bound to 3,4 Dichlorobenzoate 2QVZ ; 2.5 ; 4-Chlorobenzoyl-CoA Ligase/Synthetase, I303A mutation, bound to 3-Chlorobenzoate 2QVY ; 2.76 ; 4-Chlorobenzoyl-CoA Ligase/Synthetase, I303G mutation, bound to 3,4-Dichlorobenzoate 2QVX ; 2.7 ; 4-Chlorobenzoyl-CoA Ligase/Synthetase, I303G mutation, bound to 3-Chlorobenzoate 3DLP ; 2.6 ; 4-Chlorobenzoyl-CoA Ligase/Synthetase, Mutant D402P, bound to 4CB 3TSY ; 3.1 ; 4-Coumaroyl-CoA Ligase::Stilbene Synthase fusion protein 1SP8 ; 2 ; 4-Hydroxyphenylpyruvate Dioxygenase 1SP9 ; 3 ; 4-Hydroxyphenylpyruvate Dioxygenase 3TSN ; 2.63 ; 4-hydroxythreonine-4-phosphate dehydrogenase from Campylobacter jejuni 3OAW ; 2.75 ; 4-Methylpteridineones as Orally Active and Selective PI3K/mTOR Dual Inhibitors 4OTA ; 2.75 ; 4-OXALOCROTONATE TAUTOMERASE OBSERVED AS AN OCTODECAMER, ORTHORHOMBIC CRYSTAL FORM 4OTB ; 2.5 ; 4-OXALOCROTONATE TAUTOMERASE OBSERVED AS AN OCTODECAMER, RHOMBOHEDRAL CRYSTAL FORM 4OTC ; 2.28 ; 4-OXALOCROTONATE TAUTOMERASE OBSERVED AS AN OCTODECAMER, TRIGONAL CRYSTAL FORM 1OTF ; 1.9 ; 4-OXALOCROTONATE TAUTOMERASE-TRICLINIC CRYSTAL FORM 2Q9M ; 2.05 ; 4-Substituted Trinems as Broad Spectrum-Lactamase Inhibitors: Structure-based Design, Synthesis and Biological Activity 2Q9N ; 2.2 ; 4-Substituted Trinems as Broad Spectrum-Lactamase Inhibitors: Structure-based Design, Synthesis and Biological Activity 1FSU ; 2.5 ; 4-SULFATASE (HUMAN) 3V0C ; 4.3 ; 4.3 angstrom crystal structure of an inactive BoNT/A (E224Q/R363A/Y366F) 3R9J ; 4.3 ; 4.3A resolution structure of a MinD-MinE(I24N) protein complex 2XEA ; 4.6 ; 4.6 ANGSTROM CRYO-EM RECONSTRUCTION OF TOBACCO MOSAIC VIRUS FROM IMAGES RECORDED AT 300 KEV ON A 4KX4K CCD CAMERA 2LNQ ; ; 40-residue D23N beta amyloid fibril 3TPU ; 3.1 ; 42F3 p5E8/H2-Ld complex 3TF7 ; 2.75 ; 42F3 QL9/H2-Ld complex 3TJH ; 2.12 ; 42F3-p3A1/H2-Ld complex 3TFK ; 2.753 ; 42F3-p4B10/H2-Ld 1GAF ; 1.95 ; 48G7 HYBRIDOMA LINE FAB COMPLEXED WITH HAPTEN 5-(PARA-NITROPHENYL PHOSPHONATE)-PENTANOIC ACID 1BP8 ; ; 4:2:1 mithramycin:Mg++:d(ACCCGGGT)2 complex 1N0R ; 1.5 ; 4ANK: A designed ankyrin repeat protein with four identical consensus repeats 3CB8 ; 2.77 ; 4Fe-4S-Pyruvate formate-lyase activating enzyme in complex with AdoMet and a peptide substrate 3C8F ; 2.25 ; 4Fe-4S-Pyruvate formate-lyase Activating Enzyme with partially disordered AdoMet 1X9Q ; 1.5 ; 4m5.3 anti-fluorescein single chain antibody fragment (scFv) 1NYP ; ; 4th LIM domain of PINCH protein 3QSK ; 1.75 ; 5 Histidine Variant of the anti-RNase A VHH in Complex with RNAse A 1NTS ; ; 5'(dCCPUPCPCPUPUP)3':3'(rAGGAGGAAA)5', where P=propynyl 1NTQ ; ; 5'(dCCUCCUU)3':3'(rAGGAGGAAA)5' 1NTT ; ; 5'(dCPCPUPCPCPUPUP)3':(rAGGAGGAAA)5', where P=propynyl 423D ; 1.6 ; 5'-D(*AP*CP*CP*GP*AP*CP*GP*TP*CP*GP*GP*T)-3' 424D ; 2.7 ; 5'-D(*AP*CP*CP*GP*AP*CP*GP*TP*CP*GP*GP*T)-3' 425D ; 2.8 ; 5'-D(*AP*CP*CP*GP*GP*TP*AP*CP*CP*GP*GP*T)-3' 427D ; 1.1 ; 5'-D(*CP*GP*CP*(CH2-DM1)GP*CP*G)-3' 403D ; 1.4 ; 5'-D(*CP*GP*CP*(HYD)AP*AP*AP*TP*TP*TP*GP*CP*G)-3', 2'-(4-ETHOXYPHENYL)-5-(4-METHYL-1-PIPERAZINYL)-2,5'-BI-BENZIMIDAZOLE 447D ; 2.2 ; 5'-D(*CP*GP*CP*GP*AP*AP*TP*TP*CP*GP*CP*G)-3' 442D ; 1.6 ; 5'-D(*CP*GP*CP*GP*AP*AP*TP*TP*CP*GP*CP*G)-3', BENZIMIDAZOLE DERIVATIVE COMPLEX 444D ; 2.4 ; 5'-D(*CP*GP*CP*GP*AP*AP*TP*TP*CP*GP*CP*G)-3', BENZIMIDAZOLE DERIVATIVE COMPLEX 445D ; 2.6 ; 5'-D(*CP*GP*CP*GP*AP*AP*TP*TP*CP*GP*CP*G)-3', Benzimidazole derivative complex 448D ; 2.2 ; 5'-D(*CP*GP*CP*GP*AP*AP*TP*TP*CP*GP*CP*G)-3', BENZIMIDAZOLE DERIVATIVE COMPLEX 449D ; 2.1 ; 5'-D(*CP*GP*CP*GP*AP*AP*TP*TP*CP*GP*CP*G)-3', BENZIMIDAZOLE DERIVATIVE COMPLEX 453D ; 1.8 ; 5'-D(*CP*GP*CP*GP*AP*AP*TP*TP*CP*GP*CP*G)-3'-BENZIMIDAZOLE COMPLEX 1FTD ; 2 ; 5'-D(*CP*GP*CP*GP*AP*AP*TP*TP*CP*GP*CP*G)-3'-SYMMETRIC BIS-BENZIMIDAZOLE COMPLEX 443D ; 1.6 ; 5'-D(*CP*GP*CP*GP*AP*AP*TP*TP*CP*GP*CP*G)-3'/ BENZIMIDAZOLE DERIVATIVE COMPLEX 2KBD ; ; 5'-D(*CP*TP*GP*GP*GP*GP*AP*CP*TP*TP*TP*CP*CP*AP*GP*G)-3', 5'-D(*CP*CP*TP*GP*GP*AP*AP*AP*GP*TP*CP*CP*CP*CP*AP*G)-3' 2B1D ; 2.5 ; 5'-D(*GP*CP*AP*GP*AP*CP*GP*TP*CP*TP*GP*C)-3' Methionine Repressor binding site 2B1C ; 2.2 ; 5'-D(*GP*CP*GP*TP*GP*GP*GP*AP*CP*C)-3' Zif268 binding site 2B1B ; 1.9 ; 5'-D(*GP*CP*GP*TP*GP*GP*GP*CP*AP*C)-3' Zif268 binding site 1B3P ; ; 5'-D(*GP*GP*AP*GP*GP*AP*T)-3' 431D ; 1.15 ; 5'-D(*GP*GP*CP*CP*AP*AP*TP*TP*GP*G)-3' 414D ; 1.9 ; 5'-D(*GP*GP*GP*GP*CP*GP*CP*CP*CP*C)-3' 421D ; 1.8 ; 5'-D(*TP*TP*CP*TP*TP*(BRO)CP*TP*TP*C)-3', 5'-R(*GP*AP*AP*GP*AP*AP*GP*AP*A)-3' 1JE1 ; 1.8 ; 5'-DEOXY-5'-METHYLTHIOADENOSINE PHOSPHORYLASE COMPLEX WITH GUANOSINE AND SULFATE 1JDS ; 1.8 ; 5'-DEOXY-5'-METHYLTHIOADENOSINE PHOSPHORYLASE COMPLEX WITH PHOSPHATE (SPACE GROUP P21) 3T60 ; 2.396 ; 5'-Diphenyl Nucleoside Inhibitors of Plasmodium falciparum dUTPase 3T64 ; 1.65 ; 5'-Diphenyl Nucleoside Inhibitors of Plasmodium falciparum dUTPase 3T6Y ; 2.6 ; 5'-Diphenyl Nucleoside Inhibitors of Plasmodium falciparum dUTPase 3T70 ; 1.8 ; 5'-Diphenyl Nucleoside Inhibitors of Plasmodium falciparum dUTPase 2H8G ; 1.5 ; 5'-Methylthioadenosine Nucleosidase from Arabidopsis thaliana 1HPU ; 1.85 ; 5'-NUCLEOTIDASE (CLOSED FORM), COMPLEX WITH AMPCP 1HO5 ; 2.1 ; 5'-NUCLEOTIDASE (E. COLI) IN COMPLEX WITH ADENOSINE AND PHOSPHATE 1OI8 ; 2.1 ; 5'-NUCLEOTIDASE (E. COLI) WITH AN ENGINEERED DISULFIDE BRIDGE (P90C, L424C) 1OID ; 2.1 ; 5'-NUCLEOTIDASE (E. COLI) WITH AN ENGINEERED DISULFIDE BRIDGE (S228C, P513C) 1OIE ; 2.33 ; 5'-NUCLEOTIDASE (E. COLI) WITH AN ENGINEERED DISULFIDE BRIDGE (S228C, P513C) 1HP1 ; 1.7 ; 5'-NUCLEOTIDASE (OPEN FORM) COMPLEX WITH ATP 1USH ; 1.73 ; 5'-NUCLEOTIDASE FROM E. COLI 2USH ; 2.22 ; 5'-NUCLEOTIDASE FROM E. COLI 406D ; 1.8 ; 5'-R(*CP*AP*CP*CP*GP*GP*AP*UP*GP*GP*UP*(BRO) UP*CP*GP*GP*UP*G)-3' 402D ; 2.3 ; 5'-R(*CP*GP*CP*CP*AP*GP*CP*G)-3' 377D ; 1.76 ; 5'-R(*CP*GP*UP*AP*CP*DG)-3' 439D ; 1.6 ; 5'-R(*CP*UP*GP*GP*GP*CP*GP*G)-3', 5'-R(*CP*CP*GP*CP*CP*UP*GP*G)-3' 422D ; 2.6 ; 5'-R(*GP*AP*UP*CP*AP*CP*UP*UP*CP*GP*GP*U)-3' 418D ; 2.4 ; 5'-R(*GP*UP*GP*CP*AP*CP*A)-D(P*C)-3' 435D ; 1.4 ; 5'-R(*UP*AP*GP*CP*CP*CP*C)-3', 5'-R(*GP*GP*GP*GP*CP*UP*A)-3' 434D ; 1.16 ; 5'-R(*UP*AP*GP*CP*UP*CP*C)-3', 5'-R(*GP*GP*GP*GP*CP*UP*A)-3' 1B0A ; 2.56 ; 5,10, METHYLENE-TETRAHYDROPHOLATE DEHYDROGENASE/CYCLOHYDROLASE FROM E COLI. 1V93 ; 1.9 ; 5,10-Methylenetetrahydrofolate Reductase from Thermus thermophilus HB8 2C16 ; 2.02 ; 5-(4-CARBOXY-2-OXO-BUTANE-1-SULFINYL)-4-OXO-PENTANOIC ACID ACID BOUND TO PORPHOBILINOGEN SYNTHASE FROM PSEUDOMONAS AERUGINOSA 2C18 ; 1.93 ; 5-(4-CARBOXY-2-OXO-BUTANE-1-SULFONYL)-4-OXO-PENTANOIC ACID BOUND TO PORPHOBILINOGEN SYNTHASE FROM PSEUDOMONAS AERUGINOSA 2C15 ; 1.48 ; 5-(4-CARBOXY-2-OXO-BUTOXY)-4-OXO-PENTANOIC ACID ACID BOUND TO PORPHOBILINOGEN SYNTHASE FROM PSEUDOMONAS AERUGINOSA 2C14 ; 1.9 ; 5-(4-CARBOXY-2-OXO-BUTYLAMINO)-4-OXO-PENTANOIC ACID ACID BOUND TO PORPHOBILINOGEN SYNTHASE FROM PSEUDOMONAS AERUGINOSA 2C19 ; 2.05 ; 5-(4-CARBOXY-2-OXO-BUTYLSULFANYL)-4-OXO-PENTANOIC ACID ACID BOUND TO PORPHOBILINOGEN SYNTHASE FROM PSEUDOMONAS AERUGINOSA 1AW5 ; 2.3 ; 5-AMINOLEVULINATE DEHYDRATASE FROM SACCHAROMYCES CEREVISIAE 2BWN ; 2.1 ; 5-AMINOLEVULINATE SYNTHASE FROM RHODOBACTER CAPSULATUS 2BWP ; 2.7 ; 5-AMINOLEVULINATE SYNTHASE FROM RHODOBACTER CAPSULATUS IN COMPLEX WITH GLYCINE 2BWO ; 2.8 ; 5-AMINOLEVULINATE SYNTHASE FROM RHODOBACTER CAPSULATUS IN COMPLEX WITH SUCCINYL-COA 4AFJ ; 1.98 ; 5-aryl-4-carboxamide-1,3-oxazoles: potent and selective GSK-3 inhibitors 1OTG ; 2.1 ; 5-CARBOXYMETHYL-2-HYDROXYMUCONATE ISOMERASE 3HT8 ; 1.6 ; 5-chloro-2-methylphenol in complex with T4 lysozyme L99A/M102Q 5EAS ; 2.25 ; 5-EPI-ARISTOLOCHENE SYNTHASE FROM NICOTIANA TABACUM 5EAU ; 2.15 ; 5-EPI-ARISTOLOCHENE SYNTHASE FROM NICOTIANA TABACUM 5EAT ; 2.8 ; 5-EPI-ARISTOLOCHENE SYNTHASE FROM NICOTIANA TABACUM WITH SUBSTRATE ANALOG FARNESYL HYDROXYPHOSPHONATE 3TAG ; 2.95 ; 5-fluorocytosine paired with dAMP in RB69 gp43 3TAF ; 3 ; 5-fluorocytosine paired with ddGMP in RB69 gp43 2ZNX ; 2.3 ; 5-Fluorotryptophan Incorporated ScFv10 Complexed to Hen Egg Lysozyme 2C13 ; 2.15 ; 5-HYDROXY-LEVULINIC ACID BOUND TO PORPHOBILINOGEN SYNTHASE FROM PSEUDOMONAS AERUGINOSA 3TAE ; 2.71 ; 5-hydroxycytosine paired with dAMP in RB69 gp43 3TAB ; 2.8 ; 5-hydroxycytosine paired with dGMP in RB69 gp43 2E7F ; 2.2 ; 5-methyltetrahydrofolate corrinoid/iron sulfur protein methyltransferase complexed with methyltetrahydrofolate to 2.2 Angsrom resolution 3ZZN ; 2.9 ; 5-Mutant (R79W, R151A, E279A, E299A,E313A) Lactate-Dehydrogenase from Thermus thermophillus 3IJK ; 1.3 ; 5-OMe modified DNA 8mer 3LTR ; 1.3 ; 5-OMe-dU containing DNA 8mer 3IJN ; 1.8 ; 5-SeMe-Cytidine modified DNA 8mer 3LTU ; 1.4 ; 5-SeMe-dU containing DNA 8mer 3IKI ; 1.38 ; 5-SMe-dU containing DNA octamer 3KQ8 ; 1.6 ; 5-Te-uridine derivatized DNA-8mer 2B66 ; 5.9 ; 50S ribosomal subunit from a crystal structure of release factor RF1, tRNAs and mRNA bound to the ribosome. This file contains the 50S subunit from a crystal structure of release factor RF1, tRNAs and mRNA bound to the ribosome and is described in remark 400 2B9N ; 6.76 ; 50S ribosomal subunit from a crystal structure of release factor RF2, tRNAs and mRNA bound to the ribosome. This file contains the 50S subunit from a crystal structure of release factor RF1, tRNAs and mRNA bound to the ribosome and is described in remark 400. 2B9P ; 6.46 ; 50S ribosomal subunit from a crystal structure of the ribosome in complex with tRNAs and mRNA with a stop codon in the A-site. This file contains the 50S subunit from a crystal structure of the ribosome in complex with tRNAs and mRNA with a stop codon in the A-site and is described in remark 400. 2RDO ; 9.1 ; 50S subunit with EF-G(GDPNP) and RRF bound 3NI3 ; 1.34 ; 54-Membered ring macrocyclic beta-sheet peptide 1AB4 ; 2.8 ; 59KDA FRAGMENT OF GYRASE A FROM E. COLI 4JPO ; 5 ; 5A resolution structure of Proteasome Assembly Chaperone Hsm3 in complex with a C-terminal fragment of Rpt1 2GRZ ; 1.6 ; 5ns Photoproduct of the M37V mutant of Scapharca HbI 1C2X ; 7.5 ; 5S RRNA STRUCTURE FITTED TO A CRYO-ELECTRON MICROSCOPIC MAP AT 7.5 ANGSTROMS RESOLUTION 1IQ4 ; 1.8 ; 5S-RRNA BINDING RIBOSOMAL PROTEIN L5 FROM BACILLUS STEAROTHERMOPHILUS 1TEM ; 1.95 ; 6 ALPHA HYDROXYMETHYL PENICILLOIC ACID ACYLATED ON THE TEM-1 BETA-LACTAMASE FROM ESCHERICHIA COLI 3Q3B ; 2.7 ; 6-Amino-4-(pyrimidin-4-yl)pyridones: Novel Glycogen Synthase Kinase-3 Inhibitors 1HKA ; 1.5 ; 6-HYDROXYMETHYL-7,8-DIHYDROPTERIN PYROPHOSPHOKINASE 3N4C ; 1.9 ; 6-Phenyl-1H-imidazo[4,5-c]pyridine-4-carbonitrile as cathepsin S inhibitors 2PBG ; 2.5 ; 6-PHOSPHO-BETA-D-GALACTOSIDASE FORM-B 3PBG ; 2.7 ; 6-PHOSPHO-BETA-GALACTOSIDASE FORM-C 4PBG ; 2.5 ; 6-PHOSPHO-BETA-GALACTOSIDASE FORM-CST 1BIF ; 2 ; 6-PHOSPHOFRUCTO-2-KINASE/FRUCTOSE-2,6-BISPHOSPHATASE BIFUNCTIONAL ENZYME COMPLEXED WITH ATP-G-S AND PHOSPHATE 3BIF ; 2.3 ; 6-PHOSPHOFRUCTO-2-KINASE/FRUCTOSE-2,6-BISPHOSPHATASE EMPTY 6-PF-2K ACTIVE SITE 2BIF ; 2.4 ; 6-PHOSPHOFRUCTO-2-KINASE/FRUCTOSE-2,6-BISPHOSPHATASE H256A MUTANT WITH F6P IN PHOSPHATASE ACTIVE SITE 3E15 ; 2 ; 6-phosphogluconolactonase from Plasmodium vivax 1B66 ; 1.9 ; 6-PYRUVOYL TETRAHYDROPTERIN SYNTHASE 1B6Z ; 2 ; 6-PYRUVOYL TETRAHYDROPTERIN SYNTHASE 1GTQ ; 2.3 ; 6-PYRUVOYL TETRAHYDROPTERIN SYNTHASE 2I91 ; 2.65 ; 60kDa Ro autoantigen in complex with a fragment of misfolded RNA 1EHL ; 2.4 ; 64M-2 ANTIBODY FAB COMPLEXED WITH D(5HT)(6-4)T 1BUL ; 1.89 ; 6ALPHA-(HYDROXYPROPYL)PENICILLANATE ACYLATED ON NMC-A BETA-LACTAMASE FROM ENTEROBACTER CLOACAE 2IZ1 ; 2.3 ; 6PDH COMPLEXED WITH PEX INHIBITOR SYNCHROTRON DATA 1AHH ; 2.3 ; 7 ALPHA-HYDROXYSTEROID DEHYDROGENASE COMPLEXED WITH NAD+ 1AHI ; 2.3 ; 7 ALPHA-HYDROXYSTEROID DEHYDROGENASE COMPLEXED WITH NADH AND 7-OXO GLYCOCHENODEOXYCHOLIC ACID 1CBK ; 2.02 ; 7,8-DIHYDRO-6-HYDROXYMETHYLPTERIN-PYROPHOSPHOKINASE FROM HAEMOPHILUS INFLUENZAE 1NBU ; 1.6 ; 7,8-Dihydroneopterin Aldolase Complexed with Product From Mycobacterium Tuberculosis 1B9L ; 2.9 ; 7,8-DIHYDRONEOPTERIN TRIPHOSPHATE EPIMERASE 4KIL ; 1.75 ; 7-(4-fluorophenyl)-3-hydroxyquinolin-2(1H)-one bound to influenza 2009 H1N1 endonuclease 1FMC ; 1.8 ; 7-ALPHA-HYDROXYSTEROID DEHYDROGENASE COMPLEX WITH NADH AND 7-OXO GLYCOCHENODEOXYCHOLIC ACID 3OPI ; 1.1 ; 7-DEAZA-2'-DEOXYADENOSINE modification in B-FORM DNA 6FDR ; 1.4 ; 7-FE FERREDOXIN FROM AZOTOBACTER VINELANDII AT 100K, NA DITHIONITE REDUCED AT PH 8.5, RESOLUTION 1.4 A 7FD1 ; 1.3 ; 7-FE FERREDOXIN FROM AZOTOBACTER VINELANDII AT PH 8.5, 100 K, 1.35 A 6FD1 ; 1.35 ; 7-FE FERREDOXIN FROM AZOTOBACTER VINELANDII LOW TEMPERATURE, 1.35 A 7FDR ; 1.4 ; 7-FE FERREDOXIN FROM AZOTOBACTER VINELANDII, NA DITHIONITE REDUCED, PH 8.5, 1.4A RESOLUTION, 100 K 1BC6 ; ; 7-FE FERREDOXIN FROM BACILLUS SCHLEGELII, NMR, 20 STRUCTURES 1BD6 ; ; 7-FE FERREDOXIN FROM BACILLUS SCHLEGELII, NMR, MINIMIZED AVERAGE STRUCTURE 1KAY ; 1.7 ; 70KD HEAT SHOCK COGNATE PROTEIN ATPASE DOMAIN, K71A MUTANT 1KAZ ; 1.7 ; 70KD HEAT SHOCK COGNATE PROTEIN ATPASE DOMAIN, K71E MUTANT 1KAX ; 1.7 ; 70KD HEAT SHOCK COGNATE PROTEIN ATPASE DOMAIN, K71M MUTANT 2HGR ; 4.51 ; 70S T.Th. ribosome functional complex with mRNA and E- and P-site tRNAs at 4.5A. This entry 2HGr contains 30S ribosomal subunit. The 50S ribosomal subunit can be found in PDB entry 2HGU. 2HGU ; 4.51 ; 70S T.Th. ribosome functional complex with mRNA and E- and P-site tRNAs at 4.5A. This entry 2HGU contains 50S ribosomal subunit. The 30S ribosomal subunit can be found in PDB entry 2HGR. 2IWQ ; 1.8 ; 7TH PDZ DOMAIN OF MULTIPLE PDZ DOMAIN PROTEIN MPDZ 3I4M ; 3.7 ; 8-oxoguanine containing RNA polymerase II elongation complex D 3I4N ; 3.9 ; 8-oxoguanine containing RNA polymerase II elongation complex E 2X5V ; 3 ; 80 microsecond laue diffraction snapshot from crystals of a photosynthetic reaction centre 3 millisecond following photoactivation. 2X5U ; 3 ; 80 microsecond laue diffraction snapshot from crystals of a photosynthetic reaction centre without illumination. 1U45 ; 2.01 ; 8oxoguanine at the pre-insertion site of the polymerase active site 1DYL ; 9 ; 9 ANGSTROM RESOLUTION CRYO-EM RECONSTRUCTION STRUCTURE OF SEMLIKI FOREST VIRUS (SFV) AND FITTING OF THE CAPSID PROTEIN STRUCTURE IN THE EM DENSITY 1FN2 ; 1.6 ; 9-AMINO-(N-(2-DIMETHYLAMINO)BUTYL)ACRIDINE-4-CARBOXAMIDE BOUND TO D(CGTACG)2 1RQY ; 1.55 ; 9-amino-[N-(2-dimethylamino)proply]-acridine-4-carboxamide bound to d(CGTACG)2 1S6R ; 2.24 ; 908R class c beta-lactamase bound to iodo-acetamido-phenyl boronic acid 460D ; 1.2 ; A ""HYDRAT-ION SPINE"" IN A B-DNA MINOR GROOVE 461D ; 1.5 ; A ""HYDRAT-ION SPINE"" IN A B-DNA MINOR GROOVE 397D ; 1.3 ; A 1.3 A RESOLUTION CRYSTAL STRUCTURE OF THE HIV-1 TRANS-ACTIVATION RESPONSE REGION RNA STEM REVEALS A METAL ION-DEPENDENT BULGE CONFORMATION 1TC1 ; 1.41 ; A 1.4 ANGSTROM CRYSTAL STRUCTURE FOR THE HYPOXANTHINE PHOSPHORIBOSYLTRANSFERASE OF TRYPANOSOMA CRUZI 3NKB ; 1.916 ; A 1.9A crystal structure of the HDV ribozyme precleavage suggests both Lewis acid and general acid mechanisms contribute to phosphodiester cleavage 1OQM ; 2.1 ; A 1:1 complex between alpha-lactalbumin and beta1,4-galactosyltransferase in the presence of UDP-N-acetyl-galactosamine 1HP7 ; 2.1 ; A 2.1 ANGSTROM STRUCTURE OF AN UNCLEAVED ALPHA-1-ANTITRYPSIN SHOWS VARIABILITY OF THE REACTIVE CENTER AND OTHER LOOPS 3IGM ; 2.2 ; A 2.2A crystal structure of the AP2 domain of PF14_0633 from P. falciparum, bound as a domain-swapped dimer to its cognate DNA 1Y62 ; 2.45 ; A 2.4 crystal structure of conkunitzin-S1, a novel Kunitz-fold cone snail neurotoxin. 3CQS ; 2.8 ; A 3'-OH, 2',5'-phosphodiester substitution in the hairpin ribozyme active site reveals similarities with protein ribonucleases 2NWC ; 3.02 ; A 3.02 angstrom crystal structure of wild-type apo GroEL in a monoclinic space group 1B37 ; 1.9 ; A 30 ANGSTROM U-SHAPED CATALYTIC TUNNEL IN THE CRYSTAL STRUCTURE OF POLYAMINE OXIDASE 1B5Q ; 1.9 ; A 30 ANGSTROM U-SHAPED CATALYTIC TUNNEL IN THE CRYSTAL STRUCTURE OF POLYAMINE OXIDASE 2KQO ; ; A 3D-structural model of unsulphated chondroitin from high-field NMR: 4-sulphation has little effect on backbone conformation 3Q8W ; 3.64 ; A b-aminoacyl containing thiazolidine derivative and DPPIV complex 1NKE ; 1.8 ; A BACILLUS DNA POLYMERASE I PRODUCT COMPLEX BOUND TO A CYTOSINE-THYMINE MISMATCH AFTER A SINGLE ROUND OF PRIMER EXTENSION, FOLLOWING INCORPORATION OF DCTP. 1NK8 ; 1.9 ; A BACILLUS DNA POLYMERASE I PRODUCT COMPLEX BOUND TO A GUANINE-THYMINE MISMATCH AFTER A SINGLE ROUND OF PRIMER EXTENSION, FOLLOWING INCORPORATION OF DCTP. 1NKC ; 1.8 ; A BACILLUS DNA POLYMERASE I PRODUCT COMPLEX BOUND TO A GUANINE-THYMINE MISMATCH AFTER FIVE ROUNDS OF PRIMER EXTENSION, FOLLOWING INCORPORATION OF DCTP, DGTP, DTTP, AND DATP. 1NKB ; 2 ; A BACILLUS DNA POLYMERASE I PRODUCT COMPLEX BOUND TO A GUANINE-THYMINE MISMATCH AFTER THREE ROUNDS OF PRIMER EXTENSION, FOLLOWING INCORPORATION OF DCTP, DGTP, AND DTTP. 1NK9 ; 1.9 ; A BACILLUS DNA POLYMERASE I PRODUCT COMPLEX BOUND TO A GUANINE-THYMINE MISMATCH AFTER TWO ROUNDS OF PRIMER EXTENSION, FOLLOWING INCORPORATION OF DCTP AND DGTP. 2DYW ; 1.13 ; A Backbone binding DNA complex 1FNZ ; 2.05 ; A bark lectin from robinia pseudoacacia in complex with N-acetylgalactosamine 3T8V ; 1.8 ; A bestatin-based chemical biology strategy reveals distinct roles for malaria M1- and M17-family aminopeptidases 3T8W ; 2 ; A bestatin-based chemical biology strategy reveals distinct roles for malaria M1- and M17-family aminopeptidases 1XBH ; ; A BETA-HAIRPIN MIMIC FROM FCERI-ALPHA-CYCLO(L-262) 1C4B ; ; A BETA-HAIRPIN MIMIC FROM FCERI-ALPHA-CYCLO(RD-262) 1HAA ; ; A BETA-HAIRPIN STRUCTURE IN A 13-MER PEPTIDE THAT BINDS A-BUNGAROTOXIN WITH HIGH AFFINITY AND NEUTRALIZES ITS TOXICITY 1HAJ ; ; A BETA-HAIRPIN STRUCTURE IN A 13-MER PEPTIDE THAT BINDS A-BUNGAROTOXIN WITH HIGH AFFINITY AND NEUTRALIZES ITS TOXICITY 3CWO ; 3.1 ; A beta/alpha-barrel built by the combination of fragments from different folds 2DND ; 2.2 ; A BIFURCATED HYDROGEN-BONDED CONFORMATION IN THE D(A.T) BASE PAIRS OF THE DNA DODECAMER D(CGCAAATTTGCG) AND ITS COMPLEX WITH DISTAMYCIN 3EM2 ; 2.3 ; A bimolecular anti-parallel-stranded Oxytricha nova telomeric quadruplex in complex with a 3,6-disubstituted acridine BSU-6038 3EUI ; 2.2 ; A bimolecular anti-parallel-stranded Oxytricha nova telomeric quadruplex in complex with a 3,6-disubstituted acridine BSU-6042 in a large unit cell 3EQW ; 2.2 ; A bimolecular anti-parallel-stranded Oxytricha nova telomeric quadruplex in complex with a 3,6-disubstituted acridine BSU-6042 in small unit cell 3ERU ; 2 ; A bimolecular anti-parallel-stranded Oxytricha nova telomeric quadruplex in complex with a 3,6-disubstituted acridine BSU-6045 3ES0 ; 2.2 ; A bimolecular anti-parallel-stranded Oxytricha nova telomeric quadruplex in complex with a 3,6-disubstituted acridine BSU-6048 3ET8 ; 2.45 ; A bimolecular anti-parallel-stranded Oxytricha nova telomeric quadruplex in complex with a 3,6-disubstituted acridine BSU-6054 3EUM ; 1.78 ; A bimolecular anti-parallel-stranded Oxytricha nova telomeric quadruplex in complex with a 3,6-disubstituted acridine BSU-6066 3NYP ; 1.179 ; A bimolecular anti-parallel-stranded Oxytricha nova telomeric quadruplex in complex with a 3,6-disubstituted acridine ligand containing bis-3-fluoropyrrolidine end side chains 3NZ7 ; 1.1 ; A bimolecular anti-parallel-stranded Oxytricha nova telomeric quadruplex in complex with a 3,6-disubstituted acridine ligand containing bis-3-fluoropyrrolidine end side chains 3CE5 ; 2.5 ; A bimolecular parallel-stranded human telomeric quadruplex in complex with a 3,6,9-trisubstituted acridine molecule BRACO19 3VEQ ; 2.25 ; A binary complex betwwen bovine pancreatic trypsin and a engineered mutant trypsin inhibitor 1BKX ; 2.6 ; A BINARY COMPLEX OF THE CATALYTIC SUBUNIT OF CAMP-DEPENDENT PROTEIN KINASE AND ADENOSINE FURTHER DEFINES CONFORMATIONAL FLEXIBILITY 2L8I ; ; A biocompatible backbone modification? - Structure and dynamics of a triazole-linked DNA duplex 3GSJ ; 1.8 ; A Bulky Rhodium Complex Bound to an Adenosine-Adenosine DNA Mismatch 3GSK ; 1.6 ; A Bulky Rhodium Complex Bound to an Adenosine-Adenosine DNA Mismatch 3ZUA ; ; A C39-like domain 1G49 ; 1.9 ; A CARBOXYLIC ACID BASED INHIBITOR IN COMPLEX WITH MMP3 1HY7 ; 1.5 ; A CARBOXYLIC ACID BASED INHIBITOR IN COMPLEX WITH MMP3 1MBL ; 2 ; A catalytically-impaired class A beta-lactamase: 2 Angstroms crystal structure and kinetics of the Bacillus licheniformis E166A mutant 1CPD ; 2.2 ; A CATION BINDING MOTIF STABILIZES THE COMPOUND I RADICAL OF CYTOCHROME C PEROXIDASE 1CPE ; 2.2 ; A CATION BINDING MOTIF STABILIZES THE COMPOUND I RADICAL OF CYTOCHROME C PEROXIDASE 1CPF ; 2.2 ; A CATION BINDING MOTIF STABILIZES THE COMPOUND I RADICAL OF CYTOCHROME C PEROXIDASE 1CPG ; 2.2 ; A CATION BINDING MOTIF STABILIZES THE COMPOUND I RADICAL OF CYTOCHROME C PEROXIDASE 1L83 ; 1.7 ; A CAVITY-CONTAINING MUTANT OF T4 LYSOZYME IS STABILIZED BY BURIED BENZENE 1L84 ; 1.9 ; A CAVITY-CONTAINING MUTANT OF T4 LYSOZYME IS STABILIZED BY BURIED BENZENE 1HBV ; 2.3 ; A CHECK ON RATIONAL DRUG DESIGN. CRYSTAL STRUCTURE OF A COMPLEX OF HIV-1 PROTEASE WITH A NOVEL GAMMA-TURN MIMETIC 1OSH ; 1.8 ; A Chemical, Genetic, and Structural Analysis of the nuclear bile acid receptor FXR 4EXK ; 1.28 ; A chimera protein containing MBP fused to the C-terminal domain of the uncharacterized protein STM14_2015 from Salmonella enterica 3O3Y ; 1.35 ; A chimeric alpha+alpha/beta peptide based on the CHR domain sequence of gp41 1UZH ; 2.2 ; A CHIMERIC CHLAMYDOMONAS, SYNECHOCOCCUS RUBISCO ENZYME 2WD2 ; 1.49 ; A CHIMERIC MICROTUBULE DISRUPTOR WITH EFFICACY ON A TAXANE RESISTANT CELL LINE 3IA3 ; 3.2 ; A cis-proline in alpha-hemoglobin stabilizing Protein directs the structural reorganization of alpha-hemoglobin 1QRG ; 1.72 ; A CLOSER LOOK AND THE ACTIVE SITE OF GAMMA-CARBONIC ANHYDRASES: HIGH RESOLUTION CRYSTALLOGRAPHIC STUDIES OF THE CARBONIC ANHYDRASE FROM METHANOSARCINA THERMOPHILA 1QRM ; 1.95 ; A CLOSER LOOK AT THE ACTIVE SITE OF GAMMA-CARBONIC ANHYDRASES: HIGH RESOLUTION CRYSTAL STRUCTURES OF THE CARBONIC ANHYDRASE FROM METHANOSARCINA THERMOPHILA 1QRE ; 1.46 ; A CLOSER LOOK AT THE ACTIVE SITE OF GAMMA-CARBONIC ANHYDRASES: HIGH RESOLUTION CRYSTALLOGRAPHIC STUDIES OF THE CARBONIC ANHYDRASE FROM METHANOSARCINA THERMOPHILA 1QRF ; 1.55 ; A CLOSER LOOK AT THE ACTIVE SITE OF GAMMA-CARBONIC ANHYDRASES: HIGH RESOLUTION CRYSTALLOGRAPHIC STUDIES OF THE CARBONIC ANHYDRASE FROM METHANOSARCINA THERMOPHILA 1QRL ; 1.85 ; A CLOSER LOOK AT THE ACTIVE SITE OF GAMMA-CARBONIC ANHYDRASES: HIGH RESOLUTION CRYSTALLOGRAPHIC STUDIES OF THE CARBONIC ANHYDRASE FROM METHANOSARCINA THERMOPHILA 4AOL ; 3.8 ; A combinatorial method solves the crystal structure of group II chaperonin TRiC (CCT) 3H8C ; 2.5 ; A combined crystallographic and molecular dynamics study of cathepsin-L retro-binding inhibitors (compound 14) 3H89 ; 2.5 ; A combined crystallographic and molecular dynamics study of cathepsin-L retro-binding inhibitors(compound 4) 3H8B ; 1.8 ; A combined crystallographic and molecular dynamics study of cathepsin-L retro-binding inhibitors(compound 9) 1YXW ; 2.2 ; A common binding site for disialyllactose and a tri-peptide in the C-fragment of tetanus neurotoxin 1YYN ; 2.3 ; A common binding site for disialyllactose and a tri-peptide in the C-fragment of tetanus neurotoxin 2FSD ; 2.3 ; A Common Fold for the Receptor Binding Domains of Lactococcal Phages? The Crystal Structure of the Head Domain of Phage bIL170 1CEC ; 2.15 ; A COMMON PROTEIN FOLD AND SIMILAR ACTIVE SITE IN TWO DISTINCT FAMILIES OF BETA-GLYCANASES 1XYZ ; 1.4 ; A COMMON PROTEIN FOLD AND SIMILAR ACTIVE SITE IN TWO DISTINCT FAMILIES OF BETA-GLYCANASES 2C53 ; 1.8 ; A COMPARATIVE STUDY OF URACIL DNA GLYCOSYLASES FROM HUMAN AND HERPES SIMPLEX VIRUS TYPE 1 2C56 ; 2.1 ; A COMPARATIVE STUDY OF URACIL DNA GLYCOSYLASES FROM HUMAN AND HERPES SIMPLEX VIRUS TYPE 1 3GY2 ; 1.57 ; A comparative study on the inhibition of bovine beta-trypsin by bis-benzamidines diminazene and pentamidine by X-ray crystallography and ITC 3GY3 ; 1.7 ; A comparative study on the inhibition of bovine beta-trypsin by bis-benzamidines diminazene and pentamidine by X-ray crystallography and ITC 3GY4 ; 1.55 ; A comparative study on the inhibition of bovine beta-trypsin by bis-benzamidines diminazene and pentamidine by X-ray crystallography and ITC 3GY5 ; 1.57 ; A comparative study on the inhibition of bovine beta-trypsin by bis-benzamidines diminazene and pentamidine by X-ray crystallography and ITC 3GY7 ; 1.55 ; A comparative study on the inhibition of bovine beta-trypsin by bis-benzamidines diminazene and pentamidine by X-ray crystallography and ITC 3GY8 ; 1.75 ; A comparative study on the inhibition of bovine beta-trypsin by bis-benzamidines diminazene and pentamidine by X-ray crystallography and ITC 3GY6 ; 1.7 ; A comparative study on the inhibition of bovine beta-trypsin by the bis-benzamidines diminazene and pentamidine 1KB7 ; ; A COMPARISON OF NMR SOLUTION STRUCTURES OF THE RECEPTOR BINDING DOMAINS OF PSEUDOMONAS AERUGINOSA PILI STRAINS PAO, KB7, AND PAK: IMPLICATIONS FOR RECEPTOR BINDING AND SYNTHETIC VACCINE DESIGN 1KB8 ; ; A COMPARISON OF NMR SOLUTION STRUCTURES OF THE RECEPTOR BINDING DOMAINS OF PSEUDOMONAS AERUGINOSA PILI STRAINS PAO, KB7, AND PAK: IMPLICATIONS FOR RECEPTOR BINDING AND SYNTHETIC VACCINE DESIGN 1NIL ; ; A COMPARISON OF NMR SOLUTION STRUCTURES OF THE RECEPTOR BINDING DOMAINS OF PSEUDOMONAS AERUGINOSA PILI STRAINS PAO, KB7, AND PAK: IMPLICATIONS FOR RECEPTOR BINDING AND SYNTHETIC VACCINE DESIGN 1NIM ; ; A COMPARISON OF NMR SOLUTION STRUCTURES OF THE RECEPTOR BINDING DOMAINS OF PSEUDOMONAS AERUGINOSA PILI STRAINS PAO, KB7, AND PAK: IMPLICATIONS FOR RECEPTOR BINDING AND SYNTHETIC VACCINE DESIGN 1PAN ; ; A COMPARISON OF NMR SOLUTION STRUCTURES OF THE RECEPTOR BINDING DOMAINS OF PSEUDOMONAS AERUGINOSA PILI STRAINS PAO, KB7, AND PAK: IMPLICATIONS FOR RECEPTOR BINDING AND SYNTHETIC VACCINE DESIGN 1PAO ; ; A COMPARISON OF NMR SOLUTION STRUCTURES OF THE RECEPTOR BINDING DOMAINS OF PSEUDOMONAS AERUGINOSA PILI STRAINS PAO, KB7, AND PAK: IMPLICATIONS FOR RECEPTOR BINDING AND SYNTHETIC VACCINE DESIGN 2HWB ; 3 ; A COMPARISON OF THE ANTI-RHINOVIRAL DRUG BINDING POCKET IN HRV14 AND HRV1A 2HWC ; 3 ; A COMPARISON OF THE ANTI-RHINOVIRAL DRUG BINDING POCKET IN HRV14 AND HRV1A 2HWD ; 3.8 ; A COMPARISON OF THE ANTI-RHINOVIRAL DRUG BINDING POCKET IN HRV14 AND HRV1A 2HWE ; 3.8 ; A COMPARISON OF THE ANTI-RHINOVIRAL DRUG BINDING POCKET IN HRV14 AND HRV1A 2HWF ; 3.8 ; A COMPARISON OF THE ANTI-RHINOVIRAL DRUG BINDING POCKET IN HRV14 AND HRV1A 5I1B ; 2.1 ; A COMPARISON OF THE HIGH RESOLUTION STRUCTURES OF HUMAN AND MURINE INTERLEUKIN-1B 8I1B ; 2.4 ; A COMPARISON OF THE HIGH RESOLUTION STRUCTURES OF HUMAN AND MURINE INTERLEUKIN-1B 3LDH ; 3 ; A comparison of the structures of apo dogfish m4 lactate dehydrogenase and its ternary complexes 2SBT ; 2.8 ; A COMPARISON OF THE THREE-DIMENSIONAL STRUCTURES OF SUBTILISIN BPN AND SUBTILISIN NOVO 3BYT ; 2.3 ; A complex between a variant of staphylococcal enterotoxin C3 and the variable domain of the murine T cell receptor beta chain 8.2 1HKN ; 2 ; A COMPLEX BETWEEN ACIDIC FIBROBLAST GROWTH FACTOR AND 5-AMINO-2-NAPHTHALENESULFONATE 3ML6 ; 3.5 ; a complex between Dishevlled2 and clathrin adaptor AP-2 1AHW ; 3 ; A COMPLEX OF EXTRACELLULAR DOMAIN OF TISSUE FACTOR WITH AN INHIBITORY FAB (5G9) 3ZEB ; 2.2 ; A complex of GlpG with isocoumarin inhibitor covalently bonded to serine 201 and histidine 150 1UZX ; 1.85 ; A COMPLEX OF THE VPS23 UEV WITH UBIQUITIN 3STB ; 2.5 ; A complex of two editosome proteins and two nanobodies 2QCS ; 2.2 ; A complex structure between the Catalytic and Regulatory subunit of Protein Kinase A that represents the inhibited state 4AIS ; 2 ; A complex structure of BtGH84 4AIU ; 2.25 ; A complex structure of BtGH84 1IKF ; 2.5 ; A CONFORMATION OF CYCLOSPORIN A IN AQUEOUS ENVIRONMENT REVEALED BY THE X-RAY STRUCTURE OF A CYCLOSPORIN-FAB COMPLEX 3EY1 ; 1.6 ; A Conformational Transition in the Structure of a 2'-Thiomethyl-Modified DNA Visualized at High Resolution 3EY2 ; 1.04 ; A Conformational Transition in the Structure of a 2'-Thiomethyl-Modified DNA Visualized at High Resolution 3EY3 ; 1.25 ; A Conformational Transition in the Structure of a 2'-Thiomethyl-Modified DNA Visualized at High Resolution 3DA7 ; 2.25 ; A conformationally strained, circular permutant of barnase 1Q8C ; 2 ; A conserved hypothetical protein from Mycoplasma genitalium shows structural homology to NusB proteins 3KXE ; 2.6 ; A conserved mode of protein recognition and binding in a ParD-ParE toxin-antitoxin complex 2AYS ; 1.86 ; A conserved non-metallic binding site in the C-terminal lobe of lactoferrin: Structure of the complex of C-terminal lobe of bovine lactoferrin with N-acetyl galactosamine at 1.86 A resolution 1OK7 ; 1.65 ; A Conserved protein binding-site on Bacterial Sliding Clamps 282D ; 2.4 ; A CONTINOUS TRANSITION FROM A-DNA TO B-DNA IN THE 1:1 COMPLEX BETWEEN NOGALAMYCIN AND THE HEXAMER DCCCGGG 1OPZ ; ; A core mutation affecting the folding properties of a soluble domain of the ATPase protein CopA from Bacillus subtilis 1OQ3 ; ; A core mutation affecting the folding properties of a soluble domain of the ATPase protein CopA from Bacillus subtilis 2KN5 ; ; A Correspondence Between Solution-State Dynamics of an Individual Protein and the Sequence and Conformational Diversity of its Family 2K0E ; ; A Coupled Equilibrium Shift Mechanism in Calmodulin-Mediated Signal Transduction 1QWH ; 1.36 ; a covalent dimer of transthyretin that affects the amyloid pathway 148L ; 1.9 ; A COVALENT ENZYME-SUBSTRATE INTERMEDIATE WITH SACCHARIDE DISTORTION IN A MUTANT T4 LYSOZYME 1LQT ; 1.05 ; A covalent modification of NADP+ revealed by the atomic resolution structure of FprA, a Mycobacterium tuberculosis oxidoreductase 2QK7 ; 2.4 ; A covalent S-F heterodimer of staphylococcal gamma-hemolysin 2RPN ; ; A crucial role for high intrinsic specificity in the function of yeast SH3 domains 4RUB ; 2.7 ; A CRYSTAL FORM OF RIBULOSE-1,5-BISPHOSPHATE CARBOXYLASE(SLASH)OXYGENASE FROM NICOTIANA TABACUM IN THE ACTIVATED STATE 3SJ2 ; 1.36 ; A Crystal Structure of a Model of the Repeating r(CGG) Transcript Found in Fragile X Syndrome 2P54 ; 1.79 ; a crystal structure of PPAR alpha bound with SRC1 peptide and GW735 4GDF ; 2.8 ; A Crystal Structure of SV40 Large T Antigen 1SZP ; 3.25 ; A Crystal Structure of the Rad51 Filament 4AE6 ; 2.1 ; A Crystal Structure of the Sperm Specific Isoform of Protein Kinase A (PKA) Subunit CalphaS Reveals a Binding Pocket for Hydrophobic Moieties 4AE9 ; 2.3 ; A Crystal Structure of the Sperm Specific Isoform of Protein Kinase A (PKA) Subunit CalphaS Reveals a Binding Pocket for Hydrophobic Moieties 3OTJ ; 2.15 ; A Crystal Structure of Trypsin Complexed with BPTI (Bovine Pancreatic Trypsin Inhibitor) by X-ray/Neutron Joint Refinement 3OTJ ; 1.6 ; A Crystal Structure of Trypsin Complexed with BPTI (Bovine Pancreatic Trypsin Inhibitor) by X-ray/Neutron Joint Refinement 227D ; 2.2 ; A CRYSTALLOGRAPHIC AND SPECTROSCOPIC STUDY OF THE COMPLEX BETWEEN D(CGCGAATTCGCG)2 AND 2,5-BIS(4-GUANYLPHENYL)FURAN, AN ANALOGUE OF BERENIL. STRUCTURAL ORIGINS OF ENHANCED DNA-BINDING AFFINITY 1FX1 ; 2 ; A CRYSTALLOGRAPHIC STRUCTURAL STUDY OF THE OXIDATION STATES OF DESULFOVIBRIO VULGARIS FLAVODOXIN 1HRS ; 2.6 ; A CRYSTALLOGRAPHIC STUDY OF HAEM BINDING TO FERRITIN 283D ; 2.3 ; A CURVED RNA HELIX INCORPORATING AN INTERNAL LOOP WITH G-A AND A-A NON-WATSON-CRICK BASE PAIRING 3G8Q ; 2.4 ; A cytidine deaminase edits C-to-U in transfer RNAs in archaea 2GW0 ; 1.55 ; A D(TGGGGT)- sodium and calcium complex. 3EHB ; 2.32 ; A D-Pathway Mutation Decouples the Paracoccus Denitrificans Cytochrome c Oxidase by Altering the side chain orientation of a distant, conserved Glutamate 4DZM ; 1.94 ; A de novo designed Coiled Coil CC-Di 4DZN ; 1.59 ; A de novo designed Coiled Coil CC-pIL 4DZL ; 2.3 ; A de novo designed Coiled Coil CC-Tri 4DZK ; 1.79 ; A de novo designed Coiled Coil CC-Tri-N13 2JAB ; 1.7 ; A DESIGNED ANKYRIN REPEAT PROTEIN EVOLVED TO PICOMOLAR AFFINITY TO HER2 4HB1 ; 2.9 ; A DESIGNED FOUR HELIX BUNDLE PROTEIN. 3R5K ; 2.86 ; A designed redox-controlled caspase-7 1IFH ; 2.8 ; A DETAILED ANALYSIS OF THE FREE AND BOUND CONFORMATION OF AN ANTIBODY: X-RAY STRUCTURES OF ANTI-PEPTIDE FAB 17(SLASH)9 AND THREE DIFFERENT FAB-PEPTIDE COMPLEXES 2SCU ; 2.3 ; A detailed description of the structure of Succinyl-COA synthetase from Escherichia coli 1SZR ; 2.15 ; A Dimer interface mutant of ornithine decarboxylase reveals structure of gem diamine intermediate 1FS5 ; 1.73 ; A DISCOVERY OF THREE ALTERNATE CONFORMATIONS IN THE ACTIVE SITE OF GLUCOSAMINE-6-PHOSPHATE ISOMERASE 2KJI ; ; A divergent ins protein in c. elegans structurally resemble insulin and activates the human insulin receptor 1N4L ; 2 ; A DNA analogue of the polypurine tract of HIV-1 3NAO ; 5.03 ; A DNA Crystal Designed to Contain Two Molecules per Asymmetric Unit Cell 309D ; 2.6 ; A DNA DECAMER WITH A STICKY END: THE CRYSTAL STRUCTURE OF D-CGACGATCGT 1D89 ; 2.3 ; A DNA DODECAMER CONTAINING AN ADENINE TRACT CRYSTALLIZES IN A UNIQUE LATTICE AND EXHIBITS A NEW BEND 1SP6 ; ; A DNA duplex containing a cholesterol adduct (alpha-anomer) 1SSJ ; ; A DNA DUPLEX CONTAINING A CHOLESTEROL ADDUCT (BETA-ANOMER) 2VZB ; 2.3 ; A Dodecameric Thioferritin in the Bacterial Domain, Characterization of the Bacterioferritin-Related Protein from Bacteroides fragilis 3NUH ; 3.103 ; A domain insertion in E. coli GyrB adopts a novel fold that plays a critical role in gyrase function 3I8N ; 2.145 ; A domain of a conserved functionally known protein from Vibrio parahaemolyticus RIMD 2210633. 3I8O ; 2.638 ; A domain of a functionally unknown protein from Methanocaldococcus jannaschii DSM 2661. 1Q0P ; 1.8 ; A domain of Factor B 3O2P ; 2.233 ; A Dual E3 Mechanism for Rub1 Ligation to Cdc53: Dcn1(P)-Cdc53(WHB) 3O6B ; 3.1 ; A Dual E3 Mechanism for Rub1 Ligation to Cdc53: Dcn1(P)-Cdc53(WHB) low resolution 1T31 ; 1.9 ; A Dual Inhibitor of the Leukocyte Proteases Cathepsin G and Chymase with Therapeutic Efficacy in Animals Models of Inflammation 1T32 ; 1.85 ; A Dual Inhibitor of the Leukocyte Proteases Cathepsin G and Chymase with Therapeutic Efficacy in Animals Models of Inflammation 2FY1 ; ; A dual mode of RNA recognition by the RBMY protein 1SJK ; ; A DUPLEX DNA WITH AN ABASIC SITE IN A DA TRACT, ALPHA FORM, NMR, MINIMIZED AVERAGE STRUCTURE 1SJL ; ; A DUPLEX DNA WITH AN ABASIC SITE IN A DA TRACT, BETA FORM, NMR, MINIMIZED AVERAGE STRUCTURE 2WDB ; 2.03 ; A FAMILY 32 CARBOHYDRATE-BINDING MODULE, FROM THE MU TOXIN PRODUCED BY CLOSTRIDIUM PERFRINGENS, IN COMPLEX WITH BETA-D-GLCNAC-BETA(1,2)MANNOSE 2W1U ; 2 ; A FAMILY 32 CARBOHYDRATE-BINDING MODULE, FROM THE MU TOXIN PRODUCED BY CLOSTRIDIUM PERFRINGENS, IN COMPLEX WITH BETA-D-GLCNAC-BETA(1,3)GALNAC 2P4Z ; 2.1 ; A Ferredoxin-like Metallo-beta-lactamase Superfamily Protein from Thermoanaerobacter tengcongensis 1BMW ; ; A fibronectin type III fold in plant allergens: The solution structure of Phl PII from timothy grass pollen, NMR, 38 STRUCTURES 1ORO ; 2.4 ; A FLEXIBLE LOOP AT THE DIMER INTERFACE IS A PART OF THE ACTIVE SITE OF THE ADJACENT MONOMER OF ESCHERICHIA COLI OROTATE PHOSPHORIBOSYLTRANSFERASE 1PX6 ; 2.1 ; A folding mutant of human class pi glutathione transferase, created by mutating aspartate 153 of the wild-type protein to asparagine 1PX7 ; 2.03 ; A folding mutant of human class pi glutathione transferase, created by mutating aspartate 153 of the wild-type protein to glutamate 1MD3 ; 2.03 ; A folding mutant of human class pi glutathione transferase, created by mutating glycine 146 of the wild-type protein to alanine 1MD4 ; 2.1 ; A folding mutant of human class pi glutathione transferase, created by mutating glycine 146 of the wild-type protein to valine 1GM0 ; ; A FORM OF THE PHEROMONE-BINDING PROTEIN FROM BOMBYX MORI 1P8F ; 1.85 ; A four location model to explain the stereospecificity of proteins. 1PB1 ; 1.7 ; A four location model to explain the stereospecificity of proteins. 1MKO ; 2.18 ; A Fourth Quaternary Structure of Human Hemoglobin A at 2.18 A Resolution 2XNY ; 7.5 ; A FRAGMENT OF STREPTOCOCCAL M1 PROTEIN IN COMPLEX WITH HUMAN FIBRINOGEN 2JTK ; ; A functional domain of a Wnt signal protein 1G6R ; 2.8 ; A FUNCTIONAL HOT SPOT FOR ANTIGEN RECOGNITION IN A SUPERAGONIST TCR/MHC COMPLEX 3A1M ; 2 ; A fusion protein of a beta helix region of gene product 5 and the foldon region of bacteriophage T4 2KQG ; ; A G-rich sequence within the c-kit oncogene promoter forms a parallel G-quadruplex having asymmetric G-tetrad dynamics 2KQH ; ; A G-rich sequence within the c-kit oncogene promoter forms a parallel G-quadruplex having asymmetric G-tetrad dynamics 1K51 ; 1.8 ; A G55A Mutation Induces 3D Domain Swapping in the B1 Domain of Protein L from Peptostreptococcus magnus 3QI2 ; 2.797 ; A Galpha P-loop mutation prevents transition to the activated state: G42R bound to RGS14 GoLoco 3QE0 ; 3 ; A Galpha-i1 P-loop mutation prevents transition to the activated state 1G0U ; 2.4 ; A GATED CHANNEL INTO THE PROTEASOME CORE PARTICLE 3UPC ; 2.8 ; A general strategy for the generation of human antibody variable domains with increased aggregation resistance 3UPA ; 1.8 ; A general strategy for the generation of human antibody variable domains with increased aggregation resistance 2DD7 ; 1.9 ; A GFP-like protein from marine copepod, Chiridius poppei 3MFQ ; 2.598 ; A Glance into the Metal Binding Specificity of TroA: Where Elaborate Behaviors Occur in the Active Center 1HPG ; 1.5 ; A glutamic acid specific serine protease utilizes a novel histidine triad in substrate binding 3EXU ; 1.81 ; A glycoside hydrolase family 11 xylanase with an extended thumb region 190L ; 2 ; A HELIX INITIATION SIGNAL IN T4 LYSOZYME IDENTIFIED BY POLYALANINE MUTAGENESIS 191L ; 1.95 ; A HELIX INITIATION SIGNAL IN T4 LYSOZYME IDENTIFIED BY POLYALANINE MUTAGENESIS 192L ; 1.9 ; A HELIX INITIATION SIGNAL IN T4 LYSOZYME IDENTIFIED BY POLYALANINE MUTAGENESIS 3CK4 ; 1.7 ; A heterospecific leucine zipper tetramer 3CRP ; 1.7 ; A heterospecific leucine zipper tetramer 3D7D ; 1.69 ; A high resolution crystal structure of human glutamate carboxypeptidase II (GCPII) in a complex with DCFBD, a urea-based inhibitor 3D7H ; 1.55 ; A high resolution crystal structure of human glutamate carboxypeptidase II (GCPII) in a complex with DCIBzL, a urea-based inhibitor 3D7F ; 1.54 ; A high resolution crystal structure of human glutamate carboxypeptidase II (GCPII) in a complex with DCIT, a urea-based inhibitor 3D7G ; 1.75 ; A high resolution crystal structure of human glutamate carboxypeptidase II (GCPII) in a complex with DCMC, a urea-based inhibitor 2OR4 ; 1.62 ; A high resolution crystal structure of human glutamate carboxypeptidase II in complex with quisqualic acid 1S2R ; 1.53 ; A High Resolution Crystal Structure of [d(CGCAAATTTGCG)]2 2PVW ; 1.71 ; A high resolution structure of human glutamate carboxypeptidase II (GCPII) in complex with 2-(phosphonomethyl)pentanedioic acid (2-PMPA) 2OOT ; 1.64 ; A High Resolution Structure of Ligand-free Human Glutamate Carboxypeptidase II 2IH9 ; 2 ; A high-dose crystal structure of a recombinant Melanocarbus albomyces laccase 2KOD ; ; A high-resolution NMR structure of the dimeric C-terminal domain of HIV-1 CA 3HSS ; 1.9 ; A higher resolution structure of Rv0554 from Mycobacterium tuberculosis complexed with malonic acid 1Q1M ; 2.6 ; A Highly Efficient Approach to a Selective and Cell Active PTP1B inhibitors 3TVB ; 1.08 ; A Highly Symmetric DNA G-4 Quadruplex/drug Complex 1X0M ; 2.2 ; a Human Kynurenine Aminotransferase II Homologue from Pyrococcus horikoshii OT3 3NCC ; 2.5 ; A human Prolactin receptor antagonist in complex with the mutant extracellular domain H188A of the human prolactin receptor 1VDW ; 1.3 ; A hypothetical protein PH1897 from Pyrococcus horikoshii with similarities for Inositol-1 monophosphatase 3L45 ; 1.8 ; A Joint Neutron and X-ray structure of Oxidized Amicyanin 3L45 ; 1.5 ; A Joint Neutron and X-ray structure of Oxidized Amicyanin 1A8W ; ; A K+ CATION-INDUCED CONFORMATIONAL SWITCH WITHIN A LOOP SPANNING SEGMENT OF A DNA QUADRUPLEX CONTAINING G-G-G-C REPEATS, NMR, 8 STRUCTURES 2JQC ; ; A L-amino acid mutant of a D-amino acid containing conopeptide 2PHI ; 2.2 ; A LARGE CONFORMATIONAL CHANGE IS FOUND IN THE CRYSTAL STRUCTURE OF THE PORCINE PANCREATIC PHOSPHOLIPASE A2 POINT MUTANT F63V 1LRV ; 2.6 ; A LEUCINE-RICH REPEAT VARIANT WITH A NOVEL REPETITIVE PROTEIN STRUCTURAL MOTIF 1YTS ; 2.5 ; A LIGAND-INDUCED CONFORMATIONAL CHANGE IN THE YERSINIA PROTEIN TYROSINE PHOSPHATASE 1BH7 ; ; A LOW ENERGY STRUCTURE FOR THE FINAL CYTOPLASMIC LOOP OF BAND 3, NMR, MINIMIZED AVERAGE STRUCTURE 2IH8 ; 2 ; A low-dose crystal structure of a recombinant Melanocarpus albomyces laccase 2QJ2 ; 1.81 ; A Mechanistic Basis for Converting a Receptor Tyrosine Kinase Agonist to an Antagonist 2QJ4 ; 2.5 ; A Mechanistic Basis for Converting a Receptor Tyrosine Kinase Agonist to an Antagonist 2Z3C ; 1.79 ; A Mechanistic view of Enzyme Inhibition and Peptide Hydrolysis in the Active Site of the SARS-CoV 3C-Like peptidase 2Z3D ; 2.1 ; A Mechanistic view of Enzyme Inhibition and Peptide Hydrolysis in the Active Site of the SARS-CoV 3C-Like peptidase 2Z3E ; 2.32 ; A Mechanistic view of Enzyme Inhibition and Peptide Hydrolysis in the Active Site of the SARS-CoV 3C-Like peptidase 4AMS ; 2.6 ; A Megaviridae ORFan gene encode a new nucleotidyl transferase 4AMQ ; 2.17 ; A Megaviridae Orfan gene encodes a new nucleotidyl transferase 1XIS ; 1.6 ; A METAL-MEDIATED HYDRIDE SHIFT MECHANISM FOR XYLOSE ISOMERASE BASED ON THE 1.6 ANGSTROMS STREPTOMYCES RUBIGINOSUS STRUCTURES WITH XYLITOL AND D-XYLOSE 2XIS ; 1.71 ; A METAL-MEDIATED HYDRIDE SHIFT MECHANISM FOR XYLOSE ISOMERASE BASED ON THE 1.6 ANGSTROMS STREPTOMYCES RUBIGINOSUS STRUCTURES WITH XYLITOL AND D-XYLOSE 3XIS ; 1.6 ; A METAL-MEDIATED HYDRIDE SHIFT MECHANISM FOR XYLOSE ISOMERASE BASED ON THE 1.6 ANGSTROMS STREPTOMYCES RUBIGINOSUS STRUCTURES WITH XYLITOL AND D-XYLOSE 4XIS ; 1.6 ; A METAL-MEDIATED HYDRIDE SHIFT MECHANISM FOR XYLOSE ISOMERASE BASED ON THE 1.6 ANGSTROMS STREPTOMYCES RUBIGINOSUS STRUCTURES WITH XYLITOL AND D-XYLOSE 3NQW ; 2.9 ; A metazoan ortholog of SpoT hydrolyzes ppGpp and plays a role in starvation responses 3NR1 ; 1.9 ; A metazoan ortholog of SpoT hydrolyzes ppGpp and plays a role in starvation responses 2WXD ; 1.6 ; A MICROMOLAR O-SULFATED THIOHYDROXIMATE INHIBITOR BOUND TO PLANT MYROSINASE 1N09 ; ; A minimal beta-hairpin peptide scaffold for beta-turn display 3Q5U ; 2.5 ; A minimal NLS from human scramblase 4 complexed with importin alpha 2P7D ; 2.25 ; A Minimal, 'Hinged' Hairpin Ribozyme Construct Solved with Mimics of the Product Strands at 2.25 Angstroms Resolution 1DS7 ; 2.06 ; A MINOR FMN-DEPENDENT NITROREDUCTASE FROM ESCHERICHIA COLI B 2AEW ; 2.7 ; A model for growth hormone receptor activation based on subunit rotation within a receptor dimer 5TGL ; 3 ; A MODEL FOR INTERFACIAL ACTIVATION IN LIPASES FROM THE STRUCTURE OF A FUNGAL LIPASE-INHIBITOR COMPLEX 1XS9 ; ; A MODEL OF THE TERNARY COMPLEX FORMED BETWEEN MARA, THE ALPHA-CTD OF RNA POLYMERASE AND DNA 4ERS ; 2.637 ; A Molecular Basis for Negative Regulation of the Glucagon Receptor 4AXY ; 1.24 ; A molecular basis for the action of the collagen-specific chaperone Hsp47-SERPINH1 and its structure-specific client recognition. 3MAM ; 1.8 ; A molecular switch changes the low to the high affinity state in the substrate binding protein AfProX 2QA4 ; 3 ; A more complete structure of the the L7/L12 stalk of the Haloarcula marismortui 50S large ribosomal subunit 1LM3 ; 2.7 ; A Multi-generation Analysis of Cytochrome b562 Redox Variants: Evolutionary Strategies for Modulating Redox Potential Revealed Using a Library Approach 3NCB ; 2.1 ; A mutant human Prolactin receptor antagonist H180A in complex with the extracellular domain of the human prolactin receptor 3N06 ; 2 ; A mutant human Prolactin receptor antagonist H27A in complex with the extracellular domain of the human prolactin receptor 3NCE ; 2 ; A mutant human Prolactin receptor antagonist H27A in complex with the mutant extracellular domain H188A of the human prolactin receptor 3N0P ; 2.1 ; A mutant human Prolactin receptor antagonist H30A in complex with the extracellular domain of the human prolactin receptor 3NCF ; 2.8 ; A mutant human Prolactin receptor antagonist H30A in complex with the mutant extracellular domain H188A of the human prolactin receptor 2DD9 ; 2.3 ; A mutant of GFP-like protein from Chiridius poppei 3HHT ; 1.16 ; A mutant of the nitrile hydratase from Geobacillus pallidus having enhanced thermostability 1WCS ; 2.8 ; A MUTANT OF TRYPANOSOMA RANGELI SIALIDASE DISPLAYING TRANS-SIALIDASE ACTIVITY 2F7D ; 1.9 ; A mutant rabbit cathepsin K with a nitrile inhibitor 1KPD ; ; A MUTANT RNA PSEUDOKNOT THAT PROMOTES RIBOSOMAL FRAMESHIFTING IN MOUSE MAMMARY TUMOR VIRUS, NMR, MINIMIZED AVERAGE STRUCTURE 1QOH ; 2.35 ; A MUTANT SHIGA-LIKE TOXIN IIE 2BOS ; 2 ; A MUTANT SHIGA-LIKE TOXIN IIE BOUND TO ITS RECEPTOR 2A9N ; 3 ; A Mutation Designed to Alter Crystal Packing Permits Structural Analysis of a Tight-binding Fluorescein-scFv complex 2LKW ; ; A Myristoylated Polyproline Type II Helix Functions as a Novel Fusion Peptide During Cell-Cell Membrane Fusion Induced by the Baboon Reovirus p15 FAST Protein 2F8O ; 1.7 ; A Native to Amyloidogenic Transition Regulated by a Backbone Trigger 1N2R ; 1.7 ; A natural selected dimorphism in HLA B*44 alters self, peptide reportoire and T cell recognition. 3TAX ; 1.88 ; A Neutral Diphosphate Mimic Crosslinks the Active Site of Human O-GlcNAc Transferase 1JJB ; 2.3 ; A neutral molecule in cation-binding site: Specific binding of PEG-SH to Acetylcholinesterase from Torpedo californica 3FHP ; 2 ; A neutron crystallographic analysis of a porcine 2Zn insulin at 2.0 A resolution 2JIM ; 2.45 ; A NEW CATALYTIC MECHANISM OF PERIPLASMIC NITRATE REDUCTASE FROM DESULFOVIBRIO DESULFURICANS ATCC 27774 FROM CRYSTALLOGRAPHIC AND EPR DATA AND BASED ON DETAILED ANALYSIS OF THE SIXTH LIGAND 2JIO ; 2.2 ; A NEW CATALYTIC MECHANISM OF PERIPLASMIC NITRATE REDUCTASE FROM DESULFOVIBRIO DESULFURICANS ATCC 27774 FROM CRYSTALLOGRAPHIC AND EPR DATA AND BASED ON DETAILED ANALYSIS OF THE SIXTH LIGAND 2JIP ; 2.3 ; A NEW CATALYTIC MECHANISM OF PERIPLASMIC NITRATE REDUCTASE FROM DESULFOVIBRIO DESULFURICANS ATCC 27774 FROM CRYSTALLOGRAPHIC AND EPR DATA AND BASED ON DETAILED ANALYSIS OF THE SIXTH LIGAND 2JIQ ; 2.44 ; A NEW CATALYTIC MECHANISM OF PERIPLASMIC NITRATE REDUCTASE FROM DESULFOVIBRIO DESULFURICANS ATCC 27774 FROM CRYSTALLOGRAPHIC AND EPR DATA AND BASED ON DETAILED ANALYSIS OF THE SIXTH LIGAND 2JIR ; 2.35 ; A NEW CATALYTIC MECHANISM OF PERIPLASMIC NITRATE REDUCTASE FROM DESULFOVIBRIO DESULFURICANS ATCC 27774 FROM CRYSTALLOGRAPHIC AND EPR DATA AND BASED ON DETAILED ANALYSIS OF THE SIXTH LIGAND 2V3V ; 1.99 ; A NEW CATALYTIC MECHANISM OF PERIPLASMIC NITRATE REDUCTASE FROM DESULFOVIBRIO DESULFURICANS ATCC 27774 FROM CRYSTALLOGRAPHIC AND EPR DATA AND BASED ON DETAILED ANALYSIS OF THE SIXTH LIGAND 2V45 ; 2.4 ; A NEW CATALYTIC MECHANISM OF PERIPLASMIC NITRATE REDUCTASE FROM DESULFOVIBRIO DESULFURICANS ATCC 27774 FROM CRYSTALLOGRAPHIC AND EPR DATA AND BASED ON DETAILED ANALYSIS OF THE SIXTH LIGAND 3AID ; 2.5 ; A NEW CLASS OF HIV-1 PROTEASE INHIBITOR: THE CRYSTALLOGRAPHIC STRUCTURE, INHIBITION AND CHEMICAL SYNTHESIS OF AN AMINIMIDE PEPTIDE ISOSTERE 3E9S ; 2.5 ; A new class of papain-like protease/deubiquitinase inhibitors blocks SARS virus replication 3SRK ; 2.65 ; A new class of suicide inhibitor blocks nucleotide binding to pyruvate kinase 2ZXM ; 3.01 ; A New Class of Vitamin D Receptor Ligands that Induce Structural Rearrangement of the Ligand-binding Pocket 2ZXN ; 2.1 ; A New Class of Vitamin D Receptor Ligands that Induce Structural Rearrangement of the Ligand-binding Pocket 2QCA ; 1.33 ; A New Crystal Form of Bovine Pancreatic RNase A in Complex with 2'-Deoxyguanosine-5'-monophosphate 3M3J ; 1.6 ; A new crystal form of Lys48-linked diubiquitin 1GP9 ; 2.5 ; A NEW CRYSTAL FORM OF THE NK1 SPLICE VARIANT OF HGF/SF DEMONSTRATES EXTENSIVE HINGE MOVEMENT AND SUGGESTS THAT THE NK1 DIMER ORIGINATES BY DOMAIN SWAPPING 1EHV ; 1.8 ; A NEW CRYSTAL STRUCTURE FOR THE DODECAMER C-G-C-G-A-A-T-T-C-G-C-G: SYMMETRY EFFECTS ON SEQUENCE-DEPENDENT DNA STRUCTURE 3U7B ; 1.94 ; A new crystal structure of a Fusarium oxysporum GH10 xylanase reveals the presence of an extended loop on top of the catalytic cleft 3T7U ; 2.9 ; A NeW Crytal structure of APC-ARM 3ZBO ; 1.58 ; A new family of proteins related to the HEAT-like repeat DNA glycosylases with affinity for branched DNA structures 1Y75 ; 2.3 ; A new form of catalytically inactive phospholipase A2 with an unusual disulphide bridge Cys 32- Cys 49 reveals recognition for N-acetylglucosmine 3EY0 ; 2.52 ; A new form of DNA-drug interaction in the minor groove of a coiled coil 1O87 ; 2.1 ; A NEW MGGDP COMPLEX OF THE FFH NG DOMAIN 3SMA ; 2 ; A new N-acetyltransferase fold in the structure and mechanism of the phosphonate biosynthetic enzyme FrbF 1CHZ ; 1.76 ; A NEW NEUROTOXIN FROM BUTHUS MARTENSII KARSCH 1NCF ; 2.25 ; A NEW PARADIGM FOR TUMOR NECROSIS FACTOR SIGNALLING 3MHY ; 1.4 ; A New PII Protein Structure 1ENU ; 1.95 ; A new target for shigellosis: Rational design and crystallographic studies of inhibitors of tRNA-guanine transglycosylase 1F3E ; 1.85 ; A NEW TARGET FOR SHIGELLOSIS: RATIONAL DESIGN AND CRYSTALLOGRAPHIC STUDIES OF INHIBITORS OF TRNA-GUANINE TRANSGLYCOSYLASE 4ESV ; 3.2 ; A New Twist on the Translocation Mechanism of Helicases from the Structure of DnaB with its Substrates 3DGN ; 2.7 ; A non-biological ATP binding protein crystallized in the presence of 100 mM ADP 3LT9 ; 2.55 ; A non-biological ATP binding protein with a single point mutation (D65V), that contributes to optimized folding and ligand binding 3LT8 ; 2.55 ; A non-biological ATP binding protein with a single point mutation (D65V), that contributes to optimized folding and ligand binding, crystallized in the presence of 100 mM ATP. 3DGO ; 2.5 ; A non-biological ATP binding protein with a Tyr-Phe mutation in the ligand binding domain 2V4E ; 2.4 ; A NON-CYTOTOXIC DSRED VARIANT FOR WHOLE-CELL LABELING 2OKW ; 1.9 ; A non-invasive GFP-based biosensor for mercury ions 2OKY ; 2.4 ; A non-invasive GFP-based biosensor for mercury ions 3OAY ; 1.95 ; A non-self sugar mimic of the HIV glycan shield shows enhanced antigenicity 3OAZ ; 1.75 ; A non-self sugar mimic of the HIV glycan shield shows enhanced antigenicity 3OB0 ; 2.85 ; A non-self sugar mimic of the HIV glycan shield shows enhanced antigenicity 1U8C ; 3.1 ; A novel adaptation of the integrin PSI domain revealed from its crystal structure 1UW1 ; 1.94 ; A NOVEL ADP- AND ZINC-BINDING FOLD FROM FUNCTION-DIRECTED IN VITRO EVOLUTION 1HDA ; 2.2 ; A NOVEL ALLOSTERIC MECHANISM IN HAEMOGLOBIN. STRUCTURE OF BOVINE DEOXYHAEMOGLOBIN, ABSENCE OF SPECIFIC CHLORIDE-BINDING SITES AND ORIGIN OF THE CHLORIDE-LINKED BOHR EFFECT IN BOVINE AND HUMAN HAEMOGLOBIN 2FVJ ; 1.99 ; A novel anti-adipogenic partial agonist of peroxisome proliferator-activated receptor-gamma (PPARG) recruits pparg-coactivator-1 alpha (PGC1A) but potentiates insulin signaling in vitro 1EUJ ; 1.8 ; A NOVEL ANTI-TUMOR CYTOKINE CONTAINS A RNA-BINDING MOTIF PRESENT IN AMINOACYL-TRNA SYNTHETASES 3KCK ; 2.2 ; A Novel Chemotype of Kinase Inhibitors 1TNS ; ; A NOVEL CLASS OF WINGED HELIX-TURN-HELIX PROTEIN: THE DNA-BINDING DOMAIN OF MU TRANSPOSASE 1TNT ; ; A NOVEL CLASS OF WINGED HELIX-TURN-HELIX PROTEIN: THE DNA-BINDING DOMAIN OF MU TRANSPOSASE 2J9Q ; 2.65 ; A NOVEL CONFORMATION FOR THE TPR DOMAIN OF PEX5P 4HEX ; 2.001 ; A novel conformation of calmodulin 1WCT ; ; A NOVEL CONOTOXIN FROM CONUS TEXTILE WITH UNUSUAL POST-TRANSLATIONAL MODIFICATIONS REDUCES PRESYNAPTIC CALCIUM INFLUX, NMR, 1 STRUCTURE, GLYCOSYLATED PROTEIN 3U4N ; 1.98 ; A novel covalently linked insulin dimer 2CZQ ; 1.05 ; A novel cutinase-like protein from Cryptococcus sp. 2L60 ; ; A novel design concept: New Y-receptor agonists with increased membrane recruitment, Y2 affinity and selectivity 1HUL ; 2.4 ; A NOVEL DIMER CONFIGURATION REVEALED BY THE CRYSTAL STRUCTURE AT 2.4 ANGSTROMS RESOLUTION OF HUMAN INTERLEUKIN-5 2IBM ; 3.2 ; A novel dimer interface and conformational changes revealed by an X-ray structure of B. subtilis SecA 1RAM ; 2.7 ; A NOVEL DNA RECOGNITION MODE BY NF-KB P65 HOMODIMER 2RAM ; 2.4 ; A NOVEL DNA RECOGNITION MODE BY NF-KB P65 HOMODIMER 2JRA ; ; A novel domain-swapped solution NMR structure of protein RPA2121 from Rhodopseudomonas palustris. Northeast Structural Genomics Target RpT6 1URR ; 1.5 ; A NOVEL DROSOPHILA MELANOGASTER ACYLPHOSPHATASE (ACPDRO2) 375D ; 2.4 ; A NOVEL END-TO-END BINDING OF TWO NETROPSINS TO THE DNA DECAMER D(CCCCCIIIII)2 474D ; 2.4 ; A NOVEL END-TO-END BINDING OF TWO NETROPSINS TO THE DNA DECAMER D(CCCCCIIIII)2 3T3M ; 2.6 ; A Novel High Affinity Integrin alphaIIbbeta3 Receptor Antagonist That Unexpectedly Displaces Mg2+ from the beta3 MIDAS 3T3P ; 2.2 ; A Novel High Affinity Integrin alphaIIbbeta3 Receptor Antagonist That Unexpectedly Displaces Mg2+ from the beta3 MIDAS 3QYY ; 1.9 ; A Novel Interaction Mode between a Microbial GGDEF Domain and the Bis-(3, 5 )-cyclic di-GMP 1H21 ; 2.5 ; A NOVEL IRON CENTRE IN THE SPLIT-SORET CYTOCHROME C FROM DESULFOVIBRIO DESULFURICANS ATCC 27774 2JQW ; ; A novel lectin-like peptide from Odorrana grahami 2NPQ ; 1.8 ; A Novel Lipid Binding Site in the p38 alpha MAP Kinase 2BW7 ; 2.3 ; A NOVEL MECHANISM FOR ADENYLYL CYCLASE INHIBITION FROM THE CRYSTAL STRUCTURE OF ITS COMPLEX WITH CATECHOL ESTROGEN 3RI6 ; 2.2 ; A Novel Mechanism of Sulfur Transfer Catalyzed by O-Acetylhomoserine Sulfhydrylase in Methionine Biosynthetic Pathway of Wolinella succinogenes 1JAC ; 2.43 ; A NOVEL MODE OF CARBOHYDRATE RECOGNITION IN JACALIN, A MORACEAE PLANT LECTIN WITH A BETA-PRISM 1HL6 ; 2.5 ; A NOVEL MODE OF RBD-PROTEIN RECOGNITION IN THE Y14-MAGO COMPLEX 1S20 ; 2.2 ; A novel NAD binding protein revealed by the crystal structure of E. Coli 2,3-diketogulonate reductase (YiaK) NORTHEAST STRUCTURAL GENOMICS CONSORTIUM TARGET ER82 1NXE ; 2.3 ; A Novel NADH Allosteric Regulator Site is Found on the Surface of the Hexameric Type II Phe383Ala Variant of Citrate Synthase 3UT3 ; 2.42 ; A novel PAI-I inhibitor and its structural mechanism 1YZI ; 2.07 ; A novel quaternary structure of human carbonmonoxy hemoglobin 3TGE ; 1.96 ; A novel series of potent and selective PDE5 inhibitor1 3TGG ; 1.91 ; A novel series of potent and selective PDE5 inhibitor2 1GHZ ; 1.39 ; A NOVEL SERINE PROTEASE INHIBITION MOTIF INVOLVING A MULTI-CENTERED SHORT HYDROGEN BONDING NETWORK AT THE ACTIVE SITE 1GI0 ; 1.42 ; A NOVEL SERINE PROTEASE INHIBITION MOTIF INVOLVING A MULTI-CENTERED SHORT HYDROGEN BONDING NETWORK AT THE ACTIVE SITE 1GI1 ; 1.42 ; A NOVEL SERINE PROTEASE INHIBITION MOTIF INVOLVING A MULTI-CENTERED SHORT HYDROGEN BONDING NETWORK AT THE ACTIVE SITE 1GI2 ; 1.38 ; A NOVEL SERINE PROTEASE INHIBITION MOTIF INVOLVING A MULTI-CENTERED SHORT HYDROGEN BONDING NETWORK AT THE ACTIVE SITE 1GI3 ; 1.44 ; A NOVEL SERINE PROTEASE INHIBITION MOTIF INVOLVING A MULTI-CENTERED SHORT HYDROGEN BONDING NETWORK AT THE ACTIVE SITE 1GI4 ; 1.37 ; A NOVEL SERINE PROTEASE INHIBITION MOTIF INVOLVING A MULTI-CENTERED SHORT HYDROGEN BONDING NETWORK AT THE ACTIVE SITE 1GI5 ; 1.6 ; A NOVEL SERINE PROTEASE INHIBITION MOTIF INVOLVING A MULTI-CENTERED SHORT HYDROGEN BONDING NETWORK AT THE ACTIVE SITE 1GI6 ; 1.49 ; A NOVEL SERINE PROTEASE INHIBITION MOTIF INVOLVING A MULTI-CENTERED SHORT HYDROGEN BONDING NETWORK AT THE ACTIVE SITE 1GI7 ; 1.79 ; A NOVEL SERINE PROTEASE INHIBITION MOTIF INVOLVING A MULTI-CENTERED SHORT HYDROGEN BONDING NETWORK AT THE ACTIVE SITE 1GI8 ; 1.75 ; A NOVEL SERINE PROTEASE INHIBITION MOTIF INVOLVING A MULTI-CENTERED SHORT HYDROGEN BONDING NETWORK AT THE ACTIVE SITE 1GI9 ; 1.8 ; A NOVEL SERINE PROTEASE INHIBITION MOTIF INVOLVING A MULTI-CENTERED SHORT HYDROGEN BONDING NETWORK AT THE ACTIVE SITE 1GHV ; 1.85 ; A NOVEL SERINE PROTEASE INHIBITION MOTIF INVOLVING A MULTI-CENTERED SHORT HYDROGEN BONDING NETWORK AT THE ACTIVE SITE 1GHW ; 1.75 ; A NOVEL SERINE PROTEASE INHIBITION MOTIF INVOLVING A MULTI-CENTERED SHORT HYDROGEN BONDING NETWORK AT THE ACTIVE SITE 1GHX ; 1.65 ; A NOVEL SERINE PROTEASE INHIBITION MOTIF INVOLVING A MULTI-CENTERED SHORT HYDROGEN BONDING NETWORK AT THE ACTIVE SITE 1GHY ; 1.85 ; A NOVEL SERINE PROTEASE INHIBITION MOTIF INVOLVING A MULTI-CENTERED SHORT HYDROGEN BONDING NETWORK AT THE ACTIVE SITE 2XBP ; 1.2 ; A NOVEL SIGNAL TRANSDUCTION PROTEIN PII VARIANT FROM SYNECHOCOCCUS ELONGATUS PCC7942 INDICATES A TWO-STEP PROCESS FOR NAGK PII COMPLEX FORMATION 1MOA ; 1.9 ; A NOVEL SITE-DIRECTED MUTANT OF MYOGLOBIN WITH AN UNUSUALLY HIGH O2 AFFINITY AND LOW AUTOOXIDATION RATE 2SPL ; 1.7 ; A NOVEL SITE-DIRECTED MUTANT OF MYOGLOBIN WITH AN UNUSUALLY HIGH O2 AFFINITY AND LOW AUTOOXIDATION RATE 2SPM ; 1.7 ; A NOVEL SITE-DIRECTED MUTANT OF MYOGLOBIN WITH AN UNUSUALLY HIGH O2 AFFINITY AND LOW AUTOOXIDATION RATE 2SPN ; 1.7 ; A NOVEL SITE-DIRECTED MUTANT OF MYOGLOBIN WITH AN UNUSUALLY HIGH O2 AFFINITY AND LOW AUTOOXIDATION RATE 2SPO ; 1.7 ; A NOVEL SITE-DIRECTED MUTANT OF MYOGLOBIN WITH AN UNUSUALLY HIGH O2 AFFINITY AND LOW AUTOOXIDATION RATE 3ZH8 ; 2.739 ; A novel small molecule aPKC inhibitor 2JYN ; ; A novel solution NMR structure of protein yst0336 from Saccharomyces cerevisiae. Northeast Structural Genomics Consortium target YT51/Ontario Centre for Structural Proteomics target yst0336 1TFI ; ; A NOVEL ZN FINGER MOTIF IN THE BASAL TRANSCRIPTIONAL MACHINERY: THREE-DIMENSIONAL NMR STUDIES OF THE NUCLEIC-ACID BINDING DOMAIN OF TRANSCRIPTIONAL ELONGATION FACTOR TFIIS 1GB1 ; ; A NOVEL, HIGHLY STABLE FOLD OF THE IMMUNOGLOBULIN BINDING DOMAIN OF STREPTOCOCCAL PROTEIN G 2GB1 ; ; A NOVEL, HIGHLY STABLE FOLD OF THE IMMUNOGLOBULIN BINDING DOMAIN OF STREPTOCOCCAL PROTEIN G 4SKN ; 2.9 ; A NUCLEOTIDE-FLIPPING MECHANISM FROM THE STRUCTURE OF HUMAN URACIL-DNA GLYCOSYLASE BOUND TO DNA 2IPZ ; 1.35 ; A Parallel Coiled-Coil Tetramer with Offset Helices 1R2L ; ; A parallel stranded DNA duplex with an A-G mismatch base-pair 2HRI ; 2.09 ; A parallel stranded human telomeric quadruplex in complex with the porphyrin TMPyP4 2LFM ; ; A partially folded structure of amyloid-beta(1 40) in an aqueous environment 2G38 ; 2.2 ; A PE/PPE Protein Complex from Mycobacterium tuberculosis 2KIE ; ; A PH domain within OCRL bridges clathrin mediated membrane trafficking to phosphoinositide metabolis 2KIG ; ; A PH domain within OCRL bridges clathrin mediated membrane trafficking to phosphoinositide metabolism 2GAR ; 1.8 ; A PH-DEPENDENT STABLIZATION OF AN ACTIVE SITE LOOP OBSERVED FROM LOW AND HIGH PH CRYSTAL STRUCTURES OF MUTANT MONOMERIC GLYCINAMIDE RIBONUCLEOTIDE TRANSFORMYLASE 3GAR ; 1.9 ; A PH-DEPENDENT STABLIZATION OF AN ACTIVE SITE LOOP OBSERVED FROM LOW AND HIGH PH CRYSTAL STRUCTURES OF MUTANT MONOMERIC GLYCINAMIDE RIBONUCLEOTIDE TRANSFORMYLASE 2CHW ; 2.6 ; A PHARMACOLOGICAL MAP OF THE PI3-K FAMILY DEFINES A ROLE FOR P110 ALPHA IN SIGNALING: THE STRUCTURE OF COMPLEX OF PHOSPHOINOSITIDE 3-KINASE GAMMA WITH INHIBITOR PIK-39 2CHX ; 2.5 ; A PHARMACOLOGICAL MAP OF THE PI3-K FAMILY DEFINES A ROLE FOR P110ALPHA IN SIGNALING: THE STRUCTURE OF COMPLEX OF PHOSPHOINOSITIDE 3-KINASE GAMMA WITH INHIBITOR PIK-90 2CHZ ; 2.6 ; A PHARMACOLOGICAL MAP OF THE PI3-K FAMILY DEFINES A ROLE FOR P110ALPHA IN SIGNALING: THE STRUCTURE OF COMPLEX OF PHOSPHOINOSITIDE 3-KINASE GAMMA WITH INHIBITOR PIK-93 2JWO ; ; A PHD finger motif in the C-terminus of RAG2 modulates recombination activity 1SOL ; ; A PIP2 AND F-ACTIN-BINDING SITE OF GELSOLIN, RESIDUE 150-169 (NMR, AVERAGED STRUCTURE) 3GLJ ; 1.89 ; A polymorph of carboxypeptidase B zymogen structure 1GED ; 2 ; A positive charge route for the access of nadh to heme formed in the distal heme pocket of cytochrome p450nor 2BCH ; 1.1 ; A possible of Second calcium ion in interfacial binding: Atomic and Medium resolution crystal structures of the quadruple mutant of phospholipase A2 2BD1 ; 1.9 ; A possible role of the second calcium ion in interfacial binding: Atomic and medium resolution crystal structures of the quadruple mutant of phospholipase A2 3DS9 ; 1.758 ; A potent peptidomimetic inhibitor of botulinum neurotoxin serotype A has a very different conformation than SNAP-25 substrate 3DSE ; 1.9 ; A potent peptidomimetic inhibitor of botulinum neurotoxin serotype A has a very different conformation than SNAP-25 substrate 11BG ; 1.9 ; A POTENTIAL ALLOSTERIC SUBSITE GENERATED BY DOMAIN SWAPPING IN BOVINE SEMINAL RIBONUCLEASE 1VHH ; 1.7 ; A POTENTIAL CATALYTIC SITE WITHIN THE AMINO-TERMINAL SIGNALLING DOMAIN OF SONIC HEDGEHOG 1CL8 ; 1.8 ; A PRE-TRANSITION STATE ECO RI ENDONUCLEASE/COGNATE DNA (TCGCGAPTTCGCG) COMPLEX WITH DNA BASE ANALOG PURINE (P) 1ADD ; 2.4 ; A PRE-TRANSITION STATE MIMIC OF AN ENZYME: X-RAY STRUCTURE OF ADENOSINE DEAMINASE WITH BOUND 1-DEAZA-ADENOSINE AND ZINC-ACTIVATED WATER 1GRZ ; 5 ; A PREORGANIZED ACTIVE SITE IN THE CRYSTAL STRUCTURE OF THE TETRAHYMENA RIBOZYME 1APB ; 1.76 ; A PRO TO GLY MUTATION IN THE HINGE OF THE ARABINOSE-BINDING PROTEIN ENHANCES BINDING AND ALTERS SPECIFICITY: SUGAR-BINDING AND CRYSTALLOGRAPHIC STUDIES 1BAP ; 1.75 ; A PRO TO GLY MUTATION IN THE HINGE OF THE ARABINOSE-BINDING PROTEIN ENHANCES BINDING AND ALTERS SPECIFICITY: SUGAR-BINDING AND CRYSTALLOGRAPHIC STUDIES 9ABP ; 1.97 ; A PRO TO GLY MUTATION IN THE HINGE OF THE ARABINOSE-BINDING PROTEIN ENHANCES BINDING AND ALTERS SPECIFICITY: SUGAR-BINDING AND CRYSTALLOGRAPHIC STUDIES 1AYP ; 2.57 ; A PROBE MOLECULE COMPOSED OF SEVENTEEN PERCENT OF TOTAL DIFFRACTING MATTER GIVES CORRECT SOLUTIONS IN MOLECULAR REPLACEMENT 2XD0 ; 3 ; A PROCESSED NON-CODING RNA REGULATES A BACTERIAL ANTIVIRAL SYSTEM 2XDB ; 2.55 ; A PROCESSED NON-CODING RNA REGULATES A BACTERIAL ANTIVIRAL SYSTEM 2XDD ; 3.2 ; A PROCESSED NON-CODING RNA REGULATES A BACTERIAL ANTIVIRAL SYSTEM 2KR0 ; ; A proteasome protein 3ANW ; 2.65 ; A protein complex essential initiation of DNA replication 1OQU ; 2 ; A protein coordinated tri-nuclear Fe complex formed during soaking of crystals of the ribonucleotide reductase R2F protein from Corynebacterium Ammoniagenes 2L83 ; ; A protein from Haloferax volcanii 2J0N ; 2.1 ; A PROTEOLYTICALLY TRUNCATED FORM OF SHIGELLA FLEXNERI IPAD 1EHJ ; ; A PROTON-NMR INVESTIGATION OF THE FULLY REDUCED CYTOCHROME C7 FROM DESULFUROMONAS ACETOXIDANS 1F22 ; ; A PROTON-NMR INVESTIGATION OF THE FULLY REDUCED CYTOCHROME C7 FROM DESULFUROMONAS ACETOXIDANS. COMPARISON BETWEEN THE REDUCED AND THE OXIDIZED FORMS. 2CMN ; 2.3 ; A PROXIMAL ARGININE RESIDUE IN THE SWITCHING MECHANISM OF THE FIXL OXYGEN SENSOR 2DWP ; 2.7 ; A pseudo substrate complex of 6-phosphofructo-2-kinase of PFKFB 2CGQ ; 1.83 ; A PUTATIVE ACYL CARRIER PROTEIN(RV0033) FROM MYCOBACTERIUM TUBERCULOSIS 2FUJ ; 1.7 ; A putative acyl-CoA thioesterase from Xanthomonas campestris (XC229) 3MAH ; 2.31 ; A putative c-terminal regulatory domain of aspartate kinase from porphyromonas gingivalis w83. 3NQR ; 2 ; A putative CBS domain-containing protein from Salmonella typhimurium LT2 3ELN ; 1.42 ; A Putative Fe2+-bound Persulfenate Intermediate in Cysteine Dioxygenase 3IV4 ; 1.5 ; A putative oxidoreductase with a thioredoxin fold 2B78 ; 2 ; A putative sam-dependent methyltransferase from Streptococcus mutans 3JRK ; 1.97 ; A putative tagatose 1,6-diphosphate aldolase from Streptococcus pyogenes 2CGF ; 2.2 ; A RADICICOL ANALOGUE BOUND TO THE ATP BINDING SITE OF THE N-TERMINAL DOMAIN OF THE YEAST HSP90 CHAPERONE 3IGT ; 1.9 ; A rare nucleotide base tautomer in the structure of an asymmetric DNA junction 5ER1 ; 2 ; A rational approach to the design of antihypertensives. X-ray studies of complexes between aspartic proteinases and aminoalcohol renin inhibitors 1VKQ ; 1.6 ; A re-determination of the structure of the triple mutant (K53,56,120M) of phospholipase A2 at 1.6A resolution using sulphur-SAS at 1.54A wavelength 2CHR ; 3 ; A RE-EVALUATION OF THE CRYSTAL STRUCTURE OF CHLOROMUCONATE CYCLOISOMERASE 1GSM ; 1.9 ; A REASSESSMENT OF THE MADCAM-1 STRUCTURE AND ITS ROLE IN INTEGRIN RECOGNITION. 3J1X ; ; A refined model of the prototypical Salmonella typhimurium T3SS basal body reveals the molecular basis for its assembly 3J1W ; ; A refined model of the prototypical Salmonella typhimurium T3SS basal body reveals the molecular basis for its assembly 3J1V ; ; A refined model of the prototypical Salmonella typhimurium T3SS basal body reveals the molecular basis for its assembly 1DMZ ; ; A REFINED NMR STRUCTURE OF A NEW PHOPHOPEPTIDE-BINDING DOMAIN CONTAINING THE FHA2 OF RAD53 1H6I ; 3.54 ; A REFINED STRUCTURE OF HUMAN AQUAPORIN 1 3CIQ ; 2.9 ; A regulatable switch mediates self-association in an immunoglobulin fold 3BO2 ; 3.31 ; A relaxed active site following exon ligation by a group I intron 3BO3 ; 3.4 ; A relaxed active site following exon ligation by a group I intron 3BO4 ; 3.33 ; A relaxed active site following exon ligation by a group I intron 3LFK ; 1.6 ; A reported archaeal mechanosensitive channel is a structural homolog of MarR-like transcriptional regulators 2B5B ; ; A reptilian defensin with anti-bacterial and anti-viral activity 2I1A ; 2.3 ; A Retroviral Protease-Like Domain in the Eukaryotic Protein Ddi1 3HJH ; 1.95 ; A rigid N-terminal clamp restrains the motor domains of the bacterial transcription-repair coupling factor 3RTR ; 3.21 ; A RING E3-substrate complex poised for ubiquitin-like protein transfer: structural insights into cullin-RING ligases 3U3I ; 2.304 ; A RNA binding protein from Crimean-Congo hemorrhagic fever virus 3CM8 ; 2.899 ; A RNA polymerase subunit structure from virus 2D09 ; 1.8 ; A Role for Active Site Water Molecules and Hydroxyl Groups of Substrate for Oxygen Activation in Cytochrome P450 158A2 1MIH ; 2.7 ; A ROLE FOR CHEY GLU 89 IN CHEZ-MEDIATED DEPHOSPHORYLATION OF THE E. COLI CHEMOTAXIS RESPONSE REGULATOR CHEY 2QV2 ; 2.4 ; A role of the Lowe syndrome protein OCRL in early steps of the endocytic pathway 3MNN ; 2.5 ; A Ruthenium Antitumour Agent Forms Specific Histone Protein Adducts in the Nucleosome Core 1GHB ; 2 ; A SECOND ACTIVE SITE IN CHYMOTRYPSIN? THE X-RAY CRYSTAL STRUCTURE OF N-ACETYL-D-TRYPTOPHAN BOUND TO GAMMA-CHYMOTRYPSIN 1GHA ; 2.2 ; A SECOND ACTIVE SITE IN CHYMOTRYPSIN? THE X-RAY CRYSTAL STRUCTURE OF N-ACETYL-D-TRYPTOPHAN BOUND TO GAMMA-CHYMOTRYPSIN 4F04 ; 2.3 ; A Second Allosteric site in E. coli Aspartate Transcarbamoylase: R-state ATCase with UTP bound 2FSZ ; 2.2 ; A second binding site for hydroxytamoxifen within the coactivator-binding groove of estrogen receptor beta 3NWK ; 2.09 ; A second C2221 form of concanavalin A (Canavalia ensiformis) 2WHX ; 2.2 ; A SECOND CONFORMATION OF THE NS3 PROTEASE-HELICASE FROM DENGUE VIRUS 1HD7 ; 1.95 ; A SECOND DIVALENT METAL ION IN THE ACTIVE SITE OF A NEW CRYSTAL FORM OF HUMAN APURINIC/APYRIDINIMIC ENDONUCLEASE, APE1, AND ITS IMPLICATIONS FOR THE CATALYTIC MECHANISM 1E9N ; 2.2 ; A SECOND DIVALENT METAL ION IN THE ACTIVE SITE OF A NEW CRYSTAL FORM OF HUMAN APURINIC/APYRIMIDINIC ENDONUCLEASE, APE1, AND ITS IMPLICATIONS FOR THE CATALYTIC MECHANISM 2BN4 ; 2.91 ; A SECOND FMN-BINDING SITE IN YEAST NADPH-CYTOCHROME P450 REDUCTASE SUGGESTS A NOVEL MECHANISM OF ELECTRON TRANSFER BY DIFLAVIN REDUCTASE 2BF4 ; 3 ; A SECOND FMN-BINDING SITE IN YEAST NADPH-CYTOCHROME P450 REDUCTASE SUGGESTS A NOVEL MECHANISM OF ELECTRON TRANSFER BY DIFLAVIN REDUCTASES. 3EIU ; 3.43 ; A second transient position of ATP on its trail to the nucleotide-binding site of subunit B of the motor protein A1Ao ATP synthase 1TGL ; 1.9 ; A SERINE PROTEASE TRIAD FORMS THE CATALYTIC CENTRE OF A TRIACYLGLYCEROL LIPASE 2AYR ; 1.9 ; A SERM Designed for the Treatment of Uterine Leiomyoma with Unique Tissue Specificity for Uterus and Ovaries in Rats 2HY6 ; 1.25 ; A seven-helix coiled coil 1RMX ; ; A SHORT LEXITROPSIN THAT RECOGNIZES THE DNA MINOR GROOVE AT 5'-ACTAGT-3': UNDERSTANDING THE ROLE OF ISOPROPYL-THIAZOLE 1RN9 ; ; A SHORT LEXITROPSIN THAT RECOGNIZES THE DNA MINOR GROOVE AT 5'-ACTAGT-3': UNDERSTANDING THE ROLE OF ISOPROPYL-THIAZOLE 1ULH ; 2.31 ; A short peptide insertion crucial for angiostatic activity of human tryptophanyl-tRNA synthetase 1INV ; 2.4 ; A SIALIC ACID DERIVED PHOSPHONATE ANALOG INHIBITS DIFFERENT STRAINS OF INFLUENZA VIRUS NEURAMINIDASE WITH DIFFERENT EFFICIENCIES 1INW ; 2.4 ; A SIALIC ACID DERIVED PHOSPHONATE ANALOG INHIBITS DIFFERENT STRAINS OF INFLUENZA VIRUS NEURAMINIDASE WITH DIFFERENT EFFICIENCIES 1INX ; 2.4 ; A SIALIC ACID DERIVED PHOSPHONATE ANALOG INHIBITS DIFFERENT STRAINS OF INFLUENZA VIRUS NEURAMINIDASE WITH DIFFERENT EFFICIENCIES 1INY ; 2.4 ; A SIALIC ACID DERIVED PHOSPHONATE ANALOG INHIBITS DIFFERENT STRAINS OF INFLUENZA VIRUS NEURAMINIDASE WITH DIFFERENT EFFICIENCIES 3AUB ; 1 ; A simplified BPTI variant stabilized by the A14G and A38V substitutions 3AUH ; 1.2 ; A simplified BPTI variant with poly Arg amino acid tag (C3R) at the C-terminus 3AUI ; 1.851 ; A simplified BPTI variant with poly Glu amino acid tag (C3E) at the C-terminus 3AUE ; 2.28 ; A simplified BPTI variant with poly His amino acid tag (C5H) at the C-terminus 3AUG ; 1.398 ; A simplified BPTI variant with poly Pro amino acid tag (C5P) at the C-terminus 3AUC ; 1.91 ; A simplified BPTI variant with poly SER (C5S) amino acid tag at the c-terminus 161D ; 1.9 ; A SINGLE 2'-HYDROXYL GROUP CONVERTS B-DNA TO A-DNA: CRYSTAL STRUCTURE OF THE DNA-RNA CHIMERIC DECAMER DUPLEX D(CCGGC)R(G)D(CCGG) WITH A NOVEL INTERMOLECULAR G.C BASE-PAIRED QUADRUPLET 2B83 ; 2.25 ; A single amino acid substitution in the Clostridium beijerinckii alcohol dehydrogenase is critical for thermostabilization 2LMS ; ; A single GalNAc residue on Threonine-106 modifies the dynamics and the structure of Interferon alpha-2a around the glycosylation site 1SMI ; 2 ; A single mutation of P450 BM3 induces the conformational rearrangement seen upon substrate-binding in wild-type enzyme 3RGV ; 2.9 ; A single TCR bound to MHCI and MHC II reveals switchable TCR conformers 1BWM ; ; A SINGLE-CHAIN T CELL RECEPTOR 1E3A ; 1.8 ; A SLOW PROCESSING PRECURSOR PENICILLIN ACYLASE FROM ESCHERICHIA COLI 2E5L ; 3.3 ; A snapshot of the 30S ribosomal subunit capturing mRNA via the Shine- Dalgarno interaction 1U3N ; ; A SOD-like protein from B. subtilis, unstructured in solution, becomes ordered in the crystal: implications for function and for fibrillogenesis 3EBN ; 2.4 ; A Special Dimerization of SARS-CoV Main Protease C-Terminal Domain Due to Domain-swapping 2YJY ; 2.598 ; A SPECIFIC AND MODULAR BINDING CODE FOR CYTOSINE RECOGNITION IN PUF DOMAINS 4IT8 ; 1.5 ; A sperm whale myoglobin mutant L29H Mb with two distal histidines 4DKS ; 2.7 ; A spindle-shaped virus protein (chymotrypsin treated) 2G1T ; 1.8 ; A Src-like Inactive Conformation in the Abl Tyrosine Kinase Domain 2G2F ; 2.7 ; A Src-like Inactive Conformation in the Abl Tyrosine Kinase Domain 2G2H ; 2 ; A Src-like Inactive Conformation in the Abl Tyrosine Kinase Domain 2G2I ; 3.12 ; A Src-like Inactive Conformation in the Abl Tyrosine Kinase Domain 1LNA ; 1.9 ; A STRUCTURAL ANALYSIS OF METAL SUBSTITUTIONS IN THERMOLYSIN 1LNB ; 1.8 ; A STRUCTURAL ANALYSIS OF METAL SUBSTITUTIONS IN THERMOLYSIN 1LNC ; 1.8 ; A STRUCTURAL ANALYSIS OF METAL SUBSTITUTIONS IN THERMOLYSIN 1LND ; 1.7 ; A STRUCTURAL ANALYSIS OF METAL SUBSTITUTIONS IN THERMOLYSIN 1LNE ; 1.7 ; A STRUCTURAL ANALYSIS OF METAL SUBSTITUTIONS IN THERMOLYSIN 1LNF ; 1.7 ; A structural analysis of metal substitutions in thermolysin 1OGA ; 1.4 ; A STRUCTURAL BASIS FOR IMMUNODOMINANT HUMAN T-CELL RECEPTOR RECOGNITION. 2EYR ; 2.4 ; A structural basis for selection and cross-species reactivity of the semi-invariant NKT cell receptor in CD1d/glycolipid recognition 2EYS ; 2.21 ; A structural basis for selection and cross-species reactivity of the semi-invariant NKT cell receptor in CD1d/glycolipid recognition 2EYT ; 2.6 ; A structural basis for selection and cross-species reactivity of the semi-invariant NKT cell receptor in CD1d/glycolipid recognition 3C7A ; 2.1 ; A structural basis for substrate and stereo selectivity in octopine dehydrogenase (ODH-NADH) 3C7C ; 3.1 ; A structural basis for substrate and stereo selectivity in octopine dehydrogenase (ODH-NADH-L-Arginine) 3C7D ; 2.5 ; A structural basis for substrate and stereo selectivity in octopine dehydrogenase (ODH-NADH-Pyruvate) 3BEO ; 1.7 ; A Structural Basis for the allosteric regulation of non-hydrolyzing UDP-GlcNAc 2-epimerases 4DJB ; 2.053 ; A Structural Basis for the Assembly and Functions of a Viral Polymer that Inactivates Multiple Tumor Suppressors 1LPM ; 2.18 ; A STRUCTURAL BASIS FOR THE CHIRAL PREFERENCES OF LIPASES 1LPS ; 2.18 ; A STRUCTURAL BASIS FOR THE CHIRAL PREFERENCES OF LIPASES 1J7E ; 2.55 ; A Structural Basis for the Unique Binding Features of the Human Vitamin D-binding Protein 1EPL ; 2 ; A STRUCTURAL COMPARISON OF 21 INHIBITOR COMPLEXES OF THE ASPARTIC PROTEINASE FROM ENDOTHIA PARASITICA 1EPM ; 1.6 ; A STRUCTURAL COMPARISON OF 21 INHIBITOR COMPLEXES OF THE ASPARTIC PROTEINASE FROM ENDOTHIA PARASITICA 1EPN ; 1.6 ; A STRUCTURAL COMPARISON OF 21 INHIBITOR COMPLEXES OF THE ASPARTIC PROTEINASE FROM ENDOTHIA PARASITICA 3S0M ; 2.31 ; A Structural Element that Modulates Proton-Coupled Electron Transfer in Oxalate Decarboxylase 2ON3 ; 3 ; A structural insight into the inhibition of human and Leishmania donovani ornithine decarboxylases by 3-aminooxy-1-aminopropane 2OO0 ; 1.9 ; A structural insight into the inhibition of human and Leishmania donovani ornithine decarboxylases by 3-aminooxy-1-aminopropane 1SSB ; 2 ; A STRUCTURAL INVESTIGATION OF CATALYTICALLY MODIFIED F12OL AND F12OY SEMISYNTHETIC RIBONUCLEASES 1SSA ; 2 ; A STRUCTURAL INVESTIGATION OF CATALYTICALLY MODIFIED F12OL AND F12OY SEMISYNTHETIC RIBONUCLEASES 3LUT ; 2.9 ; A Structural Model for the Full-length Shaker Potassium Channel Kv1.2 1Z9I ; ; A Structural Model for the Membrane-Bound Form of the Juxtamembrane Domain of the Epidermal Growth Factor Receptor 4BHP ; ; A structural model of CAP mutant (T127L and S128I) in cGMP-bound state 4BH9 ; ; A structural model of CAP mutant (T127L and S128I) in the apo state 2VSG ; 2.7 ; A Structural Motif in the Variant Surface Glycoproteins of Trypanosoma Brucei 2FVP ; 2.25 ; A Structural Study of the CA Dinucleotide Step in the Integrase Processing Site of Moloney Murine Leukemia Virus 2FVQ ; 2.3 ; A Structural Study of the CA Dinucleotide Step in the Integrase Processing Site of Moloney Murine Leukemia Virus 2FVR ; 2.2 ; A Structural Study of the CA Dinucleotide Step in the Integrase Processing Site of Moloney Murine Leukemia Virus 2FVS ; 2.35 ; A Structural Study of the CA Dinucleotide Step in the Integrase Processing Site of Moloney Murine Leukemia Virus 2VJ1 ; 2.25 ; A STRUCTURAL VIEW OF THE INACTIVATION OF THE SARS-CORONAVIRUS MAIN PROTEINASE BY BENZOTRIAZOLE ESTERS 3GE9 ; 2.61 ; A Structurally Atypical ThyX from Corynebacterium glutamicum NCHU 87078 Is Not Required for Thymidylate Biosynthesis 3KZ3 ; 1.64 ; A structure of a lambda repressor fragment mutant 1ZV7 ; 1.7 ; A structure-based mechanism of SARS virus membrane fusion 1ZV8 ; 1.94 ; A structure-based mechanism of SARS virus membrane fusion 1ZVA ; 1.5 ; A structure-based mechanism of SARS virus membrane fusion 1ZVB ; 1.7 ; A structure-based mechanism of SARS virus membrane fusion 4GDJ ; 2 ; A subtype N10 neuraminidase-like protein of A/little yellow-shouldered bat/Guatemala/060/2010 4GDI ; 1.95 ; A subtype N10 neuraminidase-like protein of A/little yellow-shouldered bat/Guatemala/164/2009 485D ; 0.97 ; A SULFATE POCKET FORMED BY THREE GOU PAIRS IN THE STRUCTURE OF A NONAMERIC RNA 1ZI0 ; 2.6 ; A Superhelical Spiral in Escherichia coli DNA Gyrase A C-terminal Domain Imparts Unidirectional Supercoiling Bias 1AGS ; 2.5 ; A SURFACE MUTANT (G82R) OF A HUMAN ALPHA-GLUTATHIONE S-TRANSFERASE SHOWS DECREASED THERMAL STABILITY AND A NEW MODE OF MOLECULAR ASSOCIATION IN THE CRYSTAL 2ONT ; 2.4 ; A swapped dimer of the HIV-1 capsid C-terminal domain 3NSU ; 2 ; A Systematic Screen for Protein-Lipid Interactions in Saccharomyces cerevisiae 3PJP ; 1.6 ; A Tandem SH2 Domain in Transcription Elongation Factor Spt6 Binds the Phosphorylated RNA Polymerase II C-terminal Repeat Domain(CTD) 2VSU ; 1.9 ; A TERNARY COMPLEX OF HYDROXYCINNAMOYL-COA HYDRATASE-LYASE (HCHL) WITH ACETYL-COENZYME A AND VANILLIN GIVES INSIGHTS INTO SUBSTRATE SPECIFICITY AND MECHANISM. 2DCK ; 2.1 ; A tetragonal-lattice structure of alkaliphilic XynJ from Bacillus sp. 41M-1 225D ; ; A TETRAMERIC DNA STRUCTURE WITH PROTONATED CYTOSINE:CYTOSINE BASE PAIRS 3M79 ; 2.1 ; A tetrameric Zn-bound cytochrome cb562 complex with covalently and non-covalently stabilized interfaces crystallized in the presence of Cu(II) and Zn(II) 4F5L ; 1.4 ; A Theoretical Optimized Mutant for the Conversion of Substrate Specificity and Activity of Aspartate Aminotransferase to Tyrosine Aminotransferase: Chimera P7. 1VZK ; 1.77 ; A THIOPHENE BASED DIAMIDINE FORMS A ""SUPER"" AT BINDING MINOR GROOVE AGENT 1MP7 ; ; A Third Complex of Post-Activated Neocarzinostatin Chromophore with DNA. Bulge DNA Binding from the Minor Groove 1BBB ; 1.7 ; A THIRD QUATERNARY STRUCTURE OF HUMAN HEMOGLOBIN A AT 1.7-ANGSTROMS RESOLUTION 1RMN ; ; A THREE-DIMENSIONAL MODEL FOR THE HAMMERHEAD RIBOZYME BASED ON FLUORESCENCE MEASUREMENTS 417D ; 1.5 ; A THYMINE-LIKE BASE ANALOGUE FORMS WOBBLE PAIRS WITH ADENINE 4FFB ; 2.882 ; A TOG:alpha/beta-tubulin Complex Structure Reveals Conformation-Based Mechanisms For a Microtubule Polymerase 2UZR ; 1.94 ; A TRANSFORMING MUTATION IN THE PLECKSTRIN HOMOLOGY DOMAIN OF AKT1 IN CANCER (AKT1-PH_E17K) 2UZS ; 2.46 ; A TRANSFORMING MUTATION IN THE PLECKSTRIN HOMOLOGY DOMAIN OF AKT1 IN CANCER (AKT1-PH_E17K) 2KZG ; ; A Transient and Low Populated Protein Folding Intermediate at Atomic Resolution 1F51 ; 3 ; A TRANSIENT INTERACTION BETWEEN TWO PHOSPHORELAY PROTEINS TRAPPED IN A CRYSTAL LATTICE REVEALS THE MECHANISM OF MOLECULAR RECOGNITION AND PHOSPHOTRANSFER IN SINGAL TRANSDUCTION 1DQ4 ; 2.9 ; A transient unlocked concanavalin A structure with MN2+ bound in the transition metal ion binding site S1 and an empty calcium binding site S2 3H7Z ; 2.51 ; A transition from strong right-handed to canonical left-handed supercoiling in a conserved coiled coil segment of trimeric autotransporter adhesins - the M1 mutant structure 3LT7 ; 1.5 ; A transition from strong right-handed to canonical left-handed supercoiling in a conserved coiled coil segment of trimeric autotransporter adhesins - the M3 mutant structure 3LT6 ; 1.8 ; A transition from strong right-handed to canonical left-handed supercoiling in a conserved coiled coil segment of trimeric autotransporter adhesins - the Mutant 4 structure 3H7X ; 2 ; A transition from strong right-handed to canonical left-handed supercoiling in a conserved coiled coil segment of trimeric autotransporter adhesins - the wildtype structure 3FOP ; 3 ; A Triangular Cytochrome b562 Superstructure Mediated by Ni Coordination - Hexagonal Form 3FOO ; 2.4 ; A Triangular Cytochrome b562 Superstructure Mediated by Ni Coordination - Monoclinic Form 1GIS ; 1.7 ; A TRICHOSANTHIN(TCS) MUTANT(E85Q) COMPLEX STRUCTURE WITH 2'-DEOXY-ADENOSIN-5'-MONOPHOSPHATE 1GIU ; 1.8 ; A TRICHOSANTHIN(TCS) MUTANT(E85R) COMPLEX STRUCTURE WITH ADENINE 2WW4 ; 2 ; a triclinic crystal form of E. coli 4-diphosphocytidyl-2C-methyl-D- erythritol kinase 1VLN ; 2.4 ; A TRICLINIC CRYSTAL FORM OF THE LECTIN CONCANAVALIN A 3R6Q ; 2.4 ; A triclinic-lattice structure of aspartase from Bacillus sp. YM55-1 198D ; 1.97 ; A TRIGONAL FORM OF THE IDARUBICIN-D(CGATCG) COMPLEX: CRYSTAL AND MOLECULAR STRUCTURE AT 2.0 ANGSTROMS RESOLUTION 3HFE ; 1.7 ; A trimeric form of the Kv7.1 A domain Tail 3HFC ; 2.45 ; A trimeric form of the Kv7.1 A domain Tail, L602M/L606M mutant Semet 1QIU ; 2.4 ; A TRIPLE BETA-SPIRAL IN THE ADENOVIRUS FIBRE SHAFT REVEALS A NEW STRUCTURAL MOTIF FOR BIOLOGICAL FIBRES 3D17 ; 2.8 ; A triply ligated crystal structure of relaxed state human hemoglobin 1FV7 ; ; A TWO B-Z JUNCTION CONTAINING DNA RESOLVES INTO AN ALL RIGHT HANDED DOUBLE HELIX 1BAH ; ; A TWO DISULFIDE DERIVATIVE OF CHARYBDOTOXIN WITH DISULFIDE 13-33 REPLACED BY TWO ALPHA-AMINOBUTYRIC ACIDS, NMR, 30 STRUCTURES 2DCJ ; 2.24 ; A two-domain structure of alkaliphilic XynJ from Bacillus sp. 41M-1 3ALE ; 2.5 ; A type III polyketide synthase that produces diarylheptanoid 4I6J ; 2.7 ; A ubiquitin ligase-substrate complex 4JNH ; 2.402 ; A unique spumavirus gag N-terminal domain with functional properties of orthoretroviral Matrix and Capsid 4JMR ; 2.9 ; A unique spumavirus gag N-terminal domain with functional properties of orthoretroviral Matrix and Capsid 3R0Q ; 2.61 ; A Uniquely Open Conformation Revealed in the Crystal Structure of Arabidopsis Thaliana Protein Arginine Methyltransferase 10 1K50 ; 1.8 ; A V49A Mutation Induces 3D Domain Swapping in the B1 Domain of Protein L from Peptostreptococcus magnus 1SQ8 ; ; a variant 434 repressor DNA binding domain devoid of hydroxyl groups, NMR, 20 STRUCTURES 4I6E ; 2.7 ; A vertebrate cryptochrome 4I6G ; 2.2 ; a vertebrate cryptochrome with FAD 1CSH ; 1.65 ; A very short hydrogen bond provides only moderate stabilization of an enzyme: inhibitor complex of citrate synthase 1CSI ; 1.7 ; A very short hydrogen bond provides only moderate stabilization of an enzyme: inhibitor complex of citrate synthase 2JBY ; 2.41 ; A VIRAL PROTEIN UNEXPECTEDLY MIMICS THE STRUCTURE AND FUNCTION OF PRO-SURVIVAL BCL-2 2XXP ; 1.692 ; A widespread family of bacterial cell wall assembly proteins 2XXQ ; 1.77 ; A widespread family of bacterial cell wall assembly proteins 2CE9 ; 2.12 ; A WRPW PEPTIDE BOUND TO THE GROUCHO-TLE WD40 DOMAIN. 3LG2 ; 2.6 ; A Ykr043C/ fructose-1,6-bisphosphate product complex following ligand soaking 1ZNM ; ; A zinc finger with an artificial beta-turn, original sequence taken from the third zinc finger domain of the human transcriptional repressor protein YY1 (YING and YANG 1, a delta transcription factor), nmr, 34 structures 376D ; 2.1 ; A ZIPPER-LIKE DNA DUPLEX D(GCGAAAGCT) 3M15 ; 2.6 ; A Zn-mediated asymmetric trimer of a cytochrome cb562 variant (D74A-RIDC1) 3M4B ; 2.5 ; A Zn-mediated tetrahedral protein lattice cage 3M4C ; 1.9 ; A Zn-mediated tetrahedral protein lattice cage encapsulating a microperoxidase 413D ; 1.8 ; A'-FORM RNA DOUBLE HELIX IN THE SINGLE CRYSTAL STRUCTURE OF R(UGAGCUUCGGCUC) 1JJP ; ; A(GGGG) Pentad-Containing Dimeric DNA Quadruplex Involving Stacked G(anti)G(anti)G(anti)G(syn) Tetrads 1EEG ; ; A(GGGG)A HEXAD PAIRING ALIGMENT FOR THE D(G-G-A-G-G-A-G) SEQUENCE 1DNZ ; 1.6 ; A-DNA DECAMER ACCGGCCGGT WITH MAGNESIUM BINDING SITES 138D ; 1.8 ; A-DNA DECAMER D(GCGGGCCCGC)-HEXAGONAL CRYSTAL FORM 137D ; 1.7 ; A-DNA DECAMER D(GCGGGCCCGC)-ORTHORHOMBIC CRYSTAL FORM 1DPL ; 0.83 ; A-DNA DECAMER GCGTA(T23)TACGC WITH INCORPORATED 2'-METHOXY-3'-METHYLENEPHOSPHATE-THYMIDINE 1I5W ; 1.4 ; A-DNA DECAMER GCGTA(TLN)ACGC 1MA8 ; 1.3 ; A-DNA decamer GCGTA(UMS)ACGC with incorporated 2'-methylseleno-uridine 1DNO ; 1.4 ; A-DNA/RNA DODECAMER R(GCG)D(TATACGC) MG BINDING SITES 1Y26 ; 2.1 ; A-riboswitch-adenine complex 2F4S ; 2.8 ; A-site RNA in complex with neamine 1UUE ; 2.6 ; A-SPECTRIN SH3 DOMAIN (V44T, D48G MUTANT) 1E6H ; 2.01 ; A-SPECTRIN SH3 DOMAIN A11V, M25I, V44I, V58L MUTANTS 1E6G ; 2.3 ; A-SPECTRIN SH3 DOMAIN A11V, V23L, M25I, V53I, V58L MUTANT 1E7O ; 3.2 ; A-SPECTRIN SH3 DOMAIN A11V, V23L, M25V, V44I, V58L MUTATIONS 1H8K ; 2.7 ; A-SPECTRIN SH3 DOMAIN A11V, V23L, M25V, V53I, V58L MUTANT 1BK2 ; 2.01 ; A-SPECTRIN SH3 DOMAIN D48G MUTANT 1HD3 ; 1.98 ; A-SPECTRIN SH3 DOMAIN F52Y MUTANT 1NEV ; ; A-tract decamer 1AL5 ; ; A-TRACT RNA DODECAMER, NMR, 12 STRUCTURES 2IXA ; 2.3 ; A-ZYME, N-ACETYLGALACTOSAMINIDASE 1ZHA ; 1.74 ; A. aeolicus KDO8PS R106G mutant in complex with PEP and R5P 3T9Z ; 1.82 ; A. fulgidus GlnK3, ligand-free 3TA1 ; 1.9 ; A. fulgidus GlnK3, MgADP complex 3TA0 ; 2.3 ; A. fulgidus GlnK3, MgATP complex 3TA2 ; 1.9 ; A. fulgidus GlnK3, MgATP/2-OG complex 4EB5 ; 2.53 ; A. fulgidus IscS-IscU complex structure 4EB7 ; 2.75 ; A. fulgidus IscS-IscU complex structure 2ZYI ; 2.3 ; A. Fulgidus lipase with fatty acid fragment and calcium 2ZYS ; 3.1 ; A. Fulgidus lipase with fatty acid fragment and chloride 2ZYR ; 1.77 ; A. Fulgidus lipase with fatty acid fragment and magnesium 2XVN ; 2.35 ; A. FUMIGATUS CHITINASE A1 PHENYL-METHYLGUANYLUREA COMPLEX 4B64 ; 2.28 ; A. fumigatus ornithine hydroxylase (SidA) bound to NADP and Lysine 4B63 ; 1.9 ; A. fumigatus ornithine hydroxylase (SidA) bound to NADP and ornithine 4B69 ; 2.3 ; A. fumigatus ornithine hydroxylase (SidA) bound to ornithine 4B68 ; 2.29 ; A. fumigatus ornithine hydroxylase (SidA), re-oxidised state bound to NADP and Arg 4B67 ; 2.75 ; A. fumigatus ornithine hydroxylase (SidA), re-oxidised state bound to NADP and ornithine 4B66 ; 2.9 ; A. fumigatus ornithine hydroxylase (SidA), reduced state bound to NADP and Arg 4B65 ; 2.32 ; A. fumigatus ornithine hydroxylase (SidA), reduced state bound to NADP(H) 2Y8U ; 1.99 ; A. nidulans chitin deacetylase 1U1H ; 2.55 ; A. thaliana cobalamine independent methionine synthase 1U1J ; 2.4 ; A. thaliana cobalamine independent methionine synthase 1U1U ; 2.95 ; A. thaliana cobalamine independent methionine synthase 1U22 ; 2.65 ; A. thaliana cobalamine independent methionine synthase 3LGS ; 2.2 ; A. thaliana MTA nucleosidase in complex with S-adenosylhomocysteine 3U7Q ; 1 ; A. vinelandii nitrogenase MoFe protein at atomic resolution 2B8H ; 2.2 ; A/NWS/whale/Maine/1/84 (H1N9) reassortant influenza virus neuraminidase 1AUQ ; 2.3 ; A1 DOMAIN OF VON WILLEBRAND FACTOR 2PQD ; 1.77 ; A100G CP4 EPSPS liganded with (R)-difluoromethyl tetrahedral reaction intermediate analog 4A6A ; 2.9 ; A115V variant of dCTP deaminase-dUTPase from Mycobacterium tuberculosis in complex with dTTP 2JPX ; ; A18H Vpu TM structure in lipid bilayers 1SZG ; 2.7 ; A198G:L230A flavocytochrome b2 with sulfite bound 1SZF ; 2.7 ; A198G:L230A mutant flavocytochrome b2 with pyruvate bound 1C17 ; ; A1C12 SUBCOMPLEX OF F1FO ATP SYNTHASE 4JFO ; 2.11 ; A2 HLA complex with E1A heteroclitic variant of Melanoma peptide 4JFP ; 1.91 ; A2 HLA complex with G4A heteroclitic variant of Melanoma peptide 4JFQ ; 1.9 ; A2 HLA complex with L8A heteroclitic variant of Melanoma peptide 4GKN ; 2.753 ; A2-MHC Complex carrying FATGIGIITV 4GKS ; 2.346 ; A2-MHC Complex carrying FLTGIGIITV 3ZJD ; 1.87 ; A20 OTU domain in reduced, active state at 1.87 A resolution 3ZJE ; 1.84 ; A20 OTU domain in reversibly oxidised (SOH) state 3ZJF ; 2.2 ; A20 OTU domain with irreversibly oxidised Cys103 from 270 min H2O2 soak. 3ZJG ; 1.92 ; A20 OTU domain with irreversibly oxidised Cys103 from 60 min H2O2 soak. 1AO3 ; 2.2 ; A3 DOMAIN OF VON WILLEBRAND FACTOR 1BH2 ; 2.1 ; A326S MUTANT OF AN INHIBITORY ALPHA SUBUNIT 3AM3 ; 2.5 ; A372M mutant of Enoyl-ACP Reductase from Plasmodium falciparum (PfENR) in complex with triclosan 3AM4 ; 2.3 ; A372M mutant of Enoyl-ACP Reductase from Plasmodium falciparum (PfENR) in complex with triclosan variant T1 2YEO ; 1.08 ; A39L MUTATION OF SCORPION TOXIN LQH-ALPHA-IT 1YKJ ; 2 ; A45G p-hydroxybenzoate hydroxylase with p-hydroxybenzoate bound 1UXM ; 1.9 ; A4V MUTANT OF HUMAN SOD1 3AA5 ; 2.1 ; A52F E.coli RNase HI 3AA2 ; 1.9 ; A52I E. coli RNase HI 3AA3 ; 2.2 ; A52L E. coli RNase HI 3AA4 ; 1.79 ; A52V E.coli RNase HI 455D ; 1.43 ; A6/A18 INTER-STRAND DITHIOBIS(PROPANE)-CROSSLINKED DODECAMER (CGCGAATTCGCG)2 3H4M ; 3.106 ; AAA ATPase domain of the proteasome- activating nucleotidase 1FT7 ; 2.2 ; AAP COMPLEXED WITH L-LEUCINEPHOSPHONIC ACID 2I13 ; 1.96 ; Aart, a six finger zinc finger designed to recognize ANN triplets 3C9U ; 1.48 ; AaThiL complexed with ADP and TPP 3C9S ; 2.2 ; AaThiL complexed with AMPPCP 3C9T ; 2.6 ; AaThiL complexed with AMPPCP and TMP 3C9R ; 2.3 ; AaThiL complexed with ATP 2YHG ; 1.08 ; AB INITIO PHASING OF A NUCLEOSIDE HYDROLASE-RELATED HYPOTHETICAL PROTEIN FROM SACCHAROPHAGUS DEGRADANS THAT IS ASSOCIATED WITH CARBOHYDRATE METABOLISM 1CKU ; 1.2 ; AB INITIO SOLUTION AND REFINEMENT OF TWO HIGH POTENTIAL IRON PROTEIN STRUCTURES AT ATOMIC RESOLUTION 1W5I ; 2.3 ; ABA DOES NOT AFFECT TOPOLOGY OF PLI. 2JUV ; ; AbaA3-DKP-insulin 2OLK ; 2.1 ; ABC Protein ArtP in complex with ADP-beta-S 2OLJ ; 2.05 ; ABC Protein ArtP in complex with ADP/Mg2+ 2Q0H ; 2.2 ; ABC Protein ArtP in complex with ADP/Mg2+, ATP-gamma-S hydrolyzed 3C41 ; 2.25 ; ABC protein ArtP in complex with AMP-PNP/Mg2+ 3C4J ; 2.33 ; ABC protein ArtP in complex with ATP-gamma-S 2OUK ; 2.15 ; ABC Protein ArtP in complex with Sulphate 2ONK ; 3.1 ; ABC transporter ModBC in complex with its binding protein ModA 4KQC ; 1.62 ; ABC transporter, LacI family transcriptional regulator from Brachyspira murdochii 2QI9 ; 2.6 ; ABC-transporter BtuCD in complex with its periplasmic binding protein BtuF 2RIN ; 1.8 ; ABC-transporter choline binding protein in complex with acetylcholine 2REG ; 1.9 ; ABC-transporter choline binding protein in complex with choline 2REJ ; 2.6 ; ABC-transporter choline binding protein in unliganded semi-closed conformation 1SO8 ; 2.3 ; Abeta-bound human ABAD structure [also known as 3-hydroxyacyl-CoA dehydrogenase type II (Type II HADH), Endoplasmic reticulum-associated amyloid beta-peptide binding protein (ERAB)] 3S5A ; 1.7 ; ABH2 cross-linked to undamaged dsDNA-2 with cofactors 3S57 ; 1.6 ; ABH2 cross-linked with undamaged dsDNA-1 containing cofactors 3S9V ; 2.3 ; abietadiene synthase from Abies grandis 2HZ0 ; 2.1 ; Abl kinase domain in complex with NVP-AEG082 2HZN ; 2.7 ; Abl kinase domain in complex with NVP-AFG210 2HZI ; 1.7 ; Abl kinase domain in complex with PD180970 2HZ4 ; 2.8 ; Abl kinase domain unligated and in complex with tetrahydrostaurosporine 3MS9 ; 1.8 ; ABL kinase in complex with imatinib and a fragment (FRAG1) in the myristate pocket 3MSS ; 1.95 ; Abl kinase in complex with imatinib and fragment (FRAG2) in the myristate site 1S22 ; 1.6 ; Absolute Stereochemistry of Ulapualide A 3SIO ; 2.32 ; Ac-AChBP ligand binding domain (not including beta 9-10 linker) mutated to human alpha-7 nAChR 3SH1 ; 2.9 ; Ac-AChBP ligand binding domain mutated to human alpha-7 nAChR 3T4M ; 3 ; Ac-AChBP ligand binding domain mutated to human alpha-7 nAChR (intermediate) 4EFH ; 2.48 ; Acanthamoeba Actin complex with Spir domain D 1PRQ ; 2.5 ; ACANTHAMOEBA CASTELLANII PROFILIN IA 1ACF ; 2 ; ACANTHAMOEBA CASTELLANII PROFILIN IB 2ACG ; 2.5 ; ACANTHAMOEBA CASTELLANII PROFILIN II 2DRK ; 1.42 ; Acanthamoeba myosin I SH3 domain bound to Acan125 2DRM ; 1.35 ; Acanthamoeba myosin I SH3 domain bound to Acan125 1E3Z ; 1.93 ; ACARBOSE COMPLEX OF CHIMAERIC AMYLASE FROM B. AMYLOLIQUEFACIENS AND B. LICHENIFORMIS AT 1.93A 1XCW ; 2 ; Acarbose Rearrangement Mechanism Implied by the Kinetic and Structural Analysis of Human Pancreatic alpha-Amylase in Complex with Analogues and Their Elongated Counterparts 1XCX ; 1.9 ; Acarbose Rearrangement Mechanism Implied by the Kinetic and Structural Analysis of Human Pancreatic alpha-Amylase in Complex with Analogues and Their Elongated Counterparts 1XD0 ; 2 ; Acarbose Rearrangement Mechanism Implied by the Kinetic and Structural Analysis of Human Pancreatic alpha-Amylase in Complex with Analogues and Their Elongated Counterparts 1XD1 ; 2.2 ; Acarbose Rearrangement Mechanism Implied by the Kinetic and Structural Analysis of Human Pancreatic alpha-Amylase in Complex with Analogues and Their Elongated Counterparts 1J0D ; 2.2 ; ACC deaminase mutant complexed with ACC 1J0E ; 2.45 ; ACC deaminase mutant reacton intermediate 1J0C ; 2.75 ; ACC deaminase mutated to catalytic residue 1ZEZ ; 2 ; ACC Holliday Junction 1LTM ; 1.7 ; ACCELERATED X-RAY STRUCTURE ELUCIDATION OF A 36 KDA MURAMIDASE/TRANSGLYCOSYLASE USING WARP 1IKD ; ; ACCEPTOR STEM, NMR, 30 STRUCTURES 1SJS ; 2.42 ; ACCESS TO PHOSPHORYLATION IN ISOCITRATE DEHYDROGENASE MAY OCCUR BY DOMAIN SHIFTING 1STA ; 1.7 ; ACCOMMODATION OF INSERTION MUTATIONS ON THE SURFACE AND IN THE INTERIOR OF STAPHYLOCOCCAL NUCLEASE 1STB ; 2 ; ACCOMMODATION OF INSERTION MUTATIONS ON THE SURFACE AND IN THE INTERIOR OF STAPHYLOCOCCAL NUCLEASE 2NU2 ; 1.65 ; Accommodation of positively-charged residues in a hydrophobic specificity pocket: Crystal structures of SGPB in complex with OMTKY3 variants Lys18I and Arg18I 2NU3 ; 1.8 ; Accommodation of positively-charged residues in a hydrophobic specificity pocket: Crystal structures of SGPB in complex with OMTKY3 variants Lys18I and Arg18I 2NU4 ; 1.75 ; Accommodation of positively-charged residues in a hydrophobic specificity pocket: Crystal structures of SGPB in complex with OMTKY3 variants Lys18I and Arg18I 1S37 ; ; Accomodation of Mispair-Aligned N3T-Ethyl-N3T DNA Interstrand Crosslink 1PLC ; 1.33 ; ACCURACY AND PRECISION IN PROTEIN CRYSTAL STRUCTURE ANALYSIS: RESTRAINED LEAST-SQUARES REFINEMENT OF THE CRYSTAL STRUCTURE OF POPLAR PLASTOCYANIN AT 1.33 ANGSTROMS RESOLUTION 1PNC ; 1.6 ; ACCURACY AND PRECISION IN PROTEIN CRYSTAL STRUCTURE ANALYSIS: TWO INDEPENDENT REFINEMENTS OF THE STRUCTURE OF POPLAR PLASTOCYANIN AT 173K 1PND ; 1.6 ; ACCURACY AND PRECISION IN PROTEIN CRYSTAL STRUCTURE ANALYSIS: TWO INDEPENDENT REFINEMENTS OF THE STRUCTURE OF POPLAR PLASTOCYANIN AT 173K 1KH0 ; 1.9 ; Accurate Computer Base Design of a New Backbone Conformation in the Second Turn of Protein L 1TUY ; 3 ; Acetate Kinase complexed with ADP, AlF3 and acetate 1TUU ; 2.5 ; Acetate Kinase crystallized with ATPgS 2IIR ; 3.3 ; Acetate kinase from a hypothermophile Thermotoga maritima 2B9V ; 2 ; Acetobacter turbidans alpha-amino acid ester hydrolase 2B4K ; 3.3 ; Acetobacter turbidans alpha-amino acid ester hydrolase complexed with phenylglycine 1NX9 ; 2.2 ; Acetobacter turbidans alpha-amino acid ester hydrolase S205A mutant complexed with ampicillin 1RYY ; 2.8 ; Acetobacter turbidans alpha-amino acid ester hydrolase Y206A mutant 1YVE ; 1.65 ; ACETOHYDROXY ACID ISOMEROREDUCTASE COMPLEXED WITH NADPH, MAGNESIUM AND INHIBITOR IPOHA (N-HYDROXY-N-ISOPROPYLOXAMATE) 1QMG ; 1.6 ; ACETOHYDROXYACID ISOMEROREDUCTASE COMPLEXED WITH ITS REACTION PRODUCT DIHYDROXY-METHYLVALERATE, MANGANESE AND ADP-RIBOSE. 1PG3 ; 2.3 ; Acetyl CoA Synthetase, Acetylated on Lys609 1PG4 ; 1.75 ; Acetyl CoA Synthetase, Salmonella enterica 2XLC ; 2.7 ; ACETYL XYLAN ESTERASE FROM BACILLUS PUMILUS CECT5072 BOUND TO PARAOXON 2XLB ; 1.9 ; ACETYL XYLAN ESTERASE FROM BACILLUS PUMILUS WITHOUT LIGANDS 1OD2 ; 2.7 ; ACETYL-COA CARBOXYLASE CARBOXYLTRANSFERASE DOMAIN 1OD4 ; 2.7 ; ACETYL-COA CARBOXYLASE CARBOXYLTRANSFERASE DOMAIN 1UYT ; 2.5 ; Acetyl-CoA carboxylase carboxyltransferase domain 1UYR ; 2.5 ; ACETYL-COA CARBOXYLASE CARBOXYLTRANSFERASE DOMAIN IN COMPLEX WITH INHIBITOR DICLOFOP 1UYS ; 2.8 ; Acetyl-CoA carboxylase carboxyltransferase domain in complex with inhibitor haloxyfop 1UYV ; 2.6 ; Acetyl-CoA carboxylase carboxyltransferase domain L1705I/V1967I mutant 2P2J ; 2.3 ; Acetyl-CoA Synthetase, K609A mutation 2P2M ; 2.11 ; Acetyl-CoA Synthetase, R194A mutation 2P20 ; 2.22 ; Acetyl-CoA Synthetase, R584A mutation 2P2Q ; 2.42 ; Acetyl-CoA Synthetase, R584E mutation 2P2B ; 2.2 ; Acetyl-CoA Synthetase, V386A mutation 2P2F ; 2.58 ; Acetyl-CoA Synthetase, wild-type with acetate, AMP, and CoA bound 2X2C ; 2.41 ; ACETYL-CYPA:CYCLOSPORINE COMPLEX 2X2D ; 1.95 ; ACETYL-CYPA:HIV-1 N-TERM CAPSID DOMAIN COMPLEX 1DM3 ; 2 ; ACETYLATED BIOSYNTHETIC THIOLASE FROM ZOOGLOEA RAMIGERA IN COMPLEX WITH ACETYL-COA 2XNT ; 3.21 ; ACETYLCHOLINE BINDING PROTEIN (ACHBP) AS TEMPLATE FOR HIERARCHICAL IN SILICO SCREENING PROCEDURES TO IDENTIFY STRUCTURALLY NOVEL LIGANDS FOR THE NICOTINIC RECEPTORS 2XNU ; 2.55 ; ACETYLCHOLINE BINDING PROTEIN (ACHBP) AS TEMPLATE FOR HIERARCHICAL IN SILICO SCREENING PROCEDURES TO IDENTIFY STRUCTURALLY NOVEL LIGANDS FOR THE NICOTINIC RECEPTORS 2XNV ; 2.44 ; ACETYLCHOLINE BINDING PROTEIN (ACHBP) AS TEMPLATE FOR HIERARCHICAL IN SILICO SCREENING PROCEDURES TO IDENTIFY STRUCTURALLY NOVEL LIGANDS FOR THE NICOTINIC RECEPTORS 1EEA ; 4.5 ; Acetylcholinesterase 1FSS ; 3 ; ACETYLCHOLINESTERASE (E.C. 3.1.1.7) COMPLEXED WITH FASCICULIN-II 1VOT ; 2.5 ; ACETYLCHOLINESTERASE (E.C. 3.1.1.7) COMPLEXED WITH HUPERZINE A 1OCE ; 2.7 ; ACETYLCHOLINESTERASE (E.C. 3.1.1.7) COMPLEXED WITH MF268 1GQS ; 3 ; ACETYLCHOLINESTERASE (E.C. 3.1.1.7) COMPLEXED WITH NAP 1GQR ; 2.2 ; ACETYLCHOLINESTERASE (E.C. 3.1.1.7) COMPLEXED WITH RIVASTIGMINE 1QTI ; 2.5 ; Acetylcholinesterase (E.C.3.1.1.7) 1AX9 ; 2.8 ; ACETYLCHOLINESTERASE COMPLEXED WITH EDROPHONIUM, LAUE DATA 2ACK ; 2.4 ; ACETYLCHOLINESTERASE COMPLEXED WITH EDROPHONIUM, MONOCHROMATIC DATA 2E7Z ; 1.26 ; Acetylene Hydratase from Pelobacter acetylenicus 2X2W ; 2 ; Acetylglutamate kinase from Escherichia coli bound to its product N- acetyl-L-glutamyl-5-phosphate 1OHB ; 1.9 ; ACETYLGLUTAMATE KINASE FROM ESCHERICHIA COLI COMPLEXED WITH ADP AND SULPHATE 1OHA ; 1.9 ; ACETYLGLUTAMATE KINASE FROM ESCHERICHIA COLI COMPLEXED WITH MGADP AND N-ACETYL-L-GLUTAMATE 1OH9 ; 1.91 ; ACETYLGLUTAMATE KINASE FROM ESCHERICHIA COLI COMPLEXED WITH MGADP, N-ACETYL-L-GLUTAMATE AND THE TRANSITION-STATE MIMIC ALF4- 2WXB ; 2 ; ACETYLGLUTAMATE KINASE FROM ESCHERICHIA COLI FREE OF SUBSTRATES 2BTY ; 2.75 ; ACETYLGLUTAMATE KINASE FROM THERMOTOGA MARITIMA COMPLEXED WITH ITS INHIBITOR ARGININE 1VEF ; 1.35 ; Acetylornithine aminotransferase from Thermus thermophilus HB8 1WKG ; 2.25 ; Acetylornithine aminotransferase from thermus thermophilus HB8 1WKH ; 2.25 ; Acetylornithine aminotransferase from thermus thermophilus HB8 2FBM ; 2.28 ; Acetyltransferase domain of CDY1 2OU2 ; 2.3 ; Acetyltransferase domain of Human HIV-1 Tat interacting protein, 60kDa, isoform 3 3IWG ; 2.3 ; Acetyltransferase from GNAT family from Colwellia psychrerythraea. 2ATR ; 2.01 ; Acetyltransferase, GNAT family protein SP0256 from Streptococcus pneumoniae TIGR4 1G66 ; 0.9 ; ACETYLXYLAN ESTERASE AT 0.90 ANGSTROM RESOLUTION 1BS9 ; 1.1 ; ACETYLXYLAN ESTERASE FROM P. PURPUROGENUM REFINED AT 1.10 ANGSTROMS 2UZ6 ; 2.4 ; AChBP-targeted a-conotoxin correlates distinct binding orientations with nAChR subtype selectivity. 1QON ; 2.72 ; ACHE FROM DROSOPHILA MELANOGASTER COMPLEX WITH TACRINE DERIVATIVE 9-(3-IODOBENZYLAMINO)-1,2,3,4-TETRAHYDROACRIDINE 1DX4 ; 2.7 ; ACHE FROM DROSOPHILA MELANOGASTER COMPLEX WITH TACRINE DERIVATIVE 9-(3-PHENYLMETHYLAMINO)-1,2,3,4-TETRAHYDROACRIDINE 2W6C ; 2.69 ; ACHE IN COMPLEX WITH A BIS-(-)-NOR-MEPTAZINOL DERIVATIVE 2W9I ; 2.43 ; AChE in complex with methylene blue 1U65 ; 2.61 ; Ache W. CPT-11 3DPD ; 2.85 ; Achieving multi-isoform PI3K inhibition in a series of substituted 3,4-Dihydro-2H-benzo[1,4]oxazines 2IGX ; 1.7 ; Achiral, Cheap and Potent Inhibitors of Plasmepsins II 2IGY ; 2.6 ; Achiral, Cheap and Potent Inhibitors of Plasmepsins II 1YPP ; 2.4 ; ACID ANHYDRIDE HYDROLASE 1BXO ; 0.95 ; ACID PROTEINASE (PENICILLOPEPSIN) (E.C.3.4.23.20) COMPLEX WITH PHOSPHONATE INHIBITOR: METHYL CYCLO[(2S)-2-[[(1R)-1-(N-(L-N-(3-METHYLBUTANOYL)VALYL-L-ASPARTYL)AMINO)-3-METHYLBUT YL] HYDROXYPHOSPHINYLOXY]-3-(3-AMINOMETHYL) PHENYLPROPANOATE 2WEC ; 1.5 ; ACID PROTEINASE (PENICILLOPEPSIN) (E.C.3.4.23.20) COMPLEX WITH PHOSPHONATE INHIBITOR: METHYL(2S)-[1-(((N-(1-NAPHTHALENEACETYL))-L-VALYL)AMINOMETHYL)HYDROXY PHOSPHINYLOXY]-3-PHENYLPROPANOATE, SODIUM SALT 2WEB ; 1.5 ; ACID PROTEINASE (PENICILLOPEPSIN) (E.C.3.4.23.20) COMPLEX WITH PHOSPHONATE INHIBITOR: METHYL(2S)-[1-(((N-FORMYL)-L-VALYL)AMINO-2-(2-NAPHTHYL)ETHYL)HYDROXYPHOSPHINYLOXY]-3-PHENYLPROPANOATE, SODIUM SALT 2WEA ; 1.25 ; ACID PROTEINASE (PENICILLOPEPSIN) (E.C.3.4.23.20) COMPLEX WITH PHOSPHONATE INHIBITOR: METHYL[CYCLO-7[(2R)-((N-VALYL) AMINO)-2-(HYDROXYL-(1S)-1-METHYOXYCARBONYL-2-PHENYLETHOXY) PHOSPHINYLOXY-ETHYL]-1-NAPHTHALENEACETAMIDE], SODIUM SALT 2WED ; 1.5 ; ACID PROTEINASE (PENICILLOPEPSIN) (E.C.3.4.23.20) COMPLEX WITH PHOSPHONATE MACROCYCLIC INHIBITOR:METHYL[CYCLO-7[(2R)-((N-VALYL)AMINO)-2-(HYDROXYL-(1S)-1-METHYOXYCARBONYL-2-PHENYLETHOXY)PHOSPHINYLOXY-ETHYL]-1-NAPHTHALENEACETAMIDE], SODIUM SALT 1BXQ ; 1.41 ; ACID PROTEINASE (PENICILLOPEPSIN) COMPLEX WITH PHOSPHONATE INHIBITOR. 2NT0 ; 1.79 ; Acid-beta-glucosidase low pH, glycerol bound 2V3F ; 1.95 ; ACID-BETA-GLUCOSIDASE PRODUCED IN CARROT 2V3D ; 1.96 ; ACID-BETA-GLUCOSIDASE WITH N-BUTYL-DEOXYNOJIRIMYCIN 2V3E ; 2 ; ACID-BETA-GLUCOSIDASE WITH N-NONYL-DEOXYNOJIRIMYCIN 3K1X ; 1.98 ; Acidic Fibroblast Growth Factor (FGF-1) complexed with dobesilate 3JUT ; 2.25 ; Acidic Fibroblast Growth Factor (FGF-1) complexed with gentisic acid 2K43 ; ; Acidic fibroblast growth factor solution structure in the FGF-1-C2A binary complex: key component in the fibroblast growthfactor non-classical pathway 3FXY ; 2 ; Acidic Mammalian Chinase, Catalytic Domain 1PSJ ; 2 ; ACIDIC PHOSPHOLIPASE A2 FROM AGKISTRODON HALYS PALLAS 1GP7 ; 2.6 ; ACIDIC PHOSPHOLIPASE A2 FROM VENOM OF OPHIOPHAGUS HANNAH 2HCT ; 1.95 ; Acidic residues at the active sites of CD38 and ADP-ribosyl cyclase determine NAAPD synthesis and hydrolysis activities 1H1O ; 2.13 ; ACIDITHIOBACILLUS FERROOXIDANS CYTOCHROME C4 STRUCTURE SUPPORTS A COMPLEX-INDUCED TUNING OF ELECTRON TRANSFER 1ECE ; 2.4 ; ACIDOTHERMUS CELLULOLYTICUS ENDOCELLULASE E1 CATALYTIC DOMAIN IN COMPLEX WITH A CELLOTETRAOSE 2WT9 ; 1.65 ; ACINETOBACTER BAUMANII NICOTINAMIDASE PYRAZINAMIDEASE 2WTA ; 1.7 ; ACINETOBACTER BAUMANII NICOTINAMIDASE PYRAZINAMIDEASE 3ZPC ; 2.2 ; Acinetobacter baumannii RibD, form 1 3ZPG ; 1.99 ; Acinetobacter baumannii RibD, form 2 4ID7 ; 3 ; ACK1 kinase in complex with the inhibitor cis-3-[8-amino-1-(4-phenoxyphenyl)imidazo[1,5-a]pyrazin-3-yl]cyclobutanol 1B0M ; 2.5 ; ACONITASE R644Q:FLUOROCITRATE COMPLEX 3RTO ; 1.8 ; Acoustically mounted porcine insulin microcrystals yield an X-ray SAD structure 452D ; 1.6 ; ACRIDINE BINDING TO DNA 1C3H ; 2.1 ; ACRP30 CALCIUM COMPLEX 1ZPV ; 1.9 ; ACT domain protein from Streptococcus pneumoniae 1QAG ; 3 ; Actin binding region of the dystrophin homologue utrophin 3TU5 ; 3 ; Actin complex with Gelsolin Segment 1 fused to Cobl segment 1RDW ; 2.3 ; Actin Crystal Dynamics: Structural Implications for F-actin Nucleation, Polymerization and Branching Mediated by the Anti-parallel Dimer 1RFQ ; 3 ; Actin Crystal Dynamics: Structural Implications for F-actin Nucleation, Polymerization and Branching Mediated by the Anti-parallel Dimer 2Q36 ; 2.5 ; Actin Dimer Cross-linked between Residues 191 and 374 and complexed with Kabiramide C 2Q1N ; 2.7 ; Actin Dimer Cross-linked Between Residues 41 and 374 2Q31 ; 2.7 ; Actin Dimer Cross-linked Between Residues 41 and 374 and proteolytically cleaved by subtilisin between residues 47 and 48. 3CJC ; 3.9 ; Actin dimer cross-linked by V. cholerae MARTX toxin and complexed with DNase I and Gelsolin-segment 1 3CJB ; 3.21 ; Actin dimer cross-linked by V. cholerae MARTX toxin and complexed with Gelsolin-segment 1 3B5U ; ; Actin filament model from extended form of acromsomal bundle in the Limulus sperm 3B63 ; 9.5 ; Actin filament model in the extended form of acromsomal bundle in the Limulus sperm 2Y83 ; 22.9 ; Actin filament pointed end 2A42 ; 1.85 ; Actin-DNAse I Complex 1CJA ; 2.9 ; ACTIN-FRAGMIN KINASE, CATALYTIC DOMAIN FROM PHYSARUM POLYCEPHALUM 3P5U ; 1.5 ; Actinidin from Actinidia arguta planch (Sarusashi) 3P5V ; 1.9 ; Actinidin from Actinidia arguta planch (Sarusashi) 3P5W ; 2.2 ; Actinidin from Actinidia arguta planch (Sarusashi) 3P5X ; 2.2 ; Actinidin from Actinidia arguta planch (Sarusashi) 3E35 ; 2.2 ; Actinobacteria-specific protein of unknown function, SCO1997 1MNV ; 2.6 ; Actinomycin D binding to ATGCTGCAT 1I3W ; 1.7 ; ACTINOMYCIN D BINDING TO CGATCGATCG 2RHC ; 2.1 ; Actinorhodin ketordeuctase, actKR, with NADP+ and Inhibitor Emodin 2RH4 ; 2.3 ; Actinorhodin ketoreductase, actKR, with NADPH and Inhibitor Emodin 3QRW ; 2.792 ; Actinorhodin Polyketide Ketoreductase Mutant P94L bound to NADPH 3CSD ; 2.29 ; Actinorhodin Polyketide Ketoreductase Mutant P94L bound to NADPH and the Inhibitor Emodin 3RI3 ; 2.292 ; Actinorhodin Polyketide Ketoreductase Mutant P94L bound to NADPH and the Inhibitor Emodin 1XR3 ; 2.71 ; Actinorhodin Polyketide Ketoreductase with NADP and the Inhibitor Isoniazid bound 1X7G ; 2.3 ; Actinorhodin Polyketide Ketoreductase, act KR, with NADP bound 1X7H ; 2.3 ; Actinorhodin Polyketide Ketoreductase, with NADPH bound 1AF8 ; ; ACTINORHODIN POLYKETIDE SYNTHASE ACYL CARRIER PROTEIN FROM STREPTOMYCES COELICOLOR A3(2), NMR, 24 STRUCTURES 2AF8 ; ; ACTINORHODIN POLYKETIDE SYNTHASE ACYL CARRIER PROTEIN FROM STREPTOMYCES COELICOLOR A3(2), NMR, MINIMIZED AVERAGE STRUCTURE 1ACX ; 2 ; ACTINOXANTHIN STRUCTURE AT THE ATOMIC LEVEL (RUSSIAN) 3NCG ; 2.49 ; Activated Calcium-Dependent Protein Kinase 1 from Cryptosporidium parvum (CpCDPK1) in complex with bumped kinase inhibitor NM-PP1 3MWU ; 1.98 ; Activated Calcium-Dependent Protein Kinase 1 from Cryptosporidium parvum (CpCDPK1) in complex with bumped kinase inhibitor RM-1-95 4A0Q ; 1.9 ; Activated Conformation of Integrin alpha1 I-Domain mutant 2WB4 ; 2.8 ; ACTIVATED DIGUANYLATE CYCLASE PLED IN COMPLEX WITH C-DI-GMP 2FJU ; 2.2 ; Activated Rac1 bound to its effector phospholipase C beta 2 2V0N ; 2.71 ; ACTIVATED RESPONSE REGULATOR PLED IN COMPLEX WITH C-DIGMP AND GTP-ALPHA-S 1BWV ; 2.4 ; Activated Ribulose 1,5-Bisphosphate Carboxylase/Oxygenase (RUBISCO) Complexed with the Reaction Intermediate Analogue 2-Carboxyarabinitol 1,5-Bisphosphate 1UPM ; 2.3 ; ACTIVATED SPINACH RUBISCO COMPLEXED WITH 2-CARBOXYARABINITOL 2 BISPHOSPHAT AND CA2+. 8RUC ; 1.6 ; ACTIVATED SPINACH RUBISCO COMPLEXED WITH 2-CARBOXYARABINITOL BISPHOSPHATE 1RXO ; 2.2 ; ACTIVATED SPINACH RUBISCO IN COMPLEX WITH ITS SUBSTRATE RIBULOSE-1,5-BISPHOSPHATE AND CALCIUM 1AA1 ; 2.2 ; ACTIVATED SPINACH RUBISCO IN COMPLEX WITH THE PRODUCT 3-PHOSPHOGLYCERATE 3F75 ; 1.99 ; Activated Toxoplasma gondii cathepsin L (TgCPL) in complex with its propeptide 1AUS ; 2.2 ; ACTIVATED UNLIGANDED SPINACH RUBISCO 1BJA ; 2.19 ; ACTIVATION DOMAIN OF THE PHAGE T4 TRANSCRIPTION FACTOR MOTA 1AVF ; 2.36 ; ACTIVATION INTERMEDIATE 2 OF HUMAN GASTRICSIN FROM HUMAN STOMACH 2W22 ; 2.2 ; ACTIVATION MECHANISM OF BACTERIAL THERMOALKALOPHILIC LIPASES 3MJI ; 2.5 ; Activation of catalytic cysteine without a base in a Mutant Penicillin Acylase Precursor 2FNM ; 1.8 ; Activation of human carbonic anhdyrase II by exogenous proton donors 2FNK ; 1.8 ; Activation of Human Carbonic Anhydrase II by exogenous proton donors 2FNN ; 1.8 ; Activation of human carbonic anhydrase II by exogenous proton donors 2VTX ; 2.5 ; ACTIVATION OF NUCLEOPLASMIN, AN OLIGOMERIC HISTONE CHAPERONE, CHALLENGES ITS STABILITY 1GQT ; 2.34 ; ACTIVATION OF RIBOKINASE BY MONOVALENT CATIONS 3R8D ; 2.8 ; Activation of the Human Nuclear Xenobiotic Receptor PXR by the Reverse Transcriptase-Targeted Anti-HIV Drug PNU-142721 4EHT ; 1.95 ; Activator of the 2-Hydroxyisocaproyl-CoA dehydratase from Clostridium difficile with bound ADP 4EHU ; 1.6 ; Activator of the 2-Hydroxyisocaproyl-CoA Dehydratase from Clostridium difficile with bound ADPNP 4EIA ; 3 ; Activator of the 2-Hydroxyisocaproyl-CoA Dehydratase from Clostridium difficile without nucleotide 3GQY ; 1.85 ; Activator-Bound Structure of Human Pyruvate Kinase M2 3GR4 ; 1.6 ; Activator-Bound Structure of Human Pyruvate Kinase M2 3H6O ; 2 ; Activator-Bound Structure of Human Pyruvate Kinase M2 3U2Z ; 2.1 ; Activator-Bound Structure of Human Pyruvate Kinase M2 3ME3 ; 1.95 ; Activator-Bound Structure of Human Pyruvate Kinase M2 1RQI ; 2.42 ; Active Conformation of Farnesyl Pyrophosphate Synthase Bound to Isopentyl Pyrophosphate and Dimethylallyl S-Thiolodiphosphate 1RQJ ; 1.95 ; Active Conformation of Farnesyl Pyrophosphate Synthase Bound to Isopentyl Pyrophosphate and Risedronate 2QY0 ; 2.6 ; Active dimeric structure of the catalytic domain of C1r reveals enzyme-product like contacts 1DVM ; 2.4 ; ACTIVE FORM OF HUMAN PAI-1 1KYA ; 2.4 ; ACTIVE LACCASE FROM TRAMETES VERSICOLOR COMPLEXED WITH 2,5-XYLIDINE 1H9B ; 2.4 ; ACTIVE MUTANT (Q365->C) OF GLUCOSE 6-PHOSPHATE DEHYDROGENASE FROM LEUCONOSTOC MESENTEROIDES 1H93 ; 2.2 ; ACTIVE MUTANT (S215->C) OF GLUCOSE 6-PHOSPHATE DEHYDROGENASE FROM LEUCONOSTOC MESENTEROIDES 1OAJ ; 1.73 ; ACTIVE SITE COPPER AND ZINC IONS MODULATE THE QUATERNARY STRUCTURE OF PROKARYOTIC CU,ZN SUPEROXIDE DISMUTASE 1OAL ; 1.5 ; ACTIVE SITE COPPER AND ZINC IONS MODULATE THE QUATERNARY STRUCTURE OF PROKARYOTIC CU,ZN SUPEROXIDE DISMUTASE 2D26 ; 3.3 ; Active site distortion is sufficient for proteinase inhibit second crystal structure of covalent serpin-proteinase complex 2AUN ; 2.4 ; Active site His285Ala mutant of LD-carboxypeptidase 4DEF ; 1.64 ; Active site loop dynamics of a class IIa fructose 1,6-bisphosphate aldolase from M. tuberculosis 4DEL ; 1.58 ; Active site loop dynamics of a class IIa fructose 1,6-bisphosphate aldolase from M. tuberculosis 4A7Y ; 2.8 ; Active site metal depleted aldos-2-ulose dehydratase 1FPC ; 2.3 ; ACTIVE SITE MIMETIC INHIBITION OF THROMBIN 3HAT ; 2.5 ; ACTIVE SITE MIMETIC INHIBITION OF THROMBIN 1E7M ; 2.54 ; ACTIVE SITE MUTANT (D177->N) OF GLUCOSE 6-PHOSPHATE DEHYDROGENASE FROM LEUCONOSTOC MESENTEROIDES 1E7Y ; 2.48 ; ACTIVE SITE MUTANT (D177->N) OF GLUCOSE 6-PHOSPHATE DEHYDROGENASE FROM LEUCONOSTOC MESENTEROIDES COMPLEXED WITH SUBSTRATE AND NADPH 1SNM ; 1.74 ; ACTIVE SITE MUTANT GLU-43 (RIGHT ARROW) ASP IN STAPHYLOCOCCAL NUCLEASE DISPLAYS NONLOCAL STRUCTURAL CHANGES 2JCS ; 2.5 ; ACTIVE SITE MUTANT OF DNK FROM D. MELANOGASTER WITH DTTP BOUND 3IQM ; 3.4 ; Active site mutants of B. subtilis SecA 3IQY ; 3.3 ; Active site mutants of B. subtilis SecA 1HM2 ; 2 ; ACTIVE SITE OF CHONDROITINASE AC LYASE REVEALED BY THE STRUCTURE OF ENZYME-OLIGOSACCHARIDE COMPLEXES AND MUTAGENESIS 1HM3 ; 2.1 ; ACTIVE SITE OF CHONDROITINASE AC LYASE REVEALED BY THE STRUCTURE OF ENZYME-OLIGOSACCHARIDE COMPLEXES AND MUTAGENESIS 1HMW ; 2.3 ; ACTIVE SITE OF CHONDROITINASE AC LYASE REVEALED BY THE STRUCTURE OF ENZYME-OLIGOSACCHARIDE COMPLEXES AND MUTAGENESIS 1HMU ; 2 ; ACTIVE SITE OF CHONDROITINASE AC LYASE REVEALED BY THE STRUCTURE OF ENZYME-OLIGOSACCHARIDE COMPLEXES AND MUTAGENESIS 2UWX ; 2.39 ; ACTIVE SITE RESTRUCTURING REGULATES LIGAND RECOGNITION IN CLASS A PENICILLIN-BINDING PROTEINS 2XD1 ; 3 ; ACTIVE SITE RESTRUCTURING REGULATES LIGAND RECOGNITION IN CLASS A PENICILLIN-BINDING PROTEINS 2BG1 ; 1.9 ; ACTIVE SITE RESTRUCTURING REGULATES LIGAND RECOGNITION IN CLASSA PENICILLIN-BINDING PROTEINS (PBPS) 1C0E ; 2.2 ; Active Site S19A Mutant of Bovine Heart Phosphotyrosyl Phosphatase 2AUM ; 2.4 ; Active site Ser115Ala mutant of LD-carboxypeptidase 1ORB ; 2 ; ACTIVE SITE STRUCTURAL FEATURES FOR CHEMICALLY MODIFIED FORMS OF RHODANESE 1JNW ; 2.07 ; Active Site Structure of E. coli pyridoxine 5'-phosphate Oxidase 1WAY ; 2.02 ; ACTIVE SITE THROMBIN INHIBITORS 1WBG ; 2.2 ; ACTIVE SITE THROMBIN INHIBITORS 4G8L ; 2.8 ; Active state of intact sensor domain of human RNase L with 2-5A bound 1AXA ; 2 ; ACTIVE-SITE MOBILITY IN HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 PROTEASE AS DEMONSTRATED BY CRYSTAL STRUCTURE OF A28S MUTANT 4CEL ; 2.2 ; ACTIVE-SITE MUTANT D214N DETERMINED AT PH 6.0 WITH NO LIGAND BOUND IN THE ACTIVE SITE 3CEL ; 2 ; ACTIVE-SITE MUTANT E212Q DETERMINED AT PH 6.0 WITH CELLOBIOSE BOUND IN THE ACTIVE SITE 2CEL ; 2 ; ACTIVE-SITE MUTANT E212Q DETERMINED AT PH 6.0 WITH NO LIGAND BOUND IN THE ACTIVE SITE 4GZI ; 1.68 ; Active-site mutant of potato endo-1,3-beta-glucanase in complex with laminaratriose 4GZJ ; 1.55 ; Active-site mutant of potato endo-1,3-beta-glucanase in complex with laminaratriose and laminaratetrose 1TXX ; 2.2 ; ACTIVE-SITE VARIANT OF E.COLI THIOREDOXIN 2ARP ; 2 ; Activin A in complex with Fs12 fragment of follistatin 3T57 ; 2.1 ; Activity and Crystal Structure of Arabidopsis UDP-N-acetylglucosamine acyltransferase 1ALD ; 2 ; ACTIVITY AND SPECIFICITY OF HUMAN ALDOLASES 3AAT ; 2.8 ; ACTIVITY AND STRUCTURE OF THE ACTIVE-SITE MUTANTS R386Y AND R386F OF ESCHERICHIA COLI ASPARTATE AMINOTRANSFERASE 1BUD ; 1.9 ; ACUTOLYSIN A FROM SNAKE VENOM OF AGKISTRODON ACUTUS AT PH 5.0 1BSW ; 1.95 ; ACUTOLYSIN A FROM SNAKE VENOM OF AGKISTRODON ACUTUS AT PH 7.5 1WUT ; 2.26 ; Acyl Ureas as Human Liver Glycogen Phosphorylase Inhibitors for the Treatment of Type 2 Diabetes 1HBK ; 2 ; ACYL-COA BINDING PROTEIN FROM PLASMODIUM FALCIPARUM 1XNV ; 2.3 ; Acyl-CoA Carboxylase Beta Subunit from S. coelicolor (PccB), apo form #1 1XNW ; 2.6 ; Acyl-CoA Carboxylase Beta Subunit from S. coelicolor (PccB), apo form #2, mutant D422I 1XO6 ; 2.2 ; Acyl-CoA Carboxylase Beta Subunit from S. coelicolor (PccB), apo form #3 2BU3 ; 1.4 ; ACYL-ENZYME INTERMEDIATE BETWEEN ALR0975 AND GLUTATHIONE AT PH 3.4 2ACY ; 1.8 ; ACYL-PHOSPHATASE (COMMON TYPE) FROM BOVINE TESTIS 4HXF ; 1.601 ; Acylaminoacyl peptidase in complex with Z-Gly-Gly-Phe-chloromethyl ketone 2BJE ; 1.9 ; ACYLPHOSPHATASE FROM SULFOLOBUS SOLFATARICUS. MONCLINIC P21 SPACE GROUP 2W4D ; 2.4 ; Acylphosphatase variant G91A from Pyrococcus horikoshii 3TOQ ; 2 ; Acylphosphatase with mesophilic surface and thermophilic core 3TNV ; 1.6 ; Acylphosphatase with thermophilic surface and mesophilic core 3U0W ; 2 ; AD related murine antibody Fragment 2J12 ; 1.5 ; AD37 FIBRE HEAD IN COMPLEX WITH CAR D1 2WBW ; 1.55 ; Ad37 fibre head in complex with CAR D1 and sialic acid 4ATZ ; 1.95 ; Ad5 knob in complex with a designed ankyrin repeat protein 1SFE ; 2.1 ; ADA O6-METHYLGUANINE-DNA METHYLTRANSFERASE FROM ESCHERICHIA COLI 1A4L ; 2.6 ; ADA STRUCTURE COMPLEXED WITH DEOXYCOFORMYCIN AT PH 7.0 1A4M ; 1.95 ; ADA STRUCTURE COMPLEXED WITH PURINE RIBOSIDE AT PH 7.0 4DD8 ; 2.1 ; ADAM-8 metalloproteinase domain with bound batimastat 2AO7 ; 2.9 ; Adam10 Disintegrin and cysteine- rich domain 2AIG ; 2.6 ; ADAMALYSIN II WITH PEPTIDOMIMETIC INHIBITOR POL647 3AIG ; 2.8 ; ADAMALYSIN II WITH PEPTIDOMIMETIC INHIBITOR POL656 4AIG ; 2 ; ADAMALYSIN II WITH PHOSPHONATE INHIBITOR 3Q2G ; 2.3 ; Adamts1 in complex with a novel N-hydroxyformamide inhibitors 3Q2H ; 2.33 ; Adamts1 in complex with N-hydroxyformamide inhibitors of ADAM-TS4 3FCZ ; 2.804 ; Adaptive protein evolution grants organismal fitness by improving catalysis and flexibility 3U2A ; 1.7 ; Adaptor dependent degradation of a cell-cycle regulator reveals diversity in substrate architectures 2BIR ; 2.3 ; ADDITIVITY OF SUBSTRATE BINDING IN RIBONUCLEASE T1 (Y42A MUTANT) 1U49 ; 2.15 ; Adenine-8oxoguanine mismatch at the polymerase active site 1NK5 ; 2.1 ; ADENINE-ADENINE MISMATCH AT THE POLYMERASE ACTIVE SITE 1NK0 ; 1.7 ; ADENINE-GUANINE MISMATCH AT THE POLYMERASE ACTIVE SITE 2ADM ; 2.6 ; ADENINE-N6-DNA-METHYLTRANSFERASE TAQI 1G38 ; 2 ; ADENINE-SPECIFIC METHYLTRANSFERASE M. TAQ I/DNA COMPLEX 1NDP ; 2.2 ; ADENOSINE 5'-DIPHOSPHATE BINDING AND THE ACTIVE SITE OF NUCLEOSIDE DIPHOSPHATE KINASE 2FJA ; 2 ; adenosine 5'-phosphosulfate reductase in complex with substrate 1VFL ; 1.8 ; Adenosine deaminase 1UIO ; 2.4 ; ADENOSINE DEAMINASE (HIS 238 ALA MUTANT) 1UIP ; 2.4 ; ADENOSINE DEAMINASE (HIS 238 GLU MUTANT) 4DC3 ; 2.4 ; Adenosine kinase from Schistosoma mansoni in complex with 2-fluoroadenosine 3VAQ ; 2.44 ; Adenosine kinase from Schistosoma mansoni in complex with adenosine 3UQ6 ; 2.3 ; Adenosine kinase from Schistosoma mansoni in complex with adenosine and AMP 3VAS ; 2.26 ; Adenosine kinase from Schistosoma mansoni in complex with adenosine in occluded loop conformation 3UQ9 ; 2.343 ; Adenosine kinase from Schistosoma mansoni in complex with tubercidin 2FJB ; 1.7 ; Adenosine-5'-phosphosulfate reductase im complex with products 2FJD ; 1.84 ; adenosine-5-phosphosulfate reductase in complex with sulfite (covalent adduct) 2FJE ; 1.8 ; adenosine-5-phosphosulfate reductase oxidized state 1CBU ; 2.3 ; ADENOSYLCOBINAMIDE KINASE/ADENOSYLCOBINAMIDE PHOSPHATE GUANYLYLTRANSFERASE (COBU) FROM SALMONELLA TYPHIMURIUM 1ANV ; 2.7 ; ADENOVIRUS 5 DBP/URANYL FLUORIDE SOAK 1UXB ; 1.75 ; ADENOVIRUS AD19P FIBRE HEAD IN COMPLEX WITH SIALYL-LACTOSE 1H7Z ; 1.6 ; ADENOVIRUS AD3 FIBRE HEAD 2QLK ; 2.02 ; Adenovirus AD35 fibre head 1UXE ; 2 ; ADENOVIRUS AD37 FIBRE HEAD 1UXA ; 1.5 ; ADENOVIRUS AD37 FIBRE HEAD IN COMPLEX WITH SIALYL-LACTOSE 1V1I ; 1.9 ; ADENOVIRUS FIBRE SHAFT SEQUENCE N-TERMINALLY FUSED TO THE BACTERIOPHAGE T4 FIBRITIN FOLDON TRIMERISATION MOTIF WITH A LONG LINKER 1V1H ; 1.9 ; ADENOVIRUS FIBRE SHAFT SEQUENCE N-TERMINALLY FUSED TO THE BACTERIOPHAGE T4 FIBRITIN FOLDON TRIMERISATION MOTIF WITH A SHORT LINKER 3N0Z ; 1.7 ; Adenylate cyclase class IV with active site ligand 3AT 3N0Y ; 1.7 ; Adenylate cyclase class IV with active site ligand APC 4AKE ; 2.2 ; ADENYLATE KINASE 1P3J ; 1.9 ; Adenylate Kinase from Bacillus subtilis 1ZAK ; 3.5 ; ADENYLATE KINASE FROM MAIZE IN COMPLEX WITH THE INHIBITOR P1,P5-BIS(ADENOSINE-5'-)PENTAPHOSPHATE (AP5A) 1KI9 ; 2.76 ; Adenylate kinase from Methanococcus thermolithotrophicus 1KHT ; 2.5 ; Adenylate kinase from Methanococcus voltae 1NKS ; 2.57 ; ADENYLATE KINASE FROM SULFOLOBUS ACIDOCALDARIUS 1AK2 ; 1.92 ; ADENYLATE KINASE ISOENZYME-2 2AK2 ; 2.1 ; ADENYLATE KINASE ISOENZYME-2 1ZIN ; 1.6 ; ADENYLATE KINASE WITH BOUND AP5A 1ZAU ; 3.15 ; Adenylation domain of NAD+ dependent DNA ligase from M.tuberculosis 1SON ; 2.55 ; ADENYLOSUCCINATE SYNTHETASE IN COMPLEX WITH THE NATURAL FEEDBACK INHIBITOR AMP 1SOO ; 2.6 ; ADENYLOSUCCINATE SYNTHETASE INHIBITED BY HYDANTOCIDIN 5'-MONOPHOSPHATE 2FJT ; 1.901 ; Adenylyl cyclase class iv from Yersinia pestis 2ANS ; 2.5 ; ADIPOCYTE LIPID BINDING PROTEIN COMPLEXED WITH 1-ANILINO-8-NAPHTHALENE SULFONATE 1ADL ; 1.6 ; ADIPOCYTE LIPID BINDING PROTEIN COMPLEXED WITH ARACHIDONIC ACID: X-RAY CRYSTALLOGRAPHIC AND TITRATION CALORIMETRY STUDIES 3DFV ; 3.1 ; Adjacent GATA DNA binding 1K98 ; 3.75 ; AdoMet complex of MetH C-terminal fragment 1AMW ; 1.85 ; ADP BINDING SITE IN THE HSP90 MOLECULAR CHAPERONE 1XXI ; 4.1 ; ADP Bound E. coli Clamp Loader Complex 3IQX ; 3.5 ; ADP complex of C.therm. Get3 in closed form 1XJQ ; 2.06 ; ADP Complex OF HUMAN PAPS SYNTHETASE 1 3DSR ; 2.7 ; ADP in transition binding site in the subunit B of the energy converter A1Ao ATP synthase 3ZQ6 ; 2.107 ; ADP-ALF4 COMPLEX OF M. THERM. TRC40 2WOJ ; 1.994 ; ADP-ALF4 COMPLEX OF S. CEREVISIAE GET3 4AM7 ; 3.25 ; ADP-BOUND C-TERMINAL DOMAIN OF ACTIN-RELATED PROTEIN ARP8 FROM S. CEREVISIAE 4GVA ; 1.83 ; ADP-bound form of the ERK2 kinase 3KJG ; 2.3 ; ADP-bound state of CooC1 1MOZ ; 3.17 ; ADP-ribosylation factor-like 1 (ARL1) from Saccharomyces cerevisiae 2YZV ; 1.6 ; ADP-ribosylglycohydrolase-related protein complex 2YZW ; 1.7 ; ADP-ribosylglycohydrolase-related protein complex 1R4B ; 1.85 ; ADP-ribosyltransferase C3bot2 from Clostridium botulinum, monoclinic form 1R45 ; 1.57 ; ADP-ribosyltransferase C3bot2 from Clostridium botulinum, triclinic form 2ADR ; ; ADR1 DNA-BINDING DOMAIN FROM SACCHAROMYCES CEREVISIAE, NMR, 25 STRUCTURES 1CJE ; 2.5 ; ADRENODOXIN FROM BOVINE 1E1K ; 1.95 ; ADRENODOXIN REDUCTASE IN COMPLEX WITH NADP+ OBTAINED BY A SOAKING EXPERIMENT 1E1M ; 1.85 ; ADRENODOXIN REDUCTASE IN COMPLEX WITH NADPH OBTAINED BY A SOAKING EXPERIMENT 1E6E ; 2.3 ; ADRENODOXIN REDUCTASE/ADRENODOXIN COMPLEX OF MITOCHONDRIAL P450 SYSTEMS 2WLB ; 2.6 ; ADRENODOXIN-LIKE FERREDOXIN ETP1FD(516-618) OF SCHIZOSACCHAROMYCES POMBE MITOCHONDRIA 3DZT ; 1.8 ; AeD7-leukotriene E4 complex 1YIY ; 1.9 ; Aedes aegypti kynurenine aminotransferase 1YIZ ; 1.55 ; Aedes aegypti kynurenine aminotrasferase 2R5C ; 1.96 ; Aedes Kynurenine Aminotransferase in Complex with Cysteine 2R5E ; 1.84 ; Aedes kynurenine aminotransferase in complex with glutamine 4I3M ; 1.95 ; Aer2 poly-HAMP domains: L44H HAMP1 CW-lock mutant 4I44 ; 2.88 ; Aer2 poly-HAMP domains: V33G HAMP1 inverted signaling mutant 3P9O ; 1.45 ; Aerobic ternary complex of urate oxidase with azide and chloride 1IGB ; 2.3 ; AEROMONAS PROTEOLYTICA AMINOPEPTIDASE COMPLEXED WITH THE INHIBITOR PARA-IODO-D-PHENYLALANINE HYDROXAMATE 2QR5 ; 2.2 ; Aeropyrum pernix acylaminoacyl peptidase, H367A mutant 4GQF ; 2.3 ; Aeropyrum pernix Peroxiredoxin Q Enzyme in the Locally Unfolded Conformation 1UT2 ; 3.3 ; AFAE-3 ADHESIN FROM ESCHERICHIA COLI 2JDG ; 2 ; AFFILIN BASED ON HUMAN GAMMA-B CRYSTALLIN 2VEZ ; 1.45 ; AFGNA1 CRYSTAL STRUCTURE COMPLEXED WITH ACETYL-COA AND GLUCOSE-6P GIVES NEW INSIGHTS INTO CATALYSIS 1GVE ; 1.38 ; AFLATOXIN ALDEHYDE REDUCTASE (AKR7A1) FROM RAT LIVER 2KH4 ; ; Aflatoxin Formamidopyrimidine alpha anomer in single strand DNA 1AQQ ; ; AG-SUBSTITUTED METALLOTHIONEIN FROM SACCHAROMYCES CEREVISIAE, NMR, 10 STRUCTURES 1AOO ; ; AG-SUBSTITUTED METALLOTHIONEIN FROM SACCHAROMYCES CEREVISIAE, NMR, MINIMIZED AVERAGE STRUCTURE 2ERB ; 1.5 ; AgamOBP1, and odorant binding protein from Anopheles gambiae complexed with PEG 1RJO ; 1.67 ; AGAO + Xe 3KII ; 1.9 ; AGAO 5-phenoxy-2,3-pentadienylamine complex 3KN4 ; 2.05 ; AGAO 6-phenyl-2,3-hexadienylamine complex 1W5Z ; 1.86 ; AGAO COVALENT COMPLEX WITH BENZYLHYDRAZINE 1W4N ; 1.65 ; AGAO COVALENT COMPLEX WITH TRANYLCYPROMINE 1W6G ; 1.55 ; AGAO HOLOENZYME AT 1.55 ANGSTROMS 1W6C ; 2.2 ; AGAO HOLOENZYME IN A SMALL CELL, AT 2.2 ANGSTROMS 2BT3 ; 1.73 ; AGAO IN COMPLEX WITH RUTHENIUM-C4-WIRE AT 1.73 ANGSTROMS 2CG1 ; 1.67 ; AGAO IN COMPLEX WITH WC11B (RU-WIRE INHIBITOR, 11-CARBON LINKER, DATA SET B) 2CFG ; 1.55 ; AGAO IN COMPLEX WITH WC4D3 (RU-WIRE INHIBITOR, 4-CARBON LINKER, DELTA ENANTIOMER, DATA SET 3) 2CFD ; 1.6 ; AGAO IN COMPLEX WITH WC4L3 (RU-WIRE INHIBITOR, 4-CARBON LINKER, LAMBDA ENANTIOMER, DATA SET 3) 2CFK ; 1.8 ; AGAO IN COMPLEX WITH WC5 (RU-WIRE INHIBITOR, 5-CARBON LINKER) 2CFL ; 1.8 ; AGAO IN COMPLEX WITH WC6B (RU-WIRE INHIBITOR, 6-CARBON LINKER, DATA SET B) 2CFW ; 1.74 ; AGAO IN COMPLEX WITH WC7A (RU-WIRE INHIBITOR, 7-CARBON LINKER, DATA SET A) 2CG0 ; 1.8 ; AGAO IN COMPLEX WITH WC9A (RU-WIRE INHIBITOR, 9-CARBON LINKER, DATA SET A) 1SIH ; 1.73 ; AGAO in covalent complex with the inhibitor MOBA (""4-(4-methylphenoxy)-2-butyn-1-amine"") 1SII ; 1.7 ; AGAO in covalent complex with the inhibitor NOBA (""4-(2-naphthyloxy)-2-butyn-1-amine"") 1ZFM ; 2.2 ; AGC Duplex B-DNA 2WG0 ; 2.2 ; AGED CONJUGATE OF TORPEDO CALIFORNICA ACETYLCHOLINESTERASE WITH SOMAN (OBTAINED BY IN CRYSTALLO AGING) 3DKK ; 2.31 ; Aged Form of Human Butyrylcholinesterase Inhibited by Tabun 2WIF ; 2.25 ; AGED FORM OF HUMAN BUTYRYLCHOLINESTERASE INHIBITED BY TABUN ANALOGUE TA1 2WSL ; 2 ; AGED FORM OF HUMAN BUTYRYLCHOLINESTERASE INHIBITED BY TABUN ANALOGUE TA4 2WIL ; 3.1 ; AGED FORM OF HUMAN BUTYRYLCHOLINESTERASE INHIBITED BY TABUN ANALOGUE TA5 2C0P ; 2.5 ; AGED FORM OF MOUSE ACETYLCHOLINESTERASE INHIBITED BY TABUN 3DL7 ; 2.5 ; Aged Form of Mouse Acetylcholinesterase Inhibited by Tabun- Update 2ZR1 ; 2.6 ; Agglutinin from Abrus Precatorius 2Q3N ; 3.5 ; Agglutinin from Abrus Precatorius (APA-I) 1RZO ; 2.63 ; Agglutinin from Ricinus communis with galactoaza 1JLX ; 2.2 ; AGGLUTININ IN COMPLEX WITH T-DISACCHARIDE 1BJJ ; 2.8 ; AGKISTRODOTOXIN, A PHOSPHOLIPASE A2-TYPE PRESYNAPTIC NEUROTOXIN FROM AGKISTRODON HALYS PALLAS 1A2A ; 2.8 ; AGKISTROTOXIN, A PHOSPHOLIPASE A2-TYPE PRESYNAPTIC NEUROTOXIN FROM AGKISTRODON HALYS PALLAS 3S7G ; 3.13 ; Aglycosylated human igg1 fc fragment 3HVM ; 2.1 ; Agmatine Deiminase from Helicobacter pylori 2JER ; 1.65 ; AGMATINE DEIMINASE OF ENTEROCOCCUS FAECALIS CATALYZING ITS REACTION. 2X6T ; 2.36 ; AGME BOUND TO ADP-B-MANNOSE 2X86 ; 2.8 ; AGME BOUND TO ADP-B-MANNOSE 3QAK ; 2.71 ; Agonist bound structure of the human adenosine A2a receptor 1HYK ; ; AGOUTI-RELATED PROTEIN (87-132) (AC-AGRP(87-132)) 1WW7 ; 1.9 ; Agrocybe cylindracea galectin (Ligand-free) 1WW5 ; 2.2 ; Agrocybe cylindracea galectin complexed with 3'-sulfonyl lactose 1WW6 ; 2.2 ; Agrocybe cylindracea galectin complexed with lactose 1WW4 ; 2.3 ; Agrocybe cylindracea galectin complexed with NeuAca2-3lactose 2JCC ; 2.5 ; AH3 RECOGNITION OF MUTANT HLA-A2 W167A 2KIV ; ; AIDA-1 SAM domain tandem 3Q9J ; 2.55 ; AIIFL segment derived from Alzheimer's Amyloid-Beta displayed on 42-membered macrocycle scaffold 3T4G ; 1.7 ; AIIGLMV segment from Alzheimer's Amyloid-Beta displayed on 54-membered macrocycle scaffold 3FOD ; 1.4 ; AILSST segment from Islet Amyloid Polypeptide 4AIF ; 2.006 ; AIP TPR domain in complex with human Hsp90 peptide 4APO ; 1.895 ; AIP TPR domain in complex with human Tomm20 peptide 2W3G ; 1.4 ; AIR-OXIDIZED STRUCTURE OF THE FIRST GAF DOMAIN OF MYCOBACTERIUM TUBERCULOSIS DOSS 2OM9 ; 2.8 ; Ajulemic acid, a synthetic cannabinoid bound to PPAR gamma 2VFY ; 1.8 ; AKAP18 DELTA CENTRAL DOMAIN 2VFK ; 1.5 ; AKAP18 DELTA CENTRAL DOMAIN - AMP 2VFL ; 2.25 ; AKAP18 DELTA CENTRAL DOMAIN - CMP 3R94 ; 2.013 ; AKR1C3 complex with flurbiprofen 3R8G ; 1.799 ; AKR1C3 complex with ibuprofen 3UGR ; 1.65 ; AKR1C3 complex with indomethacin at pH 6.8 3UG8 ; 1.73 ; AKR1C3 complex with indomethacin at pH 7.5 3R6I ; 1.95 ; AKR1C3 complex with meclofenamic acid 3R58 ; 2.3 ; AKR1C3 complex with naproxen 3UFY ; 1.9 ; AKR1C3 complex with R-naproxen 3R7M ; 2.1 ; AKR1C3 complex with sulindac 3R8H ; 1.9 ; AKR1C3 complex with zomepirac 3UWE ; 1.68 ; AKR1C3 complexed with 3-phenoxybenzoic acid 3R43 ; 2 ; AKR1C3 complexed with mefenamic acid 3OCB ; 2.7 ; Akt1 kinase domain with pyrrolopyrimidine inhibitor 4EKK ; 2.8 ; Akt1 with AMP-PNP 4EKL ; 2 ; Akt1 with GDC0068 3CDY ; 2.43 ; AL-09 H87Y, immunoglobulin light chain variable domain 3U7A ; 2 ; AL-09 Y32F Y96F 3U79 ; 1.62 ; AL-103 Y32F Y96F 1SGP ; 1.4 ; ALA 18 VARIANT OF TURKEY OVOMUCOID INHIBITOR THIRD DOMAIN COMPLEXED WITH STREPTOMYCES GRISEUS PROTEINASE B 2FMO ; 2.25 ; Ala177Val mutant of E. coli Methylenetetrahydrofolate Reductase 2FMN ; 2.05 ; Ala177Val mutant of E. coli Methylenetetrahydrofolate Reductase complex with LY309887 2IFI ; ; Ala6 Variant of ImI Conotoxin 1B6Q ; 1.8 ; ALANINE 31 PROLINE MUTANT OF ROP PROTEIN 1GMG ; 1.9 ; ALANINE 31 PROLINE MUTANT OF ROP PROTEIN, MONOCLINIC FORM 1XI9 ; 2.33 ; Alanine aminotransferase from Pyrococcus furiosus Pfu-1397077-001 1OMO ; 2.32 ; alanine dehydrogenase dimer w/bound NAD (archaeal) 1SFT ; 1.9 ; ALANINE RACEMASE 1L6G ; 2 ; Alanine racemase bound with N-(5'-phosphopyridoxyl)-D-alanine 1L6F ; 2 ; Alanine racemase bound with N-(5'-phosphopyridoxyl)-L-alanine 1BD0 ; 1.6 ; ALANINE RACEMASE COMPLEXED WITH ALANINE PHOSPHONATE 3HA1 ; 1.95 ; Alanine racemase from Bacillus Anthracis (Ames) 1EPV ; 2.2 ; ALANINE RACEMASE WITH BOUND INHIBITOR DERIVED FROM D-CYCLOSERINE 1NIU ; 2.2 ; ALANINE RACEMASE WITH BOUND INHIBITOR DERIVED FROM L-CYCLOSERINE 2SFP ; 1.9 ; ALANINE RACEMASE WITH BOUND PROPIONATE INHIBITOR 4I8A ; 2.9 ; Alanine-glyoxylate aminotransferase variant S187F 1V7O ; 2.62 ; Alanyl-tRNA synthetase editing domain homologue protein from Pyrococcus horikoshii 3OQV ; 1.9 ; AlbC, a cyclodipeptide synthase from Streptomyces noursei 2WKW ; 2.03 ; ALCALIGENES ESTERASE COMPLEXED WITH PRODUCT ANALOGUE 1CDO ; 2.05 ; ALCOHOL DEHYDROGENASE (E.C.1.1.1.1) (EE ISOZYME) COMPLEXED WITH NICOTINAMIDE ADENINE DINUCLEOTIDE (NAD), AND ZINC 2XAA ; 2.8 ; ALCOHOL DEHYDROGENASE ADH-'A' FROM RHODOCOCCUS RUBER DSM 44541 AT PH 8.5 IN COMPLEX WITH NAD AND BUTANE-1,4-DIOL 1JQB ; 1.97 ; Alcohol Dehydrogenase from Clostridium Beijerinckii: Crystal Structure of Mutant with Enhanced Thermal Stability 1A4U ; 1.92 ; ALCOHOL DEHYDROGENASE FROM DROSOPHILA LEBANONENSIS 1B14 ; 2.4 ; Alcohol Dehydrogenase from Drosophila Lebanonensis Binary Complex with NAD+ 1SBY ; 1.1 ; Alcohol dehydrogenase from Drosophila lebanonensis complexed with NAD+ and 2,2,2-trifluoroethanol at 1.1 A resolution 1B16 ; 1.4 ; ALCOHOL DEHYDROGENASE FROM DROSOPHILA LEBANONENSIS TERNARY COMPLEX WITH NAD-3-PENTANONE 1B15 ; 2.2 ; ALCOHOL DEHYDROGENASE FROM DROSOPHILA LEBANONENSIS TERNARY COMPLEX WITH NAD-ACETONE 1B2L ; 1.6 ; ALCOHOL DEHYDROGENASE FROM DROSOPHILA LEBANONENSIS: TERNARY COMPLEX WITH NAD-CYCLOHEXANONE 1Y9A ; 1.81 ; Alcohol Dehydrogenase from Entamoeba histolotica in complex with cacodylate 1R37 ; 2.3 ; Alcohol dehydrogenase from sulfolobus solfataricus complexed with NAD(H) and 2-ethoxyethanol 1JVB ; 1.85 ; ALCOHOL DEHYDROGENASE FROM THE ARCHAEON SULFOLOBUS SOLFATARICUS 1AG8 ; 2.65 ; ALDEHYDE DEHYDROGENASE FROM BOVINE MITOCHONDRIA 1A4Z ; 2.75 ; ALDEHYDE DEHYDROGENASE FROM BOVINE MITOCHONDRIA COMPLEX WITH NAD (REDUCED) AND SAMARIUM (III) 2ALR ; 2.48 ; ALDEHYDE REDUCTASE 1AE4 ; 2.4 ; ALDEHYDE REDUCTASE COMPLEXED WITH COFACTOR AND INHIBITOR, ALPHA CARBON ATOMS ONLY 2VFU ; 1.9 ; ALDITOL OXIDASE FROM STREPTOMYCES COELICOLOR A3(2): COMPLEX WITH MANNITOL 2VFT ; 1.6 ; ALDITOL OXIDASE FROM STREPTOMYCES COELICOLOR A3(2): COMPLEX WITH SORBITOL 2VFV ; 1.72 ; ALDITOL OXIDASE FROM STREPTOMYCES COELICOLOR A3(2): COMPLEX WITH SULPHITE 2VFS ; 1.6 ; ALDITOL OXIDASE FROM STREPTOMYCES COELICOLOR A3(2): COMPLEX WITH XYLITOL 2VFR ; 1.1 ; ALDITOL OXIDASE FROM STREPTOMYCES COELICOLOR A3(2): NATIVE ENZYME 1YNP ; 1.25 ; aldo-keto reductase AKR11C1 from Bacillus halodurans (apo form) 1YNQ ; 1.3 ; aldo-keto reductase AKR11C1 from Bacillus halodurans (holo form) 3V35 ; 1.9 ; Aldose reductase complexed with a nitro compound 3V9Q ; 2 ; Aldose reductase complexed with a phenolic compound 3V36 ; 2 ; Aldose reductase complexed with glceraldehyde 2IKG ; 1.43 ; Aldose reductase complexed with nitrophenyl-oxadiazol type inhibitor at 1.43 A 1AH3 ; 2.3 ; ALDOSE REDUCTASE COMPLEXED WITH TOLRESTAT INHIBITOR 3DN5 ; 1.45 ; Aldose Reductase in complex with novel biarylic inhibitor 3U2C ; 1 ; Aldose reductase in complex with NSAID-type inhibitor at 1.0 A resolution 2AGT ; 1 ; Aldose Reductase Mutant Leu 300 Pro complexed with Fidarestat 2F2K ; 1.94 ; Aldose reductase tertiary complex with NADPH and DEG 3G9E ; 2.3 ; Aleglitaar. a new. potent, and balanced dual ppara/g agonist for the treatment of type II diabetes 3G8I ; 2.2 ; Aleglitazar, a new, potent, and balanced PPAR alpha/gamma agonist for the treatment of type II diabetes 1SUI ; 2.7 ; Alfalfa caffeoyl coenzyme A 3-O-methyltransferase 3GZE ; 1.98 ; Algal prolyl 4-hydroxylase complexed with zinc and (Ser-Pro)5 peptide substrate 4E1Y ; 2.1 ; Alginate lyase A1-III H192A apo form 4F10 ; 2.2 ; Alginate lyase A1-III H192A complexed with tetrasaccharide 4F13 ; 2.208 ; Alginate lyase A1-III Y246F complexed with tetrasaccharide 1J1T ; 2 ; Alginate lyase from Alteromonas sp.272 3F73 ; 3 ; Alignment of guide-target seed duplex within an argonaute silencing complex 2UXY ; 1.25 ; ALIPHATIC AMIDASE 3C3R ; 2.02 ; ALIX BRO1 CHMP4C complex 3C3O ; 2.15 ; ALIX Bro1-domain:CHMIP4A co-crystal structure 3C3Q ; 2.1 ; ALIX Bro1-domain:CHMIP4B co-crystal structure 3GXL ; 1.8 ; ALK-5 kinase complex with GW857175 2WOU ; 2.3 ; ALK5 IN COMPLEX WITH 4-((4-((2,6-DIMETHYL-3-PYRIDYL)OXY)-2-PYRIDYL)AMINO)BENZENESULFONAMIDE 2WOT ; 1.85 ; ALK5 IN COMPLEX WITH 4-((5,6-DIMETHYL-2-(2-PYRIDYL)-3-PYRIDYL)OXY)-N-(3,4,5-TRIMETHOXYPHENYL)PYRIDIN-2-AMINE 3OH6 ; 2.894 ; AlkA Undamaged DNA Complex: Interrogation of a C:G base pair 3OGD ; 2.8 ; AlkA Undamaged DNA Complex: Interrogation of a G*:C base pair 3OH9 ; 2.802 ; AlkA Undamaged DNA Complex: Interrogation of a T:A base pair 2DIE ; 2.1 ; Alkaline alpha-amylase AmyK from Bacillus sp. KSM-1378 1G01 ; 1.9 ; ALKALINE CELLULASE K CATALYTIC DOMAIN 1G0C ; 1.9 ; ALKALINE CELLULASE K CATALYTIC DOMAIN-CELLOBIOSE COMPLEX 1WSD ; 1.5 ; Alkaline M-protease form I crystal strcuture 2ANH ; 2.4 ; ALKALINE PHOSPHATASE (D153H) 1ANI ; 2.5 ; ALKALINE PHOSPHATASE (D153H, K328H) 1URA ; 2.04 ; ALKALINE PHOSPHATASE (D51ZN) 1EW9 ; 2 ; ALKALINE PHOSPHATASE (E.C. 3.1.3.1) COMPLEX WITH MERCAPTOMETHYL PHOSPHONATE 1EW8 ; 2.2 ; ALKALINE PHOSPHATASE (E.C. 3.1.3.1) COMPLEX WITH PHOSPHONOACETIC ACID 1HQA ; 2.25 ; ALKALINE PHOSPHATASE (H412Q) 1ANJ ; 2.3 ; ALKALINE PHOSPHATASE (K328H) 1URB ; 2.14 ; ALKALINE PHOSPHATASE (N51MG) 1B8J ; 1.9 ; ALKALINE PHOSPHATASE COMPLEXED WITH VANADATE 1ZED ; 1.57 ; Alkaline phosphatase from human placenta in complex with p-nitrophenyl-phosphonate 1ALI ; 2.2 ; ALKALINE PHOSPHATASE MUTANT (H412N) 1ALJ ; 2.6 ; ALKALINE PHOSPHATASE MUTANT (H412N) 1HJK ; 2.3 ; ALKALINE PHOSPHATASE MUTANT H331Q 1AKL ; 2 ; ALKALINE PROTEASE FROM PSEUDOMONAS AERUGINOSA IFO3080 3Q3T ; 2.6 ; Alkyl Amine Renin Inhibitors: Filling S1 from S3 2UUV ; 1.99 ; ALKYLDIHYDROXYACETONEPHOSPHATE SYNTHASE IN P1 2UUU ; 1.95 ; ALKYLDIHYDROXYACETONEPHOSPHATE SYNTHASE IN P212121 1G1M ; 2.25 ; ALL-FERROUS NITROGENASE IRON PROTEIN FROM AZOTOBACTER VINELANDII 3QVJ ; 2.1 ; Allantoin racemase from Klebsiella pneumoniae 3QVK ; 1.999 ; Allantoin racemase from Klebsiella pneumoniae 3QVL ; 1.822 ; Allantoin racemase from Klebsiella pneumoniae 3DY5 ; 3.51 ; Allene oxide synthase 8R-lipoxygenase from Plexaura homomalla 1W2Q ; ; ALLERGEN ARAH6 FROM PEANUT (ARACHIS HYPOGAEA) 1WHO ; 1.9 ; ALLERGEN PHL P 2 1WHP ; 3 ; ALLERGEN PHL P 2 2HOX ; 1.4 ; alliinase from allium sativum (garlic) 2JUU ; ; allo-ThrA3 DKP-insulin 3MML ; 2.5 ; Allophanate Hydrolase Complex from Mycobacterium smegmatis, Msmeg0435-Msmeg0436 1ALL ; 2.3 ; ALLOPHYCOCYANIN 3DBJ ; 2.9 ; Allophycocyanin from Thermosynechococcus vulcanus 4GAU ; 3.3 ; Allosteric control of the ribosome by small-molecule antibiotics 4GAS ; 3.3 ; Allosteric control of the ribosome by small-molecule antibiotics 4GAR ; 3.3 ; Allosteric control of the ribosome by small-molecule antibiotics 4GAQ ; 3.3 ; Allosteric control of the ribosome by small-molecule antibiotics 2GPA ; 2 ; ALLOSTERIC INHIBITION OF GLYCOGEN PHOSPHORYLASE A BY A POTENTIAL ANTIDIABETIC DRUG 3AMV ; 2.1 ; ALLOSTERIC INHIBITION OF GLYCOGEN PHOSPHORYLASE A BY A POTENTIAL ANTIDIABETIC DRUG 1T48 ; 2.2 ; Allosteric Inhibition of Protein Tyrosine Phosphatase 1B 1T49 ; 1.9 ; Allosteric Inhibition of Protein Tyrosine Phosphatase 1B 1T4J ; 2.7 ; Allosteric Inhibition of Protein Tyrosine Phosphatase 1B 2I80 ; 2.19 ; Allosteric inhibition of Staphylococcus aureus D-alanine:D-alanine ligase revealed by crystallographic studies 2I87 ; 2 ; Allosteric inhibition of Staphylococcus aureus D-alanine:D-alanine ligase revealed by crystallographic studies 2I8C ; 2.46 ; Allosteric inhibition of Staphylococcus aureus D-alanine:D-alanine ligase revealed by crystallographic studies 4EHL ; 1.799 ; Allosteric Modulation of Caspase-3 through Mutagenesis 4EHN ; 1.69 ; Allosteric Modulation of Caspase-3 through Mutagenesis 4EHF ; 1.655 ; Allosteric Modulation of Caspase-3 through Mutagenesis 4EHD ; 1.581 ; Allosteric Modulation of Caspase-3 through Mutagenesis 4EHA ; 1.696 ; Allosteric Modulation of Caspase-3 through Mutagenesis 4EHH ; 1.78 ; Allosteric Modulation of Caspase-3 through Mutagenesis 4EHK ; 1.668 ; Allosteric Modulation of Caspase-3 through Mutagenesis 3I5E ; 0.98 ; Allosteric Modulation of DNA by Small Molecules 3I5L ; 1.18 ; Allosteric Modulation of DNA by Small Molecules 3K8Y ; 1.3 ; Allosteric modulation of H-Ras GTPase 3K9L ; 1.8 ; Allosteric modulation of H-Ras GTPase 3K9N ; 2 ; Allosteric modulation of H-Ras GTPase 4JNF ; 1.621 ; Allosteric opening of the polypeptide-binding site when an Hsp70 binds ATP 4JN4 ; 2.3 ; Allosteric opening of the polypeptide-binding site when an Hsp70 binds ATP 4JNE ; 1.96 ; Allosteric opening of the polypeptide-binding site when an Hsp70 binds ATP 4EJF ; 2.6465 ; Allosteric peptides that bind to a caspase zymogen and mediate caspase tetramerization 4FGT ; 2 ; Allosteric peptidic inhibitor of human thymidylate synthase that stabilizes inactive conformation of the enzyme. 3Q1Y ; 2.03 ; Allosteric regulation by Lysine residue: A novel anion-hole formation in the ribokinase family 3GDN ; 1.67 ; Almond hydroxynitrile lyase in complex with benzaldehyde 4APW ; 19.7 ; Alp12 filament structure 1XGB ; ; ALPHA CONOTOXIN GI: 2-13;3-7 DISULFIDE BOND ISOMER NMR, 24 STRUCTURES 1XGC ; ; ALPHA CONOTOXIN GI: 2-3;7-13 DISULFIDE BOND ISOMER, NMR, 25 STRUCTURES 1XGA ; ; ALPHA CONOTOXIN GI: 2-7;3-13 (NATIVE) DISULFIDE BOND ISOMER, NMR, 35 STRUCTURES 2JUR ; ; alpha RgIA, a Novel Conotoxin that Blocks the alpha9-alpha10 nAChR 2JUS ; ; alpha RgIA, a Novel Conotoxin that Blocks the alpha9-alpha10 nAChR 2JUT ; ; alpha RgIA, a Novel Conotoxin that Blocks the alpha9-alpha10 nAChR 1EA0 ; 3 ; ALPHA SUBUNIT OF A. BRASILENSE GLUTAMATE SYNTHASE 1OLP ; 2.5 ; Alpha Toxin from Clostridium Absonum 1GWW ; 1.8 ; ALPHA-,1,3 GALACTOSYLTRANSFERASE - ALPHA-D-GLUCOSE COMPLEX 1GX0 ; 1.8 ; ALPHA-,1,3 GALACTOSYLTRANSFERASE - BETA-D-GALACTOSE COMPLEX 1GWV ; 2.5 ; ALPHA-,1,3 GALACTOSYLTRANSFERASE - LACTOSE COMPLEX 1GX4 ; 1.46 ; ALPHA-,1,3 GALACTOSYLTRANSFERASE - N-ACETYL LACTOSAMINE COMPLEX 1HCU ; 2.37 ; ALPHA-1,2-MANNOSIDASE FROM TRICHODERMA REESEI 4ACQ ; 4.3 ; Alpha-2 Macroglobulin 1B9K ; 1.9 ; ALPHA-ADAPTIN APPENDAGE DOMAIN, FROM CLATHRIN ADAPTOR AP2 2VUM ; 3.4 ; Alpha-amanitin inhibited complete RNA polymerase II elongation complex 1MPX ; 1.9 ; ALPHA-AMINO ACID ESTER HYDROLASE LABELED WITH SELENOMETHIONINE 3BCF ; 2.3 ; Alpha-amylase B from Halothermothrix orenii 3BC9 ; 1.35 ; Alpha-amylase B in complex with acarbose 3BCD ; 2.2 ; Alpha-amylase B in complex with maltotetraose and alpha-cyclodextrin 1AQH ; 2 ; ALPHA-AMYLASE FROM ALTEROMONAS HALOPLANCTIS 1B0I ; 2.4 ; ALPHA-AMYLASE FROM ALTEROMONAS HALOPLANCTIS 1AQM ; 1.85 ; ALPHA-AMYLASE FROM ALTEROMONAS HALOPLANCTIS COMPLEXED WITH TRIS 1BAG ; 2.5 ; ALPHA-AMYLASE FROM BACILLUS SUBTILIS COMPLEXED WITH MALTOPENTAOSE 1BVZ ; 2.6 ; ALPHA-AMYLASE II (TVAII) FROM THERMOACTINOMYCES VULGARIS R-47 2KER ; ; alpha-amylase inhibitor Parvulustat (Z-2685) from Streptomyces parvulus 1HC9 ; 1.8 ; alpha-bungarotoxin complexed with high affinity peptide 1L7C ; 2.5 ; alpha-catenin fragment, residues 385-651 1H6G ; 2.2 ; ALPHA-CATENIN M-DOMAIN 1B45 ; ; ALPHA-CNIA CONOTOXIN FROM CONUS CONSORS, NMR, 43 STRUCTURES 1CNL ; ; ALPHA-CONOTOXIN IMI 1PEN ; 1.1 ; ALPHA-CONOTOXIN PNI1 1AKG ; 1.1 ; ALPHA-CONOTOXIN PNIB FROM CONUS PENNACEUS 1WVC ; 2.5 ; alpha-D-glucose-1-phosphate cytidylyltransferase complexed with CTP 1QZM ; 1.9 ; alpha-domain of ATPase 4E17 ; 2.304 ; Alpha-E-catenin is an autoinhibited molecule that co-activates vinculin 4E18 ; 2.403 ; Alpha-E-catenin is an autoinhibited molecule that co-activates vinculin 1CSR ; 1.7 ; Alpha-fluoro acid and alpha-fluoro amide analogs of acetyl-coa as inhibitors of of citrate synthase: effect of pka matching on binding affinity and hydrogen bond length 1CSS ; 1.7 ; ALPHA-FLUORO ACID AND ALPHA-FLUORO AMIDE ANALOGS OF ACETYL-COA AS INHIBITORS OF OF CITRATE SYNTHASE: EFFECT OF PKA MATCHING ON BINDING AFFINITY AND HYDROGEN BOND LENGTH 2J44 ; 2.1 ; ALPHA-GLUCAN BINDING BY A STREPTOCOCCAL VIRULENCE FACTOR 2J73 ; 1.4 ; ALPHA-GLUCAN RCOGNITION BY A FAMILY 41 CARBOHYDRATE-BINDING MODULE FROM THERMOTOGA MARITIMA PULLULANASE PULA 2J71 ; 1.69 ; ALPHA-GLUCAN RECOGNITION BY A FAMILY 41 CARBOHYDRATE-BINDING MODULE FROM THERMOTOGA MARITIMA PULLULANASE PULA 2J72 ; 1.49 ; ALPHA-GLUCAN RECOGNITION BY A FAMILY 41 CARBOHYDRATE-BINDING MODULE FROM THERMOTOGA MARITIMA PULLULANASE PULA 2J43 ; 1.6 ; ALPHA-GLUCAN RECOGNITION BY FAMILY 41 CARBOHYDRATE-BINDING MODULES FROM STREPTOCOCCAL VIRULENCE FACTORS 1OBB ; 1.9 ; ALPHA-GLUCOSIDASE A, AGLA, FROM THERMOTOGA MARITIMA IN COMPLEX WITH MALTOSE AND NAD+ 2ZE0 ; 2 ; Alpha-glucosidase GSJ 1XV5 ; 1.73 ; alpha-glucosyltransferase (AGT) in complex with UDP 1YA6 ; 2.4 ; alpha-glucosyltransferase in complex with UDP and a 13-mer DNA containing a central A:G mismatch 1Y8Z ; 1.9 ; alpha-glucosyltransferase in complex with UDP and a 13-mer DNA containing a HMU base at 1.9 A resolution 1Y6G ; 2.8 ; alpha-glucosyltransferase in complex with UDP and a 13_mer DNA containing a HMU base at 2.8 A resolution 1Y6F ; 2.4 ; alpha-glucosyltransferase in complex with UDP-glucose and DNA containing an abasic site 3LAY ; 2.7 ; Alpha-Helical barrel formed by the decamer of the zinc resistance-associated protein (STM4172) from Salmonella enterica subsp. enterica serovar Typhimurium str. LT2 7AHL ; 1.89 ; ALPHA-HEMOLYSIN FROM STAPHYLOCOCCUS AUREUS 3OKJ ; 2.7 ; Alpha-keto-aldehyde binding mechanism reveals a novel lead structure motif for proteasome inhibition 3OJ8 ; 1.9 ; Alpha-Ketoheterocycle Inhibitors of Fatty Acid Amide Hydrolase Containing Additional Conformational Contraints in the Acyl Side Chain 2ZWY ; 2.75 ; alpha-L-fucosidase 2ZX9 ; 2.62 ; alpha-L-fucosidase complexed with inhibitor, B4 2ZWZ ; 2.36 ; alpha-L-fucosidase complexed with inhibitor, Core1 2ZX5 ; 2.65 ; alpha-L-fucosidase complexed with inhibitor, F10 2ZX6 ; 2.42 ; alpha-L-fucosidase complexed with inhibitor, F10-1C 2ZX7 ; 2.48 ; alpha-L-fucosidase complexed with inhibitor, F10-2C 2ZX8 ; 2.33 ; alpha-L-fucosidase complexed with inhibitor, F10-2C-O 2ZXA ; 2.57 ; alpha-L-fucosidase complexed with inhibitor, FNJ-acetyl 2ZXD ; 2.15 ; alpha-L-fucosidase complexed with inhibitor, iso-6FNJ 2ZXB ; 2.61 ; alpha-L-fucosidase complexed with inhibitor, ph-6FNJ 1A4V ; 1.8 ; ALPHA-LACTALBUMIN 1HFX ; 1.9 ; ALPHA-LACTALBUMIN 1HFY ; 2.3 ; ALPHA-LACTALBUMIN 1HFZ ; 2.3 ; ALPHA-LACTALBUMIN 1BMR ; ; ALPHA-LIKE TOXIN LQH III FROM SCORPION LEIURUS QUINQUESTRIATUS HEBRAEUS, NMR, 25 STRUCTURES 1TAL ; 1.5 ; ALPHA-LYTIC PROTEASE AT 120 K (SINGLE STRUCTURE MODEL) 3PRO ; 1.8 ; ALPHA-LYTIC PROTEASE COMPLEXED WITH C-TERMINAL TRUNCATED PRO REGION 4PRO ; 2.4 ; ALPHA-LYTIC PROTEASE COMPLEXED WITH PRO REGION 1GBJ ; 2 ; ALPHA-LYTIC PROTEASE WITH MET 190 REPLACED BY ALA 1GBA ; 2.15 ; ALPHA-LYTIC PROTEASE WITH MET 190 REPLACED BY ALA AND GLY 216 REPLACED BY ALA 1GBB ; 2.15 ; Alpha-lytic protease with met 190 replaced by ALA AND GLY 216 replaced by ALA complex with METHOXYSUCCINYL-ALA-ALA-PRO-ALANINE BORONIC ACID 1GBC ; 2.2 ; ALPHA-LYTIC PROTEASE WITH MET 190 REPLACED BY ALA AND GLY 216 REPLACED BY ALA COMPLEX WITH METHOXYSUCCINYL-ALA-ALA-PRO-LEUCINE BORONIC ACID 1GBD ; 2.2 ; ALPHA-LYTIC PROTEASE WITH MET 190 REPLACED BY ALA AND GLY 216 REPLACED BY ALA COMPLEX WITH METHOXYSUCCINYL-ALA-ALA-PRO-PHENYLALANINE BORONIC ACID 1GBE ; 2.3 ; ALPHA-LYTIC PROTEASE WITH MET 190 REPLACED BY ALA AND GLY 216 REPLACED BY LEU 1GBF ; 2.15 ; ALPHA-LYTIC PROTEASE WITH MET 190 REPLACED BY ALA AND GLY 216 REPLACED BY LEU COMPLEX WITH METHOXYSUCCINYL-ALA-ALA-PRO-ALANINE BORONIC ACID 1GBH ; 2.2 ; ALPHA-LYTIC PROTEASE WITH MET 190 REPLACED BY ALA AND GLY 216 REPLACED BY LEU COMPLEX WITH METHOXYSUCCINYL-ALA-ALA-PRO-LEUCINE BORONIC ACID 1GBI ; 2.3 ; ALPHA-LYTIC PROTEASE WITH MET 190 REPLACED BY ALA AND GLY 216 REPLACED BY LEU COMPLEX WITH METHOXYSUCCINYL-ALA-ALA-PRO-PHENYLALANINE BORONIC ACID 1GBK ; 2.13 ; ALPHA-LYTIC PROTEASE WITH MET 190 REPLACED BY ALA COMPLEX WITH METHOXYSUCCINYL-ALA-ALA-PRO-ALANINE BORONIC ACID 1GBL ; 2.15 ; ALPHA-LYTIC PROTEASE WITH MET 190 REPLACED BY ALA COMPLEX WITH METHOXYSUCCINYL-ALA-ALA-PRO-LEUCINE BORONIC ACID 1GBM ; 2.28 ; ALPHA-LYTIC PROTEASE WITH MET 190 REPLACED BY ALA COMPLEX WITH METHOXYSUCCINYL-ALA-ALA-PRO-PHENYLALANINE BORONIC ACID 1X74 ; 1.79 ; Alpha-methylacyl-CoA racemase from Mycobacterium tuberculosis- mutational and structural characterization of the fold and active site 3ASI ; 2.3 ; Alpha-Neurexin-1 ectodomain fragment; LNS5-EGF3-LNS6 2JUQ ; ; alpha-RgIA, a Novel Conotoxin that Blocks the alpha9-alpha10 nAChR 1J2P ; 2.6 ; alpha-ring from the proteasome from archaeoglobus fulgidus 2F2V ; 1.85 ; alpha-spectrin SH3 domain A56G mutant 2CDT ; 2.54 ; ALPHA-SPECTRIN SH3 DOMAIN A56S MUTANT 2F2W ; 1.7 ; alpha-spectrin SH3 domain R21A mutant 2F2X ; 1.6 ; alpha-spectrin SH3 domain R21G mutant 1G2B ; 1.12 ; ALPHA-SPECTRIN SRC HOMOLOGY 3 DOMAIN, CIRCULAR PERMUTANT, CUT AT N47-D48 1TUD ; 1.77 ; ALPHA-SPECTRIN SRC HOMOLOGY 3 DOMAIN, CIRCULAR PERMUTANT, CUT AT N47-D48 1TUC ; 2.02 ; ALPHA-SPECTRIN SRC HOMOLOGY 3 DOMAIN, CIRCULAR PERMUTANT, CUT AT S19-P20 1QKX ; 1.8 ; ALPHA-SPECTRIN SRC HOMOLOGY 3 DOMAIN, N47A MUTANT IN THE DISTAL LOOP. 1QKW ; 2 ; ALPHA-SPECTRIN SRC HOMOLOGY 3 DOMAIN, N47G MUTANT IN THE DISTAL LOOP. 1AEY ; ; ALPHA-SPECTRIN SRC HOMOLOGY 3 DOMAIN, SOLUTION NMR, 15 STRUCTURES 1ABZ ; ; ALPHA-T-ALPHA, A DE NOVO DESIGNED PEPTIDE, NMR, 23 STRUCTURES 1UMA ; 2 ; ALPHA-THROMBIN (HIRUGEN) COMPLEXED WITH NA-(N,N-DIMETHYLCARBAMOYL)-ALPHA-AZALYSINE 1W7G ; 1.65 ; ALPHA-THROMBIN COMPLEX WITH SULFATED HIRUDIN (RESIDUES 54-65) AND L-ARGININE TEMPLATE INHIBITOR CS107 1TOM ; 1.8 ; ALPHA-THROMBIN COMPLEXED WITH HIRUGEN 1BCU ; 2 ; ALPHA-THROMBIN COMPLEXED WITH HIRUGEN AND PROFLAVIN 1CA1 ; 1.9 ; ALPHA-TOXIN FROM CLOSTRIDIUM PERFRINGENS 3FDM ; 2.26 ; alpha/beta foldamer in complex with Bcl-xL 2Q0X ; 2.2 ; Alpha/Beta hydrolase fold protein of unknown function 3C3H ; 2.2 ; alpha/beta-Peptide helix bundles: A GCN4-pLI analogue with an (alpha-alpha-beta) backbone and cyclic beta residues 3C3F ; 2 ; alpha/beta-Peptide helix bundles: The GCN4-pLI side chain sequence on an (alpha-alpha-alpha-beta) backbone 3C3G ; 1.8 ; alpha/beta-Peptide helix bundles: The GCN4-pLI side chain sequence on an (alpha-alpha-beta) backbone 3HF0 ; 2.1 ; alpha/beta-Peptide helix crystallized from detergent solution: GCN4-pLI side chain sequence on an (alpha-alpha-beta-alpha-beta-alpha-beta) backbone with cyclic beta-residues 1QMN ; 2.27 ; Alpha1-antichymotrypsin serpin in the delta conformation (partial loop insertion) 1KCT ; 3.46 ; ALPHA1-ANTITRYPSIN 4GUA ; 2.854 ; Alphavirus P23pro-zbd 1HML ; 1.7 ; ALPHA_LACTALBUMIN POSSESSES A DISTINCT ZINC BINDING SITE 1AZ1 ; 1.8 ; ALRESTATIN BOUND TO C298A/W219Y MUTANT HUMAN ALDOSE REDUCTASE 1MNI ; 2.07 ; ALTERATION OF AXIAL COORDINATION BY PROTEIN ENGINEERING IN MYOGLOBIN. BIS-IMIDAZOLE LIGATION IN THE HIS64-->VAL(SLASH)VAL68-->HIS DOUBLE MUTANT 2GIG ; 1.83 ; Alteration of sequence specificity of the type II restriction endonuclease HINCII through an indirect readout mechanism 1HJF ; 1.6 ; ALTERATION OF THE CO-SUBSTRATE SELECTIVITY OF DEACETOXYCEPHALOSPORIN C SYNTHASE: THE ROLE OF ARGININE-258 1HJG ; 1.5 ; ALTERATION OF THE CO-SUBSTRATE SELECTIVITY OF DEACETOXYCEPHALOSPORIN C SYNTHASE: THE ROLE OF ARGININE-258 2Q1E ; 2.55 ; Altered dimer interface decreases stability in an amyloidogenic kappa1 Bence Jones protein. 1H2G ; 2 ; ALTERED SUBSTRATE SPECIFICITY MUTANT OF PENICILLIN ACYLASE 1JEA ; 2 ; ALTERED TOPOLOGY AND FLEXIBILITY IN ENGINEERED SUBTILISIN 3CCX ; 2.3 ; ALTERING SUBSTRATE SPECIFICITY AT THE HEME EDGE OF CYTOCHROME C PEROXIDASE 4CCX ; 1.9 ; ALTERING SUBSTRATE SPECIFICITY AT THE HEME EDGE OF CYTOCHROME C PEROXIDASE 1CCK ; 2.1 ; ALTERING SUBSTRATE SPECIFICITY OF CYTOCHROME C PEROXIDASE TOWARDS A SMALL MOLECULAR SUBSTRATE PEROXIDASE BY SUBSTITUTING TYROSINE FOR PHE 202 2RLA ; 3 ; ALTERING THE BINUCLEAR MANGANESE CLUSTER OF ARGINASE DIMINISHES THERMOSTABILITY AND CATALYTIC FUNCTION 3RLA ; 2.54 ; ALTERING THE BINUCLEAR MANGANESE CLUSTER OF ARGINASE DIMINISHES THERMOSTABILITY AND CATALYTIC FUNCTION 4RLA ; 2.94 ; ALTERING THE BINUCLEAR MANGANESE CLUSTER OF ARGINASE DIMINISHES THERMOSTABILITY AND CATALYTIC FUNCTION 5RLA ; 2.74 ; ALTERING THE BINUCLEAR MANGANESE CLUSTER OF ARGINASE DIMINISHES THERMOSTABILITY AND CATALYTIC FUNCTION 12CA ; 2.4 ; ALTERING THE MOUTH OF A HYDROPHOBIC POCKET. STRUCTURE AND KINETICS OF HUMAN CARBONIC ANHYDRASE II MUTANTS AT RESIDUE VAL-121 3K47 ; 2.05 ; Alternate Binding Modes Observed for the E- and Z-Isomers of 2,4-Diaminofuro[2,3-d]pyrimidines as Ternary Complexes with NADPH and Mouse Dihydrofolate Reductase 3K45 ; 1.6 ; Alternate Binding Modes Observed for the E- and Z-isomers of 2,4-Diaminofuro[2,3d]pyrimidines as Ternary Complexes with NADPH and Mouse Dihydrofolate Reductase 1C6X ; 2.5 ; ALTERNATE BINDING SITE FOR THE P1-P3 GROUP OF A CLASS OF POTENT HIV-1 PROTEASE INHIBITORS AS A RESULT OF CONCERTED STRUCTURAL CHANGE IN 80'S LOOP. 1C6Y ; 2.5 ; ALTERNATE BINDING SITE FOR THE P1-P3 GROUP OF A CLASS OF POTENT HIV-1 PROTEASE INHIBITORS AS A RESULT OF CONCERTED STRUCTURAL CHANGE IN 80'S LOOP. 1C70 ; 2.5 ; ALTERNATE BINDING SITE FOR THE P1-P3 GROUP OF A CLASS OF POTENT HIV-1 PROTEASE INHIBITORS AS A RESULT OF CONCERTED STRUCTURAL CHANGE IN 80'S LOOP. 1C6Z ; 2.5 ; ALTERNATE BINDING SITE FOR THE P1-P3 GROUP OF A CLASS OF POTENT HIV-1 PROTEASE INHIBITORS AS A RESULT OF CONCERTED STRUCTURAL CHANGE IN 80'S LOOP. 254D ; 1.9 ; ALTERNATING AND NON-ALTERNATING DG-DC HEXANUCLEOTIDES CRYSTALLIZE AS CANONICAL A-DNA 256D ; 2.2 ; ALTERNATING AND NON-ALTERNATING DG-DC HEXANUCLEOTIDES CRYSTALLIZE AS CANONICAL A-DNA 257D ; 2.3 ; ALTERNATING AND NON-ALTERNATING DG-DC HEXANUCLEOTIDES CRYSTALLIZE AS CANONICAL A-DNA 275D ; 2 ; ALTERNATING AND NON-ALTERNATING DG-DC HEXANUCLEOTIDES CRYSTALLIZE AS CANONICAL A-DNA 5ZNF ; ; ALTERNATING ZINC FINGERS IN THE HUMAN MALE ASSOCIATED PROTEIN ZFY: 2D NMR STRUCTURE OF AN EVEN FINGER AND IMPLICATIONS FOR ""JUMPING-LINKER"" DNA RECOGNITION 7ZNF ; ; ALTERNATING ZINC FINGERS IN THE HUMAN MALE ASSOCIATED PROTEIN ZFY: 2D NMR STRUCTURE OF AN EVEN FINGER AND IMPLICATIONS FOR ""JUMPING-LINKER"" DNA RECOGNITION 3P4B ; 1.45 ; Alternatingly modified 2'Fluoro RNA octamer f/rA2U2-P3 3P4C ; 1.15 ; Alternatingly modified 2'Fluoro RNA octamer f/rA2U2-R32 3P4D ; 1.85 ; Alternatingly modified 2'Fluoro RNA octamer f/rC4G4 1G00 ; 2.3 ; ALTERNATION OF DNA AND SOLVENT LAYERS IN THE A FORM OF D(GGCGCC) OBTAINED BY ETHANOL CRYSTALLIZATION 3RUD ; 2.3 ; Alternative analogs as viable substrates of UDP-hexose 4-epimerases 3RUE ; 2.8 ; Alternative analogs as viable substrates of UDP-hexose 4-epimerases 3RUF ; 2 ; Alternative analogs as viable substrates of UDP-hexose 4-epimerases 3RUH ; 2.88 ; Alternative analogs as viable substrates of UDP-hexose 4-epimerases 3IMB ; 1.89 ; Alternative binding mode of restriction endonuclease BcnI to cognate DNA 4CLA ; 2 ; ALTERNATIVE BINDING MODES FOR CHLORAMPHENICOL AND 1-SUBSTITUTED CHLORAMPHENICOL ANALOGUES REVEALED BY SITE-DIRECTED MUTAGENESIS AND X-RAY CRYSTALLOGRAPHY OF CHLORAMPHENICOL ACETYLTRANSFERASE 2NNW ; 2.7 ; Alternative conformations of Nop56/58-fibrillarin complex and implication for induced-fit assenly of box C/D RNPs 3BJ5 ; 2.2 ; Alternative conformations of the x region of human protein disulphide-isomerase modulate exposure of the substrate binding b' domain 2RIU ; 1.7 ; Alternative models for two crystal structures of Candida albicans 3,4-dihydroxy-2-butanone 4-phosphate synthase- alternate interpreation 1SIP ; 2.3 ; ALTERNATIVE NATIVE FLAP CONFORMATION REVEALED BY 2.3 ANGSTROMS RESOLUTION STRUCTURE OF SIV PROTEINASE 2FUN ; 3 ; alternative p35-caspase-8 complex 1RYF ; 1.75 ; Alternative Splicing of Rac1 Generates Rac1b, a Self-activating GTPase 1RYH ; 1.75 ; Alternative Splicing of Rac1 Generates Rac1b, a Self-activating GTPase 2RSU ; ; Alternative structure of Ubiquitin 1D56 ; 1.7 ; ALTERNATIVE STRUCTURES FOR ALTERNATING POLY(DA-DT) TRACTS: THE STRUCTURE OF THE B-DNA DECAMER C-G-A-T-A-T-A-T-C-G 1D57 ; 2 ; ALTERNATIVE STRUCTURES FOR ALTERNATING POLY(DA-DT) TRACTS: THE STRUCTURE OF THE B-DNA DECAMER C-G-A-T-A-T-A-T-C-G 1JTM ; 1.9 ; Alternative Structures of a Sequence Extended T4 Lysozyme Show that the Highly Conserved Beta-Sheet has Weak Intrinsic Folding Propensity 1JTN ; 2.3 ; Alternative Structures of a Sequence Extended T4 Lysozyme Show that the Highly Conserved Beta-Sheet Region has weak intrinsic Folding Propensity 1E8S ; 4 ; ALU DOMAIN OF THE MAMMALIAN SRP (POTENTIAL ALU RETROPOSITION INTERMEDIATE) 1HZ3 ; ; ALZHEIMER'S DISEASE AMYLOID-BETA PEPTIDE (RESIDUES 10-35) 1Z40 ; 1.901 ; AMA1 from Plasmodium falciparum 2O9L ; ; AMBER refined NMR Structure of the Sigma-54 RpoN Domain Bound to the-24 Promoter Element 3RM4 ; 1.9 ; AMCase in complex with Compound 1 3RM8 ; 1.8 ; AMCase in complex with Compound 2 3RM9 ; 2.1 ; AMCase in complex with Compound 3 3RME ; 1.8 ; AMCase in complex with Compound 5 1AAC ; 1.31 ; AMICYANIN OXIDIZED, 1.31 ANGSTROMS 1BXA ; 1.3 ; AMICYANIN REDUCED, PH 4.4, 1.3 ANGSTROMS 2RAC ; 1.3 ; AMICYANIN REDUCED, PH 7.7, 1.3 ANGSTROMS 2IH7 ; ; Amidated Pro6 Analogue of CMrVIA conotoxin 2IHA ; ; Amidated variant of CMrVIA conotoxin 1QO0 ; 2.25 ; AMIDE RECEPTOR OF THE AMIDASE OPERON OF PSEUDOMONAS AERUGINOSA (AMIC) COMPLEXED WITH THE POSITIVE REGULATOR AMIR. 1PEA ; 2.1 ; AMIDE RECEPTOR/NEGATIVE REGULATOR OF THE AMIDASE OPERON OF PSEUDOMONAS AERUGINOSA (AMIC) COMPLEXED WITH ACETAMIDE 1QNL ; 2.7 ; AMIDE RECEPTOR/NEGATIVE REGULATOR OF THE AMIDASE OPERON OF PSEUDOMONAS AERUGINOSA (AMIC) COMPLEXED WITH BUTYRAMIDE 1B4D ; 2 ; AMIDOCARBAMATE INHIBITOR OF GLYCOGEN PHOSPHORYLASE 1ND1 ; 1.93 ; Amino acid sequence and crystal structure of BaP1, a metalloproteinase from Bothrops asper snake venom that exerts multiple tissue-damaging activities. 1HLM ; 2.9 ; AMINO ACID SEQUENCE OF A GLOBIN FROM THE SEA CUCUMBER CAUDINA (MOLPADIA) ARENICOLA 1R1O ; 2.8 ; Amino Acid Sulfonamides as Transition-State Analogue Inhibitors of Arginase 1ECL ; 1.9 ; AMINO TERMINAL 67KDA DOMAIN OF ESCHERICHIA COLI DNA TOPOISOMERASE I (RESIDUES 2-590 OF MATURE PROTEIN) CLONING ARTIFACT ADDS TWO RESIDUES TO THE AMINO-TERMINUS WHICH WERE NOT OBSERVED IN THE EXPERIMENTAL ELECTRON DENSITY (GLY-2, SER-1). 1VCC ; 1.6 ; AMINO TERMINAL 9KDA DOMAIN OF VACCINIA VIRUS DNA TOPOISOMERASE I RESIDUES 1-77, EXPERIMENTAL ELECTRON DENSITY FOR RESIDUES 1-77 1ZYM ; 2.5 ; AMINO TERMINAL DOMAIN OF ENZYME I FROM ESCHERICHIA COLI 1EZD ; ; AMINO TERMINAL DOMAIN OF ENZYME I FROM ESCHERICHIA COLI NMR, 16 STRUCTURES 1EZA ; ; AMINO TERMINAL DOMAIN OF ENZYME I FROM ESCHERICHIA COLI NMR, RESTRAINED REGULARIZED MEAN STRUCTURE 2EZB ; ; AMINO TERMINAL DOMAIN OF ENZYME I FROM ESCHERICHIA COLI, NMR, 14 STRUCTURES 2EZC ; ; AMINO TERMINAL DOMAIN OF ENZYME I FROM ESCHERICHIA COLI, NMR, 14 STRUCTURES 1EZB ; ; AMINO TERMINAL DOMAIN OF ENZYME I FROM ESCHERICHIA COLI, NMR, 17 STRUCTURES 1EZC ; ; AMINO TERMINAL DOMAIN OF ENZYME I FROM ESCHERICHIA COLI, NMR, 17 STRUCTURES 2EZA ; ; AMINO TERMINAL DOMAIN OF ENZYME I FROM ESCHERICHIA COLI, NMR, RESTRAINED REGULARIZED MEAN STRUCTURE 1QDN ; 2.3 ; AMINO TERMINAL DOMAIN OF THE N-ETHYLMALEIMIDE SENSITIVE FUSION PROTEIN (NSF) 1SUH ; ; AMINO-TERMINAL DOMAIN OF EPITHELIAL CADHERIN IN THE CALCIUM BOUND STATE, NMR, 20 STRUCTURES 1A7I ; ; AMINO-TERMINAL LIM DOMAIN FROM QUAIL CYSTEINE AND GLYCINE-RICH PROTEIN, NMR, MINIMIZED AVERAGE STRUCTURE 1ZFO ; ; AMINO-TERMINAL LIM-DOMAIN PEPTIDE OF LASP-1, NMR 2H11 ; 1.89 ; Amino-terminal Truncated Thiopurine S-Methyltransferase Complexed with S-Adenosyl-L-Homocysteine 3CUL ; 2.8 ; Aminoacyl-tRNA synthetase ribozyme 3CUN ; 3 ; Aminoacyl-tRNA synthetase ribozyme 4BBF ; 2 ; Aminoalkylpyrimidine Inhibitor Complexes with JAK2 4BBE ; 1.9 ; Aminoalkylpyrimidine Inhibitor Complexes with JAK2 1I2K ; 1.79 ; AMINODEOXYCHORISMATE LYASE FROM ESCHERICHIA COLI 1UA0 ; 2.1 ; Aminofluorene DNA adduct at the pre-insertion site of a DNA polymerase 1M44 ; 1.6 ; Aminoglycoside 2'-N-acetyltransferase from Mycobacterium tuberculosis-APO Structure 1M4I ; 1.5 ; Aminoglycoside 2'-N-acetyltransferase from Mycobacterium tuberculosis-Complex with Coenzyme A and Kanamycin A 1M4G ; 1.8 ; Aminoglycoside 2'-N-acetyltransferase from Mycobacterium tuberculosis-Complex with Coenzyme A and Ribostamycin 1M4D ; 1.8 ; Aminoglycoside 2'-N-acetyltransferase from Mycobacterium tuberculosis-Complex with Coenzyme A and Tobramycin 1S5K ; 2.4 ; Aminoglycoside N-Acetyltransferase AAC(6')-Iy in Complex with CoA and N-terminal His(6)-tag (crystal form 1) 1S60 ; 3 ; Aminoglycoside N-Acetyltransferase AAC(6')-Iy in Complex with CoA and N-terminal His(6)-tag (crystal form 2) 1S3Z ; 2 ; Aminoglycoside N-Acetyltransferase AAC(6')-Iy in Complex with CoA and Ribostamycin 4ACU ; 1.75 ; Aminoimidazoles as BACE-1 Inhibitors. X-RAY CRYSTAL STRUCTURE OF BETA SECRETASE COMPLEXED WITH COMPOUND 14 4ACX ; 2 ; Aminoimidazoles as BACE-1 Inhibitors. X-RAY CRYSTAL STRUCTURE OF BETA SECRETASE COMPLEXED WITH COMPOUND 23 2EK8 ; 1.8 ; Aminopeptidase from Aneurinibacillus sp. strain AM-1 2EK9 ; 1.97 ; Aminopeptidase from Aneurinibacillus sp. strain AM-1 with Bestatin 1CP7 ; 1.58 ; AMINOPEPTIDASE FROM STREPTOMYCES GRISEUS 4FUK ; 1.75 ; Aminopeptidase from Trypanosoma brucei 2ZXG ; 1.55 ; Aminopeptidase N complexed with the aminophosphinic inhibitor of PL250, a transition state analogue 1JAW ; 2.7 ; AMINOPEPTIDASE P FROM E. COLI LOW PH FORM 1A16 ; 2.3 ; AMINOPEPTIDASE P FROM E. COLI WITH THE INHIBITOR PRO-LEU 1M35 ; 2.4 ; Aminopeptidase P from Escherichia coli 1N51 ; 2.3 ; Aminopeptidase P in complex with the inhibitor apstatin 1ZJC ; 1.8 ; Aminopeptidase S from S. aureus 2VVC ; 1.95 ; AMINOPYRROLIDINE FACTOR XA INHIBITOR 2VVU ; 2.3 ; AMINOPYRROLIDINE FACTOR XA INHIBITOR 2VWL ; 1.8 ; AMINOPYRROLIDINE FACTOR XA INHIBITOR 2VWM ; 1.96 ; AMINOPYRROLIDINE FACTOR XA INHIBITOR 2VWN ; 1.61 ; AMINOPYRROLIDINE FACTOR XA INHIBITOR 2VWO ; 1.6 ; AMINOPYRROLIDINE FACTOR XA INHIBITOR 2VVV ; 1.73 ; AMINOPYRROLIDINE-RELATED TRIAZOLE FACTOR XA INHIBITOR 2HXX ; 2 ; Aminotryptophan Barstar 1E50 ; 2.6 ; AML1/CBF COMPLEX 1H9D ; 2.6 ; AML1/CBF-BETA/DNA COMPLEX 2B2H ; 1.54 ; Ammonium Transporter Amt-1 from A. fulgidus (AS) 2B2I ; 1.85 ; Ammonium Transporter Amt-1 from A. fulgidus (MA) 2B2J ; 1.85 ; Ammonium Transporter Amt-1 from A. fulgidus (Xe) 2B2F ; 1.72 ; Ammonium Transporter Amt-1 from A.fulgidus (Native) 1AM0 ; ; AMP RNA APTAMER COMPLEX, NMR, 8 STRUCTURES 3S1Y ; 1.4 ; AMP-C BETA-LACTAMASE (PSEUDOMONAS AERUGINOSA) in complex with a beta-lactamase inhibitor 3S22 ; 1.65 ; AMP-C BETA-LACTAMASE (PSEUDOMONAS AERUGINOSA) in complex with an inhibitor 2WZX ; 1.4 ; AMP-C BETA-LACTAMASE (PSEUDOMONAS AERUGINOSA)IN COMPLEX WITH COMPOUND M-02 2WZZ ; 1.57 ; AMP-C BETA-LACTAMASE (PSEUDOMONAS AERUGINOSA)IN COMPLEX WITH COMPOUND M-03 3KG2 ; 3.6 ; AMPA subtype ionotropic glutamate receptor in complex with competitive antagonist ZK 200775 2PU4 ; 2 ; AmpC beta-lacamase with bound covalent oxadiazole inhibitor 1FSW ; 1.9 ; AMPC BETA-LACTAMASE FROM E. COLI COMPLEXED WITH INHIBITOR CEPHALOTHINBORONIC ACID 1FSY ; 1.75 ; AMPC BETA-LACTAMASE FROM E. COLI COMPLEXED WITH INHIBITOR CLOXACILLINBORONIC ACID 1C3B ; 2.25 ; AMPC BETA-LACTAMASE FROM E. COLI COMPLEXED WITH INHIBITOR, BENZO(B)THIOPHENE-2-BORONIC ACID (BZB) 2BLS ; 2 ; AMPC BETA-LACTAMASE FROM ESCHERICHIA COLI 3BLS ; 2.3 ; AMPC BETA-LACTAMASE FROM ESCHERICHIA COLI 2RCX ; 2 ; AmpC Beta-lactamase in complex with (1R)-1-(2-Thiophen-2-yl-acetylamino)-1-(3-(2-carboxyvinyl)-phenyl) methylboronic acid 2HDU ; 1.49 ; AmpC beta-lactamase in complex with 2-acetamidothiophene-3-carboxylic acid 2HDQ ; 2.1 ; AmpC beta-lactamase in complex with 2-carboxythiophene 1XGI ; 1.96 ; AmpC beta-lactamase in complex with 3-(3-nitro-phenylsulfamoyl)-thiophene-2-carboxylic acid 1XGJ ; 1.97 ; AmpC beta-lactamase in complex with 3-(4-carboxy-2-hydroxy-phenylsulfamoyl)-thiophene-2-carboxylic acid 2HDR ; 2.2 ; AmpC beta-lactamase in complex with 4-Amino-3-hydroxybenzoic acid 2HDS ; 1.16 ; AmpC beta-lactamase in complex with 4-Methanesulfonylamino benzoic acid 2I72 ; 2.2 ; AmpC beta-lactamase in complex with 5-diformylaminomethyl-benzo[b]thiophen-2-boronic acid 3BM6 ; 2.1 ; AmpC beta-lactamase in complex with a p.carboxyphenylboronic acid 1MXO ; 1.83 ; AmpC beta-lactamase in complex with an m.carboxyphenylglycylboronic acid bearing the cephalothin R1 side chain 1MY8 ; 1.72 ; AmpC beta-lactamase in complex with an M.carboxyphenylglycylboronic acid bearing the cephalothin R1 side chain 3GQZ ; 1.8 ; AmpC beta-lactamase in complex with Fragment-based Inhibitor 3GR2 ; 1.8 ; AmpC beta-lactamase in complex with Fragment-based Inhibitor 3GRJ ; 2.49 ; AmpC beta-lactamase in complex with Fragment-based Inhibitor 3GSG ; 2.1 ; AmpC beta-lactamase in complex with Fragment-based Inhibitor 3GTC ; 1.9 ; AmpC beta-lactamase in complex with Fragment-based Inhibitor 3GV9 ; 1.8 ; AmpC beta-lactamase in complex with Fragment-based Inhibitor 3GVB ; 1.8 ; AmpC beta-lactamase in complex with Fragment-based Inhibitor 2FFY ; 1.07 ; AmpC beta-lactamase N289A mutant in complex with a boronic acid deacylation transition state analog compound SM3 2PU2 ; 1.86 ; AmpC beta-lactamase with bound Phthalamide inhibitor 2R9W ; 1.8 ; AmpC beta-lactamase with bound Phthalamide inhibitor 2R9X ; 1.9 ; AmpC beta-lactamase with bound Phthalamide inhibitor 3FKW ; 1.498 ; AmpC K67R mutant apo structure 3FKV ; 1.847 ; AmpC K67R mutant complexed with benzo(b)thiophene-2-boronic acid (bzb) 3QQT ; 1.9 ; Amphiphilic nanotubes in the crystal structure of a biosurfactant protein hydrophobin HFBII 1URU ; 2.6 ; AMPHIPHYSIN BAR DOMAIN FROM DROSOPHILA 3IQW ; 3 ; AMPPNP complex of C. therm. Get3 1AVA ; 1.9 ; AMY2/BASI PROTEIN-PROTEIN COMPLEX FROM BARLEY SEED 1QCM ; ; AMYLOID BETA PEPTIDE (25-35), NMR, 20 STRUCTURES 3MOQ ; 2.054 ; Amyloid beta(18-41) peptide fusion with new antigen receptor variable domain from sharks 3SGO ; 2.557 ; Amyloid-related segment of alphaB-crystallin residues 90-100 3SGP ; 1.4016 ; Amyloid-related segment of alphaB-crystallin residues 90-100 mutant V91L 3SGS ; 1.703 ; Amyloid-related segment of alphaB-crystallin residues 95-100 1LYY ; 1.8 ; AMYLOIDOGENIC VARIANT (ASP67HIS) OF HUMAN LYSOZYME 1LOZ ; 1.8 ; AMYLOIDOGENIC VARIANT (I56T) VARIANT OF HUMAN LYSOZYME 1G5A ; 1.4 ; AMYLOSUCRASE FROM NEISSERIA POLYSACCHAREA 1MW0 ; 2.01 ; Amylosucrase mutant E328Q co-crystallized with maltoheptaose then soaked with maltoheptaose. 1MVY ; 2 ; Amylosucrase mutant E328Q co-crystallized with maltoheptaose. 1ZS2 ; 2.16 ; Amylosucrase Mutant E328Q in a ternary complex with sucrose and maltoheptaose 1MW2 ; 2.1 ; Amylosucrase soaked with 100mM sucrose 1MW1 ; 2.1 ; Amylosucrase soaked with 14mM sucrose. 1MW3 ; 2 ; Amylosucrase soaked with 1M sucrose 1SPD ; 2.4 ; AMYOTROPHIC LATERAL SCLEROSIS AND STRUCTURAL DEFECTS IN CU,ZN SUPEROXIDE DISMUTASE 2LET ; ; AN 1H NMR DETERMINATION OF THE THREE DIMENSIONAL STRUCTURES OF MIRROR IMAGE FORMS OF A LEU-5 VARIANT OF THE TRYPSIN INHIBITOR ECBALLIUM ELATERIUM (EETI-II) 3U37 ; 2.1 ; An Acetyl Xylan Esterase (Est2A) from the Rumen Bacterium Butyrivibrio proteoclasticus. 4DEV ; 2 ; An Acetyl Xylan Esterase (Est2A) from the Rumen Bacterium Butyrivibrio proteoclasticus. 2GM4 ; 3.5 ; An activated, tetrameric gamma-delta resolvase: Hin chimaera bound to cleaved DNA 2GM5 ; 2.1 ; An activated, truncated gamma-delta resolvase tetramer 1EFE ; ; AN ACTIVE MINI-PROINSULIN, M2PI 1A72 ; 2.6 ; AN ACTIVE-SITE DOUBLE MUTANT (PHE93->TRP, VAL203->ALA) OF HORSE LIVER ALCOHOL DEHYDROGENASE IN COMPLEX WITH THE ISOSTERIC NAD ANALOG CPAD 257L ; 1.9 ; AN ADAPTABLE METAL-BINDING SITE ENGINEERED INTO T4 LYSOZYME 258L ; 1.8 ; AN ADAPTABLE METAL-BINDING SITE ENGINEERED INTO T4 LYSOZYME 259L ; 1.92 ; AN ADAPTABLE METAL-BINDING SITE ENGINEERED INTO T4 LYSOZYME 260L ; 1.8 ; AN ADAPTABLE METAL-BINDING SITE ENGINEERED INTO T4 LYSOZYME 1H0T ; ; AN AFFIBODY IN COMPLEX WITH A TARGET PROTEIN: STRUCTURE AND COUPLED FOLDING 1U0V ; 1.9 ; An Aldol Switch Discovered in Stilbene Synthases Mediates Cyclization of Specificity of Type III Polyketide Synthases: 18xCHS structure 1U0W ; 2 ; An Aldol Switch Discovered in Stilbene Synthases Mediates Cyclization Specificity of Type III Polyketide Synthases: 18xCHS+resveratrol Structure 1U0U ; 2.11 ; An Aldol Switch Discovered in Stilbene Synthases Mediates Cyclization Specificity of Type III Polyketide Synthases: Pine stilbene synthase structure 1DGD ; 2.8 ; AN ALKALI METAL ION SIZE-DEPENDENT SWITCH IN THE ACTIVE SITE STRUCTURE OF DIALKYLGLYCINE DECARBOXYLASE 1DGE ; 2.8 ; AN ALKALI METAL ION SIZE-DEPENDENT SWITCH IN THE ACTIVE SITE STRUCTURE OF DIALKYLGLYCINE DECARBOXYLASE 2F8Q ; 2.2 ; An alkali thermostable F/10 xylanase from alkalophilic Bacillus sp. NG-27 2FGL ; 2.2 ; An alkali thermostable F/10 xylanase from alkalophilic Bacillus sp. NG-27 3GS5 ; 2.75 ; An all-RNA hairpin ribozyme A38N1dA variant with a product mimic substrate strand 3GS8 ; 2.85 ; An all-RNA hairpin ribozyme A38N1dA38 variant with a transition-state mimic substrate strand 3GS1 ; 2.85 ; An all-RNA Hairpin Ribozyme with mutation A38N1dA 1X9C ; 2.19 ; An all-RNA Hairpin Ribozyme with mutation U39C 1X9K ; 3.17 ; An all-RNA Hairpin Ribozyme with mutation U39C 1RD4 ; 2.4 ; An allosteric inhibitor of LFA-1 bound to its I-domain 1NFD ; 2.8 ; AN ALPHA-BETA T CELL RECEPTOR (TCR) HETERODIMER IN COMPLEX WITH AN ANTI-TCR FAB FRAGMENT DERIVED FROM A MITOGENIC ANTIBODY 3F87 ; 2.4 ; An alpha/beta-Peptide Helix Bundle with a Pure beta-Amino Acid Core and a Distinctive Quarternary Structure: GCN4pLI derivative with beta residues at a and d heptad positions - higher symmetry crystal 3F86 ; 2 ; An alpha/beta-Peptide Helix Bundle with a Pure beta-Amino Acid Core and a Distinctive Quaternary Structure: GCN4pLI derivative with beta residues at a and d heptad positions 2OSN ; 2.5 ; An alternate description of a crystal structure of phospholipase A2 from Bungarus caeruleus 1MDG ; 1.5 ; An Alternating Antiparallel Octaplex in an RNA Crystal Structure 2DD2 ; ; An alternating sheared AA pair in 5'GGUGAAGGCU/3'PCCGAAGCCG: I. The major conformation with A6/A15/A16 stack 2DD3 ; ; An alternating sheared AA pair in 5'GGUGAAGGCU/3'PCCGAAGCCG: II. The minor conformation with A6/A5/A16 stack 1G99 ; 2.5 ; AN ANCIENT ENZYME: ACETATE KINASE FROM METHANOSARCINA THERMOPHILA 2ACQ ; 1.76 ; AN ANION BINDING SITE IN HUMAN ALDOSE REDUCTASE: MECHANISTIC IMPLICATIONS FOR THE BINDING OF CITRATE, CACODYLATE, AND GLUCOSE-6-PHOSPHATE 2ACR ; 1.76 ; AN ANION BINDING SITE IN HUMAN ALDOSE REDUCTASE: MECHANISTIC IMPLICATIONS FOR THE BINDING OF CITRATE, CACODYLATE, AND GLUCOSE-6-PHOSPHATE 2ACS ; 1.76 ; AN ANION BINDING SITE IN HUMAN ALDOSE REDUCTASE: MECHANISTIC IMPLICATIONS FOR THE BINDING OF CITRATE, CACODYLATE, AND GLUCOSE-6-PHOSPHATE 2QTO ; 3.201 ; An anisotropic model for potassium channel KcsA 1W5J ; 2.2 ; AN ANTI-PARALLEL FOUR HELIX BUNDLE 1W5K ; 1.92 ; AN ANTI-PARALLEL FOUR HELIX BUNDLE 1W5G ; 2.16 ; AN ANTI-PARALLEL FOUR HELIX BUNDLE (ACETIMIDE MODIFICATION). 1W5H ; 2.5 ; AN ANTI-PARALLEL FOUR HELIX BUNDLE. 1W5L ; 2.17 ; AN ANTI-PARALLEL TO PARALLEL SWITCH. 2FAT ; 1.77 ; An anti-urokinase plasminogen activator receptor (UPAR) antibody: Crystal structure and binding epitope 4K8R ; 3.22 ; An Antibody Against the C-terminal Domain of PCSK9 lowers LDL Cholesterol Levels in vivo 4JN1 ; 1.89 ; An Antidote for Dabigatran 4JN2 ; 1.71 ; An Antidote for Dabigatran 2O4V ; 1.94 ; An arginine ladder in OprP mediates phosphate specific transfer across the outer membrane 2L19 ; ; An arsenate reductase in the intermediate state 2L18 ; ; An arsenate reductase in the phosphate binding state 2L17 ; ; An arsenate reductase in the reduced state 2KIK ; ; An artificial di-iron oxo-protein with phenol oxidase activity 1SA3 ; 1.95 ; An asymmetric complex of restriction endonuclease MspI on its palindromic DNA recognition site 1PZU ; 3.1 ; An asymmetric NFAT1-RHR homodimer on a pseudo-palindromic, Kappa-B site 3J32 ; 4.5 ; An asymmetric unit map from electron cryo-microscopy of Haliotis diversicolor molluscan hemocyanin isoform 1 (HdH1) 3P9A ; 1.755 ; An atomic view of the nonameric small terminase subunit of Bacteriophage P22 1CBV ; 2.66 ; AN AUTOANTIBODY TO SINGLE-STRANDED DNA: COMPARISON OF THE THREE-DIMENSIONAL STRUCTURES OF THE UNLIGANDED FAB AND A DEOXYNUCLEOTIDE-FAB COMPLEX 1NBV ; 2 ; AN AUTOANTIBODY TO SINGLE-STRANDED DNA: COMPARISON OF THE THREE-DIMENSIONAL STRUCTURES OF THE UNLIGANDED FAB AND A DEOXYNUCLEOTIDE-FAB COMPLEX 3AG7 ; 1.8 ; An auxilin-like J-domain containing protein, JAC1 J-domain 1GSU ; 1.94 ; AN AVIAN CLASS-MU GLUTATHIONE S-TRANSFERASE, CGSTM1-1 AT 1.94 ANGSTROM RESOLUTION 2CE8 ; 2.03 ; AN EH1 PEPTIDE BOUND TO THE GROUCHO-TLE WD40 DOMAIN. 4GT7 ; 2.61 ; An engineered disulfide bond reversibly traps the IgE-Fc3-4 in a closed, non-receptor binding conformation 1PIO ; 2.8 ; AN ENGINEERED STAPHYLOCOCCUS AUREUS PC1 BETA-LACTAMASE THAT HYDROLYSES THIRD GENERATION CEPHALOSPORINS 1KL4 ; 1.7 ; AN ENGINEERED STREPTAVIDIN WITH IMPROVED AFFINITY FOR THE STREP-TAG II PEPTIDE : apo-SAM2 1KL3 ; 1.7 ; an engineered streptavidin with improved affinity for the strep-tag II peptide : SAm1-StrepII 1KL5 ; 1.8 ; an engineered streptavidin with improved affinity for the strep-tag II peptide : SAm2-StrepII 1KFF ; 1.9 ; An engineered streptavidin with improved affinity for the strep-tag II peptide: apo-SAM1 1GKO ; 2.1 ; AN ENGINEERED TRANSTHYRETIN MONOMER THAT IS NON-AMYLOIDOGENIC - UNLESS PARTIALLY DENATURED 3MI7 ; 2.2 ; An Enhanced Repressor of Human Papillomavirus E2 Protein 2AEP ; 2.1 ; An epidemiologically significant epitope of a 1998 influenza virus neuraminidase forms a highly hydrated interface in the NA-antibody complex. 2AEQ ; 3 ; An epidemiologically significant epitope of a 1998 influenza virus neuraminidase forms a highly hydrated interface in the NA-antibody complex. 2H6M ; 1.4 ; An episulfide cation (thiiranium ring) trapped in the active site of HAV 3C proteinase inactivated by peptide-based ketone inhibitors 2H9H ; 1.39 ; An episulfide cation (thiiranium ring) trapped in the active site of HAV 3C proteinase inactivated by peptide-based ketone inhibitors 2HAL ; 1.35 ; An episulfide cation (thiiranium ring) trapped in the active site of HAV 3C proteinase inactivated by peptide-based ketone inhibitors 3QE4 ; 2.3 ; An evolved aminoacyl-tRNA Synthetase with atypical polysubstrate specificity 2DMF ; ; An extended conformation of the RWD domain of human Ring finger protein 25 1Q1H ; 2.9 ; An extended winged helix domain in general transcription factor E/IIE alpha 3LDY ; 1.97 ; An extraordinary mechanism of DNA perturbation exhibited by the rare-cutting HNH restriction endonuclease PacI 2KKK ; ; An i-motif structure with intercalated T T pairs 1VCR ; 9.5 ; An icosahedral assembly of light-harvesting chlorophyll a/b protein complex from pea thylakoid membranes 3PWV ; 2.696 ; An immmunodominant CTL epitope from rinderpest virus presented by cattle MHC class I molecule N*01801 (BoLA-A11) 3PWU ; 1.899 ; An immmunodominant CTL epitope from rinderpest virus presented by cattle MHC class I molecule N*01801(BoLA-A11) 3J2T ; 9.5 ; An improved model of the human apoptosome 4P2P ; 2.4 ; AN INDEPENDENT CRYSTALLOGRAPHIC REFINEMENT OF PORCINE PHOSPHOLIPASE A2 AT 2.4 ANGSTROMS RESOLUTION 3Q01 ; 2.1 ; An induced fit mechanism regulates p53 DNA binding kinetics to confer sequence specificity 3Q05 ; 2.4 ; An induced fit mechanism regulates p53 DNA binding kinetics to confer sequence specificity 3Q06 ; 3.2 ; An induced fit mechanism regulates p53 DNA binding kinetics to confer sequence specificity 3MN3 ; 2.38 ; An inhibited conformation for the protein kinase domain of the Saccharomyces cerevisiae AMPK homolog Snf1 3V16 ; 2.05 ; An intramolecular pi-cation latch in phosphatidylinositol-specific phospholipase C from S.aureus controls substrate access to the active site 1MYQ ; ; An intramolecular quadruplex of (GGA)(4) triplet repeat DNA with a G:G:G:G tetrad and a G(:A):G(:A):G(:A):G heptad, and its dimeric interaction 3GDD ; 2.8 ; An inverted anthraquinone-DNA crystal structure 2TPK ; ; AN INVESTIGATION OF THE STRUCTURE OF THE PSEUDOKNOT WITHIN THE GENE 32 MESSENGER RNA OF BACTERIOPHAGE T2 USING HETERONUCLEAR NMR METHODS 2NQ2 ; 2.4 ; An inward-facing conformation of a putative metal-chelate type ABC transporter. 1M1U ; 2.3 ; AN ISOLEUCINE-BASED ALLOSTERIC SWITCH CONTROLS AFFINITY AND SHAPE SHIFTING IN INTEGRIN CD11B A-DOMAIN 1NHR ; 2.1 ; AN L40C MUTATION CONVERTS THE CYSTEINE-SULFENIC ACID REDOX CENTRE IN ENTEROCOCCAL NADH PEROXIDASE TO A DISULFIDE 1NHS ; 2 ; AN L40C MUTATION CONVERTS THE CYSTEINE-SULFENIC ACID REDOX CENTRE IN ENTEROCOCCAL NADH PEROXIDASE TO A DISULFIDE 1BDK ; ; AN NMR, CD, MOLECULAR DYNAMICS, AND FLUOROMETRIC STUDY OF THE CONFORMATION OF THE BRADYKININ ANTAGONIST B-9340 IN WATER AND IN AQUEOUS MICELLAR SOLUTIONS 1PUT ; ; AN NMR-DERIVED MODEL FOR THE SOLUTION STRUCTURE OF OXIDIZED PUTIDAREDOXIN, A 2FE, 2-S FERREDOXIN FROM PSEUDOMONAS 1SN9 ; 1.2 ; An Oligomeric Domain-Swapped Beta-Beta-Alpha Mini-Protein 1SNA ; 1.5 ; An Oligomeric Domain-Swapped Beta-Beta-Alpha Mini-Protein 1SNE ; 1.5 ; An Oligomeric Domain-Swapped Beta-Beta-Alpha Mini-Protein 2FMX ; 1.82 ; An open conformation of switch I revealed by Sar1-GDP crystal structure at low Mg(2+) 3EAM ; 2.9 ; An open-pore structure of a bacterial pentameric ligand-gated ion channel 3KXO ; 2.1 ; An orally active inhibitor bound at the active site of HPGDS 2PHB ; 2.3 ; An Orally Efficacious Factor Xa Inhibitor 1SBG ; 2.3 ; AN ORALLY-BIOAVAILABLE HIV-1 PROTEASE INHIBITOR CONTAINING AN IMIDAZOLE-DERIVED PEPTIDE BOND REPLACEMENT. CRYSTALLOGRAPHIC AND PHARMACOKINETIC ANALYSIS 2VOX ; 1.9 ; An oxidized tryptophan facilitates copper-binding in Methylococcus capsulatus secreted protein MopE. The structure of mercury soaked MopE to 1.9AA 2VOV ; 1.35 ; An oxidized tryptophan facilitates copper-binding in Methylococcus capsulatus secreted protein MopE. The structure of native MopE to 1. 35AA 2VOW ; 1.65 ; An oxidized tryptophan facilitates copper-binding in Methylococcus capsulatus secreted protein MopE. The structure of recombinant MopE to 1.65AA 3QJP ; 3.2986 ; An RAMP protein binding different RNA substrates 3DHA ; 0.95 ; An Ultral High Resolution Structure of N-Acyl Homoserine Lactone Hydrolase with the Product N-Hexanoyl-L-Homoserine Bound at An Alternative Site 4APK ; 3.8 ; An unbiased approach solves the crystal structure of group II chaperonin TRiC (CCT) 4B2T ; 5.5 ; An unbiased statistical approach solves the crystal structures of the group II chaperonin CCT TRiC 1HXI ; 1.6 ; AN UNEXPECTED EXTENDED CONFORMATION FOR THE THIRD TPR MOTIF OF THE PEROXIN PEX5 FROM TRYPANOSOMA BRUCEI 2QPD ; 3.25 ; An unexpected outcome of surface-engineering an integral membrane protein: Improved crystallization of cytochrome ba3 oxidase from Thermus thermophilus 2QPE ; 2.9 ; An unexpected outcome of surface-engineering an integral membrane protein: Improved crystallization of cytochrome ba3 oxidase from Thermus thermophilus 1ADS ; 1.65 ; AN UNLIKELY SUGAR SUBSTRATE SITE IN THE 1.65 ANGSTROMS STRUCTURE OF THE HUMAN ALDOSE REDUCTASE HOLOENZYME IMPLICATED IN DIABETIC COMPLICATIONS 1TIA ; 2.1 ; AN UNUSUAL BURIED POLAR CLUSTER IN A FAMILY OF FUNGAL LIPASES 1TFG ; 1.95 ; AN UNUSUAL FEATURE REVEALED BY THE CRYSTAL STRUCTURE AT 2.2 ANGSTROMS RESOLUTION OF HUMAN TRANSFORMING GROWTH FACTOR-BETA2 1WQC ; ; An unusual fold for potassium channel blockers : NMR structure of three toxins from the scorpion Opisthacanthus madagascariensis 1WQD ; ; An unusual fold for potassium channel blockers: NMR structure of three toxins from the scorpion Opisthacanthus madagascariensis 1WQE ; ; An unusual fold for potassium channel blockers: NMR structure of three toxins from the scorpion Opisthacanthus madagascariensis 2NMR ; 2.1 ; An unusual twin-His arrangement in the pore of ammonia channels is essential for substrate conductance 2NOP ; 2 ; An unusual twin-His arrangement in the pore of ammonia channels is essential for substrate conductance 2NOW ; 2.2 ; An unusual twin-His arrangement in the pore of ammonia channels is essential for substrate conductance 2NPC ; 2.1 ; An unusual twin-His arrangement in the pore of ammonia channels is essential for substrate conductance 2NPD ; 2.1 ; An unusual twin-His arrangement in the pore of ammonia channels is essential for substrate conductance 2NPE ; 2.1 ; An unusual twin-His arrangement in the pore of ammonia channels is essential for substrate conductance 2NPG ; 2 ; An unusual twin-His arrangement in the pore of ammonia channels is essential for substrate conductance 2NPJ ; 2 ; An unusual twin-His arrangement in the pore of ammonia channels is essential for substrate conductance 2NPK ; 2 ; An unusual twin-His arrangement in the pore of ammonia channels is essential for substrate conductance 4EHI ; 2.28 ; An X-ray Crystal Structure of a putative Bifunctional Phosphoribosylaminoimidazolecarboxamide Formyltransferase/IMP Cyclohydrolase 4EHJ ; 2.71 ; An X-ray Structure of a Putative Phosphogylcerate Kinase from Francisella tularensis subsp. tularensis SCHU S4 4FEY ; 2.3 ; An X-ray Structure of a Putative Phosphogylcerate Kinase with Bound ADP from Francisella tularensis subsp. tularensis SCHU S4 8LYZ ; 2.5 ; AN X-RAY STUDY OF THE STRUCTURE AND BINDING PROPERTIES OF IODINE-INACTIVATED LYSOZYME 2K2V ; ; Anabaena CcbP in the calcium-bound form 1P78 ; 2.25 ; Anabaena HU-DNA cocrystal structure (AHU2) 1P51 ; 2.5 ; Anabaena HU-DNA cocrystal structure (AHU6) 1P71 ; 1.9 ; Anabaena HU-DNA corcrystal structure (TR3) 1EWY ; 2.38 ; ANABAENA PCC7119 FERREDOXIN:FERREDOXIN-NADP+-REDUCTASE COMPLEX 1CZP ; 1.17 ; ANABAENA PCC7119 [2FE-2S] FERREDOXIN IN THE REDUCED AND OXIXIZED STATE AT 1.17 A 1XIO ; 2 ; Anabaena sensory rhodopsin 2II7 ; 2.8 ; Anabaena sensory rhodopsin transducer 2II8 ; 2.1 ; Anabaena sensory rhodopsin transducer 2II9 ; 2 ; Anabaena sensory rhodopsin transducer 2IIA ; 1.8 ; Anabaena sensory rhodopsin transducer 4EV1 ; 1.95 ; Anabaena Tic22 (protein transport) 4DUL ; 3 ; ANAC019 NAC domain crystal form IV 3SWP ; 4.113 ; ANAC019 NAC domain in complex with DNA 2XWP ; 1.9 ; ANAEROBIC COBALT CHELATASE (CBIK) FROM SALMONELLA TYPHIMURIUM IN COMPLEX WITH METALATED TETRAPYRROLE 2XWS ; 1.6 ; ANAEROBIC COBALT CHELATASE (CBIX) FROM ARCHAEOGLOBUS FULGIDUS 2XWQ ; 2.01 ; ANAEROBIC COBALT CHELATASE FROM ARCHEAOGLOBUS FULGIDUS (CBIX) IN COMPLEX WITH METALATED SIROHYDROCHLORIN PRODUCT 1QGO ; 2.4 ; ANAEROBIC COBALT CHELATASE IN COBALAMIN BIOSYNTHESIS FROM SALMONELLA TYPHIMURIUM 3OBP ; 1.5 ; Anaerobic complex of urate oxidase with uric acid 2EI0 ; 1.6 ; Anaerobic Crystal Structure Analysis of 1,2-dihydroxynaphthalene dioxygenase from Pseudomonas sp. strain C18 complexed with 3,4-dihydroxybiphenyl 2EHZ ; 1.35 ; Anaerobic Crystal Structure Analysis of 1,2-dihydroxynaphthalene dioxygenase from Pseudomonas sp. strain C18 complexed with 4-methylcatechol 2EI3 ; 1.9 ; Anaerobic Crystal Structure Analysis of the 1,2-dihydroxynaphthalene dioxygenase from Pseudomonas sp. strain C18 complexes with 2,3-dihydroxybiphenyl 4IXK ; 2.1 ; Anaerobic crystal structure of iron soaked (2 h) ferritin from Pseudo-nitzschia multiseries 4ITW ; 2 ; Anaerobic crystal structure of iron soaked (75 min) ferritin from Pseudo-nitzschia multiseries 2EI1 ; 1.52 ; Anaerobic Crystal Strucutre Analysis of the 1,2-dihydroxynaphthalene dioxygeanse of Pseudomonas sp. strain C18 complexes to 1,2-dihydroxynaphthalene 1QYO ; 1.8 ; Anaerobic precylization intermediate crystal structure for S65G Y66G GFP variant 1F1V ; 1.9 ; ANAEROBIC SUBSTRATE COMPLEX OF HOMOPROTOCATECHUATE 2,3-DIOXYGENASE FROM ARTHROBACTER GLOBIFORMIS. (COMPLEX WITH 3,4-DIHYDROXYPHENYLACETATE) 2PPA ; 1.69 ; Anaerobically manipulated wild type oxidized AfNiR bound to nitrous oxide 1DAU ; ; Analog of dickerson-drew DNA dodecamer with 6'-alpha-methyl carbocyclic thymidines, NMR, minimized average structure 2LSQ ; ; Analog of the fragment 197-221 of beta-1 adrenoreceptor 1ELA ; 2 ; Analogous inhibitors of elastase do not always bind analogously 1ELB ; 2.1 ; Analogous inhibitors of elastase do not always bind analogously 1ELC ; 1.75 ; Analogous inhibitors of elastase do not always bind analogously 1LPN ; 2.18 ; ANALOGS OF REACTION INTERMEDIATES IDENTIFY A UNIQUE SUBSTRATE BINDING SITE IN CANDIDA RUGOSA LIPASE 1LPO ; 2.18 ; ANALOGS OF REACTION INTERMEDIATES IDENTIFY A UNIQUE SUBSTRATE BINDING SITE IN CANDIDA RUGOSA LIPASE 1LPP ; 2.18 ; ANALOGS OF REACTION INTERMEDIATES IDENTIFY A UNIQUE SUBSTRATE BINDING SITE IN CANDIDA RUGOSA LIPASE 2IWU ; 2.8 ; ANALOGUES OF RADICICOL BOUND TO THE ATP-BINDING SITE OF HSP90 2IWX ; 1.5 ; ANALOGUES OF RADICICOL BOUND TO THE ATP-BINDING SITE OF HSP90. 1B95 ; 2.05 ; ANALYSIS OF A MUTATIONAL HOT-SPOT IN THE ECORV RESTRICTION ENDONUCLEASE: A CATALYTIC ROLE FOR A MAIN CHAIN CARBONYL GROUP 1B96 ; 2.3 ; ANALYSIS OF A MUTATIONAL HOT-SPOT IN THE ECORV RESTRICTION ENDONUCLEASE: A CATALYTIC ROLE FOR A MAIN CHAIN CARBONYL GROUP 1B97 ; 1.9 ; ANALYSIS OF A MUTATIONAL HOT-SPOT IN THE ECORV RESTRICTION ENDONUCLEASE: A CATALYTIC ROLE FOR A MAIN CHAIN CARBONYL GROUP 3QT9 ; 2.05 ; Analysis of a new family of widely distributed metal-independent alpha mannosidases provides unique insight into the processing of N-linked glycans, Clostridium perfringens CPE0426 complexed with alpha-1,6-linked 1-thio-alpha-mannobiose 3QRY ; 1.75 ; Analysis of a new family of widely distributed metal-independent alpha mannosidases provides unique insight into the processing of N-linked glycans, Streptococcus pneumoniae SP_2144 1-deoxymannojirimycin complex 3QSP ; 2.1 ; Analysis of a new family of widely distributed metal-independent alpha mannosidases provides unique insight into the processing of N-linked glycans, Streptococcus pneumoniae SP_2144 non-productive substrate complex with alpha-1,6-mannobiose 3QT3 ; 2.35 ; Analysis of a New Family of Widely Distributed Metal-independent alpha-Mannosidases Provides Unique Insight into the Processing of N-linked Glycans, Clostridium perfringens CPE0426 apo-structure 3QPF ; 2.15 ; Analysis of a New Family of Widely Distributed Metal-independent alpha-Mannosidases Provides Unique Insight into the Processing of N-linked Glycans, Streptococcus pneumoniae SP_2144 apo-structure 1I13 ; 1.84 ; ANALYSIS OF AN INVARIANT ASPARTIC ACID IN HPRTS-ALANINE MUTANT 1I0L ; 1.72 ; ANALYSIS OF AN INVARIANT ASPARTIC ACID IN HPRTS-ASPARAGINE MUTANT 1I14 ; 1.92 ; ANALYSIS OF AN INVARIANT ASPARTIC ACID IN HPRTS-GLUTAMIC ACID MUTANT 1I0I ; 2.06 ; ANALYSIS OF AN INVARIANT ASPARTIC ACID IN HPRTS-GLUTAMINE MUTANT 1LY3 ; 1.9 ; ANALYSIS OF QUINAZOLINE AND PYRIDOPYRIMIDINE N9-C10 REVERSED BRIDGE ANTIFOLATES IN COMPLEX WITH NADP+ AND PNEUMOCYSTIS CARINII DIHYDROFOLATE REDUCTASE 1LY4 ; 2.1 ; Analysis of quinazoline and PYRIDO[2,3D]PYRIMIDINE N9-C10 reversed bridge antifolates in complex with NADP+ and Pneumocystis carinii dihydrofolate reductase 2CRD ; ; ANALYSIS OF SIDE-CHAIN ORGANIZATION ON A REFINED MODEL OF CHARYBDOTOXIN: STRUCTURAL AND FUNCTIONAL IMPLICATIONS 1YO5 ; 2 ; Analysis of the 2.0A crystal structure of the protein-DNA complex of human PDEF Ets domain bound to the prostate specific antigen regulatory site 1HDB ; 2.2 ; ANALYSIS OF THE CRYSTAL STRUCTURE, MOLECULAR MODELING AND INFRARED SPECTROSCOPY OF THE DISTAL BETA-HEME POCKET VALINE67(E11)-THREONINE MUTATION OF HEMOGLOBIN 1L55 ; 1.9 ; ANALYSIS OF THE INTERACTION BETWEEN CHARGED SIDE CHAINS AND THE ALPHA-HELIX DIPOLE USING DESIGNED THERMOSTABLE MUTANTS OF PHAGE T4 LYSOZYME 1L56 ; 1.8 ; ANALYSIS OF THE INTERACTION BETWEEN CHARGED SIDE CHAINS AND THE ALPHA-HELIX DIPOLE USING DESIGNED THERMOSTABLE MUTANTS OF PHAGE T4 LYSOZYME 1L57 ; 1.9 ; ANALYSIS OF THE INTERACTION BETWEEN CHARGED SIDE CHAINS AND THE ALPHA-HELIX DIPOLE USING DESIGNED THERMOSTABLE MUTANTS OF PHAGE T4 LYSOZYME 1L58 ; 1.65 ; ANALYSIS OF THE INTERACTION BETWEEN CHARGED SIDE CHAINS AND THE ALPHA-HELIX DIPOLE USING DESIGNED THERMOSTABLE MUTANTS OF PHAGE T4 LYSOZYME 1L59 ; 1.75 ; ANALYSIS OF THE INTERACTION BETWEEN CHARGED SIDE CHAINS AND THE ALPHA-HELIX DIPOLE USING DESIGNED THERMOSTABLE MUTANTS OF PHAGE T4 LYSOZYME 1L60 ; 1.7 ; ANALYSIS OF THE INTERACTION BETWEEN CHARGED SIDE CHAINS AND THE ALPHA-HELIX DIPOLE USING DESIGNED THERMOSTABLE MUTANTS OF PHAGE T4 LYSOZYME 1L61 ; 1.8 ; ANALYSIS OF THE INTERACTION BETWEEN CHARGED SIDE CHAINS AND THE ALPHA-HELIX DIPOLE USING DESIGNED THERMOSTABLE MUTANTS OF PHAGE T4 LYSOZYME 1L62 ; 1.7 ; ANALYSIS OF THE INTERACTION BETWEEN CHARGED SIDE CHAINS AND THE ALPHA-HELIX DIPOLE USING DESIGNED THERMOSTABLE MUTANTS OF PHAGE T4 LYSOZYME 1L63 ; 1.75 ; ANALYSIS OF THE INTERACTION BETWEEN CHARGED SIDE CHAINS AND THE ALPHA-HELIX DIPOLE USING DESIGNED THERMOSTABLE MUTANTS OF PHAGE T4 LYSOZYME 1ITM ; ; ANALYSIS OF THE SOLUTION STRUCTURE OF HUMAN INTERLEUKIN 4 DETERMINED BY HETERONUCLEAR THREE-DIMENSIONAL NUCLEAR MAGNETIC RESONANCE TECHNIQUES 1KXW ; 1.96 ; ANALYSIS OF THE STABILIZATION OF HEN LYSOZYME WITH THE HELIX DIPOLE AND CHARGED SIDE CHAINS 1KXX ; 1.71 ; ANALYSIS OF THE STABILIZATION OF HEN LYSOZYME WITH THE HELIX DIPOLE AND CHARGED SIDE CHAINS 1KXY ; 1.79 ; ANALYSIS OF THE STABILIZATION OF HEN LYSOZYME WITH THE HELIX DIPOLE AND CHARGED SIDE CHAINS 1RFP ; 1.75 ; ANALYSIS OF THE STABILIZATION OF HEN LYSOZYME WITH THE HELIX DIPOLE AND CHARGED SIDE CHAINS 1UIA ; 1.76 ; ANALYSIS OF THE STABILIZATION OF HEN LYSOZYME WITH THE HELIX DIPOLE AND CHARGED SIDE CHAINS 1UIB ; 1.76 ; ANALYSIS OF THE STABILIZATION OF HEN LYSOZYME WITH THE HELIX DIPOLE AND CHARGED SIDE CHAINS 1UIC ; 1.95 ; ANALYSIS OF THE STABILIZATION OF HEN LYSOZYME WITH THE HELIX DIPOLE AND CHARGED SIDE CHAINS 1UID ; 1.95 ; ANALYSIS OF THE STABILIZATION OF HEN LYSOZYME WITH THE HELIX DIPOLE AND CHARGED SIDE CHAINS 1UIE ; 1.95 ; ANALYSIS OF THE STABILIZATION OF HEN LYSOZYME WITH THE HELIX DIPOLE AND CHARGED SIDE CHAINS 1UIF ; 1.85 ; ANALYSIS OF THE STABILIZATION OF HEN LYSOZYME WITH THE HELIX DIPOLE AND CHARGED SIDE CHAINS 1UIG ; 1.95 ; ANALYSIS OF THE STABILIZATION OF HEN LYSOZYME WITH THE HELIX DIPOLE AND CHARGED SIDE CHAINS 1UIH ; 1.75 ; ANALYSIS OF THE STABILIZATION OF HEN LYSOZYME WITH THE HELIX DIPOLE AND CHARGED SIDE CHAINS 3FM9 ; 2.7 ; Analysis of the Structural Determinants Underlying Discrimination between Substrate and Solvent in beta-Phosphoglucomutase Catalysis 1PD8 ; 2.1 ; Analysis of Three Crystal Structure Determinations of a 5-Methyl-6-N-Methylanilino Pyridopyrimidine Antifolate Complex with Human Dihydrofolate Reductase 1PD9 ; 2.2 ; Analysis of Three Crystal Structure Determinations of a 5-Methyl-6-N-Methylanilino Pyridopyrimidine antifolate Complex with Human Dihydrofolate Reductase 1PDB ; 2.2 ; Analysis of Three Crystal Structure Determinations of a 5-Methyl-6-N-Methylanilino Pyridopyrimidine Antifolate Complex with Human Dihydrofolate Reductase 1MVS ; 1.9 ; Analysis of Two Polymorphic Forms of a Pyrido[2,3-d]pyrimidine N9-C10 Reverse-Bridge Antifolate Binary Complex with Human Dihydrofolate Reductase 1MVT ; 1.8 ; Analysis of Two Polymorphic Forms of a Pyrido[2,3-d]pyrimidine N9-C10 Reverse-Bridge Antifolate Binary Complex with Human Dihydrofolate Reductase 1Q38 ; ; Anastellin 1GES ; 1.74 ; ANATOMY OF AN ENGINEERED NAD-BINDING SITE 1GET ; 2 ; ANATOMY OF AN ENGINEERED NAD-BINDING SITE 1GEU ; 2.2 ; ANATOMY OF AN ENGINEERED NAD-BINDING SITE 1OJI ; 2.15 ; ANATOMY OF GLYCOSYNTHESIS: STRUCTURE AND KINETICS OF THE HUMICOLA INSOLENS CEL7BE197A AND E197S GLYCOSYNTHASE MUTANTS 1OJJ ; 1.4 ; ANATOMY OF GLYCOSYNTHESIS: STRUCTURE AND KINETICS OF THE HUMICOLA INSOLENS CEL7BE197A AND E197S GLYCOSYNTHASE MUTANTS 1OJK ; 1.5 ; ANATOMY OF GLYCOSYNTHESIS: STRUCTURE AND KINETICS OF THE HUMICOLA INSOLENS CEL7BE197A AND E197S GLYCOSYNTHASE MUTANTS 3ZDJ ; 2.4 ; Ancestral (ENCA) beta-lactamase class A 4B88 ; 2.05 ; Ancestral (GNCA) Beta-lactamase class A 2Q3Y ; 2.4 ; Ancestral Corticiod Receptor in Complex with DOC 2Q1H ; 1.9 ; Ancestral Corticoid Receptor in Complex with Aldosterone 2Q1V ; 1.95 ; Ancestral corticoid receptor in complex with cortisol 3SE7 ; 3.07 ; ancient VanA 3RF4 ; 1.8 ; Ancylostoma ceylanicum mif in complex with furosemide 3RF5 ; 2.1 ; Ancylostoma ceylanicum mif in complex with n-(2,3,4,5,6-pentafluoro-benzyl)-4-sulfamoyl-benzamide 3S6S ; 2.4 ; Ancylostoma-secreted protein Ac-ASP-7 2LMU ; ; Androcam at high calcium 2LMV ; ; Androcam at high calcium with three explicit Ca2+ 2PIO ; 2.03 ; Androgen receptor LBD with small molecule 2PIP ; 1.8 ; Androgen receptor LBD with small molecule 2PIQ ; 2.4 ; androgen receptor LBD with small molecule 2PIR ; 2.1 ; Androgen receptor LBD with small molecule 2PIT ; 1.76 ; Androgen receptor LBD with small molecule 2PIU ; 2.12 ; Androgen receptor LBD with small molecule 2PKL ; 2.49 ; Androgen receptor LBD with small molecule 2PIV ; 1.95 ; Androgen receptor with small molecule 2PIW ; 2.58 ; Androgen receptor with small molecule 3CFA ; 1.75 ; Anemonia sulcata red fluorescent protein asRFP 1Q0C ; 2.1 ; Anerobic Substrate Complex of Homoprotocatechuate 2,3-Dioxygenase from Brevibacterium fuscum. (Complex with 3,4-Dihydroxyphenylacetate) 4EPU ; 2.098 ; Ang1 fibrinogen-related domain (FReD) 4JZC ; 1.9 ; Angiopoietin-2 fibrinogen domain TAG mutant 1Z3S ; 2.35 ; Angiopoietin-2 Receptor Binding Domain 2GY7 ; 3.7 ; Angiopoietin-2/Tie2 Complex Crystal Structure 2JP8 ; ; Angiotensin 1-7 3NXQ ; 1.99 ; Angiotensin Converting Enzyme N domain glycsoylation mutant (Ndom389) in complex with RXP407 3QBG ; 1.8 ; Anion-free blue form of pharaonis halorhodopsin 1S8L ; 2.3 ; Anion-free form of the D85S mutant of bacteriorhodopsin from crystals grown in the presence of halide 1E54 ; 2.1 ; ANION-SELECTIVE PORIN FROM COMAMONAS ACIDOVORANS 3F49 ; 1.7 ; Anion-triggered Engineered Subtilisin SUBT_BACAM 2STA ; 1.8 ; ANIONIC SALMON TRYPSIN IN COMPLEX WITH SQUASH SEED INHIBITOR (CUCURBITA MAXIMA TRYPSIN INHIBITOR I) 2STB ; 1.8 ; ANIONIC SALMON TRYPSIN IN COMPLEX WITH SQUASH SEED INHIBITOR (CUCURBITA PEPO TRYPSIN INHIBITOR II) 1MBQ ; 1.8 ; Anionic Trypsin from Pacific Chum Salmon 3FP6 ; 1.49 ; Anionic trypsin in complex with bovine pancreatic trypsin inhibitor (BPTI) determined to the 1.49 A resolution limit 1AND ; 2.3 ; ANIONIC TRYPSIN MUTANT WITH ARG 96 REPLACED BY HIS 1ANB ; 2.8 ; ANIONIC TRYPSIN MUTANT WITH SER 214 REPLACED BY GLU 1ANC ; 2.2 ; ANIONIC TRYPSIN MUTANT WITH SER 214 REPLACED BY LYS 3FP7 ; 1.46 ; Anionic trypsin variant S195A in complex with bovine pancreatic trypsin inhibitor (BPTI) cleaved at the scissile bond (LYS15-ALA16) determined to the 1.46 A resolution limit 3FP8 ; 1.46 ; Anionic trypsin variant S195A in complex with bovine pancreatic trypsin inhibitor (BPTI) determined to the 1.46 A resolution limit 1ANE ; 2.2 ; ANIONIC TRYPSIN WILD TYPE 3LSW ; 1.752 ; Aniracetam bound to the ligand binding domain of GluA3 2BF9 ; 0.99 ; ANISOTROPIC REFINEMENT OF AVIAN (TURKEY) PANCREATIC POLYPEPTIDE AT 0.99 ANGSTROMS RESOLUTION. 2IGD ; 1.1 ; ANISOTROPIC STRUCTURE OF PROTEIN G IGG-BINDING DOMAIN III AT 1.1 ANGSTROM RESOLUTION 7BNA ; 1.9 ; ANISOTROPIC THERMAL-PARAMETER REFINEMENT OF THE DNA DODECAMER CGCGAATTCGCG BY THE SEGMENTED RIGID-BODY METHOD 2PFD ; 3.42 ; Anisotropically refined structure of FTCD 3LJN ; 2.9 ; Ankyrin repeat protein from Leishmania major 1W7B ; 1.52 ; ANNEXIN A2: DOES IT INDUCE MEMBRANE AGGREGATION BY A NEW MULTIMERIC STATE OF THE PROTEIN. 1N00 ; 2.1 ; Annexin Gh1 from cotton 1AII ; 1.95 ; ANNEXIN III 1ANN ; 2.3 ; ANNEXIN IV 1AOW ; 3 ; ANNEXIN IV 1G5N ; 1.9 ; ANNEXIN V COMPLEX WITH HEPARIN OLIGOSACCHARIDES 2IE7 ; 1.75 ; Annexin V under 2.0 MPa pressure of nitrous oxide 2IE6 ; 1.83 ; Annexin V under 2.0 MPa pressure of xenon 1DM5 ; 1.93 ; ANNEXIN XII E105K HOMOHEXAMER CRYSTAL STRUCTURE 1LZ9 ; 1.7 ; ANOMALOUS SIGNAL OF SOLVENT BROMINES USED FOR PHASING OF LYSOZYME 2G4X ; 1.95 ; Anomalous substructure od ribonuclease A (P3221) 2G4O ; 2 ; anomalous substructure of 3-ISOPROPYLMALATE DEHYDROGENASE 2G4N ; 2.3 ; Anomalous substructure of alpha-lactalbumin 2G4H ; 2 ; Anomalous substructure of apoferritin 2G4I ; 2.4 ; Anomalous substructure of Concanavalin A 2G4J ; 1.85 ; Anomalous substructure of Glucose isomerase 2G4K ; 1.82 ; Anomalous substructure of human ADP-ribosylhydrolase 3 2G4L ; 1.84 ; Anomalous substructure of hydroxynitrile lyase 2G4P ; 1.84 ; Anomalous substructure of lysozyme at pH 4.5 2G4Q ; 1.84 ; Anomalous substructure of lysozyme at pH 8.0 2G4R ; 1.92 ; anomalous substructure of MogA 2G4S ; 2.15 ; Anomalous substructure of NBR1PB1 2G4U ; 1.84 ; Anomalous substructure of porcine pancreatic elastaase (Ca) 2G4T ; 2.15 ; anomalous substructure of porcine pancreatic elastase (Na) 2G4V ; 2.14 ; anomalous substructure of proteinase K 2G4W ; 1.84 ; anomalous substructure of ribonuclease A (C2) 2G4Z ; 1.98 ; anomalous substructure of thermolysin 2ILL ; 2.2 ; Anomalous substructure of Titin-A168169 2G51 ; 1.84 ; anomalous substructure of trypsin (p1) 2G52 ; 1.84 ; Anomalous substructure of trypsin (P21) 2G55 ; 1.82 ; Anomalous substructure of trypsin (P3121) 1JLV ; 1.75 ; Anopheles dirus species B glutathione S-transferases 1-3 1JLW ; 2.45 ; Anopheles dirus species B glutathione S-transferases 1-4 4E05 ; 2.304 ; Anophelin from the malaria vector inhibits thrombin through a novel reverse-binding mechanism 4E06 ; 3.196 ; Anophelin from the malaria vector inhibits thrombin through a novel reverse-binding mechanism 1AGD ; 2.05 ; ANTAGONIST HIV-1 GAG PEPTIDES INDUCE STRUCTURAL CHANGES IN HLA B8-HIV-1 GAG PEPTIDE (GGKKKYKL-INDEX PEPTIDE) 1AGC ; 2.1 ; ANTAGONIST HIV-1 GAG PEPTIDES INDUCE STRUCTURAL CHANGES IN HLA B8-HIV-1 GAG PEPTIDE (GGKKKYQL-7Q MUTATION) 1AGE ; 2.3 ; ANTAGONIST HIV-1 GAG PEPTIDES INDUCE STRUCTURAL CHANGES IN HLA B8-HIV-1 GAG PEPTIDE (GGKKKYRL-7R MUTATION) 1AGF ; 2.2 ; ANTAGONIST HIV-1 GAG PEPTIDES INDUCE STRUCTURAL CHANGES IN HLA B8-HIV-1 GAG PEPTIDE (GGKKRYKL-5R MUTATION) 1AGB ; 2.2 ; ANTAGONIST HIV-1 GAG PEPTIDES INDUCE STRUCTURAL CHANGES IN HLA B8-HIV-1 GAG PEPTIDE (GGRKKYKL-3R MUTATION) 1KX8 ; 2.8 ; Antennal Chemosensory Protein A6 from Mamestra brassicae, tetragonal form 1KX9 ; 1.65 ; ANTENNAL CHEMOSENSORY PROTEIN A6 FROM THE MOTH MAMESTRA BRASSICAE 9ANT ; 2.4 ; ANTENNAPEDIA HOMEODOMAIN-DNA COMPLEX 1GP4 ; 2.1 ; ANTHOCYANIDIN SYNTHASE FROM ARABIDOPSIS THALIANA (SELENOMETHIONINE SUBSTITUTED) 2BRT ; 2.2 ; ANTHOCYANIDIN SYNTHASE FROM ARABIDOPSIS THALIANA COMPLEXED WITH NARINGENIN 1GP5 ; 2.2 ; ANTHOCYANIDIN SYNTHASE FROM ARABIDOPSIS THALIANA COMPLEXED WITH TRANS-DIHYDROQUERCETIN 1GP6 ; 1.75 ; ANTHOCYANIDIN SYNTHASE FROM ARABIDOPSIS THALIANA COMPLEXED WITH TRANS-DIHYDROQUERCETIN (WITH 30 MIN EXPOSURE TO O2) 1AHL ; ; ANTHOPLEURIN-A,NMR, 20 STRUCTURES 1APF ; ; ANTHOPLEURIN-B, NMR, 20 STRUCTURES 1D54 ; 1.4 ; ANTHRACYCLINE BINDING TO DNA: HIGH RESOLUTION STRUCTURE OF D(TGTACA) COMPLEXED WITH 4'-EPIADRIAMYCIN 110D ; 1.9 ; ANTHRACYCLINE-DNA INTERACTIONS AT UNFAVOURABLE BASE BASE-PAIR TRIPLET-BINDING SITES: STRUCTURES OF D(CGGCCG)/DAUNOMYCIN AND D(TGGCCA)/ADRIAMYCIN COMPL 1DA9 ; 1.7 ; ANTHRACYCLINE-DNA INTERACTIONS AT UNFAVOURABLE BASE BASE-PAIR TRIPLET-BINDING SITES: STRUCTURES OF D(CGGCCG)/DAUNOMYCIN AND D(TGGCCA)/ADRIAMYCIN COMPL 1O17 ; 2.05 ; ANTHRANILATE PHOSPHORIBOSYL-TRANSFERASE (TRPD) 3GBR ; 2.25 ; Anthranilate phosphoribosyl-transferase (TRPD) double mutant D83G F149S from S. solfataricus 2GVQ ; 2.43 ; Anthranilate phosphoribosyl-transferase (TRPD) from S. solfataricus in complex with anthranilate 2BPQ ; 1.9 ; ANTHRANILATE PHOSPHORIBOSYLTRANSFERASE (TRPD) FROM MYCOBACTERIUM TUBERCULOSIS (APO STRUCTURE) 3QR9 ; 1.87 ; Anthranilate phosphoribosyltransferase (trpD) from Mycobacterium tuberculosis (apo structure) 3UU1 ; 1.82 ; Anthranilate phosphoribosyltransferase (trpD) from Mycobacterium tuberculosis (complex with inhibitor ACS142) 3R88 ; 1.73 ; Anthranilate phosphoribosyltransferase (trpD) from Mycobacterium tuberculosis (complex with inhibitor ACS145) 3QQS ; 1.97 ; Anthranilate phosphoribosyltransferase (TRPD) from Mycobacterium tuberculosis (complex with inhibitor ACS172) 3QS8 ; 2 ; Anthranilate phosphoribosyltransferase (trpD) from Mycobacterium tuberculosis (complex with inhibitor ACS174) 3R6C ; 1.83 ; Anthranilate phosphoribosyltransferase (trpD) from Mycobacterium tuberculosis (complex with inhibitor ACS179) 3QSA ; 2.18 ; Anthranilate phosphoribosyltransferase (trpD) from Mycobacterium tuberculosis (complex with inhibitor TAMU-A7) 1ZXY ; 2.56 ; Anthranilate Phosphoribosyltransferase from Sulfolobus solfataricus in complex with PRPP and Magnesium 1ZYK ; 2.4 ; Anthranilate Phosphoribosyltransferase in complex with PRPP, anthranilate and magnesium 1GXB ; 2.65 ; ANTHRANILATE PHOSPHORIBOSYLTRANSFERASE IN COMPLEX WITH PYROPHOSPHATE AND MAGNESIUM 1I7Q ; 1.95 ; ANTHRANILATE SYNTHASE FROM S. MARCESCENS 1I7S ; 2.4 ; ANTHRANILATE SYNTHASE FROM SERRATIA MARCESCENS IN COMPLEX WITH ITS END PRODUCT INHIBITOR L-TRYPTOPHAN 4DV8 ; 1.632 ; Anthrax Lethal Factor metalloproteinase in complex with the Hydroxamic acid based small molecule PT8421 1ACC ; 2.1 ; ANTHRAX PROTECTIVE ANTIGEN 1J7N ; 2.3 ; Anthrax Toxin Lethal factor 2W60 ; 1.5 ; ANTI CITRULLINATED COLLAGEN TYPE 2 ANTIBODY ACC4 2W65 ; 2.21 ; ANTI CITRULLINATED COLLAGEN TYPE 2 ANTIBODY ACC4 IN COMPLEX WITH A CITRULLINATED PEPTIDE 1CL7 ; 3 ; ANTI HIV1 PROTEASE FAB 1MF2 ; 2.6 ; ANTI HIV1 PROTEASE FAB COMPLEX 3IU4 ; 1.75 ; anti NeuGcGM3 ganglioside chimeric antibody chP3 4HFW ; 2.601 ; Anti Rotavirus Antibody 1AY1 ; 2.2 ; ANTI TAQ FAB TP7 2VQ1 ; 2.5 ; ANTI TRIMERIC LEWIS X FAB54-5C10-A 1GHF ; 2.7 ; ANTI-ANTI-IDIOTYPE GH1002 FAB FRAGMENT 2CK0 ; 2.2 ; ANTI-ANTI-IDIOTYPIC ANTIBODY AGAINST HUMAN ANGIOTENSIN II, COMPLEX WITH A SYNTHETIC CYCLIC PEPTIDE 3CK0 ; 3 ; ANTI-ANTI-IDIOTYPIC ANTIBODY AGAINST HUMAN ANGIOTENSIN II, COMPLEX WITH HUMAN ANGIOTENSIN II 1CK0 ; 2.5 ; ANTI-ANTI-IDIOTYPIC ANTIBODY AGAINST HUMAN ANGIOTENSIN II, UNLIGANDED FORM 3O11 ; 2.8 ; Anti-beta-amyloid antibody c706 fab in space group c2 3MCL ; 1.7 ; Anti-beta-amyloid antibody c706 fab in space group P21 1JV5 ; 2.2 ; Anti-blood group A Fv 1CLO ; 2.1 ; ANTI-CARCINOEMBRYONIC ANTIGEN MONOCLONAL ANTIBODY A5B7 2A1W ; 2.7 ; Anti-cocaine antibody 7.5.21, crystal form I 2A77 ; 1.8 ; Anti-Cocaine Antibody 7.5.21, Crystal Form II 2AI0 ; 2.2 ; Anti-Cocaine Antibody 7.5.21, Crystal Form III 1RFD ; 2.09 ; ANTI-COCAINE ANTIBODY M82G2 1QYG ; 1.81 ; ANTI-COCAINE ANTIBODY M82G2 COMPLEXED WITH BENZOYLECGONINE 1Q72 ; 1.7 ; Anti-Cocaine Antibody M82G2 Complexed with Cocaine 1RIV ; 2.2 ; Anti-Cocaine Antibody M82G2 Complexed With meta-Oxybenzoylecgonine 1RIU ; 2 ; Anti-Cocaine Antibody M82G2 Complexed With Norbenzoylecgonine 2OJZ ; 2.73 ; Anti-DNA antibody ED10 3P0V ; 2.85 ; anti-EGFR/HER3 Fab DL11 alone 3P0Y ; 1.8 ; anti-EGFR/HER3 Fab DL11 in complex with domain III of EGFR extracellular region 3P11 ; 3.7 ; anti-EGFR/HER3 Fab DL11 in complex with domains I-III of the HER3 extracellular region 2KK9 ; ; Anti-group A streptococcal vaccine epitope: structure, stability and its ability to interact with HLA class II molecules 1YMH ; 2.6 ; anti-HCV Fab 19D9D6 complexed with protein L (PpL) mutant A66W 1AIF ; 2.9 ; ANTI-IDIOTYPIC FAB 409.5.3 (IGG2A) FAB FROM MOUSE 3OJD ; 2 ; Anti-Indolicidin monoclonal antibody V2D2 (Fab fragment) 1UZ8 ; 1.8 ; ANTI-LEWIS X FAB FRAGMENT IN COMPLEX WITH LEWIS X 1UZ6 ; 2.05 ; ANTI-LEWIS X FAB FRAGMENT UNCOMPLEXED 3EYV ; 2.5 ; Anti-Lewis Y Fab fragment with Lewis Y antigen in the presence of zinc ions 1LQQ ; ; ANTI-MAMMAL AND ANTI-INSECT LQQIII SCORPION TOXIN, NMR, 15 STRUCTURES 3GM0 ; 2.4 ; Anti-methamphetamine single chain Fv in complex with MDMA 1Q0Y ; 2 ; Anti-Morphine Antibody 9B1 Complexed with Morphine 1Q0X ; 1.6 ; Anti-morphine Antibody 9B1 Unliganded Form 1BLN ; 2.8 ; ANTI-P-GLYCOPROTEIN FAB MRK-16 1CFQ ; 2.8 ; ANTI-P24 (HIV-1) FAB FRAGMENT CB41 1HH6 ; 2.6 ; ANTI-P24 (HIV-1) FAB FRAGMENT CB41 COMPLEXED WITH A PEPTIDE 1HH9 ; 2.7 ; ANTI-P24 (HIV-1) FAB FRAGMENT CB41 COMPLEXED WITH A PEPTIDE 1HI6 ; 2.55 ; ANTI-P24 (HIV-1) FAB FRAGMENT CB41 COMPLEXED WITH A PEPTIDE 1BOG ; 2.6 ; ANTI-P24 (HIV-1) FAB FRAGMENT CB41 COMPLEXED WITH AN EPITOPE-HOMOLOGOUS PEPTIDE 1CFN ; 2.65 ; ANTI-P24 (HIV-1) FAB FRAGMENT CB41 COMPLEXED WITH AN EPITOPE-RELATED PEPTIDE 1CFT ; 2.8 ; ANTI-P24 (HIV-1) FAB FRAGMENT CB41 COMPLEXED WITH AN EPITOPE-UNRELATED D-PEPTIDE 1CFS ; 2.75 ; ANTI-P24 (HIV-1) FAB FRAGMENT CB41 COMPLEXED WITH AN EPITOPE-UNRELATED PEPTIDE 3U1C ; 1.8 ; Anti-parallel dimer of N-terminal 98-aa fragment of smooth muscle tropomyosin alpha 3O6L ; 2.1 ; Anti-Tat HIV 11H6H1 Fab' complexed with a 15-mer Tat peptide 3O6M ; 2.4 ; Anti-Tat HIV 11H6H1 Fab' complexed with a 9-mer Tat peptide 3LS5 ; 1.9 ; Anti-tetrahydrocannabinol Fab Fragment, Free Form 2JR3 ; ; Antibacterial Peptide from Eggshell Matrix: Structure and Self-assembly of beta-defensin Like Peptide from the Chinese Soft-shelled Turtle Eggshell 1T51 ; ; Antibiotic Activity and Structural Analysis of a Scorpion-derived Antimicrobial peptide IsCT and Its Analogs 1T52 ; ; Antibiotic Activity and Structural Analysis of a Scorpion-derived Antimicrobial peptide IsCT and Its Analogs 1T54 ; ; Antibiotic Activity and Structural Analysis of a Scorpion-derived Antimicrobial peptide IsCT and Its Analogs 1T55 ; ; Antibiotic Activity and Structural Analysis of a Scorpion-derived Antimicrobial peptide IsCT and Its Analogs 1NY9 ; ; Antibiotic binding domain of a TipA-class multidrug resistance transcriptional regulator 3G5V ; 2.001 ; Antibodies Specifically Targeting a Locally Misfolded Region of Tumor Associated EGFR 3G5X ; 2.3 ; Antibodies Specifically Targeting a Locally Misfolded Region of Tumor Associated EGFR 3G5Y ; 1.59 ; Antibodies Specifically Targeting a Locally Misfolded Region of Tumor Associated EGFR 3G5Z ; 2.6 ; Antibodies Specifically Targeting a Locally Misfolded Region of Tumor Associated EGFR 3OAU ; 1.9 ; Antibody 2G12 Recognizes Di-Mannose Equivalently in Domain- and Non-Domain-Exchanged Forms, but only binds the HIV-1 Glycan Shield if Domain-Exchanged 1KEG ; 2.4 ; Antibody 64M-2 Fab complexed with dTT(6-4)TT 3VW3 ; 2.5 ; Antibody 64M-5 Fab in complex with a double-stranded DNA (6-4) photoproduct 1MEX ; 1.25 ; Antibody Catalysis of a Bimolecular Cycloaddition Reaction 2PCP ; 2.2 ; ANTIBODY FAB COMPLEXED WITH PHENCYCLIDINE 3VG0 ; 2.27 ; Antibody Fab fragment 3C2A ; 2.1 ; Antibody Fab fragment 447-52D in complex with UG1033 peptide 1I7Z ; 2.3 ; ANTIBODY GNC92H2 BOUND TO LIGAND 1OAY ; 2.66 ; Antibody multispecificity mediated by conformational diversity 3I75 ; 1.95 ; Antibody Structure 1BEY ; 3.25 ; ANTIBODY TO CAMPATH-1H HUMANIZED FAB 1HEZ ; 2.7 ; ANTIBODY-ANTIGEN COMPLEX 1MHH ; 2.1 ; Antibody-antigen complex 1LNM ; 1.9 ; ANTICALIN DIGA16 IN COMPLEX WITH DIGITOXIGENIN 3DLW ; 2.7 ; Antichymotrypsin 1VIP ; 2.2 ; ANTICOAGULANT CLASS II PHOSPHOLIPASE A2 FROM THE VENOM OF VIPERA RUSSELLI RUSSELLI 1COU ; ; ANTICOAGULANT PROTEIN FROM THE NEMATODE ANCYLOSTOMA CANINUM 1G6E ; ; ANTIFUNGAL PROTEIN FROM STREPTOMYCES TENDAE TU901, 30-CONFORMERS ENSEMBLE 1GH5 ; ; ANTIFUNGAL PROTEIN FROM STREPTOMYCES TENDAE TU901, NMR AVERAGE STRUCTURE 1VA5 ; 2.02 ; Antigen 85C with octylthioglucoside in active site 3GIV ; 2 ; Antigen processing influences HIV-specific cytotoxic T lymphocyte immunodominance 2HRP ; 2.2 ; ANTIGEN-ANTIBODY COMPLEX 1JFQ ; 1.9 ; ANTIGEN-BINDING FRAGMENT OF THE MURINE ANTI-PHENYLARSONATE ANTIBODY 36-71, ""FAB 36-71"" 2L24 ; ; Antimicrobial peptide 2JSO ; ; Antimicrobial resistance protein 2CCF ; 1.7 ; ANTIPARALLEL CONFIGURATION OF PLI E20S 2B1F ; 1.5 ; Antiparallel four-stranded coiled coil specified by a 3-3-1 hydrophobic heptad repeat 2B22 ; 2 ; Antiparallel four-stranded coiled coil specified by a 3-3-1 hydrophobic heptad repeat 1RB4 ; 1.9 ; ANTIPARALLEL TRIMER OF GCN4-LEUCINE ZIPPER CORE MUTANT AS N16A TETRAGONAL AUTOMATIC SOLUTION 1RB6 ; 1.9 ; ANTIPARALLEL TRIMER OF GCN4-LEUCINE ZIPPER CORE MUTANT AS N16A TETRAGONAL FORM 1RB5 ; 1.9 ; ANTIPARALLEL TRIMER OF GCN4-LEUCINE ZIPPER CORE MUTANT AS N16A TRIGONAL FORM 1CX5 ; ; ANTISENSE DNA/RNA HYBRID CONTAINING MODIFIED BACKBONE 1SR5 ; 3.1 ; ANTITHROMBIN-ANHYDROTHROMBIN-HEPARIN TERNARY COMPLEX STRUCTURE 1AZX ; 2.9 ; ANTITHROMBIN/PENTASACCHARIDE COMPLEX 1KYF ; 1.22 ; AP-2 CLATHRIN ADAPTOR ALPHA-APPENDAGE IN COMPLEX WITH EPS15 DPF PEPTIDE 1KYU ; 1.8 ; AP-2 CLATHRIN ADAPTOR ALPHA-APPENDAGE IN COMPLEX WITH EPS15 DPF PEPTIDE 1KY6 ; 2 ; AP-2 CLATHRIN ADAPTOR ALPHA-APPENDAGE IN COMPLEX WITH EPSIN DPW PEPTIDE 1KYD ; 2 ; AP-2 CLATHRIN ADAPTOR ALPHA-APPENDAGE IN COMPLEX WITH EPSIN DPW PEPTIDE 1W63 ; 4 ; AP1 CLATHRIN ADAPTOR CORE 2VGL ; 2.6 ; AP2 CLATHRIN ADAPTOR CORE 2XA7 ; 3.1 ; AP2 CLATHRIN ADAPTOR CORE IN ACTIVE COMPLEX WITH CARGO PEPTIDES 2JKT ; 3.4 ; AP2 CLATHRIN ADAPTOR CORE with CD4 Dileucine peptide RM(phosphoS) EIKRLLSE Q to E mutant 2JKR ; 2.98 ; AP2 CLATHRIN ADAPTOR CORE with Dileucine peptide RM(phosphoS)QIKRLLSE 3IK3 ; 1.9 ; AP24534, a Pan-BCR-ABL Inhibitor for Chronic Myeloid Leukemia, Potently Inhibits the T315I Mutant and Overcomes Mutation-Based Resistance 3YGS ; 2.5 ; APAF-1 CARD IN COMPLEX WITH PRODOMAIN OF PROCASPASE-9 1GQP ; 2.2 ; APC10/DOC1 SUBUNIT OF S. CEREVISIAE 1WCG ; 1.1 ; APHID MYROSINASE 1ASS ; 2.3 ; APICAL DOMAIN OF THE CHAPERONIN FROM THERMOPLASMA ACIDOPHILUM 1ASX ; 2.8 ; APICAL DOMAIN OF THE CHAPERONIN FROM THERMOPLASMA ACIDOPHILUM 3S0G ; 1.85 ; Apis mellifera OBP 14 double mutant Gln44Cys, His97Cys 3S0D ; 1.24 ; Apis mellifera OBP 14 in complex with the citrus odorant citralva (3,7-dimethylocta-2,6-dienenitrile) 3RZS ; 1.88 ; Apis mellifera OBP14 in complex with Ta6Br14 3S0B ; 1.22 ; Apis mellifera OBP14 in complex with the fluorescent probe 1-N-phenylnaphthylamine (NPN) 3S0E ; 1.6 ; Apis mellifera OBP14 in complex with the odorant eugenol (2-methoxy-4(2-propenyl)-phenol) 3S0F ; 2.03 ; Apis mellifera OBP14 native apo, crystal form 2 3S0A ; 1.15 ; Apis mellifera OBP14, native apo-protein 3R72 ; 1.15 ; Apis mellifera odorant binding protein 5 1LBE ; 2.4 ; APLYSIA ADP RIBOSYL CYCLASE 1R15 ; 2.4 ; Aplysia ADP ribosyl cyclase with bound nicotinamide and R5P 1R16 ; 2 ; Aplysia ADP ribosyl cyclase with bound pyridylcarbinol and R5P 2W8F ; 2.7 ; APLYSIA CALIFORNICA ACHBP BOUND TO IN SILICO COMPOUND 31 2W8G ; 2.6 ; APLYSIA CALIFORNICA ACHBP BOUND TO IN SILICO COMPOUND 35 2Y7Y ; 1.895 ; APLYSIA CALIFORNICA ACHBP IN APO STATE 4AFO ; 2.88 ; Aplysia californica AChBP in complex with Cytisine 4AFT ; 3.2 ; Aplysia californica AChBP in complex with Varenicline 4DBM ; 2.3 ; Aplysia californica-AChBP in complex with triazole 18 1MBA ; 1.6 ; APLYSIA LIMACINA MYOGLOBIN. CRYSTALLOGRAPHIC ANALYSIS AT 1.6 ANGSTROMS RESOLUTION 3MBA ; 2 ; APLYSIA LIMACINA MYOGLOBIN. CRYSTALLOGRAPHIC ANALYSIS AT 1.6 ANGSTROMS RESOLUTION 4MBA ; 2 ; APLYSIA LIMACINA MYOGLOBIN. CRYSTALLOGRAPHIC ANALYSIS AT 1.6 ANGSTROMS RESOLUTION 2J16 ; 2.7 ; APO & SULPHATE BOUND FORMS OF SDP-1 3DHZ ; 1.63 ; Apo (iron free) structure of C. ammoniagenes R2 protein 2BGQ ; 2.5 ; APO ALDOSE REDUCTASE FROM BARLEY 1WLR ; 2.1 ; Apo aminopeptidase P from E. coli 1PIW ; 3 ; APO AND HOLO STRUCTURES OF AN NADP(H)-DEPENDENT CINNAMYL ALCOHOL DEHYDROGENASE FROM SACCHAROMYCES CEREVISIAE 1Q1N ; 3.15 ; APO AND HOLO STRUCTURES OF AN NADP(H)-DEPENDENT CINNAMYL ALCOHOL DEHYDROGENASE FROM SACCHAROMYCES CEREVISIAE 3T8S ; 3.77 ; Apo and InsP3-bound Crystal Structures of the Ligand-Binding Domain of an InsP3 Receptor 3K6W ; 2.45 ; Apo and ligand bound structures of ModA from the archaeon Methanosarcina acetivorans 3C6Q ; 2.3 ; Apo and ligand-bound form of a thermophilic glucose/xylose binding protein 3N4T ; 2.2 ; apo APH(2"")-IVa form I 3N4V ; 2.4 ; apo APH(2"")-IVa form III 3BKU ; 2.1 ; Apo C-terminal Domain of NikR 3PXR ; 2 ; Apo CDK2 crystallized from Jeffamine 2V5J ; 1.6 ; APO CLASS II ALDOLASE HPCH 4I1U ; 2.05 ; Apo crystal structure of a dephospho-CoA kinase from Burkholderia vietnamiensis 4E76 ; 2.5 ; Apo crystal structure of HCV NS5B genotype 2A JFH-1 isolate with beta hairpin loop deletion 3HQN ; 2 ; Apo crystal structure of Leishmania mexicana(LmPYK)pyruvate kinase 1ZM8 ; 1.9 ; Apo Crystal structure of Nuclease A from Anabaena sp. 3ILY ; 2.2 ; Apo crystal structure of protein tyrosine phosphatase from Entamoeba histolytica featuring a disordered active site 1EVX ; 2 ; APO CRYSTAL STRUCTURE OF THE HOMING ENDONUCLEASE, I-PPOI 1AOV ; 4 ; APO DUCK OVOTRANSFERRIN 1ZCV ; 1.98 ; apo form of a mutant of glycogenin in which Asp159 is replaced by Asn 1ZCY ; 1.99 ; apo form of a mutant of glycogenin in which Asp159 is replaced by Ser 1EUH ; 1.82 ; APO FORM OF A NADP DEPENDENT ALDEHYDE DEHYDROGENASE FROM STREPTOCOCCUS MUTANS 3APZ ; 2.6 ; Apo form of Arabidopsis medium/long-chain length prenyl pyrophosphate synthase 3TEO ; 2.4 ; APO Form of carbon disulfide hydrolase (selenomethionine form) 2ARA ; 2.8 ; APO FORM OF ESCHERICHIA COLI REGULATORY PROTEIN ARAC 3ZSS ; 1.8 ; APO FORM OF GLGE ISOFORM 1 FROM STREPTOMYCES COELICOLOR 1O05 ; 2.25 ; Apo form of human mitochondrial aldehyde dehydrogenase 2GCA ; 2.4 ; apo form of L. casei FPGS 2PRY ; 2.35 ; Apo form of S. cerevisiae orotate phosphoribosyltransferase 1ZCU ; 2 ; apo form of the 162S mutant of glycogenin 2JCG ; 2.6 ; APO FORM OF THE CATABOLITE CONTROL PROTEIN A (CCPA) FROM BACILLUS MEGATERIUM, WITH THE DNA BINDING DOMAIN 3NSF ; 2 ; Apo form of the multicopper oxidase CueO 2C0M ; 2.5 ; APO FORM OF THE TPR DOMAIN OF THE PEX5P RECEPTOR 1XJA ; 2.4 ; Apo form of the Y31V mutant dimerization domain fragment of Escherichia coli regulatory protein AraC 3AEY ; 1.92 ; Apo form of threonine synthase from Thermus thermophilus HB8 2VOZ ; 1.7 ; APO FUTA2 FROM SYNECHOCYSTIS PCC6803 3I69 ; 2.38 ; Apo Glutathione Transferase A1-1 GIMF-helix mutant 2AXQ ; 1.7 ; Apo histidine-tagged saccharopine dehydrogenase (L-Glu forming) from Saccharomyces cerevisiae 4EJ8 ; 2.347 ; Apo HIV Protease (PR) dimer in closed form with fragment 1F1 in the outside/top of flap 4EJL ; 2.445 ; Apo HIV Protease (PR) dimer in closed form with fragment 1F1-N in the outside/top of flap 3D93 ; 1.1 ; Apo Human carbonic anhydrase II bound with substrate carbon dioxide 3SPJ ; 3.307 ; Apo inward rectifier potassium channel Kir2.2 I223L mutant 2O8Y ; 2.4 ; Apo IRAK4 Kinase Domain 2V65 ; 2.35 ; APO LDH FROM THE PSYCHROPHILE C. GUNNARI 3SPU ; 2.1 ; apo NDM-1 Crystal Structure 2FW0 ; 1.55 ; Apo Open Form of Glucose/Galactose Binding Protein 1AIV ; 3 ; APO OVOTRANSFERRIN 1XGD ; 2.1 ; Apo R268A human aldose reductase 2OAM ; 2.3 ; Apo RebH from Lechevalieria aerocolonigenes 1FF9 ; 2 ; APO SACCHAROPINE REDUCTASE 1E5L ; 2.4 ; APO SACCHAROPINE REDUCTASE FROM MAGNAPORTHE GRISEA 2WYL ; 2.59 ; APO STRUCTURE OF A METALLO-B-LACTAMASE 4GMF ; 1.85 ; Apo Structure of a Thiazolinyl Imine Reductase from Yersinia enterocolitica (Irp3) 1SXH ; 2.75 ; apo structure of B. megaterium transcription regulator 1W50 ; 1.75 ; APO STRUCTURE OF BACE (BETA SECRETASE) 3TPJ ; 1.61 ; APO structure of BACE1 3TPL ; 2.5 ; APO Structure of BACE1 3FJP ; 2.3 ; Apo structure of Biotin protein ligase from Aquifex aeolicus 2YG1 ; 1.9 ; APO STRUCTURE OF CELLOBIOHYDROLASE 1 (CEL7A) FROM HETEROBASIDION ANNOSUM 2ZQ7 ; 0.94 ; Apo structure of Class A beta-lactamase Toho-1 E166A/R274N/R276N triple mutant 2ZQ8 ; 1.03 ; Apo structure of class a beta-lactamase Toho-1 R274N/R276N double mutant 1ZMO ; 2 ; Apo structure of haloalcohol dehalogenase HheA of Arthrobacter sp. AD2 1PW2 ; 1.95 ; APO STRUCTURE OF HUMAN CYCLIN-DEPENDENT KINASE 2 3HGW ; 2.25 ; Apo Structure of Pseudomonas aeruginosa Isochorismate-Pyruvate Lyase I87T mutant 3V7L ; 2.66 ; Apo Structure of Rat DNA polymerase beta K72E variant 2CEY ; 1.7 ; APO STRUCTURE OF SIAP 2X0O ; 2.4 ; APO STRUCTURE OF THE ALCALIGIN BIOSYNTHESIS PROTEIN C (ALCC) FROM BORDETELLA BRONCHISEPTICA 2V28 ; 1.95 ; APO STRUCTURE OF THE COLD ACTIVE PHENYLALANINE HYDROXYLASE FROM COLWELLIA PSYCHRERYTHRAEA 34H 2P6U ; 3.14 ; Apo structure of the Hel308 superfamily 2 helicase 4FN7 ; 1.25 ; Apo Structure of the Mtb enoyol CoA isomerase (Rv0632c) 3LF1 ; 2.315 ; Apo structure of The Short Chain Oxidoreductase Q9HYA2 from Pseudomonas aeruginosa PAO1 Containing an Atypical Catalytic Center 2X0D ; 2.28 ; APO STRUCTURE OF WSAF 3EQQ ; 3.2 ; Apo Toluene 2,3-Dioxygenase 2EZ2 ; 1.85 ; Apo tyrosine phenol-lyase from Citrobacter freundii at pH 8.0 2PC0 ; 1.4 ; Apo Wild-type HIV Protease in the open conformation 2RG7 ; 2.05 ; Apo- Crystal Structure of a Periplasmic Heme Binding Protein from Shigella dysenteriae 1CBI ; 2.7 ; APO-CELLULAR RETINOIC ACID BINDING PROTEIN I 1XCA ; 2.3 ; APO-CELLULAR RETINOIC ACID BINDING PROTEIN II 1SWA ; 1.9 ; APO-CORE-STREPTAVIDIN AT PH 4.5 1SWC ; 1.8 ; APO-CORE-STREPTAVIDIN AT PH 4.5 1SWB ; 1.85 ; APO-CORE-STREPTAVIDIN AT PH 7.5 1SWD ; 1.9 ; APO-CORE-STREPTAVIDIN IN COMPLEX WITH BIOTIN (TWO UNOCCUPIED BINDING SITES) AT PH 4.5 1SWE ; 2.06 ; APO-CORE-STREPTAVIDIN IN COMPLEX WITH BIOTIN AT PH 4.5 2ZYG ; 2.1 ; Apo-form of dimeric 6-phosphogluconate dehydrogenase 3FN4 ; 1.96 ; Apo-form of NAD-dependent formate dehydrogenase from bacterium Moraxella sp.C-1 in closed conformation 3NAQ ; 1.7 ; Apo-form of NAD-dependent formate dehydrogenase from higher-plant Arabidopsis thaliana 3FUT ; 1.52 ; Apo-form of T. thermophilus 16S rRNA A1518 and A1519 methyltransferase (KsgA) in space group P21212 3FUV ; 1.95 ; Apo-form of T. thermophilus 16S rRNA A1518 and A1519 methyltransferase (KsgA) in space group P43212 2NXC ; 1.59 ; Apo-form of T. thermophilus ribosomal protein L11 methyltransferase (PrmA) 2KLS ; ; Apo-form of the second Ca2+ binding domain of NCX1.4 3H7G ; 1.65 ; Apo-FR with AU ions 2Z5R ; 2.5 ; Apo-Fr with high content of Pd ions 2Z5Q ; 2.1 ; Apo-Fr with intermediate content of Pd ion 2Z5P ; 1.65 ; Apo-Fr with low content of Pd ions 3KDS ; 2.601 ; apo-FtsH crystal structure 3FI6 ; 1.8 ; apo-H49AFr with high content of Pd ions 2C9R ; 2 ; APO-H91F COPC 3GZ0 ; 1.26 ; Apo-human carbonic anhydrase II revisited: Implications of the loss of a metal in protein structure, stability and solvent network 2HAV ; 2.7 ; Apo-Human Serum Transferrin (Glycosylated) 2HAU ; 2.7 ; Apo-Human Serum Transferrin (Non-Glycosylated) 1BV4 ; 1.85 ; APO-MANNOSE-BINDING PROTEIN-C 1Q5V ; 2.3 ; Apo-NikR 2CA9 ; 2.05 ; apo-NIKR from helicobacter pylori in closed trans-conformation 1PZC ; 1.85 ; APO-PSEUDOAZURIN (METAL FREE PROTEIN) 4A10 ; 2.25 ; Apo-structure of 2-octenoyl-CoA carboxylase reductase CinF from streptomyces sp. 2BLL ; 2.3 ; APO-STRUCTURE OF THE C-TERMINAL DECARBOXYLASE DOMAIN OF ARNA 1OBQ ; 1.85 ; APOCRUSTACYANIN C1 CRYSTALS GROWN IN SPACE AND EARTH USING VAPOUR DIFFUSION GEOMETRY 1OBU ; 2 ; APOCRUSTACYANIN C1 CRYSTALS GROWN IN SPACE AND EARTH USING VAPOUR DIFFUSION GEOMETRY 1IEU ; ; APOCYTOCHROME B5, PH 6.2, 298 K, NMR, 10 STRUCTURES 1IET ; ; APOCYTOCHROME B5, PH 6.2, 298 K, NMR, MINIMIZED AVERAGE STRUCTURE 2H34 ; 2.8 ; Apoenzyme crystal structure of the tuberculosis serine/threonine kinase, PknE 3KAJ ; 2 ; Apoenzyme structure of homoglutathione synthetase from Glycine max in open conformation 3F34 ; 1.68 ; Apoferritin: complex with 2,6-diethylphenol 3F35 ; 1.92 ; Apoferritin: complex with 2,6-diethylphenol 3F37 ; 1.54 ; Apoferritin: complex with 2,6-dimethylphenol 3F38 ; 1.75 ; Apoferritin: complex with 2,6-dimethylphenol 3F36 ; 1.7 ; Apoferritin: complex with 2-isopropylphenol 3F39 ; 1.85 ; Apoferritin: complex with phenol 3F33 ; 1.7 ; Apoferritin: complex with propofol 3U90 ; 1.9 ; apoferritin: complex with SDS 2BMV ; 2.11 ; APOFLAVODOXIN FROM HELICOBACTER PYLORI 1NFO ; 2 ; APOLIPOPROTEIN E2 (APOE2, D154A MUTATION) 1BZ4 ; 1.85 ; APOLIPOPROTEIN E3 (APO-E3), TRUNCATION MUTANT 165 1NFN ; 1.8 ; APOLIPOPROTEIN E3 (APOE3) 1OR2 ; 2.5 ; APOLIPOPROTEIN E3 (APOE3) TRUNCATION MUTANT 165 1OR3 ; 1.73 ; APOLIPOPROTEIN E3 (APOE3), TRIGONAL TRUNCATION MUTANT 165 1H7I ; 1.9 ; APOLIPOPROTEIN E3 22KD FRAGMENT LYS146GLN MUTANT 1EA8 ; 1.95 ; APOLIPOPROTEIN E3 22KD FRAGMENT LYS146GLU MUTANT 1B68 ; 2 ; APOLIPOPROTEIN E4 (APOE4), 22K FRAGMENT 1GS9 ; 1.7 ; APOLIPOPROTEIN E4, 22K DOMAIN 2IZC ; 1.4 ; APOSTREPTAVIDIN PH 2.0 I222 COMPLEX 2IZA ; 1.46 ; APOSTREPTAVIDIN PH 2.00 I4122 STRUCTURE 2IZD ; 1.6 ; APOSTREPTAVIDIN PH 3.0 I222 COMPLEX 2IZE ; 1.57 ; APOSTREPTAVIDIN PH 3.08 I222 COMPLEX 2IZB ; 1.2 ; APOSTREPTAVIDIN PH 3.12 I4122 STRUCTURE 2RTA ; 1.39 ; APOSTREPTAVIDIN, PH 2.97, SPACE GROUP I4122 2RTB ; 1.5 ; APOSTREPTAVIDIN, PH 3.32, SPACE GROUP I222 2RTC ; 1.5 ; APOSTREPTAVIDIN, PH 3.60, SPACE GROUP I222 1SLF ; 1.76 ; APOSTREPTAVIDIN, PH 5.6, TWO MOLECULES OF (SO4)2 BOUND AT THE BIOTIN BINDING SITE 3N4U ; 2.2 ; app APH(2"")-IVa form II 1R4M ; 3 ; APPBP1-UBA3-NEDD8, an E1-ubiquitin-like protein complex 1R4N ; 3.6 ; APPBP1-UBA3-NEDD8, an E1-ubiquitin-like protein complex with ATP 3IUR ; 2.05 ; apPEP_D266Nx+H2H3 opened state 3IUN ; 2.4 ; apPEP_D622N opened state 3IUQ ; 2.1 ; apPEP_D622N+PP closed state 3MUN ; 2.1 ; APPEP_PEPCLOSE closed state 3MUO ; 1.95 ; APPEP_PEPCLOSE+PP closed state 3IVM ; 2.05 ; apPEP_WT+PP closed state 3IUL ; 1.95 ; apPEP_WT1 opened state 3IUJ ; 1.8 ; apPEP_WT2 opened state 3IUM ; 2.25 ; apPEP_WTX opened state 1CRY ; 3 ; APPLICATION OF AN AUTOMATIC MOLECULAR REPLACEMENT PROCEDURE TO CRYSTAL STRUCTURE OF CYTOCHROME C2 FROM RHODOPSEUDOMONAS VIRIDIS 1ULA ; 2.75 ; APPLICATION OF CRYSTALLOGRAPHIC AND MODELING METHODS IN THE DESIGN OF PURINE NUCLEOSIDE PHOSPHORYLASE INHIBITORS 1ULB ; 2.75 ; APPLICATION OF CRYSTALLOGRAPHIC AND MODELING METHODS IN THE DESIGN OF PURINE NUCLEOSIDE PHOSPHORYLASE INHIBITORS 3ED8 ; 2.7 ; Application of the superfolder YFP bimolecular fluorescence complementation for studying protein-protein interactions in vitro 3KT9 ; 1.65 ; Aprataxin FHA Domain 3U1J ; 1.8 ; Aprotinin bound to Dengue virus protease 1XNJ ; 1.98 ; APS complex of human PAPS synthetase 1 2JC5 ; 1.5 ; APURINIC APYRIMIDINIC (AP) ENDONUCLEASE (NAPE) FROM NEISSERIA MENINGITIDIS 1A9G ; ; APURINIC DNA WITH BOUND WATER AT THE DAMAGED SITE AND N3 OF CYTOSINE, BETA FORM, NMR, 1 STRUCTURE 1A9H ; ; APURINIC DNA WITH BOUND WATER AT THE DAMAGED SITE AND O2 OF CYTOSINE, BETA FORM, NMR, 1 STRUCTURE 1A9I ; ; APYRIMIDINIC DNA WITH BOUND WATER AT THE DAMAGED SITE, ALPHA FORM, NMR, 1 STRUCTURE 1A9J ; ; APYRIMIDINIC DNA WITH BOUND WATER AT THE DAMAGED SITE, BETA FORM, NMR, 1 STRUCTURE 4DZT ; 1.95 ; Aqualysin I: the crystal structure of a serine protease from an extreme thermophile, Thermus aquaticus YT-1 3LLQ ; 2.01 ; Aquaporin structure from plant pathogen Agrobacterium Tumerfaciens 1SOR ; 3 ; Aquaporin-0 membrane junctions reveal the structure of a closed water pore 1Z0Q ; ; Aqueous Solution Structure of the Alzheimer's Disease Abeta Peptide (1-42) 1TZ7 ; 2.15 ; Aquifex aeolicus amylomaltase 2R6R ; 1.7 ; Aquifex aeolicus FtsZ 2R75 ; 1.402 ; Aquifex aeolicus FtsZ with 8-morpholino-GTP 2VF3 ; 2.2 ; AQUIFEX AEOLICUS ISPE IN COMPLEX WITH LIGAND 1FX6 ; 2.06 ; AQUIFEX AEOLICUS KDO8P SYNTHASE 1LRN ; 2.1 ; Aquifex aeolicus KDO8P synthase H185G mutant in complex with Cadmium 1LRO ; 1.8 ; Aquifex aeolicus KDO8P synthase H185G mutant in complex with PEP and Cadmium 1LRQ ; 1.8 ; Aquifex aeolicus KDO8P synthase H185G mutant in complex with PEP, A5P and Cadmium 1JCX ; 1.8 ; Aquifex aeolicus KDO8P synthase in complex with API and Cadmium 1FXP ; 1.8 ; AQUIFEX AEOLICUS KDO8P SYNTHASE IN COMPLEX WITH CADMIUM 1FY6 ; 1.89 ; AQUIFEX AEOLICUS KDO8P SYNTHASE IN COMPLEX WITH CADMIUM AND A5P 1FWN ; 1.94 ; AQUIFEX AEOLICUS KDO8P SYNTHASE IN COMPLEX WITH PEP 1FXQ ; 1.8 ; AQUIFEX AEOLICUS KDO8P SYNTHASE IN COMPLEX WITH PEP AND A5P 1FWS ; 1.9 ; AQUIFEX AEOLICUS KDO8P SYNTHASE IN COMPLEX WITH PEP AND CADMIUM 1FWW ; 1.85 ; AQUIFEX AEOLICUS KDO8P SYNTHASE IN COMPLEX WITH PEP, A5P AND CADMIUM 1FWT ; 1.9 ; AQUIFEX AEOLICUS KDO8P SYNTHASE IN COMPLEX WITH PEP, E4P AND CADMIUM 1JCY ; 1.9 ; Aquifex aeolicus KDO8P synthase in complex with R5P, PEP and Cadmium 1PE1 ; 1.74 ; Aquifex aeolicus KDO8PS in complex with cadmium and 2-PGA 1PCW ; 1.85 ; Aquifex aeolicus KDO8PS in complex with cadmium and APP, a bisubstrate inhibitor 2A2I ; 1.95 ; Aquifex aeolicus KDO8PS in complex with PEP, A5P, Zn2+ 2A21 ; 1.8 ; Aquifex aeolicus KDO8PS in complex with PEP, PO4, and Zn2+ 1PCK ; 1.8 ; Aquifex aeolicus KDO8PS in complex with Z-methyl-PEP 1ZJI ; 2.25 ; Aquifex aeolicus KDO8PS R106G mutant in complex with 2PGA and R5P 3SWG ; 1.81 ; AQUIFEX AEOLICUS MurA in complex with UDP-N-acetylmuramic acid and covalent adduct of PEP with Cys124 3NO0 ; 1.3004 ; Aquifex aeolicus type IIA topoisomerase C-terminal domain 2XKI ; 1.3 ; AQUO-MET STRUCTURE OF C.LACTEUS MINI-HB 4FWZ ; 1.9 ; Aquoferric CuB myoglobin (L29H F43H sperm whale myoglobin) 4FWX ; 1.9 ; Aquoferric F33Y CuB myoglobin (F33Y L29H F43H sperm whale myoglobin) 4F6B ; 1.64 ; Aquomet structure of His100Phe Cerebratulus lacteus mini-hemoglobin 4F6G ; 1.64 ; Aquomet Structure of His100Trp Cerebratulus lacteus mini-hemoglobin 1A6K ; 1.1 ; AQUOMET-MYOGLOBIN, ATOMIC RESOLUTION 2PIX ; 2.4 ; AR LBD with small molecule 2QPY ; 2.5 ; AR LBD with small molecule 3BTR ; 2.6 ; AR-NLS:Importin-alpha complex 2LOU ; ; AR55 solubilised in DPC micelles 2LOV ; ; AR55 solubilised in LPPG micelles 2LOT ; ; AR55 solubilised in SDS micelles 4G01 ; 2.2 ; ARA7-GDP-Ca2+/VPS9a 2EFC ; 2.09 ; Ara7-GDP/AtVps9a 2EFH ; 2.1 ; Ara7-GDP/AtVps9a(D185N) 2EFE ; 2.08 ; Ara7-GDPNH2/AtVps9a 2EFD ; 3 ; Ara7/AtVps9a 2EBI ; ; Arabidopsis GT-1 DNA-binding domain with T133D phosphomimetic mutation 3T4O ; 1.75 ; Arabidopsis histidine kinase 4 sensor domain in complex with dihydrozeatin 3T4S ; 1.6 ; Arabidopsis histidine kinase 4 sensor domain in complex with kinetin 3T4K ; 1.77 ; Arabidopsis histidine kinase 4 sensor domain in complex with N-benzyladenine 3T4J ; 1.65 ; Arabidopsis histidine kinase 4 sensor domain in complex with N-isopentenyl adenine 3T4T ; 1.7 ; Arabidopsis histidine kinase 4 sensor domain in complex with thiadiazuron 3T4L ; 1.53 ; Arabidopsis histidine kinase 4 sensor domain in complex with trans-zeatin 3T4Q ; 2.3 ; Arabidopsis histidine kinase 4 sensor domain in complex with trans-zeatin riboside (hydrolysed) 3E9Y ; 3 ; Arabidopsis thaliana acetohydroxyacid synthase in complex with monosulfuron 3EA4 ; 2.8 ; Arabidopsis thaliana acetohydroxyacid synthase in complex with monosulfuron-ester 1W07 ; 2 ; ARABIDOPSIS THALIANA ACYL-COA OXIDASE 1 3T34 ; 2.405 ; Arabidopsis thaliana dynamin-related protein 1A (AtDRP1A) in prefission state 3T35 ; 3.592 ; Arabidopsis thaliana dynamin-related protein 1A in postfission state 2IX4 ; 1.95 ; ARABIDOPSIS THALIANA MITOCHONDRIAL BETA-KETOACYL ACP SYNTHASE HEXANOIC ACID COMPLEX 1W0I ; 2.1 ; ARABIDOPSIS THALIANA MITOCHONDRIAL KAS 2WTB ; 2.5 ; ARABIDOPSIS THALIANA MULTIFUCTIONAL PROTEIN, MFP2 1PA2 ; 1.45 ; ARABIDOPSIS THALIANA PEROXIDASE A2 1QO4 ; 3 ; ARABIDOPSIS THALIANA PEROXIDASE A2 AT ROOM TEMPERATURE 1QGJ ; 1.9 ; ARABIDOPSIS THALIANA PEROXIDASE N 1VOK ; 2.1 ; ARABIDOPSIS THALIANA TBP (DIMER) 1BDV ; 2.8 ; ARC FV10 COCRYSTAL 1BAZ ; 1.9 ; ARC REPRESSOR MUTANT PHE10VAL 1B28 ; ; ARC REPRESSOR MYL MUTANT FROM SALMONELLA BACTERIOPHAGE P22 2LX0 ; ; Arced helix (ArcH) NMR structure of the reovirus p14 fusion-associated small transmembrane (FAST) protein transmembrane domain (TMD) in dodecyl phosphocholine (DPC) micelles 1AVB ; 1.9 ; ARCELIN-1 FROM PHASEOLUS VULGARIS L 1IOA ; 2.7 ; ARCELIN-5, A LECTIN-LIKE DEFENSE PROTEIN FROM PHASEOLUS VULGARIS 2OX1 ; 2.33 ; Archaeal Dehydroquinase 2ZJ2 ; 2.4 ; Archaeal DNA helicase Hjm apo state in form 1 2ZJ8 ; 2 ; Archaeal DNA helicase Hjm apo state in form 2 2ZJ5 ; 2.4 ; Archaeal DNA helicase Hjm complexed with ADP in form 1 2ZJA ; 2.7 ; Archaeal DNA helicase Hjm complexed with AMPPCP in form 2 4BA2 ; 2.501 ; Archaeal exosome (Rrp4-Rrp41(D182A)-Rrp42) bound to inorganic phosphate 4BA1 ; 1.8 ; Archaeal exosome (Rrp4-Rrp41(D182A)-Rrp42) bound to inorganic phosphate 2BA0 ; 2.7 ; Archaeal exosome core 2BA1 ; 2.7 ; Archaeal exosome core 1OK4 ; 2.1 ; ARCHAEAL FRUCTOSE 1,6-BISPHOSPHATE ALDOLASE COVALENTLY BOUND TO THE SUBSTRATE DIHYDROXYACETONE PHOSPHATE 1JT8 ; ; ARCHAEAL INITIATION FACTOR-1A, AIF-1A 3E54 ; 2.5 ; Archaeal Intron-encoded Homing Endonuclease I-Vdi141I Complexed With DNA 3AII ; 1.65 ; Archaeal non-discriminating glutamyl-tRNA synthetase from Methanothermobacter thermautotrophicus 3VMF ; 2.3 ; Archaeal protein 2PMZ ; 3.4 ; Archaeal RNA polymerase from Sulfolobus solfataricus 4B1O ; 4.323 ; Archaeal RNAP-DNA binary complex at 4.32Ang 4B1P ; 4.323 ; Archaeal RNAP-DNA binary complex at 4.32Ang 3ODM ; 2.95 ; Archaeal-type phosphoenolpyruvate carboxylase 4II7 ; 3.59 ; Archaellum Assembly ATPase FlaI 4IHQ ; 2 ; Archaellum Assembly ATPase FlaI bound to ADP 3NE2 ; 3 ; Archaeoglobus fulgidus aquaporin 3M7N ; 2.4 ; archaeoglobus fulgidus exosome with RNA bound to the active site 3M85 ; 3 ; Archaeoglobus fulgidus exosome y70a with RNA bound to the active site 1I0S ; 1.65 ; ARCHAEOGLOBUS FULGIDUS FERRIC REDUCTASE COMPLEX WITH NADP+ 3O8W ; 2.28 ; Archaeoglobus fulgidus GlnK1 1GL9 ; 3.2 ; ARCHAEOGLOBUS FULGIDUS REVERSE GYRASE COMPLEXED WITH ADPNP 4AF1 ; 2 ; Archeal Release Factor aRF1 3BG0 ; 3.15 ; Architecture of a Coat for the Nuclear Pore Membrane 3BG1 ; 3 ; Architecture of a Coat for the Nuclear Pore Membrane 2CF2 ; 4.3 ; ARCHITECTURE OF MAMMALIAN FATTY ACID SYNTHASE 3SOH ; 3.5 ; Architecture of the Flagellar Rotor 3RJ1 ; 4.3 ; Architecture of the Mediator Head module 1S5L ; 3.5 ; Architecture of the photosynthetic oxygen evolving center 2CDH ; 4.2 ; ARCHITECTURE OF THE THERMOMYCES LANUGINOSUS FUNGAL FATTY ACID SYNTHASE AT 5 ANGSTROM RESOLUTION. 4B6W ; 2.35 ; Architecture of Trypanosoma brucei Tubulin-Binding cofactor B 1GLN ; 2.5 ; ARCHITECTURES OF CLASS-DEFINING AND SPECIFIC DOMAINS OF GLUTAMYL-TRNA SYNTHETASE 2WJ9 ; 1.62 ; ARDB 1JQU ; 2.6 ; Are Carboxy Terminii of Helices Coded by the Local Sequence or by Tertiary Structure Contacts 1LLH ; 1.8 ; ARE CARBOXY TERMINII OF HELICES CODED BY THE LOCAL SEQUENCE OR BY TERTIARY STRUCTURE CONTACTS 1S9D ; 1.8 ; ARF1[DELTA 1-17]-GDP-MG IN COMPLEX WITH BREFELDIN A AND A SEC7 DOMAIN 1R8S ; 1.46 ; ARF1[DELTA1-17]-GDP IN COMPLEX WITH A SEC7 DOMAIN CARRYING THE MUTATION OF THE CATALYTIC GLUTAMATE TO LYSINE 2OLM ; 1.48 ; ArfGap domain of HIV-1 Rev binding protein 1ARJ ; ; ARG-BOUND TAR RNA, NMR 2PLZ ; 1.36 ; Arg-modified human beta-defensin 1 (HBD1) 1U85 ; ; ARG326-TRP mutant of the third zinc finger of BKLF 2ONN ; 2.75 ; Arg475Gln Mutant of Human Mitochondrial Aldehyde Dehydrogenase, Apo form 2ONP ; 2 ; Arg475Gln Mutant of Human Mitochondrial Aldehyde Dehydrogenase, complexed with NAD+ 2ONO ; 2.15 ; Arg475Gln Mutant of Mitochondrial Aldehyde Dehydrogenase, apo form, pseudo-merohedrally twinned 1G3Y ; 2.8 ; ARG80ALA DTXR 3CEV ; 2.4 ; ARGINASE FROM BACILLUS CALDEVELOX, COMPLEXED WITH L-ARGININE 5CEV ; 2.5 ; ARGINASE FROM BACILLUS CALDEVELOX, L-LYSINE COMPLEX 4CEV ; 2.7 ; ARGINASE FROM BACILLUS CALDEVELOX, L-ORNITHINE COMPLEX 2CEV ; 2.15 ; ARGINASE FROM BACILLUS CALDEVELOX, NATIVE STRUCTURE AT PH 8.5 1CEV ; 2.4 ; ARGINASE FROM BACILLUS CALDOVELOX, NATIVE STRUCTURE AT PH 5.6 2ZAV ; 1.7 ; Arginase I (homo sapiens): native and unliganded structure at 1.70 A resolution 1ZPE ; 1.7 ; Arginase I covalently modified with butylamine at Q19C 1ZPG ; 1.9 ; Arginase I covalently modified with propylamine at Q19C 1T5F ; 2.2 ; arginase I-AOH complex 2A0M ; 1.603 ; Arginase superfamily protein from Trypanosoma cruzi 1T4P ; 2.6 ; Arginase-dehydro-ABH complex 1T4R ; 2.6 ; arginase-descarboxy-nor-NOHA complex 1T4T ; 2.2 ; arginase-dinor-NOHA complex 1T5G ; 2.4 ; Arginase-F2-L-Arginine complex 1T4S ; 2.8 ; arginase-L-valine complex 1NND ; 2.3 ; Arginine 116 is Essential for Nucleic Acid Recognition by the Fingers Domain of Moloney Murine Leukemia Virus Reverse Transcriptase 1ACM ; 2.8 ; ARGININE 54 IN THE ACTIVE SITE OF ESCHERICHIA COLI ASPARTATE TRANSCARBAMOYLASE IS CRITICAL FOR CATALYSIS: A SITE-SPECIFIC MUTAGENESIS, NMR AND X-RAY CRYSTALLOGRAPHY STUDY 2BUF ; 2.95 ; ARGININE FEED-BACK INHIBITABLE ACETYLGLUTAMATE KINASE 1XIM ; 2.2 ; ARGININE RESIDUES AS STABILIZING ELEMENTS IN PROTEINS 2XIM ; 2.3 ; ARGININE RESIDUES AS STABILIZING ELEMENTS IN PROTEINS 3XIM ; 2.3 ; ARGININE RESIDUES AS STABILIZING ELEMENTS IN PROTEINS 3VPC ; 1.87 ; ArgX from Sulfolobus tokodaii complexed with ADP 3VPB ; 1.8 ; ArgX from Sulfolobus tokodaii complexed with LysW/Glu/ADP/Mg/Zn/Sulfate 1GV7 ; 2.1 ; ARH-I, AN ANGIOGENIN/RNASE A CHIMERA 1UN5 ; 2.6 ; ARH-II, AN ANGIOGENIN/RNASE A CHIMERA 2P0H ; 1.9 ; ArhGAP9 PH domain in complex with Ins(1,3,4)P3 2P0F ; 1.91 ; ArhGAP9 PH domain in complex with Ins(1,3,5)P3 2P0D ; 1.811 ; ArhGAP9 PH domain in complex with Ins(1,4,5)P3 1DGP ; 2.8 ; ARISTOLOCHENE SYNTHASE FARNESOL COMPLEX 2OA6 ; 2.15 ; Aristolochene synthase from Aspergillus terreus complexed with pyrophosphate 1AY8 ; 2.3 ; AROMATIC AMINO ACID AMINOTRANSFERASE COMPLEX WITH 3-PHENYLPROPIONATE 1AY5 ; 2.5 ; AROMATIC AMINO ACID AMINOTRANSFERASE COMPLEX WITH MALEATE 2AY3 ; 2.4 ; AROMATIC AMINO ACID AMINOTRANSFERASE WITH 3-(3,4-DIMETHOXYPHENYL)PROPIONIC ACID 2AY4 ; 2.2 ; AROMATIC AMINO ACID AMINOTRANSFERASE WITH 3-(P-TOLYL)PROPIONIC ACID 2AY6 ; 2.2 ; AROMATIC AMINO ACID AMINOTRANSFERASE WITH 3-INDOLEBUTYRIC ACID 2AY5 ; 2.4 ; AROMATIC AMINO ACID AMINOTRANSFERASE WITH 3-INDOLEPROPIONIC ACID 2AY8 ; 2.2 ; AROMATIC AMINO ACID AMINOTRANSFERASE WITH 4-(2-THIENYL)BUTYRIC ACID 2AY1 ; 2.2 ; AROMATIC AMINO ACID AMINOTRANSFERASE WITH 4-AMINOHYDROCINNAMIC ACID 2AY7 ; 2.4 ; AROMATIC AMINO ACID AMINOTRANSFERASE WITH 4-PHENYLBUTYRIC ACID 2AY9 ; 2.5 ; AROMATIC AMINO ACID AMINOTRANSFERASE WITH 5-PHENYLVALERIC ACID 2AY2 ; 2.4 ; AROMATIC AMINO ACID AMINOTRANSFERASE WITH CYCLOHEXANE PROPIONIC ACID 1AY4 ; 2.33 ; AROMATIC AMINO ACID AMINOTRANSFERASE WITHOUT SUBSTRATE 3A4J ; 1.25 ; arPTE (K185R/D208G/N265D/T274N) 3PO2 ; 3.3 ; Arrested RNA Polymerase II elongation complex 3PO3 ; 3.3 ; Arrested RNA Polymerase II reactivation intermediate 1AYR ; 3.3 ; ARRESTIN FROM BOVINE ROD OUTER SEGMENTS 1CF1 ; 2.8 ; ARRESTIN FROM BOVINE ROD OUTER SEGMENTS 1VQX ; ; ARRESTIN-BOUND NMR STRUCTURES OF THE PHOSPHORYLATED CARBOXY-TERMINAL DOMAIN OF RHODOPSIN, REFINED 1RXE ; 1.7 ; ArsC complexed with MNB 2FXI ; 1.8 ; Arsenate reductase (ArsC from pI258) C10S/C15A double mutant with sulfate in its active site 1JZW ; 1.76 ; Arsenate Reductase + Sodium Arsenate From E. coli 1SD9 ; 1.65 ; ARSENATE REDUCTASE C12S MUTANT +0.4M ARSENATE FROM E. COLI 1S3C ; 1.25 ; ARSENATE REDUCTASE C12S MUTANT FROM E. COLI 1I9D ; 1.65 ; ARSENATE REDUCTASE FROM E. COLI 3F0I ; 1.88 ; Arsenate reductase from Vibrio cholerae. 1SK2 ; 1.54 ; ARSENATE REDUCTASE R60A MUTANT +0.4M ARSENATE FROM E. COLI 1SK0 ; 1.8 ; ARSENATE REDUCTASE R60A MUTANT +0.4M ARSENITE FROM E. COLI 1S3D ; 1.54 ; ARSENATE REDUCTASE R60A MUTANT FROM E. COLI 1SK1 ; 1.55 ; ARSENATE REDUCTASE R60K MUTANT +0.4M ARSENATE FROM E. COLI 1SJZ ; 1.8 ; ARSENATE REDUCTASE R60K MUTANT +0.4M ARSENITE FROM E. COLI 1SD8 ; 1.59 ; ARSENATE REDUCTASE R60K MUTANT FROM E. COLI 1J9B ; 1.26 ; ARSENATE REDUCTASE+0.4M ARSENITE FROM E. COLI 3ENZ ; 2.03 ; Arsenolytic structure of Plasmodium falciparum purine nucleoside phosphorylase with hypoxanthine, ribose and arsenate ion 4FSD ; 1.75 ; ArsM arsenic(III) S-adenosylmethionine methyltransferase with As(III) 4FR0 ; 2.75 ; ArsM arsenic(III) S-adenosylmethionine methyltransferase with SAM 2K4J ; ; ArsR DNA Binding Domain 2OQG ; 1.54 ; ArsR-like Transcriptional Regulator from Rhodococcus sp. RHA1 3VSR ; 2 ; Arthrobacter sp. K-1 beta-fructofuranosidase 3VSS ; 1.97 ; Arthrobacter sp. K-1 beta-fructofuranosidase complexed with fructose 1BQX ; ; ARTIFICIAL FE8S8 FERREDOXIN: THE D13C VARIANT OF BACILLUS SCHLEGELII FE7S8 FERREDOXIN 1BWE ; ; ARTIFICIAL FE8S8 FERREDOXIN: THE D13C VARIANT OF BACILLUS SCHLEGELII FE7S8 FERREDOXIN 1A3O ; 1.8 ; ARTIFICIAL MUTANT (ALPHA Y42H) OF DEOXY HEMOGLOBIN 3PK2 ; 1.9 ; Artificial Transfer Hydrogenases for the Enantioselective Reduction of Cyclic Imines 1N95 ; 2.3 ; Aryl Tetrahydrophyridine Inhbitors of Farnesyltranferase: Glycine, Phenylalanine and Histidine Derivatives 1N94 ; 3.5 ; Aryl Tetrahydropyridine Inhbitors of Farnesyltransferase: Glycine, Phenylalanine and Histidine Derivates 1E2T ; 2.8 ; ARYLAMINE N-ACETYLTRANSFERASE (NAT) FROM SALMONELLA TYPHIMURIUM 1W6F ; 2.1 ; ARYLAMINE N-ACETYLTRANSFERASE FROM MYCOBACTERIUM SMEGMATIS WITH THE ANTI-TUBERCULAR DRUG ISONIAZID BOUND IN THE ACTIVE SITE. 1HDH ; 1.3 ; ARYLSULFATASE FROM PSEUDOMONAS AERUGINOSA 1W9M ; 1.35 ; AS-ISOLATED HYBRID CLUSTER PROTEIN FROM DESULFOVIBRIO VULGARIS X-RAY STRUCTURE AT 1.35A RESOLUTION USING IRON ANOMALOUS SIGNAL 3KM2 ; 3.1 ; As-isolated TOMATO CHLOROPLAST SUPEROXIDE DISMUTASE 1VPT ; 1.8 ; AS11 VARIANT OF VACCINIA VIRUS PROTEIN VP39 IN COMPLEX WITH S-ADENOSYL-L-METHIONINE 2X3B ; 2.28 ; ASAP1 INACTIVE MUTANT E294A, AN EXTRACELLULAR TOXIC ZINC METALLOENDOPEPTIDASE 2X3A ; 2 ; ASAP1 INACTIVE MUTANT E294Q, AN EXTRACELLULAR TOXIC ZINC METALLOENDOPEPTIDASE 2X3C ; 1.99 ; ASAP1 INACTIVE MUTANT E294Q, AN EXTRACELLULAR TOXIC ZINC METALLOENDOPEPTIDASE 3FJU ; 1.6 ; Ascaris suum carboxypeptidase inhibitor in complex with human carboxypeptidase A1 1OAF ; 1.4 ; ASCOBATE PEROXIDASE FROM SOYBEAN CYTOSOL IN COMPLEX WITH ASCORBATE 1V0H ; 1.46 ; ASCOBATE PEROXIDASE FROM SOYBEAN CYTOSOL IN COMPLEX WITH SALICYLHYDROXAMIC ACID 2YDG ; 2 ; ASCORBATE CO-CRYSTALLIZED HEWL. 2WD4 ; 1.4 ; ASCORBATE PEROXIDASE AS A HEME OXYGENASE: W41A VARIANT PRODUCT WITH T-BUTYL PEROXIDE 1OAG ; 1.75 ; ASCORBATE PEROXIDASE FROM SOYBEAN CYTOSOL 2CL4 ; 1.8 ; ASCORBATE PEROXIDASE R172A MUTANT 2Y6A ; 2 ; ASCORBATE PEROXIDASE R38A MUTANT 2Y6B ; 1.9 ; ASCORBATE PEROXIDASE R38K MUTANT 3ZCG ; 1.491 ; Ascorbate peroxidase W41A-H42C mutant 3ZCH ; 2 ; Ascorbate peroxidase W41A-H42M mutant 3ZCY ; 2 ; Ascorbate peroxidase W41A-H42Y mutant 2L7P ; ; ASHH2 a CW domain 2F4T ; 3 ; Asite RNA + designer antibiotic 2F4U ; 2.6 ; Asite RNA + designer antibiotic 1XNL ; ; ASLV fusion peptide 1SGN ; 1.8 ; ASN 18 VARIANT OF TURKEY OVOMUCOID INHIBITOR THIRD DOMAIN COMPLEXED WITH STREPTOMYCES GRISEUS PROTEINASE B 2ZGD ; 1.9 ; Asn-hydroxylation stabilises the ankyrin repeat domain fold 2ZGG ; 2 ; Asn-hydroxylation stabilises the ankyrin repeat domain fold 2OGY ; 2.3 ; Asn199Ala Mutant of the 5-methyltetrahydrofolate corrinoid/iron sulfur protein methyltransferase complexed with methyltetrahydrofolate to 2.3 Angstrom resolution 2SGD ; 1.8 ; ASP 18 VARIANT OF TURKEY OVOMUCOID INHIBITOR THIRD DOMAIN COMPLEXED WITH STREPTOMYCES GRISEUS PROTEINASE B AT PH 10.7 1SGD ; 1.8 ; ASP 18 VARIANT OF TURKEY OVOMUCOID INHIBITOR THIRD DOMAIN COMPLEXED WITH STREPTOMYCES GRISEUS PROTEINASE B AT PH 6.5 1EKS ; 2.5 ; ASP128ALA VARIANT OF MOAC PROTEIN FROM E. COLI 3S1F ; 2 ; Asp169Glu mutant of maize cytokinin oxidase/dehydrogenase complexed with N6-isopentenyladenine 1DZN ; 2.8 ; ASP170SER MUTANT OF VANILLYL-ALCOHOL OXIDASE 2BWT ; 2.9 ; ASP260ALA ESCHERICHIA COLI AMINOPEPTIDASE P 2BWU ; 2.2 ; ASP271ALA ESCHERICHIA COLI AMINOPEPTIDASE P 3PGR ; 2.6 ; Asp348Arg mutant of EcFadL 1C99 ; ; ASP61 DEPROTONATED FORM OF SUBUNIT C OF THE F1FO ATP SYNTHASE OF ESCHERICHIA COLI 2CF7 ; 1.5 ; ASP74ALA MUTANT CRYSTAL STRUCTURE FOR DPS-LIKE PEROXIDE RESISTANCE PROTEIN DPR FROM STREPTOCOCCUS SUIS. 1YNV ; 1.2 ; Asp79 makes a large, unfavorable contribution to the stability of RNase Sa 2E2A ; 2.1 ; ASP81LEU ENZYME IIA FROM THE LACTOSE SPECIFIC PTS FROM LACTOCOCCUS LACTIS 4ECA ; 2.2 ; ASPARAGINASE FROM E. COLI, MUTANT T89V WITH COVALENTLY BOUND ASPARTATE 1HFJ ; 2.4 ; ASPARAGINASE FROM ERWINIA CHRYSANTHEMI, HEXAGONAL FORM WITH SULFATE 1HFK ; 2.17 ; ASPARAGINASE FROM ERWINIA CHRYSANTHEMI, HEXAGONAL FORM WITH WEAK SULFATE 11AS ; 2.5 ; ASPARAGINE SYNTHETASE MUTANT C51A, C315A COMPLEXED WITH L-ASPARAGINE 12AS ; 2.2 ; ASPARAGINE SYNTHETASE MUTANT C51A, C315A COMPLEXED WITH L-ASPARAGINE AND AMP 2XTI ; 2.4 ; ASPARAGINYL-TRNA SYNTHETASE FROM BRUGIA MALAYI COMPLEXED WITH ATP:MG AND L-ASP-BETA-NOH ADENYLATE:PPI:MG 2XGT ; 1.9 ; ASPARAGINYL-TRNA SYNTHETASE FROM BRUGIA MALAYI COMPLEXED WITH THE SULPHAMOYL ANALOGUE OF ASPARAGINYL-ADENYLATE 1CQ7 ; 2.4 ; ASPARTATE AMINOTRANSFERASE (E.C. 2.6.1.1) COMPLEXED WITH C5-PYRIDOXAL-5P-PHOSPHATE 1CQ8 ; 2.4 ; ASPARTATE AMINOTRANSFERASE (E.C. 2.6.1.1) COMPLEXED WITH C6-PYRIDOXAL-5P-PHOSPHATE 1G4X ; 2.2 ; ASPARTATE AMINOTRANSFERASE ACTIVE SITE MUTANT N194A/R292L 1G7X ; 2.2 ; ASPARTATE AMINOTRANSFERASE ACTIVE SITE MUTANT N194A/R292L/R386L 1G7W ; 2.2 ; ASPARTATE AMINOTRANSFERASE ACTIVE SITE MUTANT N194A/R386L 1G4V ; 2 ; ASPARTATE AMINOTRANSFERASE ACTIVE SITE MUTANT N194A/Y225F 1IX6 ; 2.2 ; Aspartate Aminotransferase Active Site Mutant V39F 1IX7 ; 2.2 ; Aspartate Aminotransferase Active Site Mutant V39F maleate complex 1IX8 ; 2.2 ; Aspartate Aminotransferase Active Site Mutant V39F/N194A 1CQ6 ; 2.7 ; ASPARTATE AMINOTRANSFERASE COMPLEX WITH C4-PYRIDOXAL-5P-PHOSPHATE 1C9C ; 2.4 ; ASPARTATE AMINOTRANSFERASE COMPLEXED WITH C3-PYRIDOXAL-5'-PHOSPHATE 5EAA ; 2.4 ; ASPARTATE AMINOTRANSFERASE FROM E. COLI, C191S MUTATION 1B4X ; 2.45 ; ASPARTATE AMINOTRANSFERASE FROM E. COLI, C191S MUTATION, WITH BOUND MALEATE 1QIS ; 1.9 ; ASPARTATE AMINOTRANSFERASE FROM ESCHERICHIA COLI, C191F MUTATION, WITH BOUND MALEATE 1QIT ; 1.9 ; ASPARTATE AMINOTRANSFERASE FROM ESCHERICHIA COLI, C191W MUTATION, WITH BOUND MALEATE 1QIR ; 2.2 ; ASPARTATE AMINOTRANSFERASE FROM ESCHERICHIA COLI, C191Y MUTATION, WITH BOUND MALEATE 1J32 ; 2.1 ; Aspartate Aminotransferase from Phormidium lapideum 1YAA ; 2.05 ; ASPARTATE AMINOTRANSFERASE FROM SACCHAROMYCES CEREVISIAE CYTOPLASM 1BJW ; 1.8 ; ASPARTATE AMINOTRANSFERASE FROM THERMUS THERMOPHILUS 1BKG ; 2.6 ; ASPARTATE AMINOTRANSFERASE FROM THERMUS THERMOPHILUS WITH MALEATE 1AHE ; 2.3 ; ASPARTATE AMINOTRANSFERASE HEXAMUTANT 1AHF ; 2.3 ; ASPARTATE AMINOTRANSFERASE HEXAMUTANT 1AHG ; 2.5 ; ASPARTATE AMINOTRANSFERASE HEXAMUTANT 1AHX ; 2 ; ASPARTATE AMINOTRANSFERASE HEXAMUTANT 1AHY ; 2.3 ; ASPARTATE AMINOTRANSFERASE HEXAMUTANT 1YOO ; 2.4 ; ASPARTATE AMINOTRANSFERASE MUTANT ATB17 WITH ISOVALERIC ACID 1CZC ; 2.5 ; ASPARTATE AMINOTRANSFERASE MUTANT ATB17/139S/142N WITH GLUTARIC ACID 1CZE ; 2.4 ; ASPARTATE AMINOTRANSFERASE MUTANT ATB17/139S/142N WITH SUCCINIC ACID 2D7Y ; 2.66 ; Aspartate Aminotransferase Mutant MA 2D63 ; 2.05 ; Aspartate Aminotransferase Mutant MA With Isovaleric Acid 2D61 ; 2.01 ; Aspartate Aminotransferase Mutant MA With Maleic Acid 2D66 ; 2.18 ; Aspartate Aminotransferase Mutant MAB 2D7Z ; 2.65 ; Aspartate Aminotransferase Mutant MAB Complexed with Maleic Acid 2D65 ; 2.3 ; Aspartate Aminotransferase Mutant MABC 2D64 ; 2.05 ; Aspartate Aminotransferase Mutant MABC With Isovaleric Acid 2D5Y ; 1.98 ; Aspartate Aminotransferase Mutant MC With Isovaleric Acid 3K7Y ; 2.8 ; Aspartate Aminotransferase of Plasmodium falciparum 1BQD ; 2.1 ; ASPARTATE AMINOTRANSFERASE P138A/P195A DOUBLE MUTANT 1BQA ; 2.1 ; ASPARTATE AMINOTRANSFERASE P195A MUTANT 1OXP ; 2.5 ; ASPARTATE AMINOTRANSFERASE, H-ASP COMPLEX, CLOSED CONFORMATION 1OXO ; 2.3 ; ASPARTATE AMINOTRANSFERASE, H-ASP COMPLEX, OPEN CONFORMATION 1ARG ; 2.2 ; Aspartate aminotransferase, phospho-5'-pyridoxyl aspartate complex 1ARI ; 2.3 ; Aspartate aminotransferase, W140H mutant, maleate complex 1ARH ; 2.3 ; ASPARTATE AMINOTRANSFERASE, Y225R/R386A MUTANT 1BRM ; 2.5 ; ASPARTATE BETA-SEMIALDEHYDE DEHYDROGENASE FROM ESCHERICHIA COLI 1GL3 ; 2.6 ; ASPARTATE BETA-SEMIALDEHYDE DEHYDROGENASE IN COMPLEX WITH NADP AND SUBSTRATE ANALOGUE S-METHYL CYSTEINE SULFOXIDE 1TU0 ; 2.55 ; Aspartate Transcarbamoylase Catalytic Chain Mutant E50A Complex with Phosphonoacetamide 1TUG ; 2.1 ; Aspartate Transcarbamoylase Catalytic Chain Mutant E50A Complex with Phosphonoacetamide, Malonate, and Cytidine-5-Prime-Triphosphate (CTP) 1TTH ; 2.8 ; Aspartate Transcarbamoylase Catalytic Chain Mutant Glu50Ala Complexed with N-(Phosphonacetyl-L-Aspartate) (PALA) 4FYV ; 2.0976 ; Aspartate Transcarbamoylase Complexed with dCTP 1D09 ; 2.1 ; ASPARTATE TRANSCARBAMOYLASE COMPLEXED WITH N-PHOSPHONACETYL-L-ASPARTATE (PALA) 1NBE ; 2.6 ; ASPARTATE TRANSCARBAMOYLASE REGULATORY CHAIN MUTANT (T82A) 1Q95 ; 2.46 ; Aspartate Transcarbamylase (ATCase) of Escherichia coli: A New Crystalline R State Bound to PALA, or to Product Analogues Phosphate and Citrate 1R0B ; 2.9 ; Aspartate Transcarbamylase (ATCase) of Escherichia coli: A New Crystalline R State Bound to PALA, or to Product Analogues Phosphate and Citrate 2ASI ; 2.15 ; ASPARTIC PROTEINASE 1FY2 ; 1.2 ; Aspartyl Dipeptidase 1FYE ; 1.2 ; Aspartyl Dipeptidase (Anisotropic B-Factor Refinement) 3I7F ; 2.8 ; Aspartyl tRNA synthetase from Entamoeba histolytica 1G51 ; 2.4 ; ASPARTYL TRNA SYNTHETASE FROM THERMUS THERMOPHILUS AT 2.4 A RESOLUTION 1B8A ; 1.9 ; ASPARTYL-TRNA SYNTHETASE 3NEL ; 1.954 ; Aspartyl-tRNA synthetase complexed with aspartic acid 3NEM ; 1.89 ; Aspartyl-tRNA synthetase complexed with aspartyl adenylate 1L0W ; 2.01 ; Aspartyl-tRNA synthetase-1 from space-grown crystals 1CYL ; ; ASPECTS OF RECEPTOR BINDING AND SIGNALLING OF INTERLEUKIN-4 INVESTIGATED BY SITE-DIRECTED MUTAGENESIS AND NMR SPECTROSCOPY 2CYK ; ; ASPECTS OF RECEPTOR BINDING AND SIGNALLING OF INTERLEUKIN-4 INVESTIGATED BY SITE-DIRECTED MUTAGENESIS AND NMR SPECTROSCOPY 1IBQ ; 2.14 ; ASPERGILLOPEPSIN FROM ASPERGILLUS PHOENICIS 2Z8G ; 1.7 ; Aspergillus niger ATCC9642 isopullulanase complexed with isopanose 3K4P ; 2.4 ; Aspergillus niger Phytase 3K4Q ; 2.2 ; Aspergillus niger Phytase in complex with myo-inositol hexakis sulfate 1OXR ; 1.93 ; Aspirin induces its Anti-inflammatory effects through its specific binding to Phospholipase A2: Crystal structure of the complex formed between Phospholipase A2 and Aspirin at 1.9A resolution 3TOK ; 1.74 ; Assaying the energies of biological halogen bonds. 1VDF ; 2.05 ; ASSEMBLY DOMAIN OF CARTILAGE OLIGOMERIC MATRIX PROTEIN 1FBM ; 2.7 ; ASSEMBLY DOMAIN OF CARTILAGE OLIGOMERIC MATRIX PROTEIN IN COMPLEX WITH ALL-TRANS RETINOL 4BFQ ; 2.4 ; Assembly of a triple pi-stack of ligands in the binding site of Aplysia californica acetylcholine binding protein (AChBP) 2LRM ; ; Assignment and structure of E coli periplasmic protein YmgD 2LRV ; ; Assignment of E coli periplasmic protein YmgD 2JUA ; ; Assignment, structure, and dynamics of de novo designed protein S836 1CEY ; ; ASSIGNMENTS, SECONDARY STRUCTURE, GLOBAL FOLD, AND DYNAMICS OF CHEMOTAXIS Y PROTEIN USING THREE-AND FOUR-DIMENSIONAL HETERONUCLEAR (13C,15N) NMR SPECTROSCOPY 3VM1 ; 1.5 ; assimilatory nitrite reductase (Nii3) - N226K mutant - HCO3 complex from tobacco leaf 3VLX ; 1.35 ; Assimilatory nitrite reductase (Nii3) - N226K mutant - ligand free form from tobacco leaf 3VM0 ; 1.695 ; Assimilatory nitrite reductase (Nii3) - N226K mutant - NO2 complex from tobacco leaf 3VLZ ; 2.07 ; Assimilatory nitrite reductase (Nii3) - N226K mutant - SO3 full complex from tobacco leaf 3VLY ; 1.55 ; Assimilatory nitrite reductase (Nii3) - N226K mutant - SO3 partial complex from tobacco leaf 3VKT ; 1.3 ; Assimilatory nitrite reductase (Nii3) - NH2OH complex from tobbaco leaf 3VKS ; 1.4 ; Assimilatory nitrite reductase (Nii3) - NO complex from tobbaco leaf 3VKR ; 1.6 ; Assimilatory nitrite reductase (Nii3) - NO2 complex from tobbaco leaf analysed with high X-ray dose 3VKP ; 1.4 ; Assimilatory nitrite reductase (Nii3) - NO2 complex from tobbaco leaf analysed with low X-ray dose 3VKQ ; 1.6 ; Assimilatory nitrite reductase (Nii3) - NO2 complex from tobbaco leaf analysed with middle X-ray dose 3B0G ; 1.25 ; Assimilatory nitrite reductase (Nii3) from tobbaco leaf 3B0H ; 2.306 ; Assimilatory nitrite reductase (Nii4) from tobbaco root 2K88 ; ; Association of subunit d (Vma6p) and E (Vma4p) with G (Vma10p) and the NMR solution structure of subunit G (G1-59) of the Saccharomyces cerevisiae V1VO ATPase 3IYA ; 22 ; Association of the pr peptides with dengue virus blocks membrane fusion at acidic pH 2RMD ; ; Astressin-B 2RM9 ; ; Astressin2B 1VSK ; 2.2 ; ASV INTEGRASE CORE DOMAIN D64N MUTATION IN CITRATE BUFFER PH 6.0 1VSL ; 2.2 ; ASV INTEGRASE CORE DOMAIN D64N MUTATION WITH ZINC CATION 1VSM ; 2.15 ; ASV INTEGRASE CORE DOMAIN IN CITRATE BUFFER PH 5.0 1VSI ; 2.2 ; ASV INTEGRASE CORE DOMAIN WITH CA(II) COFACTOR 1VSJ ; 2.1 ; ASV INTEGRASE CORE DOMAIN WITH CD(II) COFACTORS 1A5W ; 2 ; ASV INTEGRASE CORE DOMAIN WITH HIV-1 INTEGRASE INHIBITOR Y3 1A5X ; 1.9 ; ASV INTEGRASE CORE DOMAIN WITH HIV-1 INTEGRASE INHIBITOR Y3 1A5V ; 1.9 ; ASV INTEGRASE CORE DOMAIN WITH HIV-1 INTEGRASE INHIBITOR Y3 AND MN CATION 1VSD ; 1.7 ; ASV INTEGRASE CORE DOMAIN WITH MG(II) COFACTOR AND HEPES LIGAND, HIGH MG CONCENTRATION FORM 1VSE ; 2.2 ; ASV INTEGRASE CORE DOMAIN WITH MG(II) COFACTOR AND HEPES LIGAND, LOW MG CONCENTRATION FORM 1VSF ; 2.05 ; ASV INTEGRASE CORE DOMAIN WITH MN(II) COFACTOR AND HEPES LIGAND, HIGH MG CONCENTRATION FORM 1VSH ; 1.95 ; ASV INTEGRASE CORE DOMAIN WITH ZN(II) COFACTORS 3G6W ; 2.9 ; Asymetric GTP bound structure of UPRTase from Sulfolobus solfataricus containing PRPP-mg2+ in half of the active sites and R5P and PPi in the other half 3QFQ ; 2.9001 ; Asymmetric Assembly of Merkel Cell Polyomavirus Large T-antigen Origin Binding Domains at the Viral Origin 1OFH ; 2.5 ; ASYMMETRIC COMPLEX BETWEEN HSLV AND I-DOMAIN DELETED HSLU (H. INFLUENZAE) 1OFI ; 3.2 ; ASYMMETRIC COMPLEX BETWEEN HSLV AND I-DOMAIN DELETED HSLU (H. INFLUENZAE) 3UCC ; 1.5 ; Asymmetric complex of human neuron specific enolase-1-PGA/PEP 3UCD ; 1.41 ; Asymmetric complex of human neuron specific enolase-2-PGA/PEP 3UJE ; 1.55 ; Asymmetric complex of human neuron specific enolase-3-PGA/PEP 3UJF ; 2.1 ; Asymmetric complex of human neuron specific enolase-4-PGA/PEP 3UJR ; 1.4 ; Asymmetric complex of human neuron specific enolase-5-PGA/PEP 3UJS ; 1.65 ; Asymmetric complex of human neuron specific enolase-6-PGA/PEP 1H6S ; 3 ; ASYMMETRIC CONDUCTIVITY OF ENGINEERED PROTEINS 4A8A ; 14.2 ; Asymmetric cryo-EM reconstruction of E. coli DegQ 12-mer in complex with lysozyme 4CRX ; 2.2 ; ASYMMETRIC DNA-BENDING IN THE CRE-LOXP SITE-SPECIFIC RECOMBINATION SYNAPSE 5CRX ; 2.7 ; ASYMMETRIC DNA-BENDING IN THE CRE-LOXP SITE-SPECIFIC RECOMBINATION SYNAPSE 2GIF ; 2.9 ; Asymmetric structure of trimeric AcrB from Escherichia coli 2HRT ; 3 ; Asymmetric structure of trimeric AcrB from Escherichia coli 2WX4 ; 2.8 ; ASYMMETRIC TRIMER OF THE DROSOPHILA MELANOGASTER DCP1 C-TERMINAL DOMAIN 2WX3 ; 2.31 ; ASYMMETRIC TRIMER OF THE HUMAN DCP1A C-TERMINAL DOMAIN 2ONE ; 2 ; ASYMMETRIC YEAST ENOLASE DIMER COMPLEXED WITH RESOLVED 2'-PHOSPHOGLYCERATE AND PHOSPHOENOLPYRUVATE 1VTW ; 1.2 ; AT Base Pairs Are Less Stable than GC Base Pairs in Z-DNA: The Crystal Structure of D(M(5)CGTAM(5)CG) 1ZFC ; 2 ; ATC Duplex B-DNA 1ZF3 ; 1.84 ; ATC Four-stranded DNA Holliday Junction 1ZF4 ; 1.65 ; ATC Four-stranded DNA Holliday Junction 9ATC ; 2.4 ; ATCASE Y165F MUTANT 3S2R ; 1.14 ; ATChloroNEET (H87C mutant) 1SAA ; ; ATF-2 RECOGNITION SITE, NMR, 10 STRUCTURES 4J2G ; 2.29 ; Atg13 HORMA domain 3T7E ; 2.25 ; Atg8 transfer from Atg7 to Atg3: a distinctive E1-E2 architecture and mechanism in the autophagy pathway 3T7F ; 1.89 ; Atg8 transfer from Atg7 to Atg3: a distinctive E1-E2 architecture and mechanism in the autophagy pathway 3T7G ; 2.08 ; Atg8 transfer from Atg7 to Atg3: a distinctive E1-E2 architecture and mechanism in the autophagy pathway 3T7H ; 1.6 ; Atg8 transfer from Atg7 to Atg3: a distinctive E1-E2 architecture and mechanism in the autophagy pathway 1SBT ; 2.5 ; ATOMIC COORDINATES FOR SUBTILISIN BPN (OR NOVO) 3IYL ; 3.3 ; Atomic CryoEM Structure of a Nonenveloped Virus Suggests How Membrane Penetration Protein is Primed for Cell Entry 2BTV ; 3.5 ; ATOMIC MODEL FOR BLUETONGUE VIRUS (BTV) CORE 2YPW ; 12.4 ; Atomic model for the N-terminus of TraO fitted in the full-length structure of the bacterial pKM101 type IV secretion system core complex 1VAS ; 2.75 ; ATOMIC MODEL OF A PYRIMIDINE DIMER SPECIFIC EXCISION REPAIR ENZYME COMPLEXED WITH A DNA SUBSTRATE: STRUCTURAL BASIS FOR DAMAGED DNA RECOGNITION 3IYU ; 3.8 ; Atomic model of an infectious rotavirus particle 3N09 ; 3.8 ; Atomic model of an infectious rotavirus particle 3KTT ; 4 ; Atomic model of bovine TRiC CCT2(beta) subunit derived from a 4.0 Angstrom cryo-EM map 2BZX ; 2.8 ; ATOMIC MODEL OF CRKL-SH3C MONOMER 3MFP ; 6.6 ; Atomic model of F-actin based on a 6.6 angstrom resolution cryoEM map 3LOS ; 4.3 ; Atomic Model of Mm-cpn in the Closed State 3J1P ; 6.5 ; Atomic model of rabbit hemorrhagic disease virus 2BGZ ; 12 ; ATOMIC MODEL OF THE BACTERIAL FLAGELLAR BASED ON DOCKING AN X-RAY DERIVED HOOK STRUCTURE INTO AN EM MAP. 3A69 ; 7.1 ; Atomic model of the bacterial flagellar hook based on docking an X-ray derived structure and terminal two alpha-helices into an 7.1 angstrom resolution cryoEM map 2Y7H ; 18 ; Atomic model of the DNA-bound methylase complex from the Type I restriction-modification enzyme EcoKI (M2S1). Based on fitting into EM map 1534. 3IYF ; 8 ; Atomic Model of the Lidless Mm-cpn in the Open State 2Y7C ; 18 ; Atomic model of the Ocr-bound methylase complex from the Type I restriction-modification enzyme EcoKI (M2S1). Based on fitting into EM map 1534. 2XKV ; 13.5 ; Atomic Model of the SRP-FtsY Early Conformation 2LPZ ; ; Atomic model of the Type-III Secretion System Needle 1HRB ; 5.5 ; ATOMIC MODELS FOR THE POLYPEPTIDE BACKBONES OF MYOHEMERYTHRIN AND HEMERYTHRIN 1CBN ; 0.83 ; ATOMIC RESOLUTION (0.83 ANGSTROMS) CRYSTAL STRUCTURE OF THE HYDROPHOBIC PROTEIN CRAMBIN AT 130 K 2VHK ; 0.94 ; ATOMIC RESOLUTION (0.94 A) STRUCTURE OF PURIFIED THAUMATIN I GROWN IN SODIUM L-TARTRATE AT 22C 2VU6 ; 0.95 ; ATOMIC RESOLUTION (0.95 A) STRUCTURE OF PURIFIED THAUMATIN I GROWN IN SODIUM MESO-TARTRATE AT 19 C. 2VHR ; 0.95 ; ATOMIC RESOLUTION (0.95A) STRUCTURE OF PURIFIED THAUMATIN I GROWN IN SODIUM L-TARTRATE AT 4 C 1VL9 ; 0.97 ; Atomic resolution (0.97A) structure of the triple mutant (K53,56,121M) of bovine pancreatic phospholipase A2 2VI3 ; 0.98 ; ATOMIC RESOLUTION (0.98 A) STRUCTURE OF PURIFIED THAUMATIN I GROWN IN SODIUM DL-TARTRATE AT 20 C 1GQV ; 0.98 ; ATOMIC RESOLUTION (0.98A) STRUCTURE OF EOSINOPHIL-DERIVED NEUROTOXIN 2VI1 ; 1.04 ; ATOMIC RESOLUTION (1.04 A) STRUCTURE OF PURIFIED THAUMATIN I GROWN IN SODIUM D-TARTRATE AT 22 C. 2VI2 ; 1.08 ; ATOMIC RESOLUTION (1.05 A) STRUCTURE OF PURIFIED THAUMATIN I GROWN IN SODIUM D-TARTRATE AT 4C 1NKD ; 1.09 ; ATOMIC RESOLUTION (1.07 ANGSTROMS) STRUCTURE OF THE ROP MUTANT <2AA> 2VU7 ; 1.08 ; ATOMIC RESOLUTION (1.08 A) STRUCTURE OF PURIFIED THAUMATIN I GROWN IN SODIUM MESO-TARTRATE AT 4 C 2VI4 ; 1.1 ; ATOMIC RESOLUTION (1.10 A) STRUCTURE OF PURIFIED THAUMATIN I GROWN IN SODIUM DL-TARTRATE AT 6 C. 1Q0E ; 1.15 ; Atomic resolution (1.15 ) crystal structure of bovine copper, zinc superoxide dismutase 1CZ9 ; 1.2 ; ATOMIC RESOLUTION ASV INTEGRASE CORE DOMAIN (D64N) FROM CITRATE 1CXQ ; 1.02 ; ATOMIC RESOLUTION ASV INTEGRASE CORE DOMAIN FROM AMMONIUM SULFATE 1CZB ; 1.06 ; ATOMIC RESOLUTION ASV INTEGRASE CORE DOMAIN FROM HEPES 1BZP ; 1.15 ; ATOMIC RESOLUTION CRYSTAL STRUCTURE ANALYSIS OF NATIVE DEOXY AND CO MYOGLOBIN FROM SPERM WHALE AT ROOM TEMPERATURE 1BZR ; 1.15 ; ATOMIC RESOLUTION CRYSTAL STRUCTURE ANALYSIS OF NATIVE DEOXY AND CO MYOGLOBIN FROM SPERM WHALE AT ROOM TEMPERATURE 1BZ6 ; 1.2 ; ATOMIC RESOLUTION CRYSTAL STRUCTURE AQUOMET-MYOGLOBIN FROM SPERM WHALE AT ROOM TEMPERATURE 1L2X ; 1.25 ; Atomic Resolution Crystal Structure of a Viral RNA Pseudoknot 2O90 ; 1.07 ; Atomic resolution crystal structure of E.coli dihydroneopterin aldolase in complex with neopterin 2V0A ; 1.15 ; ATOMIC RESOLUTION CRYSTAL STRUCTURE OF HUMAN SUPEROXIDE DISMUTASE 3U23 ; 1.11 ; Atomic resolution crystal structure of the 2nd SH3 domain from human CD2AP (CMS) in complex with a proline-rich peptide from human RIN3 2FWH ; 0.99 ; atomic resolution crystal structure of the C-terminal domain of the electron transfer catalyst DsbD (reduced form at pH7) 2WFI ; 0.75 ; ATOMIC RESOLUTION CRYSTAL STRUCTURE OF THE PPIASE DOMAIN OF HUMAN CYCLOPHILIN G 2WFJ ; 0.75 ; Atomic resolution crystal structure of the PPIase domain of human cyclophilin G in complex with cyclosporin A. 3EA6 ; 0.92 ; Atomic resolution of crystal structure of SEK 2KQ4 ; ; Atomic resolution protein structure determination by three-dimensional transferred echo double resonance solid-state nuclear magnetic resonance spectroscopy 2LGI ; ; Atomic Resolution Protein Structures using NMR Chemical Shift Tensors 4LZT ; 0.95 ; ATOMIC RESOLUTION REFINEMENT OF TRICLINIC HEW LYSOZYME AT 295K 2ZL5 ; 1.47 ; Atomic resolution structural characterization of recognition of histo-blood group antigen by Norwalk virus 2ZL6 ; 1.43 ; Atomic resolution structural characterization of recognition of histo-blood group antigens by Norwalk virus 2ZL7 ; 1.35 ; Atomic resolution structural characterization of recognition of histo-blood group antigens by Norwalk virus 1OE3 ; 1.15 ; ATOMIC RESOLUTION STRUCTURE OF 'HALF APO' NIR 1M69 ; 1.1 ; Atomic Resolution Structure of 5Br-9amino-DACA with d[CGTACG]2 2BWD ; 1.15 ; ATOMIC RESOLUTION STRUCTURE OF ACHROMOBACTER CYCLOCLASTES CU NITRITE REDUCTASE WITH ENDOGENOUSLY BOUND NITRITE AND NO 1KWF ; 0.94 ; Atomic Resolution Structure of an Inverting Glycosidase in Complex with Substrate 2HEU ; 1.04 ; Atomic resolution structure of apo-form of RafE from Streptococcus pneumoniae 1VB0 ; 0.92 ; Atomic resolution structure of atratoxin-b, one short-chain neurotoxin from Naja atra 1MXT ; 0.95 ; Atomic resolution structure of Cholesterol oxidase (Streptomyces sp. SA-COO) 1N4W ; 0.92 ; ATOMIC RESOLUTION STRUCTURE OF CHOLESTEROL OXIDASE @ pH 7.3 (STREPTOMYCES SP. SA-COO) 1N1P ; 0.95 ; ATOMIC RESOLUTION STRUCTURE OF CHOLESTEROL OXIDASE @ pH 7.4 (STREPTOMYCES SP. SA-COO) 2GEW ; 0.97 ; Atomic resolution structure of cholesterol oxidase @ pH 9.0 (Streptomyces sp. SA-COO) 1N4V ; 1 ; ATOMIC RESOLUTION STRUCTURE OF CHOLESTEROL OXIDASE @pH 5.8 (STREPTOMYCES SP. SA-COO) 1YLT ; 1.1 ; Atomic resolution structure of CTX-M-14 beta-lactamase 1YLP ; 1.2 ; Atomic resolution structure of CTX-M-27 beta-lactamase 1YLJ ; 0.98 ; Atomic resolution structure of CTX-M-9 beta-lactamase 2C9V ; 1.07 ; ATOMIC RESOLUTION STRUCTURE OF CU-ZN HUMAN SUPEROXIDE DISMUTASE 3BWH ; 1 ; Atomic resolution structure of cucurmosin, a novel type 1 RIP from the sarcocarp of Cucurbita moschata 1OE2 ; 1.12 ; ATOMIC RESOLUTION STRUCTURE OF D92E MUTANT OF ALCALIGENES XYLOSOXIDANS NITRITE REDUCTASE 1EUW ; 1.05 ; ATOMIC RESOLUTION STRUCTURE OF E. COLI DUTPASE 1OEX ; 1.1 ; ATOMIC RESOLUTION STRUCTURE OF ENDOTHIAPEPSIN IN COMPLEX WITH A HYDROXYETHYLENE TRANSITION STATE ANALOGUE INHIBITOR H261 1O7J ; 1 ; ATOMIC RESOLUTION STRUCTURE OF ERWINIA CHRYSANTHEMI L-ASPARAGINASE 2WUR ; 0.9 ; ATOMIC RESOLUTION STRUCTURE OF GFP MEASURED ON A ROTATING ANODE 1A7S ; 1.12 ; ATOMIC RESOLUTION STRUCTURE OF HBP 1GWE ; 0.88 ; ATOMIC RESOLUTION STRUCTURE OF MICROCOCCUS LYSODEIKTICUS CATALASE 1GWH ; 1.74 ; ATOMIC RESOLUTION STRUCTURE OF MICROCOCCUS LYSODEIKTICUS CATALASE COMPLEXED WITH NADPH 2V8U ; 1.05 ; ATOMIC RESOLUTION STRUCTURE OF MN CATALASE FROM THERMUS THERMOPHILUS 1OEW ; 0.9 ; ATOMIC RESOLUTION STRUCTURE OF NATIVE ENDOTHIAPEPSIN 2BWI ; 1.1 ; ATOMIC RESOLUTION STRUCTURE OF NITRITE -SOAKED ACHROMOBACTER CYCLOCLASTES CU NITRITE REDUCTASE 2BW5 ; 1.12 ; ATOMIC RESOLUTION STRUCTURE OF NO-BOUND ACHROMOBACTER CYCLOCLASTES CU NITRITE REDUCTASE 1QV0 ; 1.1 ; Atomic resolution structure of obelin from Obelia longissima 1QV1 ; 1.1 ; Atomic resolution structure of obelin from Obelia longissima 3W07 ; 1.03 ; Atomic resolution structure of orotidine 5'-monophosphate decarboxylase from Methanothermobacter thermoautotrophicus bound with UMP. 2BW4 ; 0.9 ; ATOMIC RESOLUTION STRUCTURE OF RESTING STATE OF THE ACHROMOBACTER CYCLOCLASTES CU NITRITE REDUCTASE 1KF2 ; 1.1 ; Atomic Resolution Structure of RNase A at pH 5.2 1KF3 ; 1.05 ; Atomic Resolution Structure of RNase A at pH 5.9 1KF4 ; 1.1 ; Atomic Resolution Structure of RNase A at pH 6.3 1KF5 ; 1.15 ; Atomic Resolution Structure of RNase A at pH 7.1 1KF7 ; 1.15 ; Atomic Resolution Structure of RNase A at pH 8.0 1KF8 ; 1.15 ; Atomic resolution structure of RNase A at pH 8.8 2CNQ ; 1 ; ATOMIC RESOLUTION STRUCTURE OF SAICAR-SYNTHASE FROM SACCHAROMYCES CEREVISIAE COMPLEXED WITH ADP, AICAR, SUCCINATE 2CNU ; 1.05 ; ATOMIC RESOLUTION STRUCTURE OF SAICAR-SYNTHASE FROM SACCHAROMYCES CEREVISIAE COMPLEXED WITH ASPARTIC ACID 1DJT ; 1.2 ; ATOMIC RESOLUTION STRUCTURE OF SCORPION ALPHA-LIKE TOXIN BMK M1 IN A NEW CRYSTAL FORM 1LU0 ; 1.03 ; Atomic Resolution Structure of Squash Trypsin Inhibitor: Unexpected Metal Coordination 2BF6 ; 0.97 ; ATOMIC RESOLUTION STRUCTURE OF THE BACTERIAL SIALIDASE NANI FROM CLOSTRIDIUM PERFRINGENS IN COMPLEX WITH ALPHA-SIALIC ACID (NEU5AC). 2VZP ; 1.05 ; ATOMIC RESOLUTION STRUCTURE OF THE C-TERMINAL CBM35 FROM AMYCOLATOPSIS ORIENTALIS EXO-CHITOSANASE CSXA 2JLI ; 1.13 ; ATOMIC RESOLUTION STRUCTURE OF THE CYTOPLASMIC DOMAIN OF YERSINIA PESTIS YSCU, A REGULATORY SWITCH INVOLVED IN TYPE III SECRETION 2BAX ; 1.1 ; Atomic Resolution Structure of the Double Mutant (K53,56M) of Bovine Pancreatic Phospholipase A2 1R2M ; 1 ; Atomic resolution structure of the HFBII hydrophobin: a self-assembling amphiphile 1H1N ; 1.12 ; ATOMIC RESOLUTION STRUCTURE OF THE MAJOR ENDOGLUCANASE FROM THERMOASCUS AURANTIACUS 1OE1 ; 1.04 ; ATOMIC RESOLUTION STRUCTURE OF THE WILDTYPE NATIVE NITRITE REDUCTASE FROM ALCALIGENES XYLOSOXIDANS 3PUC ; 0.96 ; Atomic resolution structure of titin domain M7 2XOM ; 0.95 ; ATOMIC RESOLUTION STRUCTURE OF TMCBM61 IN COMPLEX WITH BETA-1,4-GALACTOTRIOSE 3D1P ; 0.98 ; Atomic resolution structure of uncharacterized protein from Saccharomyces cerevisiae 3CUX ; 1.7 ; Atomic Resolution Structures of Escherichia coli and Bacillis anthracis Malate Synthase A: Comparison with Isoform G and Implications for Structure Based Drug Design 3CUZ ; 1.04 ; Atomic Resolution Structures of Escherichia coli and Bacillis anthracis Malate Synthase A: Comparison with Isoform G and Implications for Structure Based Drug Design 3CV1 ; 1.68 ; Atomic Resolution Structures of Escherichia coli and Bacillis anthracis Malate Synthase A: Comparison with Isoform G and Implications for Structure Based Drug Design 3CV2 ; 1.4 ; Atomic Resolution Structures of Escherichia coli and Bacillis anthracis Malate Synthase A: Comparison with Isoform G and Implications for Structure Based Drug Design 1HJ9 ; 0.95 ; ATOMIC RESOLUTION STRUCTURES OF TRYPSIN PROVIDE INSIGHT INTO STRUCTURAL RADIATION DAMAGE 1BBH ; 1.8 ; ATOMIC STRUCTURE OF A CYTOCHROME C' WITH AN UNUSUAL LIGAND-CONTROLLED DIMER DISSOCIATION AT 1.8 ANGSTROMS RESOLUTION 1T8Z ; 1.45 ; Atomic Structure of A Novel Tryptophan-Zipper Pentamer 1S9U ; 1.38 ; Atomic structure of a putative anaerobic dehydrogenase component 1SZT ; 2.4 ; ATOMIC STRUCTURE OF A THERMOSTABLE SUBDOMAIN OF HIV-1 GP41 2ADA ; 2.4 ; ATOMIC STRUCTURE OF ADENOSINE DEAMINASE COMPLEXED WITH A TRANSITION-STATE ANALOG: UNDERSTANDING CATALYSIS AND IMMUNODEFICIENCY MUTATIONS 3RWN ; 1 ; Atomic structure of bacteriophage sf6 tail needle knob 1N40 ; 1.06 ; Atomic structure of CYP121, a mycobacterial P450 4HRF ; 1.68 ; Atomic structure of DUSP26 1FKF ; 1.7 ; ATOMIC STRUCTURE OF FKBP-FK506, AN IMMUNOPHILIN-IMMUNOSUPPRESSANT COMPLEX 1FKK ; 2.2 ; ATOMIC STRUCTURE OF FKBP12, AN IMMUNOPHILIN BINDING PROTEIN 1FKJ ; 1.7 ; ATOMIC STRUCTURE OF FKBP12-FK506, AN IMMUNOPHILIN IMMUNOSUPPRESSANT COMPLEX 1FKL ; 1.7 ; ATOMIC STRUCTURE OF FKBP12-RAPAYMYCIN, AN IMMUNOPHILIN-IMMUNOSUPPRESSANT COMPLEX 1MNZ ; 0.99 ; Atomic structure of Glucose isomerase 2BPA ; 3 ; ATOMIC STRUCTURE OF SINGLE-STRANDED DNA BACTERIOPHAGE PHIX174 AND ITS FUNCTIONAL IMPLICATIONS 1ATN ; 2.8 ; Atomic structure of the actin:DNASE I complex 1ECM ; 2.2 ; ATOMIC STRUCTURE OF THE BURIED CATALYTIC POCKET OF ESCHERICHIA COLI CHORISMATE MUTASE 1EAA ; 2.6 ; ATOMIC STRUCTURE OF THE CUBIC CORE OF THE PYRUVATE DEHYDROGENASE MULTIENZYME COMPLEX 1EAB ; 2.6 ; ATOMIC STRUCTURE OF THE CUBIC CORE OF THE PYRUVATE DEHYDROGENASE MULTIENZYME COMPLEX 1EAC ; 2.6 ; ATOMIC STRUCTURE OF THE CUBIC CORE OF THE PYRUVATE DEHYDROGENASE MULTIENZYME COMPLEX 1EAD ; 2.6 ; ATOMIC STRUCTURE OF THE CUBIC CORE OF THE PYRUVATE DEHYDROGENASE MULTIENZYME COMPLEX 1EAE ; 2.6 ; ATOMIC STRUCTURE OF THE CUBIC CORE OF THE PYRUVATE DEHYDROGENASE MULTIENZYME COMPLEX 1EAF ; 2.6 ; ATOMIC STRUCTURE OF THE CUBIC CORE OF THE PYRUVATE DEHYDROGENASE MULTIENZYME COMPLEX 1ENV ; 2.6 ; ATOMIC STRUCTURE OF THE ECTODOMAIN FROM HIV-1 GP41 2IJ2 ; 1.2 ; Atomic structure of the heme domain of flavocytochrome P450-BM3 2ESW ; 2.01 ; Atomic structure of the N-terminal SH3 domain of mouse beta PIX,p21-activated kinase (PAK)-interacting exchange factor 1FKB ; 1.7 ; ATOMIC STRUCTURE OF THE RAPAMYCIN HUMAN IMMUNOPHILIN FKBP-12 COMPLEX 1HJR ; 2.5 ; ATOMIC STRUCTURE OF THE RUVC RESOLVASE: A HOLLIDAY JUNCTION-SPECIFIC ENDONUCLEASE FROM E. COLI 1TPS ; 1.9 ; ATOMIC STRUCTURE OF THE TRYPSIN-A90720A COMPLEX: A UNIFIED APPROACH TO STRUCTURE AND FUNCTION 1TYN ; 2 ; ATOMIC STRUCTURE OF THE TRYPSIN-CYCLOTHEONAMIDE A COMPLEX: LESSONS FOR THE DESIGN OF SERINE PROTEASE INHIBITORS 3OV5 ; 1.04 ; Atomic structure of the Xanthomonas citri VirB7 globular domain. 2NXU ; ; Atomic structure of translation initiation factor aIF2 beta-subunit from Archaebacteria sulfolobus solfataricus: high resolution NMR in solution 3FAP ; 1.85 ; ATOMIC STRUCTURES OF THE RAPAMYCIN ANALOGS IN COMPLEX WITH BOTH HUMAN FKBP12 AND FRB DOMAIN OF FRAP 4FAP ; 2.8 ; ATOMIC STRUCTURES OF THE RAPAMYCIN ANALOGS IN COMPLEX WITH BOTH HUMAN FKBP12 AND FRB DOMAIN OF FRAP 1SOS ; 2.5 ; ATOMIC STRUCTURES OF WILD-TYPE AND THERMOSTABLE MUTANT RECOMBINANT HUMAN CU, ZN SUPEROXIDE DISMUTASE 1HET ; 1.15 ; ATOMIC X-RAY STRUCTURE OF LIVER ALCOHOL DEHYDROGENASE CONTAINING A HYDROXIDE ADDUCT TO NADH 1HEU ; 1.15 ; ATOMIC X-RAY STRUCTURE OF LIVER ALCOHOL DEHYDROGENASE CONTAINING CADMIUM AND A HYDROXIDE ADDUCT TO NADH 1HF3 ; 1.95 ; ATOMIC X-RAY STRUCTURE OF LIVER ALCOHOL DEHYDROGENASE CONTAINING CADMIUM AND A HYDROXIDE ADDUCT TO NADH 1VUE ; ; Atomic-level structure of the entire HIV-1 capsid 1VUF ; ; Atomic-level structure of the entire HIV-1 capsid 1VU4 ; ; Atomic-level structure of the entire HIV-1 capsid 1VUS ; ; Atomic-level structure of the entire HIV-1 capsid 1VUT ; ; Atomic-level structure of the entire HIV-1 capsid 1VUQ ; ; Atomic-level structure of the entire HIV-1 capsid 1VUR ; ; Atomic-level structure of the entire HIV-1 capsid 1VUL ; ; Atomic-level structure of the entire HIV-1 capsid 1VUM ; ; Atomic-level structure of the entire HIV-1 capsid 1VUN ; ; Atomic-level structure of the entire HIV-1 capsid 1VUO ; ; Atomic-level structure of the entire HIV-1 capsid 1VUP ; ; Atomic-level structure of the entire HIV-1 capsid 1VU9 ; ; Atomic-level structure of the entire HIV-1 capsid 1VUA ; ; Atomic-level structure of the entire HIV-1 capsid 1VU7 ; ; Atomic-level structure of the entire HIV-1 capsid 1VU8 ; ; Atomic-level structure of the entire HIV-1 capsid 1VUC ; ; Atomic-level structure of the entire HIV-1 capsid 1VUD ; ; Atomic-level structure of the entire HIV-1 capsid 1VU5 ; ; Atomic-level structure of the entire HIV-1 capsid 1VUK ; ; Atomic-level structure of the entire HIV-1 capsid 1VU6 ; ; Atomic-level structure of the entire HIV-1 capsid 1VUI ; ; Atomic-level structure of the entire HIV-1 capsid 1VUJ ; ; Atomic-level structure of the entire HIV-1 capsid 1VUG ; ; Atomic-level structure of the entire HIV-1 capsid 1VUH ; ; Atomic-level structure of the entire HIV-1 capsid 1VV6 ; ; Atomic-level structure of the entire HIV-1 capsid (186 hexamers + 12 pentamers) 1VVI ; ; Atomic-level structure of the entire HIV-1 capsid (186 hexamers + 12 pentamers) 1VV5 ; ; Atomic-level structure of the entire HIV-1 capsid (186 hexamers + 12 pentamers) 1VV3 ; ; Atomic-level structure of the entire HIV-1 capsid (186 hexamers + 12 pentamers) 1VV4 ; ; Atomic-level structure of the entire HIV-1 capsid (186 hexamers + 12 pentamers) 1VV2 ; ; Atomic-level structure of the entire HIV-1 capsid (186 hexamers + 12 pentamers) 1VV0 ; ; Atomic-level structure of the entire HIV-1 capsid (186 hexamers + 12 pentamers) 1VV1 ; ; Atomic-level structure of the entire HIV-1 capsid (186 hexamers + 12 pentamers) 1VUZ ; ; Atomic-level structure of the entire HIV-1 capsid (186 hexamers + 12 pentamers) 1VUY ; ; Atomic-level structure of the entire HIV-1 capsid (186 hexamers + 12 pentamers) 1VUW ; ; Atomic-level structure of the entire HIV-1 capsid (186 hexamers + 12 pentamers) 1VUX ; ; Atomic-level structure of the entire HIV-1 capsid (186 hexamers + 12 pentamers) 1VUU ; ; Atomic-level structure of the entire HIV-1 capsid (186 hexamers + 12 pentamers) 1VUV ; ; Atomic-level structure of the entire HIV-1 capsid (186 hexamers + 12 pentamers) 1VV7 ; ; Atomic-level structure of the entire HIV-1 capsid (186 hexamers + 12 pentamers) 1VVF ; ; Atomic-level structure of the entire HIV-1 capsid (186 hexamers + 12 pentamers) 1VVG ; ; Atomic-level structure of the entire HIV-1 capsid (186 hexamers + 12 pentamers) 1VVH ; ; Atomic-level structure of the entire HIV-1 capsid (186 hexamers + 12 pentamers) 1VV9 ; ; Atomic-level structure of the entire HIV-1 capsid (186 hexamers + 12 pentamers) 1VVA ; ; Atomic-level structure of the entire HIV-1 capsid (186 hexamers + 12 pentamers) 1VVB ; ; Atomic-level structure of the entire HIV-1 capsid (186 hexamers + 12 pentamers) 1VV8 ; ; Atomic-level structure of the entire HIV-1 capsid (186 hexamers + 12 pentamers) 2G8C ; 1.15 ; Atomic-resolution crystal structure of Borrelia burgdorferi OspA via surface entropy reduction 2JE4 ; 1.07 ; ATOMIC-RESOLUTION CRYSTAL STRUCTURE OF CHEMICALLY- SYNTHESIZED HIV-1 PROTEASE IN COMPLEX WITH JG-365 2J9J ; 1.04 ; Atomic-resolution Crystal Structure of Chemically-Synthesized HIV-1 Protease Complexed with Inhibitor JG-365 2J9K ; 1.2 ; Atomic-resolution Crystal Structure of Chemically-Synthesized HIV-1 Protease Complexed with Inhibitor MVT-101 2QT4 ; 1.3 ; Atomic-resolution crystal structure of the natural form of Scytovirin 2QSK ; 1 ; Atomic-resolution crystal structure of the Recombinant form of Scytovirin 2A28 ; 1.07 ; Atomic-resolution crystal structure of the second SH3 domain of yeast Bzz1 determined from a pseudomerohedrally twinned crystal 2V1Q ; 1.2 ; ATOMIC-RESOLUTION STRUCTURE OF THE YEAST SLA1 SH3 DOMAIN 3 1RAW ; ; ATP BINDING RNA APTAMER IN COMPLEX WITH AMP, NMR, 10 STRUCTURES 1AM1 ; 2 ; ATP BINDING SITE IN THE HSP90 MOLECULAR CHAPERONE 2NT8 ; 1.68 ; ATP bound at the active site of a PduO type ATP:co(I)rrinoid adenosyltransferase from Lactobacillus reuteri 2FGH ; 2.8 ; ATP bound gelsolin 1W7A ; 2.27 ; ATP BOUND MUTS 2HIX ; 2.87 ; ATP dependent DNA ligase from S. solfataricus bound to ATP 3SL2 ; 1.61 ; ATP Forms a Stable Complex with the Essential Histidine Kinase WalK (YycG) Domain 1USY ; 2.52 ; ATP PHOSPHORIBOSYL TRANSFERASE (HISG:HISZ) COMPLEX FROM THERMOTOGA MARITIMA 1Z7M ; 2.9 ; ATP Phosphoribosyl transferase (HisZG ATP-PRTase) from Lactococcus lactis 1Z7N ; 3.25 ; ATP Phosphoribosyl transferase (HisZG ATP-PRTase) from Lactococcus lactis with bound PRPP substrate 1NH7 ; 2.7 ; ATP PHOSPHORIBOSYLTRANSFERASE (ATP-PRTASE) FROM MYCOBACTERIUM TUBERCULOSIS 1NH8 ; 1.8 ; ATP PHOSPHORIBOSYLTRANSFERASE (ATP-PRTASE) FROM MYCOBACTERIUM TUBERCULOSIS IN COMPLEX WITH AMP AND HISTIDINE 1G8F ; 1.95 ; ATP SULFURYLASE FROM S. CEREVISIAE 1G8G ; 2.6 ; ATP SULFURYLASE FROM S. CEREVISIAE: THE BINARY PRODUCT COMPLEX WITH APS 1G8H ; 2.8 ; ATP SULFURYLASE FROM S. CEREVISIAE: THE TERNARY PRODUCT COMPLEX WITH APS AND PPI 1L2P ; 1.55 ; ATP Synthase b Subunit Dimerization Domain 3UD0 ; 2 ; ATP synthase C10 ring in proton-unlocked conformation at PH 5.5 3U2Y ; 2.5 ; ATP synthase c10 ring in proton-unlocked conformation at pH 6.1 3U2F ; 2 ; ATP synthase c10 ring in proton-unlocked conformation at PH 8.3 3U32 ; 2 ; ATP synthase c10 ring reacted with DCCD at pH 5.5 1MT0 ; 2.6 ; ATP-binding domain of hemolysin B from Escherichia coli 1B0U ; 1.5 ; ATP-BINDING SUBUNIT OF THE HISTIDINE PERMEASE FROM SALMONELLA TYPHIMURIUM 4GT3 ; 1.68 ; ATP-bound form of the ERK2 kinase 1R6O ; 2.25 ; ATP-dependent Clp protease ATP-binding subunit clpA/ATP-dependent Clp protease adaptor protein clpS 1A0I ; 2.6 ; ATP-DEPENDENT DNA LIGASE FROM BACTERIOPHAGE T7 COMPLEX WITH ATP 2CFM ; 1.8 ; ATP-DEPENDENT DNA LIGASE FROM PYROCOCCUS FURIOSUS 2HIV ; 2.05 ; ATP-dependent DNA ligase from S. solfataricus 3TY6 ; 2.498 ; ATP-dependent Protease HslV from Bacillus anthracis str. Ames 1VE4 ; 1.2 ; ATP-Phosphoribosyltransferase(hisG) from Thermus thermophilus HB8 4AB2 ; 8.5 ; ATP-triggered molecular mechanics of the chaperonin GroEL 4AB3 ; 8.5 ; ATP-triggered molecular mechanics of the chaperonin GroEL 4AAU ; 8.5 ; ATP-triggered molecular mechanics of the chaperonin GroEL 4AAS ; 8.5 ; ATP-triggered molecular mechanics of the chaperonin GroEL 4AAR ; 8 ; ATP-triggered molecular mechanics of the chaperonin GroEL 4AAQ ; 8 ; ATP-triggered molecular mechanics of the chaperonin GroEL 1MO7 ; ; ATPase 1MO8 ; ; ATPase 3BH0 ; 2.35 ; ATPase Domain of G40P 1HJO ; 2.3 ; ATPase domain of human heat shock 70kDa protein 1 1T4G ; 2 ; ATPase in complex with AMP-PNP 1XU4 ; 2.4 ; ATPASE IN COMPLEX WITH AMP-PNP, MAGNESIUM AND POTASSIUM CO-F 1XXH ; 3.45 ; ATPgS Bound E. Coli Clamp Loader Complex 1AXH ; ; ATRACOTOXIN-HVI FROM HADRONYCHE VERSUTA (AUSTRALIAN FUNNEL-WEB SPIDER, NMR, 20 STRUCTURES 2KBT ; ; Attachment of an NMR-invisible solubility enhancement tag (INSET) using a sortase-mediated protein ligation method 2JP5 ; ; ATWLPPR an anti-angiogenic peptide 2J7I ; 2.9 ; ATYPICAL POLYPROLINE RECOGNITION BY THE CMS N-TERMINAL SH3 DOMAIN. CMS:CD2 HETERODIMER 2J6O ; 2.23 ; ATYPICAL POLYPROLINE RECOGNITION BY THE CMS N-TERMINAL SH3 DOMAIN. CMS:CD2 HETEROTRIMER 2AAN ; 1.85 ; Auracyanin A: A ""blue"" copper protein from the green thermophilic photosynthetic bacterium,chloroflexus aurantiacus 1OV8 ; 1.9 ; Auracyanin B structure in space group, P65 1QHQ ; 1.55 ; AURACYANIN, A BLUE COPPER PROTEIN FROM THE GREEN THERMOPHILIC PHOTOSYNTHETIC BACTERIUM CHLOROFLEXUS AURANTIACUS 1BQB ; 1.72 ; AUREOLYSIN, STAPHYLOCOCCUS AUREUS METALLOPROTEINASE 3H0Y ; 2.5 ; Aurora A in complex with a bisanilinopyrimidine 3H0Z ; 2.92 ; Aurora A in complex with a bisanilinopyrimidine 4DEE ; 2.3 ; Aurora A in complex with ADP 4DEB ; 3.05 ; Aurora A in complex with RK2-17-01 3UNZ ; 2.8 ; Aurora A in Complex with RPM1679 3UO4 ; 2.45 ; Aurora A in complex with RPM1680 3UP2 ; 2.3001 ; Aurora A in complex with RPM1686 3UOD ; 2.5002 ; Aurora A in complex with RPM1693 3UOJ ; 2.9003 ; Aurora A in complex with RPM1715 3UOH ; 2.8002 ; Aurora A in complex with RPM1722 3UOL ; 2.4 ; Aurora A in complex with SO2-162 3UP7 ; 3.05 ; Aurora A in complex with YL1-038-09 4DEA ; 2.45 ; Aurora A in complex with YL1-038-18 4DED ; 3.05 ; Aurora A in complex with YL1-038-21 3UO5 ; 2.7012 ; Aurora A in complex with YL1-038-31 3UO6 ; 2.8002 ; Aurora A in complex with YL5-083 3UOK ; 2.9506 ; Aurora A in complex with YL5-81-1 3H10 ; 2.2 ; Aurora A inhibitor complex 2C6E ; 2.1 ; AURORA A KINASE ACTIVATED MUTANT (T287D) IN COMPLEX WITH A 5-AMINOPYRIMIDINYL QUINAZOLINE INHIBITOR 2C6D ; 2.2 ; AURORA A KINASE ACTIVATED MUTANT (T287D) IN COMPLEX WITH ADPNP 3MYG ; 2.4 ; Aurora A Kinase complexed with SCH 1473759 3P9J ; 2.8 ; Aurora A kinase domain with phthalazinone pyrazole inhibitor 3ZTX ; 1.95 ; Aurora kinase selective inhibitors identified using a Taxol-induced checkpoint sensitivity screen. 2BMC ; 2.6 ; AURORA-2 T287D T288D COMPLEXED WITH PHA-680632 2X6D ; 2.796 ; AURORA-A BOUND TO AN INHIBITOR 2X6E ; 3.35 ; AURORA-A BOUND TO AN INHIBITOR 2WTV ; 2.4 ; AURORA-A INHIBITOR STRUCTURE 2WTW ; 3.302 ; AURORA-A INHIBITOR STRUCTURE (2ND CRYSTAL FORM) 2DWB ; 2.5 ; Aurora-A kinase complexed with AMPPNP 2XRU ; 2.9 ; AURORA-A T288E COMPLEXED WITH PHA-828300 1U37 ; ; Auto-inhibition Mechanism of X11s/Mints Family Scaffold Proteins Revealed by the Closed Conformation of the Tandem PDZ Domains 1U38 ; ; Auto-inhibition Mechanism of X11s/Mints Family Scaffold Proteins Revealed by the Closed Conformation of the Tandem PDZ Domains 1U39 ; ; Auto-inhibition Mechanism of X11s/Mints Family Scaffold Proteins Revealed by the Closed Conformation of the Tandem PDZ Domains 1U3B ; ; Auto-inhibition Mechanism of X11s/Mints Family Scaffold Proteins Revealed by the Closed Conformation of the Tandem PDZ Domains 1QWT ; 2.1 ; Auto-inhibitory interferon regulation factor-3 (IRF3) transactivation domain 1RNR ; 2.5 ; AUTOCATALYTIC GENERATION OF DOPA IN THE ENGINEERED PROTEIN R2 F208Y FROM ESCHERICHIA COLI RIBONUCLEOTIDE REDUCTASE AND CRYSTAL STRUCTURE OF THE DOPA-208 PROTEIN 3OBV ; 2.75 ; Autoinhibited Formin mDia1 Structure 2OZO ; 2.6 ; Autoinhibited intact human ZAP-70 1TKI ; 2 ; AUTOINHIBITED SERINE KINASE DOMAIN OF THE GIANT MUSCLE PROTEIN TITIN 3KY9 ; 2.731 ; Autoinhibited Vav1 1CXR ; ; AUTOMATED 2D NOESY ASSIGNMENT AND STRUCTURE CALCULATION OF CRAMBIN(S22/I25) WITH SELF-CORRECTING DISTANCE GEOMETRY BASED NOAH/DIAMOD PROGRAMS 2K22 ; ; Automated NMR Structure of the TA0895 by FAPSY 2K24 ; ; Automated NMR Structure of the TA0956 by FAPSY 2K25 ; ; Automated NMR Structure of the UBB by FAPSY 1NH5 ; ; AUTOMATIC ASSIGNMENT OF NMR DATA AND DETERMINATION OF THE PROTEIN STRUCTURE OF A NEW WORLD SCORPION NEUROTOXIN USING NOAH/DIAMOD 2K6X ; ; Autoregulation of a Group 1 Bacterial Sigma Factor Involves the Formation of a Region 1.1- Induced Compacted Structure 4DWL ; 2.69 ; Avd molecule from Bordetella bacteriophage DGR 1ITT ; 1 ; Average Crystal Structure of (Pro-Pro-Gly)9 at 1.0 angstroms Resolution 1KSM ; ; AVERAGE NMR SOLUTION STRUCTURE OF CA LN CALBINDIN D9K 1C9Q ; ; AVERAGE NMR SOLUTION STRUCTURE OF THE BIR-2 DOMAIN OF XIAP 1F9X ; ; AVERAGE NMR SOLUTION STRUCTURE OF THE BIR-3 DOMAIN OF XIAP 1JAV ; ; AVERAGE NMR SOLUTION STRUCTURE OF THE TRP-RICH PEPTIDE OF HIV GP41 BOUND TO DPC MICELLES 2JOL ; ; Average NMR structure of the catalytic domain of guanine nucleotide exchange factor BopE from Burkholderia pseudomallei 1S2F ; ; Average solution structure of a pseudo-5'-splice site from the negative regulator of splicing of Rous Sarcoma virus 1EKI ; ; AVERAGE SOLUTION STRUCTURE OF D(TTGGCCAA)2 BOUND TO CHROMOMYCIN-A3 AND COBALT 1N6V ; ; Average structure of the interferon-binding ectodomain of the human type I interferon receptor 1QTG ; ; AVERAGED NMR MODEL OF SWITCH ARC, A DOUBLE MUTANT OF ARC REPRESSOR 1JOK ; ; Averaged structure for Staphylococcal nuclease-H124L in ternary complex with Ca2+ and thymidine-3',5'-bisphosphate 1JOO ; ; Averaged structure for unligated Staphylococcal nuclease-H124L 2H88 ; 1.74 ; Avian Mitochondrial Respiratory Complex II at 1.8 Angstrom Resolution 1YQ4 ; 2.33 ; Avian respiratory complex ii with 3-nitropropionate and ubiquinone 2FBW ; 2.1 ; Avian respiratory complex II with carboxin bound 2H89 ; 2.4 ; Avian Respiratory Complex II with Malonate Bound 1YQ3 ; 2.2 ; Avian respiratory complex ii with oxaloacetate and ubiquinone 1ASV ; 2.2 ; Avian sarcoma virus integrase catalytic core domain 1ASU ; 1.7 ; AVIAN SARCOMA VIRUS INTEGRASE CATALYTIC CORE DOMAIN CRYSTALLIZED FROM 2% PEG 400, 2M AMMONIUM SULFATE, HEPES PH 7.5 1ASW ; 1.8 ; AVIAN SARCOMA VIRUS INTEGRASE CATALYTIC CORE DOMAIN CRYSTALLIZED FROM 20% PEG 4000, 10% ISOPROPANOL, HEPES PH 7.5 USING SELENOMETHIONINE SUBSTITUTED PROTEIN; DATA COLLECTED AT-165 DEGREES C 2A5B ; 2.49 ; Avidin complexed with 8-oxodeoxyguanosine 2CAM ; 2.2 ; AVIDIN MUTANT (K3E,K9E,R26D,R124L) 2FHL ; 1.05 ; avidin related protein (AVR4)-BNA complex 2FHN ; 1.3 ; Avidin related protein AVR4 (C122S, K109I mutant) in complex with BNA 1LDQ ; 2.7 ; avidin-homobiotin complex 1LDO ; 2.2 ; avidin-norbioitn complex 3M5M ; 1.7 ; Avoiding drug resistance against HCV NS3/4A protease inhibitors 2OPZ ; 3 ; AVPF bound to BIR3-XIAP 1WBI ; 1.4 ; AVR2 1OA8 ; 1.7 ; AXH DOMAIN OF HUMAN SPINOCEREBELLAR ATAXIN-1 1V06 ; ; AXH DOMAIN OF THE TRANSCRIPTION FACTOR HBP1 FROM M.MUSCULUS 3MFL ; 1.78 ; Axial Ligand Swapping In Double Mutant Maintains Intradiol-cleavage Chemistry in Protocatechuate 3,4-Dioxygenase 3MI1 ; 1.74 ; Axial Ligand Swapping In Double Mutant Maintains Intradiol-cleavage Chemistry in Protocatechuate 3,4-Dioxygenase 3MI5 ; 1.78 ; Axial Ligand Swapping In Double Mutant Maintains Intradiol-cleavage Chemistry in Protocatechuate 3,4-Dioxygenase 3MV4 ; 1.59 ; Axial Ligand Swapping In Double Mutant Maintains Intradiol-cleavage Chemistry in Protocatechuate 3,4-Dioxygenase 3MV6 ; 1.86 ; Axial Ligand Swapping In Double Mutant Maintains Intradiol-cleavage Chemistry in Protocatechuate 3,4-Dioxygenase 3T63 ; 1.54 ; Axial Ligand Swapping In Double Mutant Maintains Intradiol-cleavage Chemistry in Protocatechuate 3,4-Dioxygenase 3T67 ; 1.67 ; Axial Ligand Swapping In Double Mutant Maintains Intradiol-cleavage Chemistry in Protocatechuate 3,4-Dioxygenase 2VHB ; 1.76 ; AZIDE ADDUCT OF THE BACTERIAL HEMOGLOBIN FROM VITREOSCILLA STERCORARIA 2E86 ; 1.5 ; Azide bound to copper containing nitrite reductase from A. faecalis S-6 3BGO ; 1.8 ; Azide complex of Engineered Subtilisin SUBT_BACAM 1RSV ; 2.2 ; azide complex of the diferrous E238A mutant R2 subunit of ribonucleotide reductase 1RSR ; 2 ; azide complex of the diferrous F208A mutant R2 subunit of ribonucleotide reductase 2CK3 ; 1.95 ; AZIDE INHIBITED BOVINE F1-ATPASE 1YAZ ; 1.7 ; AZIDE-BOUND YEAST CU(II)/ZN SUPEROXIDE DISMUTASE ROOM TEMPERATURE (298K) STRUCTURE 1NNI ; 2.5 ; Azobenzene Reductase from Bacillus subtilis 1FRH ; 2.3 ; AZOTOBACTER VINELANDII FERREDOXIN I: ALTERATION OF INDIVIDUAL SURFACE CHARGES AND THE [4FE-4S] CLUSTER REDUCTION POTENTIAL 1FRI ; 2.1 ; AZOTOBACTER VINELANDII FERREDOXIN I: ALTERATION OF INDIVIDUAL SURFACE CHARGES AND THE [4FE-4S] CLUSTER REDUCTION POTENTIAL 1FRJ ; 2.3 ; AZOTOBACTER VINELANDII FERREDOXIN I: ALTERATION OF INDIVIDUAL SURFACE CHARGES AND THE [4FE-4S] CLUSTER REDUCTION POTENTIAL 1FRK ; 2.1 ; AZOTOBACTER VINELANDII FERREDOXIN I: ALTERATION OF INDIVIDUAL SURFACE CHARGES AND THE [4FE-4S] CLUSTER REDUCTION POTENTIAL 1FRL ; 2.3 ; AZOTOBACTER VINELANDII FERREDOXIN I: ALTERATION OF INDIVIDUAL SURFACE CHARGES AND THE [4FE-4S] CLUSTER REDUCTION POTENTIAL 1FRM ; 2.3 ; AZOTOBACTER VINELANDII FERREDOXIN I: ALTERATION OF INDIVIDUAL SURFACE CHARGES AND THE [4FE-4S] CLUSTER REDUCTION POTENTIAL 1FDD ; 1.9 ; AZOTOBACTER VINELANDII FERREDOXIN I: ASPARTATE 15 FACILITATES PROTON TRANSFER TO THE REDUCED [3FE-4S] CLUSTER 2PYG ; 2.1 ; Azotobacter vinelandii Mannuronan C-5 epimerase AlgE4 A-module 2PYH ; 2.7 ; Azotobacter vinelandii Mannuronan C-5 epimerase AlgE4 A-module complexed with mannuronan trisaccharide 1ATG ; 1.2 ; AZOTOBACTER VINELANDII PERIPLASMIC MOLYBDATE-BINDING PROTEIN 1LWX ; 2.3 ; AZT DIPHOSPHATE BINDING TO NUCLEOSIDE DIPHOSPHATE KINASE 1RT3 ; 3 ; AZT DRUG RESISTANT HIV-1 REVERSE TRANSCRIPTASE COMPLEXED WITH 1051U91 2ZQC ; 1.07 ; Aztreonam acyl-intermediate structure of class a beta-lactam Toho-1 E166A/R274N/R276N triple mutant 3FQY ; 1.9 ; Azurin C112D 3FQ2 ; 1.91 ; Azurin C112D/M121F 3FQ1 ; 1.9 ; Azurin C112D/M121I 3FPY ; 2.1 ; Azurin C112D/M121L 1JVL ; 2 ; Azurin dimer, covalently crosslinked through bis-maleimidomethylether 1JVO ; 2.75 ; Azurin dimer, crosslinked via disulfide bridge 1E65 ; 1.85 ; AZURIN FROM PSEUDOMONAS AERUGINOSA, APO FORM 1E5Y ; 2 ; AZURIN FROM PSEUDOMONAS AERUGINOSA, REDUCED FORM, PH 5.5 1E5Z ; 2 ; AZURIN FROM PSEUDOMONAS AERUGINOSA, REDUCED FORM, PH 9.0 3N2J ; 1.35 ; Azurin H117G, oxidized form 2TSA ; 2.2 ; AZURIN MUTANT M121A 2TSB ; 2.3 ; AZURIN MUTANT M121A-AZIDE 1URI ; 1.94 ; AZURIN MUTANT WITH MET 121 REPLACED BY GLN 1ETJ ; 2.3 ; AZURIN MUTANT WITH MET 121 REPLACED BY GLU 1A4C ; 2.45 ; AZURIN MUTANT WITH MET 121 REPLACED BY HIS, PH 3.5 CRYSTAL FORM, DATA COLLECTED AT-180 DEGREES CELSIUS 1A4A ; 1.89 ; AZURIN MUTANT WITH MET 121 REPLACED BY HIS, PH 6.5 CRYSTAL FORM, DATA COLLECTED AT 16 DEGREES CELSIUS 1A4B ; 1.91 ; AZURIN MUTANT WITH MET 121 REPLACED BY HIS, PH 6.5 CRYSTAL FORM, DATA COLLECTED AT-180 DEGREES CELSIUS 1ZEW ; 2.25 ; B-DNA 1ZF0 ; 1.5 ; B-DNA 1DCV ; 2.5 ; B-DNA DECAMER WITH CENTRAL TA DINUCLEOTIDE 1EI4 ; 1.43 ; B-DNA DODECAMER CGCGAAT(TLC)CGCG WITH INCORPORATED [3.3.0]BICYCLO-ARABINO-THYMINE-5'-PHOSPHATE 1QV4 ; 2.5 ; B-DNA Dodecamer CGTGAATTCACG complexed with minor groove binder methylproamine 1QV8 ; 2.5 ; B-DNA Dodecamer d(CGCGAATTCGCG)2 complexed with proamine 2QEG ; 1.6 ; B-DNA with 7-deaza-dG modification 1DPN ; 0.95 ; B-DODECAMER CGCGAA(TAF)TCGCG WITH INCORPORATED 2'-DEOXY-2'-FLUORO-ARABINO-FURANOSYL THYMINE 3IE4 ; 1.45 ; b-glucan binding domain of Drosophila GNBP3 defines a novel family of pattern recognition receptor 1GNX ; 1.68 ; B-GLUCOSIDASE FROM STREPTOMYCES SP 1GON ; 2.2 ; B-GLUCOSIDASE FROM STREPTOMYCES SP 3Q96 ; 3.1 ; B-Raf kinase domain in complex with a tetrahydronaphthalene inhibitor 4EHG ; 3.5 ; B-Raf Kinase Domain in Complex with an Aminopyridimine-based Inhibitor 4EHE ; 3.3 ; B-Raf Kinase Domain in Complex with an Aminothienopyrimidine-based Inhibitor 4JVG ; 3.09 ; B-Raf Kinase in Complex with Birb796 3C4C ; 2.57 ; B-Raf Kinase in Complex with PLX4720 4FK3 ; 2.65 ; B-Raf Kinase V600E Oncogenic Mutant in Complex with PLX3203 3OG7 ; 2.45 ; B-Raf Kinase V600E oncogenic mutant in complex with PLX4032 4G9R ; 3.2 ; B-Raf V600E Kinase Domain Bound to a Type II Dihydroquinazoline Inhibitor 3IDP ; 2.7 ; B-Raf V600E kinase domain in complex with an aminoisoquinoline inhibitor 2Y5P ; 1.3 ; B-REPEAT OF LISTERIA MONOCYTOGENES INLB (INTERNALIN B) 2RJ4 ; 1.47 ; B-specific alpha-1,3-galactosyltransferase G176R +UDP+ADA 2RJ9 ; 1.69 ; B-specific alpha-1,3-galactosyltransferase (GTB) + UDP+ Amino-deoxy-acceptor 2RJ8 ; 1.69 ; B-specific alpha-1,3-galactosyltransferase (GTB) +UDP+ H-antigen disaccharide 2RJ1 ; 1.55 ; B-specific alpha-1,3-galactosyltransferase (GTB) G176R mutant + UDP + H-antigen disaccharide 2RJ0 ; 1.52 ; B-specific alpha-1,3-galactosyltransferase G176R mutant + UDP+ Mn2+ 2RJ6 ; 1.41 ; B-specific alpha-1,3-galactosyltransferase G176R S235G mutant (AABB) + H-antigen disaccharide 2RJ7 ; 1.7 ; B-specific alpha-1,3-galactosyltransferase G176R S235G mutant (AABB) + UDPGal + Deoxy-acceptor 2RJ5 ; 1.45 ; B-specific alpha-1,3-galactosyltransferase G176R S235G mutant (AABB) +UDP 2RIY ; 1.55 ; B-specific-1,3-galactosyltransferase (GTB)+H-antigen acceptor 2RIX ; 1.75 ; B-specific-1,3-galactosyltransferase)(GTB) + UDP 2G8U ; 2.7 ; B. halodurans RNase H catalytic domain D132N mutant in complex with Mg2+ and RNA/DNA hybrid (non-P nick at the active site) 2G8K ; 1.65 ; B. halodurans RNase H catalytic domain D192N mutant in complex with Ca2+ and RNA/DNA hybrid (non-P nick at the active site) 2G8H ; 1.85 ; B. halodurans RNase H catalytic domain D192N mutant in complex with Mg2+ and RNA/DNA hybrid (non-P nick at the active site) 2G8I ; 1.65 ; B. halodurans RNase H catalytic domain D192N mutant in complex with Mn2+ and RNA/DNA hybrid (non-P nick at the active site) 2G8W ; 2.05 ; B. halodurans RNase H catalytic domain E188A mutant in complex with Ca2+ and RNA/DNA hybrid 2G8F ; 1.65 ; B. halodurans RNase H catalytic domain E188A mutant in complex with Mg2+ and RNA/DNA hybrid (non-P nick at the active site) 2G8V ; 1.85 ; B. halodurans RNase H catalytic domain E188A mutant in complex with Mg2+ and RNA/DNA hybrid (reaction product) 4AOO ; 2.3 ; B. subtilis dUTPase YncF in complex with dU PPi and Mg in H32 4AOZ ; 2.05 ; B. subtilis dUTPase YncF in complex with dU, PPi and Mg (P212121) 4B0H ; 1.18 ; B. subtilis dUTPase YncF in complex with dU, PPi and Mg b (P212121) 3ZQD ; ; B. subtilis L,D-transpeptidase 4AO5 ; 1.6 ; B. subtilis prophage dUTPase YosS in complex with dUMP 3VDY ; 2.8 ; B. subtilis SsbB/ssDNA 3CKC ; 1.5 ; B. thetaiotaomicron SusD 3CK7 ; 2.1 ; B. thetaiotaomicron SusD with alpha-cyclodextrin 3CK8 ; 2.1 ; B. thetaiotaomicron SusD with beta-cyclodextrin 3CK9 ; 2.2 ; B. thetaiotaomicron SusD with maltoheptaose 3CKB ; 2.3 ; B. thetaiotaomicron SusD with maltotriose 3LCZ ; 2.06 ; B.licheniformis Anti-TRAP can assemble into two types of dodecameric particles with the same symmetry but inverted orientation of trimers 3B3D ; 2.3 ; B.subtilis YtbE 3F7J ; 1.7 ; B.subtilis YvgN 3I97 ; 2.9 ; B1 domain of human Neuropilin-1 bound with small molecule EG00229 1A6U ; 2.1 ; B1-8 FV FRAGMENT 1A6V ; 1.8 ; B1-8 FV FRAGMENT COMPLEXED WITH A (4-HYDROXY-3-NITROPHENYL) ACETATE COMPOUND 1A6W ; 2 ; B1-8 FV FRAGMENT COMPLEXED WITH A (4-HYDROXY-5-IODO-3-NITROPHENYL) ACETATE COMPOUND 2J85 ; 2.39 ; B116 OF SULFOLOBUS TURRETED ICOSAHEDRAL VIRUS (STIV) 4AQZ ; ; B2 domain of Neisseria meningitidis Pilus assembly protein PilQ 2IV9 ; 1.9 ; B2-APPENDAGE FROM AP2 IN COMPLEX WITH EPS15 PEPTIDE 1JY4 ; ; B4DIMER: A DE NOVO DESIGNED EIGHT-STRANDED BETA-SHEET ASSEMBLED USING A DISULFIDE BOND 1JY6 ; ; B4DIMERA: A DE NOVO DESIGNED FOUR-STRANDED BETA-SHEET ASSEMBLED USING A DISULFIDE BOND 1W51 ; 2.55 ; BACE (BETA SECRETASE) IN COMPLEX WITH A NANOMOLAR NON-PEPTIDIC INHIBITOR 3BRA ; 2.3 ; BACE-1 complexed with compound 1 3BUF ; 2.3 ; BACE-1 complexed with compound 2 3BUG ; 2.5 ; BACE-1 complexed with compound 3 3BUH ; 2.3 ; BACE-1 complexed with compound 4 4DPF ; 1.8 ; BACE-1 in complex with a HEA-macrocyclic type inhibitor 3KYR ; 2.6 ; Bace-1 in complex with a norstatine type inhibitor 3N4L ; 2.7 ; BACE-1 in complex with ELN380842 3NSH ; 2.2 ; BACE-1 in complex with ELN475957 4DPI ; 1.9 ; BACE-1 in complex with HEA-macrocyclic inhibitor, MV078512 3IGB ; 2.238 ; Bace-1 with Compound 3 3L3A ; 2.362 ; Bace-1 with the aminopyridine Compound 32 3OOZ ; 1.8 ; Bace1 in complex with the aminohydantoin Compound 102 3LHG ; 2.1 ; Bace1 in complex with the aminohydantoin Compound 4g 3L38 ; 2.1 ; Bace1 in complex with the aminopyridine Compound 44 2QU2 ; 2.6 ; BACE1 with Compound 1 2QU3 ; 2 ; BACE1 with Compound 2 3IN3 ; 2 ; Bace1 with Compound 30 3IN4 ; 2.3 ; Bace1 with Compound 38 3IND ; 2.246 ; Bace1 with the aminohydantoin Compound 29 3INF ; 1.852 ; Bace1 with the aminohydantoin Compound 37 3INH ; 1.8 ; Bace1 with the aminohydantoin Compound R-58 3INE ; 1.996 ; Bace1 with the aminohydantoin Compound S-34 3ZKM ; 1.85 ; BACE2 FAB COMPLEX 3ZKN ; 2 ; BACE2 FAB INHIBITOR COMPLEX 3ZL7 ; 3.2 ; BACE2 FYNOMER COMPLEX 3ZKG ; 1.9 ; BACE2 MUTANT APO STRUCTURE 3ZKI ; 2.4 ; BACE2 MUTANT STRUCTURE WITH LIGAND 3ZLQ ; 2.1 ; BACE2 XAPERONE COMPLEX 4BEL ; 1.85 ; BACE2 XAPERONE COMPLEX 4BFB ; 2.21 ; BACE2 XAPERONE COMPLEX 3ZKQ ; 1.51 ; BACE2 XAPERONE COMPLEX 3ZKS ; 2.11 ; BACE2 XAPERONE COMPLEX WITH INHIBITOR 2YOW ; 1.8 ; Bacillus amyloliquefaciens CBM33 2YOX ; 1.9 ; Bacillus amyloliquefaciens CBM33 in complex with Cu(I) after photoreduction 2YOY ; 1.7 ; Bacillus amyloliquefaciens CBM33 in complex with Cu(I) reduced using ascorbate 3S9U ; 1.9 ; Bacillus anthracis Dihydrofolate Reductase bound to propargyl-linked TMP analog, UCP120J 3E0B ; 2.25 ; Bacillus anthracis Dihydrofolate Reductase complexed with NADPH and 2,4-diamino-5-(3-(2,5-dimethoxyphenyl)prop-1-ynyl)-6-ethylpyrimidine (UCP120B) 3MMX ; 2.552 ; Bacillus anthracis NadD (baNadD) in complex with compound 1_02_3 3HFJ ; 2.02 ; Bacillus anthracis nicotinate mononucleotide adenylytransferase (nadD) in complex with inhibitor CID 3289443 1HZ9 ; 1.8 ; BACILLUS CALDOLYTICUS COLD-SHOCK PROTEIN MUTANTS TO STUDY DETERMINANTS OF PROTEIN STABILITY 1HZA ; 1.8 ; BACILLUS CALDOLYTICUS COLD-SHOCK PROTEIN MUTANTS TO STUDY DETERMINANTS OF PROTEIN STABILITY 1HZB ; 1.28 ; BACILLUS CALDOLYTICUS COLD-SHOCK PROTEIN MUTANTS TO STUDY DETERMINANTS OF PROTEIN STABILITY 1HZC ; 1.32 ; BACILLUS CALDOLYTICUS COLD-SHOCK PROTEIN MUTANTS TO STUDY DETERMINANTS OF PROTEIN STABILITY 1I5F ; 1.4 ; BACILLUS CALDOLYTICUS COLD-SHOCK PROTEIN MUTANTS TO STUDY DETERMINANTS OF PROTEIN STABILITY 3JX7 ; 1.6 ; Bacillus cereus alkylpurine DNA glycosylase AlkD bound to DNA containing a 3-METHYLADENINE analog 3JXY ; 1.5 ; Bacillus cereus Alkylpurine DNA Glycosylase AlkD Bound to DNA Containing a GT Mismatch 3JY1 ; 1.754 ; Bacillus cereus Alkylpurine DNA Glycosylase AlkD Bound to DNA Containing an Abasic Site (across from C) 3JXZ ; 1.75 ; Bacillus cereus Alkylpurine DNA Glycosylase AlkD Bound to DNA Containing an Abasic Site (across from T) 1B90 ; 2.5 ; BACILLUS CEREUS BETA-AMYLASE APO FORM 1B9Z ; 2.1 ; BACILLUS CEREUS BETA-AMYLASE COMPLEXED WITH MALTOSE 2BG8 ; 2.5 ; BACILLUS CEREUS METALLO-BETA-LACTAMASE (BCII) ARG (121) CYS MUTANT. SOLVED AT PH4.5 USING 20 MICROMOLAR ZNSO4 IN THE BUFFER. 1MM DTT AND 1MM TCEP-HCL WERE USED AS REDUCING AGENTS. 2BG7 ; 2.1 ; BACILLUS CEREUS METALLO-BETA-LACTAMASE (BCII) ARG (121) CYS MUTANT. SOLVED AT PH4.5 USING 20 MICROMOLAR ZNSO4 IN THE BUFFER. 1MM DTT WAS USED AS A REDUCING AGENT. CYS221 IS OXIDIZED. 2BFZ ; 2.3 ; BACILLUS CEREUS METALLO-BETA-LACTAMASE (BCII) ARG (121) CYS MUTANT. SOLVED AT PH4.5 USING 20MM ZNSO4 IN BUFFER. 1MM DTT WAS USED AS A REDUCING AGENT. CYS221 IS OXIDIZED. 2BG2 ; 2.4 ; Bacillus cereus metallo-beta-lactamase (BcII) Arg (121) Cys mutant. Solved at pH4.5 using 20mM ZnSO4 in the buffer. 1mM DTT and 1mM TCEP- HCl were used as reducing agents. Cys221 is reduced. 2BG6 ; 2.3 ; Bacillus cereus metallo-beta-lactamase (BcII) Arg (121) Cys mutant. Solved at pH5 using 20 Micromolar ZnSO4 in the buffer. 1mM DTT was used as a reducing agent. Cys221 is oxidized. 2BFL ; 1.8 ; BACILLUS CEREUS METALLO-BETA-LACTAMASE (BCII) ARG (121) CYS MUTANT. SOLVED AT PH5 USING 20MM ZNSO4 IN BUFFER. 1MM DTT WAS USED AS A REDUCING AGENT. 2BGA ; 2.7 ; BACILLUS CEREUS METALLO-BETA-LACTAMASE (BCII) ARG (121) CYS MUTANT. SOLVED AT PH7 USING 20 MICROMOLAR ZNSO4 IN THE BUFFER. 1MM DTT WAS USED AS A REDUCING AGENT. CYS221 IS OXIDIZED. 2BFK ; 2 ; BACILLUS CEREUS METALLO-BETA-LACTAMASE (BCII) ARG (121) CYS MUTANT. SOLVED AT PH7 USING 20MM ZNSO4 IN BUFFER. 1MM DTT WAS USED AS A REDUCING AGENT 3KNR ; 1.71 ; Bacillus cereus metallo-beta-lactamase Cys221Asp mutant, 1 mM Zn(II) 3KNS ; 1.58 ; Bacillus cereus metallo-beta-lactamase Cys221Asp mutant, 20 mM Zn(II) 3I0V ; 1.6 ; Bacillus cereus metallo-beta-lactamase: apo form 3UN5 ; 1.8 ; Bacillus cereus phosphopentomutase T85E variant 3UNY ; 1.95 ; Bacillus cereus phosphopentomutase T85E variant soaked with glucose 1,6-bisphosphate 3I13 ; 1.74 ; Bacillus cereus Zn-dependent metallo-beta-lactamase at pH 5.8 1OT1 ; 2 ; Bacillus circulans strain 251 Cyclodextrin glycosyl transferase mutant D135A 1OT2 ; 2.1 ; Bacillus circulans strain 251 Cyclodextrin glycosyl transferase mutant D135N 1KCK ; 2.43 ; Bacillus circulans strain 251 Cyclodextrin glycosyl transferase mutant N193G 1EO5 ; 2 ; Bacillus circulans strain 251 cyclodextrin glycosyltransferase in complex with maltoheptaose 1EO7 ; 2.48 ; BACILLUS CIRCULANS STRAIN 251 CYCLODEXTRIN GLYCOSYLTRANSFERASE IN COMPLEX WITH MALTOHEXAOSE 1DTU ; 2.4 ; BACILLUS CIRCULANS STRAIN 251 CYCLODEXTRIN GLYCOSYLTRANSFERASE: A MUTANT Y89D/S146P COMPLEXED TO AN HEXASACCHARIDE INHIBITOR 1PJ9 ; 2 ; Bacillus circulans strain 251 loop mutant 183-195 1PEZ ; 2.32 ; Bacillus circulans strain 251 mutant A230V 1KCL ; 1.94 ; Bacillus ciruclans strain 251 Cyclodextrin glycosyl transferase mutant G179L 3TYJ ; 2.15 ; Bacillus collagen-like protein of anthracis P159S mutant 1W9X ; 2.1 ; BACILLUS HALMAPALUS ALPHA AMYLASE 1ZBI ; 1.85 ; Bacillus halodurans RNase H catalytic domain mutant D132N in complex with 12-mer RNA/DNA hybrid 1ZBL ; 2.2 ; Bacillus halodurans RNase H catalytic domain mutant D192N in complex with 12-mer RNA/DNA hybrid 3ZZL ; 1.67 ; BACILLUS HALODURANS TRP RNA-BINDING ATTENUATION PROTEIN (TRAP): A 12-SUBUNIT ASSEMBLY 1C9N ; 1.5 ; BACILLUS LENTUS SUBSTILISIN VARIANT (SER 87) K27R/V104Y/N123S/T274A 1NDQ ; 1.8 ; Bacillus lentus subtilisin 1C9J ; 1.8 ; BACILLUS LENTUS SUBTILISIN K27R/N87S/V104Y/N123S/T274A VARIANT 1NDU ; 1.6 ; Bacillus lentus subtilisin variant S101G/V104N 1C9M ; 1.67 ; BACILLUS LENTUS SUBTILSIN (SER 87) N76D/S103A/V104I 1BLI ; 1.9 ; BACILLUS LICHENIFORMIS ALPHA-AMYLASE 1GBG ; 1.8 ; BACILLUS LICHENIFORMIS BETA-GLUCANASE 1XWL ; 1.7 ; BACILLUS STEAROTHERMOPHILUS (NEWLY IDENTIFIED STRAIN AS YET UNNAMED) DNA POLYMERASE FRAGMENT 1ZIP ; 1.85 ; BACILLUS STEAROTHERMOPHILUS ADENYLATE KINASE 1HVX ; 2 ; BACILLUS STEAROTHERMOPHILUS ALPHA-AMYLASE 1JQA ; 2.05 ; Bacillus stearothermophilus glycerol dehydrogenase complex with glycerol 1JQ5 ; 1.7 ; Bacillus Stearothermophilus Glycerol dehydrogenase complex with NAD+ 1H2E ; 1.69 ; BACILLUS STEAROTHERMOPHILUS PHOE (PREVIOUSLY KNOWN AS YHFR) IN COMPLEX WITH PHOSPHATE 1H2F ; 2 ; BACILLUS STEAROTHERMOPHILUS PHOE (PREVIOUSLY KNOWN AS YHFR) IN COMPLEX WITH TRIVANADATE 1EBB ; 2.3 ; BACILLUS STEAROTHERMOPHILUS YHFR 1UX1 ; 2.36 ; BACILLUS SUBTILIS CYTIDINE DEAMINASE WITH A CYS53HIS AND AN ARG56GLN SUBSTITUTION 1UWZ ; 1.99 ; BACILLUS SUBTILIS CYTIDINE DEAMINASE WITH AN ARG56 - ALA SUBSTITUTION 1UX0 ; 1.99 ; BACILLUS SUBTILIS CYTIDINE DEAMINASE WITH AN ARG56 - GLN SUBSTITUTION 3ZH9 ; 2.1 ; Bacillus subtilis DNA clamp loader delta protein (YqeN) 1R4Z ; 1.8 ; Bacillus subtilis lipase A with covalently bound Rc-IPG-phosphonate-inhibitor 1R50 ; 1.45 ; Bacillus subtilis lipase A with covalently bound Sc-IPG-phosphonate-inhibitor 2EV0 ; 1.65 ; Bacillus subtilis manganese transport regulator (MNTR) bound to cadmium 2EV5 ; 2 ; Bacillus subtilis manganese transport regulator (MNTR) bound to calcium 2F5E ; 2.2 ; Bacillus subtilis manganese transport regulator (MNTR) bound to manganese, AB conformation, pH 6.5 1ON1 ; 1.75 ; Bacillus Subtilis Manganese Transport Regulator (Mntr) Bound To Manganese, AB Conformation. 2F5D ; 1.9 ; Bacillus subtilis manganese transport regulator (MNTR) bound to manganese, AC conformation, pH 6.5 2F5F ; 2.4 ; Bacillus subtilis manganese transport regulator (MNTR) bound to manganese, AC conformation, pH 8.5 2F5C ; 2.4 ; Bacillus subtilis Manganese transport regulator (MNTR) bound to manganese, hexagonal crystal form 2EV6 ; 1.7 ; Bacillus subtilis manganese transport regulator (MNTR) bound to zinc 1ON2 ; 1.61 ; Bacillus subtilis Manganese Transport Regulator (MntR), D8M Mutant, Bound to Manganese 1BN8 ; 1.8 ; BACILLUS SUBTILIS PECTATE LYASE 2BSP ; 1.8 ; BACILLUS SUBTILIS PECTATE LYASE R279K MUTANT 2Y1T ; 1.89 ; BACILLUS SUBTILIS PROPHAGE DUTPASE IN COMPLEX WITH DUDP 2FXV ; 2.05 ; Bacillus subtilis Xanthine Phosphoribosyltransferase in Complex with Guanosine 5'-monophosphate (GMP) 1QD9 ; 1.7 ; Bacillus subtilis YABJ 1WAC ; 3 ; BACK-PRIMING MODE OF PHI6 RNA-DEPENDENT RNA POLYMERASE 2LJP ; ; Backbone 1H, 13C, and 15N Chemical Shift Assignments for E.coli Ribonuclease P protein 2KZ3 ; ; Backbone 1H, 13C, and 15N Chemical Shift Assignments for human Rad51D from 1 to 83 2LXD ; ; Backbone 1H, 13C, and 15N Chemical Shift Assignments for LMO2(LIM2)-Ldb1(LID) 2KSW ; ; Backbone 1H, 13C, and 15N Chemical Shift Assignments for Oryctin 2LGT ; ; Backbone 1H, 13C, and 15N Chemical Shift Assignments for QFM(Y)F 2LN7 ; ; Backbone 1H, 13C, and 15N Chemical Shift Assignments for the catalytic domain of B. anthracis SrtD 2L2N ; ; Backbone 1H, 13C, and 15N Chemical Shift Assignments for the first dsRBD of protein HYL1 2GI9 ; 1.14 ; Backbone Conformational Constraints in a Microcrystalline U-15N-Labeled Protein by 3D Dipolar-Shift Solid-State NMR Spectroscopy 1FH1 ; ; BACKBONE FOLD OF NODF 3K1Q ; 4.5 ; Backbone model of an aquareovirus virion by cryo-electron microscopy and bioinformatics 1RWD ; ; Backbone NMR Structure of a Mutant P. Furiosus Rubredoxin Using Residual Dipolar Couplings 1RWS ; ; Backbone Solution Structure of mixed alpha/beta protein PF1061 1SF0 ; ; BACKBONE SOLUTION STRUCTURE OF MIXED ALPHA/BETA PROTEIN PF1061 1XGF ; 2.61 ; Backbone Structure of COCOSIN, an 11S storage protein from cocos nucifera 2LOQ ; ; Backbone structure of human membrane protein FAM14B (Interferon alpha-inducible protein 27-like protein 1) 2LOM ; ; Backbone structure of human membrane protein HIGD1A 2LON ; ; Backbone structure of human membrane protein HIGD1B 2LOR ; ; Backbone structure of human membrane protein TMEM141 2LOP ; ; Backbone structure of human membrane protein TMEM14A 2LOO ; ; Backbone structure of human membrane protein TMEM14A from NOE data 2LOS ; ; Backbone structure of human membrane protein TMEM14C 2KSD ; ; Backbone structure of the membrane domain of E. coli histidine kinase receptor ArcB, Center for Structures of Membrane Proteins (CSMP) target 4310C 2KSF ; ; Backbone structure of the membrane domain of E. coli histidine kinase receptor KdpD, Center for Structures of Membrane Proteins (CSMP) target 4312C 2KSE ; ; Backbone structure of the membrane domain of E. coli histidine kinase receptor QseC, Center for Structures of Membrane Proteins (CSMP) target 4311C 2LD9 ; ; Backbone Structure of Ubiquitin determined using Backbone amide NOEs and Backbone N-H and N-C RDCs 3IYM ; 4.7 ; Backbone Trace of the Capsid Protein Dimer of a Fungal Partitivirus from Electron Cryomicroscopy and Homology Modeling 3GTQ ; 3.8 ; Backtracked RNA polymerase II complex induced by damage 3GTG ; 3.78 ; Backtracked RNA polymerase II complex with 12mer RNA 3GTJ ; 3.42 ; Backtracked RNA polymerase II complex with 13mer RNA 3GTL ; 3.38 ; Backtracked RNA polymerase II complex with 13mer with G<>U mismatch 3GTO ; 4 ; Backtracked RNA polymerase II complex with 15mer RNA 3GTK ; 3.8 ; Backtracked RNA polymerase II complex with 18mer RNA 3GTP ; 3.9 ; Backtracked RNA polymerase II complex with 24mer RNA 1L7V ; 3.2 ; Bacterial ABC Transporter Involved in B12 Uptake 2WUS ; 2.9 ; BACTERIAL ACTIN MREB ASSEMBLES IN COMPLEX WITH CELL SHAPE PROTEIN RODZ 3TEG ; 2.2044 ; Bacterial and Eukaryotic Phenylalanyl-tRNA Synthetases Catalyze Misaminoacylation of tRNAPhe with 3,4-Dihydroxy-L-Phenylalanine (L-Dopa) 1QBB ; 2 ; BACTERIAL CHITOBIASE COMPLEXED WITH CHITOBIOSE (DINAG) 1QBA ; 1.85 ; BACTERIAL CHITOBIASE, GLYCOSYL HYDROLASE FAMILY 20 1JU4 ; 1.63 ; BACTERIAL COCAINE ESTERASE COMPLEX WITH PRODUCT 1JU3 ; 1.58 ; BACTERIAL COCAINE ESTERASE COMPLEX WITH TRANSITION STATE ANALOG 1E9R ; 2.4 ; BACTERIAL CONJUGATIVE COUPLING PROTEIN TRWBDELTAN70. TRIGONAL FORM IN COMPLEX WITH SULPHATE. 1E9S ; 2.5 ; BACTERIAL CONJUGATIVE COUPLING PROTEIN TRWBDELTAN70. UNBOUND MONOCLINIC FORM. 1RA5 ; 1.4 ; Bacterial cytosine deaminase D314A mutant bound to 5-fluoro-4-(S)-hydroxyl-3,4-dihydropyrimidine. 1R9Y ; 1.57 ; Bacterial cytosine deaminase D314A mutant. 1RA0 ; 1.12 ; Bacterial cytosine deaminase D314G mutant bound to 5-fluoro-4-(S)-hydroxy-3,4-dihydropyrimidine. 1R9X ; 1.58 ; Bacterial cytosine deaminase D314G mutant. 1RAK ; 1.32 ; Bacterial cytosine deaminase D314S mutant bound to 5-fluoro-4-(S)-hydroxyl-3,4-dihydropyrimidine. 1R9Z ; 1.32 ; Bacterial cytosine deaminase D314S mutant. 3G77 ; 1.8 ; Bacterial cytosine deaminase V152A/F316C/D317G mutant 1VHB ; 1.83 ; BACTERIAL DIMERIC HEMOGLOBIN FROM VITREOSCILLA STERCORARIA 2J69 ; 3 ; BACTERIAL DYNAMIN-LIKE PROTEIN BDLP 2J68 ; 3.1 ; BACTERIAL DYNAMIN-LIKE PROTEIN BDLP, GDP BOUND 2W6D ; 9 ; BACTERIAL DYNAMIN-LIKE PROTEIN LIPID TUBE BOUND 2VQ7 ; 2.6 ; BACTERIAL FLAVIN-CONTAINING MONOOXYGENASE IN COMPLEX WITH NADP: NATIVE DATA 2VQB ; 2.8 ; BACTERIAL FLAVIN-CONTAINING MONOOXYGENASE IN COMPLEX WITH NADP: SOAKING IN AERATED SOLUTION 1LZL ; 1.3 ; Bacterial Heroin Esterase 1LZK ; 1.45 ; BACTERIAL HEROIN ESTERASE COMPLEX WITH TRANSITION STATE ANALOG DIMETHYLARSENIC ACID 1LUC ; 1.5 ; BACTERIAL LUCIFERASE 1XKJ ; 2.5 ; BACTERIAL LUCIFERASE BETA2 HOMODIMER 3RCE ; 3.4 ; Bacterial oligosaccharyltransferase PglB 4FPP ; 2.2 ; Bacterial phosphotransferase 4HBH ; 2.93 ; Bacterial Photosynthetic Reaction Center from Rhodobacter sphaeroides with ILE M265 replaced with ASN 4HBJ ; 2.74 ; Bacterial Photosynthetic Reaction Center from Rhodobacter sphaeroides with ILE M265 replaced with GLN 4H9L ; 2.77 ; Bacterial Photosynthetic Reaction Center from Rhodobacter sphaeroides with ILE M265 replaced with SER 4H99 ; 2.97 ; Bacterial Photosynthetic Reaction Center from Rhodobacter sphaeroides with ILE M265 replaced with THR 1GYZ ; ; BACTERIAL RIBOSOMAL PROTEIN L20 FROM AQUIFEX AEOLICUS 1PED ; 2.15 ; BACTERIAL SECONDARY ALCOHOL DEHYDROGENASE (APO-FORM) 4B3X ; 1.95 ; Bacterial translation initiation factor IF2 (1-363), apo form 4B47 ; 2.301 ; Bacterial translation initiation factor IF2 (1-363), complex with GDP at pH8.0 4B48 ; 2.8 ; Bacterial translation initiation factor IF2 (1-363), complex with GTP 1NBC ; 1.75 ; BACTERIAL TYPE 3A CELLULOSE-BINDING DOMAIN 1MPA ; 2.6 ; BACTERICIDAL ANTIBODY AGAINST NEISSERIA MENINGITIDIS 2MPA ; 2.6 ; BACTERICIDAL ANTIBODY AGAINST NEISSERIA MENINGITIDIS 4AM2 ; 1.8 ; Bacterioferritin from Blastochloris viridis 4AM4 ; 1.68 ; Bacterioferritin from Blastochloris viridis 4AM5 ; 1.58 ; Bacterioferritin from Blastochloris viridis 1GAV ; 3.4 ; BACTERIOPHAGE GA PROTEIN CAPSID 1HJI ; ; BACTERIOPHAGE HK022 NUN-PROTEIN-NUTBOXB-RNA COMPLEX 2FRP ; 7.5 ; Bacteriophage HK97 Expansion Intermediate IV 2FTE ; ; Bacteriophage HK97 Expansion Intermediate IV 2FT1 ; 3.9 ; Bacteriophage HK97 Head II 2FS3 ; 4.2 ; Bacteriophage HK97 K169Y Head I 2FSY ; 3.8 ; Bacteriophage HK97 Pepsin-treated Expansion Intermediate IV 2GP1 ; 5.2 ; Bacteriophage HK97 Prohead II crystal structure 1RH6 ; 1.7 ; Bacteriophage Lambda Excisionase (Xis)-DNA Complex 1C5E ; 1.1 ; BACTERIOPHAGE LAMBDA HEAD PROTEIN D 3D3D ; 2.6 ; Bacteriophage lambda lysozyme complexed with a chitohexasaccharide 1D9U ; 2.6 ; BACTERIOPHAGE LAMBDA LYSOZYME COMPLEXED WITH A CHITOHEXASACHARIDE 1QFQ ; ; Bacteriophage Lambda N-protein-NutboxB-RNA Complex 1G5B ; 2.15 ; BACTERIOPHAGE LAMBDA SER/THR PROTEIN PHOSPHATASE 3C82 ; 1.68 ; Bacteriophage lysozyme T4 lysozyme mutant K85A/R96H 1AQ3 ; 2.8 ; BACTERIOPHAGE MS2 CAPSID PROTEIN/RNA COMPLEX 1BCO ; 2.4 ; BACTERIOPHAGE MU TRANSPOSASE CORE DOMAIN 1BCM ; 2.8 ; BACTERIOPHAGE MU TRANSPOSASE CORE DOMAIN WITH 2 MONOMERS PER ASYMMETRIC UNIT 3LJ4 ; 3.251 ; Bacteriophage P22 Portal Protein Bound to Middle Tail Factor gp4. This file contain the first biological assembly 1VT0 ; 3.251 ; Bacteriophage P22 Portal Protein bound to middle Tail Factor GP4. This file contain the second biological assembly 2EX3 ; 3 ; Bacteriophage phi29 DNA polymerase bound to terminal protein 1QBE ; 3.5 ; BACTERIOPHAGE Q BETA CAPSID 1N80 ; 2.45 ; Bacteriophage T4 baseplate structural protein gp8 1N8B ; 2.9 ; Bacteriophage T4 baseplate structural protein gp8 1YUE ; 2.9 ; Bacteriophage T4 capsid vertex protein gp24 1C1K ; 1.45 ; BACTERIOPHAGE T4 GENE 59 HELICASE ASSEMBLY PROTEIN 1QEX ; 2.3 ; BACTERIOPHAGE T4 GENE PRODUCT 9 (GP9), THE TRIGGER OF TAIL CONTRACTION AND THE LONG TAIL FIBERS CONNECTOR 1S2E ; 2.3 ; BACTERIOPHAGE T4 GENE PRODUCT 9 (GP9), THE TRIGGER OF TAIL CONTRACTION AND THE LONG TAIL FIBERS CONNECTOR, ALTERNATIVE FIT OF THE FIRST 19 RESIDUES 3EZK ; 34 ; Bacteriophage T4 gp17 motor assembly based on crystal structures and cryo-EM reconstructions 256L ; 1.8 ; BACTERIOPHAGE T4 LYSOZYME 1D9W ; 1.91 ; BACTERIOPHAGE T4 LYSOZYME MUTANT 3C83 ; 1.84 ; Bacteriophage T4 lysozyme mutant D89A in wildtype background at room temperature 3CDO ; 1.87 ; Bacteriophage T4 lysozyme mutant R96V in wildtype background at low temperature 3IZG ; 10.9 ; Bacteriophage T7 prohead shell EM-derived atomic model 4RNP ; 3 ; BACTERIOPHAGE T7 RNA POLYMERASE, HIGH SALT CRYSTAL FORM, LOW TEMPERATURE DATA, ALPHA-CARBONS ONLY 1PY6 ; 1.8 ; Bacteriorhodopsin crystallized from bicells 1XJI ; 2.2 ; Bacteriorhodopsin crystallized in bicelles at room temperature 1JV6 ; 2 ; BACTERIORHODOPSIN D85S/F219L DOUBLE MUTANT AT 2.00 ANGSTROM RESOLUTION 1C8R ; 1.8 ; BACTERIORHODOPSIN D96N BR STATE AT 2.0 A RESOLUTION 1C8S ; 2 ; BACTERIORHODOPSIN D96N LATE M STATE INTERMEDIATE 1M0K ; 1.43 ; BACTERIORHODOPSIN K INTERMEDIATE AT 1.43 A RESOLUTION 1O0A ; 1.62 ; BACTERIORHODOPSIN L INTERMEDIATE AT 1.62 A RESOLUTION 1M0M ; 1.43 ; BACTERIORHODOPSIN M1 INTERMEDIATE AT 1.43 A RESOLUTION 1P8H ; 1.52 ; BACTERIORHODOPSIN M1 INTERMEDIATE PRODUCED AT ROOM TEMPERATURE 2WJL ; 2.15 ; BACTERIORHODOPSIN MUTANT E194D 2WJK ; 2.3 ; BACTERIORHODOPSIN MUTANT E204D 1P8U ; 1.62 ; BACTERIORHODOPSIN N' INTERMEDIATE AT 1.62 A RESOLUTION 1JV7 ; 2.25 ; BACTERIORHODOPSIN O-LIKE INTERMEDIATE STATE OF THE D85S MUTANT AT 2.25 ANGSTROM RESOLUTION 2NTW ; 1.53 ; Bacteriorhodopsin, wild type, after illumination to produce the L intermediate 2NTU ; 1.53 ; Bacteriorhodopsin, wild type, before illumination 1F50 ; 1.7 ; BACTERIORHODOPSIN-BR STATE OF THE E204Q MUTANT AT 1.7 ANGSTROM RESOLUTION 1F4Z ; 1.8 ; BACTERIORHODOPSIN-M PHOTOINTERMEDIATE STATE OF THE E204Q MUTANT AT 1.8 ANGSTROM RESOLUTION 1BRX ; 2.3 ; BACTERIORHODOPSIN/LIPID COMPLEX 1M0L ; 1.47 ; BACTERIORHODOPSIN/LIPID COMPLEX AT 1.47 A RESOLUTION 1C3W ; 1.55 ; BACTERIORHODOPSIN/LIPID COMPLEX AT 1.55 A RESOLUTION 2I1X ; 2 ; Bacteriorhodopsin/lipid complex, D96A mutant 2I20 ; 2.08 ; Bacteriorhodopsin/lipid complex, M state of D96A mutant 2I21 ; 1.84 ; Bacteriorhodopsin/lipid complex, T46V mutant 2Z55 ; 2.5 ; Bacterioruberin in the trimeric structure of archaerhodopsin-2 2JIW ; 1.95 ; BACTEROIDES THETAIOTAOMICRON GH84 O-GLCNACASE IN COMPLEX WITH 2-ACETYLAMINO-2-DEOXY-1-EPIVALIENAMINE 2J47 ; 1.98 ; BACTEROIDES THETAIOTAOMICRON GH84 O-GLCNACASE IN COMPLEX WITH A IMIDAZOLE-PUGNAC HYBRID INHIBITOR 2J4G ; 2.25 ; BACTEROIDES THETAIOTAOMICRON GH84 O-GLCNACASE IN COMPLEX WITH N-BUTYL-THIAZOLINE INHIBITOR 2CHO ; 1.85 ; BACTEROIDES THETAIOTAOMICRON HEXOSAMINIDASE WITH O-GLCNACASE ACTIVITY 2CHN ; 1.95 ; BACTEROIDES THETAIOTAOMICRON HEXOSAMINIDASE WITH O-GLCNACASE ACTIVITY - NAG-THIAZOLINE COMPLEX 3SA2 ; 2.25 ; Bacuills anthracis Dihydrofolate Reductase bound propargyl-linked TMP analog, UCP1014 3SA1 ; 2.5 ; Bacuills anthracis Dihydrofolate Reductase bound propargyl-linked TMP analog, UCP1021 3SAI ; 2.25 ; Bacuills anthracis Dihydrofolate Reductase bound to propargyl-linked TMP analog, UCP1015 1I6Z ; ; BAG DOMAIN OF BAG1 COCHAPERONE 3QBR ; 2.601 ; BakBH3 in complex with sjA 1HHU ; 0.89 ; Balhimycin in complex with D-Ala-D-Ala 1GO6 ; 0.98 ; Balhimycin in complex with Lys-D-ala-D-ala 3ZZV ; 1.68 ; BambL complexed with Htype2 tetrasaccharide 3MLA ; 1.75 ; BaNadD in complex with inhibitor 1_02 3MLB ; 1.8 ; BaNadD in complex with inhibitor 1_02_1 2BMY ; 2.5 ; BANANA LECTIN 2BN0 ; 2.8 ; BANANA LECTIN BOUND TO LAMINARIBIOSE 2BMZ ; 2.4 ; BANANA LECTIN BOUND TO XYL-B1,3 MAN-A-O-METHYL (XM) 2K56 ; ; Bank Vole Prion Protein (121-231) 1C40 ; 2.3 ; BAR-HEADED GOOSE HEMOGLOBIN (AQUOMET FORM) 1A4F ; 2 ; BAR-HEADED GOOSE HEMOGLOBIN (OXY FORM) 3KCH ; 1.94 ; Baranase crosslinked by glutaraldehyde 3GOM ; 2.3 ; Barium bound to the Holliday junction sequence d(TCGGCGCCGA)4 3GOJ ; 2.6 ; Barium bound to the Holliday sequence d(CCGGCGCCGG)4 3VG5 ; 2 ; Barium derivative of human LFABP 3VG6 ; 2.22 ; Barium derivative of human LFABP 3FQB ; 1.67 ; Barium interactions with Z-DNA 1AQ0 ; 2 ; BARLEY 1,3-1,4-BETA-GLUCANASE IN MONOCLINIC SPACE GROUP 2VDG ; 1.92 ; BARLEY ALDOSE REDUCTASE 1 COMPLEX WITH BUTANOL 3BSH ; 3 ; Barley alpha-amylase isozyme 1 (AMY1) double mutant Y105A/Y380A in complex with inhibitor acarbose 3BSG ; 1.95 ; Barley alpha-amylase isozyme 1 (AMY1) H395A mutant 1BG9 ; 2.8 ; BARLEY ALPHA-AMYLASE WITH SUBSTRATE ANALOGUE ACARBOSE 2Y5E ; 2.49 ; BARLEY LIMIT DEXTRINASE IN COMPLEX WITH ALPHA-CYCLODEXTRIN 2Y4S ; 2.1 ; BARLEY LIMIT DEXTRINASE IN COMPLEX WITH BETA-CYCLODEXTRIN 1LIP ; ; BARLEY LIPID TRANSFER PROTEIN (NMR, 4 STRUCTURES) 2WHD ; 2.6 ; BARLEY NADPH-DEPENDENT THIOREDOXIN REDUCTASE 2 1BNR ; ; BARNASE 1BNE ; 2.1 ; BARNASE A43C/S80C DISULFIDE MUTANT 2KF6 ; ; Barnase bound to d(CGAC) high pressure 2KF5 ; ; Barnase bound to d(CGAC), low pressure 2F4Y ; 2.15 ; Barnase cross-linked with glutaraldehyde 2F56 ; 1.955 ; Barnase cross-linked with glutaraldehyde soaked in 6M urea 2KF4 ; ; Barnase high pressure structure 1BRI ; 1.9 ; BARNASE MUTANT WITH ILE 76 REPLACED BY ALA 1BRJ ; 2 ; BARNASE MUTANT WITH ILE 88 REPLACED BY ALA 1BRK ; 2 ; BARNASE MUTANT WITH ILE 96 REPLACED BY ALA 1BRH ; 2 ; BARNASE MUTANT WITH LEU 14 REPLACED BY ALA 1BNG ; 2.1 ; BARNASE S85C/H102C DISULFIDE MUTANT 1BNF ; 2 ; BARNASE T70C/S92C DISULFIDE MUTANT 1A2P ; 1.5 ; BARNASE WILDTYPE STRUCTURE AT 1.5 ANGSTROMS RESOLUTION 1BNI ; 2.1 ; BARNASE WILDTYPE STRUCTURE AT PH 6.0 1B2X ; 1.8 ; BARNASE WILDTYPE STRUCTURE AT PH 7.5 FROM A CRYO_COOLED CRYSTAL AT 100K 1BNJ ; 2.1 ; BARNASE WILDTYPE STRUCTURE AT PH 9.0 2KF3 ; ; Barnase, low pressure reference NMR structure 1A19 ; 2.76 ; BARSTAR (FREE), C82A MUTANT 3NAZ ; 3 ; Basal state form of Yeast Glycogen Synthase 1DNS ; 2 ; BASE ONLY BINDING OF SPERMINE IN THE DEEP GROOVE OF THE A-DNA OCTAMER D(GTGTACAC) 4FS2 ; 2.05 ; Base pairing mechanism of N2,3-ethenoguanine with dCTP by human polymerase iota 4FS1 ; 2.5 ; Base pairing mechanism of N2,3-ethenoguanine with dTTP by human polymerase iota 1D40 ; 1.3 ; BASE SPECIFIC BINDING OF COPPER(II) TO Z-DNA: THE 1.3-ANGSTROMS SINGLE CRYSTAL STRUCTURE OF D(M5CGUAM5CG) IN THE PRESENCE OF CUCL2 206D ; 2.5 ; BASE-PAIR OPENING AND SPERMINE BINDING-B-DNA FEATURES DISPLAYED IN THE CRYSTAL STRUCTURE OF A GAL OPERON FRAGMENT: IMPLICATIONS FOR PROTEIN-DNA RECOGNITION 1QP5 ; 2.6 ; BASE-PAIRING SHIFT IN A DODECAMER CONTAINING A (CA)N TRACT 330D ; 2.7 ; BASE-PAIRING SHIFT IN THE MAJOR GROOVE OF (CA)N TRACTS BY B-DNA CRYSTAL STRUCTURES 2AWE ; 2.1 ; Base-Tetrad Swapping Results in Dimerization of RNA Quadruplexes: Implications for Formation of I-Motif RNA Octaplex 1BLA ; ; BASIC FIBROBLAST GROWTH FACTOR (FGF-2) MUTANT WITH CYS 78 REPLACED BY SER AND CYS 96 REPLACED BY SER, NMR 1BLD ; ; BASIC FIBROBLAST GROWTH FACTOR (FGF-2) MUTANT WITH CYS 78 REPLACED BY SER AND CYS 96 REPLACED BY SER, NMR 1BFC ; 2.2 ; BASIC FIBROBLAST GROWTH FACTOR COMPLEXED WITH HEPARIN HEXAMER FRAGMENT 1BFB ; 1.9 ; BASIC FIBROBLAST GROWTH FACTOR COMPLEXED WITH HEPARIN TETRAMER FRAGMENT 9PTI ; 1.22 ; BASIC PANCREATIC TRYPSIN INHIBITOR (MET 52 OXIDIZED) 1B4W ; 2.6 ; BASIC PHOSPHOLIPASE A2 FROM AGKISTRODON HALYS PALLAS-IMPLICATIONS FOR ITS ASSOCIATION AND ANTICOAGULANT ACTIVITIES BY X-RAY CRYSTALLOGRAPHY 1PVP ; 2.35 ; BASIS FOR A SWITCH IN SUBSTRATE SPECIFICITY: CRYSTAL STRUCTURE OF SELECTED VARIANT OF CRE SITE-SPECIFIC RECOMBINASE, ALSHG BOUND TO THE ENGINEERED RECOGNITION SITE LOXM7 1PVQ ; 2.75 ; BASIS FOR A SWITCH IN SUBSTRATE SPECIFICITY: CRYSTAL STRUCTURE OF SELECTED VARIANT OF CRE SITE-SPECIFIC RECOMBINASE, LNSGG BOUND TO THE ENGINEERED RECOGNITION SITE LOXM7 1PVR ; 2.65 ; BASIS FOR A SWITCH IN SUBSTRATE SPECIFICITY: CRYSTAL STRUCTURE OF SELECTED VARIANT OF CRE SITE-SPECIFIC RECOMBINASE, LNSGG BOUND TO THE LOXP (WILDTYPE) RECOGNITION SITE 2GZB ; 1.7 ; Bauhinia bauhinioides cruzipain inhibitor (BbCI) 2K7W ; ; BAX Activation is Initiated at a Novel Interaction Site 4BDU ; 2.998 ; Bax BH3-in-Groove dimer (GFP) 4BD6 ; 2.494 ; Bax domain swapped dimer in complex with BaxBH3 4BD2 ; 2.206 ; Bax domain swapped dimer in complex with BidBH3 4BD8 ; 2.22 ; Bax domain swapped dimer induced by BimBH3 with CHAPS 4BD7 ; 2.801 ; Bax domain swapped dimer induced by octylmaltoside 1W33 ; 2.7 ; BBCRASP-1 FROM BORRELIA BURGDORFERI 2XNX ; 3.3 ; BC1 FRAGMENT OF STREPTOCOCCAL M1 PROTEIN IN COMPLEX WITH HUMAN FIBRINOGEN 2Y0E ; 1.75 ; BCEC AND THE FINAL STEP OF UGDS REACTION 2Y0D ; 2.8 ; BCEC MUTATION Y10K 2Y0C ; 1.75 ; BCEC MUTATION Y10S 2B48 ; 3.45 ; Bcl-XL 3D Domain Swapped Dimer 2WRA ; 1.1 ; BCLA LECTIN FROM BURKHOLDERIA CENOCEPACIA COMPLEXED WITH AMAN1(AMAN1-6)-3MAN TRISACCHARIDE 3TM8 ; 1.28 ; Bd1817, a HDG""Y""P protein from Bdellovibrio bacteriovorus 3TMB ; 1.7 ; Bd1817, a HDG""Y""P protein from Bdellovibrio bacteriovorus 3TMC ; 1.55 ; Bd1817, a HDG""Y""P protein from Bdellovibrio bacteriovorus 3TMD ; 2.641 ; Bd1817, a HDG""Y""P protein from Bdellovibrio bacteriovorus 3V39 ; 1.45 ; Bd3459, A Predatory Peptidoglycan Endopeptidase from Bdellovibrio bacteriovorus 1PGL ; 2.8 ; BEAN POD MOTTLE VIRUS (BPMV), MIDDLE COMPONENT 1PGW ; 2.9 ; BEAN POD MOTTLE VIRUS (BPMV), TOP COMPONENT 3NNS ; 1.9 ; BeF3 Activated DrrB Receiver Domain 3NNN ; 2.2 ; BeF3 Activated DrrD Receiver Domain 1ZES ; 1.9 ; BeF3- activated PhoB receiver domain 4I4O ; 1.12 ; BEL beta-trefoil apo crystal form 1 4I4P ; 1.279 ; BEL beta-trefoil apo crystal form 2 4I4Q ; 1.51 ; BEL beta-trefoil apo crystal form 3 4I4R ; 1.77 ; BEL beta-trefoil apo crystal form 4 4I4U ; 1.57 ; BEL beta-trefoil complex with galactose 4I4S ; 1.4 ; BEL beta-trefoil complex with lactose 4I4V ; 1.5 ; BEL beta-trefoil complex with N-acetylgalactosamine 4I4Y ; 1.9 ; BEL beta-trefoil complex with T-Antigen 4I4X ; 1.72 ; BEL beta-trefoil complex with T-Antigen disaccharide 2OMB ; 2.9 ; Bence Jones KWR Protein- Immunoglobulin Light Chain Dimer, P3(1)21 Crystal Form 2OLD ; 2.6 ; Bence Jones KWR Protein- Immunoglobulin Light Chain Dimer, P3(2)21 Crystal Form 2OMN ; 2.2 ; Bence Jones KWR Protein- Immunoglobulin Light Chain Dimer, P4(3)2(1)2 Crystal Form 1LIL ; 2.65 ; BENCE JONES PROTEIN CLE, A LAMBDA III IMMUNOGLOBULIN LIGHT-CHAIN DIMER 1B6D ; 2.74 ; BENCE JONES PROTEIN DEL: AN ENTIRE IMMUNOGLOBULIN KAPPA LIGHT-CHAIN DIMER 1BWW ; 1.7 ; BENCE-JONES IMMUNOGLOBULIN REI VARIABLE PORTION, T39K MUTANT 2F6G ; 1.908 ; BenM effector binding domain 2F78 ; 2.05 ; BenM effector binding domain with its effector benzoate 2F7A ; 1.9 ; BenM effector binding domain with its effector, cis,cis-muconate 2F6P ; 2.001 ; BenM effector binding domain- SeMet derivative 2F8D ; 2.7 ; BenM effector-Binding domain crystallized from high pH conditions 2E7E ; 1.85 ; Bent-binding of cyanide to the heme iron in rat heme oxygenase-1 3A5S ; 1.8 ; Benzalacetone synthase (I207L/L208F) 3A5Q ; 1.8 ; Benzalacetone synthase from Rheum palmatum 3A5R ; 1.6 ; Benzalacetone synthase from Rheum palmatum complexed with 4-coumaroyl-primed monoketide intermediate 3LV1 ; 2.501 ; Benzaldehyde Dehydrogenase, a Class 3 Aldehyde Dehydrogenase, with bound NADP+ 3LNS ; 2.501 ; Benzaldehyde Dehydrogenase, a Class 3 Aldehyde Dehydrogenase, with bound NADP+ and Benzoate Adduct 1V2V ; 1.8 ; Benzamidine in complex with bovine trypsin variant X(SSAI)bT.C1 1V2S ; 1.72 ; Benzamidine in complex with bovine trypsin variant X(SSFI.Glu)bT.D1 1V2J ; 1.9 ; BENZAMIDINE IN COMPLEX WITH BOVINE TRYPSIN VARIANT X(SSRI)bT.C1 1V2M ; 1.65 ; Benzamidine in complex with bovine trypsin variant X(triple.Glu)bT.A1 1V2L ; 1.6 ; Benzamidine in complex with bovine trypsin variant X(triple.Glu)bT.D1 1V2U ; 1.8 ; Benzamidine in complex with bovine trypsin varinat X(SSAI)bT.D1 1J15 ; 2 ; BENZAMIDINE IN COMPLEX WITH RAT TRYPSIN MUTANT X99/175/190RT 1J16 ; 1.6 ; BENZAMIDINE IN COMPLEX WITH RAT TRYPSIN MUTANT X99/175/190RT 1J14 ; 2.4 ; BENZAMIDINE IN COMPLEX WITH RAT TRYPSIN MUTANT X99RT 3DMX ; 1.8 ; Benzene binding in the hydrophobic cavity of T4 lysozyme L99A mutant 4ALU ; 2.6 ; Benzofuropyrimidinone Inhibitors of Pim-1 4ALV ; 2.59 ; Benzofuropyrimidinone Inhibitors of Pim-1 4ALW ; 1.92 ; Benzofuropyrimidinone Inhibitors of Pim-1 2I0G ; 2.5 ; Benzopyrans are Selective Estrogen Receptor beta Agonists (SERBAs) with Novel Activity in Models of Benign Prostatic Hyperplasia 2I0J ; 2.9 ; Benzopyrans are Selective Estrogen Receptor beta Agonists (SERBAs) with Novel Activity in Models of Benign Prostatic Hyperplasia 2POG ; 1.84 ; Benzopyrans as Selective Estrogen Receptor b Agonists (SERBAs). Part 2: Structure Activity Relationship Studies on the Benzopyran Scaffold. 3SOS ; 2.58 ; Benzothiazinone inhibitor in complex with FXIa 3LC3 ; 1.9 ; Benzothiophene Inhibitors of Factor IXa 1BFD ; 1.6 ; BENZOYLFORMATE DECARBOXYLASE FROM PSEUDOMONAS PUTIDA 1MCZ ; 2.8 ; BENZOYLFORMATE DECARBOXYLASE FROM PSEUDOMONAS PUTIDA COMPLEXED WITH AN INHIBITOR, R-MANDELATE 1DXA ; ; BENZO[A]PYRENE DIOL EPOXIDE ADDUCT OF DA IN DUPLEX DNA 1BMA ; 1.8 ; BENZYL METHYL AMINIMIDE INHIBITOR COMPLEXED TO PORCINE PANCREATIC ELASTASE 3HUK ; 1.29 ; Benzylacetate in complex with T4 lysozyme L99A/M102Q 1EH8 ; 2.5 ; BENZYLATED HUMAN O6-ALKYLGUANINE-DNA ALKYLTRANSFERASE 2IWC ; 2.1 ; BENZYLPENICILLOYL-ACYLATED MECR1 EXTRACELLULAR ANTIBIOTIC-SENSOR DOMAIN. 2PL1 ; 1.9 ; Berrylium Fluoride activated receiver domain of E.coli PhoP 1W0J ; 2.2 ; BERYLLIUM FLUORIDE INHIBITED BOVINE F1-ATPASE 1W0K ; 2.85 ; BERYLLIUM FLUORIDE INHIBITED BOVINE F1-ATPASE 2FTK ; 3.05 ; berylloflouride Spo0F complex with Spo0B 1HO9 ; ; BEST 20 NMR CONFORMERS OF D130I MUTANT T3-I2, A 32 RESIDUE PEPTIDE FROM THE ALPHA 2A ADRENERGIC RECEPTOR 1GX7 ; ; BEST MODEL OF THE ELECTRON TRANSFER COMPLEX BETWEEN CYTOCHROME C3 AND [FE]-HYDROGENASE 3H8G ; 1.5 ; Bestatin complex structure of leucine aminopeptidase from Pseudomonas putida 3DHM ; 1.8 ; Beta 2 microglobulin mutant D59P 3DHJ ; 2 ; Beta 2 microglobulin mutant W60C 2IV8 ; 2.8 ; BETA APPENDAGE IN COMPLEX WITH B-ARRESTIN PEPTIDE 2G30 ; 1.6 ; beta appendage of AP2 complexed with ARH peptide 2FGY ; 2.2 ; Beta Carbonic Anhydrase from the Carboxysomal Shell of Halothiobacillus neapolitanus (CsoSCA) 1BEC ; 1.7 ; BETA CHAIN OF A T CELL ANTIGEN RECEPTOR 1C4P ; 2.4 ; BETA DOMAIN OF STREPTOKINASE 1CPX ; 2 ; BETA FORM OF CARBOXYPEPTIDASE A (RESIDUES 3-307) FROM BOVINE PANCREAS IN AN ORTHORHOMBIC CRYSTAL FORM WITH TWO ZINC IONS IN THE ACTIVE SITE. 2BV2 ; 1.55 ; BETA GAMMA CRYSTALLIN FROM CIONA INTESTINALIS 1E5M ; 1.54 ; BETA KETOACYL ACYL CARRIER PROTEIN SYNTHASE II (KASII) FROM SYNECHOCYSTIS SP. 2AK5 ; 1.85 ; beta PIX-SH3 complexed with a Cbl-b peptide 1ZSG ; ; beta PIX-SH3 complexed with an atypical peptide from alpha-PAK 3KNQ ; 2.13 ; Beta Turn Optimization of the Gene-3-Protein of Filamentous Phage Fd 1WC2 ; 1.2 ; BETA-1,4-D-ENDOGLUCANASE CEL45A FROM BLUE MUSSEL MYTILUS EDULIS AT 1.2A 1NWG ; 2.32 ; BETA-1,4-GALACTOSYLTRANSFERASE COMPLEX WITH ALPHA-LACTALBUMIN AND N-BUTANOYL-GLUCOAMINE 1NMM ; 2 ; beta-1,4-galactosyltransferase mutant Cys342Thr complex with alpha-lactalbumin and GlcNAc 1TW1 ; 2.3 ; beta-1,4-galactosyltransferase mutant Met344His (m344H-Gal-T1) complex with UDP-galactose and magnesium 1TVY ; 2.3 ; beta-1,4-galactosyltransferase mutant Met344His (M344H-Gal-T1) complex with UDP-galactose and manganese 1EXP ; 1.8 ; BETA-1,4-GLYCANASE CEX-CD 3VUP ; 1.05 ; Beta-1,4-mannanase from the common sea hare Aplysia kurodai 1XNK ; 1.55 ; Beta-1,4-xylanase from Chaetomium thermophilum complexed with methyl thioxylopentoside 5BCA ; 2.2 ; BETA-AMYLASE FROM BACILLUS CEREUS VAR. MYCOIDES 1ITC ; 2.1 ; Beta-Amylase from Bacillus cereus var. mycoides Complexed with Maltopentaose 1J12 ; 2.1 ; Beta-Amylase from Bacillus cereus var. mycoides in Complex with alpha-EBG 1J11 ; 2 ; beta-amylase from Bacillus cereus var. mycoides in complex with alpha-EPG 1J10 ; 2.1 ; beta-amylase from Bacillus cereus var. mycoides in complex with GGX 1J0Y ; 2.1 ; Beta-amylase from Bacillus cereus var. mycoides in complex with glucose 1J0Z ; 2.2 ; Beta-amylase from Bacillus cereus var. mycoides in complex with maltose 1BFN ; 2.07 ; BETA-AMYLASE/BETA-CYCLODEXTRIN COMPLEX 1E0R ; 2.8 ; BETA-APICAL DOMAIN OF THERMOSOME 1M1E ; 2.1 ; Beta-catenin armadillo repeat domain bound to ICAT 1QZ7 ; 2.2 ; Beta-catenin binding domain of Axin in complex with beta-catenin 1TH1 ; 2.5 ; Beta-catenin in complex with a phosphorylated APC 20aa repeat fragment 1I7X ; 3 ; BETA-CATENIN/E-CADHERIN COMPLEX 1I7W ; 2 ; BETA-CATENIN/PHOSPHORYLATED E-CADHERIN COMPLEX 2RAY ; 1.798 ; beta-chlorophenetole in complex with T4 lysozyme L99A 2A8F ; 1.35 ; beta-cinnamomin after sterol removal 2AIB ; 1.1 ; beta-cinnamomin in complex with ergosterol 1BEO ; 2.2 ; BETA-CRYPTOGEIN 1LRI ; 1.45 ; BETA-CRYPTOGEIN-CHOLESTEROL COMPLEX 1EX1 ; 2.2 ; BETA-D-GLUCAN EXOHYDROLASE FROM BARLEY 1YI7 ; 1.9 ; Beta-d-xylosidase (selenomethionine) XYND from Clostridium Acetobutylicum 1Y7B ; 1.6 ; BETA-D-XYLOSIDASE, A FAMILY 43 GLYCOSIDE HYDROLASE 3PIG ; 1.87 ; beta-fructofuranosidase from Bifidobacterium longum 3PIJ ; 1.8 ; beta-fructofuranosidase from Bifidobacterium longum - complex with fructose 1W2T ; 1.87 ; BETA-FRUCTOSIDASE FROM THERMOTOGA MARITIMA IN COMPLEX WITH RAFFINOSE 1BGL ; 2.5 ; BETA-GALACTOSIDASE (CHAINS A-H) 1BGM ; 2.5 ; BETA-GALACTOSIDASE (CHAINS I-P) 1YQ2 ; 1.9 ; beta-galactosidase from Arthrobacter sp. C2-2 (isoenzyme C2-2-1) 1TBG ; 2.1 ; BETA-GAMMA DIMER OF THE HETEROTRIMERIC G-PROTEIN TRANSDUCIN 1BGA ; 2.4 ; BETA-GLUCOSIDASE A FROM BACILLUS POLYMYXA 3TA9 ; 3 ; beta-Glucosidase A from the halothermophile H. orenii 2O9R ; 2.3 ; beta-glucosidase B complexed with thiocellobiose 2JIE ; 2.3 ; BETA-GLUCOSIDASE B FROM BACILLUS POLYMYXA COMPLEXED WITH 2-F-GLUCOSE 2O9T ; 2.15 ; beta-glucosidase B from Bacillus polymyxa complexed with glucose 2O9P ; 2.1 ; beta-glucosidase B from Paenibacillus polymyxa 2Z1S ; 2.46 ; Beta-glucosidase B from paenibacillus polymyxa complexed with cellotetraose 1QOX ; 2.7 ; BETA-GLUCOSIDASE FROM BACILLUS CIRCULANS SP. ALKALOPHILUS 2J7H ; 1.95 ; BETA-GLUCOSIDASE FROM THERMOTOGA MARITIMA IN COMPLEX WITH AZAFAGOMINE 2CBV ; 1.95 ; BETA-GLUCOSIDASE FROM THERMOTOGA MARITIMA IN COMPLEX WITH CALYSTEGINE B2 2J7F ; 2.28 ; BETA-GLUCOSIDASE FROM THERMOTOGA MARITIMA IN COMPLEX WITH CARBOXYLATE-SUBSTITUTED GLUCOIMIDAZOLE 2CBU ; 1.85 ; BETA-GLUCOSIDASE FROM THERMOTOGA MARITIMA IN COMPLEX WITH CASTANOSPERMINE 2JAL ; 1.9 ; BETA-GLUCOSIDASE FROM THERMOTOGA MARITIMA IN COMPLEX WITH CYCLOPHELLITOL 2J77 ; 2.1 ; BETA-GLUCOSIDASE FROM THERMOTOGA MARITIMA IN COMPLEX WITH DEOXYNOJIRIMYCIN 2J79 ; 1.94 ; BETA-GLUCOSIDASE FROM THERMOTOGA MARITIMA IN COMPLEX WITH GALACTO-HYDROXIMOLACTAM 2J78 ; 1.65 ; BETA-GLUCOSIDASE FROM THERMOTOGA MARITIMA IN COMPLEX WITH GLUCO-HYDROXIMOLACTAM 2J7B ; 1.87 ; BETA-GLUCOSIDASE FROM THERMOTOGA MARITIMA IN COMPLEX WITH GLUCO-TETRAZOLE 2CES ; 2.15 ; BETA-GLUCOSIDASE FROM THERMOTOGA MARITIMA IN COMPLEX WITH GLUCOIMIDAZOLE 2J7D ; 2.24 ; BETA-GLUCOSIDASE FROM THERMOTOGA MARITIMA IN COMPLEX WITH METHOXYCARBONYL-SUBSTITUTED GLUCOIMIDAZOLE 2J7E ; 2.19 ; BETA-GLUCOSIDASE FROM THERMOTOGA MARITIMA IN COMPLEX WITH METHYL ACETATE-SUBSTITUTED GLUCOIMIDAZOLE 2J7G ; 1.91 ; BETA-GLUCOSIDASE FROM THERMOTOGA MARITIMA IN COMPLEX WITH METHYL ACETIC ACID-SUBSTITUTED GLUCOIMIDAZOLE 2VRJ ; 1.9 ; BETA-GLUCOSIDASE FROM THERMOTOGA MARITIMA IN COMPLEX WITH N-OCTYL-5-DEOXY-6-OXA-N-(THIO)CARBAMOYLCALYSTEGINE 2J75 ; 1.85 ; BETA-GLUCOSIDASE FROM THERMOTOGA MARITIMA IN COMPLEX WITH NOEUROMYCIN 2CET ; 1.97 ; BETA-GLUCOSIDASE FROM THERMOTOGA MARITIMA IN COMPLEX WITH PHENETHYL-SUBSTITUTED GLUCOIMIDAZOLE 2J7C ; 2.09 ; BETA-GLUCOSIDASE FROM THERMOTOGA MARITIMA IN COMPLEX WITH PHENYLAMINOMETHYL-DERIVED GLUCOIMIDAZOLE 1VFF ; 2.5 ; beta-glycosidase from Pyrococcus horikoshii 1GOW ; 2.6 ; BETA-GLYCOSIDASE FROM SULFOLOBUS SOLFATARICUS 2CEQ ; 2.14 ; BETA-GLYCOSIDASE FROM SULFOLOBUS SOLFATARICUS IN COMPLEX WITH GLUCOIMIDAZOLE 2CER ; 2.29 ; BETA-GLYCOSIDASE FROM SULFOLOBUS SOLFATARICUS IN COMPLEX WITH PHENETHYL-SUBSTITUTED GLUCOIMIDAZOLE 3AZ8 ; 3.1 ; Beta-Hydroxyacyl-Acyl Carrier Protein Dehydratase (FabZ) from Plasmodium falciparum in complex with NAS21 3AZ9 ; 2.75 ; Beta-Hydroxyacyl-Acyl Carrier Protein Dehydratase (FabZ) from Plasmodium falciparum in complex with NAS91 3AZA ; 2.7 ; Beta-Hydroxyacyl-Acyl Carrier Protein Dehydratase (FabZ) from Plasmodium falciparum in complex with NAS91-10 3AZB ; 2.6 ; Beta-Hydroxyacyl-Acyl Carrier Protein Dehydratase (FabZ) from Plasmodium falciparum in complex with NAS91-11 1B3N ; 2.65 ; BETA-KETOACYL CARRIER PROTEIN SYNTHASE AS A DRUG TARGET, IMPLICATIONS FROM THE CRYSTAL STRUCTURE OF A COMPLEX WITH THE INHIBITOR CERULENIN. 1EK4 ; 1.85 ; BETA-KETOACYL [ACYL CARRIER PROTEIN] SYNTHASE I IN COMPLEX WITH DODECANOIC ACID TO 1.85 RESOLUTION 2VBA ; 1.36 ; BETA-KETOACYL-ACP SYNTHASE I (KAS) FROM E. COLI WITH BOUND AMINO-THIAZOLE INHIBITOR 2VB8 ; 1.52 ; BETA-KETOACYL-ACP SYNTHASE I (KAS) FROM E. COLI WITH BOUND INHIBITOR THIOLACTOMYCIN 2VB9 ; 1.5 ; BETA-KETOACYL-ACP SYNTHASE I (KAS) FROM E. COLI, APO STRUCTURE 2VB7 ; 1.6 ; BETA-KETOACYL-ACP SYNTHASE I (KAS) FROM E. COLI, APO STRUCTURE AFTER SOAK IN PEG SOLUTION 1KAS ; 2.4 ; BETA-KETOACYL-ACP SYNTHASE II FROM ESCHERICHIA COLI 1F91 ; 2.4 ; BETA-KETOACYL-[ACYL-CARRIER-PROTEIN] SYNTHASE I IN COMPLEX WITH C10 FATTY ACID SUBSTRATE 1M1Z ; 1.95 ; BETA-LACTAM SYNTHETASE APO ENZYME 1MB9 ; 2.11 ; BETA-LACTAM SYNTHETASE COMPLEXED WITH ATP 1MC1 ; 2.16 ; BETA-LACTAM SYNTHETASE WITH PRODUCT (DGPC), AMP AND PPI 1MBZ ; 2.47 ; BETA-LACTAM SYNTHETASE WITH TRAPPED INTERMEDIATE 3Q7V ; 2.1 ; Beta-Lactam-Sensor Domain of BlaR1 (Apo) from Staphylococcus Aureus with Carboxylated Lys392 1I2S ; 1.7 ; BETA-LACTAMASE FROM BACILLUS LICHENIFORMIS BS3 1I2W ; 1.7 ; BETA-LACTAMASE FROM BACILLUS LICHENIFORMIS BS3 COMPLEXED WITH CEFOXITIN 1BSG ; 1.85 ; BETA-LACTAMASE FROM STREPTOMYCES ALBUS G 2BLM ; 2 ; BETA-LACTAMASE OF BACILLUS LICHENIFORMIS 749(SLASH)C AT 2 ANGSTROMS RESOLUTION 4BLM ; 2 ; BETA-LACTAMASE OF BACILLUS LICHENIFORMIS 749(SLASH)C. REFINEMENT AT 2 ANGSTROMS RESOLUTION AND ANALYSIS OF HYDRATION 1BZA ; 1.8 ; BETA-LACTAMASE TOHO-1 FROM ESCHERICHIA COLI TUH12191 2Q39 ; 2.5 ; Beta-lactoglobulin (low humidity) 2Q2M ; 2.1 ; Beta-lactoglobulin (native) 2Q2P ; 2.96 ; Beta-lactoglobulin (reverse native) 1BQC ; 1.5 ; BETA-MANNANASE FROM THERMOMONOSPORA FUSCA 1CF5 ; 2.55 ; BETA-MOMORCHARIN STRUCTURE AT 2.55 A 1C7S ; 1.8 ; BETA-N-ACETYLHEXOSAMINIDASE MUTANT D539A COMPLEXED WITH DI-N-ACETYL-BETA-D-GLUCOSAMINE (CHITOBIASE) 1C7T ; 1.9 ; BETA-N-ACETYLHEXOSAMINIDASE MUTANT E540D COMPLEXED WITH DI-N ACETYL-D-GLUCOSAMINE (CHITOBIASE) 3BMX ; 1.4 ; Beta-N-hexosaminidase (YbbD) from Bacillus subtilis 3LK6 ; 2.88 ; Beta-N-hexosaminidase N318D mutant (YBBD_N318D) from bacillus subtilis 1H6L ; 1.8 ; BETA-PROPELLER PHYTASE IN COMPLEX WITH PHOSPHATE AND CALCIUM IONS 3DM6 ; 2.6 ; Beta-secretase 1 complexed with statine-based inhibitor 1BJU ; 1.8 ; BETA-TRYPSIN COMPLEXED WITH ACPU 1BJV ; 1.8 ; BETA-TRYPSIN COMPLEXED WITH APPU 1MAX ; 1.8 ; BETA-TRYPSIN PHOSPHONATE INHIBITED 1MAY ; 1.8 ; BETA-TRYPSIN PHOSPHONATE INHIBITED 4A6L ; 2.05 ; beta-tryptase inhibitor 3K1U ; 1.55 ; Beta-xylosidase, family 43 glycosyl hydrolase from Clostridium acetobutylicum 1TW5 ; 2.3 ; beta1,4-galactosyltransferase mutant M344H-Gal-T1 in complex with Chitobiose 1PY4 ; 2.9 ; Beta2 microglobulin mutant H31Y displays hints for amyloid formations 1E42 ; 1.7 ; BETA2-ADAPTIN APPENDAGE DOMAIN, FROM CLATHRIN ADAPTOR AP2 3O81 ; 2 ; Beta2-microglobulin from Gallus gallus 1VYT ; 2.6 ; BETA3 SUBUNIT COMPLEXED WITH AID 1VYU ; 2.3 ; BETA3 SUBUNIT OF VOLTAGE-GATED CA2+-CHANNEL 1VYV ; 3 ; BETA4 SUBUNIT OF CA2+ CHANNEL 1A4S ; 2.1 ; BETAINE ALDEHYDE DEHYDROGENASE FROM COD LIVER 1BPW ; 2.8 ; BETAINE ALDEHYDE DEHYDROGENASE FROM COD LIVER 2WOX ; 2.3 ; BETAINE ALDEHYDE DEHYDROGENASE FROM PSEUDOMONAS AERUGINOSA WITH NAD(P)H-CATALYTIC THIOL ADDUCT. 1SXP ; 2.5 ; BGT in complex with a 13mer DNA containing a central A:G mismatch 1SXQ ; 1.8 ; BGT in complex with a 13mer DNA containing a central C:G base pair and UDP 1MQL ; 2.9 ; BHA of Ukr/63 1MQM ; 2.6 ; BHA/LSTa 1MQN ; 3.2 ; BHA/LSTc 3HC3 ; 1.72 ; BHA10 IgG1 Fab double mutant variant - antibody directed at human LTBR 3HC4 ; 1.62 ; BHA10 IgG1 Fab quadruple mutant variant - antibody directed at human LTBR 3HC0 ; 1.9 ; BHA10 IgG1 wild-type Fab - antibody directed at human LTBR 1UMY ; 2.5 ; BHMT FROM RAT LIVER 2AB5 ; 2.2 ; bI3 LAGLIDADG Maturase 2K1A ; ; Bicelle-embedded integrin alpha(IIB) transmembrane segment 2RMZ ; ; Bicelle-embedded integrin beta3 transmembrane segment 2HEZ ; 2.5 ; Bifidobacterium longum bile salt hydrolase 2HF0 ; 2.3 ; Bifidobacterium longum bile salt hydrolase 4A7K ; 2 ; Bifunctional Aldos-2-ulose dehydratase 2HXD ; 2.3 ; Bifunctional dCTP deaminase-dUTPase mutant enzyme variant E145A from Methanocaldococcus jannaschii in complex with alpha,beta-imido dUTP and magnesium 3GF0 ; 2.62 ; Bifunctional dCTP deaminase-dUTPase mutant enzyme variant E145Q from Methanocaldococcus jannaschii in complex with pyrophosphate and magnesium 2QXX ; 2 ; Bifunctional dCTP deaminase: dUTPase from Mycobacterium tuberculosis in complex with dTTP 2QLP ; 2.47 ; Bifunctional dCTP deaminase:dUTPase from Mycobacterium tuberculosis, apo form 1RNI ; 1.85 ; Bifunctional DNA primase/polymerase domain of ORF904 from the archaeal plasmid pRN1 1RO2 ; 1.6 ; Bifunctional DNA primase/polymerase domain of ORF904 from the archaeal plasmid pRN1- Triple mutant F50M/L107M/L110M manganese soak 1RO0 ; 1.8 ; Bifunctional DNA primase/polymerase domain of ORF904 from the archaeal plasmid pRN1- Triple mutant F50M/L107M/L110M SeMet remote 1BEA ; 1.95 ; BIFUNCTIONAL HAGEMAN FACTOR/AMYLASE INHIBITOR FROM MAIZE 1BIP ; ; BIFUNCTIONAL PROTEINASE INHIBITOR TRYPSIN/A-AMYLASE FROM SEEDS OF RAGI (ELEUSINE CORACANA GAERTNERI) 3AWI ; 3 ; Bifunctional tRNA modification enzyme MnmC from Escherichia coli 3FDL ; 1.78 ; Bim BH3 peptide in complex with Bcl-xL 3IO8 ; 2.3 ; BimL12F in complex with Bcl-xL 3IO9 ; 2.4 ; BimL12Y in complex with Mcl-1 1SKS ; 2.3 ; Binary 3' complex of T7 DNA polymerase with a DNA primer/template containing a cis-syn thymine dimer on the template 1SKW ; 2.3 ; Binary 3' complex of T7 DNA polymerase with a DNA primer/template containing a disordered cis-syn thymine dimer on the template 1SL1 ; 2.2 ; Binary 5' complex of T7 DNA polymerase with a DNA primer/template containing a cis-syn thymine dimer on the template 3HB5 ; 2 ; Binary and ternary crystal structures of a novel inhibitor of 17 beta-HSD type 1: a lead compound for breast cancer therapy 3S9D ; 1.9999 ; binary complex between IFNa2 and IFNAR2 3LW1 ; 1.28 ; Binary complex of 14-3-3 sigma and p53 pT387-peptide 3MGH ; 2.4 ; Binary complex of a DNA polymerase lambda loop mutant 3PVX ; 3.03 ; Binary complex of Aflatoxin B1 Adduct modified DNA (AFB1-FAPY) with DNA Polymerase IV 4DQS ; 1.66 ; Binary complex of Bacillus DNA Polymerase I Large Fragment and duplex DNA with rC in primer terminus paired with dG of template 4E0D ; 1.58 ; Binary complex of Bacillus DNA Polymerase I Large Fragment E658A and duplex DNA 1EH4 ; 2.8 ; BINARY COMPLEX OF CASEIN KINASE-1 FROM S. POMBE WITH AN ATP COMPETITIVE INHIBITOR, IC261 2CSN ; 2.5 ; BINARY COMPLEX OF CASEIN KINASE-1 WITH CKI7 1CSN ; 2 ; BINARY COMPLEX OF CASEIN KINASE-1 WITH MGATP 2FLN ; 2.5 ; binary complex of catalytic core of human DNA polymerase iota with DNA (template A) 3RJG ; 2 ; Binary complex of DNA Polymerase Beta with a gapped DNA containing 8odG:dA base-pair at primer Terminus 2W9B ; 2.28 ; BINARY COMPLEX OF DPO4 BOUND TO N2,N2-DIMETHYL-DEOXYGUANOSINE MODIFIED DNA 2HMY ; 2.61 ; BINARY COMPLEX OF HHAI METHYLTRANSFERASE WITH ADOMET FORMED IN THE PRESENCE OF A SHORT NONPSECIFIC DNA OLIGONUCLEOTIDE 3ISB ; 2 ; Binary complex of human DNA polymerase beta with a gapped DNA 3ISC ; 2 ; Binary complex of human DNA polymerase beta with an abasic site (THF) in the gapped DNA 3H40 ; 2.3 ; Binary complex of human DNA polymerase iota with template U/T 1M6W ; 2.3 ; Binary complex of Human glutathione-dependent formaldehyde dehydrogenase and 12-Hydroxydodecanoic acid 1MP0 ; 2.2 ; Binary Complex of Human Glutathione-Dependent Formaldehyde Dehydrogenase with NAD(H) 1JCN ; 2.5 ; BINARY COMPLEX OF HUMAN TYPE-I INOSINE MONOPHOSPHATE DEHYDROGENASE WITH 6-CL-IMP 1KDH ; 3 ; Binary Complex of Murine Terminal Deoxynucleotidyl Transferase with a Primer Single Stranded DNA 1BCP ; 2.7 ; BINARY COMPLEX OF PERTUSSIS TOXIN AND ATP 1Q5M ; 1.32 ; Binary complex of rabbit 20alpha-hydroxysteroid dehydrogenase with NADPH 2FL3 ; 2.39 ; Binary Complex of Restriction Endonuclease HinP1I with Cognate DNA 2XC9 ; 2.2 ; BINARY COMPLEX OF SULFOLOBUS SOLFATARICUS DPO4 DNA POLYMERASE AND 1, N2-ETHENOGUANINE MODIFIED DNA, MAGNESIUM FORM 2FLP ; 2.4 ; Binary complex of the catalytic core of human DNA polymerase iota with DNA (template G) 4KTQ ; 2.5 ; BINARY COMPLEX OF THE LARGE FRAGMENT OF DNA POLYMERASE I FROM T. AQUATICUS BOUND TO A PRIMER/TEMPLATE DNA 2W5Y ; 2 ; BINARY COMPLEX OF THE MIXED LINEAGE LEUKAEMIA (MLL1) SET DOMAIN WITH THE COFACTOR PRODUCT S-ADENOSYLHOMOCYSTEINE. 1J8R ; 1.8 ; BINARY COMPLEX OF THE PAPG RECEPTOR-BINDING DOMAIN BOUND TO GBO4 RECEPTOR 1J1C ; 2.1 ; Binary complex structure of human tau protein kinase I with ADP 1J1B ; 1.8 ; Binary complex structure of human tau protein kinase I with AMPPNP 1OS9 ; 1.85 ; Binary enzyme-product complexes of human MMP12 2JYB ; ; binary hvDHFR1:folate complex 2ORE ; 2.99 ; Binary Structure of Escherichia coli DNA Adenine Methyltransferase and S-adenosylhomocysteine 1W73 ; 2.1 ; BINARY STRUCTURE OF HUMAN DECR SOLVED BY SEMET SAD. 1W8D ; 2.2 ; BINARY STRUCTURE OF HUMAN DECR. 1Q0S ; 2.3 ; Binary Structure of T4DAM with AdoHcy 3RR7 ; 1.95 ; Binary Structure of the large fragment of Taq DNA polymerase bound to an abasic site 1C47 ; 2.7 ; BINDING DRIVEN STRUCTURAL CHANGES IN CRYSTALINE PHOSPHOGLUCOMUTASE ASSOCIATED WITH CHEMICAL REACTION 5MBA ; 1.9 ; BINDING MODE OF AZIDE TO FERRIC APLYSIA LIMACINA MYOGLOBIN. CRYSTALLOGRAPHIC ANALYSIS AT 1.9 ANGSTROMS RESOLUTION 1HSR ; 1.6 ; BINDING MODE OF BENZHYDROXAMIC ACID TO ARTHROMYCES RAMOSUS PEROXIDASE 1C8I ; 2 ; BINDING MODE OF HYDROXYLAMINE TO ARTHROMYCES RAMOSUS PEROXIDASE 1CK6 ; 1.9 ; BINDING MODE OF SALICYLHYDROXAMIC ACID TO ARTHROMYCES RAMOSUS PEROXIDASE 1KTI ; 1.97 ; BINDING OF 100 MM N-ACETYL-N'-BETA-D-GLUCOPYRANOSYL UREA TO GLYCOGEN PHOSPHORYLASE B: KINETIC AND CRYSTALLOGRAPHIC STUDIES 2PRI ; 2.3 ; BINDING OF 2-DEOXY-GLUCOSE-6-PHOSPHATE TO GLYCOGEN PHOSPHORYLASE B 3JQM ; 2.5 ; Binding of 5'-GTP to molybdenum cofactor biosynthesis protein MoaC from Thermus theromophilus HB8 1SPR ; 2.5 ; BINDING OF A HIGH AFFINITY PHOSPHOTYROSYL PEPTIDE TO THE SRC SH2 DOMAIN: CRYSTAL STRUCTURES OF THE COMPLEXED AND PEPTIDE-FREE FORMS 1SPS ; 2.7 ; BINDING OF A HIGH AFFINITY PHOSPHOTYROSYL PEPTIDE TO THE SRC SH2 DOMAIN: CRYSTAL STRUCTURES OF THE COMPLEXED AND PEPTIDE-FREE FORMS 1FDG ; 1.6 ; BINDING OF A MACROCYCLIC BISACRIDINE AND AMETANTRONE TO CGTACG INVOLVES SIMILAR UNUSUAL INTERCALATION PLATFORMS (AMETANTRONE COMPLEX) 1FD5 ; 1.1 ; BINDING OF A MACROCYCLIC BISACRIDINE AND AMETANTRONE TO CGTACG INVOLVES SIMILAR UNUSUAL INTERCALATION PLATFORMS (BISACRIDINE COMPLEX) 3APR ; 1.8 ; BINDING OF A REDUCED PEPTIDE INHIBITOR TO THE ASPARTIC PROTEINASE FROM RHIZOPUS CHINENSIS. IMPLICATIONS FOR A MECHANISM OF ACTION 11BA ; 2.06 ; BINDING OF A SUBSTRATE ANALOGUE TO A DOMAIN SWAPPING PROTEIN IN THE COMPLEX OF BOVINE SEMINAL RIBONUCLEASE WITH URIDYLYL-2',5'-ADENOSINE 6BNA ; 2.21 ; BINDING OF AN ANTITUMOR DRUG TO DNA. NETROPSIN AND C-G-C-G-A-A-T-T-BRC-G-C-G 2BZS ; 2 ; BINDING OF ANTI-CANCER PRODRUG CB1954 TO THE ACTIVATING ENZYME NQO2 REVEALED BY THE CRYSTAL STRUCTURE OF THEIR COMPLEX. 1B0S ; ; BINDING OF AR-1-144, A TRI-IMIDAZOLE DNA MINOR GROOVE BINDER, TO CCGG SEQUENCE ANALYZED BY NMR SPECTROSCOPY 1XC7 ; 1.83 ; Binding of beta-D-glucopyranosyl bismethoxyphosphoramidate to glycogen phosphorylase b: Kinetic and crystallographic studies 3MGS ; 3.15 ; Binding of Cesium ions to the Nucleosome Core particle 2DSU ; 2.2 ; Binding of chitin-like polysaccharide to protective signalling factor: Crystal structure of the complex formed between signalling protein from sheep (SPS-40) with a tetrasaccharide at 2.2 A resolution 2DSW ; 2.8 ; Binding of chitin-like polysaccharides to protective signalling factor: crystal structure of the complex of signalling protein from sheep (SPS-40) with a pentasaccharide at 2.8 A resolution 2PAD ; 2.8 ; BINDING OF CHLOROMETHYL KETONE SUBSTRATE ANALOGUES TO CRYSTALLINE PAPAIN 1PAD ; 2.8 ; Binding of chloromethyl ketone substrate analogues to crystalline papain 4PAD ; 2.8 ; Binding of chloromethyl ketone substrate analogues to crystalline papain 5PAD ; 2.8 ; BINDING OF CHLOROMETHYL KETONE SUBSTRATE ANALOGUES TO CRYSTALLINE PAPAIN 6PAD ; 2.8 ; Binding of chloromethyl ketone substrate analogues to crystalline papain 3MGP ; 2.44 ; Binding of Cobalt ions to the Nucleosome Core Particle 1V5Y ; 1.9 ; Binding of coumarins to NAD(P)H:FMN oxidoreductase 1V5Z ; 2 ; Binding of coumarins to NAD(P)H:FMN oxidoreductase 308D ; 1.5 ; BINDING OF DAUNOMYCIN TO B-D-GLUCOSYLATED DNA FOUND IN PROTOZOA TRYPANOSOMA BRUCEI STUDIED BY X-RAY CRYSTALLOGRAPH 1C4A ; 2.4 ; BINDING OF EXOGENOUSLY ADDED CARBON MONOXIDE AT THE ACTIVE SITE OF THE FE-ONLY HYDROGENASE (CPI) FROM CLOSTRIDIUM PASTEURIANUM 1C4C ; 2.4 ; BINDING OF EXOGENOUSLY ADDED CARBON MONOXIDE AT THE ACTIVE SITE OF THE FE-ONLY HYDROGENASE (CPI) FROM CLOSTRIDIUM PASTEURIANUM 1HLF ; 2.26 ; BINDING OF GLUCOPYRANOSYLIDENE-SPIRO-THIOHYDANTOIN TO GLYCOGEN PHOSPHORYLASE B: KINETIC AND CRYSTALLOGRAPHIC STUD 3U82 ; 3.164 ; Binding of herpes simplex virus glycoprotein D to nectin-1 exploits host cell adhesion 1SFG ; ; BINDING OF HEXA-N-ACETYLCHITOHEXAOSE: A POWDER DIFFRACTION STUDY 8BNA ; 2.2 ; BINDING OF HOECHST 33258 TO THE MINOR GROOVE OF B-DNA 4TLN ; 2.3 ; BINDING OF HYDROXAMIC ACID INHIBITORS TO CRYSTALLINE THERMOLYSIN SUGGESTS A PENTACOORDINATE ZINC INTERMEDIATE IN CATALYSIS 5TLN ; 2.3 ; BINDING OF HYDROXAMIC ACID INHIBITORS TO CRYSTALLINE THERMOLYSIN SUGGESTS A PENTACOORDINATE ZINC INTERMEDIATE IN CATALYSIS 1HGD ; 2.7 ; BINDING OF INFLUENZA VIRUS HEMAGGLUTININ TO ANALOGS OF ITS CELL-SURFACE RECEPTOR, SIALIC ACID: ANALYSIS BY PROTON NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY AND X-RAY CRYSTALLOGRAPHY 1HGE ; 2.6 ; BINDING OF INFLUENZA VIRUS HEMAGGLUTININ TO ANALOGS OF ITS CELL-SURFACE RECEPTOR, SIALIC ACID: ANALYSIS BY PROTON NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY AND X-RAY CRYSTALLOGRAPHY 1HGF ; 3 ; BINDING OF INFLUENZA VIRUS HEMAGGLUTININ TO ANALOGS OF ITS CELL-SURFACE RECEPTOR, SIALIC ACID: ANALYSIS BY PROTON NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY AND X-RAY CRYSTALLOGRAPHY 1HGG ; 2.9 ; BINDING OF INFLUENZA VIRUS HEMAGGLUTININ TO ANALOGS OF ITS CELL-SURFACE RECEPTOR, SIALIC ACID: ANALYSIS BY PROTON NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY AND X-RAY CRYSTALLOGRAPHY 1HGH ; 2.7 ; BINDING OF INFLUENZA VIRUS HEMAGGLUTININ TO ANALOGS OF ITS CELL-SURFACE RECEPTOR, SIALIC ACID: ANALYSIS BY PROTON NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY AND X-RAY CRYSTALLOGRAPHY 1HGI ; 2.7 ; BINDING OF INFLUENZA VIRUS HEMAGGLUTININ TO ANALOGS OF ITS CELL-SURFACE RECEPTOR, SIALIC ACID: ANALYSIS BY PROTON NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY AND X-RAY CRYSTALLOGRAPHY 1HGJ ; 2.7 ; BINDING OF INFLUENZA VIRUS HEMAGGLUTININ TO ANALOGS OF ITS CELL-SURFACE RECEPTOR, SIALIC ACID: ANALYSIS BY PROTON NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY AND X-RAY CRYSTALLOGRAPHY 2HU7 ; 2.01 ; Binding of inhibitors by Acylaminoacyl peptidase 2HU8 ; 2.4 ; Binding of inhibitors by Acylaminoacyl peptidase 2HU5 ; 2 ; Binding of inhibitors by Acylaminoacyl-peptidase 3O5W ; 2.7 ; Binding of kinetin in the active site of mistletoe lectin I 1SF6 ; ; BINDING OF N,N',N""-TRIACETYLCHITOTRIOSE TO HEW LYSOZYME: A POWDER DIFFRACTION STUDY 1SF4 ; ; BINDING OF N,N'-DIACETYLCHITOBIOSE TO HEW LYSOZYME: A POWDER DIFFRACTION STUDY 2PRJ ; 2.3 ; Binding of N-acetyl-beta-D-glucopyranosylamine to Glycogen Phosphorylase B 1JA2 ; ; BINDING OF N-ACETYLGLUCOSAMINE TO CHICKEN EGG LYSOZYME: A POWDER DIFFRACTION STUDY 1JA4 ; ; BINDING OF N-ACETYLGLUCOSAMINE TO CHICKEN EGG LYSOZYME: A POWDER DIFFRACTION STUDY 1JA6 ; ; BINDING OF N-ACETYLGLUCOSAMINE TO CHICKEN EGG LYSOZYME: A POWDER DIFFRACTION STUDY 1JA7 ; ; BINDING OF N-ACETYLGLUCOSAMINE TO CHICKEN EGG LYSOZYME: A POWDER DIFFRACTION STUDY 1TMN ; 1.9 ; Binding of n-carboxymethyl dipeptide inhibitors to thermolysin determined by x-ray crystallography. a novel class of transition-state analogues for zinc peptidases 4EJ1 ; 1.75 ; Binding of Nb113 camelid antibody fragment with the binary DHFR:folate complex 3MGQ ; 2.65 ; Binding of Nickel ions to the Nucleosome Core Particle 1W4O ; 1.6 ; BINDING OF NONNATURAL 3'-NUCLEOTIDES TO RIBONUCLEASE A 1W4P ; 1.69 ; BINDING OF NONNATURAL 3'-NUCLEOTIDES TO RIBONUCLEASE A 1W4Q ; 1.68 ; BINDING OF NONNATURAL 3'-NUCLEOTIDES TO RIBONUCLEASE A 1HIY ; 2.6 ; BINDING OF NUCLEOTIDES TO NDP KINASE 1SFB ; ; BINDING OF PENTA-N-ACETYLCHITOPENTAOSE TO HEW LYSOZYME: A POWDER DIFFRACTION STUDY 1H52 ; 2 ; BINDING OF PHOSPHATE AND PYROPHOSPHATE IONS AT THE ACTIVE SITE OF HUMAN ANGIOGENIN AS REVEALED BY X-RAY CRYSTALLOGRAPHY 1HBY ; 2 ; BINDING OF PHOSPHATE AND PYROPHOSPHATE IONS AT THE ACTIVE SITE OF HUMAN ANGIOGENIN AS REVEALED BY X-RAY CRYSTALLOGRAPHY 1H53 ; 2 ; Binding of Phosphate and Pyrophosphate ions at the active site of human Angiogenin as revealed by X-ray Crystallography 3MGR ; 2.3 ; Binding of Rubidium ions to the Nucleosome Core Particle 1SF7 ; ; BINDING OF TETRA-N-ACETYLCHITOTETRAOSE TO HEW LYSOZYME: A POWDER DIFFRACTION STUDY 2KCE ; 2.2 ; BINDING OF THE ANTICANCER DRUG ZD1694 TO E. COLI THYMIDYLATE SYNTHASE: ASSESSING SPECIFICITY AND AFFINITY 1D21 ; 1.7 ; BINDING OF THE ANTITUMOR DRUG NOGALAMYCIN AND ITS DERIVATIVES TO DNA: STRUCTURAL COMPARISON 1D22 ; 1.8 ; BINDING OF THE ANTITUMOR DRUG NOGALAMYCIN AND ITS DERIVATIVES TO DNA: STRUCTURAL COMPARISON 1PIV ; 2.9 ; BINDING OF THE ANTIVIRAL DRUG WIN51711 TO THE SABIN STRAIN OF TYPE 3 POLIOVIRUS: STRUCTURAL COMPARISON WITH DRUG BINDING IN RHINOVIRUS 14 380D ; 2 ; BINDING OF THE MODIFIED DAUNORUBICIN WP401 ADJACENT TO A T-G BASE PAIR INDUCES THE REVERSE WATSON-CRICK CONFORMATION: CRYSTAL STRUCTURES OF THE WP401-TGGCCG AND WP401-CGG[BR5C]CG COMPLEXES 381D ; 2.1 ; BINDING OF THE MODIFIED DAUNORUBICIN WP401 ADJACENT TO A T-G BASE PAIR INDUCES THE REVERSE WATSON-CRICK CONFORMATION: CRYSTAL STRUCTURES OF THE WP401-TGGCCG AND WP401-CGG[BR5C]CG COMPLEXES 3BXX ; 2.9 ; Binding of two substrate analogue molecules to dihydroflavonol 4-reductase alters the functional geometry of the catalytic site 3C1T ; 2.252 ; Binding of two substrate analogue molecules to dihydroflavonol 4-reductase alters the functional geometry of the catalytic site 2IOD ; 2.06 ; Binding of two substrate analogue molecules to dihydroflavonol-4-reductase alters the functional geometry of the catalytic site 2NNL ; 2.1 ; Binding of two substrate analogue molecules to dihydroflavonol-4-reductase alters the functional geometry of the catalytic site 1T1M ; 12 ; Binding position of ribosome recycling factor (RRF) on the E. coli 70S ribosome 3Q2C ; 2.5 ; Binding properties to HLA class I molecules and the structure of the leukocyte Ig-like receptor A3 (LILRA3/ILT6/LIR4/CD85e) 3GOK ; 3.2 ; Binding site mapping of protein ligands 1OKX ; 2.8 ; BINDING STRUCTURE OF ELASTASE INHIBITOR SCYPTOLIN A 1UY1 ; 1.8 ; BINDING SUB-SITE DISSECTION OF A FAMILY 6 CARBOHYDRATE-BINDING MODULE BY X-RAY CRYSTALLOGRAPHY AND ISOTHERMAL TITRATION CALORIMETRY 1UY2 ; 1.7 ; BINDING SUB-SITE DISSECTION OF A FAMILY 6 CARBOHYDRATE-BINDING MODULE BY X-RAY CRYSTALLOGRAPHY AND ISOTHERMAL TITRATION CALORIMETRY 1UY3 ; 1.89 ; BINDING SUB-SITE DISSECTION OF A FAMILY 6 CARBOHYDRATE-BINDING MODULE BY X-RAY CRYSTALLOGRAPHY AND ISOTHERMAL TITRATION CALORIMETRY 1UY4 ; 1.69 ; BINDING SUB-SITE DISSECTION OF A FAMILY 6 CARBOHYDRATE-BINDING MODULE BY X-RAY CRYSTALLOGRAPHY AND ISOTHERMAL TITRATION CALORIMETRY 3FNN ; 2.3 ; Biochemical and structural analysis of an atypical ThyX: Corynebacterium glutamicum NCHU 87078 depends on ThyA for thymidine biosynthesis 2JAH ; 1.8 ; BIOCHEMICAL AND STRUCTURAL ANALYSIS OF THE CLAVULANIC ACID DEHYDEOGENASE (CAD) FROM STREPTOMYCES CLAVULIGERUS 1H4C ; 1.65 ; BIOCHEMICAL AND STRUCTURAL ANALYSIS OF THE MOLYBDENUM COFACTOR BIOSYNTHESIS PROTEIN MOBA 1H4D ; 1.74 ; BIOCHEMICAL AND STRUCTURAL ANALYSIS OF THE MOLYBDENUM COFACTOR BIOSYNTHESIS PROTEIN MOBA 1H4E ; 1.65 ; BIOCHEMICAL AND STRUCTURAL ANALYSIS OF THE MOLYBDENUM COFACTOR BIOSYNTHESIS PROTEIN MOBA 1HJJ ; 1.65 ; BIOCHEMICAL AND STRUCTURAL ANALYSIS OF THE MOLYBDENUM COFACTOR BIOSYNTHESIS PROTEIN MOBA 1HJL ; 2 ; BIOCHEMICAL AND STRUCTURAL ANALYSIS OF THE MOLYBDENUM COFACTOR BIOSYNTHESIS PROTEIN MOBA 1DYW ; 1.8 ; BIOCHEMICAL AND STRUCTURAL CHARACTERIZATION OF A DIVERGENT LOOP CYCLOPHILIN FROM CAENORHABDITIS ELEGANS 3NNK ; 2.58 ; Biochemical and Structural Characterization of a Ureidoglycine Aminotransferase in the Klebsiella pneumoniae Uric Acid Catabolic Pathway 4AXV ; 2.17 ; Biochemical and structural characterization of the MpaA amidase as part of a conserved scavenging pathway for peptidoglycan derived peptides in gamma-proteobacteria 3DVT ; 2.3 ; Biochemical and structural characterization of the PAK1- LC8 interaction 4G68 ; 1.8 ; Biochemical and structural insights into xylan utilization by the thermophilic bacteriumcaldanaerobius polysaccharolyticus 2A8N ; 1.6 ; Biochemical and Structural Studies of A-to-I Editing by tRNA:A34 Deaminases at the Wobble Position of Transfer RNA 1N8I ; 2.1 ; Biochemical and Structural Studies of Malate Synthase from Mycobacterium tuberculosis 1N8W ; 2.7 ; Biochemical and Structural Studies of Malate Synthase from Mycobacterium tuberculosis 2HDH ; 2.2 ; BIOCHEMICAL CHARACTERIZATION AND STRUCTURE DETERMINATION OF HUMAN HEART SHORT CHAIN L-3-HYDROXYACYL COA DEHYDROGENASE PROVIDE INSIGHT INTO CATALYTIC MECHANISM 3HAD ; 2 ; BIOCHEMICAL CHARACTERIZATION AND STRUCTURE DETERMINATION OF HUMAN HEART SHORT CHAIN L-3-HYDROXYACYL COA DEHYDROGENASE PROVIDE INSIGHT INTO CATALYTIC MECHANISM 4AOA ; 2.28 ; Biochemical properties and crystal structure of a novel beta- phenylalanine aminotransferase from Variovorax paradoxus 4AO9 ; 1.5 ; Biochemical properties and crystal structure of a novel beta- phenylalanine aminotransferase from Variovorax paradoxus 3PS7 ; 2.85 ; Biochemical studies and crystal structure determination of dihydrodipicolinate synthase from Pseudomonas aeruginosa 4HFO ; 3 ; Biogenic amine-binding protein selenomethionine derivative 2J4T ; 2.02 ; Biological and Structural Features of Murine Angiogenin-4, an Angiogenic Protein 1ANT ; 3 ; BIOLOGICAL IMPLICATIONS OF A 3 ANGSTROMS STRUCTURE OF DIMERIC ANTITHROMBIN 4AOD ; 6 ; Biomphalaria glabrata Acetylcholine-binding protein type 1 (BgAChBP1) 4AOE ; 5.8 ; Biomphalaria glabrata Acetylcholine-binding protein type 2 (BgAChBP2) 2L7C ; ; Biophysical studies of lipid interacting regions of DGD2 in Arabidopsis thaliana 1N3R ; 2.8 ; Biosynthesis of pteridins. Reaction mechanism of GTP cyclohydrolase I 1N3S ; 2.55 ; Biosynthesis of pteridins. Reaction mechanism of GTP cyclohydrolase I 1N3T ; 3.2 ; Biosynthesis of pteridins. Reaction mechanism of GTP cyclohydrolase I 2M1E ; ; Biosynthetic engineered B28K-B29P human insulin monomer structure in in water solutions. 2M1D ; ; Biosynthetic engineered B28K-B29P human insulin monomer structure in in water/acetonitrile solutions. 4DD5 ; 1.25 ; Biosynthetic Thiolase (ThlA1) from Clostridium difficile 2VTZ ; 2.3 ; BIOSYNTHETIC THIOLASE FROM Z. RAMIGERA. COMPLEX OF THE C89A MUTANT WITH COENZYME A. 2WL4 ; 1.8 ; BIOSYNTHETIC THIOLASE FROM Z. RAMIGERA. COMPLEX OF THE H348A MUTANT WITH COENZYME A. 2WL5 ; 1.8 ; BIOSYNTHETIC THIOLASE FROM Z. RAMIGERA. COMPLEX OF THE H348N MUTANT WITH COENZYME A. 2WKT ; 2 ; BIOSYNTHETIC THIOLASE FROM Z. RAMIGERA. COMPLEX OF THE N316A MUTANT WITH COENZYME A. 2WKV ; 2.5 ; BIOSYNTHETIC THIOLASE FROM Z. RAMIGERA. COMPLEX OF THE N316D MUTANT WITH COENZYME A. 2VU0 ; 1.87 ; BIOSYNTHETIC THIOLASE FROM Z. RAMIGERA. COMPLEX OF THE OXIDISED ENZYME WITH COENZYME A. 2VU1 ; 1.51 ; BIOSYNTHETIC THIOLASE FROM Z. RAMIGERA. COMPLEX OF WITH O-PANTHETEINE-11-PIVALATE. 2VU2 ; 2.65 ; BIOSYNTHETIC THIOLASE FROM Z. RAMIGERA. COMPLEX WITH S-PANTETHEINE-11-PIVALATE. 2WKU ; 2.3 ; BIOSYNTHETIC THIOLASE FROM Z. RAMIGERA. THE N316H MUTANT. 2WL6 ; 2.98 ; BIOSYNTHETIC THIOLASE FROM Z. RAMIGERA. THE N316H-H348N MUTANT. 1QFL ; 1.92 ; BIOSYNTHETIC THIOLASE FROM ZOOGLOEA RAMIGERA IN COMPLEX WITH A REACTION INTERMEDIATE. 1OU6 ; 2.07 ; Biosynthetic thiolase from Zoogloea ramigera in complex with acetyl-O-pantetheine-11-pivalate 1DLV ; 2.29 ; BIOSYNTHETIC THIOLASE FROM ZOOGLOEA RAMIGERA IN COMPLEX WITH COA 1M3Z ; 1.87 ; Biosynthetic thiolase, C89A mutant, complexed with acetyl coenzyme A 1M4S ; 1.87 ; Biosynthetic thiolase, Cys89 acetylated, unliganded form 1M4T ; 1.77 ; Biosynthetic thiolase, Cys89 butyrylated 1M3K ; 1.7 ; biosynthetic thiolase, inactive C89A mutant 1M1T ; 1.94 ; Biosynthetic thiolase, Q64A mutant 1XNY ; 2.2 ; Biotin and propionyl-CoA bound to Acyl-CoA Carboxylase Beta Subunit from S. coelicolor (PccB) 1O78 ; ; BIOTIN CARBOXYL CARRIER DOMAIN OF TRANSCARBOXYLASE (1.3S) [10-48] DELETION MUTANT 1DCZ ; ; BIOTIN CARBOXYL CARRIER DOMAIN OF TRANSCARBOXYLASE (TC 1.3S) 1DD2 ; ; BIOTIN CARBOXYL CARRIER DOMAIN OF TRANSCARBOXYLASE (TC 1.3S) 3T6F ; 1.22 ; Biotin complex of Y54F core streptavidin 3EFS ; 2.3 ; Biotin protein ligase from Aquifex aeolicus in complex with biotin and ATP 3EFR ; 2.55 ; Biotin protein ligase R40G mutant from Aquifex aeolicus in complex with biotin 2IZP ; 2.1 ; BIPD - AN INVASION PRTEIN ASSOCIATED WITH THE TYPE-III SECRETION SYSTEM OF BURKHOLDERIA PSEUDOMALLEI. 2IXR ; 2.6 ; BIPD OF BURKHOLDERIA PSEUDOMALLEI 2J9T ; 2.7 ; BIPD OF BURKHOLDERIA PSEUDOMALLEI 1ULI ; 2.2 ; Biphenyl dioxygenase (BphA1A2) derived from Rhodococcus sp. strain RHA1 1ULJ ; 2.6 ; Biphenyl dioxygenase (BphA1A2) in complex with the substrate 2LJE ; ; Biphosphorylated (747pY, 759pY) beta3 integrin cytoplasmic tail under membrane mimetic conditions 1B6F ; ; BIRCH POLLEN ALLERGEN BET V 1 1BV1 ; 2 ; BIRCH POLLEN ALLERGEN BET V 1 1LLT ; 3.1 ; BIRCH POLLEN ALLERGEN BET V 1 MUTANT E45S 1QMR ; 2.15 ; BIRCH POLLEN ALLERGEN BET V 1 MUTANT N28T, K32Q, E45S, P108G 1CQA ; 2.4 ; BIRCH POLLEN PROFILIN 1A49 ; 2.1 ; BIS MG-ATP-K-OXALATE COMPLEX OF PYRUVATE KINASE 4H0W ; 2.4 ; Bismuth bound human serum transferrin 3RA7 ; 2.798 ; Bispecific digoxigenin binding antibodies for targeted payload delivery 3DHK ; 1.73 ; Bisphenylic Thrombin Inhibitors 2ZO3 ; 1.7 ; Bisphenylic Thrombin Inhibitors 1MNB ; ; BIV TAT PEPTIDE (RESIDUES 68-81), NMR, MINIMIZED AVERAGE STRUCTURE 2VV6 ; 1.5 ; BJFIXLH IN FERRIC FORM 1XJ3 ; 1.9 ; bjFixLH in unliganded ferrous form 2VV7 ; 1.81 ; BJFIXLH IN UNLIGANDED FERROUS FORM 1JXP ; 2.2 ; BK STRAIN HEPATITIS C VIRUS (HCV) NS3-NS4A 4EBN ; 2.85 ; BlaC Amoxicillin Acyl-Intermediate Complex 3VFH ; 2.57 ; BlaC E166A CDC-1 Acyl-Intermediate 3VFF ; 2.777 ; BlaC E166A CDC-OMe Acyl-Intermediate Complex 4EBP ; 2.29 ; BlaC E166A Cefotaxime Acyl-Intermediate Complex 4EBL ; 2.1 ; BlaC E166A Faropenem Acyl-Intermediate Complex 3QM9 ; 0.91 ; Blackfin tuna azido-myoglobin, atomic resolution 3QM7 ; 0.96 ; Blackfin tuna carbonmonoxy-myoglobin, atomic resolution 3QM8 ; 0.91 ; Blackfin tuna cyanomet-myoglobin, atomic resolution 3QM6 ; 0.91 ; Blackfin tuna deoxy-myoglobin, atomic resolution 2NRL ; 0.91 ; Blackfin tuna myoglobin 3QMA ; 0.94 ; Blackfin tuna myoglobin imidazole complex, atomic resolution 3QM5 ; 0.91 ; Blackfin tuna oxy-myoglobin, atomic resolution 3UY6 ; 2.1 ; BlaR1 sensor domain from Staphylococcus aureus with N439V mutation 2VZ3 ; 1.9 ; BLEACHED GALACTOSE OXIDASE 1BYL ; 2.3 ; BLEOMYCIN RESISTANCE PROTEIN FROM STREPTOALLOTEICHUS HINDUSTANUS 2J9A ; 1.73 ; blLAP in Complex with Microginin FR1 2BYC ; 1.9 ; BLRB - A BLUF PROTEIN, DARK STATE STRUCTURE 2KB2 ; ; BlrP1 BLUF 2ISK ; 2.1 ; BluB bound to flavin anion (charge transfer complex) 2ISJ ; 2.3 ; BluB bound to oxidized FMN 2ISL ; 2.9 ; BluB bound to reduced flavin (FMNH2) and molecular oxygen. (clear crystal form) 1BFP ; 2.1 ; BLUE VARIANT OF GREEN FLUORESCENT PROTEIN 3IYK ; 7 ; Bluetongue virus structure reveals a sialic acid binding domain, amphipathic helices and a central coiled coil in the outer capsid proteins 2XZ3 ; 1.95 ; BLV TM hairpin 1BMO ; 3.1 ; BM-40, FS/EC DOMAIN PAIR 3RPG ; 2.6485 ; Bmi1/Ring1b-UbcH5c complex structure 1BKT ; ; BMKTX TOXIN FROM SCORPION BUTHUS MARTENSII KARSCH, NMR, 25 STRUCTURES 4IY9 ; 2.1 ; Bmlp3 - C2 crystal form 4IY8 ; 2.36 ; Bmlp3 - P21 crystal form 1Y64 ; 3.05 ; Bni1p Formin Homology 2 Domain complexed with ATP-actin 1DKJ ; 2 ; BOBWHITE QUAIL LYSOZYME 1DKK ; 1.9 ; BOBWHITE QUAIL LYSOZYME WITH NITRATE 2BW2 ; ; BOFC FROM BACILLUS SUBTILIS 1SI9 ; 2.27 ; Boiling stable protein isolated from Populus tremula 4EFR ; 2.5 ; Bombyx mori lipoprotein 7 (crystal form II) at 2.50 A resolution 4EFQ ; 1.94 ; Bombyx mori lipoprotein 7 - platinum derivative at 1.94 A resolution 4EFP ; 1.33 ; Bombyx mori lipoprotein 7 isolated from its natural source at 1.33 A resolution 1DQE ; 1.8 ; BOMBYX MORI PHEROMONE BINDING PROTEIN 2P70 ; 2.1 ; Bombyx mori pheromone binding protein bound to bell pepper odorant 2P71 ; 2.006 ; Bombyx mori pheromone binding protein bound to iodohexadecane 3ONB ; 1.45 ; Bond breakage and relocation of a covalently bound bromine of IDD594 in a complex with hAR T113A mutant after extensive radiation dose 3ONC ; 1.06 ; Bond breakage and relocation of a covalently bound bromine of IDD594 in a complex with hAR T113A mutant after moderate radiation dose 3UNX ; 1.26 ; Bond length analysis of asp, glu and his residues in subtilisin Carlsberg at 1.26A resolution 3UNR ; 1.2 ; Bond length analysis of asp, glu and his residues in trypsin at 1.2A resolution 1BMP ; 2.8 ; BONE MORPHOGENETIC PROTEIN-7 1S3T ; 2.1 ; BORATE INHIBITED BACILLUS PASTEURII UREASE CRYSTAL STRUCTURE 1Y9U ; 1.39 ; Bordetella ferric binding protein 1LWV ; 2.3 ; Borohydride-trapped hOgg1 Intermediate Structure Co-Crystallized with 8-aminoguanine 1LWW ; 2.1 ; Borohydride-trapped hOgg1 Intermediate Structure Co-Crystallized with 8-bromoguanine 4ALY ; 2.4 ; Borrelia burgdorferi outer surface lipoprotein BBA64 4AXZ ; 2.09 ; Borrelia burgdorferi outer surface lipoprotein BBA73 3VEK ; 2.63 ; Both Zn Fingers of GATA1 Bound to Palindromic DNA Recognition Site, P1 Crystal Form 3VD6 ; 1.98 ; Both Zn Fingers of GATA1 Bound to Palindromic DNA Recognition Site, P21 Crystal Form 2ISE ; 2.2 ; Botulinum Neurotoxin A Light Chain WT Crystal Form A 2ISG ; 2 ; Botulinum Neurotoxin A Light Chain WT Crystal Form B 2ISH ; 2 ; Botulinum Neurotoxin A Light Chain WT Crystal Form C 1F82 ; 2.2 ; BOTULINUM NEUROTOXIN TYPE B CATALYTIC DOMAIN 3MPP ; 1.98 ; Botulinum Neurotoxin Type G Receptor Binding Domain 1BFZ ; ; BOUND CONFORMATION OF N-TERMINAL CLEAVAGE PRODUCT PEPTIDE MIMIC (P1-P9 OF RELEASE SITE) WHILE BOUND TO HCMV PROTEASE AS DETERMINED BY TRANSFERRED NOESY EXPERIMENTS (P1-P5 SHOWN ONLY), NMR, 32 STRUCTURES 2O8Z ; ; Bound Structure of CRF1 Extracellular Domain Antagonist 1VFA ; 1.8 ; BOUND WATER MOLECULES AND CONFORMATIONAL STABILIZATION HELP MEDIATE AN ANTIGEN-ANTIBODY ASSOCIATION 1VFB ; 1.8 ; BOUND WATER MOLECULES AND CONFORMATIONAL STABILIZATION HELP MEDIATE AN ANTIGEN-ANTIBODY ASSOCIATION 2X24 ; 2.4 ; BOVINE ACC2 CT DOMAIN IN COMPLEX WITH INHIBITOR 1AYF ; 1.85 ; BOVINE ADRENODOXIN (OXIDIZED) 1MTN ; 2.8 ; BOVINE ALPHA-CHYMOTRYPSIN:BPTI CRYSTALLIZATION 3L1F ; 1.53 ; Bovine AlphaA crystallin 3L1E ; 1.15 ; Bovine AlphaA crystallin Zinc Bound 1AVC ; 2.9 ; BOVINE ANNEXIN VI (CALCIUM-BOUND) 3PH5 ; 2.4 ; Bovine beta lactoglobulin crystallized through ligandation of yttrium cations 3PH6 ; 2.53 ; Bovine beta lactoglobulin crytsallized through ligandation of yttrium 3NPO ; 2.2 ; Bovine beta lactoglobulin unliganded form 1CJ5 ; ; BOVINE BETA-LACTOGLOBULIN A 3NQ3 ; 1.9 ; Bovine beta-lactoglobulin complex with capric acid 3NQ9 ; 1.9 ; Bovine beta-lactoglobulin complex with caprylic acid 4GNY ; 1.6367 ; Bovine beta-lactoglobulin complex with dodecyl sulfate 3UEU ; 2.1 ; Bovine beta-lactoglobulin complex with lauric acid 4DQ4 ; 2.1 ; Bovine beta-lactoglobulin complex with linoleic acid 3UEV ; 1.9 ; Bovine beta-lactoglobulin complex with myristic acid 4DQ3 ; 2.1 ; Bovine beta-lactoglobulin complex with oleic acid 3UEW ; 2 ; Bovine beta-lactoglobulin complex with palmitic acid 3UEX ; 2.1 ; Bovine beta-lactoglobulin complex with stearic acid 1B0O ; 2.5 ; BOVINE BETA-LACTOGLOBULIN COMPLEXED WITH PALMITATE, LATTICE Z 1GX9 ; 2.34 ; BOVINE BETA-LACTOGLOBULIN COMPLEXED WITH RETINOIC ACID, TRIGONAL LATTICE Z 1GXA ; 2.35 ; BOVINE BETA-LACTOGLOBULIN COMPLEXED WITH RETINOL AND PALMITIC ACID, TRIGONAL LATTICE Z 1GX8 ; 2.4 ; BOVINE BETA-LACTOGLOBULIN COMPLEXED WITH RETINOL, TRIGONAL LATTICE Z 1BEB ; 1.8 ; BOVINE BETA-LACTOGLOBULIN, LATTICE X 1G3D ; 1.8 ; BOVINE BETA-TRYPSIN BOUND TO META-AMIDINO SCHIFF BASE COPPER (II) CHELATE 1G3B ; 1.8 ; BOVINE BETA-TRYPSIN BOUND TO META-AMIDINO SCHIFF BASE MAGNESIUM(II) CHELATE 3AAV ; 1.7 ; Bovine beta-trypsin bound to meta-diamidino schiff base copper (II) chelate 3AAU ; 1.8 ; Bovine beta-trypsin bound to meta-diguanidino schiff base copper (II) chelate 3AAS ; 1.75 ; Bovine beta-trypsin bound to meta-guanidino schiff base copper (II) chelate 1G3C ; 1.8 ; BOVINE BETA-TRYPSIN BOUND TO PARA-AMIDINO SCHIFF BASE IRON(III) CHELATE 1G3E ; 1.8 ; BOVINE BETA-TRYPSIN BOUND TO PARA-AMIDINO SCHIFF-BASE COPPER (II) CHELATE 1IG5 ; 1.5 ; BOVINE CALBINDIN D9K BINDING MG2+ 1IGV ; 1.85 ; BOVINE CALBINDIN D9K BINDING MN2+ 4AA8 ; 1.801 ; Bovine chymosin at 1.8A resolution 4AUC ; 1.6 ; Bovine chymosin in complex with Pepstatin A 1CA0 ; 2.1 ; BOVINE CHYMOTRYPSIN COMPLEXED TO APPI 1CBW ; 2.6 ; BOVINE CHYMOTRYPSIN COMPLEXED TO BPTI 2CGA ; 1.8 ; BOVINE CHYMOTRYPSINOGEN A. X-RAY CRYSTAL STRUCTURE ANALYSIS AND REFINEMENT OF A NEW CRYSTAL FORM AT 1.8 ANGSTROMS RESOLUTION 1VIN ; 2 ; BOVINE CYCLIN A3 1IHG ; 1.8 ; Bovine Cyclophilin 40, monoclinic form 1IIP ; 2 ; Bovine Cyclophilin 40, Tetragonal Form 1CYO ; 1.5 ; BOVINE CYTOCHROME B(5) 1PPJ ; 2.1 ; Bovine cytochrome bc1 complex with stigmatellin and antimycin 1PP9 ; 2.1 ; Bovine cytochrome bc1 complex with stigmatellin bound 2A06 ; 2.1 ; Bovine cytochrome bc1 complex with stigmatellin bound 1PID ; 1.3 ; BOVINE DESPENTAPEPTIDE INSULIN 1EUF ; 2.4 ; BOVINE DUODENASE(NEW SERINE PROTEASE), CRYSTAL STRUCTURE 1NSE ; 1.9 ; BOVINE ENDOTHELIAL NITRIC OXIDE SYNTHASE 1DM8 ; 2.25 ; BOVINE ENDOTHELIAL NITRIC OXIDE SYNTHASE HEME DOMAIN COMPLEXED WITH 1,2,4-TRIAZOLE-CARBOXAMIDINE (H4B BOUND) 1D1Y ; 2.2 ; BOVINE ENDOTHELIAL NITRIC OXIDE SYNTHASE HEME DOMAIN COMPLEXED WITH 1,3-PBITU (H4B FREE) 1D1X ; 2 ; BOVINE ENDOTHELIAL NITRIC OXIDE SYNTHASE HEME DOMAIN COMPLEXED WITH 1,4-PBITU (H4B BOUND) 1FOI ; 1.93 ; BOVINE ENDOTHELIAL NITRIC OXIDE SYNTHASE HEME DOMAIN COMPLEXED WITH 1400W(H4B-FREE) 1D1W ; 2 ; BOVINE ENDOTHELIAL NITRIC OXIDE SYNTHASE HEME DOMAIN COMPLEXED WITH 2-AMINOTHIAZOLINE (H4B BOUND) 1D0C ; 1.65 ; BOVINE ENDOTHELIAL NITRIC OXIDE SYNTHASE HEME DOMAIN COMPLEXED WITH 3-BROMO-7-NITROINDAZOLE (H4B FREE) 1D0O ; 1.95 ; BOVINE ENDOTHELIAL NITRIC OXIDE SYNTHASE HEME DOMAIN COMPLEXED WITH 3-BROMO-7-NITROINDAZOLE (H4B PRESENT) 1DMK ; 1.9 ; BOVINE ENDOTHELIAL NITRIC OXIDE SYNTHASE HEME DOMAIN COMPLEXED WITH 4-AMINO-6-PHENYL-TETRAHYDROPTERIDINE 1DMJ ; 2.35 ; BOVINE ENDOTHELIAL NITRIC OXIDE SYNTHASE HEME DOMAIN COMPLEXED WITH 5,6-CYCLIC-TETRAHYDROPTERIDINE 1DMI ; 2 ; BOVINE ENDOTHELIAL NITRIC OXIDE SYNTHASE HEME DOMAIN COMPLEXED WITH 6S-H4B 1FOJ ; 2.1 ; BOVINE ENDOTHELIAL NITRIC OXIDE SYNTHASE HEME DOMAIN COMPLEXED WITH 7-NITROINDAZOLE-2-CARBOXAMIDINE (H4B PRESENT) 1DM7 ; 2.1 ; BOVINE ENDOTHELIAL NITRIC OXIDE SYNTHASE HEME DOMAIN COMPLEXED WITH HOMOARGININE (H4B FREE) 1ED4 ; 1.86 ; BOVINE ENDOTHELIAL NITRIC OXIDE SYNTHASE HEME DOMAIN COMPLEXED WITH IPITU (H4B FREE) 1FOP ; 2.3 ; BOVINE ENDOTHELIAL NITRIC OXIDE SYNTHASE HEME DOMAIN COMPLEXED WITH L-ARG AND NO(H4B-BOUND) 1FOO ; 2 ; BOVINE ENDOTHELIAL NITRIC OXIDE SYNTHASE HEME DOMAIN COMPLEXED WITH L-ARG AND NO(H4B-FREE) 1ED6 ; 2.05 ; BOVINE ENDOTHELIAL NITRIC OXIDE SYNTHASE HEME DOMAIN COMPLEXED WITH L-NIO (H4B FREE) 1DM6 ; 1.95 ; BOVINE ENDOTHELIAL NITRIC OXIDE SYNTHASE HEME DOMAIN COMPLEXED WITH N-(4-CHLOROPHENYL)-N'-HYDROXYGUANIDINE (H4B FREE) 1I83 ; 2 ; BOVINE ENDOTHELIAL NITRIC OXIDE SYNTHASE HEME DOMAIN COMPLEXED WITH N1,N14-BIS((S-METHYL)ISOTHIOUREIDO)TETRADECANE (H4B FREE) 1ED5 ; 1.8 ; BOVINE ENDOTHELIAL NITRIC OXIDE SYNTHASE HEME DOMAIN COMPLEXED WITH NNA(H4B FREE) 1D1V ; 1.93 ; BOVINE ENDOTHELIAL NITRIC OXIDE SYNTHASE HEME DOMAIN COMPLEXED WITH S-ETHYL-N-PHENYL-ISOTHIOUREA (H4B BOUND) 1Q2O ; 1.74 ; Bovine endothelial nitric oxide synthase N368D mutant heme domain dimer with L-N(omega)-nitroarginine-2,4-L-diaminobutyramide bound 2NSE ; 2.34 ; BOVINE ENDOTHELIAL NITRIC OXIDE SYNTHASE SUBSTRATE COMPLEX 9NSE ; 2.24 ; BOVINE ENDOTHELIAL NITRIC OXIDE SYNTHASE, ETHYL-ISOSELENOUREA COMPLEX 7NSE ; 2.35 ; BOVINE ENDOTHELIAL NITRIC OXIDE SYNTHASE, H4B-FREE, ADMA COMPLEX 6NSE ; 2.35 ; BOVINE ENDOTHELIAL NITRIC OXIDE SYNTHASE, H4B-FREE, CANAVANINE COMPLEX 5NSE ; 1.9 ; BOVINE ENDOTHELIAL NITRIC OXIDE SYNTHASE, H4B-FREE, HYDROXY-ARG COMPLEX 4NSE ; 1.95 ; BOVINE ENDOTHELIAL NITRIC OXIDE SYNTHASE, H4B-FREE, L-ARG COMPLEX 8NSE ; 2.25 ; BOVINE ENDOTHELIAL NITRIC OXIDE SYNTHASE, NNA COMPLEX 1P6M ; 2.27 ; Bovine endothelial NOS heme domain with (4S)-N-(4-amino-5-[aminoethyl]aminopentyl)-N'-nitroguanidine bound 1RS8 ; 2.3 ; Bovine endothelial NOS heme domain with D-lysine-D-nitroarginine amide bound 1RS9 ; 2.22 ; Bovine endothelial NOS heme domain with D-phenylalanine-D-nitroarginine amide bound 1P6N ; 2.5 ; Bovine endothelial NOS heme domain with L-N(omega)-nitroarginine-(4R)-amino-L-proline amide bound 1P6L ; 2.35 ; Bovine endothelial NOS heme domain with L-N(omega)-nitroarginine-2,4-L-diaminobutyric amide bound 2HX2 ; 1.95 ; Bovine eNOS heme domain complexed with (4S)-N-{4-Amino-5-[(2-aminoethyl)-hydroxyamino]-pentyl}-N'-nitroguanidine 1ZZS ; 1.85 ; Bovine eNOS N368D single mutant with L-N(omega)-Nitroarginine-(4R)-Amino-L-Proline Amide Bound 1ZZT ; 2.14 ; Bovine eNOS N368D/V106M double mutant with L-N(omega)-Nitroarginine-(4R)-Amino-L-Proline Amide Bound 3NSE ; 2.1 ; BOVINE ENOS, H4B-FREE, SEITU COMPLEX 1BEV ; 3 ; BOVINE ENTEROVIRUS VG-5-27 1E79 ; 2.4 ; Bovine F1-ATPase inhibited by DCCD (dicyclohexylcarbodiimide) 1KIG ; 3 ; BOVINE FACTOR XA 2BAF ; ; Bovine Fibrinogen alpha-C Domain 3QMU ; 3.624 ; Bovine glutamate dehydrogenase complexed with epicatechin-3-gallate (ECG) 1HWY ; 3.2 ; BOVINE GLUTAMATE DEHYDROGENASE COMPLEXED WITH NAD AND 2-OXOGLUTARATE 3MW9 ; 2.4 ; Bovine glutamate dehydrogenase complexed with NADH, GTP, glutamate 1HWZ ; 2.8 ; BOVINE GLUTAMATE DEHYDROGENASE COMPLEXED WITH NADPH, GLUTAMATE, AND GTP 3MVQ ; 2.94 ; Bovine Glutamate dehydrogenase complexed with zinc 3PSC ; 2.67 ; Bovine GRK2 in complex with Gbetagamma subunits 3PVU ; 2.48 ; Bovine GRK2 in complex with Gbetagamma subunits and a selective kinase inhibitor (CMPD101) 3PVW ; 2.49 ; Bovine GRK2 in complex with Gbetagamma subunits and a selective kinase inhibitor (CMPD103A) 3KLR ; 0.88 ; Bovine H-protein at 0.88 angstrom resolution 1V54 ; 1.8 ; Bovine heart cytochrome c oxidase at the fully oxidized state 2DYR ; 1.8 ; Bovine heart cytochrome C oxidase at the fully oxidized state 2OCC ; 2.3 ; BOVINE HEART CYTOCHROME C OXIDASE AT THE FULLY OXIDIZED STATE 2ZXW ; 2.5 ; Bovine heart cytochrome c oxidase at the fully oxidized state (1-s X-ray exposure dataset) 3ABL ; 2.1 ; Bovine heart cytochrome c oxidase at the fully oxidized state (15-s X-ray exposure dataset) 3ABM ; 1.95 ; Bovine heart cytochrome c oxidase at the fully oxidized state (200-s X-ray exposure dataset) 1V55 ; 1.9 ; Bovine heart cytochrome c oxidase at the fully reduced state 3ABK ; 2 ; Bovine heart cytochrome c oxidase at the NO-bound fully reduced state (50K) 1OCZ ; 2.9 ; BOVINE HEART CYTOCHROME C OXIDASE IN AZIDE-BOUND STATE 1OCO ; 2.8 ; BOVINE HEART CYTOCHROME C OXIDASE IN CARBON MONOXIDE-BOUND STATE 3AG2 ; 1.8 ; Bovine Heart Cytochrome c Oxidase in the Carbon Monoxide-bound Fully Reduced State at 100 K 3AG1 ; 2.2 ; Bovine Heart Cytochrome c Oxidase in the Carbon Monoxide-bound Fully Reduced State at 280 K 3AG4 ; 2.05 ; Bovine Heart Cytochrome c Oxidase in the Cyanide Ion-bound Fully Reduced State at 100 K 3ASO ; 2.3 ; Bovine heart cytochrome C oxidase in the fully oxidized state measured at 0.9 angstrom wavelength 3ASN ; 3 ; Bovine heart cytochrome C oxidase in the fully oxidized state measured at 1.7470 angstrom wavelength 1OCR ; 2.35 ; BOVINE HEART CYTOCHROME C OXIDASE IN THE FULLY REDUCED STATE 2EIJ ; 1.9 ; Bovine heart cytochrome C oxidase in the fully reduced state 3AG3 ; 1.8 ; Bovine Heart Cytochrome c Oxidase in the Nitric Oxide-bound Fully Reduced State at 100 K 2DYS ; 2.2 ; Bovine heart cytochrome C oxidase modified by DCCD 2Y69 ; 1.95 ; Bovine heart cytochrome c oxidase re-refined with molecular oxygen 2QSP ; 1.85 ; Bovine Hemoglobin at pH 5.7 2QSS ; 1.75 ; Bovine hemoglobin at pH 6.3 1BIV ; ; BOVINE IMMUNODEFICIENCY VIRUS TAT-TAR COMPLEX, NMR, 5 STRUCTURES 1D9C ; 2 ; BOVINE INTERFERON-GAMMA AT 2.0 ANGSTROMS 1D9G ; 2.9 ; BOVINE INTERFERON-GAMMA AT 2.9 ANGSTROMS 1LFC ; ; BOVINE LACTOFERRICIN (LFCINB), NMR, 20 STRUCTURES 1LCP ; 1.65 ; BOVINE LENS LEUCINE AMINOPEPTIDASE COMPLEXED WITH L-LEUCINE PHOSPHONIC ACID 1BJ7 ; 1.8 ; BOVINE LIPOCALIN ALLERGEN BOS D 2 1VDV ; 1.98 ; Bovine Milk Xanthine Dehydrogenase Y-700 Bound Form 1BMF ; 2.85 ; BOVINE MITOCHONDRIAL F1-ATPASE 1E1Q ; 2.61 ; BOVINE MITOCHONDRIAL F1-ATPASE AT 100K 1COW ; 3.1 ; BOVINE MITOCHONDRIAL F1-ATPASE COMPLEXED WITH AUROVERTIN B 1OHH ; 2.8 ; BOVINE MITOCHONDRIAL F1-ATPASE COMPLEXED WITH THE INHIBITOR PROTEIN IF1 1EFR ; 3.1 ; BOVINE MITOCHONDRIAL F1-ATPASE COMPLEXED WITH THE PEPTIDE ANTIBIOTIC EFRAPEPTIN 1H8H ; 2.9 ; BOVINE MITOCHONDRIAL F1-ATPASE CRYSTALLISED IN THE PRESENCE OF 5MM AMPPNP 1E1R ; 2.5 ; BOVINE MITOCHONDRIAL F1-ATPASE INHIBITED BY MG2+ADP AND ALUMINIUM FLUORIDE 1NPO ; 3 ; BOVINE NEUROPHYSIN II COMPLEX WITH OXYTOCIN 2HLV ; 1.65 ; Bovine Odorant Binding Protein deswapped triple mutant 2BO5 ; ; BOVINE OLIGOMYCIN SENSITIVITY CONFERRAL PROTEIN N-TERMINAL DOMAIN 1CE5 ; 1.9 ; BOVINE PANCREAS BETA-TRYPSIN IN COMPLEX WITH BENZAMIDINE 2BZA ; 1.9 ; BOVINE PANCREAS BETA-TRYPSIN IN COMPLEX WITH BENZYLAMINE 1LJV ; ; Bovine Pancreatic Polypeptide Bound to DPC Micelles 1C0B ; 1.9 ; BOVINE PANCREATIC RIBONUCLEASE A DESICCATED FOR 2.5 DAYS 1C0C ; 2 ; BOVINE PANCREATIC RIBONUCLEASE A DESICCATED FOR 4.0 DAYS 1S0R ; 1.02 ; Bovine Pancreatic Trypsin inhibited with Benzamidine at Atomic resolution 2ZJX ; 1.09 ; Bovine pancreatic trypsin inhibitor (BPTI) containing only the [5,55] disulfide bond 1QLQ ; 1.42 ; BOVINE PANCREATIC TRYPSIN INHIBITOR (BPTI) MUTANT WITH ALTERED BINDING LOOP SEQUENCE 1BHC ; 2.7 ; BOVINE PANCREATIC TRYPSIN INHIBITOR CRYSTALLIZED FROM THIOCYANATE 3IYJ ; 4.2 ; Bovine papillomavirus type 1 outer capsid 4IJ9 ; 2.55 ; Bovine PKA C-alpha in complex with 2-[[5-(4-pyridyl)-1H-1,2,4-triazol-3-yl]sulfanyl]-1-(2-thiophenyl)ethanone 4IE9 ; 1.92 ; Bovine PKA C-alpha in complex with 3-pyridylmethyl-5-methyl-1H-pyrazole-3-carboxylate 1DWY ; ; BOVINE PRION PROTEIN FRAGMENT 121-230 1DWZ ; ; BOVINE PRION PROTEIN FRAGMENT 121-230 1DX0 ; ; BOVINE PRION PROTEIN RESIDUES 23-230 1DX1 ; ; BOVINE PRION PROTEIN RESIDUES 23-230 1NL2 ; 2.3 ; BOVINE PROTHROMBIN FRAGMENT 1 IN COMPLEX WITH CALCIUM AND LYSOPHOSPHOTIDYLSERINE 1NL1 ; 1.9 ; BOVINE PROTHROMBIN FRAGMENT 1 IN COMPLEX WITH CALCIUM ION 1A9P ; 2.4 ; BOVINE PURINE NUCLEOSIDE PHOSPHORYLASE COMPLEXED WITH 9-DEAZAINOSINE AND PHOSPHATE 1A9T ; 2 ; BOVINE PURINE NUCLEOSIDE PHOSPHORYLASE COMPLEXED WITH 9-DEAZAINOSINE AND PHOSPHATE 1A9R ; 2 ; BOVINE PURINE NUCLEOSIDE PHOSPHORYLASE COMPLEXED WITH HYPOXANTHINE AND SULFATE 1A9Q ; 2 ; BOVINE PURINE NUCLEOSIDE PHOSPHORYLASE COMPLEXED WITH INOSINE 1A9S ; 2 ; BOVINE PURINE NUCLEOSIDE PHOSPHORYLASE COMPLEXED WITH INOSINE AND SULFATE 1A9O ; 2 ; BOVINE PURINE NUCLEOSIDE PHOSPHORYLASE COMPLEXED WITH PHOSPHATE 1XPT ; 1.9 ; BOVINE RIBONUCLEASE A (PHOSPHATE-FREE) 1XPS ; 1.8 ; BOVINE RIBONUCLEASE A (PHOSPHATE-FREE) (93 % HUMIDITY) 1BSR ; 1.9 ; BOVINE SEMINAL RIBONUCLEASE STRUCTURE AT 1.9 ANGSTROMS RESOLUTION 3DJO ; 1.6 ; Bovine Seminal Ribonuclease uridine 2' phosphate complex 3DJV ; 1.6 ; Bovine Seminal Ribonuclease- cytidine 3' phosphate complex 3DJX ; 1.69 ; Bovine Seminal Ribonuclease- cytidine 5' phosphate complex 3DJP ; 1.6 ; Bovine Seminal Ribonuclease- Uridine 3' phosphate complex 3DJQ ; 1.53 ; Bovine Seminal Ribonuclease- Uridine 5' diphosphate complex 1UVU ; 2.8 ; BOVINE THROMBIN--BM12.1700 COMPLEX 1UVT ; 2.5 ; BOVINE THROMBIN--BM14.1248 COMPLEX 1UVS ; 2.8 ; BOVINE THROMBIN--BM51.1011 COMPLEX 3D4U ; 1.7 ; Bovine thrombin-activatable fibrinolysis inhibitor (TAFIa) in complex with tick-derived carboxypeptidase inhibitor. 1QA0 ; 1.8 ; BOVINE TRYPSIN 2-AMINOBENZIMIDAZOLE COMPLEX 1QBN ; 1.8 ; Bovine Trypsin 2-[amino(imino)methyl]-2-hydroxyphenoxy]-6-[3-(4,5-dihydro-1H-imidazol-2-yl)phenoxy]pyridine-4-carboxylic Acid (ZK-806688) Complex 1QB6 ; 1.8 ; BOVINE TRYPSIN 3,3'-[3,5-DIFLUORO-4-METHYL-2, 6-PYRIDINEDIYLBIS(OXY)]BIS(BENZENECARBOXIMIDAMIDE) (ZK-805623) COMPLEX 1QB9 ; 1.8 ; BOVINE TRYPSIN 7-[[2-[[1-(1-IMINOETHYL)PIPERIDIN-4-YL]OXY]-9H-CARBOZOL-9-YL] METHYL]NAPHTHALENE-2-CARBOXIMIDAMIDE (ZK-806450) COMPLEX 1QBO ; 1.8 ; BOVINE TRYPSIN 7-[[6-[[1-(1-IMINOETHYL)PIPERIDIN-4-YL]OXY]-2-METHYL-BENZIMIDAZOL-1-YL]METHYL]NAPHTHALENE-2-CARBOXIMIDAMID ZK-806711 INHIBITOR COMPLEX 4I8H ; 0.75 ; Bovine trypsin at 0.75 resolution 3MI4 ; 0.8 ; Bovine trypsin at 0.8 A resolution, non-restrained refinement 3MFJ ; 0.8 ; Bovine trypsin at 0.8 A resolution, restrained refinement 4I8G ; 0.8 ; Bovine trypsin at 0.8 resolution 4I8K ; 0.85 ; Bovine trypsin at 0.85 resolution 4I8J ; 0.87 ; Bovine trypsin at 0.87 A resolution 4I8L ; 0.87 ; Bovine trypsin at 0.87 resolution 2FX4 ; 1.65 ; Bovine trypsin bound by 4-piperidinebutyrate to make acylenzyme complex 1TAW ; 1.8 ; BOVINE TRYPSIN COMPLEXED TO APPI 1AZ8 ; 1.8 ; BOVINE TRYPSIN COMPLEXED TO BIS-PHENYLAMIDINE INHIBITOR 1AUJ ; 2.1 ; BOVINE TRYPSIN COMPLEXED TO META-CYANO-BENZYLIC INHIBITOR 2FX6 ; 1.57 ; bovine trypsin complexed with 2-aminobenzamidazole 1TX8 ; 1.7 ; Bovine Trypsin complexed with AMSO 1TX7 ; 1.75 ; Bovine Trypsin complexed with p-amidinophenylmethylphosphinic acid (AMPA) 1F0U ; 1.9 ; BOVINE TRYPSIN COMPLEXED WITH RPR128515 1F0T ; 1.8 ; BOVINE TRYPSIN COMPLEXED WITH RPR131247 2XTT ; 0.93 ; BOVINE TRYPSIN IN COMPLEX WITH EVOLUTIONARY ENHANCED SCHISTOCERCA GREGARIA PROTEASE INHIBITOR 1 (SGPI-1-P02) 2BTC ; 1.5 ; BOVINE TRYPSIN IN COMPLEX WITH SQUASH SEED INHIBITOR (CUCURBITA PEPO TRYPSIN INHIBITOR II) 3LJJ ; 1.55 ; Bovine trypsin in complex with UB-THR 10 3LJO ; 1.5 ; Bovine trypsin in complex with UB-THR 11 3Q00 ; 1.7 ; Bovine trypsin variant X(tripleGlu217Ile227) in comlex with small molecule inhibitor 3PWB ; 1.63 ; Bovine trypsin variant X(tripleGlu217Ile227) in complex with small molecule inhibitor 3PWC ; 1.6 ; Bovine trypsin variant X(tripleGlu217Ile227) in complex with small molecule inhibitor 3PYH ; 2 ; Bovine trypsin variant X(tripleGlu217Ile227) in complex with small molecule inhibitor 3UY9 ; 3.22 ; Bovine trypsin variant X(tripleGlu217Phe227) in complex with small molecule inhibitor 3UWI ; 1.43 ; Bovine trypsin variant X(tripleGlu217Phe227) in complex with small molecule inhibitor 3V0X ; 1.9 ; Bovine trypsin variant X(tripleGlu217Phe227) in complex with small molecule inhibitor 3V12 ; 1.8 ; Bovine trypsin variant X(tripleGlu217Phe227) in complex with small molecule inhibitor 3V13 ; 1.63 ; Bovine trypsin variant X(tripleGlu217Phe227) in complex with small molecule inhibitor 3PM3 ; 1.53 ; Bovine trypsin variant X(tripleIle227) in complex with small molecule inhibitor 3PMJ ; 1.45 ; Bovine trypsin variant X(tripleIle227) in complex with small molecule inhibitor 3PLB ; 1.18 ; Bovine trypsin variant X(tripleIle227) in complex with small molecule inhibitor 3PLK ; 1.53 ; Bovine trypsin variant X(tripleIle227) in complex with small molecule inhibitor 3PLP ; 1.63 ; Bovine trypsin variant X(tripleIle227) in complex with small molecule inhibitor 3UNQ ; 1.62 ; Bovine trypsin variant X(triplePhe227) in complex with small molecule inhibitor 3UQO ; 1.8 ; Bovine trypsin variant X(triplePhe227) in complex with small molecule inhibitor 3UNS ; 1.8 ; Bovine trypsin variant X(triplePhe227) in complex with small molecule inhibitor 3UOP ; 1.69 ; Bovine trypsin variant X(triplePhe227) in complex with small molecule inhibitor 3UUZ ; 2.1 ; Bovine trypsin variant X(triplePhe227) in complex with small molecule inhibitor 3UQV ; 2.4 ; Bovine trypsin variant X(triplePhe227) in complex with small molecule inhibitor 3UPE ; 1.54 ; Bovine trypsin variant X(triplePhe227) in complex with small molecule inhibitor 1QB1 ; 1.8 ; Bovine Trypsin with 1-[2-[5-[amino(imino)methyl]-2-hydroxyphenoxy]-6-[3-(4,5-dihydro-1-methyl-1H-imidazol-2-yl)phenoxy]pyridin-4-yl]piperidine-3-carboxylic Acid (ZK-806974) 1K1I ; 2.2 ; BOVINE TRYPSIN-INHIBITOR COMPLEX 1K1J ; 2.2 ; BOVINE TRYPSIN-INHIBITOR COMPLEX 1K1L ; 2.5 ; BOVINE TRYPSIN-INHIBITOR COMPLEX 1K1M ; 2.2 ; BOVINE TRYPSIN-INHIBITOR COMPLEX 1K1O ; 2 ; BOVINE TRYPSIN-INHIBITOR COMPLEX 1K1P ; 1.9 ; BOVINE TRYPSIN-INHIBITOR COMPLEX 1K1N ; 2 ; BOVINE TRYPSIN-INHIBITOR COMPLEX 2CJQ ; 2.6 ; BOVINE VIRAL DIARRHEA VIRUS CP7-R12 RNA-DEPENDENT RNA POLYMERASE 3AX7 ; 2.34 ; Bovine Xanthine Oxidase, protease cleaved form 3AMZ ; 2.1 ; Bovine Xanthine Oxidoreductase urate bound form 3AX9 ; 2.3 ; Bovine xanthone oxidase, protease cleaved form 2W3P ; 1.5 ; BOXC CRYSTAL STRUCTURE 4AK6 ; 1.9 ; BpGH117_H302E mutant glycoside hydrolase 4AW7 ; 1.33 ; BpGH86A: A beta-porphyranase of glycoside hydrolase family 86 from the human gut bacterium Bacteroides plebeius 2JPF ; ; Bpp3783_115-220 2H05 ; 1.8 ; Br Derivitation of A-DNA Octamer GTG(Ubr)ACAC 4E26 ; 2.55 ; BRAF in complex with an organic inhibitor 7898734 4H58 ; 3.1 ; BRAF in complex with compound 3 1B8M ; 2.75 ; BRAIN DERIVED NEUROTROPHIC FACTOR, NEUROTROPHIN-4 1Q7F ; 1.95 ; Brain Tumor NHL domain 3LQV ; 2.38 ; Branch Recognition by SF3b14 1UM9 ; 2.2 ; branched-chain 2-oxo acid dehydrogenase (E1) from Thermus thermophilus HB8 in apo-form 1UMB ; 2.1 ; branched-chain 2-oxo acid dehydrogenase (E1) from Thermus thermophilus HB8 in holo-form 1UMD ; 1.9 ; branched-chain 2-oxo acid dehydrogenase (E1) from Thermus thermophilus HB8 with 4-methyl-2-oxopentanoate as an intermediate 1UMC ; 2.4 ; branched-chain 2-oxo acid dehydrogenase (E1) from Thermus thermophilus HB8 with 4-methylpentanoate 1GKX ; 2.3 ; BRANCHED-CHAIN ALPHA-KETOACID DEHYDROGENASE KINASE (BCK) 1GKZ ; 2.2 ; BRANCHED-CHAIN ALPHA-KETOACID DEHYDROGENASE KINASE (BCK) COMPLXED WITH ADP 1GJV ; 2.7 ; Branched-chain alpha-ketoacid dehydrogenase kinase (BCK) complxed with ATP-gamma-S 1A3G ; 2.5 ; BRANCHED-CHAIN AMINO ACID AMINOTRANSFERASE FROM ESCHERICHIA COLI 17RA ; ; BRANCHPOINT HELIX FROM YEAST AND BINDING SITE FOR PHAGE GA/MS2 COAT PROTEINS, NMR, 12 STRUCTURES 1CWU ; 2.5 ; BRASSICA NAPUS ENOYL ACP REDUCTASE A138G MUTANT COMPLEXED WITH NAD+ AND THIENODIAZABORINE 1ENO ; 1.9 ; BRASSICA NAPUS ENOYL ACP REDUCTASE/NAD BINARY COMPLEX AT PH 8.0 AND ROOM TEMPERATURE 1ENP ; 2.6 ; BRASSICA NAPUS ENOYL ACP REDUCTASE/NADH BINARY COMPLEX AT PH 8.0 AND ROOM TEMPERATURE 1CDZ ; 3.2 ; BRCT DOMAIN FROM DNA-REPAIR PROTEIN XRCC1 4HXL ; 1.52 ; Brd4 Bromodomain 1 complex with 3-CYCLOHEXYL-N-{3-(2-OXO-2,3-DIHYDRO-1,3-THIAZOL-4-YL)-5-[(THIOPHEN-2-YLSULFONYL)AMINO]PHENYL}PROPANAMIDE inhibitor 4HXO ; 1.76 ; Brd4 Bromodomain 1 complex with 3-{[(3-METHYL-1,2-OXAZOL-5-YL)METHYL]SULFANYL}[1,2,4]TRIAZOLO[4,3-A]PYRIDINE inhibitor 4HXN ; 1.49 ; Brd4 Bromodomain 1 complex with 4-(2-FLUOROPHENYL)-1,3-THIAZOL-2(3H)-ONE inhibitor 4HXP ; 1.73 ; Brd4 Bromodomain 1 complex with 4-(2-OXO-1,3-OXAZOLIDIN-3-YL)BENZAMIDE inhibitor 4HXK ; 1.61 ; Brd4 Bromodomain 1 complex with 6,7-DIHYDROTHIENO[3,2-C]PYRIDIN-5(4H)-YL(1H-IMIDAZOL-1-YL)METHANONE inhibitor 4DON ; 1.52 ; Brd4 Bromodomain 1 complex with a fragment 3,4-Dihydro-3-methyl-2(1H)-quinazolinon 4HXS ; 1.43 ; Brd4 Bromodomain 1 complex with N-[3-(2-OXO-2,3-DIHYDRO-1,3-THIAZOL-4-YL)PHENYL]-1-PHENYLMETHANESULFONAMIDE inhibitor 4HXR ; 1.53 ; Brd4 Bromodomain 1 complex with N-[3-(2-OXO-2,3-DIHYDRO-1,3-THIAZOL-4-YL)PHENYL]THIOPHENE-2-SULFONAMIDE inhibitor 4HXM ; 1.5 ; Brd4 Bromodomain 1 complex with N-{3-(2-OXO-2,3-DIHYDRO-1,3-THIAZOL-4-YL)-5-[(THIOPHEN-2-YLSULFONYL)AMINO]PHENYL}BUTANAMIDE inhibitor 2NOV ; 2.67 ; Breakage-reunion domain of S.pneumoniae topo IV: crystal structure of a gram-positive quinolone target 1JKM ; 1.85 ; BREFELDIN A ESTERASE, A BACTERIAL HOMOLOGUE OF HUMAN HORMONE SENSITIVE LIPASE 2YAD ; 2.2 ; BRICHOS domain of Surfactant protein C precursor protein 2IOV ; 1.8 ; Bright-state structure of the reversibly switchable fluorescent protein Dronpa 2V0E ; ; BRK DOMAIN FROM HUMAN CHD7 2V0F ; ; BRK DOMAIN FROM HUMAN CHD7 1JS9 ; 3.4 ; Brome Mosaic Virus 3S8Y ; 2.1 ; Bromide soaked structure of an esterase from the oil-degrading bacterium Oleispira antarctica 3QBK ; 2.2 ; Bromide-bound form of pharaonis halorhodopsin 3VQH ; 1.95 ; Bromine SAD partially resolves multiple binding modes for PKA inhibitor H-89 3SGM ; 1.7006 ; Bromoderivative-2 of amyloid-related segment of alphaB-crystallin residues 90-100 3SGN ; 2.807 ; Bromoderivative-8 of amyloid-related segment of alphaB-crystallin residues 90-100 1E6I ; 1.87 ; Bromodomain from GCN5 complexed with acetylated H4 peptide 4A9K ; 1.81 ; BROMODOMAIN OF HUMAN CREBBP WITH N-(4-hydroxyphenyl)acetamide 3DN2 ; 1.8 ; Bromopentafluorobenzene binding in the hydrophobic cavity of T4 lysozyme L99A mutant 1A8Q ; 1.75 ; BROMOPEROXIDASE A1 1BRO ; 2.05 ; BROMOPEROXIDASE A2 1BRT ; 1.5 ; BROMOPEROXIDASE A2 MUTANT M99T 4F91 ; 2.697 ; Brr2 Helicase Region 4F92 ; 2.662 ; Brr2 Helicase Region S1087L 4F93 ; 2.92 ; Brr2 Helicase Region S1087L, Mg-ATP 2KHC ; ; Bruno RRM3+ 1BRY ; 2.1 ; BRYODIN TYPE I RIP 1KNV ; 2.17 ; Bse634I restriction endonuclease 3LVV ; 2.2 ; BSO-inhibited ScGCL 3HQ2 ; 2.9 ; BsuCP Crystal Structure 3EHN ; 2.8 ; BT1043 with N-acetyllactosamine 1BUO ; 1.9 ; BTB DOMAIN FROM PLZF 2WZH ; 2.2 ; BTGH84 D242N IN COMPLEX WITH MEUMB-DERIVED OXAZOLINE 2WZI ; 1.9 ; BTGH84 D243N IN COMPLEX WITH 5F-OXAZOLINE 2XJ7 ; 2 ; BTGH84 IN COMPLEX WITH 6-ACETAMIDO-6-DEOXY-CASTANOSPERMINE 2W67 ; 2.25 ; BTGH84 IN COMPLEX WITH FMA34 2W66 ; 2.27 ; BTGH84 IN COMPLEX WITH HQ602 2XM2 ; 1.95 ; BTGH84 IN COMPLEX WITH LOGNAC 2XM1 ; 2 ; BTGH84 IN COMPLEX WITH N-ACETYL GLUCONOLACTAM 2WCA ; 2.3 ; BTGH84 IN COMPLEX WITH N-BUTYL PUGNAC 2VVN ; 1.85 ; BTGH84 IN COMPLEX WITH NH-BUTYLTHIAZOLINE 2W4X ; 2.42 ; BTGH84 IN COMPLEX WITH STZ 2X0H ; 2.21 ; BTGH84 MICHAELIS COMPLEX 2VVS ; 2.24 ; BTGH84 STRUCTURE IN COMPLEX WITH PUGNAC 2I3S ; 1.9 ; Bub3 complex with Bub1 GLEBS motif 2I3T ; 2.8 ; Bub3 complex with Mad3 (BubR1) GLEBS motif 2H8U ; 2.1 ; Bucain, a cardiotoxin from the Malayan Krait Bungarus candidus 1B77 ; 2.1 ; BUILDING A REPLISOME STRUCTURE FROM INTERACTING PIECES: A SLIDING CLAMP COMPLEXED WITH AN INTERACTION PEPTIDE FROM DNA POLYMERASE 1K8S ; ; BULGED ADENOSINE IN AN RNA DUPLEX 1H8P ; 1.82 ; BULL SEMINAL PLASMA PDC-109 FIBRONECTIN TYPE II MODULE 3RBC ; 2.7 ; Bullfrog M ferritin with iron(III) bound to the ferroxidase site 1RCE ; 2.4 ; BULLFROG RED CELL L FERRITIN SULFATE/MN/PH 6.3 1RCG ; 2.2 ; BULLFROG RED CELL L FERRITIN SULFATE/MN/PH 6.3 1RCC ; 2.4 ; BULLFROG RED CELL L FERRITIN TARTRATE/MG/PH 5.5 1RCD ; 2 ; BULLFROG RED CELL L FERRITIN TARTRATE/MG/PH 5.5 1RCI ; 2 ; BULLFROG RED CELL L FERRITIN TARTRATE/MG/PH 5.5 1GEV ; 2.1 ; BURIED POLAR MUTANT HUMAN LYSOZYME 1GEZ ; 1.8 ; BURIED POLAR MUTANT HUMAN LYSOZYME 1GF0 ; 1.8 ; BURIED POLAR MUTANT HUMAN LYSOZYME 1GF3 ; 1.8 ; BURIED POLAR MUTANT HUMAN LYSOZYME 1GF4 ; 1.8 ; BURIED POLAR MUTANT HUMAN LYSOZYME 1GF5 ; 1.8 ; BURIED POLAR MUTANT HUMAN LYSOZYME 1GF6 ; 1.8 ; BURIED POLAR MUTANT HUMAN LYSOZYME 1GF7 ; 1.8 ; BURIED POLAR MUTANT HUMAN LYSOZYME 1YS1 ; 1.1 ; Burkholderia cepacia lipase complexed with hexylphosphonic acid (R)-2-methyl-3-phenylpropyl ester 1YS2 ; 1.5 ; Burkholderia cepacia lipase complexed with hexylphosphonic acid (S) 2-methyl-3-phenylpropyl ester 2NW6 ; 1.8 ; Burkholderia cepacia lipase complexed with S-inhibitor 2IA6 ; 2.5 ; Bypass of Major Benzopyrene-dG Adduct by Y-Family DNA Polymerase with Unique Structural Gap 2IBK ; 2.25 ; Bypass of Major Benzopyrene-dG Adduct by Y-Family DNA Polymerase with Unique Structural Gap 1ZMF ; 1.88 ; C domain of human cyclophilin-33(hcyp33) 1QVP ; ; C terminal SH3-like domain from Diphtheria toxin Repressor residues 144-226. 3IZ1 ; 6 ; C-alpha model fitted into the EM structure of Cx26M34A 3IZ2 ; 10 ; C-alpha model fitted into the EM structure of Cx26M34Adel2-7 2D25 ; 1.75 ; C-C-A-G-G-C-M5C-T-G-G; HELICAL FINE STRUCTURE, HYDRATION, AND COMPARISON WITH C-C-A-G-G-C-C-T-G-G 1L3W ; 3.08 ; C-cadherin Ectodomain 1N2T ; 2 ; C-DES Mutant K223A with GLY Covalenty Linked to the PLP-cofactor 1OZS ; ; C-domain of human cardiac troponin C in complex with the inhibitory region of human cardiac troponin I 3H13 ; 2.2 ; c-FLIPL protease-like domain 2I0V ; 2.8 ; c-FMS tyrosine kinase in complex with a quinolone inhibitor 1IAQ ; 2.9 ; C-H-RAS P21 PROTEIN MUTANT WITH THR 35 REPLACED BY SER (T35S) COMPLEXED WITH GUANOSINE-5'-[B,G-IMIDO] TRIPHOSPHATE 2R9S ; 2.4 ; c-Jun N-terminal Kinase 3 with 3,5-Disubstituted Quinoline inhibitor 3QTI ; 2 ; c-Met Kinase in Complex with NVP-BVU972 2OKV ; 2 ; c-Myc DNA Unwinding Element Binding Protein 1A1A ; 2 ; C-SRC (SH2 DOMAIN WITH C188A MUTATION) COMPLEXED WITH ACE-FORMYL PHOSPHOTYR-GLU-(N,N-DIPENTYL AMINE) 1A08 ; 2.2 ; C-SRC (SH2 DOMAIN) COMPLEXED WITH ACE-DIFLUORO PHOSPHOTYR-GLU-(N,N-DIPENTYL AMINE) 1A09 ; 2 ; C-src (SH2 domain) complexed with ace-formyl phosphotyr-glu-(n,n-dipentyl amine) 1A07 ; 2.2 ; C-SRC (SH2 DOMAIN) COMPLEXED WITH ACE-MALONYL TYR-GLU-(N,N-DIPENTYL AMINE) 1A1E ; 2.2 ; C-SRC (SH2 DOMAIN) COMPLEXED WITH ACE-PHOSPHOTYR-GLU-(3-BUTYLPIPERIDINE) 1A1B ; 2.2 ; C-SRC (SH2 DOMAIN) COMPLEXED WITH ACE-PHOSPHOTYR-GLU-(N,N-DIPENTYL AMINE) 1A1C ; 2.4 ; C-SRC (SH2 DOMAIN) COMPLEXED WITH ACE-PHOSPHOTYR-GLU-(N-ME(-(CH2)3-CYCLOPENTYL)) 3UQF ; 2.27 ; c-SRC kinase domain in complex with BKI RM-1-89 3UQG ; 2.2 ; c-SRC kinase domain in complex with bumpless BKI analog UW1243 4DGG ; 2.65 ; c-SRC kinase domain in complex with RM-1-176 3F6X ; 2.35 ; c-Src kinase domain in complex with small molecule inhibitor 3DQW ; 2.017 ; c-Src kinase domain Thr338Ile mutant in complex with ATPgS 1QWE ; ; C-SRC SH3 DOMAIN COMPLEXED WITH LIGAND APP12 1QWF ; ; C-SRC SH3 DOMAIN COMPLEXED WITH LIGAND VSL12 1YI6 ; 2 ; C-term tail segment of human tyrosine kinase (258-533) 3K7D ; 2.4 ; C-terminal (adenylylation) domain of E.coli Glutamine Synthetase Adenylyltransferase 3DIW ; 2.1 ; c-terminal beta-catenin bound TIP-1 structure 2VZQ ; 1.7 ; C-TERMINAL CBM35 FROM AMYCOLATOPSIS ORIENTALIS EXO-CHITOSANASE CSXA IN COMPLEX WITH DIGALACTURONIC ACID 2VZR ; 1.95 ; C-TERMINAL CBM35 FROM AMYCOLATOPSIS ORIENTALIS EXO-CHITOSANASE CSXA IN COMPLEX WITH GLUCURONIC ACID 1HF9 ; ; C-TERMINAL COILED-COIL DOMAIN FROM BOVINE IF1 4GIF ; 2.8 ; C-terminal coiled-coil domain of transient receptor potential channel TRPP3 (PKD2L1, Polycystin-L) 2XOZ ; 2.374 ; C-terminal cysteine rich domain of human CHFR bound to AMP 2XP0 ; 1.978 ; C-terminal cysteine-rich domain of human CHFR 2XOC ; 1.89 ; C-TERMINAL CYSTEINE-RICH DOMAIN OF HUMAN CHFR BOUND TO MADPR 2XOY ; 2.6 ; C-TERMINAL CYSTEINE-RICH DOMAIN OF HUMAN CHFR BOUND TO P(1), P(2)-DIADENOSINE-5'-PYROPHOSPHATE 1SOP ; ; C-terminal cystine-rich domain of Minicollagen-I from Hydra 2B0L ; 2.9 ; C-terminal DNA binding domain of transcriptional pleiotropic repressor CodY. 1QMC ; ; C-TERMINAL DNA-BINDING DOMAIN OF HIV-1 INTEGRASE, NMR, 42 STRUCTURES 1VPC ; ; C-TERMINAL DOMAIN (52-96) OF THE HIV-1 REGULATORY PROTEIN VPR, NMR, 1 STRUCTURE 1RTG ; 2.6 ; C-TERMINAL DOMAIN (HAEMOPEXIN-LIKE DOMAIN) OF HUMAN MATRIX METALLOPROTEINASE-2 2P5M ; 1.95 ; C-terminal domain hexamer of AhrC bound with L-arginine 4AM6 ; 2.7 ; C-TERMINAL DOMAIN OF ACTIN-RELATED PROTEIN ARP8 FROM S. CEREVISIAE 3GAB ; 2.5 ; C-terminal domain of Bacillus subtilis MutL crystal form I 3KDG ; 2 ; C-terminal domain of Bacillus subtilis MutL crystal form II 2XR4 ; 1.9 ; C-TERMINAL DOMAIN OF BC2L-C LECTIN FROM BURKHOLDERIA CENOCEPACIA 1K4Z ; 2.3 ; C-terminal Domain of Cyclase Associated Protein 1KQ5 ; 3 ; C-terminal Domain of Cyclase Associated Protein with PRO 505 Replaced by SER (P505S) 1WSU ; 2.3 ; C-terminal domain of elongation factor selB complexed with SECIS RNA 2E5U ; ; C-terminal domain of Epsilon subunit of F1F0-ATP synthase from the Thermophilic Bacillus PS3 2E5T ; ; C-terminal domain of Epsilon subunit of F1F0-ATP synthase from the Thermophilic bacillus PS3 in the presence of ATP condition 1XXC ; 2.8 ; C-TERMINAL DOMAIN OF ESCHERICHIA COLI ARGININE REPRESSOR 1XXB ; 2.6 ; C-TERMINAL DOMAIN OF ESCHERICHIA COLI ARGININE REPRESSOR/ L-ARGININE COMPLEX 1XXA ; 2.2 ; C-TERMINAL DOMAIN OF ESCHERICHIA COLI ARGININE REPRESSOR/ L-ARGININE COMPLEX; PB DERIVATIVE 1YUA ; ; C-TERMINAL DOMAIN OF ESCHERICHIA COLI TOPOISOMERASE I 1GEN ; 2.15 ; C-TERMINAL DOMAIN OF GELATINASE A 3TBF ; 2.28 ; C-terminal domain of glucosamine-fructose-6-phosphate aminotransferase from Francisella tularensis. 3LOF ; 2.4 ; C-terminal domain of human heat shock 70kDa protein 1B. 2LSK ; ; C-terminal domain of human REV1 in complex with DNA-polymerase H (eta) 2JDQ ; 2.2 ; C-TERMINAL DOMAIN OF INFLUENZA A VIRUS POLYMERASE PB2 SUBUNIT IN COMPLEX WITH HUMAN IMPORTIN ALPHA5 4EW5 ; 1.87 ; C-terminal domain of inner membrane protein CigR from Salmonella enterica. 1RMJ ; ; C-terminal domain of insulin-like growth factor (IGF) binding protein-6: structure and interaction with IGF-II 1ZT3 ; 1.8 ; C-terminal domain of Insulin-like Growth Factor Binding Protein-1 isolated from human amniotic fluid 1ZT5 ; 1.818 ; C-terminal domain of Insulin-like Growth Factor Binding Protein-1 isolated from human amniotic fluid complexed with Iron(II) 2ZP2 ; 3.01 ; C-terminal domain of KipI from Bacillus subtilis 2KVE ; ; C-terminal domain of mesencephalic astrocyte-derived neurotrophic factor (MANF) 1MKH ; 2.01 ; C-terminal domain of methionyl-tRNA synthetase from Pyrococcus abyssi 1MKC ; ; C-TERMINAL DOMAIN OF MIDKINE 1C8Z ; 1.9 ; C-TERMINAL DOMAIN OF MOUSE BRAIN TUBBY PROTEIN 1I7E ; 1.95 ; C-Terminal Domain Of Mouse Brain Tubby Protein bound to Phosphatidylinositol 4,5-bis-phosphate 3KZ7 ; 1.95 ; C-terminal domain of Murine FKBP25 rapamycin complex 2JRB ; ; C-terminal domain of ORF1p from mouse LINE-1 3IR9 ; 2.207 ; C-terminal domain of Peptide Chain Release Factor from Methanosarcina mazei. 3DED ; 2.14 ; C-terminal domain of Probable hemolysin from Chromobacterium violaceum 3RKV ; 2.41 ; C-terminal domain of protein C56C10.10, a putative peptidylprolyl isomerase, from Caenorhabditis elegans 3FW2 ; 1.74 ; C-terminal domain of putative thiol-disulfide oxidoreductase from Bacteroides thetaiotaomicron. 1NRF ; 2.5 ; C-terminal domain of the Bacillus licheniformis BlaR penicillin-receptor 1AA3 ; ; C-TERMINAL DOMAIN OF THE E. COLI RECA, NMR, MINIMIZED AVERAGE STRUCTURE 1H8G ; 2.4 ; C-TERMINAL DOMAIN OF THE MAJOR AUTOLYSIN (C-LYTA) FROM STREPTOCOCCUS PNEUMONIAE 1IGU ; 2.2 ; C-terminal Domain of the Transcriptional Repressor Protein KorB 1IGQ ; 1.7 ; C-terminal Domain of Transcriptional Repressor Protein KorB 1JAD ; 2.4 ; C-terminal Domain of Turkey PLC-beta 3N1B ; 2.398 ; C-terminal domain of Vps54 subunit of the GARP complex 2UWM ; 2.31 ; C-TERMINAL DOMAIN(WH2-WH4) OF ELONGATION FACTOR SELB IN COMPLEX WITH SECIS RNA 2FH2 ; 2.5 ; C-terminal half of gelsolin soaked in EGTA at pH 4.5 2FH4 ; 3 ; C-terminal half of gelsolin soaked in EGTA at pH 8 2FH1 ; 1.55 ; C-terminal half of gelsolin soaked in low calcium at pH 4.5 2FH3 ; 2.87 ; C-terminal half of gelsolin soaked in low calcium at pH 8 1VVD ; ; C-TERMINAL HALF OF VACCINIA VIRUS COMPLEMENT CONTROL PROTEIN, NMR, 21 STRUCTURES 1VVE ; ; C-TERMINAL HALF OF VACCINIA VIRUS COMPLEMENT CONTROL PROTEIN, NMR, 21 STRUCTURES 1VVC ; ; C-TERMINAL HALF OF VACCINIA VIRUS COMPLEMENT CONTROL PROTEIN, NMR, MINIMIZED AVERAGE STRUCTURE 1KHM ; ; C-TERMINAL KH DOMAIN OF HNRNP K (KH3) 1H30 ; 2.2 ; C-TERMINAL LG DOMAIN PAIR OF HUMAN GAS6 1B9W ; 1.8 ; C-TERMINAL MEROZOITE SURFACE PROTEIN 1 FROM PLASMODIUM CYNOMOLGI 4ETP ; 2.3 ; C-terminal motor and motor homology domain of Kar3Vik1 fused to a synthetic heterodimeric coiled coil 1UG3 ; 2.24 ; C-terminal portion of human eIF4GI 1RXZ ; 2 ; C-terminal region of A. fulgidus FEN-1 complexed with A. fulgidus PCNA 1RXM ; 2.8 ; C-terminal region of FEN-1 bound to A. fulgidus PCNA 3EGN ; 2.5 ; C-terminal RNA Recognition Motif of the U11/U12 65K Protein 2EYX ; ; C-Terminal SH3 domain of CT10-Regulated Kinase 1HP3 ; ; C-TERMINAL TRUNCATION OF OMEGA-ATRACOTOXIN-HV2A (CT-HV2A) 1HEH ; ; C-TERMINAL XYLAN BINDING DOMAIN FROM CELLULOMONAS FIMI XYLANASE 11A 1HEJ ; ; C-TERMINAL XYLAN BINDING DOMAIN FROM CELLULOMONAS FIMI XYLANASE 11A 2L46 ; ; C-terminal zinc finger of the HIVNCp7 with platinated DNA 2L44 ; ; C-terminal zinc knuckle of the HIVNCp7 2L45 ; ; C-terminal zinc knuckle of the HIVNCp7 with DNA 3KBF ; 1.3 ; C. elegans Cu,Zn Superoxide Dismutase 4AG7 ; 1.55 ; C. elegans glucosamine-6-phosphate N-acetyltransferase (GNA1): coenzyme A adduct 4AG9 ; 1.76 ; C. elegans glucosamine-6-phosphate N-acetyltransferase (GNA1): ternary complex with coenzyme A and GlcNAc 3RHW ; 3.26 ; C. elegans glutamate-gated chloride channel (GluCl) in complex with Fab and ivermectin 3RIF ; 3.345 ; C. elegans glutamate-gated chloride channel (GluCl) in complex with Fab, ivermectin and glutamate. 3RIA ; 3.8 ; C. elegans glutamate-gated chloride channel (GluCl) in complex with Fab, ivermectin and iodide. 3RI5 ; 3.4 ; C. elegans glutamate-gated chloride channel (GluCl) in complex with Fab, ivermectin and picrotoxin 1GRW ; 2.6 ; C. ELEGANS MAJOR SPERM PROTEIN 2DAP ; 2.2 ; C. GLUTAMICUM DAP DEHYDROGENASE IN COMPLEX WITH DAP 1DAP ; 2.2 ; C. GLUTAMICUM DAP DEHYDROGENASE IN COMPLEX WITH NADP+ 3DAP ; 2.2 ; C. GLUTAMICUM DAP DEHYDROGENASE IN COMPLEX WITH NADP+ AND THE INHIBITOR 5S-ISOXAZOLINE 1D2K ; 2.2 ; C. IMMITIS CHITINASE 1 AT 2.2 ANGSTROMS RESOLUTION 3KHJ ; 2.8 ; C. parvum inosine monophosphate dehydrogenase bound by inhibitor C64 2IUA ; 2.7 ; C. TRACHOMATIS LPXD 2B5A ; 1.543 ; C.BclI, Control Element of the BclI Restriction-Modification System 3UFD ; 2.8 ; C.Esp1396I bound to its highest affinity operator site OM 2XKG ; 1.6 ; C.LACTEUS MINI-HB LEU86ALA MUTANT 4AVD ; 1.5 ; C.lacteus nerve Hb in complex with CO 4AVE ; 1.9 ; C.lacteus nerve Hb in the deoxy form 2FNF ; ; C1 domain of Nore1 3OQR ; 2.4 ; C112D/M121E Azurin, pH 10.0 3NP3 ; 2.1 ; C112D/M121E Pseudomonas Aeruginosa Azurin 3NP4 ; 2.25 ; C112D/M121E Pseudomonas aeruginosa Azurin 1RYW ; 2.3 ; C115S MurA liganded with reaction products 2NU6 ; 2.55 ; C123aA Mutant of E. coli Succinyl-CoA Synthetase 2NU7 ; 2.2 ; C123aS Mutant of E. coli Succinyl-CoA Synthetase 2NU8 ; 2.15 ; C123aT Mutant of E. coli Succinyl-CoA Synthetase 2NU9 ; 2.9 ; C123aT Mutant of E. coli Succinyl-CoA Synthetase Orthorhombic Crystal Form 2NUA ; 2.95 ; C123aV Mutant of E. coli Succinyl-CoA Synthetase 1DBZ ; 2.65 ; C153S MUTANT OF PEA FRUCTOSE-1,6-BISPHOSPHATASE 3OOJ ; 2.5 ; C1A mutant of E. coli GlmS in complex with glucose-6P and glutamate 1AB0 ; 1.9 ; C1G/V32D/F57H MUTANT OF MURINE ADIPOCYTE LIPID BINDING PROTEIN AT PH 4.5 3F5V ; 1.36 ; C2 Crystal form of mite allergen DER P 1 3PZV ; 2.867 ; C2 crystal form of the endo-1,4-beta-glucanase from Bacillus subtilis 168 1F4N ; 1.9 ; C2 CRYSTAL STRUCTURE OF ALA2ILE2-6, A VERSION OF ROP WITH A REPACKED HYDROPHOBIC CORE AND A NEW FOLD. 1DSY ; 2.6 ; C2 DOMAIN FROM PROTEIN KINASE C (ALPHA) COMPLEXED WITH CA2+ AND PHOSPHATIDYLSERINE 1A25 ; 2.7 ; C2 DOMAIN FROM PROTEIN KINASE C (BETA) 1BDY ; 2.2 ; C2 DOMAIN FROM PROTEIN KINASE C DELTA 1BCI ; ; C2 DOMAIN OF CYTOSOLIC PHOSPHOLIPASE A2, NMR, MINIMIZED AVERAGE STRUCTURE 1WFJ ; ; C2 domain-containing protein from putative elicitor-responsive gene 2NRC ; 2.05 ; C28A Mutant of Succinyl-CoA:3-Ketoacid CoA Transferase from Pig Heart 2NRB ; 2 ; C28S Mutant of Succinyl-CoA:3-Ketoacid CoA Transferase from Pig Heart 2K45 ; ; C2A domain of synaptototagmin I solution structure in the FGF-1-C2A binary complex: key component in the fibroblast growthfactor non-classical pathway 2WIN ; 3.9 ; C3 CONVERTASE (C3BBB) STABILIZED BY SCIN 1UZI ; 1.89 ; C3 EXOENZYME FROM CLOSTRIDIUM BOTULINUM, TETRAGONAL FORM 1XMC ; 2 ; C323M mutant structure of mouse carnitine octanoyltransferase 3K79 ; 1.96 ; C38A, C52V Cysteine-Free Variant of Rop (Rom) 3G6J ; 3.1 ; C3b in complex with a C3b specific Fab 3VCB ; 2.4 ; C425S mutant of the C-terminal cytoplasmic domain of non-structural protein 4 from mouse hepatitis virus A59 1HZF ; 2.3 ; C4ADG FRAGMENT OF HUMAN COMPLEMENT FACTOR C4A 2ZIA ; 1.8 ; C4S dCK variant of dCK in complex with cladribine+UDP 2ZI6 ; 1.77 ; C4S dCK variant of dCK in complex with D-dA+UDP 2NO1 ; 1.91 ; C4S dCK variant of dCK in complex with D-dC+ADP 2ZI7 ; 1.97 ; C4S dCK variant of dCK in complex with D-dG+UDP 2NO6 ; 1.9 ; C4S dCK variant of dCK in complex with FTC+ADP 2NO0 ; 1.8 ; C4S dCK variant of dCK in complex with gemcitabine+ADP 2ZI4 ; 2.1 ; C4S dCK variant of dCK in complex with L-dA+ADP 2ZI5 ; 1.77 ; C4S dCK variant of dCK in complex with L-dA+UDP 2NO7 ; 1.7 ; C4S dCK variant of dCK in complex with L-dC+ADP 2ZI9 ; 2.51 ; C4S-E247A dCK variant of dCK in complex with cladribine+ADP 2ZI3 ; 2.3 ; C4S-E247A dCK variant of dCK in complex with D-dA+ADP 3NT0 ; 1.8 ; C500S (T1D) Mutant of CueO soaked in and bound to Cu(I) 3NSC ; 1.5 ; C500S MUTANT OF CueO BOUND TO Cu(II) 2JRE ; ; C60-1, a PDZ domain designed using statistical coupling analysis 4AF2 ; 1.97 ; C61S mutant of thiol peroxidase form E. coli. 1YOB ; 2.25 ; C69A Flavodoxin II from Azotobacter vinelandii 2GBT ; 1.7 ; C6A/C111A CuZn Superoxide dismutase 2GBU ; 2 ; C6A/C111A/C57A/C146A apo CuZn Superoxide dismutase 2GBV ; 2 ; C6A/C111A/C57A/C146A holo CuZn Superoxide dismutase 3C9V ; 4.7 ; C7 Symmetrized Structure of Unliganded GroEL at 4.7 Angstrom Resolution from CryoEM 1RWJ ; 1.7 ; c7-type three-heme cytochrome domain 3QD9 ; 3.3 ; C72S/C353S mutant of Trypanosoma brucei QSOX containing an interdomain disulfide 3T58 ; 2.4 ; C76A/C455S mutant of mouse QSOX1 containing an interdomain disulfide 3T59 ; 2.8 ; C76A/C455S mutant of mouse QSOX1 containing an interdomain disulfide 1GPX ; ; C85S GAPDX, NMR, 20 STRUCTURES 1ES3 ; 2.2 ; C98A mutant of streptomyces K15 DD-transpeptidase 1ES4 ; 1.9 ; C98N mutant of streptomyces K15 DD-transpeptidase 2LJT ; ; C9L,C14L-LeuA 2HHU ; 1.8 ; C:O6-methyl-guanine in the polymerase postinsertion site (-1 basepair position) 2HHT ; 2.05 ; C:O6-methyl-guanine pair in the polymerase-2 basepair position 3IYG ; 4 ; Ca model of bovine TRiC/CCT derived from a 4.0 Angstrom cryo-EM map 3JXH ; 1.701 ; CA-like domain of human PTPRG 3JXF ; 2.004 ; CA-like domain of human PTPRZ 3JXG ; 1.7 ; CA-like domain of mouse PTPRG 2KBM ; ; Ca-S100A1 interacting with TRTK12 1W2M ; 2.4 ; CA-SUBSTITUTED FORM OF E. COLI AMINOPEPTIDASE P 4EIG ; 2.5 ; CA1698 camel antibody fragment in complex with DHFR 3UOM ; 2.02 ; Ca2+ complex of Human skeletal calsequestrin 3KLA ; 1.65 ; Ca2+ release from the endoplasmic reticulum of NY-ESO-1 specific T cells is modulated by the affinity of T cell receptor and by the use of the CD8 co-receptor 1KJU ; 6 ; Ca2+-ATPase in the E2 State 1JHW ; 2.8 ; Ca2+-binding Mimicry in the Crystal Structure of the Eu3+-Bound Mutant Human Macrophage Capping Protein Cap G 3ZWH ; 1.94 ; Ca2+-bound S100A4 C3S, C81S, C86S and F45W mutant complexed with myosin IIA 1IJ6 ; 3.1 ; CA2+-BOUND STRUCTURE OF MULTIDOMAIN EF-HAND PROTEIN, CBP40, FROM TRUE SLIME MOLD 1JWD ; ; Ca2+-induced Structural Changes in Calcyclin: High-resolution Solution Structure of Ca2+-bound Calcyclin. 1S6I ; ; Ca2+-regulatory region (CLD) from soybean calcium-dependent protein kinase-alpha (CDPK) in the presence of Ca2+ and the junction domain (JD) 2K7O ; ; Ca2+-S100B, refined with RDCs 1MQ1 ; ; Ca2+-S100B-TRTK-12 complex 1YC7 ; 1.6 ; cAbAn33 VHH fragment against VSG 1YC8 ; 2.7 ; cAbAn33- Y37V/E44G/R45L triple mutant 1ZMY ; 3 ; cAbBCII-10 VHH framework with CDR loops of cAbLys3 grafted on it and in complex with hen egg white lysozyme 3EBA ; 1.85 ; CAbHul6 FGLW mutant (humanized) in complex with human lysozyme 3S6U ; 2.7 ; Caclcium-bound Ac-ASP-7 1BHL ; 2.2 ; CACODYLATED CATALYTIC DOMAIN OF HIV-1 INTEGRASE 3PM8 ; 2 ; CAD domain of PFF0520w, Calcium dependent protein kinase 2X28 ; 2.15 ; CADMIUM BOUND STRUCTURE OF SPOROSAG 3VG3 ; 2.22 ; Cadmium derivative of human LFABP 3VG4 ; 2.5 ; Cadmium derivative of human LFABP 1CVM ; 2.4 ; CADMIUM INHIBITED CRYSTAL STRUCTURE OF PHYTASE FROM BACILLUS AMYLOLIQUEFACIENS 2EIL ; 2.1 ; Cadmium ion binding structure of bovine heart cytochrome C oxidase in the fully oxidized state 2EIK ; 2.1 ; Cadmium ion binding structure of bovine heart cytochrome C oxidase in the fully reduced state 1ELM ; 2 ; CADMIUM-SUBSTITUTED BOVINE PACREATIC CARBOXYPEPTIDASE A (ALFA-FORM) AT PH 5.5 AND 2 MM CHLORIDE IN MONOCLINIC CRYSTAL FORM. 1ELL ; 1.76 ; CADMIUM-SUBSTITUTED BOVINE PANCREATIC CARBOXYPEPTIDASE A (ALFA-FORM) AT PH 7.5 AND 0.25 M CHLORIDE IN MONOCLINIC CRYSTAL FORM. 1EE3 ; 1.7 ; Cadmium-substituted bovine pancreatic carboxypeptidase A (alfa-form) at pH 7.5 and 2 mM chloride in monoclinic crystal form 1R0I ; 1.5 ; cadmium-substituted rubredoxin 2OS7 ; 2.9 ; Caf1M periplasmic chaperone tetramer 1BF0 ; ; CALCICLUDINE (CAC) FROM GREEN MAMBA DENDROASPIS ANGUSTICEPS, NMR, 15 STRUCTURES 1UOV ; 1.65 ; CALCIUM BINDING DOMAIN C2B 1UOW ; 1.04 ; CALCIUM BINDING DOMAIN C2B 2AAA ; 2.1 ; CALCIUM BINDING IN ALPHA-AMYLASES: AN X-RAY DIFFRACTION STUDY AT 2.1 ANGSTROMS RESOLUTION OF TWO ENZYMES FROM ASPERGILLUS 2P0Q ; ; Calcium binding protein in the calcium-binding form 2P0P ; ; Calcium binding protein in the free form 3TEC ; 2 ; CALCIUM BINDING TO THERMITASE. CRYSTALLOGRAPHIC STUDIES OF THERMITASE AT 0, 5 AND 100 MM CALCIUM 1QMD ; 2.2 ; CALCIUM BOUND CLOSED FORM ALPHA-TOXIN FROM CLOSTRIDIUM PERFRINGENS 1ALV ; 1.9 ; CALCIUM BOUND DOMAIN VI OF PORCINE CALPAIN 1WD9 ; 2.6 ; Calcium bound form of human peptidylarginine deiminase type4 (PAD4) 2WFK ; 2.3 ; CALCIUM BOUND LIPL32 2IIC ; 2.93 ; Calcium bound structure of alpha-11 giardin 3CHK ; 1.65 ; Calcium bound structure of alpha-14 giardin 3GNK ; 2.1 ; Calcium bound to the Holliday junction sequence d(TCGGCGCCGA)4 2C4S ; 3 ; CALCIUM CHONDROITIN 4-SULFATE. MOLECULAR CONFORMATION AND ORGANIZATION OF POLYSACCHARIDE CHAINS IN A PROTEOGLYCAN 476D ; 1.3 ; CALCIUM FORM OF B-DNA UNDECAMER GCGAATTCGCG 463D ; 1.45 ; CALCIUM FORM OF D(CGCGAATTCGCG)2 1UWO ; ; CALCIUM FORM OF HUMAN S100B, NMR, 20 STRUCTURES 477D ; 1.7 ; CALCIUM FORM OF THE B-DNA DODECAMER GGCGAATTCGCG 1WD8 ; 2.8 ; Calcium free form of human peptidylarginine deiminase type4 (PAD4) 1GNV ; 1.9 ; CALCIUM INDEPENDENT SUBTILISIN BPN' MUTANT 3AR3 ; 2.3 ; Calcium pump crystal structure with bound ADP and TG 2ZBG ; 2.55 ; Calcium pump crystal structure with bound AlF4 and TG in the absence of calcium 3AR8 ; 2.6 ; Calcium pump crystal structure with bound AlF4, TNP-AMP and TG 3AR2 ; 2.5 ; Calcium pump crystal structure with bound AMPPCP and Ca2+ 3AR4 ; 2.15 ; Calcium pump crystal structure with bound ATP and TG in the absence of Ca2+ 2ZBF ; 2.4 ; Calcium pump crystal structure with bound BeF3 and TG in the absence of calcium 2ZBE ; 3.8 ; Calcium pump crystal structure with bound BeF3 in the absence of calcium and TG 3AR9 ; 2.6 ; Calcium pump crystal structure with bound BeF3, TNP-AMP and TG in the absence of calcium 3AR6 ; 2.2 ; Calcium pump crystal structure with bound TNP-ADP and TG in the absence of calcium 3AR5 ; 2.2 ; Calcium pump crystal structure with bound TNP-AMP and TG 3AR7 ; 2.15 ; Calcium pump crystal structure with bound TNP-ATP and TG in the absence of Ca2+ 4HKR ; 3.3511 ; Calcium release-activated calcium (CRAC) channel ORAI 4HKS ; 3.3516 ; Calcium release-activated calcium (CRAC) channel ORAI, K163W mutant 1OTM ; 1.93 ; Calcium-binding mutant of the internalin B LRR domain 1OTN ; 1.97 ; Calcium-binding mutant of the Internalin B LRR domain 1OTO ; 1.96 ; Calcium-binding mutant of the internalin B LRR domain 1NKF ; ; CALCIUM-BINDING PEPTIDE, NMR, 30 STRUCTURES 1B8L ; 1.7 ; Calcium-bound D51A/E101D/F102W Triple Mutant of Beta Carp Parvalbumin 1SMG ; ; CALCIUM-BOUND E41A MUTANT OF THE N-DOMAIN OF CHICKEN TROPONIN C, NMR, 40 STRUCTURES 1KP4 ; 1.6 ; CALCIUM-BOUND FORM OF PROKARYOTIC PHOSPHOLIPASE A2 3SH5 ; 2.8 ; Calcium-bound Laminin G like domain 3 from human perlecan 3JVT ; 2.1 ; Calcium-bound Scallop Myosin Regulatory Domain (Lever Arm) with Reconstituted Complete Light Chains 4J9Y ; 1.51 ; Calcium-calmodulin complexed with the calmodulin binding domain from a small conductance potassium channel splice variant 4G28 ; 1.63 ; Calcium-calmodulin complexed with the calmodulin binding domain from a small conductance potassium channel splice variant and EBIO-1 4J9Z ; 1.66 ; Calcium-calmodulin complexed with the calmodulin binding domain from a small conductance potassium channel splice variant and NS309 4G27 ; 1.65 ; Calcium-calmodulin complexed with the calmodulin binding domain from a small conductance potassium channel splice variant and phenylurea 3DF0 ; 2.95 ; Calcium-dependent complex between m-calpain and calpastatin 3I79 ; 2.04 ; Calcium-Dependent Protein Kinase 1 from Toxoplasma gondii (TgCDPK1) 3I7C ; 1.98 ; Calcium-Dependent Protein Kinase 1 from Toxoplasma gondii (TgCDPK1) in complex with bumped kinase inhibitor NA-PP2 3I7B ; 1.988 ; Calcium-Dependent Protein Kinase 1 from Toxoplasma gondii (TgCDPK1) in complex with bumped kinase inhibitor NM-PP1 3N51 ; 2.1 ; Calcium-Dependent Protein Kinase 1 from Toxoplasma gondii (TgCDPK1) in complex with bumped kinase inhibitor RM-1-95 3T3U ; 2.1 ; Calcium-Dependent Protein Kinase 1 from Toxoplasma gondii (TgCDPK1) in complex with Bumped Kinase Inhibitor, RM-1-130 3SX9 ; 2.65 ; Calcium-Dependent Protein Kinase 1 from Toxoplasma gondii (TgCDPK1) in complex with Bumped Kinase Inhibitor, RM-1-132 3T3V ; 2.04 ; Calcium-Dependent Protein Kinase 1 from Toxoplasma gondii (TgCDPK1) in complex with Bumped Kinase Inhibitor, RM-1-87 3SXF ; 2.04 ; Calcium-Dependent Protein Kinase 1 from Toxoplasma gondii (TgCDPK1) in complex with Bumped Kinase Inhibitor, RM-1-89 3UPZ ; 2.2 ; Calcium-Dependent Protein Kinase 1 from Toxoplasma gondii (TgCDPK1) in complex with bumpless BKI analog UW1243 3V51 ; 1.95 ; Calcium-Dependent Protein Kinase 1 from Toxoplasma gondii (TgCDPK1) in complex with inhibitor RM-1-176 3V5P ; 2.1 ; Calcium-Dependent Protein Kinase 1 from Toxoplasma gondii (TgCDPK1) in complex with inhibitor UW1288 3V5T ; 2.13 ; Calcium-Dependent Protein Kinase 1 from Toxoplasma gondii (TgCDPK1) in complex with inhibitor UW1299 3UPX ; 2.27 ; Calcium-Dependent Protein Kinase 1 from Toxoplasma gondii (TgCDPK1) in complex with inhibitor UW1300 3NYV ; 1.88 ; Calcium-Dependent Protein Kinase 1 from Toxoplasma gondii (TgCDPK1) in complex with non-specific inhibitor WHI-P180 2WCE ; 1.77 ; CALCIUM-FREE (APO) S100A12 2WCF ; 2.78 ; CALCIUM-FREE (APO) S100A12 1CFC ; ; CALCIUM-FREE CALMODULIN 1CFD ; ; CALCIUM-FREE CALMODULIN 3EKJ ; 2.8 ; Calcium-free GCaMP2 (calcium binding deficient mutant) 2JWW ; ; Calcium-free rat alpha-parvalbumin 3JTD ; 2.57 ; Calcium-free Scallop Myosin Regulatory Domain with ELC-D19A Point Mutation 1SUB ; 1.75 ; CALCIUM-INDEPENDENT SUBTILISIN BY DESIGN 1SUC ; 1.8 ; CALCIUM-INDEPENDENT SUBTILISIN BY DESIGN 1SUD ; 1.9 ; CALCIUM-INDEPENDENT SUBTILISIN BY DESIGN 1SL8 ; 1.7 ; Calcium-loaded apo-aequorin from Aequorea victoria 1RLW ; 2.4 ; CALCIUM-PHOSPHOLIPID BINDING DOMAIN FROM CYTOSOLIC PHOSPHOLIPASE A2 3EK7 ; 1.85 ; Calcium-saturated GCaMP2 dimer 3EK4 ; 2.65 ; Calcium-saturated GCaMP2 Monomer 3EK8 ; 2.8 ; Calcium-saturated GCaMP2 T116V/G87R mutant monomer 3EKH ; 2 ; Calcium-saturated GCaMP2 T116V/K378W mutant monomer 1DQ1 ; 2.15 ; Calcium;Calcium concanavalin A 1V48 ; 2.2 ; Calf spleen purine nucleoside phosphorylase (PNP) binary complex with 9-(5,5-difluoro-5-phosphonopenthyl)guanine 2PIK ; ; CALICHEAMICIN GAMMA1I-DNA COMPLEX, NMR, 6 STRUCTURES 1HF8 ; 2 ; CALM-N N-TERMINAL DOMAIN OF CLATHRIN ASSEMBLY LYMPHOID MYELOID LEUKAEMIA PROTEIN 1HG5 ; 2 ; CALM-N N-TERMINAL DOMAIN OF CLATHRIN ASSEMBLY LYMPHOID MYELOID LEUKAEMIA PROTEIN, INOSITOL(1,2,3,4,5,6)P6 COMPLEX 1HG2 ; 2 ; CALM-N N-TERMINAL DOMAIN OF CLATHRIN ASSEMBLY LYMPHOID MYELOID LEUKAEMIA PROTEIN, INOSITOL(4,5)P2 COMPLEX 1HFA ; 2 ; CALM-N N-TERMINAL DOMAIN OF CLATHRIN ASSEMBLY LYMPHOID MYELOID LEUKAEMIA PROTEIN, PI(4,5)P2 COMPLEX 4E50 ; 2.7 ; Calmodulin and Ng peptide complex 4E53 ; 2.69 ; Calmodulin and Nm peptide complex 3GP2 ; 1.46 ; Calmodulin bound to peptide from calmodulin kinase II (CaMKII) 3GOF ; 1.45 ; Calmodulin bound to peptide from macrophage nitric oxide synthase 2O60 ; 1.55 ; Calmodulin bound to peptide from neuronal nitric oxide synthase 1WRZ ; 2 ; Calmodulin complexed with a peptide from a human death-associated protein kinase 2K0F ; ; Calmodulin complexed with calmodulin-binding peptide from smooth muscle myosin light chain kinase 2VAY ; 1.94 ; CALMODULIN COMPLEXED WITH CAV1.1 IQ PEPTIDE 1QIW ; 2.3 ; CALMODULIN COMPLEXED WITH N-(3,3,-DIPHENYLPROPYL)-N'-[1-R-(3,4-BIS-BUTOXYPHENYL)-ETHYL]-PROPYLENEDIAMINE (DPD) 1QIV ; 2.64 ; CALMODULIN COMPLEXED WITH N-(3,3,-DIPHENYLPROPYL)-N'-[1-R-(3,4-BIS-BUTOXYPHENYL)-ETHYL]-PROPYLENEDIAMINE (DPD), 1:2 COMPLEX 1A29 ; 2.74 ; CALMODULIN COMPLEXED WITH TRIFLUOPERAZINE (1:2 COMPLEX) 1LIN ; 2 ; CALMODULIN COMPLEXED WITH TRIFLUOPERAZINE (1:4 COMPLEX) 1ZUZ ; 1.91 ; Calmodulin in complex with a mutant peptide from human DRP-1 kinase 1AHR ; 1.8 ; CALMODULIN MUTANT WITH A TWO RESIDUE DELETION IN THE CENTRAL HELIX 1CLL ; 1.7 ; CALMODULIN STRUCTURE REFINED AT 1.7 ANGSTROMS RESOLUTION 2KNE ; ; Calmodulin wraps around its binding domain in the plasma membrane CA2+ pump anchored by a novel 18-1 motif 2KZ2 ; ; Calmodulin, C-terminal domain, F92E mutant 1DMO ; ; CALMODULIN, NMR, 30 STRUCTURES 1A06 ; 2.5 ; CALMODULIN-DEPENDENT PROTEIN KINASE FROM RAT 2LC5 ; ; Calmodulin-like Protein from Entamoeba histolytica: Solution Structure and Calcium-Binding Properties of a Partially Folded Protein 2O5G ; 1.08 ; Calmodulin-smooth muscle light chain kinase peptide complex 2F3Y ; 1.45 ; Calmodulin/IQ domain complex 2F3Z ; 1.6 ; Calmodulin/IQ-AA domain complex 1IQ5 ; 1.8 ; Calmodulin/nematode CA2+/Calmodulin dependent kinase kinase fragment 1CKK ; ; CALMODULIN/RAT CA2+/CALMODULIN DEPENDENT PROTEIN KINASE FRAGMENT 2G8E ; 2.25 ; Calpain 1 proteolytic core in complex with SNJ-1715, a cyclic hemiacetal-type inhibitor 2G8J ; 1.61 ; Calpain 1 proteolytic core in complex with SNJ-1945, a alpha-ketoamide-type inhibitor. 2NQI ; 2.04 ; Calpain 1 proteolytic core inactivated by WR13(R,R), an epoxysuccinyl-type inhibitor. 2NQG ; 2.04 ; Calpain 1 proteolytic core inactivated by WR18(S,S), an epoxysuccinyl-type inhibitor. 2R9C ; 1.8 ; Calpain 1 proteolytic core inactivated by ZLAK-3001, an alpha-ketoamide 2R9F ; 1.6 ; Calpain 1 proteolytic core inactivated by ZLAK-3002, an alpha-ketoamide 1NX2 ; 2.2 ; Calpain Domain VI 1AJ5 ; 2.3 ; CALPAIN DOMAIN VI APO 1NX1 ; 2 ; Calpain Domain VI Complexed with Calpastatin Inhibitory Domain C (DIC) 1NX3 ; 2.45 ; Calpain Domain VI in Complex with the Inhibitor PD150606 1DVI ; 2.3 ; CALPAIN DOMAIN VI WITH CALCIUM BOUND 1AA2 ; 2 ; CALPONIN HOMOLOGY (CH) DOMAIN FROM HUMAN BETA-SPECTRIN 1BKR ; 1.1 ; CALPONIN HOMOLOGY (CH) DOMAIN FROM HUMAN BETA-SPECTRIN AT 1.1 ANGSTROM RESOLUTION 1HHN ; ; CALRETICULIN P-DOMAIN 1QNN ; 1.8 ; CAMBIALISTIC SUPEROXIDE DISMUTASE FROM PORPHYROMONAS GINGIVALIS 4AA9 ; 1.6 ; Camel chymosin at 1.6A resolution 1QD0 ; 2.5 ; CAMELID HEAVY CHAIN VARIABLE DOMAINS PROVIDE EFFICIENT COMBINING SITES TO HAPTENS 1KXQ ; 1.6 ; Camelid VHH Domain in Complex with Porcine Pancreatic alpha-Amylase 1KXT ; 2 ; Camelid VHH Domains in Complex with Porcine Pancreatic alpha-Amylase 1KXV ; 1.6 ; Camelid VHH Domains in Complex with Porcine Pancreatic alpha-Amylase 3KK8 ; 1.72 ; CaMKII Substrate Complex A 3KK9 ; 3.206 ; CaMKII Substrate Complex B 3KL8 ; 3.372 ; CaMKIINtide Inhibitor Complex 3D0S ; 2 ; cAMP receptor protein from m.tuberculosis, cAMP-free form 1CDK ; 2 ; CAMP-DEPENDENT PROTEIN KINASE CATALYTIC SUBUNIT (E.C.2.7.1.37) (PROTEIN KINASE A) COMPLEXED WITH PROTEIN KINASE INHIBITOR PEPTIDE FRAGMENT 5-24 (PKI(5-24) ISOELECTRIC VARIANT CA) AND MN2+ ADENYLYL IMIDODIPHOSPHATE (MNAMP-PNP) AT PH 5.6 AND 7C AND 4C 2GFC ; 1.87 ; cAMP-dependent protein kinase PKA catalytic subunit with PKI-5-24 3DND ; 2.26 ; cAMP-dependent protein kinase PKA catalytic subunit with PKI-5-24 3DNE ; 2 ; cAMP-dependent protein kinase PKA catalytic subunit with PKI-5-24 1STC ; 2.3 ; CAMP-DEPENDENT PROTEIN KINASE, ALPHA-CATALYTIC SUBUNIT IN COMPLEX WITH STAUROSPORINE 1BFO ; 2.6 ; CAMPATH-1G IGG2B RAT MONOCLONAL FAB 2EF6 ; 2.1 ; Canavalia gladiata lectin complexed with Man1-3Man-OMe 2CAU ; 2.1 ; CANAVALIN FROM JACK BEAN 2CAV ; 2 ; CANAVALIN FROM JACK BEAN 1AI9 ; 1.85 ; CANDIDA ALBICANS DIHYDROFOLATE REDUCTASE 1IA3 ; 1.78 ; Candida albicans dihydrofolate reductase complex in which the dihydronicotinamide moiety of dihydro-nicotinamide-adenine-dinucleotide phosphate (NADPH) is displaced by 5-[(4-TERT-BUTYLPHENYL)SULFANYL]-2,4-QUINAZOLINEDIAMINE (GW995) 1IA4 ; 1.85 ; Candida albicans dihydrofolate reductase complex in which the dihydronicotinamide moiety of dihydro-nicotinamide-adenine-dinucleotide phosphate (NADPH) is displaced by 5-{[4-(4-MORPHOLINYL)PHENYL]SULFANYL}-2,4-QUINAZOLINEDIAMIN (GW2021) 1AOE ; 1.6 ; CANDIDA ALBICANS DIHYDROFOLATE REDUCTASE COMPLEXED WITH DIHYDRO-NICOTINAMIDE-ADENINE-DINUCLEOTIDE PHOSPHATE (NADPH) AND 1,3-DIAMINO-7-(1-ETHYEPROPYE)-7H-PYRRALO-[3,2-F]QUINAZOLINE (GW345) 1M79 ; 1.7 ; Candida albicans Dihydrofolate Reductase Complexed with Dihydro-Nicotinamide-Adenine-Dinucleotide Phosphate (NADPH) and 5-(4-methoxyphenoxy)-2,4-quinazolinediamine (GW1466) 1IA1 ; 1.7 ; Candida albicans dihydrofolate reductase complexed with dihydro-nicotinamide-adenine-dinucleotide phosphate (NADPH) and 5-(PHENYLSULFANYL)-2,4-QUINAZOLINEDIAMINE (GW997) 1M78 ; 1.71 ; CANDIDA ALBICANS DIHYDROFOLATE REDUCTASE COMPLEXED WITH DIHYDRO-NICOTINAMIDE-ADENINE-DINUCLEOTIDE PHOSPHATE (NADPH) AND 5-CHLORYL-2,4,6-QUINAZOLINETRIAMINE (GW1225) 1IA2 ; 1.82 ; Candida albicans dihydrofolate reductase complexed with dihydro-nicotinamide-adenine-dinucleotide phosphate (NADPH) and 5-[(4-METHYLPHENYL)SULFANYL]-2,4-QUINAZOLINEDIAMINE (GW578) 1M7A ; 1.76 ; CANDIDA ALBICANS DIHYDROFOLATE REDUCTASE COMPLEXED WITH DIHYDRO-NICOTINAMIDE-ADENINE-DINUCLEOTIDE PHOSPHATE (NADPH) AND 7-[2-methoxy-1-(methoxymethyl)ethyl]-7H-pyrrolo[3,2-f] quinazoline-1,3-diamine (GW557) 3QLW ; 2.504 ; Candida albicans dihydrofolate reductase complexed with NADPH and 5-[3-(2,5-dimethoxyphenyl)prop-1-yn-1-yl]-6-ethylpyrimidine-2,4-diamine (UCP120B) 4H96 ; 2.6 ; Candida albicans dihydrofolate reductase complexed with NADPH and 5-{3-[3-(2,3-dihydro-1,4-benzodioxin-6-yl)-5-methoxyphenyl]prop-1-yn-1-yl}-6-ethylpyrimidine-2,4-diamine (UCP1018) 4H97 ; 2.2 ; Candida albicans dihydrofolate reductase complexed with NADPH and 5-{3-[3-methoxy-5-(4-methylphenyl)phenyl]but-1-yn-1-yl}-6-methylpyrimidine-2,4-diamine (UCP111D4M) 4H95 ; 2.6 ; Candida albicans dihydrofolate reductase complexed with NADPH and 6-ethyl-5-{3-[3-methoxy-5-(pyridin-4-yl)phenyl]but-1-yn-1-yl}pyrimidine-2,4-diamine (UCP1006) 3QLR ; 2.149 ; Candida albicans dihydrofolate reductase complexed with NADPH and 6-methyl-5-[(3R)-3-(3,4,5-trimethoxyphenyl)pent-1-yn-1-yl]pyrimidine-2,4-diamine (UCP112A) 3QLS ; 1.733 ; Candida albicans dihydrofolate reductase complexed with NADPH and 6-methyl-5-[3-methyl-3-(3,4,5-trimethoxyphenyl)but-1-yn-1-yl]pyrimidine-2,4-diamine (UCP115A) 1PMI ; 1.7 ; Candida Albicans Phosphomannose Isomerase 3DRA ; 1.8 ; Candida albicans protein geranylgeranyltransferase-I complexed with GGPP 3QNE ; 2 ; Candida albicans seryl-tRNA synthetase 2J6I ; 1.55 ; CANDIDA BOIDINII FORMATE DEHYDROGENASE (FDH) C-TERMINAL MUTANT 2FSS ; 1.7 ; Candida boidinii formate dehydrogenase (FDH) K47E mutant 3EEM ; 2.11 ; Candida glabrata Dihydrofolate Reductase complexed with 2,4-diamino-5-[3-methyl-3-(3-methoxy-5-(2,6-dimethylphenyl)phenyl)prop-1-ynyl]-6-methylpyrimidine(UCP111D26M) and NADPH 3EEL ; 1.95 ; Candida glabrata Dihydrofolate Reductase complexed with 2,4-diamino-5-[3-methyl-3-(3-methoxy-5-(3,5-dimethylphenyl)phenyl)prop-1-ynyl]-6-methylpyrimidine(UCP11153TM) and NADPH 3EEK ; 2.03 ; Candida glabrata Dihydrofolate Reductase complexed with 2,4-diamino-5-[3-methyl-3-(3-methoxy-5-(4-methylphenyl)phenyl)prop-1-ynyl]-6-methylpyrimidine(UCP111D4M) and NADPH 3EEJ ; 2.11 ; Candida glabrata Dihydrofolate Reductase complexed with 2,4-diamino-5-[3-methyl-3-(3-methoxy-5-phenylphenyl)prop-1-ynyl]-6-methylpyrimidine(UCP111D) and NADPH 3CSE ; 1.6 ; Candida glabrata Dihydrofolate Reductase complexed with NADPH and 2,4-diamino-5-(3-(2,5-dimethoxyphenyl)prop-1-ynyl)-6-ethylpyrimidine (UCP120B) 3QLZ ; 1.94 ; Candida glabrata dihydrofolate reductase complexed with NADPH and 5-[3-(2,5-dimethoxyphenyl)prop-1-yn-1-yl]-6-propylpyrimidine-2,4-diamine (UCP130B) 4H98 ; 2.9 ; Candida glabrata dihydrofolate reductase complexed with NADPH and 5-{3-[3-(2,3-dihydro-1,4-benzodioxin-6-yl)-5-methoxyphenyl]prop-1-yn-1-yl}-6-ethylpyrimidine-2,4-diamine (UCP1018) 3ROA ; 2.301 ; Candida glabrata dihydrofolate reductase complexed with NADPH and 6-ethyl-5-[(3R)-3-[3-methoxy-5-(morpholin-4-yl)phenyl]but-1-yn-1-yl]pyrimidine-2,4-diamine (UCP1004) 3RO9 ; 2.596 ; Candida glabrata dihydrofolate reductase complexed with NADPH and 6-ethyl-5-[(3R)-3-[3-methoxy-5-(pyridin-4-yl)phenyl]but-1-yn-1-yl]pyrimidine-2,4-diamine (UCP1006) 3QLX ; 2.239 ; Candida glabrata dihydrofolate reductase complexed with NADPH and 6-methyl-5-[(3R)-3-(3,4,5-trimethoxyphenyl)pent-1-yn-1-yl]pyrimidine-2,4-diamine (UCP112A) 3QLY ; 2.519 ; Candida glabrata dihydrofolate reductase complexed with NADPH and 6-methyl-5-[3-methyl-3-(3,4,5-trimethoxyphenyl)but-1-yn-1-yl]pyrimidine-2,4-diamine (UCP115A) 2WBV ; 1.9 ; Canine adenovirus 2 fibre head in complex with sialic acid 2J2J ; 1.5 ; CANINE ADENOVIRUS FIBRE HEAD AT 1.5 A RESOLUTION 2W9L ; 2.91 ; CANINE ADENOVIRUS TYPE 2 FIBRE HEAD IN COMPLEX WITH CAR DOMAIN D1 AND SIALIC ACID 1BYU ; 2.15 ; CANINE GDP-RAN 1QG4 ; 2.5 ; CANINE GDP-RAN F72Y MUTANT 3RAN ; 2.15 ; CANINE GDP-RAN Q69L MUTANT 1QG2 ; 2.5 ; CANINE GDP-RAN R76E MUTANT 1C8D ; 3 ; CANINE PANLEUKOPENIA VIRUS EMPTY CAPSID STRUCTURE 1C8H ; 3.5 ; CANINE PARVOVIRUS STRAIN D EMPTY CAPSID STRUCTURE AT PH 5.5 4EPP ; 1.95 ; Canonical poly(ADP-ribose) glycohydrolase from Tetrahymena thermophila. 4EPQ ; 2.399 ; canonical poly(ADP-ribose) glycohydrolase RBPI inhibitor complex from Tetrahymena thermophila 1N52 ; 2.11 ; Cap Binding Complex 1N54 ; 2.72 ; Cap Binding Complex m7GpppG free 2GPQ ; ; Cap-free structure of eIF4E suggests basis for its allosteric regulation 4AFH ; 1.88 ; Capitella teleta AChBP in complex with lobeline 4B5D ; 2.195 ; Capitella teleta AChBP in complex with psychonicline (3-((2(S)- Azetidinyl)methoxy)-5-((1S,2R)-2-(2-hydroxyethyl)cyclopropyl)pyridine) 4AFG ; 2.001 ; Capitella teleta AChBP in complex with varenicline 1VD0 ; ; Capsid stabilizing protein GPD, NMR, 20 Structures 4AN5 ; 8.8 ; Capsid structure and its Stability at the Late Stages of Bacteriophage SPP1 Assembly 2VQ0 ; 3.6 ; Capsid structure of Sesbania mosaic virus coat protein deletion mutant rCP(delta 48 to 59) 2XD8 ; 4.6 ; Capsid structure of the infectious Prochlorococcus Cyanophage P-SSP7 4AY2 ; 2.8 ; Capturing 5' tri-phosphorylated RNA duplex by RIG-I 301D ; 3 ; CAPTURING THE STRUCTURE OF A CATALYTIC RNA INTERMEDIATE: RNA HAMMERHEAD RIBOZYME, MG(II)-SOAKED 300D ; 3 ; CAPTURING THE STRUCTURE OF A CATALYTIC RNA INTERMEDIATE: RNA HAMMERHEAD RIBOZYME, MN(II)-SOAKED 299D ; 3 ; CAPTURING THE STRUCTURE OF A CATALYTIC RNA INTERMEDIATE: THE HAMMERHEAD RIBOZYME 1B7B ; 2.8 ; Carbamate kinase from Enterococcus faecalis 2WE4 ; 2.02 ; CARBAMATE KINASE FROM ENTEROCOCCUS FAECALIS BOUND TO A SULFATE ION AND TWO WATER MOLECULES, WHICH MIMIC THE SUBSTRATE CARBAMYL PHOSPHATE 2WE5 ; 1.39 ; CARBAMATE KINASE FROM ENTEROCOCCUS FAECALIS BOUND TO MGADP 1JDB ; 2.1 ; CARBAMOYL PHOSPHATE SYNTHETASE FROM ESCHERICHIA COLI 1CE8 ; 2.1 ; CARBAMOYL PHOSPHATE SYNTHETASE FROM ESCHERICHIS COLI WITH COMPLEXED WITH THE ALLOSTERIC LIGAND IMP 1A9X ; 1.8 ; CARBAMOYL PHOSPHATE SYNTHETASE: CAUGHT IN THE ACT OF GLUTAMINE HYDROLYSIS 1Q15 ; 2.3 ; Carbapenam Synthetase 1Q19 ; 2.4 ; Carbapenam Synthetase 3VMI ; 2 ; Carbazole- and oxygen-bound complex between oxygenase and ferredoxin in carbazole 1,9a-dioxygenase 1UXZ ; 1.4 ; CARBOHYDRATE BINDING MODULE (CBM6CM-2) FROM CELLVIBRIO MIXTUS LICHENASE 5A 1UYX ; 1.47 ; CARBOHYDRATE BINDING MODULE (CBM6CM-2) FROM CELLVIBRIO MIXTUS LICHENASE 5A IN COMPLEX WITH CELLOBIOSE 1UYY ; 1.47 ; CARBOHYDRATE BINDING MODULE (CBM6CM-2) FROM CELLVIBRIO MIXTUS LICHENASE 5A IN COMPLEX WITH CELLOTRIOSE 1UY0 ; 1.65 ; CARBOHYDRATE BINDING MODULE (CBM6CM-2) FROM CELLVIBRIO MIXTUS LICHENASE 5A IN COMPLEX WITH GLC-1,3-GLC-1,4-GLC-1,3-GLC 1UZ0 ; 2 ; CARBOHYDRATE BINDING MODULE (CBM6CM-2) FROM CELLVIBRIO MIXTUS LICHENASE 5A IN COMPLEX WITH GLC-4GLC-3GLC-4GLC 1UYZ ; 1.6 ; CARBOHYDRATE BINDING MODULE (CBM6CM-2) FROM CELLVIBRIO MIXTUS LICHENASE 5A IN COMPLEX WITH XYLOTETRAOSE 1GMM ; 2 ; CARBOHYDRATE BINDING MODULE CBM6 FROM XYLANASE U CLOSTRIDIUM THERMOCELLUM 4B1L ; 1.65 ; CARBOHYDRATE BINDING MODULE CBM66 FROM BACILLUS SUBTILIS 4B1M ; 1.1 ; CARBOHYDRATE BINDING MODULE CBM66 FROM BACILLUS SUBTILIS 4AZZ ; 1.7 ; Carbohydrate binding module CBM66 from Bacillus subtilis 1GWK ; 2.34 ; CARBOHYDRATE BINDING MODULE FAMILY29 1GWM ; 1.15 ; CARBOHYDRATE BINDING MODULE FAMILY29 COMPLEXED WITH GLUCOHEXAOSE 1GWL ; 1.51 ; CARBOHYDRATE BINDING MODULE FAMILY29 COMPLEXED WITH MANNOHEXAOSE 2NWH ; 1.86 ; Carbohydrate kinase from Agrobacterium tumefaciens 1R13 ; 2.1 ; Carbohydrate recognition and neck domains of surfactant protein A (SP-A) 1R14 ; 2.5 ; Carbohydrate recognition and neck domains of surfactant protein A (Sp-A) containing samarium 2DP8 ; 2.5 ; Carbohydrate recognition by lactoferrin: Crystal structure of the complex of C-terminal lobe of bovine lactoferrin with trisaccharide at 2.5 A resolution 2E0S ; 2.15 ; Carbohydrate recognition of C-terminal half of lactoferrin: Crystal structure of the complex of C-lobe with rhamnose at 2.15 A resolution 1UX7 ; 1.5 ; CARBOHYDRATE-BINDING MODULE CBM36 IN COMPLEX WITH CALCIUM AND XYLOTRIOSE 2YLK ; 2.2 ; Carbohydrate-binding module CBM3b from the cellulosomal cellobiohydrolase 9A from Clostridium thermocellum 3ZQX ; 1.04 ; Carbohydrate-binding module CBM3b from the cellulosomal cellobiohydrolase 9A from Clostridium thermocellum 2V8L ; 1.8 ; Carbohydrate-binding of the starch binding domain of Rhizopus oryzae glucoamylase in complex with beta-cyclodextrin and maltoheptaose 2V8M ; 2.3 ; Carbohydrate-binding of the starch binding domain of Rhizopus oryzae glucoamylase in complex with beta-cyclodextrin and maltoheptaose 2VQ4 ; 1.25 ; CARBOHYDRATE-BINDING OF THE STARCH BINDING DOMAIN OF RHIZOPUS ORYZAE GLUCOAMYLASE IN COMPLEX WITH BETA-CYCLODEXTRIN AND MALTOHEPTAOSE 1SU7 ; 1.12 ; Carbon Monoxide Dehydrogenase from Carboxydothermus hydrogenoformans- DTT reduced state 1SUF ; 1.15 ; Carbon Monoxide Dehydrogenase from Carboxydothermus hydrogenoformans-Inactive state 1SU6 ; 1.64 ; Carbon monoxide dehydrogenase from Carboxydothermus hydrogenoformans: CO reduced state 1FFV ; 2.25 ; CARBON MONOXIDE DEHYDROGENASE FROM HYDROGENOPHAGA PSEUDOFLAVA 1FFU ; 2.35 ; CARBON MONOXIDE DEHYDROGENASE FROM HYDROGENOPHAGA PSEUDOFLAVA WHICH LACKS THE MO-PYRANOPTERIN MOIETY OF THE MOLYBDENUM COFACTOR 1SU8 ; 1.1 ; Carbon Monoxide Induced Decomposition of the Active Site [Ni-4Fe-5S] Cluster of CO Dehydrogenase 2FMG ; 1.6 ; Carbonic anhydrase activators. Activation of isoforms I, II, IV, VA, VII and XIV with L- and D- phenylalanine and crystallographic analysis of their adducts with isozyme II: sterospecific recognition within the active site of an enzyme and its consequences for the drug design, structure with L-phenylalanine 2FMZ ; 1.6 ; Carbonic anhydrase activators. Activation of isoforms I, II, IV, VA, VII and XIV with L- and D- phenylalanine, structure with D-Phenylalanine. 2EZ7 ; 2 ; Carbonic anhydrase activators. Activation of isozymes I, II, IV, VA, VII and XIV with L- and D-histidine and crystallographic analysis of their adducts with isoform II: engineering proton transfer processes within the active site of an enzyme 2FW4 ; 2 ; Carbonic anhydrase activators. The first X-ray crystallographic study of an activator of isoform I, structure with L-histidine. 3EFI ; 1.75 ; Carbonic anhydrase activators: Kinetic and X-ray crystallographic study for the interaction of d- and l-tryptophan with the mammalian isoforms I-XIV 2HKK ; 1.9 ; Carbonic anhydrase activators: Solution and X-ray crystallography for the interaction of andrenaline with various carbonic anhydrase isoforms 2ABE ; 2 ; Carbonic anhydrase activators: X-ray crystal structure of the adduct of human isozyme II with L-histidine as a platform for the design of stronger activators 3RYJ ; 1.39 ; Carbonic Anhydrase complexed with 4-sulfamoyl-N-(2,2,2-trifluoroethyl)benzamide 3RYV ; 1.2 ; Carbonic Anhydrase complexed with N-ethyl-4-sulfamoylbenzamide 3BOH ; 1.7 ; Carbonic anhydrase from marine diatom Thalassiosira weissflogii- cadmium bound domain 1 with acetate (CDCA1-R1) 3BOJ ; 1.45 ; Carbonic anhydrase from marine diatom Thalassiosira weissflogii- cadmium bound domain 1 without bound metal (CDCA1-R1) 3BOB ; 1.45 ; Carbonic anhydrase from marine diatom Thalassiosira weissflogii- cadmium bound domain 2 3BOE ; 1.4 ; Carbonic anhydrase from marine diatom Thalassiosira weissflogii- cadmium bound domain 2 with acetate (CDCA1-R2) 3BOC ; 1.8 ; Carbonic anhydrase from marine diatom Thalassiosira weissflogii- zinc bound domain 2 (CDCA1-R2) 1THJ ; 2.8 ; CARBONIC ANHYDRASE FROM METHANOSARCINA 1HEA ; 2 ; CARBONIC ANHYDRASE II (CARBONATE DEHYDRATASE) (HCA II) (E.C.4.2.1.1) MUTANT WITH LEU 198 REPLACED BY ARG (L198R) 1G3Z ; 1.86 ; CARBONIC ANHYDRASE II (F131V) 1G4O ; 1.96 ; CARBONIC ANHYDRASE II (F131V) COMPLEXED WITH 4-(AMINOSULFONYL)-N-PHENYLMETHYLBENZAMIDE 1G4J ; 1.84 ; CARBONIC ANHYDRASE II (F131V) COMPLEXED WITH 4-(AMINOSULFONYL)-N-[(2,3,4,5,6-PENTAFLUOROPHENYL)METHYL]-BENZAMIDE 1I9O ; 1.86 ; CARBONIC ANHYDRASE II (F131V) COMPLEXED WITH 4-(AMINOSULFONYL)-N-[(2,3,4-TRIFLUOROPHENYL)METHYL]-BENZAMIDE 1G46 ; 1.84 ; CARBONIC ANHYDRASE II (F131V) COMPLEXED WITH 4-(AMINOSULFONYL)-N-[(2,3-DIFLUOROPHENYL)METHYL]-BENZAMIDE 1I9P ; 1.92 ; CARBONIC ANHYDRASE II (F131V) COMPLEXED WITH 4-(AMINOSULFONYL)-N-[(2,4,6-TRIFLUOROPHENYL)METHYL]-BENZAMIDE 1I9M ; 1.84 ; CARBONIC ANHYDRASE II (F131V) COMPLEXED WITH 4-(AMINOSULFONYL)-N-[(2,4-DIFLUOROPHENYL)METHYL]-BENZAMIDE 1I9N ; 1.86 ; CARBONIC ANHYDRASE II (F131V) COMPLEXED WITH 4-(AMINOSULFONYL)-N-[(2,5-DIFLUOROPHENYL)METHYL]-BENZAMIDE 1G48 ; 1.86 ; CARBONIC ANHYDRASE II (F131V) COMPLEXED WITH 4-(AMINOSULFONYL)-N-[(2,6-DIFLUOROPHENYL)METHYL]-BENZAMIDE 1G45 ; 1.83 ; CARBONIC ANHYDRASE II (F131V) COMPLEXED WITH 4-(AMINOSULFONYL)-N-[(2-FLUOROPHENYL)METHYL]-BENZAMIDE 1I9Q ; 1.8 ; CARBONIC ANHYDRASE II (F131V) COMPLEXED WITH 4-(AMINOSULFONYL)-N-[(3,4,5-TRIFLUOROPHENYL)METHYL]-BENZAMIDE 1I9L ; 1.93 ; CARBONIC ANHYDRASE II (F131V) COMPLEXED WITH 4-(AMINOSULFONYL)-N-[(4-FLUOROPHENYL)METHYL]-BENZAMIDE 1OKL ; 2.1 ; CARBONIC ANHYDRASE II COMPLEX WITH THE 1OKL INHIBITOR 5-DIMETHYLAMINO-NAPHTHALENE-1-SULFONAMIDE 1OKM ; 2.2 ; CARBONIC ANHYDRASE II COMPLEX WITH THE 1OKM INHIBITOR 4-SULFONAMIDE-[1-(4-AMINOBUTANE)]BENZAMIDE 1OKN ; 2.4 ; CARBONIC ANHYDRASE II COMPLEX WITH THE 1OKN INHIBITOR 4-SULFONAMIDE-[1-(4-N-(5-FLUORESCEIN THIOUREA)BUTANE)] 1IF7 ; 1.98 ; Carbonic Anhydrase II Complexed With (R)-N-(3-Indol-1-yl-2-methyl-propyl)-4-sulfamoyl-benzamide 1IF8 ; 1.94 ; Carbonic Anhydrase II Complexed With (S)-N-(3-Indol-1-yl-2-methyl-propyl)-4-sulfamoyl-benzamide 1IF5 ; 2 ; Carbonic Anhydrase II Complexed With 2,6-difluorobenzenesulfonamide 1IF6 ; 2.09 ; Carbonic Anhydrase II Complexed With 3,5-difluorobenzenesulfonamide 1G54 ; 1.86 ; CARBONIC ANHYDRASE II COMPLEXED WITH 4-(AMINOSULFONYL)-N-[(2,3,4,5,6-PENTAFLUOROPHENYL)METHYL]-BENZAMIDE 1G52 ; 1.8 ; CARBONIC ANHYDRASE II COMPLEXED WITH 4-(AMINOSULFONYL)-N-[(2,3-DIFLUOROPHENYL)METHYL]-BENZAMIDE 1G53 ; 1.94 ; CARBONIC ANHYDRASE II COMPLEXED WITH 4-(AMINOSULFONYL)-N-[(2,6-DIFLUOROPHENYL)METHYL]-BENZAMIDE 1G1D ; 2.04 ; CARBONIC ANHYDRASE II COMPLEXED WITH 4-(AMINOSULFONYL)-N-[(2-FLUOROPHENYL)METHYL]-BENZAMIDE 1IF4 ; 1.93 ; Carbonic Anhydrase II Complexed With 4-fluorobenzenesulfonamide 1I91 ; 2 ; CARBONIC ANHYDRASE II COMPLEXED WITH AL-6619 2H-THIENO[3,2-E]-1,2-THIAZINE-6-SULFONAMIDE, 2-(3-HYDROXYPHENYL)-3-(4-MORPHOLINYL)-, 1,1-DIOXIDE 1I8Z ; 1.93 ; CARBONIC ANHYDRASE II COMPLEXED WITH AL-6629 2H-THIENO[3,2-E]-1,2-THIAZINE-6-SULFONAMIDE, 2-(3-METHOXYPHENYL)-3-(4-MORPHOLINYL)-, 1,1-DIOXIDE 1I90 ; 2 ; CARBONIC ANHYDRASE II COMPLEXED WITH AL-8520 2H-THIENO[3,2-E]-1,2-THIAZINE-6-SULFONAMIDE, 4-AMINO-3,4-DIHYDRO-2-(3-METHOXYPROPYL)-, 1,1-DIOXIDE, (R) 1IF9 ; 2 ; Carbonic Anhydrase II Complexed With N-[2-(1H-Indol-5-yl)-butyl]-4-sulfamoyl-benzamide 3KNE ; 1.35 ; Carbonic Anhydrase II H64C mutant in complex with an in situ formed triazole 1ZE8 ; 2 ; Carbonic anhydrase II in complex with a membrane-impermeant sulfonamide inhibitor 1ZFQ ; 1.55 ; carbonic anhydrase II in complex with ethoxzolamidphenole as sulfonamide inhibitor 1Z9Y ; 1.66 ; carbonic anhydrase II in complex with furosemide as sulfonamide inhibitor 1ZH9 ; 1.7 ; carbonic anhydrase II in complex with N-4-Methyl-1-piperazinyl-N'-(p-sulfonamide)phenylthiourea as sulfonamide inhibitor 1ZFK ; 1.56 ; carbonic anhydrase II in complex with N-4-sulfonamidphenyl-N'-4-methylbenzosulfonylurease as sulfonamide inhibitor 1OQ5 ; 1.5 ; CARBONIC ANHYDRASE II IN COMPLEX WITH NANOMOLAR INHIBITOR 3M04 ; 1.4 ; Carbonic Anhydrase II in complex with novel sulfonamide inhibitor 3M14 ; 1.38 ; Carbonic Anhydrase II in complex with novel sulfonamide inhibitor 3M2X ; 1.87 ; Carbonic Anhydrase II in complex with novel sulfonamide inhibitor 3M2Y ; 1.17 ; Carbonic Anhydrase II in complex with novel sulfonamide inhibitor 1ZGE ; 1.65 ; carbonic anhydrase II in complex with p-Sulfonamido-o,o'-dichloroaniline as sulfonamide inhibitor 2Q1B ; 1.7 ; Carbonic Anhydrase II in Complex with Saccharin 2Q38 ; 1.95 ; Carbonic Anhydrase II in complex with Saccharin at 1.95 Angstrom 1ZGF ; 1.75 ; carbonic anhydrase II in complex with trichloromethiazide as sulfonamide inhibitor 1BN1 ; 2.1 ; CARBONIC ANHYDRASE II INHIBITOR 1BN3 ; 2.2 ; CARBONIC ANHYDRASE II INHIBITOR 1BN4 ; 2.1 ; CARBONIC ANHYDRASE II INHIBITOR 1BNM ; 2.6 ; CARBONIC ANHYDRASE II INHIBITOR 1BNN ; 2.3 ; CARBONIC ANHYDRASE II INHIBITOR 1BNQ ; 2.4 ; CARBONIC ANHYDRASE II INHIBITOR 1BNT ; 2.15 ; CARBONIC ANHYDRASE II INHIBITOR 1BNU ; 2.15 ; CARBONIC ANHYDRASE II INHIBITOR 1BNV ; 2.4 ; CARBONIC ANHYDRASE II INHIBITOR 1BNW ; 2.25 ; CARBONIC ANHYDRASE II INHIBITOR 1AM6 ; 2 ; CARBONIC ANHYDRASE II INHIBITOR: ACETOHYDROXAMATE 1ZSA ; 2.5 ; CARBONIC ANHYDRASE II MUTANT E117Q, APO FORM 1ZSC ; 1.8 ; CARBONIC ANHYDRASE II MUTANT E117Q, HOLO FORM 1ZSB ; 2 ; CARBONIC ANHYDRASE II MUTANT E117Q, TRANSITION STATE ANALOGUE ACETAZOLAMIDE 3M5S ; 1.4 ; Carbonic Anhydrase II mutant H64C in complex with carbonate 3M1Q ; 1.69 ; Carbonic Anhydrase II mutant W5C-H64C with opened disulfide bond 3M1K ; 1.35 ; Carbonic Anhydrase in complex with fragment 3NI5 ; 2.1 ; Carbonic anhydrase inhibitor: C1 family 3F4X ; 1.9 ; Carbonic anhydrase inhibitors. Comparison of chlorthalidone and indapamide X-ray crystal structures in adducts with isozyme II: when three water molecules make the difference 3B4F ; 1.89 ; Carbonic anhydrase inhibitors. Interaction of 2-(hydrazinocarbonyl)-3-phenyl-1H-indole-5-sulfonamide with twelve mammalian isoforms: kinetic and X-Ray crystallographic studies 3BL0 ; 1.9 ; Carbonic anhydrase inhibitors. Interaction of 2-N,N-Dimethylamino-1,3,4-thiadiazole-5-methanesulfonamide with twelve mammalian isoforms: kinetic and X-Ray crystallographic studies 2Q1Q ; 1.9 ; Carbonic anhydrase inhibitors. Interaction of the antiepileptic drug sulthiame with twelve mammalian isoforms: kinetic and X-Ray crystallographic studies 3DD8 ; 1.9 ; Carbonic anhydrase inhibitors. Interaction of the antitumor sulfamate EMD-486019 with twelve mammalian isoforms: kinetic and X-Ray crystallographic studies 3BL1 ; 2.1 ; Carbonic anhydrase inhibitors. Sulfonamide diuretics revisited old leads for new applications 2H15 ; 1.9 ; Carbonic anhydrase inhibitors: Clashing with Ala65 as a means of designing isozyme-selective inhibitors that show low affinity for the ubiquitous isozyme II 3MNU ; 1.8 ; Carbonic anhydrase inhibitors: crystallographic and solution binding studies for the interaction of a boron containing aromatic sulfamide with mammalian isoforms I-XV 2AW1 ; 1.46 ; Carbonic anhydrase inhibitors: Valdecoxib binds to a different active site region of the human isoform II as compared to the structurally related cyclooxygenase II ""selective"" inhibitor Celecoxib 4BCW ; 1.5 ; Carbonic anhydrase IX mimic in complex with (E)-2-(5-bromo-2- hydroxyphenyl)ethenesulfonic acid 3M1W ; 1.38 ; Carbonic Anhyrdase II mutant W5CH64C with closed disulfide bond in complex with sulfate 4DWU ; 1.44 ; Carbonmonoxy dehaloperoxidase-hemoglobin A structure at 1.44 Angstrom resolution 4DWT ; 2.05 ; Carbonmonoxy dehaloperoxidase-hemoglobin A structure at 2.05 Angstrom resolution 1SPG ; 1.95 ; CARBONMONOXY HEMOGLOBIN FROM THE TELEOST FISH LEIOSTOMUS XANTHURUS 1G08 ; 1.9 ; CARBONMONOXY LIGANDED BOVINE HEMOGLOBIN PH 5.0 1G09 ; 2.04 ; CARBONMONOXY LIGANDED BOVINE HEMOGLOBIN PH 7.2 1G0A ; 2.04 ; CARBONMONOXY LIGANDED BOVINE HEMOGLOBIN PH 8.5 1G0B ; 1.9 ; CARBONMONOXY LIGANDED EQUINE HEMOGLOBIN PH 8.5 1AJG ; 1.69 ; CARBONMONOXY MYOGLOBIN AT 40 K 3GLN ; 2.26 ; Carbonmonoxy Ngb under Xenon pressure 3E55 ; 1.21 ; Carbonmonoxy Sperm Whale Myoglobin at 100 K: Laser off 3EDA ; 1.21 ; Carbonmonoxy Sperm Whale Myoglobin at 100 K: Laser on [150 min] 3ECX ; 1.21 ; Carbonmonoxy Sperm Whale Myoglobin at 100 K: Laser on [30 min] 2ZSN ; 1.21 ; Carbonmonoxy Sperm Whale Myoglobin at 100 K: Laser on [300 min] 2ZSO ; 1.21 ; Carbonmonoxy Sperm Whale Myoglobin at 100 K: Laser on [450 min] 2ZSZ ; 1.21 ; Carbonmonoxy Sperm Whale Myoglobin at 100 K: Laser on [600 min] 2ZT0 ; 1.21 ; Carbonmonoxy Sperm Whale Myoglobin at 100 K: Laser on [750 min] 2ZT1 ; 1.21 ; Carbonmonoxy Sperm Whale Myoglobin at 100 K: Laser on [810 min] 3E5I ; 1.22 ; Carbonmonoxy Sperm Whale Myoglobin at 120 K: Laser off 3EDB ; 1.21 ; Carbonmonoxy Sperm Whale Myoglobin at 120 K: Laser on [150 min] 3ECZ ; 1.21 ; Carbonmonoxy Sperm Whale Myoglobin at 120 K: Laser on [30 min] 2ZSP ; 1.21 ; Carbonmonoxy Sperm Whale Myoglobin at 120 K: Laser on [300 min] 2ZSR ; 1.21 ; Carbonmonoxy Sperm Whale Myoglobin at 120 K: Laser on [450 min] 2ZT2 ; 1.21 ; Carbonmonoxy Sperm Whale Myoglobin at 120 K: Laser on [600 min] 2ZT3 ; 1.21 ; Carbonmonoxy Sperm Whale Myoglobin at 120 K: Laser on [750 min] 2ZT4 ; 1.21 ; Carbonmonoxy Sperm Whale Myoglobin at 120 K: Laser on [810 min] 3E5O ; 1.21 ; Carbonmonoxy Sperm Whale Myoglobin at 140 K: Laser off 2ZSQ ; 1.21 ; Carbonmonoxy Sperm Whale Myoglobin at 140 K: Laser on [150 min] 3ED9 ; 1.21 ; Carbonmonoxy Sperm Whale Myoglobin at 140 K: Laser on [30 min] 2ZSS ; 1.21 ; Carbonmonoxy Sperm Whale Myoglobin at 140 K: Laser on [300 min] 2ZST ; 1.21 ; Carbonmonoxy Sperm Whale Myoglobin at 140 K: Laser on [450 min] 2ZSX ; 1.21 ; Carbonmonoxy Sperm Whale Myoglobin at 140 K: Laser on [600 min] 2ZSY ; 1.21 ; Carbonmonoxy Sperm Whale Myoglobin at 140 K: Laser on [750 min] 3E4N ; 1.21 ; Carbonmonoxy Sperm Whale Myoglobin at 40 K: Laser off 3ECL ; 1.21 ; Carbonmonoxy Sperm Whale Myoglobin at 40 K: Laser on 4F6F ; 1.56 ; Carbonmonoxy structure of His100Phe Cerebratulus lacteus mini-hemoglobin 4F6J ; 1.45 ; Carbonmonoxy structure of His100Trp Cerebratulus lacteus mini-hemoglobin 4F69 ; 1.6 ; Carbonmonoxy structure of Tyr11Phe/Gln44Leu/Thr48Val/Ala55Trp Cerebratulus lacteus mini-hemoglobin 1OUU ; 2.5 ; CARBONMONOXY TROUT HEMOGLOBIN I 1DO4 ; 1.7 ; CARBONMONOXY-MYOGLOBIN (MUTANT L29W) AFTER PHOTOLYSIS AT T<180K 1DO3 ; 1.55 ; CARBONMONOXY-MYOGLOBIN (MUTANT L29W) AFTER PHOTOLYSIS AT T>180K 1DO7 ; 1.85 ; CARBONMONOXY-MYOGLOBIN (MUTANT L29W) REBINDING STRUCTURE AFTER PHOTOLYSIS AT T< 180K 1DO1 ; 1.5 ; CARBONMONOXY-MYOGLOBIN MUTANT L29W AT 105K 1A6G ; 1.15 ; CARBONMONOXY-MYOGLOBIN, ATOMIC RESOLUTION 1CYD ; 1.8 ; CARBONYL REDUCTASE COMPLEXED WITH NADPH AND 2-PROPANOL 1SNY ; 1.75 ; Carbonyl reductase Sniffer of D. melanogaster 1UPB ; 2.35 ; CARBOXYETHYLARGININE SYNTHASE FROM STREPTOMYCES CLAVULIGERUS 1UPC ; 2.45 ; CARBOXYETHYLARGININE SYNTHASE FROM STREPTOMYCES CLAVULIGERUS 1UPA ; 2.35 ; CARBOXYETHYLARGININE SYNTHASE FROM STREPTOMYCES CLAVULIGERUS (SEMET STRUCTURE) 2IHV ; 2.3 ; Carboxyethylarginine synthase from Streptomyces clavuligerus: 5-guanidinovaleric acid complex 2IHU ; 2.05 ; Carboxyethylarginine synthase from Streptomyces clavuligerus: putative reaction intermediate complex 2IHT ; 2 ; Carboxyethylarginine synthase from Streptomyces clavuligerus: SeMet structure 2O7V ; 2.3 ; Carboxylesterase AeCXE1 from Actinidia eriantha covalently inhibited by paraoxon 1AUO ; 1.8 ; CARBOXYLESTERASE FROM PSEUDOMONAS FLUORESCENS 1IRB ; 1.9 ; CARBOXYLIC ESTER HYDROLASE 1FDK ; 1.91 ; CARBOXYLIC ESTER HYDROLASE (PLA2-MJ33 INHIBITOR COMPLEX) 1L8S ; 1.55 ; CARBOXYLIC ESTER HYDROLASE COMPLEX (DIMERIC PLA2 + LPC-ether + ACETATE + PHOSPHATE IONS) 1FXF ; 1.85 ; CARBOXYLIC ESTER HYDROLASE COMPLEX (DIMERIC PLA2 + MJ33 INHIBITOR + PHOSPHATE IONS) 1FX9 ; 2 ; CARBOXYLIC ESTER HYDROLASE COMPLEX (DIMERIC PLA2 + MJ33 INHIBITOR + SULPHATE IONS) 1MKV ; 1.89 ; CARBOXYLIC ESTER HYDROLASE COMPLEX (PLA2 + TRANSITION STATE ANALOG COMPLEX) 1UNE ; 1.5 ; CARBOXYLIC ESTER HYDROLASE, 1.5 ANGSTROM ORTHORHOMBIC FORM OF THE BOVINE RECOMBINANT PLA2 1MKT ; 1.72 ; CARBOXYLIC ESTER HYDROLASE, 1.72 ANGSTROM TRIGONAL FORM OF THE BOVINE RECOMBINANT PLA2 ENZYME 1LE7 ; 2.09 ; CARBOXYLIC ESTER HYDROLASE, C 2 2 21 space group 1MKU ; 1.8 ; CARBOXYLIC ESTER HYDROLASE, ORTHORHOMBIC FORM OF THE TRIPLE MUTANT 1LE6 ; 1.97 ; CARBOXYLIC ESTER HYDROLASE, P 1 21 1 SPACE GROUP 1KVY ; 1.9 ; CARBOXYLIC ESTER HYDROLASE, SINGLE MUTANT D49E COORDINATED TO CALCIUM 2ZP5 ; 1.9 ; Carboxylic ester hydrolase, single mutant d49k of bovine pancreatic pla2 enzyme 2ZP3 ; 1.9 ; Carboxylic ester hydrolase, single mutant d49n of bovine pancreatic pla2 enzyme 1KVX ; 1.9 ; CARBOXYLIC ESTER HYDROLASE, SINGLE MUTANT D99A OF BOVINE PANCREATIC PLA2, 1.9 A ORTHORHOMBIC FORM 2ZP4 ; 1.9 ; Carboxylic ester hydrolase, single mutant h48n of bovine pancreatic pla2 enzyme 1KVW ; 1.95 ; CARBOXYLIC ESTER HYDROLASE, SINGLE MUTANT H48Q OF BOVINE PANCREATIC PLA2 ENZYME 1MKS ; 1.9 ; CARBOXYLIC ESTER HYDROLASE, TRIGONAL FORM OF THE TRIPLE MUTANT 2A7K ; 2.24 ; carboxymethylproline synthase (CarB) from pectobacterium carotovora, apo enzyme 2A81 ; 3.15 ; carboxymethylproline synthase (CarB) from pectobacterium carotovora, complexed with acetyl CoA and bicine 1F57 ; 1.75 ; CARBOXYPEPTIDASE A COMPLEX WITH D-CYSTEINE AT 1.75 A 1BAV ; 1.6 ; CARBOXYPEPTIDASE A COMPLEXED WITH 2-BENZYL-3-IODO-PROPANOIC ACID (BIP) 3I1U ; 1.391 ; Carboxypeptidase A Inhibited by a Thiirane Mechanism-Based inactivator 3HLP ; 1.6 ; Carboxypeptidase A liganded to an organic small-molecule: conformational changes 3HUV ; 1.9 ; Carboxypeptidase A liganded to an organic small-molecule: conformational changes 3KGQ ; 1.7 ; Carboxypeptidase A liganded to an organic small-molecule: conformational changes 1ARL ; 1.88 ; CARBOXYPEPTIDASE A WITH ZN REMOVED 1ARM ; 1.76 ; CARBOXYPEPTIDASE A WITH ZN REPLACED BY HG 1CG2 ; 2.5 ; CARBOXYPEPTIDASE G2 1OBR ; 2.3 ; CARBOXYPEPTIDASE T 3QNV ; 1.69 ; Carboxypeptidase T 3V38 ; 1.5 ; Carboxypeptidase T mutant L254N 4F8Z ; 1.38 ; Carboxypeptidase T with Boc-Leu 3V7Z ; 1.61 ; Carboxypeptidase T with GEMSA 4DUK ; 1.57 ; Carboxypeptidase T with L-BENZYLSUCCINIC ACID 4DJL ; 1.55 ; Carboxypeptidase T with N-sulfamoyl-L-phenylalanine 2EWH ; 1.4 ; Carboxysome protein CsoS1A from Halothiobacillus neapolitanus 2A1B ; 2.9 ; Carboxysome shell protein ccmK2 2A10 ; 1.803 ; carboxysome shell protein ccmK4 2A18 ; 2.28 ; carboxysome shell protein ccmK4, crystal form 2 3CIM ; 1.3 ; Carboxysome shell protein, CcmK2 C-terminal deletion mutant 3DNC ; 2.05 ; Carboxysome shell protein, CcmK2 C-terminal deletion mutant, with a closer spacing between hexamers 2RCF ; 2.15 ; Carboxysome Shell protein, OrfA from H. Neapolitanus 3BN4 ; 2 ; Carboxysome Subunit, CcmK1 3DN9 ; 2.28 ; Carboxysome Subunit, CcmK1 C-terminal deletion mutant 2QW7 ; 2.4 ; Carboxysome Subunit, CcmL 2YGS ; 1.6 ; CARD DOMAIN FROM APAF-1 4DB1 ; 2.6 ; Cardiac human myosin S1dC, beta isoform complexed with Mn-AMPPNP 1CRE ; ; CARDIOTOXIN II FROM TAIWAN COBRA VENOM, NAJA NAJA ATRA: STRUCTURE IN SOLUTION AND COMPARISION AMONG HOMOLOGOUS CARDIOTOXINS 1CRF ; ; CARDIOTOXIN II FROM TAIWAN COBRA VENOM, NAJA NAJA ATRA: STRUCTURE IN SOLUTION AND COMPARISION AMONG HOMOLOGOUS CARDIOTOXINS 2CRS ; ; CARDIOTOXIN III FROM TAIWAN COBRA (NAJA NAJA ATRA) DETERMINATION OF STRUCTURE IN SOLUTION AND COMPARISON WITH SHORT NEUROTOXINS 2CRT ; ; CARDIOTOXIN III FROM TAIWAN COBRA (NAJA NAJA ATRA) DETERMINATION OF STRUCTURE IN SOLUTION AND COMPARISON WITH SHORT NEUROTOXINS 1CDT ; 2.5 ; CARDIOTOXIN V4/II FROM NAJA MOSSAMBICA MOSSAMBICA: THE REFINED CRYSTAL STRUCTURE 1YAL ; 1.7 ; CARICA PAPAYA CHYMOPAPAIN AT 1.7 ANGSTROMS RESOLUTION 1NDF ; 1.9 ; Carnitine Acetyltransferase in Complex with Carnitine 1NDI ; 2.3 ; Carnitine Acetyltransferase in complex with CoA 3U4U ; 2.2 ; Casein kinase 2 in complex with AZ-Inhibitor 1CKJ ; 2.46 ; CASEIN KINASE I DELTA TRUNCATION MUTANT CONTAINING RESIDUES 1-317 COMPLEX WITH BOUND TUNGSTATE 3NFR ; 1.57 ; Casimiroin analog inhibitor of quinone reductase 2 3C0G ; 2.19 ; CASK CaM-Kinase Domain- 3'-AMP complex, P1 form 3C0I ; 1.85 ; CASK CaM-Kinase Domain- 3'-AMP complex, P212121 form 3C0H ; 2.3 ; CASK CaM-Kinase Domain- AMPPNP complex, P1 form 3MFS ; 2.1 ; CASK-4M CaM Kinase Domain, AMPPNP 3MFU ; 2.3 ; CASK-4M CaM Kinase Domain, AMPPNP-Mn2+ 3MFT ; 2.2 ; CASK-4M CaM Kinase Domain, Mn2+ 3MFR ; 2 ; CASK-4M CaM Kinase Domain, native 3KJF ; 2 ; Caspase 3 Bound to a covalent inhibitor 3KJN ; 1.8 ; Caspase 8 bound to a covalent inhibitor 3KJQ ; 1.8 ; Caspase 8 with covalent inhibitor 3R7B ; 1.8 ; Caspase-2 bound to one copy of Ac-DVAD-CHO 3R7N ; 2.33 ; Caspase-2 bound with two copies of Ac-DVAD-CHO 3R6L ; 1.9 ; Caspase-2 T380A bound with Ac-VDVAD-CHO 3GJQ ; 2.6 ; Caspase-3 Binds Diverse P4 Residues in Peptides 3GJR ; 2.2 ; Caspase-3 Binds Diverse P4 Residues in Peptides 3GJS ; 1.9 ; Caspase-3 Binds Diverse P4 Residues in Peptides 3GJT ; 2.2 ; Caspase-3 Binds Diverse P4 Residues in Peptides 3PD0 ; 2 ; Caspase-3 E246A 3PCX ; 1.5 ; Caspase-3 E246A, K242A Double Mutant 2XZD ; 2.1 ; Caspase-3 in Complex with an Inhibitory DARPin-3.4 2Y0B ; 2.1 ; Caspase-3 in Complex with an Inhibitory DARPin-3.4_S76R 2XZT ; 2.7 ; CASPASE-3 IN COMPLEX WITH DARPIN-3.4_I78S 3PD1 ; 1.62 ; Caspase-3 K242A 1NMS ; 1.7 ; Caspase-3 tethered to irreversible inhibitor 2XYP ; 1.86 ; CASPASE-3:CAS26049945 2XYG ; 1.54 ; CASPASE-3:CAS329306 2XYH ; 1.89 ; CASPASE-3:CAS60254719 3QNW ; 2.65 ; Caspase-6 in complex with Z-VAD-FMK inhibitor 1SHJ ; 2.8 ; Caspase-7 in complex with DICA allosteric inhibitor 1SHL ; 3 ; CASPASE-7 IN COMPLEX WITH FICA ALLOSTERIC INHIBITOR 2Y1L ; 1.8 ; Caspase-8 in Complex with DARPin-8.4 1F9E ; 2.9 ; CASPASE-8 SPECIFICITY PROBED AT SUBSITE S4: CRYSTAL STRUCTURE OF THE CASPASE-8-Z-DEVD-CHO 3RJM ; 2.55 ; CASPASE2 IN COMPLEX WITH CHDI LIGAND 33c 1DXH ; 2.5 ; CATABOLIC ORNITHINE CARBAMOYLTRANSFERASE FROM PSEUDOMONAS AERUGINOSA 1RUO ; 2.7 ; CATABOLITE GENE ACTIVATOR PROTEIN (CAP) MUTANT/DNA COMPLEX + ADENOSINE-3',5'-CYCLIC-MONOPHOSPHATE 1CGP ; 3 ; CATABOLITE GENE ACTIVATOR PROTEIN (CAP)/DNA COMPLEX + ADENOSINE-3',5'-CYCLIC-MONOPHOSPHATE 1J59 ; 2.5 ; CATABOLITE GENE ACTIVATOR PROTEIN (CAP)/DNA COMPLEX + ADENOSINE-3',5'-CYCLIC-MONOPHOSPHATE 1RUN ; 2.7 ; CATABOLITE GENE ACTIVATOR PROTEIN (CAP)/DNA COMPLEX + ADENOSINE-3',5'-CYCLIC-MONOPHOSPHATE 2CGP ; 2.2 ; CATABOLITE GENE ACTIVATOR PROTEIN/DNA COMPLEX, ADENOSINE-3',5'-CYCLIC-MONOPHOSPHATE 4AJ9 ; 1.85 ; Catalase 3 from Neurospora crassa 4BIM ; 2.95 ; CATALASE 3 FROM NEUROSPORA CRASSA IN TETRAGONAL FORM EXPOSES A MODIFIED TETRAMERIC ORGANIZATION 1A4E ; 2.4 ; CATALASE A FROM SACCHAROMYCES CEREVISIAE 2CAG ; 2.7 ; CATALASE COMPOUND II 1HBZ ; 1.5 ; CATALASE FROM MICROCOCCUS LYSODEIKTICU 1QH6 ; 2 ; CATALYSIS AND SPECIFICITY IN ENZYMATIC GLYCOSIDE HYDROLASES: A 2,5B CONFORMATION FOR THE GLYCOSYL-ENZYME INTERMIDIATE REVEALED BY THE STRUCTURE OF THE BACILLUS AGARADHAERENS FAMILY 11 XYLANASE 1QH7 ; 1.78 ; CATALYSIS AND SPECIFICITY IN ENZYMATIC GLYCOSIDE HYDROLASES: A 2,5B CONFORMATION FOR THE GLYCOSYL-ENZYME INTERMIDIATE REVEALED BY THE STRUCTURE OF THE BACILLUS AGARADHAERENS FAMILY 11 XYLANASE 2PGJ ; 1.71 ; Catalysis associated conformational changes revealed by human cd38 complexed with a non-hydrolyzable substrate analog 2PGL ; 1.76 ; Catalysis associated conformational changes revealed by human CD38 complexed with a non-hydrolyzable substrate analog 4TGL ; 2.6 ; CATALYSIS AT THE INTERFACE: THE ANATOMY OF A CONFORMATIONAL CHANGE IN A TRIGLYCERIDE LIPASE 1A3L ; 1.95 ; CATALYSIS OF A DISFAVORED REACTION: AN ANTIBODY EXO DIELS-ALDERASE-TSA-INHIBITOR COMPLEX AT 1.95 A RESOLUTION 1LUW ; 2.3 ; CATALYTIC AND STRUCTURAL EFFECTS OF AMINO-ACID SUBSTITUTION AT HIS 30 IN HUMAN MANGANESE SUPEROXIDE DISMUTASE: INSERTION OF VAL CGAMMA INTO THE SUBSTRATE ACCESS CHANNEL 1LUV ; 1.85 ; CATALYTIC AND STRUCTURAL EFFECTS OF AMINO-ACID SUBSTITUTION AT HIS 30 IN HUMAN MANGANESE SUPEROXIDE DISMUTASE: INSERTION OF VAL CGAMMA INTO THE SUBSTRATE ACCESS CHANNEL 1N0N ; 1.82 ; Catalytic and Structural Effects of Amino-Acid Substitution at His30 in Human Manganese Superoxide Dismutase 2WZJ ; 2.786 ; CATALYTIC AND UBA DOMAIN OF KINASE MARK2/(PAR-1) K82R, T208E DOUBLE MUTANT 2HAK ; 2.6 ; Catalytic and ubiqutin-associated domains of MARK1/PAR-1 1Y8G ; 2.501 ; Catalytic and ubiqutin-associated domains of MARK2/PAR-1: Inactive double mutant with selenomethionine 1ZMV ; 3.105 ; Catalytic and ubiqutin-associated domains of MARK2/PAR-1: K82R mutant 1ZMW ; 2.802 ; Catalytic and ubiqutin-associated domains of MARK2/PAR-1: T208A/S212A inactive double mutant 1ZMU ; 2.9 ; Catalytic and ubiqutin-associated domains of MARK2/PAR-1: Wild type 1UM6 ; 1.8 ; catalytic antibody 21h3 1UM5 ; 1.6 ; Catalytic Antibody 21H3 with alcohol substrate 1UM4 ; 1.8 ; Catalytic Antibody 21H3 with hapten 1KEM ; 2.2 ; CATALYTIC ANTIBODY 28B4 FAB FRAGMENT 1KEL ; 1.9 ; CATALYTIC ANTIBODY 28B4 FAB FRAGMENT COMPLEXED WITH HAPTEN (1-[N-4'-NITROBENZYL-N-4'-CARBOXYBUTYLAMINO] METHYLPHOSPHONIC ACID) 1F3D ; 1.87 ; CATALYTIC ANTIBODY 4B2 IN COMPLEX WITH ITS AMIDINIUM HAPTEN. 25C8 ; 2 ; CATALYTIC ANTIBODY 5C8, FAB-HAPTEN COMPLEX 35C8 ; 2 ; CATALYTIC ANTIBODY 5C8, FAB-INHIBITOR COMPLEX 15C8 ; 2.5 ; CATALYTIC ANTIBODY 5C8, FREE FAB 1CT8 ; 2.2 ; CATALYTIC ANTIBODY 7C8 COMPLEX 1YEJ ; 1.85 ; CATALYTIC ANTIBODY COMPLEX 1KN2 ; 1.9 ; CATALYTIC ANTIBODY D2.3 COMPLEX 1KN4 ; 1.9 ; CATALYTIC ANTIBODY D2.3 COMPLEX 1YEI ; 1.9 ; CATALYTIC ANTIBODY D2.3 COMPLEX 1YEK ; 2.1 ; CATALYTIC ANTIBODY D2.3 COMPLEX 2CWT ; 1.82 ; Catalytic base deletion in copper amine oxidase from arthrobacter globiformis 1CGU ; 2.5 ; CATALYTIC CENTER OF CYCLODEXTRIN GLYCOSYLTRANSFERASE DERIVED FROM X-RAY STRUCTURE ANALYSIS COMBINED WITH SITE-DIRECTED MUTAGENESIS 1PYD ; 2.4 ; CATALYTIC CENTERS IN THE THIAMIN DIPHOSPHATE DEPENDENT ENZYME PYRUVATE DECARBOXYLASE AT 2.4 ANGSTROMS RESOLUTION 3FGU ; 2.15 ; Catalytic complex of Human Glucokinase 2GSM ; 2 ; Catalytic Core (Subunits I and II) of Cytochrome c oxidase from Rhodobacter sphaeroides 1FL2 ; 1.9 ; CATALYTIC CORE COMPONENT OF THE ALKYLHYDROPEROXIDE REDUCTASE AHPF FROM E.COLI 1QOZ ; 1.9 ; CATALYTIC CORE DOMAIN OF ACETYL XYLAN ESTERASE FROM TRICHODERMA REESEI 3BJY ; 2.41 ; Catalytic core of Rev1 in complex with DNA (modified template guanine) and incoming nucleotide 1CLX ; 1.8 ; CATALYTIC CORE OF XYLANASE A 1XYS ; 2.5 ; CATALYTIC CORE OF XYLANASE A E246C MUTANT 3DTU ; 2.15 ; Catalytic core subunits (I and II) of cytochrome c oxidase from Rhodobacter sphaeroides complexed with deoxycholic acid 3FYE ; 2.15 ; Catalytic core subunits (I and II) of cytochrome c oxidase from Rhodobacter sphaeroides in the reduced state 3FYI ; 2.2 ; Catalytic core subunits (I and II) of cytochrome C oxidase from Rhodobacter sphaeroides in the reduced state bound with cyanide 3OMI ; 2.15 ; Catalytic core subunits (I and II) of cytochrome C oxidase from Rhodobacter sphaeroides with D132A mutation 3OMN ; 2.15 ; Catalytic core subunits (I and II) of cytochrome C oxidase from Rhodobacter sphaeroides with D132A mutation in the reduced state 3OMA ; 2.3 ; Catalytic core subunits (I and II) of cytochrome C oxidase from Rhodobacter sphaeroides with K362M mutation 3OM3 ; 2.6 ; Catalytic core subunits (I and II) of cytochrome C oxidase from Rhodobacter sphaeroides with K362M mutation in the reduced state 3DJG ; 1.8 ; Catalytic cycle of human glutathione reductase near 1 A resolution 3DJJ ; 1.1 ; Catalytic cycle of human glutathione reductase near 1 A resolution 3DK4 ; 1.2 ; Catalytic cycle of human glutathione reductase near 1 A resolution 3DK8 ; 1.1 ; Catalytic cycle of human glutathione reductase near 1 A resolution 3DK9 ; 0.95 ; Catalytic cycle of human glutathione reductase near 1 A resolution 1E2O ; 3 ; CATALYTIC DOMAIN FROM DIHYDROLIPOAMIDE SUCCINYLTRANSFERASE 1C4T ; 3 ; CATALYTIC DOMAIN FROM TRIMERIC DIHYDROLIPOAMIDE SUCCINYLTRANSFERASE 1WEG ; 1.8 ; Catalytic Domain Od Muty Form Escherichia Coli K142A Mutant 1AIH ; 2.5 ; CATALYTIC DOMAIN OF BACTERIOPHAGE HP1 INTEGRASE 2FYD ; 2 ; catalytic domain of bovine beta 1, 4-galactosyltransferase in complex with alpha-lactalbumin, glucose, Mn, and UDP-N-acetylgalactosamine 3QAY ; 2 ; Catalytic domain of CD27L endolysin targeting Clostridia Difficile 2FW2 ; 2.2 ; Catalytic domain of CDY 1ITX ; 1.1 ; Catalytic Domain of Chitinase A1 from Bacillus circulans WL-12 2YIK ; 2.1 ; Catalytic domain of Clostridium thermocellum CelT 2BX2 ; 2.85 ; CATALYTIC DOMAIN OF E. COLI RNASE E 2C4R ; 3.6 ; CATALYTIC DOMAIN OF E. COLI RNASE E 2C0B ; 3.18 ; CATALYTIC DOMAIN OF E. COLI RNASE E IN COMPLEX WITH 13-MER RNA 1RR9 ; 2.1 ; Catalytic domain of E.coli Lon protease 2BOD ; 1.5 ; CATALYTIC DOMAIN OF ENDO-1,4-GLUCANASE CEL6A FROM THERMOBIFIDA FUSCA IN COMPLEX WITH METHYL CELLOBIOSYL-4-THIO-BETA-CELLOBIOSIDE 2BOE ; 1.15 ; CATALYTIC DOMAIN OF ENDO-1,4-GLUCANASE CEL6A MUTANT Y73S FROM THERMOBIFIDA FUSCA 2BOF ; 1.64 ; CATALYTIC DOMAIN OF ENDO-1,4-GLUCANASE CEL6A MUTANT Y73S FROM THERMOBIFIDA FUSCA IN COMPLEX WITH CELLOTETROSE 2BOG ; 1.04 ; CATALYTIC DOMAIN OF ENDO-1,4-GLUCANASE CEL6A MUTANT Y73S FROM THERMOBIFIDA FUSCA IN COMPLEX WITH METHYL CELLOBIOSYL-4-THIO-BETA-CELLOBIOSIDE 4FET ; 1.909 ; Catalytic domain of germination-specific lytic tansglycosylase SleB from Bacillus anthracis 3EQA ; 1.9 ; Catalytic domain of glucoamylase from aspergillus niger complexed with tris and glycerol 3A0X ; 1.89 ; Catalytic domain of histidine kinase ThkA (TM1359) (nucleotide free form 1: ammomium phosphate, monoclinic) 3A0Y ; 1.57 ; Catalytic domain of histidine kinase ThkA (TM1359) (nucleotide free form 3: 1,2-propanediol, orthorombic) 3A0Z ; 1.75 ; Catalytic domain of histidine kinase ThkA (TM1359) (nucleotide free form 4: isopropanol, orthorombic) 3A0W ; 1.69 ; Catalytic domain of histidine kinase ThkA (TM1359) for MAD phasing (nucleotide free form 2, orthorombic) 3A0T ; 1.91 ; Catalytic domain of histidine kinase ThkA (TM1359) in complex with ADP and Mg ion (trigonal) 1BI4 ; 2.5 ; CATALYTIC DOMAIN OF HIV-1 INTEGRASE 1BL3 ; 2 ; CATALYTIC DOMAIN OF HIV-1 INTEGRASE 2ITG ; 2.6 ; CATALYTIC DOMAIN OF HIV-1 INTEGRASE: ORDERED ACTIVE SITE IN THE F185H CONSTRUCT 3ITM ; 2.49 ; Catalytic domain of hPDE2A 2NQA ; 2.2 ; Catalytic Domain of Human Calpain 8 2ARY ; 2.4 ; Catalytic domain of Human Calpain-1 1ZIV ; 2.31 ; Catalytic Domain of Human Calpain-9 3LKA ; 1.8 ; Catalytic domain of human MMP-12 complexed with hydroxamic acid and paramethoxy-sulfonyl amide 4FIG ; 3.01 ; Catalytic domain of human PAK4 4FIJ ; 2.3 ; Catalytic domain of human PAK4 4FIH ; 1.97 ; Catalytic domain of human PAK4 with QKFTGLPRQW peptide 4FIF ; 2.6 ; Catalytic domain of human PAK4 with RPKPLVDP peptide 4FII ; 2 ; Catalytic domain of human PAK4 with RPKPLVDP peptide 1KW0 ; 2.5 ; Catalytic Domain of Human Phenylalanine Hydroxylase (Fe(II)) in Complex with Tetrahydrobiopterin and Thienylalanine 1J8T ; 1.7 ; Catalytic Domain of Human Phenylalanine Hydroxylase Fe(II) 1J8U ; 1.5 ; Catalytic Domain of Human Phenylalanine Hydroxylase Fe(II) in Complex with Tetrahydrobiopterin 1TAZ ; 1.77 ; Catalytic Domain Of Human Phosphodiesterase 1B 1SO2 ; 2.4 ; CATALYTIC DOMAIN OF HUMAN PHOSPHODIESTERASE 3B In COMPLEX WITH A DIHYDROPYRIDAZINE INHIBITOR 1SOJ ; 2.9 ; CATALYTIC DOMAIN OF HUMAN PHOSPHODIESTERASE 3B IN COMPLEX WITH IBMX 1XM6 ; 1.92 ; Catalytic Domain Of Human Phosphodiesterase 4B In Complex With (R)-Mesopram 1XMY ; 2.4 ; Catalytic Domain Of Human Phosphodiesterase 4B In Complex With (R)-Rolipram 1XN0 ; 2.31 ; Catalytic Domain Of Human Phosphodiesterase 4B In Complex With (R,S)-Rolipram 1Y2H ; 2.4 ; Catalytic Domain Of Human Phosphodiesterase 4B In Complex With 1-(2-chloro-phenyl)-3,5-dimethyl-1H-pyrazole-4-carboxylic acid ethyl ester 1Y2J ; 2.55 ; Catalytic Domain Of Human Phosphodiesterase 4B In Complex With 3,5-dimethyl-1-(3-nitro-phenyl)-1H-pyrazole-4-carboxylic acid ethyl ester 3LY2 ; 2.6 ; Catalytic Domain of Human Phosphodiesterase 4B in Complex with A Coumarin-Based Inhibitor 1TB5 ; 2.15 ; Catalytic Domain Of Human Phosphodiesterase 4B In Complex With AMP 1XLX ; 2.19 ; Catalytic Domain Of Human Phosphodiesterase 4B In Complex With Cilomilast 1XLZ ; 2.06 ; Catalytic Domain Of Human Phosphodiesterase 4B In Complex With Filaminast 1XM4 ; 2.31 ; Catalytic Domain Of Human Phosphodiesterase 4B In Complex With Piclamilast 1XMU ; 2.3 ; Catalytic Domain Of Human Phosphodiesterase 4B In Complex With Roflumilast 1XOS ; 2.28 ; Catalytic Domain Of Human Phosphodiesterase 4B In Complex With Sildenafil 1XOT ; 2.34 ; Catalytic Domain Of Human Phosphodiesterase 4B In Complex With Vardenafil 1F0J ; 1.77 ; CATALYTIC DOMAIN OF HUMAN PHOSPHODIESTERASE 4B2B 3O56 ; 2.42 ; Catalytic domain of human phosphodiesterase 4b2b in complex with a 5-heterocycle pyrazolopyridine inhibitor 3O57 ; 2 ; Catalytic domain of human phosphodiesterase 4b2b in complex with a 5-heterocycle pyrazolopyridine inhibitor 3FRG ; 1.7 ; Catalytic Domain of Human Phosphodiesterase 4B2B in Complex with a Quinoline Inhibitor 3GWT ; 1.75 ; Catalytic domain of human phosphodiesterase 4B2B in complex with a quinoline inhibitor 3HMV ; 2.23 ; Catalytic domain of human phosphodiesterase 4B2B in complex with a tetrahydrobenzothiophene inhibitor 1Y2E ; 2.1 ; Catalytic Domain Of Human Phosphodiesterase 4D In Complex With 1-(4-amino-phenyl)-3,5-dimethyl-1H-pyrazole-4-carboxylic acid ethyl ester 1Y2D ; 1.7 ; Catalytic Domain Of Human Phosphodiesterase 4D In Complex With 1-(4-methoxy-phenyl)-3,5-dimethyl-1H-pyrazole-4-carboxylic acid ethyl ester 1Y2K ; 1.36 ; Catalytic Domain Of Human Phosphodiesterase 4D In Complex With 3,5-dimethyl-1-(3-nitro-phenyl)-1H-pyrazole-4-carboxylic acid ethyl ester 1Y2C ; 1.67 ; Catalytic Domain Of Human Phosphodiesterase 4D In Complex With 3,5-dimethyl-1-phenyl-1H-pyrazole-4-carboxylic acid ethyl ester 1Y2B ; 1.4 ; Catalytic Domain Of Human Phosphodiesterase 4D In Complex With 3,5-dimethyl-1H-pyrazole-4-carboxylic acid ethyl ester 1TB7 ; 1.63 ; Catalytic Domain Of Human Phosphodiesterase 4D In Complex With AMP 1XOM ; 1.55 ; Catalytic Domain Of Human Phosphodiesterase 4D In Complex With Cilomilast 1XON ; 1.72 ; Catalytic Domain Of Human Phosphodiesterase 4D In Complex With Piclamilast 1XOQ ; 1.83 ; Catalytic Domain Of Human Phosphodiesterase 4D In Complex With Roflumilast 1TBB ; 1.6 ; Catalytic Domain Of Human Phosphodiesterase 4D In Complex With Rolipram 1XOR ; 1.54 ; Catalytic Domain Of Human Phosphodiesterase 4D In Complex With Zardaverine 1T9R ; 2.1 ; Catalytic Domain Of Human Phosphodiesterase 5A 1T9S ; 2 ; Catalytic Domain Of Human Phosphodiesterase 5A in Complex with GMP 1TBF ; 1.3 ; Catalytic Domain Of Human Phosphodiesterase 5A in Complex with Sildenafil 1XOZ ; 1.37 ; Catalytic Domain Of Human Phosphodiesterase 5A In Complex With Tadalafil 1XP0 ; 1.79 ; Catalytic Domain Of Human Phosphodiesterase 5A In Complex With Vardenafil 3H62 ; 1.4 ; Catalytic domain of human Serine/Threonine Phosphatase 5 (PP5c) with two Mn2+ atoms complexed with cantharidic acid 3H64 ; 1.9 ; Catalytic domain of human Serine/Threonine Phosphatase 5 (PP5c) with two Mn2+ atoms complexed with endothall 3H63 ; 1.3 ; Catalytic domain of human Serine/Threonine Phosphatase 5 (PP5c) with two Mn2+ atoms originally soaked with cantharidin (which is present in the structure in the hydrolyzed form) 3H61 ; 1.45 ; Catalytic domain of human Serine/Threonine Phosphatase 5 (PP5c) with two Mn2+ atoms originally soaked with norcantharidin (which is present in the structure in the hydrolyzed form) 3H66 ; 2.59 ; Catalytic domain of human Serine/Threonine Phosphatase 5 (PP5c) with two Zn2+ atoms 3H69 ; 2.1 ; Catalytic domain of human Serine/Threonine Phosphatase 5 (PP5c) with two Zn2+ atoms complexed with endothall 3H60 ; 2 ; Catalytic domain of human Serine/Threonine Phosphatase 5 (PP5c)with two Mn2+ atoms 3H67 ; 1.65 ; Catalytic domain of human Serine/Threonine Phosphatase 5 (PP5c)with two Zn2+ atoms complexed with cantharidic acid 3H68 ; 1.5 ; Catalytic domain of human Serine/Threonine Phosphatase 5 (PP5c)with two Zn2+ atoms originally soaked with cantharidin (which is present in the structure in the hydrolyzed form) 1BDA ; 3.35 ; CATALYTIC DOMAIN OF HUMAN SINGLE CHAIN TISSUE PLASMINOGEN ACTIVATOR IN COMPLEX WITH DANSYL-EGR-CMK (DANSYL-GLU-GLY-ARG CHLOROMETHYL KETONE) 2SRT ; ; CATALYTIC DOMAIN OF HUMAN STROMELYSIN-1 AT PH 5.5 AND 40OC COMPLEXED WITH INHIBITOR 1A5H ; 2.9 ; CATALYTIC DOMAIN OF HUMAN TWO-CHAIN TISSUE PLASMINOGEN ACTIVATOR COMPLEX OF A BIS-BENZAMIDINE 1YRP ; 3.1 ; Catalytic domain of human ZIP kinase phosphorylated at Thr265 1MK0 ; 1.6 ; catalytic domain of intron endonuclease I-TevI, E75A mutant 2XMI ; 1.74 ; Catalytic domain of mouse 2',3'-cyclic nucleotide 3'- phosphodiesterase, complexed with citrate 2Y1P ; 1.82 ; Catalytic domain of mouse 2',3'-cyclic nucleotide 3'- phosphodiesterase, complexed with citrate 2Y3X ; 2.1 ; Catalytic domain of mouse 2',3'-cyclic nucleotide 3'- phosphodiesterase, complexed with sulfate 2YDD ; 2.4 ; Catalytic domain of mouse 2',3'-cyclic nucleotide 3'- phosphodiesterase, soaked with 2',3'-cyclic AMP 2YDB ; 2.15 ; Catalytic domain of mouse 2',3'-cyclic nucleotide 3'- phosphodiesterase, soaked with 2',3'-cyclic NADP 2YDC ; 2.05 ; Catalytic domain of mouse 2',3'-cyclic nucleotide 3'- phosphodiesterase, soaked with GTP 1MUY ; 1.4 ; CATALYTIC DOMAIN OF MUTY FROM ESCHERICHIA COLI 1MUN ; 1.2 ; CATALYTIC DOMAIN OF MUTY FROM ESCHERICHIA COLI D138N MUTANT 1WEF ; 1.9 ; Catalytic Domain Of Muty From Escherichia Coli K20A Mutant 1WEI ; 1.45 ; Catalytic Domain Of Muty From Escherichia Coli K20A Mutant Complexed To Adenine 1MUD ; 1.8 ; CATALYTIC DOMAIN OF MUTY FROM ESCHERICHIA COLI, D138N MUTANT COMPLEXED TO ADENINE 1O6Y ; 2.2 ; CATALYTIC DOMAIN OF PKNB KINASE FROM MYCOBACTERIUM TUBERCULOSIS 1QRZ ; 2 ; CATALYTIC DOMAIN OF PLASMINOGEN 1EAK ; 2.66 ; CATALYTIC DOMAIN OF PROMMP-2 E404Q MUTANT 2FUM ; 2.89 ; Catalytic domain of protein kinase PknB from Mycobacterium tuberculosis in complex with mitoxantrone 3OHL ; 2.36 ; catalytic domain of stromelysin-1 in complex with N-Hydroxy-2-(4-methoxy-N-(pyridine-3-ylmethyl)phenylsulfonamido)acetamide 3OHO ; 2.5 ; catalytic domain of stromelysin-1 in complex with N-Hydroxy-2-(4-methylphenylsulfonamido)acetamide 5GCN ; ; CATALYTIC DOMAIN OF TETRAHYMENA GCN5 HISTONE ACETYLTRANSFERASE IN COMPLEX WITH COENZYME A 1M55 ; 1.4 ; Catalytic domain of the Adeno Associated Virus type 5 Rep protein 3VOG ; 1.45 ; Catalytic domain of the cellobiohydrolase, CcCel6A, from Coprinopsis cinerea 3G1N ; 2.6 ; Catalytic domain of the human E3 ubiquitin-protein ligase HUWE1 2ONI ; 2.2 ; Catalytic Domain of the Human NEDD4-like E3 Ligase 2P0C ; 2.4 ; Catalytic Domain of the Proto-oncogene Tyrosine-protein Kinase MER 1BKC ; 2 ; CATALYTIC DOMAIN OF TNF-ALPHA CONVERTING ENZYME (TACE) 3A7S ; 2.2 ; Catalytic domain of UCH37 4FML ; 1.93 ; Catalytic domain of VahC from Aeromonas hydrophila 1A5I ; 2.9 ; CATALYTIC DOMAIN OF VAMPIRE BAT (DESMODUS ROTUNDUS) SALIVA PLASMINOGEN ACTIVATOR IN COMPLEX WITH EGR-CMK (GLU-GLY-ARG CHLOROMETHYL KETONE) 3NTS ; 3.4 ; Catalytic domain of VsdC from Aeromonas hydrophila 1Y0L ; 2.5 ; Catalytic elimination antibody 34E4 in complex with hapten 3KI0 ; 1.29 ; Catalytic fragment of Cholix toxin from Vibrio Cholerae in complex with inhibitor GP-D 3KI1 ; 1.43 ; Catalytic fragment of Cholix toxin from Vibrio Cholerae in complex with inhibitor GP-F 3KI2 ; 1.28 ; Catalytic fragment of Cholix toxin from Vibrio Cholerae in complex with inhibitor GP-G 3KI3 ; 1.27 ; Catalytic fragment of Cholix toxin from Vibrio Cholerae in complex with inhibitor GP-H 3KI7 ; 1.32 ; Catalytic fragment of Cholix toxin from Vibrio Cholerae in complex with inhibitor GP-I 3KI6 ; 1.54 ; Catalytic fragment of Cholix toxin from Vibrio Cholerae in complex with inhibitor GP-L 3KI5 ; 1.55 ; Catalytic fragment of Cholix toxin from Vibrio Cholerae in complex with inhibitor GP-M 3KI4 ; 1.65 ; Catalytic fragment of Cholix toxin from Vibrio Cholerae in complex with inhibitor GP-P 3NY6 ; 1.68 ; Catalytic fragment of cholix toxin from vibrio cholerae in complex with inhibitor V30 3ESS ; 1.191 ; Catalytic fragment of Cholix toxin from Vibrio Cholerae in complex with the 1,8-Naphthalimide inhibitor 2Q6M ; 1.25 ; Catalytic fragment of Cholix toxin from Vibrio Cholerae in complex with the PJ34 inhibitor 4AYK ; ; CATALYTIC FRAGMENT OF HUMAN FIBROBLAST COLLAGENASE COMPLEXED WITH CGS-27023A, NMR, 30 STRUCTURES 3AYK ; ; CATALYTIC FRAGMENT OF HUMAN FIBROBLAST COLLAGENASE COMPLEXED WITH CGS-27023A, NMR, MINIMIZED AVERAGE STRUCTURE 4DJZ ; 3.2 ; Catalytic fragment of masp-1 in complex with its specific inhibitor developed by directed evolution on sgci scaffold 3TVJ ; 1.28 ; Catalytic fragment of MASP-2 in complex with its specific inhibitor developed by directed evolution on SGCI scaffold 3AVR ; 1.803 ; Catalytic fragment of UTX/KDM6A bound with histone H3K27me3 peptide, N-oxyalylglycine, and Ni(II) 3AVS ; 1.85 ; Catalytic fragment of UTX/KDM6A bound with N-oxyalylglycine, and Ni(II) 3ZSC ; 1.94 ; Catalytic function and substrate recognition of the pectate lyase from Thermotoga maritima 3AEX ; 2.1 ; Catalytic intermediate analogue of threonine synthase from Thermus thermophilus HB8 2AU8 ; 1.65 ; Catalytic intermediate structure of inorganic pyrophosphatase 1JYK ; 1.5 ; Catalytic Mechanism of CTP:phosphocholine Cytidylyltransferase from Streptococcus pneumoniae (LicC) 1JYL ; 2.4 ; Catalytic Mechanism of CTP:phosphocholine Cytidylyltransferase from Streptococcus pneumoniae (LicC) 9ICD ; 2.5 ; CATALYTIC MECHANISM OF NADP+-DEPENDENT ISOCITRATE DEHYDROGENASE: IMPLICATIONS FROM THE STRUCTURES OF MAGNESIUM-ISOCITRATE AND NADP+ COMPLEXES 1G72 ; 1.9 ; CATALYTIC MECHANISM OF QUINOPROTEIN METHANOL DEHYDROGENASE: A THEORETICAL AND X-RAY CRYSTALLOGRAPHIC INVESTIGATION 1ELS ; 2.4 ; CATALYTIC METAL ION BINDING IN ENOLASE: THE CRYSTAL STRUCTURE OF ENOLASE-MN2+-PHOSPHONOACETOHYDROXAMATE COMPLEX AT 2.4 ANGSTROMS RESOLUTION 2YA0 ; 1.85 ; CATALYTIC MODULE OF THE MULTI-MODULAR GLYCOGEN-DEGRADING PNEUMOCOCCAL VIRULENCE FACTOR SPUA 2YA2 ; 2.37 ; CATALYTIC MODULE OF THE MULTI-MODULAR GLYCOGEN-DEGRADING PNEUMOCOCCAL VIRULENCE FACTOR SPUA IN COMPLEX WITH AN INHIBITOR. 1LO0 ; 2 ; Catalytic Retro-Diels-Alderase Transition State Analogue Complex 488D ; 3.1 ; CATALYTIC RNA ENZYME-PRODUCT COMPLEX 2RGW ; 2.8 ; Catalytic Subunit of M. jannaschii Aspartate Transcarbamoylase 3E2P ; 3 ; Catalytic subunit of M. Jannaschii aspartate transcarbamoylase in an orthorhombic crystal form 3CSU ; 1.88 ; CATALYTIC TRIMER OF ESCHERICHIA COLI ASPARTATE TRANSCARBAMOYLASE 1LVM ; 1.8 ; CATALYTICALLY ACTIVE TOBACCO ETCH VIRUS PROTEASE COMPLEXED WITH PRODUCT 2F5S ; 2.35 ; Catalytically inactive (E3Q) MutM crosslinked to oxoG:C containing DNA CC1 2F5Q ; 2.35 ; Catalytically inactive (E3Q) MutM crosslinked to oxoG:C containing DNA CC2 1YQL ; 2.6 ; Catalytically inactive hOGG1 crosslinked with 7-deaza-8-azaguanine containing DNA 1YQM ; 2.5 ; Catalytically inactive human 8-oxoguanine glycosylase crosslinked to 7-deazaguanine containing DNA 1YQR ; 2.43 ; Catalytically inactive human 8-oxoguanine glycosylase crosslinked to oxoG containing DNA 1LVB ; 2.2 ; CATALYTICALLY INACTIVE TOBACCO ETCH VIRUS PROTEASE COMPLEXED WITH SUBSTRATE 1XEP ; 1.55 ; Catechol in complex with T4 lysozyme L99A/M102Q 1H1D ; 2 ; CATECHOL O-METHYLTRANSFERASE 1VID ; 2 ; CATECHOL O-METHYLTRANSFERASE 1JR4 ; 2.63 ; CATECHOL O-METHYLTRANSFERASE BISUBSTRATE-INHIBITOR COMPLEX 1BT1 ; 2.7 ; CATECHOL OXIDASE FROM IPOMOEA BATATAS (SWEET POTATOES) IN THE NATIVE CU(II)-CU(II) STATE 1BT3 ; 2.5 ; CATECHOL OXIDASE FROM IPOMOEA BATATAS (SWEET POTATOES) IN THE NATIVE CU(II)-CU(II) STATE 1BT2 ; 2.7 ; CATECHOL OXIDASE FROM IPOMOEA BATATAS (SWEET POTATOES) IN THE REDUCED CU(I)-CU(I) STATE 1BUG ; 2.7 ; CATECHOL OXIDASE FROM IPOMOEA BATATAS (SWEET POTATOES)-INHIBITOR COMPLEX WITH PHENYLTHIOUREA (PTU) 2CL5 ; 1.6 ; CATECHOL-O-METHYLTRANSFERASE IN COMPLEX WITH AN INHIBITOR 2LR7 ; ; Cathelicidin-PY 1PFP ; 2.3 ; CATHELIN-LIKE MOTIF OF PROTEGRIN-3 1GMY ; 1.9 ; CATHEPSIN B COMPLEXED WITH DIPEPTIDYL NITRILE INHIBITOR 3K9M ; 2.61 ; Cathepsin B in complex with stefin A 3AI8 ; 2.11 ; Cathepsin B in complex with the nitroxoline 1LYW ; 2.5 ; CATHEPSIN D AT PH 7.5 1YT7 ; 2.3 ; Cathepsin K complexed with a constrained ketoamide inhibitor 1YK8 ; 2.6 ; Cathepsin K complexed with a cyanamide-based inhibitor 1YK7 ; 2.5 ; Cathepsin K complexed with a cyanopyrrolidine inhibitor 1TU6 ; 1.75 ; Cathepsin K complexed with a ketoamide inhibitor 2BDL ; 2 ; Cathepsin K complexed with a pyrrolidine ketoamide-based inhibitor 2AUX ; 2.4 ; Cathepsin K complexed with a semicarbazone inhibitor 2AUZ ; 2.3 ; Cathepsin K complexed with a semicarbazone inhibitor 1SNK ; 2.4 ; Cathepsin K complexed with carbamate derivatized norleucine aldehyde 1Q6K ; 2.1 ; Cathepsin K complexed with t-butyl(1S)-1-cyclohexyl-2-oxoethylcarbamate 3O1G ; 1.65 ; Cathepsin K covalently bound to a 2-cyano pyrimidine inhibitor with a benzyl P3 group. 3O0U ; 1.8 ; Cathepsin K covalently bound to a cyano-pyrimidine inhibitor with improved selectivity over hERG 3OVZ ; 2.02 ; Cathepsin K in complex with a covalent inhibitor with a ketoamide warhead 3KWZ ; 1.49 ; Cathepsin K in complex with a non-selective 2-cyano-pyrimidine inhibitor 3KX1 ; 1.51 ; Cathepsin K in complex with a selective 2-cyano-pyrimidine inhibitor 4DMX ; 1.7 ; Cathepsin K inhibitor 4DMY ; 1.63 ; Cathepsin K inhibitor 2XU1 ; 1.45 ; CATHEPSIN L WITH A NITRILE INHIBITOR 2XU3 ; 0.9 ; CATHEPSIN L WITH A NITRILE INHIBITOR 2XU4 ; 1.12 ; CATHEPSIN L WITH A NITRILE INHIBITOR 2XU5 ; 1.6 ; CATHEPSIN L WITH A NITRILE INHIBITOR 2YJ2 ; 1.15 ; CATHEPSIN L WITH A NITRILE INHIBITOR 2YJ8 ; 1.3 ; CATHEPSIN L WITH A NITRILE INHIBITOR 2YJ9 ; 1.35 ; CATHEPSIN L WITH A NITRILE INHIBITOR 2YJB ; 1.4 ; CATHEPSIN L WITH A NITRILE INHIBITOR 2YJC ; 1.14 ; CATHEPSIN L WITH A NITRILE INHIBITOR 3HWN ; 2.33 ; CATHEPSIN L with AZ13010160 2R9M ; 1.97 ; Cathepsin S complexed with Compound 15 2R9N ; 2 ; Cathepsin S complexed with Compound 26 2R9O ; 2 ; Cathepsin S complexed with Compound 8 3OVX ; 1.49 ; Cathepsin S in complex with a covalent inhibitor with an aldehyde warhead 2HHN ; 1.55 ; Cathepsin S in complex with non covalent arylaminoethyl amide. 2F1G ; 1.9 ; Cathepsin S in complex with non-covalent 2-(Benzoxazol-2-ylamino)-acetamide 3KWN ; 2.1 ; Cathepsin S in complex with Thioether Acetamide P3 inhibitor 2FQ9 ; 1.65 ; Cathepsin S with nitrile inhibitor 1KYN ; 3.5 ; Cathepsin-G 2VHS ; 1.5 ; CATHSILICATEIN, A CHIMERA 1GLH ; 2 ; CATION BINDING TO A BACILLUS (1,3-1,4)-BETA-GLUCANASE. GEOMETRY, AFFINITY AND EFFECT ON PROTEIN STABILITY 1GLC ; 2.65 ; CATION PROMOTED ASSOCIATION (CPA) OF A REGULATORY AND TARGET PROTEIN IS CONTROLLED BY PHOSPHORYLATION 1GLD ; 2.93 ; CATION PROMOTED ASSOCIATION (CPA) OF A REGULATORY AND TARGET PROTEIN IS CONTROLLED BY PHOSPHORYLATION 1GLE ; 2.94 ; CATION PROMOTED ASSOCIATION (CPA) OF A REGULATORY AND TARGET PROTEIN IS CONTROLLED BY PHOSPHORYLATION 3HWB ; 3 ; Cation selective pathway of OmpF porin revealed by anomalous diffraction 3HW9 ; 2.61 ; Cation selective pathway of OmpF porin revealed by anomalous x-ray diffraction 3FAR ; 2.4 ; Cation-dependent self-cleavage activity in the duplex form of the subtype-B HIV-1 RNA Dimerization Initiation Site 1ND0 ; 2.45 ; CATIONIC CYCLIZATION ANTIBODY 4C6 COMPLEX WITH TRANSITION STATE ANALOG 1NCW ; 1.3 ; Cationic Cyclization Antibody 4C6 in Complex with Benzoic Acid 4AOQ ; 2 ; Cationic trypsin in complex with mutated Spinacia oleracea trypsin inhibitor III (SOTI-III) (F14A) 4AOR ; 1.702 ; Cationic trypsin in complex with the Spinacia oleracea trypsin inhibitor III (SOTI-III) 2F7B ; 1.9 ; CatM effector binding domain 2F7C ; 2.162 ; CatM effector binding domain with its effector cis,cis-muconate 2XFX ; 1.9 ; cattle MHC class I N01301 presenting an 11mer from Theileria parva 2W4Z ; 3.6 ; CAULOBACTER BACTERIOPHAGE 5 2W4Y ; 2.9 ; CAULOBACTER BACTERIOPHAGE 5 - VIRUS-LIKE PARTICLE 2J1K ; 2.3 ; CAV-2 FIBRE HEAD IN COMPLEX WITH CAR D1 1QSQ ; 1.9 ; CAVITY CREATING MUTATION 3Q7Z ; 1.87 ; CBAP-acylated BlaR1 sensor domain from Staphylococcus aureus 3MQK ; 2.8 ; Cbf5-Nop10-Gar1 complex binding with 17mer RNA containing ACA trinucleotide 6CEL ; 1.7 ; CBH1 (E212Q) CELLOPENTAOSE COMPLEX 5CEL ; 1.9 ; CBH1 (E212Q) CELLOTETRAOSE COMPLEX 7CEL ; 1.9 ; CBH1 (E217Q) IN COMPLEX WITH CELLOHEXAOSE AND CELLOBIOSE 1DY4 ; 1.9 ; CBH1 IN COMPLEX WITH S-PROPRANOLOL 1W90 ; 2.5 ; CBM29-2 MUTANT D114A: PROBING THE MECHANISM OF LIGAND RECOGNITION BY FAMILY 29 CARBOHYDRATE BINDING MODULES 1W8U ; 1.3 ; CBM29-2 MUTANT D83A COMPLEXED WITH MANNOHEXAOSE: PROBING THE MECHANISM OF LIGAND RECOGNITION BY FAMILY 29 CARBOHYDRATE BINDING MODULES 1W8T ; 1.4 ; CBM29-2 MUTANT K74A COMPLEXED WITH CELLULOHEXAOSE: PROBING THE MECHANISM OF LIGAND RECOGNITION BY FAMILY 29 CARBOHYDRATE BINDING MODULES 1W8Z ; 1.85 ; CBM29-2 MUTANT K85A: PROBING THE MECHANISM OF LIGAND RECOGNITION BY FAMILY 29 CARBOHYDRATE BINDING MODULES 1W9F ; 2.25 ; CBM29-2 MUTANT R112A: PROBING THE MECHANISM OF LIGAND RECOGNITION BY FAMILY 29 CARBOHYDRATE BINDING MODULES 1W8W ; 2.1 ; CBM29-2 MUTANT Y46A: PROBING THE MECHANISM OF LIGAND RECOGNITION BY FAMILY 29 CARBOHYDRATE BINDING MODULES 1WCU ; 1.5 ; CBM29_1, A FAMILY 29 CARBOHYDRATE BINDING MODULE FROM PIROMYCES EQUI 2W46 ; 1.9 ; CBM35 from Cellvibrio japonicus Abf62 1GU3 ; 2.3 ; CBM4 STRUCTURE AND FUNCTION 1GUI ; 1.9 ; CBM4 STRUCTURE AND FUNCTION 2YFU ; 1.65 ; CBM62 FROM CLOSTRIDIUM THERMOCELLUM XYL5A 2YFZ ; 1.8 ; CBM62 FROM CLOSTRIDIUM THERMOCELLUM XYL5A 2YG0 ; 1.8 ; CBM62 FROM CLOSTRIDIUM THERMOCELLUM XYL5A 2YB7 ; 1.7 ; CBM62 in complex with 6-alpha-D-Galactosyl-mannotriose 1UXX ; 1.6 ; CBM6CT FROM CLOSTRIDIUM THERMOCELLUM IN COMPLEX WITH XYLOPENTAOSE 1PBJ ; 1.4 ; CBS domain protein 2RIH ; 2.1 ; CBS domain protein PAE2072 from Pyrobaculum aerophilum 2RIF ; 2.35 ; CBS domain protein PAE2072 from Pyrobaculum aerophilum complexed with AMP 2BKA ; 1.7 ; CC3(TIP30)CRYSTAL STRUCURE 1YMZ ; ; CC45, An Artificial WW Domain Designed Using Statistical Coupling Analysis 4G91 ; 1.9 ; CCAAT-binding complex from Aspergillus nidulans 4G92 ; 1.8 ; CCAAT-binding complex from Aspergillus nidulans with DNA 1ZF1 ; 1.35 ; CCC A-DNA 3VOH ; 2.4 ; CcCel6A catalytic domain complexed with cellobiose 3VOI ; 2 ; CcCel6A catalytic domain complexed with p-nitrophenyl beta-D-cellotrioside 3VOJ ; 2.29 ; CcCel6A catalytic domain mutant D164A 3A9B ; 1.2 ; CcCel6C, a glycoside hydrolase family 6 enzyme, complexed with cellobiose 3ABX ; 1.4 ; CcCel6C, a glycoside hydrolase family 6 enzyme, complexed with p-nitrophenyl beta-D-cellotrioside 3TCJ ; 1.93 ; CcdB dimer from V. fisheri in complex with one C-terminal domain of F-plasmid CcdA 3HPW ; 1.452 ; CcdB dimer in complex with one C-terminal CcdA domain 3G7Z ; 2.351 ; CcdB dimer in complex with two C-terminal CcdA domains 1VUB ; 2.6 ; CCDB, A TOPOISOMERASE POISON FROM E. COLI 2VUB ; 2.45 ; CCDB, A TOPOISOMERASE POISON FROM E. COLI 3VUB ; 1.4 ; CCDB, A TOPOISOMERASE POISON FROM E. COLI 4VUB ; 1.45 ; CCDB, A TOPOISOMERASE POISON FROM ESCHERICHIA COLI 1X75 ; 2.8 ; CcdB:GyrA14 complex 3JSC ; 1.5 ; CcdBVfi-FormI-pH7.0 3JRZ ; 1.7 ; CcdBVfi-FormII-pH5.6 4ELY ; 1.932 ; CCDBVFI:GYRA14EC 4ELZ ; 2.2 ; CCDBVFI:GYRA14VFI 1ZEX ; 1.65 ; CCG A-DNA 3SSS ; 2.05 ; CcmK1 with residues 103-113 deleted 3SSQ ; 2.2 ; CcmK2 - form 1 dodecamer 3SSR ; 1.6 ; CcmK2 dodecamer - form 2 3HQ8 ; 2.4 ; CcpA from G. sulfurreducens S134P/V135K variant 3HQ7 ; 2.31 ; CcpA from G. sulfurreducens, G94K/K97Q/R100I variant 3HQ9 ; 1.52 ; CcpA from G. sulfurreducens, S134P variant 3OQO ; 2.97 ; Ccpa-hpr-ser46p-syn cre 2RLL ; ; CCR5 Nt(7-15) 1G3W ; 2.4 ; CD-CYS102SER DTXR 1CD1 ; 2.67 ; CD1(MOUSE) ANTIGEN PRESENTING MOLECULE 2O7N ; 1.75 ; CD11A (LFA1) I-domain complexed with 7A-[(4-cyanophenyl)methyl]-6-(3,5-dichlorophenyl)-5-oxo-2,3,5,7A-tetrahydro-1H-pyrrolo[1,2-A]pyrrole-7-carbonitrile 2ICA ; 1.56 ; CD11a (LFA1) I-domain complexed with BMS-587101 aka 5-[(5S, 9R)-9-(4-cyanophenyl)-3-(3,5-dichlorophenyl)-1-methyl-2,4-dioxo-1,3,7-triazaspiro [4.4]non-7-yl]methyl]-3-thiophenecarboxylicacid 3M6F ; 1.85 ; CD11A I-domain complexed with 6-((5S,9R)-9-(4-CYANOPHENYL)-3-(3,5-DICHLOROPHENYL)-1-METHYL-2,4-DIOXO-1,3,7- TRIAZASPIRO[4.4]NON-7-YL)NICOTINIC ACID 1ZOO ; 3 ; CD11A I-DOMAIN WITH BOUND MAGNESIUM ION 1ZOP ; 2 ; CD11A I-DOMAIN WITH BOUND MAGNESIUM ION 1LFA ; 1.8 ; CD11A I-DOMAIN WITH BOUND MN++ 1ZON ; 2 ; CD11A I-DOMAIN WITHOUT BOUND CATION 1GZP ; 2.8 ; CD1B IN COMPLEX WITH GM2 GANGLIOSIDE 1GZQ ; 2.26 ; CD1B IN COMPLEX WITH PHOPHATIDYLINOSITOL 3OV6 ; 2.502 ; CD1c in complex with MPM (mannosyl-beta1-phosphomycoketide) 1CDC ; 2 ; CD2, N-TERMINAL DOMAIN (1-99), TRUNCATED FORM 2H2T ; 1.3 ; CD23 Lectin domain, Calcium 2+-bound 1L2Z ; ; CD2BP2-GYF domain in complex with proline-rich CD2 tail segment peptide 1XMW ; ; CD3 EPSILON AND DELTA ECTODOMAIN FRAGMENT COMPLEX IN SINGLE-CHAIN CONSTRUCT 1JBJ ; ; CD3 Epsilon and gamma Ectodomain Fragment Complex in Single-Chain Construct 3U4H ; 1.878 ; CD38 structure-based inhibitor design using the N1-cyclic inosine 5'-diphosphate ribose template 3U4I ; 2.118 ; CD38 structure-based inhibitor design using the N1-cyclic inosine 5'-diphosphate ribose template 3B71 ; 2.82 ; CD4 endocytosis motif bound to the Focal Adhesion Targeting (FAT) domain of the Focal Adhesion Kinase 2ARJ ; 2.88 ; CD8alpha-alpha in complex with YTS 105.18 Fab 3KAE ; 2.298 ; Cdc27 N-terminus 2QRZ ; 2.4 ; Cdc42 bound to GMP-PCP: Induced Fit by Effector is Required 1E0A ; ; Cdc42 complexed with the GTPase binding domain of p21 activated kinase 1AJE ; ; CDC42 FROM HUMAN, NMR, 20 STRUCTURES 2KB0 ; ; Cdc42(T35A) 1CF4 ; ; CDC42/ACK GTPASE-BINDING DOMAIN COMPLEX 1AN0 ; 2.8 ; CDC42HS-GDP COMPLEX 1GGW ; ; CDC4P FROM SCHIZOSACCHAROMYCES POMBE 4G6V ; 2.64 ; CdiA-CT/CdiI toxin and immunity complex from Burkholderia pseudomallei 4G6U ; 2.353 ; CdiA-CT/CdiI toxin and immunity complex from Escherichia coli 3EZR ; 1.9 ; CDK-2 with indazole inhibitor 17 bound at its active site 3EZV ; 1.99 ; CDK-2 with indazole inhibitor 9 bound at its active site 3F5X ; 2.4 ; CDK-2-Cyclin complex with indazole inhibitor 9 bound at its active site 1R78 ; 2 ; CDK2 complex with a 4-alkynyl oxindole inhibitor 1KE5 ; 2.2 ; CDK2 complexed with N-methyl-4-{[(2-oxo-1,2-dihydro-3H-indol-3-ylidene)methyl]amino}benzenesulfonamide 3PXQ ; 1.9 ; CDK2 in complex with 3 molecules of 8-anilino-1-naphthalene sulfonate 4ACM ; 1.63 ; CDK2 IN COMPLEX WITH 3-AMINO-6-(4-{[2-(DIMETHYLAMINO)ETHYL]SULFAMOYL}-PHENYL)-N-PYRIDIN-3-YLPYRAZINE-2-CARBOXAMIDE 1H01 ; 1.79 ; CDK2 IN COMPLEX WITH A DISUBSTITUTED 2, 4-BIS ANILINO PYRIMIDINE CDK4 INHIBITOR 1H08 ; 1.8 ; CDK2 IN COMPLEX WITH A DISUBSTITUTED 2, 4-BIS ANILINO PYRIMIDINE CDK4 INHIBITOR 1H00 ; 1.6 ; CDK2 IN COMPLEX WITH A DISUBSTITUTED 4, 6-BIS ANILINO PYRIMIDINE CDK4 INHIBITOR 1H07 ; 1.85 ; CDK2 IN COMPLEX WITH A DISUBSTITUTED 4, 6-BIS ANILINO PYRIMIDINE CDK4 INHIBITOR 1V1K ; 2.31 ; CDK2 IN COMPLEX WITH A DISUBSTITUTED 4, 6-BIS ANILINO PYRIMIDINE CDK4 INHIBITOR 2VV9 ; 1.9 ; CDK2 IN COMPLEX WITH AN IMIDAZOLE PIPERAZINE 1URW ; 1.6 ; CDK2 IN COMPLEX WITH AN IMIDAZO[1,2-B]PYRIDAZINE 3QL8 ; 1.9 ; CDK2 in complex with inhibitor JWS-6-260 3QZF ; 2 ; CDK2 in complex with inhibitor JWS-6-52 3QZG ; 1.75 ; CDK2 in complex with inhibitor JWS-6-76 3PXY ; 1.8 ; CDK2 in complex with inhibitor JWS648 3R1Q ; 1.85 ; CDK2 in complex with inhibitor KVR-1-102 3QZH ; 1.95 ; CDK2 in complex with inhibitor KVR-1-124 3QZI ; 1.75 ; CDK2 in complex with inhibitor KVR-1-126 3R1S ; 1.8 ; CDK2 in complex with inhibitor KVR-1-127 3R1Y ; 1.8 ; CDK2 in complex with inhibitor KVR-1-134 3R28 ; 1.75 ; CDK2 in complex with inhibitor KVR-1-140 3QWJ ; 1.75 ; CDK2 in complex with inhibitor KVR-1-142 3QWK ; 1.85 ; CDK2 in complex with inhibitor KVR-1-150 3ROY ; 1.75 ; CDK2 in complex with inhibitor KVR-1-154 3RPO ; 1.75 ; CDK2 in complex with inhibitor KVR-1-156 3R6X ; 1.75 ; CDK2 in complex with inhibitor KVR-1-158 3RAI ; 1.7 ; CDK2 in complex with inhibitor KVR-1-160 3R71 ; 1.75 ; CDK2 in complex with inhibitor KVR-1-162 3R73 ; 1.7 ; CDK2 in complex with inhibitor KVR-1-164 3QX2 ; 1.75 ; CDK2 in complex with inhibitor KVR-1-190 3R7E ; 1.9 ; CDK2 in complex with inhibitor KVR-1-67 3R7I ; 1.85 ; CDK2 in complex with inhibitor KVR-1-74 3R7U ; 1.75 ; CDK2 in complex with inhibitor KVR-1-75 3QX4 ; 1.92 ; CDK2 in complex with inhibitor KVR-1-78 3QXO ; 1.75 ; CDK2 in complex with inhibitor KVR-1-84 3R7V ; 1.95 ; CDK2 in complex with inhibitor KVR-1-9 3RM7 ; 1.85 ; CDK2 in complex with inhibitor KVR-1-91 3RM6 ; 1.6 ; CDK2 in complex with inhibitor KVR-2-80 3R7Y ; 1.9 ; CDK2 in complex with inhibitor KVR-2-88 3R83 ; 1.75 ; CDK2 in complex with inhibitor KVR-2-92 3QQF ; 1.75 ; CDK2 in complex with inhibitor L1 3QQJ ; 1.7 ; CDK2 in complex with inhibitor L2 3QQH ; 1.87 ; CDK2 in complex with inhibitor L2-2 3QQG ; 1.9 ; CDK2 in complex with inhibitor L2-5 3QQL ; 1.85 ; CDK2 in complex with inhibitor L3 3R8M ; 1.8 ; CDK2 in complex with inhibitor L3-3 3R8L ; 1.9 ; CDK2 in complex with inhibitor L3-4 3QQK ; 1.86 ; CDK2 in complex with inhibitor L4 3RJC ; 1.85 ; CDK2 in complex with inhibitor L4-12 3S00 ; 1.8 ; CDK2 in complex with inhibitor L4-14 3QRU ; 1.95 ; CDK2 in complex with inhibitor NSK-MC1-12 3R8P ; 1.8 ; CDK2 in complex with inhibitor NSK-MC1-6 3QRT ; 1.75 ; CDK2 in complex with inhibitor NSK-MC2-55 3R8U ; 2 ; CDK2 in complex with inhibitor RC-1-132 3R8V ; 1.9 ; CDK2 in complex with inhibitor RC-1-135 3R8Z ; 1.85 ; CDK2 in complex with inhibitor RC-1-136 3QTQ ; 1.8 ; CDK2 in complex with inhibitor RC-1-137 3S0O ; 2 ; CDK2 in complex with inhibitor RC-1-138 3QTR ; 1.85 ; CDK2 in complex with inhibitor RC-1-148 3QTS ; 1.9 ; CDK2 in complex with inhibitor RC-2-12 3QTW ; 1.85 ; CDK2 in complex with inhibitor RC-2-13 3QTU ; 1.82 ; CDK2 in complex with inhibitor RC-2-132 3R9D ; 1.95 ; CDK2 in complex with inhibitor RC-2-135 3R9H ; 2.1 ; CDK2 in complex with inhibitor RC-2-142 3R9O ; 1.9 ; CDK2 in complex with inhibitor RC-2-143 3R9N ; 1.75 ; CDK2 in complex with inhibitor RC-2-21 3RAH ; 1.75 ; CDK2 in complex with inhibitor RC-2-22 3RZB ; 1.9 ; CDK2 in complex with inhibitor RC-2-23 3RAK ; 1.75 ; CDK2 in complex with inhibitor RC-2-32 3RMF ; 1.75 ; CDK2 in complex with inhibitor RC-2-33 3RAL ; 1.75 ; CDK2 in complex with inhibitor RC-2-34 3QTX ; 1.95 ; CDK2 in complex with inhibitor RC-2-35 3QTZ ; 2 ; CDK2 in complex with inhibitor RC-2-36 3QU0 ; 1.95 ; CDK2 in complex with inhibitor RC-2-38 3S1H ; 1.75 ; CDK2 in complex with inhibitor RC-2-39 3RPY ; 1.9 ; CDK2 in complex with inhibitor RC-2-40 3RPR ; 1.75 ; CDK2 in complex with inhibitor RC-2-49 3RK7 ; 1.8 ; CDK2 in complex with inhibitor RC-2-71 3RK5 ; 2 ; CDK2 in complex with inhibitor RC-2-72 3RKB ; 2 ; CDK2 in complex with inhibitor RC-2-73 3RK9 ; 1.85 ; CDK2 in complex with inhibitor RC-2-74 3RPV ; 1.8 ; CDK2 in complex with inhibitor RC-2-88 3RNI ; 1.95 ; CDK2 in complex with inhibitor RC-3-86 3QXP ; 1.75 ; CDK2 in complex with inhibitor RC-3-89 4GCJ ; 1.42 ; CDK2 in complex with inhibitor RC-3-89 3SQQ ; 1.85 ; CDK2 in complex with inhibitor RC-3-96 3PY0 ; 1.75 ; CDK2 in complex with inhibitor SU9516 3UNJ ; 1.9001 ; CDK2 in complex with inhibitor YL1-038-31 3UNK ; 2.1 ; CDK2 in complex with inhibitor YL5-083 3TIZ ; 2.02 ; CDK2 in complex with NSC 111848 4EZ3 ; 2 ; CDK2 in complex with NSC 134199 3TIY ; 1.84 ; CDK2 in complex with NSC 35676 4ERW ; 2 ; CDK2 in complex with staurosporine 4EZ7 ; 2.49 ; CDK2 in complex with staurosporine and 2 molecules of 8-anilino-1-naphthalene sulfonic acid 3TI1 ; 1.99 ; CDK2 in complex with SUNITINIB 2W17 ; 2.15 ; CDK2 IN COMPLEX WITH THE IMIDAZOLE PYRIMIDINE AMIDE, COMPOUND (S)-8B 3PXF ; 1.8 ; CDK2 in complex with two molecules of 8-anilino-1-naphthalene sulfonate 3PXZ ; 1.7 ; CDK2 ternary complex with JWS648 and ANS 3PY1 ; 2.05 ; CDK2 ternary complex with SU9516 and ANS 2I40 ; 2.8 ; Cdk2/Cyclin A complexed with a thiophene carboxamide inhibitor 1H24 ; 2.5 ; CDK2/CYCLIN A IN COMPLEX WITH A 9 RESIDUE RECRUITMENT PEPTIDE FROM E2F 1H28 ; 2.8 ; CDK2/CYCLIN A IN COMPLEX WITH AN 11-RESIDUE RECRUITMENT PEPTIDE FROM P107 1H27 ; 2.2 ; CDK2/CYCLIN A IN COMPLEX WITH AN 11-RESIDUE RECRUITMENT PEPTIDE FROM P27 1H26 ; 2.24 ; CDK2/CYCLIN A IN COMPLEX WITH AN 11-RESIDUE RECRUITMENT PEPTIDE FROM P53 1H25 ; 2.5 ; CDK2/CYCLIN A IN COMPLEX WITH AN 11-RESIDUE RECRUITMENT PEPTIDE FROM RETINOBLASTOMA-ASSOCIATED PROTEIN 3EOC ; 3.2 ; Cdk2/CyclinA complexed with a imidazo triazin-2-amine 3EID ; 3.15 ; CDK2/CyclinA complexed with a pyrazolopyridazine inhibitor 3EJ1 ; 3.22 ; CDK2/CyclinA complexed with a pyrazolopyridazine inhibitor 3MY5 ; 2.1 ; CDk2/cyclinA in complex with DRB 3NUP ; 2.6 ; CDK6 (monomeric) in complex with inhibitor 3NUX ; 2.7 ; CDK6 (monomeric) in complex with inhibitor 4EZ5 ; 2.7 ; CDK6 (monomeric) in complex with inhibitor 3TN8 ; 2.95 ; CDK9/cyclin T in complex with CAN508 3TNH ; 3.202 ; CDK9/cyclin T in complex with CAN508 2GSJ ; 1.73 ; cDNA cloning and 1.75A crystal structure determination of PPL2, a novel chimerolectin from Parkia platycephala seeds exhibiting endochitinolytic activity 1F0H ; ; Cecropin A(1-8)-magainin 2(1-12) A2 in dodecylphosphocholine micelles 1F0F ; ; Cecropin A(1-8)-magainin 2(1-12) gig deletion modification in dodecylphosphocholine micelles 1F0D ; ; Cecropin A(1-8)-magainin 2(1-12) in dodecylphosphocholine micelles 1F0G ; ; Cecropin A(1-8)-magainin 2(1-12) L2 in dodecylphosphocholine micelles 1F0E ; ; Cecropin A(1-8)-magainin 2(1-12) modified gig to P in dodecylphosphocholine micelles 3QWY ; 2.52 ; CED-2 3QWX ; 2.01 ; CED-2 1-174 2Z2M ; 2.6 ; Cefditoren-Acylated Penicillin-Binding Protein 2X (PBP2X) from Streptococcus pneumoniae 2ZQA ; 0.95 ; Cefotaxime acyl-intermediate structure of class a beta-lacta Toho-1 E166A/R274N/R276N triple mutant 1CEF ; 2.04 ; CEFOTAXIME COMPLEXED WITH THE STREPTOMYCES R61 DD-PEPTIDASE 2ZQD ; 1.19 ; Ceftazidime acyl-intermediate structure of class a beta-lact Toho-1 E166A/R274N/R276N triple mutant 3N9M ; 2.493 ; ceKDM7A from C.elegans, alone 3PUQ ; 2.25 ; CEKDM7A from C.Elegans, complex with alpha-KG 3PUR ; 2.1 ; CEKDM7A from C.Elegans, complex with D-2-HG 3N9L ; 2.796 ; ceKDM7A from C.elegans, complex with H3K4me3 peptide and NOG 3N9Q ; 2.3 ; ceKDM7A from C.elegans, complex with H3K4me3 peptide, H3K27me2 peptide and NOG 3N9O ; 2.309 ; ceKDM7A from C.elegans, complex with H3K4me3 peptide, H3K9me2 peptide and NOG 3N9P ; 2.388 ; ceKDM7A from C.elegans, complex with H3K4me3K27me2 peptide and NOG 3N9N ; 2.299 ; ceKDM7A from C.elegans, complex with H3K4me3K9me2 peptide and NOG 1QJW ; 1.9 ; CEL6A (Y169F) WITH A NON-HYDROLYSABLE CELLOTETRAOSE 1HGW ; 2.1 ; CEL6A D175A MUTANT 1HGY ; 2.2 ; CEL6A D221A MUTANT 1QK0 ; 2.1 ; CEL6A IN COMPLEX WITH M-IODOBENZYL BETA-D-GLUCOPYRANOSYL-BETA(1,4)-D-XYLOPYRANOSIDE 3ALP ; 2.804 ; Cell adhesion protein 4DRR ; 1.5 ; Cell attachment protein VP8* of a human rotavirus specifically interacts with A-type histo-blood group antigen 4DRV ; 1.56 ; Cell attachment protein VP8* of a human rotavirus specifically interacts with A-type histo-blood group antigen 4DS0 ; 1.56 ; Cell attachment protein VP8* of a human rotavirus specifically interacts with A-type histo-blood group antigen 2CEA ; 2.75 ; CELL DIVISION PROTEIN FTSH 2FPH ; 1.7 ; Cell division protein ylmH from Streptococcus pneumoniae 3R4S ; 2.15 ; Cell entry of botulinum neurotoxin type C is dependent upon interaction with two ganglioside molecules 3R4U ; 2.2 ; Cell entry of botulinum neurotoxin type C is dependent upon interaction with two ganglioside molecules 1JZU ; ; Cell transformation by the myc oncogene activates expression of a lipocalin: analysis of the gene (Q83) and solution structure of its protein product 2XPK ; 2.4 ; CELL-PENETRANT, NANOMOLAR O-GLCNACASE INHIBITORS SELECTIVE AGAINST LYSOSOMAL HEXOSAMINIDASES 1EGN ; 1.6 ; CELLOBIOHYDROLASE CEL7A (E223S, A224H, L225V, T226A, D262G) MUTANT 1Q2B ; 1.6 ; CELLOBIOHYDROLASE CEL7A WITH DISULPHIDE BRIDGE ADDED ACROSS EXO-LOOP BY MUTATIONS D241C AND D249C 1Q2E ; 1.75 ; CELLOBIOHYDROLASE CEL7A WITH LOOP DELETION 245-252 AND BOUND NON-HYDROLYSABLE CELLOTETRAOSE 1GPI ; 1.32 ; CELLOBIOHYDROLASE CEL7D (CBH 58) FROM PHANEROCHAETE CHRYSOSPORIUM. CATALYTIC MODULE AT 1.32 ANG RESOLUTION 2YOK ; 1.67 ; Cellobiohydrolase I Cel7A from Trichoderma harzianum at 1.7 A resolution 2Y9N ; 2.89 ; Cellobiohydrolase I Cel7A from Trichoderma harzianum at 2.9 A resolution 1BVW ; 1.92 ; CELLOBIOHYDROLASE II (CEL6A) FROM HUMICOLA INSOLENS 2BVW ; 1.7 ; CELLOBIOHYDROLASE II (CEL6A) FROM HUMICOLA INSOLENS IN COMPLEX WITH GLUCOSE AND CELLOTETRAOSE 1CB2 ; 2 ; CELLOBIOHYDROLASE II, CATALYTIC DOMAIN, MUTANT Y169F 3VOF ; 1.6 ; Cellobiohydrolase mutant, CcCel6C D102A, in the closed form 2A3H ; 2 ; CELLOBIOSE COMPLEX OF THE ENDOGLUCANASE CEL5A FROM BACILLUS AGARADHERANS AT 2.0 A RESOLUTION 1NAA ; 1.8 ; Cellobiose Dehydrogenase Flavoprotein Fragment in Complex with Cellobionolactam 3S4A ; 1.99 ; Cellobiose phosphorylase from Cellulomonas uda in complex with cellobiose 3S4B ; 2.4 ; Cellobiose phosphorylase from Cellulomonas uda in complex with glucose 3RSY ; 1.81 ; Cellobiose phosphorylase from Cellulomonas uda in complex with sulfate and glycerol 8A3H ; 0.97 ; Cellobiose-derived imidazole complex of the endoglucanase cel5A from Bacillus agaradhaerens at 0.97 A resolution 2Y6G ; 1.3 ; Cellopentaose binding mutated (X-2 L110F) CBM4-2 Carbohydrate Binding Module from a Thermostable Rhodothermus marinus Xylanase 3AMM ; 1.98 ; Cellotetraose complex of cellulase 12A from thermotoga maritima 3A3H ; 1.64 ; CELLOTRIOSE COMPLEX OF THE ENDOGLUCANASE CEL5A FROM BACILLUS AGARADHERANS AT 1.6 A RESOLUTION 2W7X ; 2.07 ; CELLULAR INHIBITION OF CHECKPOINT KINASE 2 AND POTENTIATION OF CYTOTOXIC DRUGS BY NOVEL CHK2 INHIBITOR PV1019 2G19 ; 1.7 ; Cellular Oxygen Sensing: Crystal Structure of Hypoxia-Inducible Factor Prolyl Hydroxylase (PHD2) 2G1M ; 2.2 ; Cellular Oxygen Sensing: Crystal Structure of Hypoxia-Inducible Factor Prolyl Hydroxylase (PHD2) 2CBR ; 2.8 ; CELLULAR RETINOIC ACID BINDING PROTEIN I IN COMPLEX WITH A RETINOBENZOIC ACID (AM80) 3CBS ; 2 ; CELLULAR RETINOIC ACID BINDING PROTEIN II IN COMPLEX WITH A SYNTHETIC RETINOIC ACID (RO-12 7310) 2CBS ; 2.1 ; CELLULAR RETINOIC ACID BINDING PROTEIN II IN COMPLEX WITH A SYNTHETIC RETINOIC ACID (RO-13 6307) 1CEO ; 1.9 ; CELLULASE (CELC) MUTANT WITH GLU 140 REPLACED BY GLN 1CEN ; 2.3 ; CELLULASE (CELC) MUTANT WITH GLU 140 REPLACED BY GLN COMPLEXED WITH CELLOHEXAOSE 1EGZ ; 2.3 ; CELLULASE CEL5 FROM ERWINIA CHRYSANTHEMI, A FAMILY GH 5-2 ENZYME 1TVN ; 1.41 ; Cellulase cel5G from Pseudoalteromonas haloplanktis, A family GH 5-2 enzyme 2X2Y ; 2.35 ; CELLULOMONAS FIMI ENDO-BETA-1,4-MANNANASE DOUBLE MUTANT 3CUF ; 1.67 ; Cellulomonas fimi Xylanase/Cellulase Cex (Cf Xyn10A) in complex with cellobiose-like isofagomine 3CUG ; 1.68 ; Cellulomonas fimi Xylanase/Cellulase Cex (Cf Xyn10A) in complex with cellotetraose-like isofagomine 3CUH ; 1.89 ; Cellulomonas fimi Xylanase/Cellulase Cex (Cf Xyn10A) in complex with cellotriose-like isofagomine 3CUJ ; 1.7 ; Cellulomonas fimi Xylanase/Cellulase Cex (Cf Xyn10A) in complex with sulfur substituted beta-1,4 xylopentaose. 3CUI ; 1.5 ; Cellulomonas fimi Xylanase/Cellulase Cex (Cf Xyn10A) in complex with sulfur substituted beta-1,4 xylotetraose 2XYL ; 1.9 ; CELLULOMONAS FIMI XYLANASE/CELLULASE COMPLEXED WITH 2-DEOXY-2-FLUORO-XYLOBIOSE 2HIS ; 1.84 ; CELLULOMONAS FIMI XYLANASE/CELLULASE DOUBLE MUTANT E127A/H205N WITH COVALENT CELLOBIOSE 3ZYP ; 1.5 ; Cellulose induced protein, Cip1 2WHM ; 1.5 ; CELLVIBRIO JAPONICUS MAN26A E121A AND E320G DOUBLE MUTANT IN COMPLEX WITH MANNOBIOSE 2VX6 ; 1.57 ; CELLVIBRIO JAPONICUS MANNANASE CJMAN26C GAL1MAN4-BOUND FORM 2VX7 ; 1.8 ; CELLVIBRIO JAPONICUS MANNANASE CJMAN26C MANNOBIOSE-BOUND FORM 2VX5 ; 1.47 ; CELLVIBRIO JAPONICUS MANNANASE CJMAN26C MANNOSE-BOUND FORM 2VX4 ; 1.7 ; CELLVIBRIO JAPONICUS MANNANASE CJMAN26C NATIVE FORM 1QOU ; 1.9 ; CEN (CENTRORADIALIS) PROTEIN FROM ANTIRRHINUM 2KSM ; ; Central B domain of Rv0899 from Mycobacterium tuberculosis 1GXE ; ; CENTRAL DOMAIN OF CARDIAC MYOSIN BINDING PROTEIN C 4GCO ; 1.6 ; Central domain of stress-induced protein-1 (STI-1) from C.elegans 2OBH ; 1.8 ; Centrin-XPC peptide 1OB4 ; 0.95 ; Cephaibol A 1OB6 ; 0.89 ; Cephaibol B 1OB7 ; 0.89 ; Cephaibol C 1ODS ; 1.9 ; CEPHALOSPORIN C DEACETYLASE FROM BACILLUS SUBTILIS 1ODT ; 1.7 ; CEPHALOSPORIN C DEACETYLASE MUTATED, IN COMPLEX WITH ACETATE 2ZQ9 ; 1.07 ; Cephalothin acyl-intermediate structure of class a beta-lactamase Toho-1 E166A/R274N/R276N triple mutant 1CEG ; 1.8 ; CEPHALOTHIN COMPLEXED WITH DD-PEPTIDASE 3RQE ; 2.8 ; Cerebral cavernous malformation 3 (CCM3) in complex with paxillin LD1 3RQF ; 2.7 ; Cerebral cavernous malformation 3 (CCM3) in complex with paxillin LD2 3RQG ; 2.5 ; Cerebral cavernous malformation 3 (CCM3) in complex with paxillin LD4 2J5W ; 2.8 ; CERULOPLASMIN REVISITED: STRUCTURAL AND FUNCTIONAL ROLES OF VARIOUS METAL CATION BINDING SITES 3IJ4 ; 3 ; Cesium sites in the crystal structure of a functional acid sensing ion channel in the desensitized state 2CHU ; 2.4 ; CEUE IN COMPLEX WITH MECAM 3P6Y ; 2.9 ; CF Im25-CF Im68-UGUAA complex 3P5T ; 2.7 ; CFIm25-CFIm68 complex 2I0Y ; 1.9 ; cFMS tyrosine kinase (FGF KID) in complex with an arylamide inhibitor 3BEA ; 2.02 ; cFMS tyrosine kinase (tie2 KID) in complex with a pyrimidinopyridone inhibitor 2I1M ; 1.8 ; cFMS tyrosine kinase (tie2 KID) in complex with an arylamide inhibitor 3KRJ ; 2.1 ; cFMS tyrosine kinase in complex with 4-Cyano-1H-imidazole-2-carboxylic acid (2-cyclohex-1-enyl-4-piperidin-4-yl-phenyl)-amide 3KRL ; 2.4 ; cFMS Tyrosine kinase in complex with 5-Cyano-furan-2-carboxylic acid [4-(4-methyl-piperazin-1-yl)-2-piperidin-1-yl-phenyl]-amide 3DPK ; 1.95 ; cFMS tyrosine kinase in complex with a pyridopyrimidinone inhibitor 1QMJ ; 2.15 ; CG-16, a homodimeric agglutinin from chicken liver 2JYZ ; ; CG7054 solution structure 1ZEY ; 1.7 ; CGG A-DNA 1ULF ; 2.36 ; CGL2 in complex with Blood Group A tetrasaccharide 1ULD ; 2.1 ; CGL2 in complex with blood group H type II 1ULC ; 2.6 ; CGL2 in complex with lactose 1ULE ; 2.15 ; CGL2 in complex with linear B2 trisaccharide 1ULG ; 2.2 ; CGL2 in complex with Thomsen-Friedenreich antigen 1UL9 ; 2.22 ; CGL2 ligandfree 1VF4 ; 2.45 ; cGSTA1-1 apo form 1VF1 ; 1.77 ; cGSTA1-1 in complex with glutathione 1VF3 ; 2.15 ; cGSTA1-1 in complex with glutathione conjugate of CDNB 1VF2 ; 2.15 ; cGSTA1-1 in complex with S-hexyl-glutathione 1A47 ; 2.56 ; CGTASE FROM THERMOANAEROBACTERIUM THERMOSULFURIGENES EM1 IN COMPLEX WITH A MALTOHEXAOSE INHIBITOR 3U4B ; 2.893 ; CH04H/CH02L Fab P4 3U46 ; 2.906 ; CH04H/CH02L P212121 4HKB ; 3.6 ; CH67 Fab (unbound) from the CH65-67 Lineage 3CBK ; 2.67 ; chagasin-cathepsin B 3CBJ ; 1.8 ; Chagasin-Cathepsin B complex 1EYP ; 2.5 ; CHALCONE ISOMERASE 1EYQ ; 1.85 ; Chalcone isomerase and naringenin 1JEP ; 2.1 ; Chalcone Isomerase Complexed with 4'-hydroxyflavanone 1FM8 ; 2.3 ; CHALCONE ISOMERASE COMPLEXED WITH 5,4'-DIDEOXYFLAVANONE 1FM7 ; 2.3 ; CHALCONE ISOMERASE COMPLEXED WITH 5-DEOXYFLAVANONE 1JX1 ; 2.3 ; Chalcone Isomerase--T48A mutant 1JX0 ; 2.85 ; Chalcone Isomerase--Y106F mutant 1ZGD ; 1.7 ; Chalcone Reductase Complexed With NADP+ at 1.7 Angstrom Resolution 1I8B ; 1.95 ; Chalcone synthase (G256F) 1I89 ; 1.86 ; Chalcone synthase (G256L) 1I88 ; 1.45 ; CHALCONE SYNTHASE (G256V) 1D6I ; 2 ; CHALCONE SYNTHASE (H303Q MUTANT) 1D6F ; 1.69 ; CHALCONE SYNTHASE C164A MUTANT 1BI5 ; 1.56 ; CHALCONE SYNTHASE FROM ALFALFA 1CHW ; 1.9 ; CHALCONE SYNTHASE FROM ALFALFA COMPLEXED WITH HEXANOYL-COA 1CML ; 1.69 ; CHALCONE SYNTHASE FROM ALFALFA COMPLEXED WITH MALONYL-COA 1CGK ; 1.84 ; CHALCONE SYNTHASE FROM ALFALFA COMPLEXED WITH NARINGENIN 1CGZ ; 1.7 ; CHALCONE SYNTHASE FROM ALFALFA COMPLEXED WITH RESVERATROL 1BQ6 ; 1.56 ; CHALCONE SYNTHASE FROM ALFALFA WITH COENZYME A 1I86 ; 1.5 ; CHALCONE SYNTHASE, G256A MUTANT 1JWX ; 1.63 ; Chalcone Synthase--F215S mutant 1D6H ; 2.15 ; CHALONE SYNTHASE (N336A MUTANT COMPLEXED WITH COA) 1QAC ; 1.8 ; CHANGE IN DIMERIZATION MODE BY REMOVAL OF A SINGLE UNSATISFIED POLAR RESIDUE 2MEA ; 2.2 ; CHANGES IN CONFORMATIONAL STABILITY OF A SERIES OF MUTANT HUMAN LYSOZYMES AT CONSTANT POSITIONS 2MEB ; 1.8 ; CHANGES IN CONFORMATIONAL STABILITY OF A SERIES OF MUTANT HUMAN LYSOZYMES AT CONSTANT POSITIONS 2MEC ; 2.2 ; CHANGES IN CONFORMATIONAL STABILITY OF A SERIES OF MUTANT HUMAN LYSOZYMES AT CONSTANT POSITIONS 2MEG ; 1.8 ; CHANGES IN CONFORMATIONAL STABILITY OF A SERIES OF MUTANT HUMAN LYSOZYMES AT CONSTANT POSITIONS. 3SOD ; 2.1 ; CHANGES IN CRYSTALLOGRAPHIC STRUCTURE AND THERMOSTABILITY OF A CU,ZN SUPEROXIDE DISMUTASE MUTANT RESULTING FROM THE REMOVAL OF BURIED CYSTEINE 1TMT ; 2.2 ; CHANGES IN INTERACTIONS IN COMPLEXES OF HIRUDIN DERIVATIVES AND HUMAN ALPHA-THROMBIN DUE TO DIFFERENT CRYSTAL FORMS 1TMU ; 2.5 ; Changes in interactions in complexes of hirudin derivatives and human alpha-thrombin due to different crystal forms 3DGS ; 1.9 ; Changing the determinants of protein stability from covalent to non-covalent interactions by in-vitro evolution: a structural and energetic analysis 2KIX ; ; Channel domain of BM2 protein from influenza B virus 3CQX ; 2.3 ; Chaperone Complex 4IT5 ; 2.152 ; Chaperone HscB from Vibrio cholerae 2WPU ; 1.92 ; CHAPERONED RUTHENIUM METALLODRUGS THAT RECOGNIZE TELOMERIC DNA 1E8P ; ; CHARACTERISATION OF THE CELLULOSE DOCKING DOMAIN FROM PIROMYCES EQUI 1E8Q ; ; CHARACTERISATION OF THE CELLULOSE DOCKING DOMAIN FROM PIROMYCES EQUI 3PB0 ; 2 ; Characterisation of the first monomeric dihydrodipicolinate synthase variant reveals evolutionary insights 3PB2 ; 1.9 ; Characterisation of the first monomeric dihydrodipicolinate synthase variant reveals evolutionary insights 2K8P ; ; Characterisation of the structural features and interactions of sclerostin: molecular insight into a key regulator of Wnt-mediated bone formation 3S1S ; 2.35 ; Characterization and crystal structure of the type IIG restriction endonuclease BpuSI 2VCE ; 1.9 ; CHARACTERIZATION AND ENGINEERING OF THE BIFUNCTIONAL N- AND O-GLUCOSYLTRANSFERASE INVOLVED IN XENOBIOTIC METABOLISM IN PLANTS 2VCH ; 1.45 ; CHARACTERIZATION AND ENGINEERING OF THE BIFUNCTIONAL N- AND O-GLUCOSYLTRANSFERASE INVOLVED IN XENOBIOTIC METABOLISM IN PLANTS 2VG8 ; 1.75 ; CHARACTERIZATION AND ENGINEERING OF THE BIFUNCTIONAL N- AND O-GLUCOSYLTRANSFERASE INVOLVED IN XENOBIOTIC METABOLISM IN PLANTS 3UFC ; 2.03 ; Characterization of a Cas6-related gene from Pyrococcus furiosus 2J7M ; 2.3 ; CHARACTERIZATION OF A FAMILY 32 CBM 2QY2 ; 2 ; Characterization of a trifunctional mimivirus mRNA capping enzyme and crystal structure of the RNA triphosphatase domainm. 1N4H ; 2.1 ; Characterization of ligands for the orphan nuclear receptor RORbeta 1NQ7 ; 1.5 ; Characterization of ligands for the orphan nuclear receptor RORbeta 2V0H ; 1.79 ; CHARACTERIZATION OF SUBSTRATE BINDING AND CATALYSIS OF THE POTENTIAL ANTIBACTERIAL TARGET N-ACETYLGLUCOSAMINE-1-PHOSPHATE URIDYLTRANSFERASE (GLMU) 2V0I ; 1.89 ; CHARACTERIZATION OF SUBSTRATE BINDING AND CATALYSIS OF THE POTENTIAL ANTIBACTERIAL TARGET N-ACETYLGLUCOSAMINE-1-PHOSPHATE URIDYLTRANSFERASE (GLMU) 2V0J ; 2 ; CHARACTERIZATION OF SUBSTRATE BINDING AND CATALYSIS OF THE POTENTIAL ANTIBACTERIAL TARGET N-ACETYLGLUCOSAMINE-1-PHOSPHATE URIDYLTRANSFERASE (GLMU) 2V0K ; 2.3 ; CHARACTERIZATION OF SUBSTRATE BINDING AND CATALYSIS OF THE POTENTIAL ANTIBACTERIAL TARGET N-ACETYLGLUCOSAMINE-1-PHOSPHATE URIDYLTRANSFERASE (GLMU) 2V0L ; 2.2 ; CHARACTERIZATION OF SUBSTRATE BINDING AND CATALYSIS OF THE POTENTIAL ANTIBACTERIAL TARGET N-ACETYLGLUCOSAMINE-1-PHOSPHATE URIDYLTRANSFERASE (GLMU) 2LDX ; 2.96 ; CHARACTERIZATION OF THE ANTIGENIC SITES ON THE REFINED 3-ANGSTROMS RESOLUTION STRUCTURE OF MOUSE TESTICULAR LACTATE DEHYDROGENASE C4 3JVR ; 1.76 ; Characterization of the Chk1 allosteric inhibitor binding site 3JVS ; 1.9 ; Characterization of the Chk1 allosteric inhibitor binding site 1R0Q ; 1.61 ; Characterization of the conversion of the malformed, recombinant cytochrome rc552 to a 2-formyl-4-vinyl (Spirographis) heme 3MOU ; 1.711 ; Characterization of the Inhibitor Binding Site of the Dehaloperoxidase-Hemoglobin from Amphitrite ornata using High-Pressure Xenon Derivatization 1QYZ ; 1.4 ; Characterization of the malformed, recombinant cytochrome rC552 1G9X ; 2.6 ; CHARACTERIZATION OF THE TWINNING STRUCTURE OF MJ1267, AN ATP-BINDING CASSETTE OF AN ABC TRANSPORTER 1LCL ; 1.8 ; CHARCOT-LEYDEN CRYSTAL PROTEIN 1QKQ ; 1.8 ; CHARCOT-LEYDEN CRYSTAL PROTEIN - MANNOSE COMPLEX 1HDK ; 1.8 ; CHARCOT-LEYDEN CRYSTAL PROTEIN - PCMBS COMPLEX 1G86 ; 1.8 ; CHARCOT-LEYDEN CRYSTAL PROTEIN/N-ETHYLMALEIMIDE COMPLEX 2AZX ; 2.8 ; Charged and uncharged tRNAs adopt distinct conformations when complexed with human tryptophanyl-tRNA synthetase 1TQG ; 0.98 ; CheA phosphotransferase domain from Thermotoga maritima 1CHD ; 1.75 ; CHEB METHYLESTERASE DOMAIN 1EBG ; 2.1 ; CHELATION OF SER 39 TO MG2+ LATCHES A GATE AT THE ACTIVE SITE OF ENOLASE: STRUCTURE OF THE BIS(MG2+) COMPLEX OF YEAST ENOLASE AND THE INTERMEDIATE ANALOG PHOSPHONOACETOHYDROXAMATE AT 2.1 ANGSTROMS RESOLUTION 1M1Y ; 3.2 ; Chemical Crosslink of Nitrogenase MoFe Protein and Fe Protein 2VUR ; 2.2 ; CHEMICAL DISSECTION OF THE LINK BETWEEN STREPTOZOTOCIN, O-GLCNAC AND PANCREATIC CELL DEATH 2L8H ; ; Chemical probe bound to HIV TAR RNA 2LPM ; ; Chemical Shift and Structure Assignments for Sma0114 2LEQ ; ; Chemical Shift Assignment and Solution Structure of ChR145 from Cytophaga Hutchinsonii, Northeast Structural Genomics Consortium Target ChR145 2LRQ ; ; Chemical Shift Assignment and Solution Structure of Fr822A from Drosophila melanogaster. Northeast Structural Genomics Consortium Target Fr822A 2LCE ; ; Chemical shift assignment of Hr4436B from Homo Sapiens, Northeast Structural Genomics Consortium 2LHL ; ; Chemical Shift Assignments and solution structure of human apo-S100A1 E32Q mutant 2JPI ; ; chemical shift assignments of PA4090 from Pseudomonas aeruginosa 2KJA ; ; Chemical shift assignments, constraints, and coordinates for CN5 scorpion toxin 2K5X ; ; Chemical shift structure of COLICIN E9 DNASE domain with its cognate immunity protein IM9 1Q2R ; 2.9 ; Chemical trapping and crystal structure of a catalytic tRNA guanine transglycosylase covalent intermediate 1Q2S ; 3.2 ; Chemical trapping and crystal structure of a catalytic tRNA guanine transglycosylase covalent intermediate 3KWX ; 2.4 ; Chemically modified Taka alpha-amylase 3OCH ; 1.79 ; Chemically Self-assembled Antibody Nanorings (CSANs): Design and Characterization of an Anti-CD3 IgM Biomimetic 5GCH ; 2.7 ; CHEMISTRY OF CAGED ENZYMES /II$. PHOTOACTIVATION OF INHIBITED CHYMOTRYPSIN 3GCH ; 1.9 ; CHEMISTRY OF CAGED ENZYMES. BINDING OF PHOTOREVERSIBLE CINNAMATES TO CHYMOTRYPSIN 1N8U ; 1.8 ; Chemosensory Protein in Complex with bromo-dodecanol 1N8V ; 1.39 ; Chemosensory Protein in complex with bromo-dodecanol 1U0S ; 1.9 ; Chemotaxis kinase CheA P2 domain in complex with response regulator CheY from the thermophile thermotoga maritima 1BC5 ; 2.2 ; CHEMOTAXIS RECEPTOR RECOGNITION BY PROTEIN METHYLTRANSFERASE CHER 1AF7 ; 2 ; CHER FROM SALMONELLA TYPHIMURIUM 1TMY ; 1.9 ; CHEY FROM THERMOTOGA MARITIMA (APO-I) 2TMY ; 2.3 ; CHEY FROM THERMOTOGA MARITIMA (APO-II) 4TMY ; 2.8 ; CHEY FROM THERMOTOGA MARITIMA (MG-IV) 3TMY ; 2.2 ; CHEY FROM THERMOTOGA MARITIMA (MN-III) 1UDR ; 1.9 ; CHEY MUTANT WITH LYS 91 REPLACED BY ASP, LYS 92 REPLACED BY ALA, ILE 96 REPLACED BY LYS AND ALA 98 REPLACED BY LEU (STABILIZING MUTATIONS IN HELIX 4) 1EAY ; 2 ; CHEY-BINDING (P2) DOMAIN OF CHEA IN COMPLEX WITH CHEY FROM ESCHERICHIA COLI 1FWP ; ; CHEY-BINDING DOMAIN OF CHEA (RESIDUES 159-227), NMR, MINIMIZED AVERAGE STRUCTURE 1A0O ; 2.95 ; CHEY-BINDING DOMAIN OF CHEA IN COMPLEX WITH CHEY 1FFG ; 2.1 ; CHEY-BINDING DOMAIN OF CHEA IN COMPLEX WITH CHEY AT 2.1 A RESOLUTION 1FFS ; 2.4 ; CHEY-BINDING DOMAIN OF CHEA IN COMPLEX WITH CHEY FROM CRYSTALS SOAKED IN ACETYL PHOSPHATE 1FFW ; 2.7 ; CHEY-BINDING DOMAIN OF CHEA IN COMPLEX WITH CHEY WITH A BOUND IMIDO DIPHOSPHATE 2XTK ; 2 ; ChiA1 from Aspergillus fumigatus in complex with acetazolamide 2XVP ; 2 ; CHIA1 FROM ASPERGILLUS FUMIGATUS, APOSTRUCTURE 3U18 ; 1.9 ; Chicago Sky Blue 6B, A Novel Inhibitor for Macrophage Migration Inhibitory Factor 1A5J ; ; CHICKEN B-MYB DNA BINDING DOMAIN, REPEAT 2 AND REPEAT3, NMR, 32 STRUCTURES 3DQX ; 2.3 ; chicken c-Src kinase domain in complex with ATPgS 1UP5 ; 1.9 ; CHICKEN CALMODULIN 1AL6 ; 1.85 ; CHICKEN CITRATE SYNTHASE COMPLEX WITH N-HYDROXYAMIDO-COA AND OXALOACETATE 1AMZ ; 1.8 ; CHICKEN CITRATE SYNTHASE COMPLEX WITH NITROMETHYLDE-COA AND MALATE 6CSC ; 2.25 ; CHICKEN CITRATE SYNTHASE COMPLEX WITH TRIFLUOROACETONYL-COA AND CITRATE 3CWB ; 3.51 ; Chicken Cytochrome BC1 Complex inhibited by an iodinated analogue of the polyketide Crocacin-D 3H1L ; 3.21 ; Chicken cytochrome BC1 complex with ascochlorin bound at QO and QI sites 3L72 ; 3.06 ; Chicken cytochrome BC1 complex with kresoxym-I-dimethyl bound 3H1K ; 3.48 ; Chicken cytochrome BC1 complex with ZN++ and an iodinated derivative of kresoxim-methyl bound 1A67 ; ; CHICKEN EGG WHITE CYSTATIN WILDTYPE, NMR, 16 STRUCTURES 3IJV ; 1.7 ; Chicken egg white lysozyme by classical hanging drop vapour diffusion method 3IJU ; 1.6 ; Chicken egg white lysozyme by highly ordered APA (Anodic Porous Alumina) nanotemplate crystallization method 1AZF ; 1.8 ; CHICKEN EGG WHITE LYSOZYME CRYSTAL GROWN IN BROMIDE SOLUTION 2L21 ; ; chicken IGF2R domain 11 1IIU ; 2.5 ; Chicken plasma retinol-binding protein (RBP) 2PTK ; 2.35 ; CHICKEN SRC TYROSINE KINASE 3R18 ; 2.4 ; Chicken sulfite oxidase double mutant with altered activity and substrate affinity 3R19 ; 2.1 ; Chicken sulfite oxidase triple mutant with altered activity and substrate affinity 2F4K ; 1.05 ; Chicken villin subdomain HP-35, K65(NLE), N68H, K70(NLE), PH9 1WY4 ; 1.55 ; Chicken villin subdomain HP-35, K65(NLE), N68H, pH5.1 1WY3 ; 0.95 ; Chicken villin subdomain HP-35, K65(NLE), N68H, pH7.0 1YRI ; 1 ; Chicken villin subdomain HP-35, N68H, pH6.4 1YRF ; 1.07 ; Chicken villin subdomain HP-35, N68H, pH6.7 2XFC ; 9 ; CHIKUNGUNYA E1 E2 ENVELOPE GLYCOPROTEINS FITTED IN SEMLIKI FOREST VIRUS cryo-EM MAP 2XFB ; 9 ; CHIKUNGUNYA E1 E2 ENVELOPE GLYCOPROTEINS FITTED IN SINDBIS VIRUS cryo- EM MAP 2JMC ; ; Chimer between Spc-SH3 and P41 3VML ; 1.56 ; Chimera 3-isopropylmalate dehydrogenase between Shewanella oneidensis MR-1 (O) and Shewanella benthica DB21 MT-2 (M) from N-terminal: 20% O middle 70% M residual 10% O 1XAC ; 2.1 ; CHIMERA ISOPROPYLMALATE DEHYDROGENASE BETWEEN BACILLUS SUBTILIS (M) AND THERMUS THERMOPHILUS (T) FROM N-TERMINAL: 20% T MIDDLE 20% M RESIDUAL 60% T, MUTATED AT S82R. LOW TEMPERATURE (100K) STRUCTURE. 1XAD ; 2.1 ; CHIMERA ISOPROPYLMALATE DEHYDROGENASE BETWEEN BACILLUS SUBTILIS (M) AND THERMUS THERMOPHILUS (T) FROM N-TERMINAL: 20% T MIDDLE 20% M RESIDUAL 60% T, MUTATED AT S82R. LOW TEMPERATURE (150K) STRUCTURE. 3FPC ; 1.4 ; Chimera of alcohol dehydrogenase by exchange of the cofactor binding domain res 153-294 of T. brockii ADH by E. histolytica ADH 3FPL ; 1.9 ; Chimera of alcohol dehydrogenase by exchange of the cofactor binding domain res 153-295 of C. beijerinckii ADH by T. brockii ADH 3FSR ; 2.2 ; Chimera of alcohol dehydrogenase by exchange of the cofactor binding domain res 153-295 of T. brockii ADH by C. beijerinckii ADH 1NGW ; 2.6 ; Chimeric Affinity Matured Fab 7g12 complexed with mesoporphyrin 1HO6 ; ; CHIMERIC ARABINONUCLEIC ACID (ANA) HAIRPIN WITH ANA/RNA HYBRID STEM 4GXP ; 3 ; Chimeric Family 1 beta-glucosidase made with non-contiguous SCHEMA 1NGX ; 1.8 ; Chimeric Germline Fab 7g12 with jeffamine fragment bound 1NGZ ; 1.6 ; Chimeric Germline Fab 7g12-apo 3H4I ; 1.3 ; Chimeric Glycosyltransferase for the generation of novel natural products 3H4T ; 1.15 ; Chimeric Glycosyltransferase for the generation of novel natural products - GtfAH1 in complex with UDP-2F-Glc 4ECB ; 2.2 ; Chimeric GST Containing Inserts of Kininogen Peptides 4ECC ; 2.2 ; Chimeric GST Containing Inserts of Kininogen Peptides 1ME0 ; ; Chimeric hairpin with 2',5'-linked RNA loop and DNA stem 1ME1 ; ; Chimeric hairpin with 2',5'-linked RNA loop and RNA stem 1JEB ; 2.1 ; Chimeric Human/Mouse Carbonmonoxy Hemoglobin (Human Zeta2 / Mouse Beta2) 1BYX ; ; CHIMERIC HYBRID DUPLEX R(GCAGUGGC).R(GCCA)D(CTGC) COMPRISING THE TRNA-DNA JUNCTION FORMED DURING INITIATION OF HIV-1 REVERSE TRANSCRIPTION 1NGY ; 2.2 ; Chimeric Mature Fab 7g12-Apo 1ROD ; ; CHIMERIC PROTEIN OF INTERLEUKIN 8 AND HUMAN MELANOMA GROWTH STIMULATING ACTIVITY PROTEIN, NMR 1HOQ ; ; CHIMERIC RNA/DNA HAIRPIN 1D97 ; 2.17 ; CHIRAL PHOSPHOROTHIOATE ANALOGUES OF B-DNA: THE CRYSTAL STRUCTURE OF RP-D(GP(S) CPGP(S)CPGP(S)C) 2VYO ; 1.5 ; Chitin deacetylase family member from Encephalitozoon cuniculi 1K9T ; 1.8 ; Chitinase a complexed with tetra-N-acetylchitotriose 2WM0 ; 1.9 ; CHITINASE A FROM SERRATIA MARCESCENS ATCC990 IN COMPLEX WITH CHITOBIO-THIAZOLINE THIOAMIDE. 2WLZ ; 1.82 ; CHITINASE A FROM SERRATIA MARCESCENS ATCC990 IN COMPLEX WITH CHITOBIO-THIAZOLINE. 2WK2 ; 2.05 ; CHITINASE A FROM SERRATIA MARCESCENS ATCC990 IN COMPLEX WITH CHITOTRIO-THIAZOLINE DITHIOAMIDE. 2WLY ; 2.4 ; CHITINASE A FROM SERRATIA MARCESCENS ATCC990 IN COMPLEX WITH CHITOTRIO-THIAZOLINE. 1E15 ; 1.9 ; CHITINASE B FROM SERRATIA MARCESCENS 1O6I ; 1.7 ; Chitinase B from Serratia marcescens complexed with the catalytic intermediate mimic cyclic dipeptide CI4. 1GPF ; 1.85 ; CHITINASE B FROM SERRATIA MARCESCENS IN COMPLEX WITH INHIBITOR PSAMMAPLIN 1E6P ; 1.7 ; CHITINASE B FROM SERRATIA MARCESCENS INACTIVE MUTANT E144Q 1E6N ; 2.25 ; CHITINASE B FROM SERRATIA MARCESCENS INACTIVE MUTANT E144Q IN COMPLEX WITH N-ACETYLGLUCOSAMINE-PENTAMER 1OGB ; 1.85 ; CHITINASE B FROM SERRATIA MARCESCENS MUTANT D142N 1OGG ; 1.97 ; CHITINASE B FROM SERRATIA MARCESCENS MUTANT D142N IN COMPLEX WITH INHIBITOR ALLOSAMIDIN 1E6Z ; 1.99 ; CHITINASE B FROM SERRATIA MARCESCENS WILDTYPE IN COMPLEX WITH CATALYTIC INTERMEDIATE 1E6R ; 2.5 ; CHITINASE B FROM SERRATIA MARCESCENS WILDTYPE IN COMPLEX WITH INHIBITOR ALLOSAMIDIN 2VZS ; 1.85 ; CHITOSAN PRODUCT COMPLEX OF AMYCOLATOPSIS ORIENTALIS EXO-CHITOSANASE CSXA 1QGI ; 1.6 ; CHITOSANASE FROM BACILLUS CIRCULANS 2D05 ; 2 ; Chitosanase From Bacillus circulans mutant K218P 2IU9 ; 3.1 ; CHLAMYDIA TRACHOMATIS LPXD WITH 100MM UDPGLCNAC (COMPLEX II) 2IU8 ; 2.2 ; CHLAMYDIA TRACHOMATIS LPXD WITH 25MM UDPGLCNAC (COMPLEX I) 4D8F ; 2.2 ; Chlamydia trachomatis NrdB with a Mn/Fe cofactor (procedure 1 - high Mn) 4D8G ; 1.75 ; Chlamydia trachomatis NrdB with a Mn/Fe cofactor (procedure 2 - low Mn) 3QRX ; 2.2 ; Chlamydomonas reinhardtii centrin bound to melittin 1UZD ; 2.4 ; CHLAMYDOMONAS,SPINACH CHIMERIC RUBISCO 2I9D ; 2.3 ; chloramphenicol acetyltransferase 1QHN ; 2.7 ; CHLORAMPHENICOL PHOSPHOTRANSFERASE FROM STREPTOMYCES VENEZUELAE 1QHY ; 2.6 ; CHLORAMPHENICOL PHOSPHOTRANSFERASE FROM STREPTOMYCES VENEZUELAE IN COMPLEX WITH ATPGAMMAS AND CHLORAMPHENICOL 1GRR ; 2.9 ; CHLORAMPHENICOL PHOSPHOTRANSFERASE IN COMPLEX WITH 2-NAC-CHLORAMPHENICOL FROM STREPTOMYCES VENEZUELAE 1QHX ; 2.5 ; CHLORAMPHENICOL PHOSPHOTRANSFERASE IN COMPLEX WITH ATP FROM STREPTOMYCES VENEZUELAE 1QHS ; 2.8 ; CHLORAMPHENICOL PHOSPHOTRANSFERASE IN COMPLEX WITH CHLORAMPHENICOL FROM STREPTOMYCES VENEZUELAE 1GRQ ; 2.9 ; CHLORAMPHENICOL PHOSPHOTRANSFERASE IN COMPLEX WITH P-AMINO-CHLORAMPHENICOL FROM STREPTOMYCES VENEZUELAE 3SO2 ; 1.6428 ; Chlorella dUTPase 1K0N ; 1.8 ; Chloride Intracellular Channel 1 (CLIC1) complexed with glutathione 2W3T ; 1.69 ; CHLORO COMPLEX OF THE NI-FORM OF E.COLI DEFORMYLASE 2YMP ; 1.96 ; Chloroacetic acid complex bound L-haloacid dehalogenase from a Rhodobacteraceae family bacterium 2BD0 ; 1.7 ; Chlorobium tepidum Sepiapterin Reductase complexed with NADP and Sepiapterin 1A7D ; 1.8 ; CHLOROMET MYOHEMERYTHRIN FROM THEMISTE ZOSTERICOLA 3DN1 ; 1.8 ; Chloropentafluorobenzene binding in the hydrophobic cavity of T4 lysozyme L99A mutant 1CPO ; 1.9 ; CHLOROPEROXIDASE 2CPO ; 2.1 ; CHLOROPEROXIDASE 2CIV ; 1.8 ; CHLOROPEROXIDASE BROMIDE COMPLEX 2CIZ ; 1.3 ; CHLOROPEROXIDASE COMPLEXED WITH ACETATE 2CIY ; 1.7 ; CHLOROPEROXIDASE COMPLEXED WITH CYANIDE AND DMSO 2CIX ; 1.8 ; CHLOROPEROXIDASE COMPLEXED WITH CYCLOPENTANEDIONE 2CJ1 ; 1.7 ; CHLOROPEROXIDASE COMPLEXED WITH FORMATE (ETHYLENE GLYCOL CRYOPROTECTANT) 2CJ2 ; 1.6 ; CHLOROPEROXIDASE COMPLEXED WITH FORMATE (SUGAR CRYOPROTECTANT) 2CJ0 ; 1.75 ; CHLOROPEROXIDASE COMPLEXED WITH NITRATE 1A8S ; 1.8 ; CHLOROPEROXIDASE F/PROPIONATE COMPLEX 1VNC ; 2.1 ; CHLOROPEROXIDASE FROM THE FUNGUS CURVULARIA INAEQUALIS 1VNE ; 2.15 ; CHLOROPEROXIDASE FROM THE FUNGUS CURVULARIA INAEQUALIS: MUTANT D292A 1VNG ; 2.2 ; CHLOROPEROXIDASE FROM THE FUNGUS CURVULARIA INAEQUALIS: MUTANT H404A 1VNH ; 2.11 ; CHLOROPEROXIDASE FROM THE FUNGUS CURVULARIA INAEQUALIS: MUTANT H496A 1VNF ; 2.35 ; CHLOROPEROXIDASE FROM THE FUNGUS CURVULARIA INAEQUALIS: MUTANT R360A 1VNI ; 2.15 ; CHLOROPEROXIDASE FROM THE FUNGUS CURVULARIA INAEQUALIS: RECOMBINANT HOLO-CHLOROPEROXIDASE 2CIW ; 1.15 ; CHLOROPEROXIDASE IODIDE COMPLEX 1A88 ; 1.9 ; CHLOROPEROXIDASE L 2J18 ; 1.75 ; CHLOROPEROXIDASE MIXTURE OF FERRIC AND FERROUS STATES (LOW DOSE DATA SET) 1A7U ; 1.75 ; CHLOROPEROXIDASE T 1A8U ; 1.6 ; CHLOROPEROXIDASE T/BENZOATE COMPLEX 1CIV ; 2.8 ; CHLOROPLAST NADP-DEPENDENT MALATE DEHYDROGENASE FROM FLAVERIA BIDENTIS 2YMQ ; 1.72 ; Chloropropionic acid complex bound L-haloacid dehalogenase from a Rhodobacteraceae family bacterium 1CEQ ; 2 ; CHLOROQUINE BINDS IN THE COFACTOR BINDING SITE OF PLASMODIUM FALCIPARUM LACTATE DEHYDROGENASE. 1CET ; 2.05 ; CHLOROQUINE BINDS IN THE COFACTOR BINDING SITE OF PLASMODIUM FALCIPARUM LACTATE DEHYDROGENASE. 3RTF ; 1.7 ; Chlorowillardiine bound to the ligand binding domain of GluA2 3RT8 ; 2.426 ; Chlorowillardiine bound to the ligand binding domain of GluA3 1C9W ; 2.4 ; CHO REDUCTASE WITH NADP+ 1S5B ; 2.13 ; Cholera holotoxin with an A-subunit Y30S mutation Form 3 1S5C ; 2.5 ; Cholera holotoxin with an A-subunit Y30S mutation, Crystal form 1 1S5D ; 1.75 ; Cholera holotoxin with an A-subunit Y30S mutation, Crystal form 2 1S5E ; 1.9 ; Cholera holotoxin, Crystal form 1 1S5F ; 2.6 ; Cholera holotoxin, Crystal form 2 1XTC ; 2.4 ; CHOLERA TOXIN 2A5G ; 2.66 ; Cholera toxin A1 subunit bound to ARF6(Q67L) 2A5F ; 2.02 ; Cholera toxin A1 subunit bound to its substrate, NAD+, and its human protein activator, ARF6 1RCV ; 1.6 ; Cholera Toxin B-Pentamer Complexed With Bivalent Nitrophenol-Galactoside Ligand BV1 1RD9 ; 1.44 ; Cholera Toxin B-Pentamer Complexed With Bivalent Nitrophenol-Galactoside Ligand BV2 1RDP ; 1.35 ; Cholera Toxin B-Pentamer Complexed With Bivalent Nitrophenol-Galactoside Ligand BV3 1RF2 ; 1.35 ; Cholera Toxin B-Pentamer Complexed With Bivalent Nitrophenol-Galactoside Ligand BV4 2CHB ; 2 ; CHOLERA TOXIN B-PENTAMER COMPLEXED WITH GM1 PENTASACCHARIDE 3CHB ; 1.25 ; CHOLERA TOXIN B-PENTAMER COMPLEXED WITH GM1 PENTASACCHARIDE 1EEI ; 2 ; CHOLERA TOXIN B-PENTAMER COMPLEXED WITH METANITROPHENYL-ALPHA-D-GALACTOSE 1PZK ; 1.35 ; Cholera Toxin B-Pentamer Complexed With N-Acyl Phenyl Galactoside 9h 1PZJ ; 1.46 ; Cholera Toxin B-Pentamer Complexed With Nitrophenyl Galactoside 5 1CT1 ; 2.3 ; CHOLERA TOXIN B-PENTAMER MUTANT G33R BOUND TO RECEPTOR PENTASACCHARIDE 1MD2 ; 1.45 ; CHOLERA TOXIN B-PENTAMER WITH DECAVALENT LIGAND BMSC-0013 1JR0 ; 1.3 ; CHOLERA TOXIN B-PENTAMER WITH LIGAND BMSC-0011 1LLR ; 1.46 ; CHOLERA TOXIN B-PENTAMER WITH LIGAND BMSC-0012 2YOO ; 1.69 ; Cholest-4-en-3-one bound structure of CYP142 from Mycobacterium smegmatis 3D4S ; 2.8 ; Cholesterol bound form of human beta2 adrenergic receptor. 1LLF ; 1.4 ; Cholesterol Esterase (Candida Cylindracea) Crystal Structure at 1.4A resolution 2BCE ; 1.6 ; CHOLESTEROL ESTERASE FROM BOS TAURUS 2I0K ; 1.6 ; Cholesterol Oxidase from Brevibacterium sterolicum- His121Ala Mutant 1B4V ; 1.5 ; CHOLESTEROL OXIDASE FROM STREPTOMYCES 1N4U ; 0.95 ; CHOLESTEROL OXIDASE FROM STREPTOMYCES @ pH 4.5 (STREPTOMYCES SP. SA-COO) 1IJH ; 1.53 ; CHOLESTEROL OXIDASE FROM STREPTOMYCES ASN485LEU MUTANT 1B8S ; 1.65 ; CHOLESTEROL OXIDASE FROM STREPTOMYCES GLU361GLN MUTANT 1CBO ; 1.8 ; CHOLESTEROL OXIDASE FROM STREPTOMYCES HIS447ASN MUTANT 1CC2 ; 2.2 ; CHOLESTEROL OXIDASE FROM STREPTOMYCES HIS447GLN MUTANT 3CNJ ; 0.95 ; Cholesterol oxidase from Streptomyces sp. F359W mutant (0.95A) 3GYI ; 1 ; Cholesterol oxidase from Streptomyces sp. N485D mutant (1.0A) 3GYJ ; 0.92 ; Cholesterol oxidase from Streptomyces sp. N485L mutant (0.92A) 1GVM ; 2.8 ; CHOLINE BINDING DOMAIN OF THE MAJOR AUTOLYSIN (C-LYTA) FROM STREPTOCOCCUS PNEUMONIAE 1HCX ; 2.6 ; CHOLINE BINDING DOMAIN OF THE MAJOR AUTOLYSIN (C-LYTA) FROM STREPTOCOCCUS PNEUMONIAE 4DA5 ; 2.4 ; Choline Kinase alpha acts through a double-displacement kinetic mechanism involving enzyme isomerisation, as determined through enzyme and inhibitor kinetics and structural biology 1C4S ; 3 ; CHONDROITIN-4-SULFATE. THE STRUCTURE OF A SULFATED GLYCOSAMINOGLYCAN 1CB8 ; 1.9 ; CHONDROITINASE AC LYASE FROM FLAVOBACTERIUM HEPARINUM 1G1B ; 1.99 ; CHORISMATE LYASE (WILD-TYPE) WITH BOUND PRODUCT 1JD3 ; 2.03 ; Chorismate lyase G90A mutant with bound product 1FW9 ; 1.4 ; CHORISMATE LYASE WITH BOUND PRODUCT 1G81 ; 1.71 ; CHORISMATE LYASE WITH BOUND PRODUCT, ORTHORHOMBIC CRYSTAL FORM 2AHC ; 2.4 ; Chorismate lyase with inhibitor Vanilate 1XLR ; 1.94 ; CHORISMATE LYASE WITH INHIBITOR VANILLATE 1TT8 ; 1 ; CHORISMATE LYASE WITH PRODUCT, 1.0 A RESOLUTION 1DBF ; 1.3 ; CHORISMATE MUTASE FROM BACILLUS SUBTILIS AT 1.30 ANGSTROM 1XHO ; 2.2 ; Chorismate mutase from Clostridium thermocellum Cth-682 1L0S ; 2.3 ; Choristoneura fumiferana (spruce budworm) antifreeze protein isoform 337 1M8N ; 2.45 ; Choristoneura Fumiferana (Spruce Budworm) Antifreeze Protein Isoform 501 2Y9Y ; 3.25 ; Chromatin Remodeling Factor ISW1a(del_ATPase) 2Y9Z ; 3.601 ; Chromatin Remodeling Factor ISW1a(del_ATPase) in DNA complex 1KNA ; 2.1 ; Chromo domain of HP1 complexed with histone H3 tail containing dimethyllysine 9. 1KNE ; 2.4 ; Chromo domain of HP1 complexed with histone H3 tail containing trimethyllysine 9 3MTS ; 2.2 ; Chromo Domain of Human Histone-Lysine N-Methyltransferase SUV39H1 1E0B ; 1.9 ; CHROMO SHADOW DOMAIN FROM FISSION YEAST SWI6 PROTEIN. 3G7L ; 2.2 ; Chromodomain of Chp1 in complex with Histone H3K9me3 peptide 1Q3L ; 1.64 ; Chromodomain Of HP1 Complexed With Histone H3 Tail Containing monomethyllysine 9. 2R0G ; 2.37 ; Chromopyrrolic acid-soaked RebC with bound 7-carboxy-K252c 4EIQ ; 2.76 ; Chromopyrrolic acid-soaked RebC-10x with bound 7-carboxy-K252c 1BF4 ; 1.6 ; CHROMOSOMAL DNA-BINDING PROTEIN SSO7D/D(GCGAACGC) COMPLEX 1VZ0 ; 2.3 ; CHROMOSOME SEGREGATION PROTEIN SPO0J FROM THERMUS THERMOPHILUS 3NE9 ; 2.5 ; Chronobacterium ammoiniagenes apo-ACPS strucutre 3NFD ; 1.89 ; Chronobacterium ammoniagenes ACPS-CoA complex 1CZI ; 2.3 ; CHYMOSIN COMPLEX WITH THE INHIBITOR CP-113972 1QH2 ; ; CHYMOTRYPSIN INHIBITOR (C2) FROM NICOTIANA ALATA 2JZM ; ; Chymotrypsin inhibitor C1 from Nicotiana alata 1CHG ; 2.5 ; CHYMOTRYPSINOGEN,2.5 ANGSTROMS CRYSTAL STRUCTURE, COMPARISON WITH ALPHA-CHYMOTRYPSIN,AND IMPLICATIONS FOR ZYMOGEN ACTIVATION 1CQ4 ; 1.8 ; CI2 MUTANT WITH TETRAGLUTAMINE (MGQQQQGM) REPLACING MET59 3MUP ; 2.6 ; cIAP1-BIR3 domain in complex with the Smac-mimetic compound Smac037 3OZ1 ; 3 ; cIAP1-BIR3 domain in complex with the Smac-mimetic compound Smac066 4EB9 ; 2.6 ; cIAP1-BIR3 in complex with a divalent Smac mimetic 3D9T ; 1.5 ; CIAP1-BIR3 in complex with N-terminal peptide from Caspase-9 (ATPFQE) 4HFG ; 2 ; CID of human RPRD1B 4FU3 ; 1.9 ; CID of human RPRD1B 4FLB ; 1.802 ; CID of human RPRD2 1D4B ; ; CIDE-N DOMAIN OF HUMAN CIDE-B 1CNT ; 2.4 ; CILIARY NEUROTROPHIC FACTOR 2K6D ; ; CIN85 Sh3-C domain in complex with ubiquitin 2JGS ; 1.9 ; CIRCULAR PERMUTANT OF AVIDIN 3ZZP ; 0.96 ; Circular permutant of ribosomal protein S6, lacking edge strand beta- 2 of wild-type S6. 3KML ; 3.011 ; Circular Permutant of the Tobacco Mosaic Virus 1P5C ; 2.5 ; Circular permutation of Helix A in T4 lysozyme 2XHH ; 1.6 ; CIRCULAR PERMUTATION PROVIDES AN EVOLUTIONARY LINK BETWEEN TWO FAMILIES OF CALCIUM-DEPENDENT CARBOHYDRATE BINDING MODULES 2XHJ ; 1.73 ; CIRCULAR PERMUTATION PROVIDES AN EVOLUTIONARY LINK BETWEEN TWO FAMILIES OF CALCIUM-DEPENDENT CARBOHYDRATE BINDING MODULES. SEMET FORM OF VCBM60. 1SWF ; 2 ; CIRCULAR PERMUTED STREPTAVIDIN E51/A46 1SWG ; 1.8 ; CIRCULAR PERMUTED STREPTAVIDIN E51/A46 IN COMPLEX WITH BIOTIN 1AJO ; 2.07 ; CIRCULARLY PERMUTED (1-3,1-4)-BETA-D-GLUCAN 4-GLUCANOHYDROLASE CPA16M-127 1AJK ; 1.8 ; CIRCULARLY PERMUTED (1-3,1-4)-BETA-D-GLUCAN 4-GLUCANOHYDROLASE CPA16M-84 1BD7 ; 2.78 ; CIRCULARLY PERMUTED BB2-CRYSTALLIN 1ALQ ; 1.8 ; CIRCULARLY PERMUTED BETA-LACTAMASE FROM STAPHYLOCOCCUS AUREUS PC1 1FW8 ; 2.3 ; CIRCULARLY PERMUTED PHOSPHOGLYCERATE KINASE FROM YEAST: PGK P72 1BH4 ; ; CIRCULIN A FROM CHASSALIA PARVIFLORA, NMR, 12 STRUCTURES 2H4B ; ; cis-4-aminomethylphenylazobenzoic acid-avian pancreatic polypeptide 1ANR ; ; CIS-ACTING RNA REGULATORY ELEMENT (HIV-1 TAR), NMR, 20 STRUCTURES 2H3S ; ; cis-Azobenzene-avian pancreatic polypeptide bound to DPC micelles 1BDB ; 2 ; CIS-BIPHENYL-2,3-DIHYDRODIOL-2,3-DEHYDROGENASE FROM PSEUDOMONAS SP. LB400 1KV0 ; 1.4 ; Cis/trans Isomerization of Non-prolyl Peptide Bond Observed in Crystal Structure of an Scorpion Toxin 2R7Z ; 3.8 ; Cisplatin lesion containing RNA polymerase II elongation complex 1AZ2 ; 2.9 ; CITRATE BOUND, C298A/W219Y MUTANT HUMAN ALDOSE REDUCTASE 1Z6K ; 2.3 ; Citrate lyase beta subunit complexed with oxaloacetate and magnesium from M. tuberculosis 1AJ8 ; 1.9 ; CITRATE SYNTHASE FROM PYROCOCCUS FURIOSUS 1O7X ; 2.7 ; CITRATE SYNTHASE FROM SULFOLOBUS SOLFATARICUS 1RGY ; 1.52 ; Citrobacter freundii GN346 Class C beta-Lactamase Complexed with Transition-State Analog of Cefotaxime 3B3I ; 1.86 ; Citrullination-dependent differential presentation of a self-peptide by HLA-B27 subtypes 1DKT ; 2.9 ; CKSHS1: HUMAN CYCLIN DEPENDENT KINASE SUBUNIT, TYPE 1 COMPLEX WITH METAVANADATE 1DKS ; 3.2 ; CKSHS1: HUMAN CYCLIN DEPENDENT KINASE SUBUNIT, TYPE 1 IN COMPLEX WITH PHOSPHATE 3ARK ; 1.81 ; Cl- binding hemoglobin component V form Propsilocerus akamusi under 1 M NaCl at pH 4.6 3ARJ ; 1.81 ; Cl- binding hemoglobin component V form Propsilocerus akamusi under 500 mM NaCl at pH 4.6 3ARL ; 1.81 ; Cl- binding hemoglobin component V form Propsilocerus akamusi under 500 mM NaCl at pH 5.5 1AD3 ; 2.6 ; CLASS 3 ALDEHYDE DEHYDROGENASE COMPLEX WITH NICOTINAMIDE-ADENINE-DINUCLEOTIDE 3BFF ; 1.9 ; class A beta-lactamase SED-G238C complexed with faropenem 3BFC ; 2.2 ; class A beta-lactamase SED-G238C complexed with imipenem 3BFG ; 2 ; class A beta-lactamase SED-G238C complexed with meropenem 2AU4 ; ; Class I GTP aptamer 1B0G ; 2.5 ; CLASS I HISTOCOMPATIBILITY ANTIGEN (HLA-A2.1)/BETA 2-MICROGLOBULIN/PEPTIDE P1049 COMPLEX 2V5K ; 2.2 ; CLASS II ALDOLASE HPCH - MAGNESIUM - OXAMATE COMPLEX 1ASY ; 2.9 ; CLASS II AMINOACYL TRANSFER RNA SYNTHETASES: CRYSTAL STRUCTURE OF YEAST ASPARTYL-TRNA SYNTHETASE COMPLEXED WITH TRNA ASP 1GYN ; 2 ; CLASS II FRUCTOSE 1,6-BISPHOSPHATE ALDOLASE WITH CADMIUM (NOT ZINC) IN THE ACTIVE SITE 1ZEN ; 2.5 ; CLASS II FRUCTOSE-1,6-BISPHOSPHATE ALDOLASE 3C56 ; 2.3 ; Class II fructose-1,6-bisphosphate aldolase from helicobacter pylori in complex with N-(3-Hydroxypropyl)-glycolohydroxamic acid bisphosphate, a competitive inhibitor 3N9S ; 1.85 ; Class II fructose-1,6-bisphosphate aldolase from helicobacter pylori in complex with N-(4-hydroxybutyl)- glycolohydroxamic acid bis-phosphate, a competitive inhibitor 3N9R ; 1.8 ; Class II fructose-1,6-bisphosphate aldolase from helicobacter pylori in complex with N-(4-hydroxybutyl)-phosphoglycolohydroxamic acid, a competitive inhibitor 3C52 ; 2.3 ; Class II fructose-1,6-bisphosphate aldolase from helicobacter pylori in complex with phosphoglycolohydroxamic acid, a competitive inhibitor 1RV8 ; 2.3 ; Class II fructose-1,6-bisphosphate aldolase from Thermus aquaticus in complex with cobalt 1B57 ; 2 ; CLASS II FRUCTOSE-1,6-BISPHOSPHATE ALDOLASE IN COMPLEX WITH PHOSPHOGLYCOLOHYDROXAMATE 3FTM ; 2.7 ; Class II ligase ribozyme product-template duplex, structure 1 3FS0 ; 2.3 ; Class II ligase ribozyme product-template duplex, structure 2 2IAD ; 2.4 ; CLASS II MHC I-AD IN COMPLEX WITH AN INFLUENZA HEMAGGLUTININ PEPTIDE 126-138 1IAO ; 2.6 ; CLASS II MHC I-AD IN COMPLEX WITH OVALBUMIN PEPTIDE 323-339 3HBE ; 1.55 ; Class IV chitinase structure from Picea abies at 1.55A 3HBD ; 1.8 ; Class IV chitinase structure from Picea abies at 1.8A 3HBH ; 2.25 ; Class IV chitinase structure from Picea abies at 2.25A 3JSO ; 2.29 ; Classic Protein With a New Twist: crystal structure of a LexA repressor DNA complex 3JSP ; 2.9 ; Classic Protein With a New Twist: crystal structure of a LexA repressor DNA complex 3PSH ; 1.5 ; Classification of a Haemophilus influenzae ABC transporter HI1470/71 through its cognate molybdate periplasmic binding protein MolA (MolA bound to Molybdate) 3PSA ; 1.7 ; Classification of a Haemophilus influenzae ABC transporter HI1470/71 through its cognate molybdate periplasmic binding protein MolA (MolA bound to tungstate) 1XI4 ; 7.9 ; Clathrin D6 Coat 3IYV ; 7.9 ; Clathrin D6 coat as full-length Triskelions 1XI5 ; 12 ; Clathrin D6 coat with auxilin J-domain 1B89 ; 2.6 ; CLATHRIN HEAVY CHAIN PROXIMAL LEG SEGMENT (BOVINE) 1BPO ; 2.6 ; CLATHRIN HEAVY-CHAIN TERMINAL DOMAIN AND LINKER 2XZG ; 1.7 ; CLATHRIN TERMINAL DOMAIN COMPLEXED WITH PITSTOP 1 4G55 ; 1.69 ; Clathrin terminal domain complexed with pitstop 2 1UTC ; 2.3 ; CLATHRIN TERMINAL DOMAIN COMPLEXED WITH TLPWDLWTT 2WOL ; 1.45 ; CLAVULANIC ACID BIOSYNTHESIS OLIGOPEPTIDE BINDING PROTEIN 2 2WOP ; 1.7 ; CLAVULANIC ACID BIOSYNTHESIS OLIGOPEPTIDE BINDING PROTEIN 2 COMPLEXED WITH ARGININE 2WOK ; 1.7 ; CLAVULANIC ACID BIOSYNTHESIS OLIGOPEPTIDE BINDING PROTEIN 2 COMPLEXED WITH BRADYKININ 2IOT ; 1.6 ; Clavulanic Acid bound to Elastase 2JAP ; 2.1 ; CLAVULANIC ACID DEHYDROGENASE: STRUCTURAL AND BIOCHEMICAL ANALYSIS OF THE FINAL STEP IN THE BIOSYNTHESIS OF THE BETA-LACTAMASE INHIBITOR CLAVULANIC ACID 4E6X ; 2.24 ; ClbP in complex boron-based inhibitor 4E6W ; 2.19 ; ClbP in complex with 3-aminophenyl boronic acid 1QMB ; 2.6 ; CLEAVED ALPHA-1-ANTITRYPSIN POLYMER 3CAA ; 2.4 ; CLEAVED ANTICHYMOTRYPSIN A347R 1AS4 ; 2.1 ; CLEAVED ANTICHYMOTRYPSIN A349R 4CAA ; 2.9 ; CLEAVED ANTICHYMOTRYPSIN T345R 3NDD ; 1.5 ; Cleaved antitrypsin with P10 Pro, and P9-P6 Asp 3NDF ; 2.7 ; Cleaved antitrypsin with P8-P6 Asp 3F02 ; 1.8 ; Cleaved human neuroserpin 9PAI ; 2.7 ; CLEAVED SUBSTRATE VARIANT OF PLASMINOGEN ACTIVATOR INHIBITOR-1 3Q4B ; 2.19 ; Clinically Useful Alkyl Amine Renin Inhibitors 3Q5H ; 2.16 ; Clinically Useful Alkyl Amine Renin Inhibitors 3NBC ; 1.01 ; Clitocybe nebularis ricin B-like lectin (CNL) in complex with lactose, crystallized at pH 4.4 3NBD ; 1.15 ; Clitocybe nebularis ricin B-like lectin (CNL) in complex with lactose, crystallized at pH 7.1 3NBE ; 1.86 ; Clitocybe nebularis ricin B-like lectin (CNL) in complex with N,N'-diacetyllactosediamine 3H6R ; 1.948 ; Clitocypin, a beta-trefoil cysteine protease inhibitor 1ZOX ; 2.1 ; CLM-1 Mouse Myeloid Receptor Extracellular Domain 2B2C ; 2.5 ; Cloning, expression, characterisation and three- dimensional structure determination of the Caenorhabditis elegans spermidine synthase 1DT0 ; 2.1 ; CLONING, SEQUENCE, AND CRYSTALLOGRAPHIC STRUCTURE OF RECOMBINANT IRON SUPEROXIDE DISMUTASE FROM PSEUDOMONAS OVALIS 3LNW ; 2.302 ; Close correlation of protein thermostability and self-buried area rate revealed by crystal structure of HPr from Thermoanaerobacter tengcongensis MB4 1BLB ; 3.3 ; CLOSE PACKING OF AN OLIGOMERIC EYE LENS BETA-CRYSTALLIN INDUCES LOSS OF SYMMETRY AND ORDERING OF SEQUENCE EXTENSIONS 3KD1 ; 2.66 ; Closed binary complex of an RB69 gp43 fingers domain mutant complexed with an acyclic GMP terminated primer template pair. 2ZTL ; 1.8 ; Closed conformation of D-3-hydroxybutyrate dehydrogenase complexed with NAD+ and L-3-hydroxybutyrate 3LI2 ; 2.2 ; Closed Conformation of HtsA Complexed with Staphyloferrin A 3GWD ; 2.3 ; Closed crystal structure of cyclohexanone monooxygenase 3R1A ; 3.5 ; Closed crystal structure of cytochrome P450 2B4 covalently bound to the mechanism-based inactivator tert-butylphenylacetylene 3MA0 ; 2.2 ; Closed liganded crystal structure of xylose binding protein from Escherichia coli 3KD5 ; 2.69 ; Closed ternary complex of an RB69 gp43 fingers domain mutant complexed with an acyclic GMP terminated primer template pair and phosphonoformic acid. 4F5Q ; 2.25 ; Closed ternary complex of R283K DNA polymerase beta 3HPH ; 2.64 ; Closed tetramer of Visna virus integrase (residues 1-219) in complex with LEDGF IBD 2FDX ; 1.65 ; CLOSTRIDIUM BEIJERINCKII FLAVODOXIN MUTANT N137A OXIDIZED 4NUL ; 1.9 ; CLOSTRIDIUM BEIJERINCKII FLAVODOXIN MUTANT: D58P OXIDIZED 1FLN ; 1.9 ; CLOSTRIDIUM BEIJERINCKII FLAVODOXIN MUTANT: D58P REDUCED 3NLL ; 2.4 ; CLOSTRIDIUM BEIJERINCKII FLAVODOXIN MUTANT: G57A OXIDIZED 4NLL ; 1.9 ; CLOSTRIDIUM BEIJERINCKII FLAVODOXIN MUTANT: G57D OXIDIZED 1FLA ; 1.9 ; CLOSTRIDIUM BEIJERINCKII FLAVODOXIN MUTANT: G57D REDUCED 1FVX ; 1.9 ; CLOSTRIDIUM BEIJERINCKII FLAVODOXIN MUTANT: G57N OXIDIZED 1FLD ; 1.8 ; CLOSTRIDIUM BEIJERINCKII FLAVODOXIN MUTANT: G57T OXIDIZED 2FLV ; 1.8 ; CLOSTRIDIUM BEIJERINCKII FLAVODOXIN MUTANT: G57T REDUCED (150K) 2FVX ; 1.8 ; CLOSTRIDIUM BEIJERINCKII FLAVODOXIN MUTANT: G57T REDUCED (277K) 5NUL ; 1.6 ; CLOSTRIDIUM BEIJERINCKII FLAVODOXIN MUTANT: G57T SEMIQUINONE (150K) 2FAX ; 1.8 ; CLOSTRIDIUM BEIJERINCKII FLAVODOXIN MUTANT: N137A OXIDIZED (150K) 6NUL ; 1.8 ; CLOSTRIDIUM BEIJERINCKII FLAVODOXIN MUTANT: N137A REDUCED (150K) 5NLL ; 1.75 ; CLOSTRIDIUM BEIJERINCKII FLAVODOXIN: OXIDIZED 5ULL ; 1.8 ; CLOSTRIDIUM BEIJERINCKII FLAVODOXIN: REDUCED 2FOX ; 1.8 ; CLOSTRIDIUM BEIJERINCKII FLAVODOXIN: SEMIQUINONE 2IMA ; 1.94 ; Clostridium botulinum Neurotoxin Serotype A Light Chain Inhibited by 2,4-dichlorocinnamic hydroxamate 2IMB ; 2.41 ; Clostridium botulinum Neurotoxin Serotype A Light Chain Inhibited by L-arginine hydroxamate 2IMC ; 2 ; Clostridium botulinum Neurotoxin Serotype A Light Chain, Residues 1-424 2ILP ; 1.9 ; Clostridium botulinum Serotype A Light Chain inhibited by 4-chlorocinnamic hydroxamate 4HEV ; 2.5 ; Clostridium Botulinum Serotype A Light Chain Inhibited By Adamantane Hydroxamate 1T3C ; 1.9 ; Clostridium botulinum type E catalytic domain E212Q mutant 3SS1 ; 2.202 ; Clostridium difficile toxin A (TcdA) glucolsyltransferase domain 3SRZ ; 2.58 ; Clostridium difficile toxin A (TcdA) glucolsyltransferase domain bound to UDP-glucose 2F6E ; 1.85 ; Clostridium difficile Toxin A C-terminal fragment 1 (TcdA-f1) 2G7C ; 2 ; Clostridium difficile Toxin A Fragment Bound to aGal(1,3)bGal(1,4)bGlcNAc 1CLF ; ; CLOSTRIDIUM PASTEURIANUM FERREDOXIN 1BE7 ; 1.65 ; CLOSTRIDIUM PASTEURIANUM RUBREDOXIN C42S MUTANT 1B13 ; 1.5 ; CLOSTRIDIUM PASTEURIANUM RUBREDOXIN G10A MUTANT 1B2O ; 1.9 ; CLOSTRIDIUM PASTEURIANUM RUBREDOXIN G10VG43A MUTANT 1B2J ; 1.6 ; CLOSTRIDIUM PASTEURIANUM RUBREDOXIN G43A MUTANT 2WXT ; 2 ; CLOSTRIDIUM PERFRINGENS ALPHA-TOXIN STRAIN NCTC8237 2WXU ; 1.8 ; CLOSTRIDIUM PERFRINGENS ALPHA-TOXIN STRAIN NCTC8237 MUTANT T74I 2WY6 ; 3.2 ; CLOSTRIDIUM PERFRINGENS ALPHA-TOXIN STRAIN NCTC8237 MUTANT T74I 2YGT ; 2.4 ; Clostridium perfringens delta-toxin 2XH6 ; 2.69 ; CLOSTRIDIUM PERFRINGENS ENTEROTOXIN 3AM2 ; 2.51 ; Clostridium perfringens enterotoxin 2YHJ ; 4 ; CLOSTRIDIUM PERFRINGENS ENTEROTOXIN AT 4.0 ANGSTROM RESOLUTION 3ZJX ; 2.4 ; Clostridium perfringens epsilon toxin mutant H149A bound to octyl glucoside 1UYJ ; 2.6 ; CLOSTRIDIUM PERFRINGENS EPSILON TOXIN SHOWS STRUCTURAL SIMILARITY WITH THE PORE FORMING TOXIN AEROLYSIN 2W47 ; 1.4 ; Clostridium thermocellum CBM35 in complex with delta-4,5- anhydrogalacturonic acid 2VPT ; 1.4 ; Clostridium thermocellum family 3 carbohydrate esterase 3PH4 ; 2.07 ; Clostridium thermocellum Ribose-5-Phosphate Isomerase B with d-allose 3PH3 ; 2.07 ; Clostridium thermocellum Ribose-5-Phosphate Isomerase B with d-ribose 3MDV ; 2.4 ; Clotrimazole complex of Cytochrome P450 46A1 2NPI ; 2.95 ; Clp1-ATP-Pcf11 complex 1R6Q ; 2.35 ; ClpNS with fragments 1YG6 ; 1.9 ; ClpP 1N67 ; 1.9 ; Clumping Factor A from Staphylococcus aureus 1YCT ; ; Clustered abasic lesions in dna: nmr solution structure of clustered bistranded +1 abasic lesion 1YCW ; ; Clustered abasic lesions in dna: nmr solution structures of clustered bistranded-1 abasic lesion 2BR3 ; 2.79 ; CMCI-D160 MG 2BR4 ; 2.59 ; CMCI-D160 MG-SAM 2BM8 ; 2.5 ; CMCI-N160 APO-STRUCTURE 2BM9 ; 2.94 ; CMCI-N160 IN COMPLEX WITH SAM 2BR5 ; 2.83 ; CMCI-N160 SAH 1CKE ; 1.75 ; CMP KINASE FROM ESCHERICHIA COLI FREE ENZYME STRUCTURE 3ASZ ; 2.25 ; CMP-complex structure of uridine kinase from Thermus thermophilus HB8 3SWF ; 2.14 ; CNGA1 621-690 containing CLZ domain 3SWY ; 1.9 ; CNGA3 626-672 containing CLZ domain 3T9V ; 1.975 ; CNQX bound to a reduced double cysteine mutant (A452C/S652C) of the ligand binding domain of GluA2 3T9U ; 1.97 ; CNQX bound to an oxidized double cysteine mutant (A452C/S652C) of the ligand binding domain of GluA2 4F1Y ; 1.79 ; CNQX bound to the ligand binding domain of GluA3 1DXC ; 1.4 ; CO complex of Myoglobin Mb-YQR at 100K 1MYZ ; 1.6 ; CO COMPLEX OF MYOGLOBIN MB-YQR AT RT SOLVED FROM LAUE DATA. 1CG8 ; 1.9 ; CO Form Hemoglobin from Dasyatis Akajei 1GCW ; 2 ; CO form hemoglobin from mustelus griseus 3SCH ; 2.1 ; Co(II)-HppE with R-HPP 1G5L ; ; CO(III)-BLEOMYCIN-OOH BOUND TO AN OLIGONUCLEOTIDE CONTAINING A PHOSPHOGLYCOLATE LESION 1GJ2 ; ; CO(III)-BLEOMYCIN-OOH BOUND TO AN OLIGONUCLEOTIDE CONTAINING A PHOSPHOGLYCOLATE LESION 2R2U ; 2.3 ; Co(III)bleomycinB2 bithiazole/C-terminal tail domain bound to d(ATTTAGTTAACTAAAT) complexed with MMLV RT catalytic fragment 2R2S ; 2.8 ; Co(III)bleomycinB2 bound to d(ATTAGTTATAACTAAT) complexed with MMLV RT catalytic fragment 2C32 ; 7.01 ; CO-AXIAL ASSOCIATION OF RECOMBINANT EYE LENS AQUAPORIN-0 OBSERVED IN LOOSELY PACKED 3D-CRYSTALS 2Y3B ; 1.554 ; CO-BOUND FORM OF CUPRIAVIDUS METALLIDURANS CH34 CNRXS 1XJ2 ; 2 ; CO-bound structure of bjFixLH 1XJ4 ; 1.8 ; CO-bound structure of BjFixLH 2VV8 ; 1.61 ; CO-BOUND STRUCTURE OF BJFIXLH 3GTM ; 3.8 ; Co-complex of Backtracked RNA polymerase II with TFIIS 4A1T ; 2.05 ; Co-Complex of the of NS3-4A protease with the inhibitory peptide CP5- 46-A (in-House data) 2W03 ; 2.95 ; CO-COMPLEX STRUCTURE OF ACHROMOBACTIN SYNTHETASE PROTEIN D (ACSD) WITH ADENOSINE, SULFATE AND CITRATE FROM PECTOBACTERIUM CHRYSANTHEMI 2X3K ; 2.5 ; CO-COMPLEX STRUCTURE OF ACHROMOBACTIN SYNTHETASE PROTEIN D (ACSD) WITH AMP AND SULFATE FROM PECTOBACTERIUM CHRYSANTHEMI 2X3J ; 2 ; CO-COMPLEX STRUCTURE OF ACHROMOBACTIN SYNTHETASE PROTEIN D (ACSD) WITH ATP AND N-CITRYL-ETHYLENEDIAMINE FROM PECTOBACTERIUM CHRYSANTHEMI 2W02 ; 2.2 ; CO-COMPLEX STRUCTURE OF ACHROMOBACTIN SYNTHETASE PROTEIN D (ACSD) WITH ATP FROM PECTOBACTERIUM CHRYSANTHEMI 2W04 ; 2.8 ; CO-COMPLEX STRUCTURE OF ACHROMOBACTIN SYNTHETASE PROTEIN D (ACSD) WITH CITRATE IN ATP BINDING SITE FROM PECTOBACTERIUM CHRYSANTHEMI 2X0Q ; 1.96 ; CO-COMPLEX STRUCTURE OF ALCALIGIN BIOSYNTHESIS PROTEIN C (ALCC) WITH ATP FROM BORDETELLA BRONCHISEPTICA 2X0P ; 2.1 ; CO-COMPLEX STRUCTURE OF ALCALIGIN BIOSYNTHETASE PROTEIN C (ALCC) WITH ADENOSINE FROM BORDETELLA BRONCHISEPTICA 4ABJ ; 1.45 ; Co-complex structure of bovine trypsin with a modified Bowman-Birk inhibitor (IcA)SFTI-1(1,14), that was 1,5-disubstituted with 1,2,3- trizol to mimic a cis amid bond 4ABI ; 1.55 ; Co-complex structure of bovine trypsin with a modified Bowman-Birk inhibitor (PtA)SFTI-1(1,14), that was 1,4-disubstituted with a 1,2,3- trizol to mimic a trans amide bond 4A1X ; 1.9 ; Co-Complex structure of NS3-4A protease with the inhibitory peptide CP5-46-A (Synchrotron data) 4A1V ; 2.2 ; Co-Complex structure of NS3-4A protease with the optimized inhibitory peptide CP5-46A-4D5E 4EAJ ; 2.609 ; Co-crystal of AMPK core with AMP soaked with ATP 4EAL ; 2.506 ; Co-crystal of AMPK core with ATP soaked with AMP 2IHN ; 3 ; Co-crystal of Bacteriophage T4 RNase H with a fork DNA substrate 1G15 ; 1.9 ; CO-CRYSTAL OF E. COLI RNASE HI WITH TWO MN2+ IONS BOUND IN THE THE ACTIVE SITE 2DWX ; 2.55 ; Co-crystal Structure Analysis of GGA1-GAE with the WNSF motif 1KNJ ; 2.8 ; Co-Crystal Structure of 2-C-methyl-D-erythritol 2,4-cyclodiphosphate Synthase (ispF) from E. coli Involved in Mevalonate-Independent Isoprenoid Biosynthesis, Complexed with CMP/MECDP/Mn2+ 3K14 ; 1.7 ; Co-crystal structure of 2C-methyl-D-erythritol 2,4-cyclodiphosphate synthase from Burkholderia pseudomallei with FOL fragment 535, ethyl 3-methyl-5,6-dihydroimidazo[2,1-b][1,3]thiazole-2-carboxylate 3F0F ; 2.09 ; Co-crystal structure of 2C-methyl-D-erythritol 2,4-cyclodiphosphate synthase from Burkholderia pseudomallei with hydrolyzed CDP 3F0G ; 2.08 ; Co-crystal structure of 2C-methyl-D-erythritol 2,4-cyclodiphosphate synthase with CMP 1W8C ; 2.05 ; CO-CRYSTAL STRUCTURE OF 6-CYCLOHEXYLMETHOXY-8-ISOPROPYL-9H-PURIN-2-YLAMINE AND MONOMERIC CDK2 3IWN ; 3.2 ; Co-crystal structure of a bacterial c-di-GMP riboswitch 2XM8 ; 3.4 ; CO-CRYSTAL STRUCTURE OF A SMALL MOLECULE INHIBITOR BOUND TO THE KINASE DOMAIN OF CHK2 4EWH ; 2.5 ; Co-crystal structure of ACK1 with inhibitor 4EAI ; 2.285 ; Co-crystal structure of an AMPK core with AMP 4EAK ; 2.5 ; Co-crystal structure of an AMPK core with ATP 4EAG ; 2.701 ; Co-crystal structure of an chimeric AMPK core with ATP 1K73 ; 3.01 ; Co-crystal Structure of Anisomycin Bound to the 50S Ribosomal Subunit 3CC4 ; 2.7 ; Co-crystal Structure of Anisomycin Bound to the 50S Ribosomal Subunit 1M1K ; 3.2 ; Co-crystal structure of azithromycin bound to the 50S ribosomal subunit of Haloarcula marismortui 1KC8 ; 3.01 ; Co-crystal Structure of Blasticidin S Bound to the 50S Ribosomal Subunit 3G71 ; 2.85 ; Co-crystal structure of Bruceantin bound to the large ribosomal subunit 1K8A ; 3 ; Co-crystal structure of Carbomycin A bound to the 50S ribosomal subunit of Haloarcula marismortui 1M90 ; 2.8 ; Co-crystal structure of CCA-Phe-caproic acid-biotin and sparsomycin bound to the 50S ribosomal subunit 1ZYS ; 1.7 ; Co-crystal structure of Checkpoint Kinase Chk1 with a pyrrolo-pyridine inhibitor 4EA1 ; 2.46 ; Co-crystal structure of dehydrosqualene synthase (Crtm) from S. aureus with SQ-109 3UFM ; 1.95 ; Co-crystal structure of Deinococcus radiodurans uracil-DNA glycosylase and the C-terminus of the single-stranded DNA-binding protein 3NRR ; 1.8 ; Co-crystal structure of dihydrofolate reductase-thymidylate synthase from Babesia bovis with dUMP, Raltitrexed and NADP 3K2H ; 2.2 ; Co-crystal structure of dihydrofolate reductase/thymidylate synthase from Babesia bovis with dUMP, Pemetrexed and NADP 1WSF ; 2.3 ; Co-crystal structure of E.coli RNase HI active site mutant (D134A*) with Mn2+ 1WSE ; 2.3 ; Co-crystal structure of E.coli RNase HI active site mutant (E48A*) with Mn2+ 1WSG ; 2.2 ; Co-crystal structure of E.coli RNase HI active site mutant (E48A/D134N*) with Mn2+ 4DT6 ; 2.6 ; Co-crystal structure of eIF4E with inhibitor 4DUM ; 2.95 ; Co-crystal structure of eIF4E with inhibitor 3UF7 ; 1.2 ; Co-crystal structure of Escherichia coli uracil-DNA glycosylase and a C-terminal fragement of the single-stranded DNA-binding protein 3I7E ; 1.7 ; Co-crystal structure of HIV-1 protease bound to a mutant resistant inhibitor UIC-98038 3G6E ; 2.7 ; Co-crystal structure of Homoharringtonine bound to the large ribosomal subunit 1MZC ; 2 ; Co-Crystal Structure Of Human Farnesyltransferase With Farnesyldiphosphate and Inhibitor Compound 33a 1LD8 ; 1.8 ; Co-crystal structure of Human Farnesyltransferase with farnesyldiphosphate and inhibitor compound 49 1LD7 ; 2 ; Co-crystal structure of Human Farnesyltransferase with farnesyldiphosphate and inhibitor compound 66 3RBQ ; 2 ; Co-crystal structure of human UNC119 (retina gene 4) and an N-terminal Transducin-alpha mimicking peptide 1UBD ; 2.5 ; CO-CRYSTAL STRUCTURE OF HUMAN YY1 ZINC FINGER DOMAIN BOUND TO THE ADENO-ASSOCIATED VIRUS P5 INITIATOR ELEMENT 4JIF ; 1.701 ; Co-crystal structure of ICAP1 PTB domain in complex with a KRIT1 peptide 3TJD ; 2.9 ; co-crystal structure of Jak2 with thienopyridine 19 3TJC ; 2.4 ; Co-crystal structure of jak2 with thienopyridine 8 3V7K ; 2.271 ; Co-crystal structure of K72E variant of rat polymerase beta: Enzyme-DNA binary complex 3BYS ; 2.2 ; co-crystal structure of Lck and aminopyrimidine amide 10b 3BYU ; 2.3 ; co-crystal structure of Lck and aminopyrimidine reverse amide 23 1Z56 ; 3.92 ; Co-Crystal Structure of Lif1p-Lig4p 4JVR ; 1.7 ; Co-crystal structure of MDM2 with inhibitor (2'S,3R,4'S,5'R)-N-(2-aminoethyl)-6-chloro-4'-(3-chloro-2-fluorophenyl)-2'-(2,2-dimethylpropyl)-2-oxo-1,2-dihydrospiro[indole-3,3'-pyrrolidine]-5'-carboxamide 4JVE ; 2.3 ; Co-crystal structure of MDM2 with inhibitor (2R,3E)-2-[(2S,3R,6S)-2,3-bis(4-chlorophenyl)-6-(4-fluorobenzyl)-5-oxomorpholin-4-yl]pent-3-enoic acid 4JV7 ; 2.2 ; Co-crystal structure of MDM2 with inhibitor (2S,5R,6S)-2-benzyl-5,6-bis(4-bromophenyl)-4-methylmorpholin-3-one 4JV9 ; 2.5 ; Co-crystal structure of MDM2 with inhibitor (2S,5R,6S)-2-benzyl-5,6-bis(4-chlorophenyl)-4-methylmorpholin-3-one 4JWR ; 2.35 ; Co-crystal structure of MDM2 with inhibitor {(2S,5R,6S)-6-(3-chlorophenyl)-5-(4-chlorophenyl)-4-[(2S)-1-hydroxybutan-2-yl]-3-oxomorpholin-2-yl}acetic acid 3I55 ; 3.11 ; Co-crystal structure of Mycalamide A Bound to the Large Ribosomal Subunit 3VNR ; 1.75 ; Co-crystal structure of NRPS adenylation protein CytC1 with aminobutyric acid and AMP from streptomyces 3VNQ ; 2.1 ; Co-crystal structure of NRPS adenylation protein CytC1 with ATP from streptomyces 3VNS ; 2.001 ; Co-crystal structure of NRPS adenylation protein CytC1 with D-valine and AMP from streptomyces 1ZCW ; 2.25 ; Co-crystal structure of Orf2 an aromatic prenyl transferase from Streptomyces sp. strain CL190 complexed with GPP 1ZB6 ; 1.95 ; Co-Crystal Structure of ORF2 an Aromatic Prenyl Transferase from Streptomyces sp. strain cl190 complexed with GSPP and 1,6-dihydroxynaphtalene 1ZDW ; 2.02 ; Co-crystal structure of Orf2 an aromatic prenyl transferase from Streptomyces sp. strain CL190 complexed with GSPP and Flaviolin 1ZDY ; 1.44 ; Co-crystal structure of Orf2 an aromatic prenyl transferase from Streptomyces sp. strain CL190 complexed with TAPS 1FT2 ; 3.4 ; CO-CRYSTAL STRUCTURE OF PROTEIN FARNESYLTRANSFERASE COMPLEXED WITH A FARNESYL DIPHOSPHATE SUBSTRATE 4DXA ; 1.95 ; Co-crystal structure of Rap1 in complex with KRIT1 3UXP ; 2.723 ; Co-crystal Structure of Rat DNA polymerase beta Mutator I260Q: Enzyme-DNA-ddTTP 1D8D ; 2 ; CO-CRYSTAL STRUCTURE OF RAT PROTEIN FARNESYLTRANSFERASE COMPLEXED WITH A K-RAS4B PEPTIDE SUBSTRATE AND FPP ANALOG AT 2.0A RESOLUTION 3BPC ; 1.85 ; co-crystal structure of S25-2 Fab in complex with 5-deoxy-4-epi-2,3-dehydro Kdo (4.8) Kdo 1KD1 ; 3 ; Co-crystal Structure of Spiramycin bound to the 50S Ribosomal Subunit of Haloarcula marismortui 1SVL ; 1.95 ; Co-crystal structure of SV40 large T antigen helicase domain and ADP 1SVM ; 1.94 ; Co-crystal structure of SV40 large T antigen helicase domain and ATP 1VTL ; 2.25 ; CO-CRYSTAL STRUCTURE OF TBP RECOGNIZING THE MINOR GROOVE OF A TATA ELEMENT 1VTN ; 2.5 ; CO-CRYSTAL STRUCTURE OF THE HNF-3/FORK HEAD DNA-RECOGNITION MOTIF RESEMBLES HISTONE H5 3RLR ; 1.7 ; Co-crystal structure of the HSP90 ATP binding domain in complex with 4-(2,4-dichloro-5-methoxyphenyl)-2,6-dimethyl-7H-pyrrolo[2,3-d]pyrimidine-5-carbonitrile 3RLQ ; 1.9 ; Co-crystal structure of the HSP90 ATP binding domain in complex with 4-(2,4-dichloro-5-methoxyphenyl)-2-methyl-7H-pyrrolo[2,3-d]pyrimidine-5- carbonitrile 3RLP ; 1.7 ; Co-crystal structure of the HSP90 ATP binding domain in complex with 4-(2,4-dichloro-5-methoxyphenyl)-6-methylpyrimidin-2-amine 3K3B ; 2.4 ; Co-crystal structure of the human kinesin Eg5 with a novel tetrahydro-beta-carboline 4DRI ; 1.45 ; Co-crystal structure of the PPIase domain of FKBP51, Rapamycin and the FRB fragment of mTOR 4DRH ; 2.3 ; Co-crystal structure of the PPIase domain of FKBP51, Rapamycin and the FRB fragment of mTOR at low pH 3KKA ; 2.4 ; Co-crystal structure of the sam domains of EPHA1 AND EPHA2 3G4S ; 3.2 ; Co-crystal structure of Tiamulin bound to the large ribosomal subunit 3D8A ; 2.55 ; Co-crystal structure of TraM-TraD complex. 3I56 ; 2.9 ; Co-crystal structure of Triacetyloleandomcyin Bound to the Large Ribosomal Subunit 1K9M ; 3 ; Co-crystal structure of tylosin bound to the 50S ribosomal subunit of Haloarcula marismortui 4AZV ; 3.291 ; Co-crystal structure of WbdD and kinase inhibitor GW435821x. 4AZT ; 2.34 ; Co-crystal structure of WbdD and kinase inhibitor LY294002. 3V7J ; 2.25 ; Co-crystal structure of Wild Type Rat polymerase beta: Enzyme-DNA binary complex 4DI5 ; 2.3 ; Co-crystal structure of WT 5-epi-Aristolochene synthase from Nicotiana tobaccum with geraniline 1TF6 ; 3.1 ; CO-CRYSTAL STRUCTURE OF XENOPUS TFIIIA ZINC FINGER DOMAIN BOUND TO THE 5S RIBOSOMAL RNA GENE INTERNAL CONTROL REGION 2H7V ; 2.6 ; Co-crystal structure of YpkA-Rac1 2G45 ; 1.99 ; Co-crystal structure of znf ubp domain from the deubiquitinating enzyme isopeptidase T (isot) in complex with ubiquitin 3EOG ; 3.391 ; Co-crystallization showing exon recognition by a group II intron 3O9M ; 2.98 ; Co-crystallization studies of full length recombinant BChE with cocaine offers insights into cocaine detoxification 1ONA ; 2.35 ; CO-CRYSTALS OF CONCANAVALIN A WITH METHYL-3,6-DI-O-(ALPHA-D-MANNOPYRANOSYL)-ALPHA-D-MANNOPYRANOSIDE 2ENR ; 2.35 ; CO-CRYSTALS OF DEMETALLIZED CONCANAVALIN A WITH CADMIUM HAVING A CADMIUM ION BOUND IN BOTH THE S1 SITE AND THE S2 SITE 1ENR ; 1.83 ; CO-CRYSTALS OF DEMETALLIZED CONCANAVALIN A WITH ZINC AND CALCIUM HAVING A ZINC ION BOUND IN THE S1 SITE AND A CALCIUM ION BOUND IN THE S2 SITE 1ENQ ; 2.5 ; CO-CRYSTALS OF DEMETALLIZED CONCANAVALIN A WITH ZINC HAVING A ZINC ION BOUND IN THE S1 SITE 3CD6 ; 2.75 ; Co-cystal of large Ribosomal Subunit mutant G2616A with CC-Puromycin 2FMY ; 2.2 ; CO-dependent transcription factor CooA from Carboxydothermus hydrogenoformans (Imidazole-bound form) 1Y39 ; 2.8 ; Co-evolution of protein and RNA structures within a highly conserved ribosomal domain 2L5G ; ; Co-ordinates and 1H, 13C and 15N chemical shift assignments for the complex of GPS2 53-90 and SMRT 167-207 2Y8T ; 1.95 ; CO-STRUCTURE OF AMA1 WITH A SURFACE EXPOSED REGION OF RON2 FROM TOXOPLASMA GONDII 2Y8S ; 2.55 ; CO-STRUCTURE OF AN AMA1 MUTANT (Y230A) WITH A SURFACE EXPOSED REGION OF RON2 FROM TOXOPLASMA GONDII 3TT0 ; 2.8 ; Co-structure of Fibroblast Growth Factor Receptor 1 kinase domain with 3-(2,6-dichloro-3,5-dimethoxy-phenyl)-1-{6-[4-(4-ethyl-piperazin-1-yl)-phenylamino]-pyrimidin-4-yl}-1-methyl-urea (BGJ398) 1X0X ; 2.75 ; Co-Structure of Homo Sapiens Glycerol-3-Phosphate Dehydrogenase 1 complex with NAD 2WOR ; 1.7 ; CO-STRUCTURE OF S100A7 WITH 1,8 ANS 4HT5 ; 2.51 ; CO2 concentrating mechanism protein P, CcmP form 1 4HT7 ; 3.301 ; CO2 concentrating mechanism protein P, CcmP form 2 3IUH ; 2 ; Co2+-bound form of Pseudomonas stutzeri L-rhamnose isomerase 1JBU ; 2 ; Coagulation Factor VII Zymogen (EGF2/Protease) in Complex with Inhibitory Exosite Peptide A-183 1FAC ; ; COAGULATION FACTOR VIII, NMR, 1 STRUCTURE 1FAX ; 3 ; COAGULATION FACTOR XA INHIBITOR COMPLEX 1FXY ; 2.15 ; COAGULATION FACTOR XA-TRYPSIN CHIMERA INHIBITED WITH D-PHE-PRO-ARG-CHLOROMETHYLKETONE 1MGX ; ; COAGULATION FACTOR, MG(II), NMR, 7 STRUCTURES (BACKBONE ATOMS ONLY) 1WHF ; ; COAGULATION FACTOR, NMR, 15 STRUCTURES 1WHE ; ; COAGULATION FACTOR, NMR, 20 STRUCTURES 1MOF ; 1.7 ; COAT PROTEIN 1Q7Q ; 3.1 ; Cobalamin-dependent methionine synthase (1-566) from T. maritima (Oxidized, Orthorhombic) 1Q7Z ; 1.7 ; Cobalamin-dependent methionine synthase (1-566) from Thermotoga maritima (Cd2+ complex) 1Q85 ; 2 ; Cobalamin-dependent methionine synthase (1-566) from Thermotoga maritima (Cd2+ complex, Se-Met) 1Q8J ; 1.9 ; Cobalamin-dependent methionine synthase (1-566) from Thermotoga maritima (Cd2+, Hcy, methyltetrahydrofolate complex) 1Q8A ; 1.7 ; Cobalamin-dependent methionine synthase (1-566) from Thermotoga maritima (Cd2+:L-Hcy complex, Se-Met) 3BOL ; 1.85 ; Cobalamin-dependent methionine synthase (1-566) from Thermotoga maritima complexed with Zn2+ 3BOF ; 1.7 ; Cobalamin-dependent methionine synthase (1-566) from Thermotoga maritima complexed with Zn2+ and Homocysteine 1Q7M ; 2.1 ; Cobalamin-dependent methionine synthase (MetH) from Thermotoga maritima (Oxidized, Monoclinic) 3TA5 ; 1.52 ; Cobalt bound structure of an archaeal member of the LigD 3'-phosphoesterase DNA repair enzyme family 2XVY ; 1.7 ; COBALT CHELATASE CBIK (PERIPLASMATIC) FROM DESULVOBRIO VULGARIS HILDENBOROUGH (CO-CRYSTALLISED WITH COBALT AND SHC) 2XVZ ; 2.4 ; COBALT CHELATASE CBIK (PERIPLASMATIC) FROM DESULVOBRIO VULGARIS HILDENBOROUGH (CO-CRYSTALLIZED WITH COBALT) 2XVX ; 1.9 ; COBALT CHELATASE CBIK (PERIPLASMATIC) FROM DESULVOBRIO VULGARIS HILDENBOROUGH (NATIVE) 1BSJ ; 3 ; COBALT DEFORMYLASE INHIBITOR COMPLEX FROM E.COLI 1XAM ; 1.86 ; Cobalt hexammine induced tautameric shift in Z-DNA: structure of d(CGCGCA).d(TGCGCG) in two crystal forms. 1XA2 ; 1.71 ; Cobalt hexammine induced tautomeric shift in Z-DNA: the structure of d(CGCGCA).d(TGCGCG) in two crystal forms 2O5S ; 1.6 ; Cobalt horse heart myoglobin, nitrite modified 2O5T ; 1.6 ; Cobalt horse heart myoglobin, oxidized 1YOG ; 1.65 ; COBALT MYOGLOBIN (DEOXY) 1YOH ; 1.65 ; COBALT MYOGLOBIN (MET) 1YOI ; 1.65 ; COBALT MYOGLOBIN (OXY) 1QQ0 ; 1.76 ; COBALT SUBSTITUTED CARBONIC ANHYDRASE FROM METHANOSARCINA THERMOPHILA 1H0N ; 2.4 ; COBALT SUBSTITUTION OF MOUSE R2 RIBONUCLEOTIDE REDUCTASE TO MODEL THE REACTIVE DIFERROUS STATE 1H0O ; 2.2 ; COBALT SUBSTITUTION OF MOUSE R2 RIBONUCLEOTIDE REDUCTASE TO MODEL THE REACTIVE DIFERROUS STATE 3MF3 ; 2.5 ; Cobalt(II)-Substituted Haemophilus influenzae B-Carbonic Anhydrase 1AO2 ; ; cobalt(III)-deglycopepleomycin determined by NMR studies 1AO4 ; ; COBALT(III)-PEPLOMYCIN COMPLEX DETERMINED BY NMR STUDIES 3I11 ; 1.45 ; Cobalt-substituted metallo-beta-lactamase from Bacillus cereus 3I15 ; 1.55 ; Cobalt-substituted metallo-beta-lactamase from Bacillus cereus: residue Cys168 fully oxidized 3I14 ; 1.55 ; Cobalt-substituted metallo-beta-lactamase from Bacillus cereus: residue Cys168 partially oxidized 1R0H ; 1.7 ; cobalt-substituted rubredoxin 1PJV ; ; Cobatoxin 1 from Centruroides noxius Scorpion venom: Chemical Synthesis, 3-D Structure in Solution, Pharmacology and Docking on K+ channels 4FDV ; 1.68 ; CobH from Rhodobacter capsulatus (SB1003) in complex with HBA 3CB0 ; 1.6 ; CobR 4EC7 ; 2.6 ; Cobra NGF in complex with lipid 3HRZ ; 2.2 ; Cobra Venom Factor (CVF) in complex with human factor B 3HS0 ; 3 ; Cobra Venom Factor (CVF) in complex with human factor B 1HY9 ; ; COCAINE AND AMPHETAMINE REGULATED TRANSCRIPT 3I2G ; 2.5 ; Cocaine Esterase with mutation G173Q, bound to DTT adduct 3I2H ; 1.65 ; Cocaine Esterase with mutation L169K, bound to DTT adduct 3I2I ; 2.14 ; Cocaine Esterase with mutation T172R, bound to DTT adduct 3PUI ; 1.53 ; Cocaine Esterase with mutations G4C, S10C 3I2F ; 2.5 ; Cocaine Esterase with mutations T172R / G173Q, bound to DTT adduct 3I2K ; 1.51 ; Cocaine Esterase, wild type, bound to a DTT adduct 3I2J ; 2.01 ; Cocaine Esterase, wild type, without a ligand 3PUH ; 2.3 ; Cocaine Esterase, wild-type biologically active dimer 1NJ9 ; 2.35 ; Cocaine hydrolytic antibody 15A10 3UCJ ; 1.85 ; Coccomyxa beta-carbonic anhydrase in complex with acetazolamide 3UCN ; 2.25 ; Coccomyxa beta-carbonic anhydrase in complex with azide 3UCO ; 2.5 ; Coccomyxa beta-carbonic anhydrase in complex with iodide 3UCK ; 2.5 ; Coccomyxa beta-carbonic anhydrase in complex with phosphate 3UCM ; 2.513 ; Coccomyxa beta-carbonic anhydrase in complex with thiocyanate 3FU2 ; 2.85 ; Cocrystal structure of a class-I preQ1 riboswitch 3K1V ; 2.2 ; Cocrystal structure of a mutant class-I preQ1 riboswitch 2RKJ ; 4.5 ; Cocrystal structure of a tyrosyl-tRNA synthetase splicing factor with a group I intron RNA 2DEU ; 3.4 ; Cocrystal structure of an RNA sulfuration enzyme MnmA and tRNA-Glu in the adenylated intermediate state 2DER ; 3.1 ; Cocrystal structure of an RNA sulfuration enzyme MnmA and tRNA-Glu in the initial tRNA binding state 2DET ; 3.4 ; Cocrystal structure of an RNA sulfuration enzyme MnmA and tRNA-Glu in the pre-reaction state 3EYZ ; 2.1 ; Cocrystal structure of Bacillus fragment DNA polymerase I with duplex DNA (open form) 3EZ5 ; 1.9 ; Cocrystal structure of Bacillus fragment DNA polymerase I with duplex DNA , dCTP, and zinc (closed form). 1BKM ; 2 ; COCRYSTAL STRUCTURE OF D-AMINO ACID SUBSTITUTED PHOSPHOPEPTIDE COMPLEX 1EJ4 ; 2.25 ; COCRYSTAL STRUCTURE OF EIF4E/4E-BP1 PEPTIDE 4H1D ; 2.8975 ; Cocrystal structure of GlpG and DFP 3RU0 ; 1.849 ; Cocrystal structure of human SMYD3 with inhibitor Sinefungin bound 4J36 ; 2.13 ; Cocrystal Structure of kynurenine 3-monooxygenase in complex with UPF 648 inhibitor(KMO-394UPF) 3GZ8 ; 2.43 ; Cocrystal structure of NUDIX domain of Shewanella oneidensis NrtR complexed with ADP ribose 3R9V ; 1.9 ; Cocrystal Structure of Proteolytically Truncated Form of IpaD from Shigella flexneri Bound to Deoxycholate 1DP7 ; 1.5 ; COCRYSTAL STRUCTURE OF RFX-DBD IN COMPLEX WITH ITS COGNATE X-BOX BINDING SITE 1F2I ; 2.35 ; COCRYSTAL STRUCTURE OF SELECTED ZINC FINGER DIMER BOUND TO DNA 1RP3 ; 2.3 ; Cocrystal structure of the flagellar sigma/anti-sigma complex, Sigma-28/FlgM 1EJ1 ; 2.2 ; COCRYSTAL STRUCTURE OF THE MESSENGER RNA 5' CAP-BINDING PROTEIN (EIF4E) BOUND TO 7-METHYL-GDP 1L8B ; 1.8 ; Cocrystal Structure of the Messenger RNA 5' Cap-binding Protein (eIF4E) bound to 7-methylGpppG 3QQU ; 2.9 ; Cocrystal structure of unphosphorylated igf with pyrimidine 8 1SKJ ; 2 ; COCRYSTAL STRUCTURE OF UREA-SUBSTITUTED PHOSPHOPEPTIDE COMPLEX 1QV9 ; 1.54 ; Coenzyme F420-dependent methylenetetrahydromethanopterin dehydrogenase (Mtd) from Methanopyrus kandleri: A methanogenic enzyme with an unusual quarternary structure 2GD1 ; 2.5 ; COENZYME-INDUCED CONFORMATIONAL CHANGES IN GLYCERALDEHYDE-3-PHOSPHATE DEHYDROGENASE FROM BACILLUS STEAROTHERMOPHILLUS 2QOJ ; 2.4 ; Coevolution of a homing endonuclease and its host target sequence 2G5G ; 1.9 ; Cofacial heme binding to ChaN of Campylobacter jejuni 1AL3 ; 1.8 ; COFACTOR BINDING FRAGMENT OF CYSB FROM KLEBSIELLA AEROGENES 1KLI ; 1.69 ; Cofactor-and substrate-assisted activation of factor VIIa 2FL5 ; 3 ; Cofactor-containing antibodies: Crystal structure of the original yellow antibody 3IDD ; 2.8 ; Cofactor-Independent Phosphoglycerate Mutase from Thermoplasma acidophilum DSM 1728 3KD8 ; 2.6 ; Cofactor-Independent Phosphoglycerate mutase from Thermoplasma Acidophilum DSM 1728 1HQZ ; 2.1 ; Cofilin homology domain of a yeast actin-binding protein ABP1P 2W1N ; 1.8 ; COHESIN AND FIBRONECTIN TYPE-III DOUBLE MODULE CONSTRUCT FROM THE CLOSTRIDIUM PERFRINGENS GLYCOSIDE HYDROLASE GH84C 2VO8 ; 1.7 ; COHESIN MODULE FROM CLOSTRIDIUM PERFRINGENS ATCC13124 FAMILY 33 GLYCOSIDE HYDROLASE. 1G1K ; 2 ; COHESIN MODULE FROM THE CELLULOSOME OF CLOSTRIDIUM CELLULOLYTICUM 1ANU ; 2.15 ; COHESIN-2 DOMAIN OF THE CELLULOSOME FROM CLOSTRIDIUM THERMOCELLUM 4IU3 ; 1.97 ; Cohesin-dockerin -X domain complex from Ruminococcus flavefacience 4IU2 ; 2.001 ; Cohesin-dockerin -X domain complex from Ruminococcus flavefacience 1OHZ ; 2.2 ; COHESIN-DOCKERIN COMPLEX FROM THE CELLULOSOME OF CLOSTRIDIUM THERMOCELLUM 1IJ0 ; 1.86 ; Coiled Coil Trimer GCN4-pVLS Ser at Buried D Position 1D7M ; 2.7 ; COILED-COIL DIMERIZATION DOMAIN FROM CORTEXILLIN I 1WT6 ; 1.6 ; Coiled-Coil domain of DMPK 3IV1 ; 2.5 ; Coiled-coil domain of tumor susceptibility gene 101 3QFL ; 1.997 ; Coiled-Coil Domain-Dependent Homodimerization of Intracellular MLA Immune Receptors Defines a Minimal Functional Module for Triggering Cell Death 3TE3 ; 2.694 ; Coiled-coil oligomerization domain of the polycystin transient receptor potential channel PKD2L1 2V71 ; 2.24 ; COILED-COIL REGION OF NUDEL 1UIX ; 1.8 ; Coiled-coil structure of the RhoA-binding domain in Rho-kinase 1P9I ; 1.17 ; Coiled-coil X-ray structure at 1.17 A resolution 1A59 ; 2.09 ; COLD-ACTIVE CITRATE SYNTHASE 2TBS ; 1.8 ; COLD-ADAPTION OF ENZYMES: STRUCTURAL COMPARISON BETWEEN SALMON AND BOVINE TRYPSINS 1AYI ; 2 ; COLICIN E7 IMMUNITY PROTEIN IM7 1GXH ; ; COLICIN E8 DNASE IMMUNITY PROTEIN: IM8 1IMP ; ; COLICIN E9 IMMUNITY PROTEIN IM9, NMR, 21 STRUCTURES 1IMQ ; ; COLICIN E9 IMMUNITY PROTEIN IM9, NMR, MINIMIZED AVERAGE STRUCTURE 1CII ; 3 ; COLICIN IA 1A87 ; 3.1 ; COLICIN N 2X3H ; 1.6 ; COLIPHAGE K5A LYASE 1BKV ; 2 ; COLLAGEN 2F6A ; 3.29 ; Collagen Adhesin and Collagen Complex Structure 2CUO ; 1.33 ; Collagen model peptide (PRO-PRO-GLY)9 1AMX ; 2 ; COLLAGEN-BINDING DOMAIN FROM A STAPHYLOCOCCUS AUREUS ADHESIN 1PEX ; 2.7 ; COLLAGENASE-3 (MMP-13) C-TERMINAL HEMOPEXIN-LIKE DOMAIN 2D1N ; 2.37 ; Collagenase-3 (MMP-13) complexed to a hydroxamic acid inhibitor 830C ; 1.6 ; COLLAGENASE-3 (MMP-13) COMPLEXED TO A SULPHONE-BASED HYDROXAMIC ACID 1HXH ; 1.22 ; COMAMONAS TESTOSTERONI 3BETA/17BETA HYDROXYSTEROID DEHYDROGENASE 2BH8 ; 1.9 ; COMBINATORIAL PROTEIN 1B11 5RXN ; 1.2 ; COMBINED CRYSTALLOGRAPHIC REFINEMENT AND ENERGY MINIMIZATION OF RUBREDOXIN AT 1.2 ANGSTROM RESOLUTION 2KMS ; ; Combined high- and low-resolution techniques reveal compact structure in central portion of factor H despite long inter-modular linkers 1F6H ; ; COMBINED RIETVELD AND STEREOCHEMICAL RESTRAINT REFINEMENT OF A PROTEIN 3SCZ ; 1.95 ; Combining crystallographic, thermodynamic, and molecular dynamics studies of Mycobacterium tuberculosis purine nucleoside phosphorylase 2WGR ; 1.7 ; COMBINING CRYSTALLOGRAPHY AND MOLECULAR DYNAMICS: THE CASE OF SCHISTOSOMA MANSONI PHOSPHOLIPID GLUTATHIONE PEROXIDASE 1K1T ; 1.2 ; Combining Mutations in HIV-1 Protease to Understand Mechanisms of Resistance 1K1U ; 1.55 ; Combining Mutations in HIV-1 Protease to Understand Mechanisms of Resistance 1K2B ; 1.7 ; Combining Mutations in HIV-1 Protease to Understand Mechanisms of Resistance 1K2C ; 2.2 ; Combining Mutations in HIV-1 Protease to Understand Mechanisms of Resistance 1UZ4 ; 1.71 ; COMMON INHIBITION OF BETA-GLUCOSIDASE AND BETA-MANNOSIDASE BY ISOFAGOMINE LACTAM REFLECTS DIFFERENT CONFORMATIONAL INTINERARIES FOR GLUCOSIDE AND MANNOSIDE HYDROLYSIS 1HIH ; 2.2 ; COMPARATIVE ANALYSIS OF THE X-RAY STRUCTURES OF HIV-1 AND HIV-2 PROTEASES IN COMPLEX WITH CGP 53820, A NOVEL PSEUDOSYMMETRIC INHIBITOR 1HII ; 2.3 ; COMPARATIVE ANALYSIS OF THE X-RAY STRUCTURES OF HIV-1 AND HIV-2 PROTEASES IN COMPLEX WITH CGP 53820, A NOVEL PSEUDOSYMMETRIC INHIBITOR 1SJI ; 2.4 ; Comparing skeletal and cardiac calsequestrin structures and their calcium binding: a proposed mechanism for coupled calcium binding and protein polymerization 1SGU ; 1.9 ; Comparing the Accumulation of Active Site and Non-active Site Mutations in the HIV-1 Protease 1SH9 ; 2.5 ; Comparing the Accumulation of Active Site and Non-active Site Mutations in the HIV-1 Protease 1NI6 ; 2.1 ; Comparisions of the Heme-Free and-Bound Crystal Structures of Human Heme Oxygenase-1 2PAS ; ; COMPARISON BETWEEN THE CRYSTAL AND THE SOLUTION STRUCTURES OF THE EF HAND PARVALBUMIN 3PAT ; ; COMPARISON BETWEEN THE CRYSTAL AND THE SOLUTION STRUCTURES OF THE EF HAND PARVALBUMIN 1PVA ; 1.65 ; COMPARISON BETWEEN THE CRYSTAL AND THE SOLUTION STRUCTURES OF THE EF HAND PARVALBUMIN (ALPHA COMPONENT FROM PIKE MUSCLE) 3LLN ; 3 ; Comparison between the orthorhombic an tetragonal form of the heptamer sequence d(GCG(xT)GCG)/d(CGCACGC). 1XIA ; 2.3 ; COMPARISON OF BACKBONE STRUCTURES OF GLUCOSE ISOMERASE FROM STREPTOMYCES AND ARTHROBACTER 1P1X ; 0.99 ; Comparison of class I aldolase binding site architecture based on the crystal structure of 2-deoxyribose-5-phosphate aldolase determined at 0.99 Angstrom resolution 1WTL ; 1.9 ; COMPARISON OF CRYSTAL STRUCTURES OF TWO HOMOLOGOUS PROTEINS: STRUCTURAL ORIGIN OF ALTERED DOMAIN INTERACTIONS IN IMMUNOGLOBULIN LIGHT CHAIN DIMERS 1OA2 ; 1.5 ; COMPARISON OF FAMILY 12 GLYCOSIDE HYDROLASES AND RECRUITED SUBSTITUTIONS IMPORTANT FOR THERMAL STABILITY 1OA3 ; 1.7 ; COMPARISON OF FAMILY 12 GLYCOSIDE HYDROLASES AND RECRUITED SUBSTITUTIONS IMPORTANT FOR THERMAL STABILITY 1OA4 ; 1.5 ; COMPARISON OF FAMILY 12 GLYCOSIDE HYDROLASES AND RECRUITED SUBSTITUTIONS IMPORTANT FOR THERMAL STABILITY 3LYT ; 1.9 ; COMPARISON OF RADIATION-INDUCED DECAY AND STRUCTURE REFINEMENT FROM X-RAY DATA COLLECTED FROM LYSOZYME CRYSTALS AT LOW AND AMBIENT TEMPERATURES 4LYT ; 1.9 ; COMPARISON OF RADIATION-INDUCED DECAY AND STRUCTURE REFINEMENT FROM X-RAY DATA COLLECTED FROM LYSOZYME CRYSTALS AT LOW AND AMBIENT TEMPERATURES 5LYT ; 1.9 ; COMPARISON OF RADIATION-INDUCED DECAY AND STRUCTURE REFINEMENT FROM X-RAY DATA COLLECTED FROM LYSOZYME CRYSTALS AT LOW AND AMBIENT TEMPERATURES 6LYT ; 1.9 ; COMPARISON OF RADIATION-INDUCED DECAY AND STRUCTURE REFINEMENT FROM X-RAY DATA COLLECTED FROM LYSOZYME CRYSTALS AT LOW AND AMBIENT TEMPERATURES 1DAJ ; 2.3 ; COMPARISON OF TERNARY COMPLEXES OF PNEUMOCYSTIS CARINII AND WILD TYPE HUMAN DIHYDROFOLATE REDUCTASE WITH COENZYME NADPH AND A NOVEL CLASSICAL ANTITUMOR FURO[2,3D]PYRIMIDINE ANTIFOLATE 1HFP ; 2.1 ; COMPARISON OF TERNARY CRYSTAL COMPLEXES OF HUMAN DIHYDROFOLATE REDUCTASE WITH NADPH AND A CLASSICAL ANTITUMOR FUROPYRIMDINE 1HFQ ; 2.1 ; COMPARISON OF TERNARY CRYSTAL COMPLEXES OF HUMAN DIHYDROFOLATE REDUCTASE WITH NADPH AND A CLASSICAL ANTITUMOR FUROPYRIMDINE 1HFR ; 2.1 ; COMPARISON OF TERNARY CRYSTAL COMPLEXES OF HUMAN DIHYDROFOLATE REDUCTASE WITH NADPH AND A CLASSICAL ANTITUMOR FUROPYRIMDINE 2GPB ; 2.3 ; COMPARISON OF THE BINDING OF GLUCOSE AND GLUCOSE-1-PHOSPHATE DERIVATIVES TO T-STATE GLYCOGEN PHOSPHORYLASE B 3GPB ; 2.3 ; COMPARISON OF THE BINDING OF GLUCOSE AND GLUCOSE-1-PHOSPHATE DERIVATIVES TO T-STATE GLYCOGEN PHOSPHORYLASE B 4GPB ; 2.3 ; COMPARISON OF THE BINDING OF GLUCOSE AND GLUCOSE-1-PHOSPHATE DERIVATIVES TO T-STATE GLYCOGEN PHOSPHORYLASE B 5GPB ; 2.3 ; COMPARISON OF THE BINDING OF GLUCOSE AND GLUCOSE-1-PHOSPHATE DERIVATIVES TO T-STATE GLYCOGEN PHOSPHORYLASE B 3MU1 ; 1.74 ; Comparison of the character and the speed of X-ray-induced structural changes of porcine pancreatic elastase at two temperatures, 100 and 15K. The data set was collected from region A of the crystal. Fifth step of radiation damage 3MTY ; 1.101 ; Comparison of the character and the speed of X-ray-induced structural changes of porcine pancreatic elastase at two temperatures, 100 and 15K. The data set was collected from region A of the crystal. First step of radiation damage 3ODF ; 1.1 ; Comparison of the character and the speed of X-ray-induced structural changes of porcine pancreatic elastase at two temperatures, 100 and 15K. The data set was collected from region A of the crystal. Second step of radiation damage 3MU0 ; 1.401 ; Comparison of the character and the speed of X-ray-induced structural changes of porcine pancreatic elastase at two temperatures, 100 and 15K. The data set was collected from region A of the crystal. Third step of radiation damage 3MU8 ; 1.553 ; Comparison of the character and the speed of X-ray-induced structural changes of porcine pancreatic elastase at two temperatures, 100 and 15K. The data set was collected from region B of the crystal. Fifth step of radiation damage 3MU4 ; 1.101 ; Comparison of the character and the speed of X-ray-induced structural changes of porcine pancreatic elastase at two temperatures, 100 and 15K. The data set was collected from region B of the crystal. First step of radiation damage 3ODD ; 1.1 ; Comparison of the character and the speed of X-ray-induced structural changes of porcine pancreatic elastase at two temperatures, 100 and 15K. The data set was collected from region B of the crystal. Second step of radiation damage 3MU5 ; 1.404 ; Comparison of the character and the speed of X-ray-induced structural changes of porcine pancreatic elastase at two temperatures, 100 and 15K. The data set was collected from region B of the crystal. Third step of radiation damage 4LZM ; 1.7 ; COMPARISON OF THE CRYSTAL STRUCTURE OF BACTERIOPHAGE T4 LYSOZYME AT LOW, MEDIUM, AND HIGH IONIC STRENGTHS 5LZM ; 1.8 ; COMPARISON OF THE CRYSTAL STRUCTURE OF BACTERIOPHAGE T4 LYSOZYME AT LOW, MEDIUM, AND HIGH IONIC STRENGTHS 6LZM ; 1.8 ; COMPARISON OF THE CRYSTAL STRUCTURE OF BACTERIOPHAGE T4 LYSOZYME AT LOW, MEDIUM, AND HIGH IONIC STRENGTHS 7LZM ; 1.8 ; COMPARISON OF THE CRYSTAL STRUCTURE OF BACTERIOPHAGE T4 LYSOZYME AT LOW, MEDIUM, AND HIGH IONIC STRENGTHS 2FX2 ; 1.9 ; COMPARISON OF THE CRYSTAL STRUCTURES OF A FLAVODOXIN IN ITS THREE OXIDATION STATES AT CRYOGENIC TEMPERATURES 3FX2 ; 1.9 ; COMPARISON OF THE CRYSTAL STRUCTURES OF A FLAVODOXIN IN ITS THREE OXIDATION STATES AT CRYOGENIC TEMPERATURES 4FX2 ; 1.9 ; COMPARISON OF THE CRYSTAL STRUCTURES OF A FLAVODOXIN IN ITS THREE OXIDATION STATES AT CRYOGENIC TEMPERATURES 5FX2 ; 1.9 ; COMPARISON OF THE CRYSTAL STRUCTURES OF A FLAVODOXIN IN ITS THREE OXIDATION STATES AT CRYOGENIC TEMPERATURES 1MSD ; 3.2 ; COMPARISON OF THE CRYSTAL STRUCTURES OF GENETICALLY ENGINEERED HUMAN MANGANESE SUPEROXIDE DISMUTASE AND MANGANESE SUPEROXIDE DISMUTASE FROM THERMUS THERMOPHILUS. DIFFERENCES IN DIMER-DIMER INTERACTIONS. 4MT2 ; 2 ; COMPARISON OF THE NMR SOLUTION STRUCTURE AND THE X-RAY CRYSTAL STRUCTURE OF RAT METALLOTHIONEIN-2 1R8H ; 1.9 ; Comparison of the structure and DNA binding properties of the E2 proteins from an oncogenic and a non-oncogenic human papillomavirus 1TPE ; 2.1 ; COMPARISON OF THE STRUCTURES AND THE CRYSTAL CONTACTS OF TRYPANOSOMAL TRIOSEPHOSPHATE ISOMERASE IN FOUR DIFFERENT CRYSTAL FORMS 1TPF ; 1.8 ; COMPARISON OF THE STRUCTURES AND THE CRYSTAL CONTACTS OF TRYPANOSOMAL TRIOSEPHOSPHATE ISOMERASE IN FOUR DIFFERENT CRYSTAL FORMS 1LRP ; 3.2 ; COMPARISON OF THE STRUCTURES OF CRO AND LAMBDA REPRESSOR PROTEINS FROM BACTERIOPHAGE LAMBDA 2HPE ; 2 ; COMPARISON OF THE STRUCTURES OF HIV-2 PROTEASE COMPLEXES IN THREE CRYSTAL SPACE GROUPS WITH AN HIV-1 PROTEASE COMPLEX STRUCTURE 2HPF ; 3 ; COMPARISON OF THE STRUCTURES OF HIV-2 PROTEASE COMPLEXES IN THREE CRYSTAL SPACE GROUPS WITH AN HIV-1 PROTEASE COMPLEX STRUCTURE 7CPA ; 2 ; COMPARISON OF THE STRUCTURES OF THREE CARBOXYPEPTIDASE A-PHOSPHONATE COMPLEXES DETERMINED BY X-RAY CRYSTALLOGRAPHY 8CPA ; 2 ; COMPARISON OF THE STRUCTURES OF THREE CARBOXYPEPTIDASE A-PHOSPHONATE COMPLEXES DETERMINED BY X-RAY CRYSTALLOGRAPHY 1GAD ; 1.8 ; COMPARISON OF THE STRUCTURES OF WILD TYPE AND A N313T MUTANT OF ESCHERICHIA COLI GLYCERALDEHYDE 3-PHOSPHATE DEHYDROGENASES: IMPLICATION FOR NAD BINDING AND COOPERATIVITY 1GAE ; 2.17 ; COMPARISON OF THE STRUCTURES OF WILD TYPE AND A N313T MUTANT OF ESCHERICHIA COLI GLYCERALDEHYDE 3-PHOSPHATE DEHYDROGENASES: IMPLICATION FOR NAD BINDING AND COOPERATIVITY 1B2W ; 2.9 ; COMPARISON OF THE THREE-DIMENSIONAL STRUCTURES OF A HUMANIZED AND A CHIMERIC FAB OF AN ANTI-GAMMA-INTERFERON ANTIBODY 1B4J ; 2.9 ; COMPARISON OF THE THREE-DIMENSIONAL STRUCTURES OF A HUMANIZED AND A CHIMERIC FAB OF AN ANTI-GAMMA-INTERFERON ANTIBODY 5RSA ; 2 ; COMPARISON OF TWO INDEPENDENTLY REFINED MODELS OF RIBONUCLEASE-A 1CZH ; 1.86 ; COMPARISONS OF WILD TYPE AND MUTANT FLAVODOXINS FROM ANACYSTIS NIDULANS. STRUCTURAL DETERMINANTS OF THE REDOX POTENTIALS. 1CZK ; 1.9 ; COMPARISONS OF WILD TYPE AND MUTANT FLAVODOXINS FROM ANACYSTIS NIDULANS. STRUCTURAL DETERMINANTS OF THE REDOX POTENTIALS. 1CZL ; 1.8 ; COMPARISONS OF WILD TYPE AND MUTANT FLAVODOXINS FROM ANACYSTIS NIDULANS. STRUCTURAL DETERMINANTS OF THE REDOX POTENTIALS. 1CZO ; 1.85 ; COMPARISONS OF WILD TYPE AND MUTANT FLAVODOXINS FROM ANACYSTIS NIDULANS. STRUCTURAL DETERMINANTS OF THE REDOX POTENTIALS. 1CZR ; 1.9 ; COMPARISONS OF WILD TYPE AND MUTANT FLAVODOXINS FROM ANACYSTIS NIDULANS. STRUCTURAL DETERMINANTS OF THE REDOX POTENTIALS. 1D04 ; 1.85 ; COMPARISONS OF WILD TYPE AND MUTANT FLAVODOXINS FROM ANACYSTIS NIDULANS. STRUCTURAL DETERMINANTS OF THE REDOX POTENTIALS. 3V2R ; 2.75 ; COMPcc in complex with fatty acids 3V2N ; 1.8 ; COMPcc in complex with fatty acids 3V2P ; 1.873 ; COMPcc in complex with fatty acids 3V2Q ; 2.2 ; COMPcc in complex with fatty acids 1SS7 ; ; Compensating bends in a 16 base-pair DNA oligomer containing a T3A3 segment 1SSV ; ; Compensating bends in a 16 base-pair DNA oligomer containing a T3A3 segment 1CNB ; 2.35 ; COMPENSATORY PLASTIC EFFECTS IN THE REDESIGN OF PROTEIN-ZINC BINDING SITES 1CNC ; 2.2 ; COMPENSATORY PLASTIC EFFECTS IN THE REDESIGN OF PROTEIN-ZINC BINDING SITES 3TDA ; 2.67 ; Competitive replacement of thioridazine by prinomastat in crystals of cytochrome P450 2D6 2WII ; 2.7 ; COMPLEMENT C3B IN COMPLEX WITH FACTOR H DOMAINS 1-4 4FXG ; 3.75 ; Complement C4 in complex with MASP-2 2I6Q ; 2.1 ; Complement component C2a 2I6S ; 2.7 ; Complement component C2a 2ODP ; 1.9 ; Complement component C2a, the catalytic fragment of C3- and C5-convertase of human complement 2ODQ ; 2.3 ; Complement component C2a, the catalytic fragment of C3- and C5-convertase of human complement 3RJ3 ; 2.35 ; Complement components factor H CCP19-20 (S1191L mutant) and C3D in complex 3OXU ; 2.1 ; Complement components factor H CCP19-20 and C3d in complex 2ATY ; ; Complement receptor chimaeric conjugate CR2-Ig 2GSX ; ; Complement Receptor Type 2 1NT9 ; 4.2 ; Complete 12-subunit RNA polymerase II 1WCM ; 3.8 ; COMPLETE 12-SUBUNIT RNA POLYMERASE II AT 3.8 ANG 2HYN ; ; Complete ensemble of NMR structures of unphosphorylated human phospholamban pentamer 2WNG ; 2.49 ; COMPLETE EXTRACELLULAR STRUCTURE OF HUMAN SIGNAL REGULATORY PROTEIN (SIRP) ALPHA 2WGM ; 2.35 ; Complete ion-coordination structure in the rotor ring of Na-dependent F-ATP synthase 2KTX ; ; COMPLETE KALIOTOXIN FROM ANDROCTONUS MAURETANICUS MAURETANICUS, NMR, 18 STRUCTURES 2JQ4 ; ; Complete resonance assignments and solution structure calculation of ATC2521 (NESG ID: AtT6) from Agrobacterium tumefaciens 1Y1W ; 4 ; Complete RNA Polymerase II elongation complex 3HOU ; 3.2 ; Complete RNA polymerase II elongation complex I with a T-U mismatch 3HOV ; 3.5 ; Complete RNA polymerase II elongation complex II 3HOW ; 3.6 ; Complete RNA polymerase II elongation complex III with a T-U mismatch and a frayed RNA 3'-uridine 3HOZ ; 3.65 ; Complete RNA polymerase II elongation complex IV with a T-U mismatch and a frayed RNA 3'-guanine 3HOX ; 3.65 ; Complete RNA polymerase II elongation complex V 3HOY ; 3.4 ; Complete RNA polymerase II elongation complex VI 1Y77 ; 4.5 ; Complete RNA Polymerase II elongation complex with substrate analogue GMPCPP 2B63 ; 3.8 ; Complete RNA Polymerase II-RNA inhibitor complex 3QE5 ; 2.5 ; Complete structure of Streptococcus mutans Antigen I/II carboxy-terminus 2YCL ; 1.95 ; complete structure of the corrinoid,iron-sulfur protein including the N-terminal domain with a 4Fe-4S cluster 1JRH ; 2.8 ; COMPLEX (ANTIBODY/ANTIGEN) 1XJ7 ; 2.7 ; Complex Androgen Receptor LBD and RAC3 peptide 3QDQ ; 2.6 ; Complex between 4-hydroxybutyrate CoA-transferase from Clostridium aminobutyricum and CoA 1CXL ; 1.81 ; COMPLEX BETWEEN A COVALENT INTERMEDIATE AND BACILLUS CIRCULANS STRAIN 251 CGTASE E257Q 1CXK ; 2.09 ; COMPLEX BETWEEN A MALTONONAOSE SUBSTRATE AND BACILLUS CIRCULANS STRAIN 251 CGTASE E257Q/D229N 2CH4 ; 3.5 ; COMPLEX BETWEEN BACTERIAL CHEMOTAXIS HISTIDINE KINASE CHEA DOMAINS P4 AND P5 AND RECEPTOR-ADAPTOR PROTEIN CHEW 1OSG ; 3 ; Complex between BAFF and a BR3 derived peptide presented in a beta-hairpin scaffold 2L5E ; ; Complex between BD1 of Brd3 and GATA-1 C-tail 1ES7 ; 2.9 ; COMPLEX BETWEEN BMP-2 AND TWO BMP RECEPTOR IA ECTODOMAINS 2WNV ; 1.25 ; COMPLEX BETWEEN C1Q GLOBULAR HEADS AND DEOXYRIBOSE 2WNU ; 2.3 ; COMPLEX BETWEEN C1Q GLOBULAR HEADS AND HEPARAN SULFATE 1AM4 ; 2.7 ; COMPLEX BETWEEN CDC42HS.GMPPNP AND P50 RHOGAP (H. SAPIENS) 1VOM ; 1.9 ; COMPLEX BETWEEN DICTYOSTELIUM MYOSIN AND MGADP AND VANADATE AT 1.9A RESOLUTION 1TEZ ; 1.8 ; COMPLEX BETWEEN DNA AND THE DNA PHOTOLYASE FROM ANACYSTIS NIDULANS 1F3R ; ; COMPLEX BETWEEN FV ANTIBODY FRAGMENT AND AN ANALOGUE OF THE MAIN IMMUNOGENIC REGION OF THE ACETYLCHOLINE RECEPTOR 1OQO ; 2.3 ; Complex between G0 version of an Fc bound to a minimized version of Protein A called Mini-Z 2ET3 ; 2.8 ; Complex Between Gentamicin C1A and the 16S-RRNA A-Site 3UIP ; 2.293 ; Complex between human RanGAP1-SUMO1, UBC9 and the IR1 domain from RanBP2 containing IR2 Motif II 3UIN ; 2.597 ; Complex between human RanGAP1-SUMO2, UBC9 and the IR1 domain from RanBP2 3UIO ; 2.602 ; Complex between human RanGAP1-SUMO2, UBC9 and the IR1 domain from RanBP2 containing IR2 Motif II 1BD2 ; 2.5 ; COMPLEX BETWEEN HUMAN T-CELL RECEPTOR B7, VIRAL PEPTIDE (TAX) AND MHC CLASS I MOLECULE HLA-A 0201 1AO7 ; 2.6 ; COMPLEX BETWEEN HUMAN T-CELL RECEPTOR, VIRAL PEPTIDE (TAX), AND HLA-A 0201 2ESI ; 3 ; Complex between Kanamycin A and the 16S-Rrna A Site. 1ESV ; 2 ; COMPLEX BETWEEN LATRUNCULIN A:RABBIT MUSCLE ALPHA ACTIN:HUMAN GELSOLIN DOMAIN 1 2ESJ ; 2.2 ; Complex between Lividomycin A and the 16S-Rrna A Site 1DMY ; 2.45 ; COMPLEX BETWEEN MURINE MITOCHONDRIAL CARBONIC ANYHDRASE V AND THE TRANSITION STATE ANALOGUE ACETAZOLAMIDE 1NMC ; 2.5 ; COMPLEX BETWEEN NC10 ANTI-INFLUENZA VIRUS NEURAMINIDASE SINGLE CHAIN ANTIBODY WITH A 15 RESIDUE LINKER AND INFLUENZA VIRUS NEURAMINIDASE 1A14 ; 2.5 ; COMPLEX BETWEEN NC10 ANTI-INFLUENZA VIRUS NEURAMINIDASE SINGLE CHAIN ANTIBODY WITH A 5 RESIDUE LINKER AND INFLUENZA VIRUS NEURAMINIDASE 2ET8 ; 2.5 ; Complex Between Neamine and the 16S-RRNA A-Site 2ET4 ; 2.4 ; Complex Between Neomycin B and the 16S-RRNA A-Site 1QO3 ; 2.3 ; Complex between NK cell receptor Ly49A and its MHC class I ligand H-2Dd 1AOI ; 2.8 ; COMPLEX BETWEEN NUCLEOSOME CORE PARTICLE (H3,H4,H2A,H2B) AND 146 BP LONG DNA FRAGMENT 1J7T ; 2.5 ; Complex between Paromomycin and the 16S-rRNA A-site at 2.5 A resolution 2BEE ; 2.6 ; Complex Between Paromomycin derivative JS4 and the 16S-Rrna A Site 2BE0 ; 2.63 ; Complex Between Paromomycin Derivative JS5-39 and the 16S-Rrna A-Site. 3C5W ; 2.8 ; Complex between PP2A-specific methylesterase PME-1 and PP2A core enzyme 1S70 ; 2.7 ; Complex between protein ser/thr phosphatase-1 (delta) and the myosin phosphatase targeting subunit 1 (MYPT1) 1EQY ; 2.3 ; COMPLEX BETWEEN RABBIT MUSCLE ALPHA-ACTIN: HUMAN GELSOLIN DOMAIN 1 1P8Z ; 2.6 ; Complex Between Rabbit Muscle alpha-Actin: Human Gelsolin Residues Val26-Glu156 2ET5 ; 2.2 ; Complex Between Ribostamycin and the 16S-RRNA A-Site 1RSU ; 1.7 ; COMPLEX BETWEEN STREPTAVIDIN AND THE STREP-TAG II PEPTIDE 1RST ; 1.7 ; COMPLEX BETWEEN STREPTAVIDIN AND THE STREP-TAG PEPTIDE 1OAI ; 1 ; COMPLEX BETWEEN TAP UBA DOMAIN AND FXFG NUCLEOPORIN PEPTIDE 3BX1 ; 1.85 ; Complex between the Barley alpha-Amylase/Subtilisin Inhibitor and the subtilisin Savinase 2F9Z ; 2.4 ; Complex between the chemotaxis deamidase CheD and the chemotaxis phosphatase CheC from Thermotoga maritima 1ELU ; 1.55 ; COMPLEX BETWEEN THE CYSTINE C-S LYASE C-DES AND ITS REACTION PRODUCT CYSTEINE PERSULFIDE. 1EBP ; 2.8 ; COMPLEX BETWEEN THE EXTRACELLULAR DOMAIN OF ERYTHROPOIETIN (EPO) RECEPTOR [EBP] AND AN AGONIST PEPTIDE [EMP1] 1EBA ; 2.7 ; COMPLEX BETWEEN THE EXTRACELLULAR DOMAIN OF ERYTHROPOIETIN (EPO) RECEPTOR [EBP] AND AN INACTIVE PEPTIDE [EMP33] CONTAINS 3,5-DIBROMOTYROSINE IN POSITION 4 (DENOTED DBY) 3TVL ; 2.3 ; Complex between the human thiamine triphosphatase and triphosphate 3DKO ; 2 ; Complex between the kinase domain of human ephrin type-a receptor 7 (epha7) and inhibitor alw-ii-49-7 1PJJ ; 1.9 ; Complex between the Lactococcus lactis Fpg and an abasic site containing DNA. 2IWG ; 2.35 ; COMPLEX BETWEEN THE PRYSPRY DOMAIN OF TRIM21 AND IGG FC 4EMJ ; 2.4 ; Complex between the reductase and ferredoxin components of toluene dioxygenase 2V9T ; 1.7 ; Complex between the second LRR domain of Slit2 and The first Ig domain from Robo1 3S9M ; 3.32 ; Complex between transferrin receptor 1 and transferrin with iron in the N-Lobe, cryocooled 1 3S9L ; 3.22 ; Complex between transferrin receptor 1 and transferrin with iron in the N-Lobe, cryocooled 2 3S9N ; 3.25 ; Complex between transferrin receptor 1 and transferrin with iron in the N-Lobe, room temperature 4AFI ; 2.8 ; Complex between Vamp7 longin domain and fragment of delta-adaptin from AP3 1VPP ; 1.9 ; COMPLEX BETWEEN VEGF AND A RECEPTOR BLOCKING PEPTIDE 1OXB ; 2.3 ; Complex between YPD1 and SLN1 response regulator domain in space group P2(1)2(1)2(1) 1OXK ; 2.1 ; Complex between YPD1 and SLN1 response regulator domain in space group P3(2) 3M94 ; 2.05 ; Complex crystal structure of Ascaris suum eIF4E-3 with m2,2,7G cap 3M93 ; 2.9 ; Complex crystal structure of Ascaris suum eIF4E-3 with m7G cap 1TXC ; 2.3 ; Complex crystal structure of SPE16 with ANS 1FSK ; 2.9 ; COMPLEX FORMATION BETWEEN A FAB FRAGMENT OF A MONOCLONAL IGG ANTIBODY AND THE MAJOR ALLERGEN FROM BIRCH POLLEN BET V 1 1BJR ; 2.44 ; COMPLEX FORMED BETWEEN PROTEOLYTICALLY GENERATED LACTOFERRIN FRAGMENT AND PROTEINASE K 1XCT ; 3.05 ; Complex HCV core-Fab 19D9D6-Protein L mutant (D55A, L57H, Y64W) in space group P21212 1XCQ ; 3.5 ; Complex HCV core-Fab 19D9D6-Protein L mutant (D55A,L57H,Y64W) in space group P21 1XF5 ; 2.6 ; Complex HCV core-Fab 19D9D6-Protein L mutant (H74C, Y64W)in space group P21212 2L0Y ; ; Complex hMia40-hCox17 2ACZ ; 3.1 ; Complex II (Succinate Dehydrogenase) From E. Coli with Atpenin A5 inhibitor co-crystallized at the ubiquinone binding site 1NEN ; 2.9 ; Complex II (Succinate Dehydrogenase) From E. Coli with Dinitrophenol-17 inhibitor co-crystallized at the ubiquinone binding site 1NEK ; 2.6 ; Complex II (Succinate Dehydrogenase) From E. Coli with ubiquinone bound 3MA2 ; 2.05 ; Complex membrane type-1 matrix metalloproteinase (MT1-MMP) with tissue inhibitor of metalloproteinase-1 (TIMP-1) 1JAQ ; 2.4 ; COMPLEX OF 1-HYDROXYLAMINE-2-ISOBUTYLMALONYL-ALA-GLY-NH2 WITH THE CATALYTIC DOMAIN OF MATRIX METALLO PROTEINASE-8 (MET80 FORM) 3UBW ; 1.9 ; Complex of 14-3-3 isoform epsilon, a Mlf1 phosphopeptide and a small fragment hit from a FBDD screen 1I76 ; 1.2 ; COMPLEX OF 2-(BIPHENYL-4-SULFONYL)-1,2,3,4-TETRAHYDRO-ISOQUINOLINE-3-CARBOXYLIC ACID (D-TIC DERIVATIVE) WITH T CATALITIC DOMAIN OF MATRIX METALLO PROTEINASE-8 (MET80 FORM) 2KMB ; 2 ; COMPLEX OF 3'-NEUAC-LEWIS-X WITH A SELECTIN-LIKE MUTANT OF MANNOSE-BINDING PROTEIN A 3KMB ; 1.95 ; COMPLEX OF 3'-SULFO-LEWIS-X WITH A SELECTIN-LIKE MUTANT OF MANNOSE-BINDING PROTEIN A 4DZU ; 2.1 ; Complex of 3-alpha bound to gp41-5 1JAO ; 2.4 ; COMPLEX OF 3-MERCAPTO-2-BENZYLPROPANOYL-ALA-GLY-NH2 WITH THE CATALYTIC DOMAIN OF MATRIX METALLO PROTEINASE-8 (MET80 FORM) 4KMB ; 2 ; COMPLEX OF 4'-SULFO-LEWIS-X WITH A SELECTIN-LIKE MUTANT OF MANNOSE-BINDING PROTEIN A 4DZV ; 2.1 ; Complex of 4-alpha/beta bound to gp41-5 3NK2 ; 2.65 ; Complex of 6-hydroxy-L-nicotine oxidase with dopamine 3NH3 ; 2.1 ; Complex of 6-hydroxy-L-nicotine oxidase with final ketone product formed during catalytic turnover 3NK0 ; 2.15 ; Complex of 6-hydroxy-L-nicotine oxidase with inhibitor bound at active site and turnover product at exit cavity 3NGC ; 2.25 ; Complex of 6-hydroxy-L-nicotine oxidase with intermediate methylmyosmine product formed during catalytic turnover 3NN0 ; 2.75 ; Complex of 6-hydroxy-L-nicotine oxidase with nicotinamide 3NHO ; 2.85 ; Complex of 6-hydroxy-L-nicotine oxidase with product bound at active site 3NK1 ; 2.2 ; Complex of 6-hydroxy-L-nicotine oxidase with serotonin 2DHN ; 2.2 ; COMPLEX OF 7,8-DIHYDRONEOPTERIN ALDOLASE FROM STAPHYLOCOCCUS AUREUS WITH 6-HYDROXYMETHYL-7,8-DIHYDROPTERIN AT 2.2 A RESOLUTION 1CXF ; 2.1 ; COMPLEX OF A (D229N/E257Q) DOUBLE MUTANT CGTASE FROM BACILLUS CIRCULANS STRAIN 251 WITH MALTOTETRAOSE AT 120 K AND PH 9.1 OBTAINED AFTER SOAKING THE CRYSTAL WITH ALPHA-CYCLODEXTRIN 2YEZ ; 2.9 ; COMPLEX OF A B21 CHICKEN MHC CLASS I MOLECULE AND A 10MER CHICKEN PEPTIDE 2YF5 ; 2.82 ; COMPLEX OF A B21 CHICKEN MHC CLASS I MOLECULE AND A 10MER CHICKEN PEPTIDE 2YF6 ; 2.8 ; COMPLEX OF A B21 CHICKEN MHC CLASS I MOLECULE AND A 10MER CHICKEN PEPTIDE 2YF1 ; 2.75 ; COMPLEX OF A B21 CHICKEN MHC CLASS I MOLECULE AND A 11MER CHICKEN PEPTIDE 2P45 ; 1.1 ; Complex of a camelid single-domain vhh antibody fragment with RNASE A at 1.1A resolution: SE5B-ORTHO-1 crystal form with five se-met sites (L4M, M34, M51, F68M, M83) in vhh scaffold. 2P49 ; 1.38 ; Complex of a camelid single-domain vhh antibody fragment with RNASE A at 1.4A resolution: native mono_1 crystal form 2P43 ; 1.65 ; Complex of a camelid single-domain vhh antibody fragment with RNASE A at 1.65A resolution: SE3-mono-1 crystal form with three se-met sites (M34, M51, M83) in vhh scaffold 2P42 ; 1.8 ; Complex of a camelid single-domain vhh antibody fragment with RNASE A at 1.8A resolution: SE3-mono-2 crystal form with three se-met sites (M34, M51, M83) in vhh scaffold 2P44 ; 1.8 ; Complex of a camelid single-domain vhh antibody fragment with RNASE A at 1.8A resolution: SE5A-mono-1 crystal form with five se-met sites (M34, M51, F68M, M83, L86M) in vhh scaffold 2P48 ; 2.3 ; Complex of a camelid single-domain vhh antibody fragment with RNASE A at 2.3A resolution: SE5B-tetra crystal form with five se-met sites (L4M, M34, M51, F68M, M83) in vhh scaffold. 2P46 ; 2.5 ; Complex of a camelid single-domain vhh antibody fragment with RNASE A at 2.5A resolution: se5b-ortho-2 crystal form with five se-met sites (L4M, M34, M51, F68M, M83) in vhh scaffold. 2P47 ; 2.5 ; Complex of a camelid single-domain vhh antibody fragment with RNASE A at 2.5A resolution: SE5B-TRI crystal form with five se-met sites (L4M, M34, M51, F68M, M83) in vhh scaffold. 3O3Z ; 2.6 ; Complex of a chimeric alpha/beta-peptide based on the gp41 CHR domain bound to a gp41 NHR domain peptide 3O40 ; 2.1 ; Complex of a chimeric alpha/beta-peptide based on the gp41 CHR domain bound to gp41-5 1H0G ; 2 ; Complex of a chitinase with the natural product cyclopentapeptide argadin from Clonostachys 1H0I ; 2 ; Complex of a chitinase with the natural product cyclopentapeptide argifin from Gliocladium 1DIT ; 2.3 ; COMPLEX OF A DIVALENT INHIBITOR WITH THROMBIN 1BZQ ; 2.8 ; COMPLEX OF A DROMEDARY SINGLE-DOMAIN VHH ANTIBODY FRAGMENT WITH RNASE A 3GXE ; 2.6 ; Complex of a Low Affinity Collagen Site with the Fibronectin 8-9FnI Domain Pair 1GZG ; 1.66 ; COMPLEX OF A MG2-DEPENDENT PORPHOBILINOGEN SYNTHASE FROM PSEUDOMONAS AERUGINOSA (MUTANT D139N) WITH 5-FLUOROLEVULINIC ACID 3HHW ; 2.7 ; Complex of a vesicular stomatitis virus empty capsid with the nucleocapsid-binding domain of the phosphoprotein 2DIJ ; 2.6 ; COMPLEX OF A Y195F MUTANT CGTASE FROM B. CIRCULANS STRAIN 251 COMPLEXED WITH A MALTONONAOSE INHIBITOR AT PH 9.8 OBTAINED AFTER SOAKING THE CRYSTAL WITH ACARBOSE AND MALTOHEXAOSE 1DJ6 ; 1 ; COMPLEX OF A Z-DNA HEXAMER, D(CG)3, WITH SYNTHETIC POLYAMINE AT ROOM TEMPERATURE 1H9A ; 2.16 ; COMPLEX OF ACTIVE MUTANT (Q365->C) OF GLUCOSE 6-PHOSPHATE DEHYDROGENASE FROM L. MESENTEROIDES WITH COENZYME NADP 1E77 ; 2.69 ; COMPLEX OF ACTIVE MUTANT (Q365->C) OF GLUCOSE 6-PHOSPHATE DEHYDROGENASE FROM LEUCONOSTOC MESENTEROIDES WITH SUBSTRATE 1H94 ; 2.5 ; COMPLEX OF ACTIVE MUTANT (S215->C) OF GLUCOSE 6-PHOSPHATE DEHYDROGENASE FROM L.MESENTEROIDES WITH COENZYME NAD 1DAN ; 2 ; Complex of active site inhibited human blood coagulation factor VIIA with human recombinant soluble tissue factor 2A2Q ; 1.8 ; Complex of Active-site Inhibited Human Coagulation Factor VIIa with Human Soluble Tissue Factor in the Presence of Ca2+, Mg2+, Na+, and Zn2+ 2PEV ; 0.9 ; Complex of Aldose Reductase with NADP+ and simaltaneously bound competetive inhibitors Fidarestat and IDD594. Concentration of Fidarestat in soaking solution exceeds concentration of IDD594. 2PF8 ; 0.85 ; Complex of Aldose Reductase with NADP+ and simaltaneously bound competetive inhibitors Fidarestat and IDD594. Concentration of Fidarestat in soaking solution is equal to concentration of IDD594. 2PFH ; 0.85 ; Complex of Aldose Reductase with NADP+ and simaltaneously bound competetive inhibitors Fidarestat and IDD594. Concentration of Fidarestat in soaking solution is less than concentration of IDD594. 1AGR ; 2.8 ; COMPLEX OF ALF4-ACTIVATED GI-ALPHA-1 WITH RGS4 1JL8 ; 3.2 ; Complex of alpha-amylase II (TVA II) from Thermoactinomyces vulgaris R-47 with beta-cyclodextrin based on a co-crystallization with methyl beta-cyclodextrin 1JIB ; 3.3 ; Complex of Alpha-amylase II (TVA II) from Thermoactinomyces vulgaris R-47 with Maltotetraose Based on a Crystal Soaked with Maltohexaose. 2VZU ; 2.1 ; COMPLEX OF AMYCOLATOPSIS ORIENTALIS EXO-CHITOSANASE CSXA D469A WITH PNP-BETA-D-GLUCOSAMINE 2VZT ; 2.2 ; COMPLEX OF AMYCOLATOPSIS ORIENTALIS EXO-CHITOSANASE CSXA E541A WITH PNP-BETA-D-GLUCOSAMINE 3O42 ; 3 ; Complex of an alpha/beta-peptide based on the gp41 CHR domain bound to gp41-5 3O43 ; 2.8 ; Complex of an alpha/beta-peptide based on the gp41 CHR domain bound to gp41-5 1XZ3 ; 1.75 ; Complex of apoferritin with isoflurane 3DOE ; 2.25 ; Complex of ARL2 and BART, Crystal Form 1 3DOF ; 3.3 ; Complex of ARL2 and BART, Crystal Form 2 1KSG ; 2.3 ; Complex of Arl2 and PDE delta, Crystal Form 1 1KSH ; 1.8 ; Complex of Arl2 and PDE delta, Crystal Form 2 (native) 1KSJ ; 2.6 ; Complex of Arl2 and PDE delta, Crystal Form 2 (SeMet) 1EAI ; 2.4 ; COMPLEX OF ASCARIS CHYMOTRPSIN/ELASTASE INHIBITOR WITH PORCINE ELASTASE 3G0I ; 2.1 ; Complex of Aspergillus niger epoxide hydrolase with valpromide (2-propylpentanamide) 4B0G ; 2.5 ; Complex of Aurora-A bound to an Imidazopyridine-based inhibitor 2BFY ; 1.8 ; COMPLEX OF AURORA-B WITH INCENP AND HESPERIDIN. 1YAK ; 2.5 ; Complex of Bacillus subtilis TenA with 4-amino-2-methyl-5-hydroxymethylpyrimidine 2ODG ; ; Complex of barrier-to-autointegration factor and LEM-domain of emerin 1MMB ; 2.1 ; COMPLEX OF BB94 WITH THE CATALYTIC DOMAIN OF MATRIX METALLOPROTEINASE-8 1G5J ; ; COMPLEX OF BCL-XL WITH PEPTIDE FROM BAD 1C9T ; 3.3 ; COMPLEX OF BDELLASTASIN WITH BOVINE TRYPSIN 1C9P ; 2.8 ; COMPLEX OF BDELLASTASIN WITH PORCINE TRYPSIN 1RTF ; 2.3 ; COMPLEX OF BENZAMIDINE WITH THE CATALYTIC DOMAIN OF HUMAN TWO CHAIN TISSUE PLASMINOGEN ACTIVATOR [(TC)-T-PA] 1UNN ; 1.9 ; COMPLEX OF BETA-CLAMP PROCESSIVITY FACTOR AND LITTLE FINGER DOMAIN OF POLIV 4A7Z ; 2.6 ; Complex of bifunctional aldos-2-ulose dehydratase with the reaction intermediate ascopyrone M 1PBO ; 2.2 ; COMPLEX OF BOVINE ODORANT BINDING PROTEIN (OBP) WITH A SELENIUM CONTAINING ODORANT 1GT1 ; 1.71 ; COMPLEX OF BOVINE ODORANT BINDING PROTEIN WITH AMINOANTHRACENE AND PYRAZINE 1GT3 ; 1.8 ; COMPLEX OF BOVINE ODORANT BINDING PROTEIN WITH DIHYDROMYRCENOL 1GT4 ; 2.1 ; COMPLEX OF BOVINE ODORANT BINDING PROTEIN WITH UNDECANAL 3AM9 ; 2.17 ; Complex of bovine xanthine dehydrogenase and trihydroxy FYX-051 2YGG ; 2.227 ; COMPLEX OF CAMBR AND CAM 1DQ9 ; 2.8 ; COMPLEX OF CATALYTIC PORTION OF HUMAN HMG-COA REDUCTASE WITH HMG-COA 1CXE ; 2.1 ; COMPLEX OF CGTASE WITH MALTOTETRAOSE AT ROOM TEMPERATURE AND PH 9.1 BASED ON DIFFRACTION DATA OF A CRYSTAL SOAKED WITH ALPHA-CYCLODEXTRIN 1CXH ; 2.41 ; COMPLEX OF CGTASE WITH MALTOTETRAOSE AT ROOM TEMPERATURE AND PH 9.6 BASED ON DIFFRACTION DATA OF A CRYSTAL SOAKED WITH MALTOHEPTAOSE 4GNT ; 2.41 ; Complex of ChREBP and 14-3-3beta 4ANM ; 1.7 ; Complex of CK2 with a CDC7 inhibitor 3ZRJ ; 1.94 ; Complex of ClpV N-domain with VipB peptide 1EM0 ; 0.9 ; COMPLEX OF D(CCTAGG) WITH TETRA-[N-METHYL-PYRIDYL] PORPHYRIN 1IOV ; 2.2 ; COMPLEX OF D-ALA:D-ALA LIGASE WITH ADP AND A PHOSPHORYL PHOSPHONATE 1K9I ; 2.5 ; Complex of DC-SIGN and GlcNAc2Man3 1K9J ; 1.9 ; Complex of DC-SIGNR and GlcNAc2Man3 3CIP ; 1.6 ; Complex of Dictyostelium Discoideum Actin with Gelsolin 3CHW ; 2.3 ; Complex of Dictyostelium discoideum Actin with Profilin and the Last Poly-Pro of Human VASP 1XDT ; 2.65 ; COMPLEX OF DIPHTHERIA TOXIN AND HEPARIN-BINDING EPIDERMAL GROWTH FACTOR 3NG7 ; 1.95 ; Complex of dithionite-reduced 6-hydroxy-L-nicotine oxidase with substrate bound at active site and inhibitor at exit cavity 1OOH ; 1.25 ; Complex of Drosophila odorant binding protein LUSH with butanol 1OOF ; 1.49 ; Complex of Drosophila odorant binding protein LUSH with ethanol 1OOG ; 1.45 ; Complex of Drosophila odorant binding protein LUSH with propanol 1KKF ; 2.6 ; Complex of E. coli Adenylosuccinate Synthetase with IMP, Hadacidin, Pyrophosphate, and Mg 1USQ ; 1.9 ; COMPLEX OF E. COLI DRAE ADHESIN WITH CHLORAMPHENICOL 5TMP ; 1.98 ; COMPLEX OF E. COLI THYMIDYLATE KINASE WITH THE BISUBSTRATE INHIBITOR AZTP5A 4TMK ; 1.98 ; COMPLEX OF E. COLI THYMIDYLATE KINASE WITH THE BISUBSTRATE INHIBITOR TP5A 1CY6 ; 2.5 ; COMPLEX OF E.COLI DNA TOPOISOMERASE I WITH 3' THYMIDINE MONOPHOSPHATE 1CY0 ; 2.45 ; COMPLEX OF E.COLI DNA TOPOISOMERASE I WITH 3'-5'-ADENOSINE DIPHOSPHATE 1CY7 ; 2.4 ; COMPLEX OF E.COLI DNA TOPOISOMERASE I WITH 5'-THYMIDINE MONOPHOSPHATE 1CY8 ; 2.45 ; COMPLEX OF E.COLI DNA TOPOISOMERASE I WITH 5'-THYMIDINE MONOPHOSPHATE AND 3'-THYMIDINE MONOPHOSPHATE 1CY1 ; 2.3 ; COMPLEX OF E.COLI DNA TOPOISOMERASE I WITH 5'PTPTPT 1CY4 ; 2.55 ; COMPLEX OF E.COLI DNA TOPOISOMERASE I WITH 5'pTpTpTp3' 1CY2 ; 2.3 ; COMPLEX OF E.COLI DNA TOPOISOMERASE I WITH TPTPTP3' 2C8I ; 14 ; COMPLEX OF ECHOVIRUS TYPE 12 WITH DOMAINS 1, 2, 3 AND 4 OF ITS RECEPTOR DECAY ACCELERATING FACTOR (CD55) BY CRYO ELECTRON MICROSCOPY AT 16 A 1UPN ; 16 ; COMPLEX OF ECHOVIRUS TYPE 12 WITH DOMAINS 3 AND 4 OF ITS RECEPTOR DECAY ACCELERATING FACTOR (CD55) BY CRYO ELECTRON MICROSCOPY AT 16 A 1RV5 ; 2.1 ; COMPLEX OF ECORV ENDONUCLEASE WITH D(AAAGAT)/D(ATCTT) 1H9I ; 1.9 ; COMPLEX OF EETI-II MUTANT WITH PORCINE TRYPSIN 1H9H ; 1.5 ; COMPLEX OF EETI-II WITH PORCINE TRYPSIN 3DEG ; 10.9 ; Complex of elongating Escherichia coli 70S ribosome and EF4(LepA)-GMPPNP 1O2F ; ; COMPLEX OF ENZYME IIAGLC AND IIBGLC PHOSPHOCARRIER PROTEIN HPR FROM ESCHERICHIA COLI NMR, RESTRAINED REGULARIZED MEAN STRUCTURE 1GGR ; ; COMPLEX OF ENZYME IIAGLC AND THE HISTIDINE-CONTAINING PHOSPHOCARRIER PROTEIN HPR FROM ESCHERICHIA COLI NMR, RESTRAINED REGULARIZED MEAN STRUCTURE 1VRC ; ; Complex of enzyme IIAmannose and the histidine-containing phosphocarrier protein HPr from escherichia coli nmr, restrained regularized mean structure 2FEW ; ; Complex of enzyme IIAMTL and phosphorylated enzyme IIBMTL from Escherichia coli NMR, restrained regularized mean structure 1J6T ; ; COMPLEX OF ENZYME IIAMTL AND THE HISTIDINE-CONTAINING PHOSPHOCARRIER PROTEIN HPR FROM ESCHERICHIA COLI NMR, RESTRAINED REGULARIZED MEAN STRUCTURE 2GYD ; 1.72 ; Complex of equine apoferritin with the H-diaziflurane photolabeling reagent 3SA0 ; 1.5947 ; Complex of ERK2 with norathyriol 1KKB ; 2.6 ; Complex of Escherichia coli Adenylosuccinate Synthetase with IMP and Hadacidin 3RY6 ; 3.8 ; Complex of fcgammariia (CD32) and the FC of human IGG1 2D0Q ; 1.65 ; Complex of Fe-type NHase with Cyclohexyl isocyanide, photo-activated for 1hr at 277K 2ZPG ; 1.39 ; Complex of Fe-type nitrile hydratase with tert-butylisonitrile, photo-activated for 120min at 293K 2ZPF ; 1.482 ; Complex of Fe-type nitrile hydratase with tert-butylisonitrile, photo-activated for 18min at 293K 2ZPH ; 1.59 ; Complex of Fe-type nitrile hydratase with tert-butylisonitrile, photo-activated for 340min at 293K 2ZPI ; 1.491 ; Complex of Fe-type nitrile hydratase with tert-butylisonitrile, photo-activated for 440min at 293K 3JWN ; 2.69 ; Complex of FimC, FimF, FimG and FimH 3O5R ; 1.1 ; Complex of Fk506 with the Fk1 domain mutant A19T of FKBP51 4H0B ; 1.26 ; Complex of G65T Myoglobin with DMSO in its Distal Cavity 4H07 ; 1.14 ; Complex of G65T Myoglobin with Phenol in its Proximal Cavity 3D32 ; 1.3 ; Complex of GABA(A) receptor-associated protein (GABARAP) with a synthetic peptide 1FS0 ; 2.1 ; COMPLEX OF GAMMA/EPSILON ATP SYNTHASE FROM E.COLI 1PY1 ; 2.6 ; Complex of GGA1-VHS domain and beta-secretase C-terminal phosphopeptide 1LF8 ; 2.3 ; Complex of GGA3-VHS Domain and CI-MPR C-terminal Phosphopeptide 2I55 ; 2.9 ; Complex of glucose-1,6-bisphosphate with phosphomannomutase from Leishmania mexicana 1NOI ; 2.5 ; COMPLEX OF GLYCOGEN PHOSPHORYLASE WITH A TRANSITION STATE ANALOGUE NOJIRIMYCIN TETRAZOLE AND PHOSPHATE IN THE T AND R STATES 1NOJ ; 2.4 ; COMPLEX OF GLYCOGEN PHOSPHORYLASE WITH A TRANSITION STATE ANALOGUE NOJIRIMYCIN TETRAZOLE AND PHOSPHATE IN THE T STATE 1NOK ; 2.4 ; COMPLEX OF GLYCOGEN PHOSPHORYLASE WITH A TRANSITION STATE ANALOGUE NOJIRIMYCIN TETRAZOLE AND PHOSPHATE IN THE T STATE 1TL7 ; 2.8 ; Complex Of Gs- With The Catalytic Domains Of Mammalian Adenylyl Cyclase: Complex With 2'(3')-O-(N-methylanthraniloyl)-guanosine 5'-triphosphate and Mn 2GVD ; 2.9 ; Complex Of Gs- With The Catalytic Domains Of Mammalian Adenylyl Cyclase: Complex With TNP-ATP and Mn 1AZS ; 2.3 ; COMPLEX OF GS-ALPHA WITH THE CATALYTIC DOMAINS OF MAMMALIAN ADENYLYL CYCLASE 1CUL ; 2.4 ; COMPLEX OF GS-ALPHA WITH THE CATALYTIC DOMAINS OF MAMMALIAN ADENYLYL CYCLASE: COMPLEX WITH 2',5'-DIDEOXY-ADENOSINE 3'-TRIPHOSPHATE AND MG 1CS4 ; 2.5 ; COMPLEX OF GS-ALPHA WITH THE CATALYTIC DOMAINS OF MAMMALIAN ADENYLYL CYCLASE: COMPLEX WITH 2'-DEOXY-ADENOSINE 3'-MONOPHOSPHATE, PYROPHOSPHATE AND MG 1CJK ; 3 ; COMPLEX OF GS-ALPHA WITH THE CATALYTIC DOMAINS OF MAMMALIAN ADENYLYL CYCLASE: COMPLEX WITH ADENOSINE 5'-(ALPHA THIO)-TRIPHOSPHATE (RP), MG, AND MN 3MAA ; 3 ; Complex of GS-Alpha with the Catalytic Domains of Mammalian Adenylyl Cyclase: Complex with Adenosine 5-O-(l-Thiophosphate) and Low Ca Concentration 3C16 ; 2.87 ; Complex of GS-Alpha with the Catalytic Domains of Mammalian Adenylyl Cyclase: Complex with Adenosine-5'-Triphosphate and Ca 1CJU ; 2.8 ; COMPLEX OF GS-ALPHA WITH THE CATALYTIC DOMAINS OF MAMMALIAN ADENYLYL CYCLASE: COMPLEX WITH BETA-L-2',3'-DIDEOXYATP AND MG 1CJV ; 3 ; COMPLEX OF GS-ALPHA WITH THE CATALYTIC DOMAINS OF MAMMALIAN ADENYLYL CYCLASE: COMPLEX WITH BETA-L-2',3'-DIDEOXYATP, MG, AND ZN 1CJT ; 2.8 ; COMPLEX OF GS-ALPHA WITH THE CATALYTIC DOMAINS OF MAMMALIAN ADENYLYL CYCLASE: COMPLEX WITH BETA-L-2',3'-DIDEOXYATP, MN, AND MG 3G82 ; 3.11 ; Complex of GS-alpha with the catalytic domains of mammalian adenylyl cyclase: complex with MANT-ITP and Mn 3C14 ; 2.68 ; Complex of GS-Alpha with the Catalytic Domains of Mammalian Adenylyl Cyclase: Complex with Pyrophosphate and Ca 3C15 ; 2.78 ; Complex of GS-Alpha with the Catalytic Domains of Mammalian Adenylyl Cyclase: Complex with Pyrophosphate and Mg 1XZ1 ; 1.75 ; Complex of halothane with apoferritin 1HTW ; 1.7 ; COMPLEX OF HI0065 WITH ADP AND MAGNESIUM 1UU1 ; 2.38 ; COMPLEX OF HISTIDINOL-PHOSPHATE AMINOTRANSFERASE (HISC) FROM THERMOTOGA MARITIMA (APO-FORM) 1G70 ; ; COMPLEX OF HIV-1 RRE-IIB RNA WITH RSG-1.2 PEPTIDE 1US7 ; 2.3 ; COMPLEX OF HSP90 AND P50 4AWO ; 1.7 ; Complex of HSP90 ATPase domain with tropane derived inhibitors 4AWP ; 1.82 ; Complex of HSP90 ATPase domain with tropane derived inhibitors 4AWQ ; 1.6 ; Complex of HSP90 ATPase domain with tropane derived inhibitors 2JKI ; 3.3 ; COMPLEX OF HSP90 N-TERMINAL AND SGT1 CS DOMAIN 2XCM ; 2.2 ; COMPLEX OF HSP90 N-TERMINAL, SGT1 CS AND RAR1 CHORD2 DOMAIN 1HAO ; 2.8 ; COMPLEX OF HUMAN ALPHA-THROMBIN WITH A 15MER OLIGONUCLEOTIDE GGTTGGTGTGGTTGG (BASED ON NMR MODEL OF DNA) 1HAP ; 2.8 ; COMPLEX OF HUMAN ALPHA-THROMBIN WITH A 15MER OLIGONUCLEOTIDE GGTTGGTGTGGTTGG (BASED ON X-RAY MODEL OF DNA) 1A3B ; 1.8 ; COMPLEX OF HUMAN ALPHA-THROMBIN WITH THE BIFUNCTIONAL BORONATE INHIBITOR BOROLOG1 1A3E ; 1.85 ; COMPLEX OF HUMAN ALPHA-THROMBIN WITH THE BIFUNCTIONAL BORONATE INHIBITOR BOROLOG2 3VBD ; 1.05 ; Complex of human carbonic anhydrase II with 4-(6-methoxy-3,4-dihydroisoquinolin-1-yl)benzenesulfonamide 3V7X ; 1.03 ; Complex of human carbonic anhydrase II with N-[2-(3,4-dimethoxyphenyl)ethyl]-4-sulfamoylbenzamide 2WV8 ; 1.9 ; Complex of human dihydroorotate dehydrogenase with the inhibitor 221290 1YD8 ; 2.8 ; COMPLEX OF HUMAN GGA3 GAT DOMAIN AND UBIQUITIN 1BKD ; 2.8 ; COMPLEX OF HUMAN H-RAS WITH HUMAN SOS-1 2VJ8 ; 1.8 ; COMPLEX OF HUMAN LEUKOTRIENE A4 HYDROLASE WITH A HYDROXAMIC ACID INHIBITOR 1OP9 ; 1.86 ; Complex of human lysozyme with camelid VHH HL6 antibody fragment 1B59 ; 1.8 ; COMPLEX OF HUMAN METHIONINE AMINOPEPTIDASE-2 COMPLEXED WITH OVALICIN 1KBQ ; 1.8 ; Complex of Human NAD(P)H quinone Oxidoreductase with 5-methoxy-1,2-dimethyl-3-(4-nitrophenoxymethyl)indole-4,7-dione (ES936) 2V4L ; 2.5 ; complex of human phosphoinositide 3-kinase catalytic subunit gamma (p110 gamma) with PIK-284 1KBO ; 2.3 ; Complex of Human recombinant NAD(P)H:Quinone Oxide reductase type 1 with 5-methoxy-1,2-dimethyl-3-(phenoxymethyl)indole-4,7-dione (ES1340) 1K6E ; 1.85 ; COMPLEX OF HYDROLYTIC HALOALKANE DEHALOGENASE LINB FROM SPHINGOMONAS PAUCIMOBILIS UT26 WITH 1,2-PROPANEDIOL (PRODUCT OF DEHALOGENATION OF 1,2-DIBROMOPROPANE) AT 1.85A 1K63 ; 1.8 ; Complex of hydrolytic haloalkane dehalogenase linb from sphingomonas paucimobilis with UT26 2-BROMO-2-PROPENE-1-OL at 1.8A resolution 2GGQ ; 2 ; complex of hypothetical glucose-1-phosphate thymidylyltransferase from sulfolobus tokodaii 1H59 ; 2.1 ; COMPLEX OF IGFBP-5 WITH IGF-I 2CZ6 ; 1.5 ; Complex of Inactive Fe-type NHase with Cyclohexyl isocyanide 2DPG ; 2.5 ; COMPLEX OF INACTIVE MUTANT (H240->N) OF GLUCOSE 6-PHOSPHATE DEHYDROGENASE FROM LEUCONOSTOC MESENTEROIDES WITH NADP+ 1A53 ; 2 ; COMPLEX OF INDOLE-3-GLYCEROLPHOSPHATE SYNTHASE FROM SULFOLOBUS SOLFATARICUS WITH INDOLE-3-GLYCEROLPHOSPHATE AT 2.0 A RESOLUTION 3RT3 ; 2.006 ; Complex of influenza virus protein with host anti-viral factor 4HEP ; 1.75 ; Complex of lactococcal phage TP901-1 with a llama vHH (vHH17) binder (nanobody) 1LDT ; 1.9 ; COMPLEX OF LEECH-DERIVED TRYPTASE INHIBITOR WITH PORCINE TRYPSIN 1RUT ; 1.3 ; Complex of LMO4 LIM domains 1 and 2 with the ldb1 LID domain 3ZX7 ; 2.84 ; Complex of lysenin with phosphocholine 2Q97 ; 2.5 ; Complex of mammalian actin with toxofilin from toxoplasma gondii 3V96 ; 1.9 ; Complex of matrix metalloproteinase-10 catalytic domain (MMP-10cd) with tissue inhibitor of metalloproteinases-1 (TIMP-1) 1KZE ; 1.8 ; Complex of MBP-C and bivalent Man-terminated glycopeptide 1KZD ; 1.9 ; Complex of MBP-C and GlcNAc-terminated core 1KZC ; 1.85 ; Complex of MBP-C and high-affinity linear trimannose 1KZA ; 1.74 ; Complex of MBP-C and Man-a13-Man 1KZB ; 1.8 ; Complex of MBP-C and trimannosyl core 4JA8 ; 1.55 ; Complex of Mitochondrial Isocitrate Dehydrogenase R140Q Mutant with AGI-6780 Inhibitor 1EL5 ; 1.8 ; COMPLEX OF MONOMERIC SARCOSINE OXIDASE WITH THE INHIBITOR DIMETHYLGLYCINE 1ELI ; 2 ; COMPLEX OF MONOMERIC SARCOSINE OXIDASE WITH THE INHIBITOR PYRROLE-2-CARBOXYLATE 1EL8 ; 1.9 ; COMPLEX OF MONOMERIC SARCOSINE OXIDASE WITH THE INHIBITOR [METHYLSELENO]CETATE 1EL9 ; 2 ; COMPLEX OF MONOMERIC SARCOSINE OXIDASE WITH THE INHIBITOR [METHYLTHIO]ACETATE 1EL7 ; 1.9 ; COMPLEX OF MONOMERIC SARCOSINE OXIDASE WITH THE INHIBITOR [METHYTELLURO]ACETATE 4GZA ; 7 ; Complex of mouse Plexin A2 - Semaphorin 3A - Neuropilin-1 3G2D ; 2.3 ; Complex of Mth0212 and a 4 bp dsDNA with 3'-overhang 3G0R ; 2.4 ; Complex of Mth0212 and an 8bp dsDNA with distorted ends 8ATC ; 2.5 ; COMPLEX OF N-PHOSPHONACETYL-L-ASPARTATE WITH ASPARTATE CARBAMOYLTRANSFERASE. X-RAY REFINEMENT, ANALYSIS OF CONFORMATIONAL CHANGES AND CATALYTIC AND ALLOSTERIC MECHANISMS 3CI5 ; 1.7 ; Complex of Phosphorylated Dictyostelium Discoideum Actin with Gelsolin 3ENE ; 2.4 ; Complex of PI3K gamma with an inhibitor 3AG9 ; 2 ; Complex of PKA with the bisubstrate protein kinase inhibitor ARC-1012 3AGL ; 2.1 ; Complex of PKA with the bisubstrate protein kinase inhibitor ARC-1039 3AGM ; 2 ; Complex of PKA with the bisubstrate protein kinase inhibitor ARC-670 3BWJ ; 2.3 ; Complex of PKA with the bisubstrate protein kinase inhibitor lead compound Arc-1034 2H4L ; 2.4 ; Complex of PMM/PGM with ribose 1-phosphate 4IEF ; 2.3 ; Complex of Porphyromonas gingivalis RgpB pro- and mature domains 1JAP ; 1.82 ; COMPLEX OF PRO-LEU-GLY-HYDROXYLAMINE WITH THE CATALYTIC DOMAIN OF MATRIX METALLO PROTEINASE-8 (MET80 FORM) 1JAN ; 2.5 ; COMPLEX OF PRO-LEU-GLY-HYDROXYLAMINE WITH THE CATALYTIC DOMAIN OF MATRIX METALLO PROTEINASE-8 (PHE79 FORM) 1I73 ; 1.4 ; COMPLEX OF PRO-LEU-L-TRP PHOSPHONATE WITH THE CATALITIC DOMAIN OF MATRIX METALLO PROTEINASE-8 (MET80 FORM) 2XGY ; 1.8 ; COMPLEX OF RABBIT ENDOGENOUS LENTIVIRUS (RELIK)CAPSID WITH CYCLOPHILIN A 2W2X ; 2.3 ; COMPLEX OF RAC2 AND PLCG2 SPPH DOMAIN 2YBF ; 2 ; COMPLEX OF RAD18 (RAD6 BINDING DOMAIN) WITH RAD6B 1IBR ; 2.3 ; COMPLEX OF RAN WITH IMPORTIN BETA 3KUC ; 1.92 ; Complex of Rap1A(E30D/K31E)GDP with RafRBD(A85K/N71R) 3L8Y ; 2.02 ; Complex of Ras with cyclen 3KUD ; 2.15 ; Complex of Ras-GDP with RafRBD(A85K) 1OYT ; 1.67 ; COMPLEX OF RECOMBINANT HUMAN THROMBIN WITH A DESIGNED FLUORINATED INHIBITOR 1QUQ ; 2.5 ; COMPLEX OF REPLICATION PROTEIN A SUBUNITS RPA14 AND RPA32 1GMP ; 1.7 ; COMPLEX OF RIBONUCLEASE FROM STREPTOMYCES AUREOFACIENS WITH 2'-GMP AT 1.7 ANGSTROMS RESOLUTION 1GMQ ; 1.8 ; COMPLEX OF RIBONUCLEASE FROM STREPTOMYCES AUREOFACIENS WITH 2'-GMP AT 1.7 ANGSTROMS RESOLUTION 1GMR ; 1.77 ; COMPLEX OF RIBONUCLEASE FROM STREPTOMYCES AUREOFACIENS WITH 2'-GMP AT 1.7 ANGSTROMS RESOLUTION 3EJ5 ; 2.5 ; complex of Ricin A chain and pyrimidine-based inhibitor 1TDG ; 1.8 ; Complex of S130G SHV-1 beta-lactamase with tazobactam 3B7A ; 1.9 ; Complex of S52A Substituted Droposphila LUSH protein with Ethanol 3B6X ; 2 ; Complex of S52A Substituted Drosophila LUSH protein with Butanol 3V50 ; 1.45 ; Complex of SHV S130G mutant beta-lactamase complexed to SA2-13 4ABS ; 3.1 ; COMPLEX OF SMPB, A TMRNA FRAGMENT AND EF-TU-GDP-KIRROMYCIN WITH THE 70S RIBOSOME 4ABR ; 3.1 ; COMPLEX OF SMPB, A TMRNA FRAGMENT AND EF-TU-GDP-KIRROMYCIN WITH THE 70S RIBOSOME 1KTK ; 3 ; Complex of Streptococcal pyrogenic enterotoxin C (SpeC) with a human T cell receptor beta chain (Vbeta2.1) 1IKI ; 1.25 ; COMPLEX OF STREPTOMYCES R61 DD-PEPTIDASE WITH THE PRODUCTS OF A SPECIFIC PEPTIDOGLYCAN SUBSTRATE FRAGMENT 3EWR ; 2.01 ; complex of substrate ADP-ribose with HCoV-229E Nsp3 ADRP domain 3EWP ; 2 ; complex of substrate ADP-ribose with IBV Nsp3 ADRP domain 3B87 ; 2 ; Complex of T57A Substituted Droposphila LUSH protein with Butanol 3B88 ; 2 ; Complex of T57A Substituted Drosophila LUSH Protein with Ethanol 1W4L ; 2.16 ; COMPLEX OF TCACHE WITH BIS-ACTING GALANTHAMINE DERIVATIVE 1W6R ; 2.05 ; COMPLEX OF TCACHE WITH GALANTHAMINE DERIVATIVE 2A5R ; ; Complex of tetra-(4-n-methylpyridyl) porphin with monomeric parallel-stranded DNA tetraplex, snap-back 3+1 3' G-tetrad, single-residue chain reversal loops, GAG triad in the context of GAAG diagonal loop, C-MYC promoter, NMR, 6 struct. 3TDT ; 2 ; COMPLEX OF TETRAHYDRODIPICOLINATE N-SUCCINYLTRANSFERASE WITH 2-AMINO-6-OXOPIMELATE AND COENZYME A 2TDT ; 2 ; COMPLEX OF TETRAHYDRODIPICOLINATE N-SUCCINYLTRANSFERASE WITH 2-AMINOPIMELATE AND COENZYME A 2XQN ; 2.62 ; COMPLEX OF THE 2ND AND 3RD LIM DOMAINS OF TES WITH THE EVH1 DOMAIN OF MENA AND THE N-TERMINAL DOMAIN OF ACTIN-LIKE PROTEIN ARP7A 1SLY ; 2.8 ; COMPLEX OF THE 70-KDA SOLUBLE LYTIC TRANSGLYCOSYLASE WITH BULGECIN A 3EZB ; ; COMPLEX OF THE AMINO TERMINAL DOMAIN OF ENZYME I AND THE HISTIDINE-CONTAINING PHOSPHOCARRIER PROTEIN HPR FROM ESCHERICHIA COLI 3EZA ; ; COMPLEX OF THE AMINO TERMINAL DOMAIN OF ENZYME I AND THE HISTIDINE-CONTAINING PHOSPHOCARRIER PROTEIN HPR FROM ESCHERICHIA COLI NMR, RESTRAINED REGULARIZED MEAN STRUCTURE 3EZE ; ; COMPLEX OF THE AMINO TERMINAL DOMAIN OF ENZYME I AND THE HISTIDINE-CONTAINING PHOSPHOCARRIER PROTEIN HPR FROM ESCHERICHIA COLI NMR, RESTRAINED REGULARIZED MEAN STRUCTURE 1UZF ; 2 ; Complex of the anti-hypertensive drug captopril an the human testicular angiotensin I-converting enzyme 1UZE ; 1.82 ; COMPLEX OF THE ANTI-HYPERTENSIVE DRUG ENALAPRILAT AND THE HUMAN TESTICULAR ANGIOTENSIN I-CONVERTING ENZYME 1JC2 ; ; COMPLEX OF THE C-DOMAIN OF TROPONIN C WITH RESIDUES 1-40 OF TROPONIN I 2LEX ; ; Complex of the C-terminal WRKY domain of AtWRKY4 and a W-box DNA 4B0M ; 1.8 ; Complex of the Caf1AN usher domain, Caf1M chaperone and Caf1 subunit from Yersinia pestis 1G6V ; 3.5 ; Complex of the camelid heavy-chain antibody fragment CAB-CA05 with bovine carbonic anhydrase 1BML ; 2.9 ; COMPLEX OF THE CATALYTIC DOMAIN OF HUMAN PLASMIN AND STREPTOKINASE 1HWK ; 2.22 ; COMPLEX OF THE CATALYTIC PORTION OF HUMAN HMG-COA REDUCTASE WITH ATORVASTATIN 1HWJ ; 2.26 ; COMPLEX OF THE CATALYTIC PORTION OF HUMAN HMG-COA REDUCTASE WITH CERIVASTATIN 1HW8 ; 2.1 ; COMPLEX OF THE CATALYTIC PORTION OF HUMAN HMG-COA REDUCTASE WITH COMPACTIN (ALSO KNOWN AS MEVASTATIN) 1HWI ; 2.3 ; COMPLEX OF THE CATALYTIC PORTION OF HUMAN HMG-COA REDUCTASE WITH FLUVASTATIN 1DQ8 ; 2.1 ; COMPLEX OF THE CATALYTIC PORTION OF HUMAN HMG-COA REDUCTASE WITH HMG AND COA 1DQA ; 2 ; COMPLEX OF THE CATALYTIC PORTION OF HUMAN HMG-COA REDUCTASE WITH HMG, COA, AND NADP+ 1HWL ; 2.1 ; COMPLEX OF THE CATALYTIC PORTION OF HUMAN HMG-COA REDUCTASE WITH ROSUVASTATIN (FORMALLY KNOWN AS ZD4522) 1HW9 ; 2.33 ; COMPLEX OF THE CATALYTIC PORTION OF HUMAN HMG-COA REDUCTASE WITH SIMVASTATIN 1C7U ; ; Complex of the DNA binding core domain of the transcription factor MEF2A with a 20mer oligonucleotide 2BRU ; ; COMPLEX OF THE DOMAIN I AND DOMAIN III OF ESCHERICHIA COLI TRANSHYDROGENASE 1OCQ ; 1.08 ; COMPLEX OF THE ENDOGLUCANASE CEL5A FROM BACILLUS AGARADHEARANS AT 1.08 ANGSTROM RESOLUTION WITH CELLOBIO-DERIVED ISOFAGOMINE 2H5A ; 1.72 ; Complex of the enzyme PMM/PGM with xylose 1-phosphate 4AW5 ; 2.33 ; Complex of the EphB4 kinase domain with an oxindole inhibitor 2HA1 ; ; Complex of the first and second type III domains of human Fibronectin in solution 2OCY ; 3.3 ; Complex of the guanine exchange factor Sec2p and the Rab GTPase Sec4p 1BVY ; 2.03 ; COMPLEX OF THE HEME AND FMN-BINDING DOMAINS OF THE CYTOCHROME P450(BM-3) 2XAT ; 3.2 ; COMPLEX OF THE HEXAPEPTIDE XENOBIOTIC ACETYLTRANSFERASE WITH CHLORAMPHENICOL AND DESULFO-COENZYME A 1AKJ ; 2.65 ; COMPLEX OF THE HUMAN MHC CLASS I GLYCOPROTEIN HLA-A2 AND THE T CELL CORECEPTOR CD8 1SEB ; 2.7 ; COMPLEX OF THE HUMAN MHC CLASS II GLYCOPROTEIN HLA-DR1 AND THE BACTERIAL SUPERANTIGEN SEB 1IRA ; 2.7 ; COMPLEX OF THE INTERLEUKIN-1 RECEPTOR WITH THE INTERLEUKIN-1 RECEPTOR ANTAGONIST (IL1RA) 1J4W ; ; COMPLEX OF THE KH3 and KH4 DOMAINS OF FBP WITH A SINGLE_STRANDED 29mer DNA OLIGONUCLEOTIDE FROM THE FUSE ELEMENT OF THE C-MYC ONCOGENE 1J5K ; ; COMPLEX OF THE KH3 DOMAIN OF HNRNP K WITH A SINGLE_STRANDED 10MER DNA OLIGONUCLEOTIDE 1NWX ; 3.5 ; COMPLEX OF THE LARGE RIBOSOMAL SUBUNIT FROM DEINOCOCCUS RADIODURANS WITH ABT-773 1NWY ; 3.3 ; COMPLEX OF THE LARGE RIBOSOMAL SUBUNIT FROM DEINOCOCCUS RADIODURANS WITH AZITHROMYCIN 1SM1 ; 3.42 ; COMPLEX OF THE LARGE RIBOSOMAL SUBUNIT FROM DEINOCOCCUS RADIODURANS WITH QUINUPRISTIN AND DALFOPRISTIN 3D2Z ; 2.8 ; Complex of the N-acetylmuramyl-L-alanine amidase AmiD from E.coli with the product L-Ala-D-gamma-Glu-L-Lys 3D2Y ; 1.75 ; Complex of the N-acetylmuramyl-L-alanine amidase AmiD from E.coli with the substrate anhydro-N-acetylmuramic acid-L-Ala-D-gamma-Glu-L-Lys 2BRR ; 1.95 ; Complex of the neisserial PorA P1.4 epitope peptide and two Fab- fragments (antibody MN20B9.34) 1ZHI ; 2.7 ; Complex of the S. cerevisiae Orc1 and Sir1 interacting domains 1TFX ; 2.6 ; COMPLEX OF THE SECOND KUNITZ DOMAIN OF TISSUE FACTOR PATHWAY INHIBITOR WITH PORCINE TRYPSIN 3HHZ ; 3.5 ; Complex of the vesicular stomatitis virus nucleocapsid and the nucleocapsid-binding domain of the phosphoprotein 1BCR ; 2.5 ; COMPLEX OF THE WHEAT SERINE CARBOXYPEPTIDASE, CPDW-II, WITH THE MICROBIAL PEPTIDE ALDEHYDE INHIBITOR, ANTIPAIN, AND ARGININE AT ROOM TEMPERATURE 1BCS ; 2.08 ; COMPLEX OF THE WHEAT SERINE CARBOXYPEPTIDASE, CPDW-II, WITH THE MICROBIAL PEPTIDE ALDEHYDE INHIBITOR, CHYMOSTATIN, AND ARGININE AT 100 DEGREES KELVIN 1NG3 ; 2.6 ; Complex of ThiO (glycine oxidase) with acetyl-glycine 1AD8 ; 2 ; COMPLEX OF THROMBIN WITH AND INHIBITOR CONTAINING A NOVEL P1 MOIETY 1VZQ ; 1.54 ; COMPLEX OF THROMBIN WITH DESIGNED INHIBITOR 7165 2G9J ; ; Complex of TM1a(1-14)Zip with TM9a(251-284): a model for the polymerization domain (""overlap region"") of tropomyosin, Northeast Structural Genomics Target OR9 1GAN ; 2.23 ; COMPLEX OF TOAD OVARY GALECTIN WITH N-ACETYLGALACTOSE 1A78 ; 2 ; COMPLEX OF TOAD OVARY GALECTIN WITH THIO-DIGALACTOSE 1UCW ; 2.2 ; COMPLEX OF TRANSALDOLASE WITH THE REDUCED SCHIFF-BASE INTERMEDIATE 1NGS ; 2.4 ; COMPLEX OF TRANSKETOLASE WITH THIAMIN DIPHOSPHATE, CA2+ AND ACCEPTOR SUBSTRATE ERYTHROSE-4-PHOSPHATE 2Z5N ; 3.2 ; Complex of Transportin 1 with hnRNP D NLS 2Z5O ; 3.2 ; Complex of Transportin 1 with JKTBP NLS 2Z5K ; 2.6 ; Complex of Transportin 1 with TAP NLS 2Z5M ; 3 ; Complex of Transportin 1 with TAP NLS, crystal form 2 1A2X ; 2.3 ; COMPLEX OF TROPONIN C WITH A 47 RESIDUE (1-47) FRAGMENT OF TROPONIN I 3K8C ; 2.1 ; Complex of Trypanosoma cruzi ribose 5-phosphate isomerase type B with 4-deoxy-4-phospho-D-erythronohydroxamic acid 3K7S ; 1.9 ; Complex of Trypanosoma cruzi ribose 5-phosphate isomerase type B with ribose 5-phosphate 2WQA ; 2.85 ; COMPLEX OF TTR AND RBP4 AND OLEIC ACID 1CIR ; ; COMPLEX OF TWO FRAGMENTS OF CI2 [(1-40)(DOT)(41-64)] 1CIQ ; 2.2 ; COMPLEX OF TWO FRAGMENTS OF CI2, RESIDUES 1-40 AND 41-64 3FCK ; 1.64 ; Complex of UNG2 and a fragment-based design inhibitor 3FCF ; 1.84 ; Complex of UNG2 and a fragment-based designed inhibitor 3FCI ; 1.27 ; Complex of UNG2 and a fragment-based designed inhibitor 3FCL ; 1.7 ; Complex of UNG2 and a fragment-based designed inhibitor 2HXM ; 1.3 ; Complex of UNG2 and a small Molecule synthetic Inhibitor 4B93 ; 2 ; Complex of Vamp7 cytoplasmic domain with 2nd ankyrin repeat domain of Varp 1C0Q ; 1 ; COMPLEX OF VANCOMYCIN WITH 2-ACETOXY-D-PROPANOIC ACID 1C0R ; 1 ; COMPLEX OF VANCOMYCIN WITH D-LACTIC ACID 1FVM ; 1.8 ; Complex of vancomycin with DI-acetyl-LYS-D-ALA-D-ALA 1QD8 ; 1 ; COMPLEX OF VANCOMYCIN WITH N-ACETYL GLYCINE 3U3E ; 1.21 ; Complex of Wild Type Myoglobin with Phenol in its Proximal Cavity 1IOW ; 1.9 ; COMPLEX OF Y216F D-ALA:D-ALA LIGASE WITH ADP AND A PHOSPHORYL PHOSPHINATE 3ESW ; 3.4 ; Complex of yeast PNGase with GlcNAc2-IAc. 2R25 ; 1.7 ; Complex of YPD1 and SLN1-R1 with bound Mg2+ and BeF3- 1NLI ; 1.93 ; Complex of [E160A-E189A] trichosanthin and adenine 1THD ; 9.5 ; COMPLEX ORGANIZATION OF DENGUE VIRUS E PROTEIN AS REVEALED BY 9.5 ANGSTROM CRYO-EM RECONSTRUCTION 1P58 ; 9.5 ; Complex Organization of Dengue Virus Membrane Proteins as Revealed by 9.5 Angstrom Cryo-EM reconstruction 1AVW ; 1.75 ; COMPLEX PORCINE PANCREATIC TRYPSIN/SOYBEAN TRYPSIN INHIBITOR, ORTHORHOMBIC CRYSTAL FORM 1AVX ; 1.9 ; COMPLEX PORCINE PANCREATIC TRYPSIN/SOYBEAN TRYPSIN INHIBITOR, TETRAGONAL CRYSTAL FORM 1CG9 ; 2.7 ; COMPLEX RECOGNITION OF THE SUPERTYPIC BW6-DETERMINANT ON HLA-B AND-C MOLECULES BY THE MONOCLONAL ANTIBODY SFR8-B6 2FSI ; 2.11 ; Complex SecA:ADP from Escherichia coli 2FSH ; 2 ; Complex SecA:AMP-PNP from Escherichia coli 2FSG ; 2.2 ; Complex SecA:ATP from Escherichia coli 3IMA ; 2.03 ; Complex strcuture of tarocystatin and papain 4H9N ; 1.95 ; Complex structure 1 of DAXX/H3.3(sub5)/H4 4H9O ; 2.053 ; Complex structure 2 of DAXX/H3.3(sub5,G90M)/H4 4H9P ; 2.198 ; Complex structure 3 of DAXX/H3.3(sub5,G90A)/H4 4H9Q ; 1.95 ; Complex structure 4 of DAXX(E225A)/H3.3(sub5)/H4 4H9R ; 2.197 ; Complex structure 5 of DAXX(E225A)/H3.3(sub5,G90A)/H4 4H9S ; 2.6 ; Complex structure 6 of DAXX/H3.3(sub7)/H4 3KDJ ; 1.878 ; Complex structure of (+)-ABA-bound PYL1 and ABI1 3RRL ; 2.29 ; Complex structure of 3-oxoadipate coA-transferase subunit A and B from Helicobacter pylori 26695 4FS9 ; 3.1 ; Complex structure of a broad specificity amino acid racemase (Bar) within the reactive intermediate 4DSC ; 1.95 ; Complex structure of abscisic acid receptor PYL3 with (+)-ABA in spacegroup of H32 at 1.95A 4DSB ; 2.7 ; Complex Structure of Abscisic Acid Receptor PYL3 with (+)-ABA in Spacegroup of I 212121 at 2.70A 4DS8 ; 2.21 ; Complex structure of abscisic acid receptor PYL3-(+)-ABA-HAB1 in the presence of Mn2+ 2ZH1 ; 2.8 ; Complex structure of AFCCA with tRNAminiDA 2ZH2 ; 2.66 ; Complex structure of AFCCA with tRNAminiDAC 2ZH3 ; 2.5 ; Complex structure of AFCCA with tRNAminiDCA 2ZH4 ; 2.65 ; Complex structure of AFCCA with tRNAminiDCG 2ZH5 ; 2.6 ; Complex structure of AFCCA with tRNAminiDCU 2ZH6 ; 2.5 ; Complex structure of AFCCA with tRNAminiDCU and ATP 2ZH7 ; 3 ; Complex structure of AFCCA with tRNAminiDG 2ZH8 ; 2.65 ; Complex structure of AFCCA with tRNAminiDGC 2ZH9 ; 2.9 ; Complex structure of AFCCA with tRNAminiDU 2ZHA ; 2.95 ; Complex structure of AFCCA with tRNAminiDU and CTP 2ZHB ; 3.05 ; Complex structure of AFCCA with tRNAminiDUC 3QLC ; 2.5 ; Complex structure of ATRX ADD domain bound to unmodified H3 1-15 peptide 3EX8 ; 2.56 ; Complex structure of bacillus subtilis RibG reduction mechanism in riboflavin biosynthesis 4G3M ; 2.56 ; Complex Structure of Bacillus subtilis RibG: The Deamination Process in Riboflavin Biosynthesis 3AQN ; 3.3 ; Complex structure of bacterial protein (apo form II) 3OGR ; 1.5 ; Complex structure of beta-galactosidase from Trichoderma reesei with galactose 3OGS ; 1.75 ; Complex structure of beta-galactosidase from Trichoderma reesei with IPTG 3OGV ; 1.4 ; Complex structure of beta-galactosidase from Trichoderma reesei with PETG 2M0U ; ; Complex structure of C-terminal CFTR peptide and extended PDZ1 domain from NHERF1 2M0V ; ; Complex structure of C-terminal CFTR peptide and extended PDZ2 domain from NHERF1 2DR5 ; 2.8 ; Complex structure of CCA adding enzyme with mini-helix lacking CCA 2DRB ; 2.8 ; Complex structure of CCA-adding enzyme with tRNAminiCCA 2DR7 ; 2.8 ; Complex structure of CCA-adding enzyme with tRNAminiDC 2DR8 ; 2.5 ; Complex structure of CCA-adding enzyme with tRNAminiDC and CTP 2DR9 ; 2.8 ; Complex structure of CCA-adding enzyme with tRNAminiDCC 2DRA ; 2.5 ; Complex structure of CCA-adding enzyme with tRNAminiDCC and ATP 2DVI ; 2.61 ; Complex structure of CCA-adding enzyme, mini-DCC and CTP 2ZU2 ; 1.8 ; complex structure of CoV 229E 3CL protease with EPDTC 2ZTX ; 1.72 ; Complex structure of CVB3 3C protease with EPDTC 2ZU3 ; 1.75 ; Complex structure of CVB3 3C protease with TG-0204998 3LQS ; 1.9 ; Complex Structure of D-Amino Acid Aminotransferase and 4-amino-4,5-dihydro-thiophenecarboxylic acid (ADTA) 3P13 ; 2.35 ; Complex Structure of D-ribose Pyranase Sa240 with D-ribose 2QKY ; 3.1 ; complex structure of dipeptidyl peptidase IV and a oxadiazolyl ketone 2L29 ; ; Complex structure of E4 mutant human IGF2R domain 11 bound to IGF-II 3K26 ; 1.58 ; Complex structure of EED and trimethylated H3K4 3K27 ; 1.76 ; Complex structure of EED and trimethylated H3K9 3L1B ; 1.9 ; Complex Structure of FXR Ligand-binding domain with a tetrahydroazepinoindole compound 3DOW ; 2.3 ; Complex structure of GABA type A receptor associated protein and its binding epitope on calreticulin 1NJU ; 2.7 ; Complex structure of HCMV Protease and a peptidomimetic inhibitor 1NKK ; 2.6 ; COMPLEX STRUCTURE OF HCMV PROTEASE AND A PEPTIDOMIMETIC INHIBITOR 1NKM ; 2.7 ; Complex structure of HCMV Protease and a peptidomimetic inhibitor 1NJT ; 2.5 ; COMPLEX STRUCTURE OF HCMV PROTEASE AND A PEPTIDOMIMETIC INHIBITOR 3Q3Y ; 1.32 ; Complex structure of HEVB EV93 main protease 3C with Compound 1 (AG7404) 3RUO ; 1.5 ; Complex structure of HevB EV93 main protease 3C with Rupintrivir (AG7088) 1BDJ ; 2.68 ; COMPLEX STRUCTURE OF HPT DOMAIN AND CHEY 1MEN ; 2.23 ; complex structure of human GAR Tfase and substrate beta-GAR 2V5P ; 4.1 ; COMPLEX STRUCTURE OF HUMAN IGF2R DOMAINS 11-13 BOUND TO IGF-II 4FBX ; 2.33 ; Complex structure of human protein kinase CK2 catalytic subunit crystallized in the presence of a bisubstrate inhibitor 4HL5 ; 2.2 ; Complex structure of human tankyrase 2 with 7-hydroxy -4'-methoxyflavone 4HKK ; 1.95 ; Complex structure of human tankyrase 2 with apigenin 4HKN ; 2.05 ; Complex structure of human tankyrase 2 with luteolin 3U9H ; 1.75 ; Complex structure of human tankyrase 2 with nicotinamide 1EB1 ; 1.8 ; Complex structure of human thrombin with N-methyl-arginine inhibitor 3F5P ; 2.9 ; Complex Structure of Insulin-like Growth Factor Receptor and 3-Cyanoquinoline Inhibitor 2ZM3 ; 2.5 ; Complex Structure of Insulin-like Growth Factor Receptor and Isoquinolinedione Inhibitor 3VPF ; 2.79 ; Complex structure of Lactobacillus casei lactate dehydrogenase penta mutant with pyruvate 3VKV ; 2.7 ; Complex structure of Lactobacillus casei lactate dehydrogenase with fructose-1,6-bisphosphate 2Z3M ; 2.7 ; complex structure of LF-transferase and dAF 2Z3P ; 2.5 ; complex structure of LF-transferase and leucine 2Z3L ; 2.75 ; complex structure of LF-transferase and peptide A 2Z3N ; 2.5 ; complex structure of LF-transferase and peptide B 2Z3O ; 2.4 ; complex structure of LF-transferase and phenylalanine 2Z3K ; 2.85 ; complex structure of LF-transferase and rAF 4FWF ; 2.7 ; Complex structure of LSD2/AOF1/KDM1b with H3K4 mimic 3KFC ; 2.4 ; Complex Structure of LXR with an agonist 4GAM ; 2.902 ; Complex structure of Methane monooxygenase hydroxylase and regulatory subunit 4F8Y ; 1.796 ; Complex structure of NADPH:quinone oxidoreductase with menadione in Streptococcus mutans 4GJT ; 3.1001 ; complex structure of nectin-4 bound to MV-H 4IP3 ; 2.3 ; Complex structure of OspI and Ubc13 1WUG ; ; complex structure of PCAF bromodomain with small chemical ligand NP1 1WUM ; ; Complex structure of PCAF bromodomain with small chemical ligand NP2 1N5Z ; 2.7 ; Complex structure of Pex13p SH3 domain with a peptide of Pex14p 2VCQ ; 1.95 ; COMPLEX STRUCTURE OF PROSTAGLANDIN D2 SYNTHASE AT 1.95A. 2VCW ; 1.95 ; COMPLEX STRUCTURE OF PROSTAGLANDIN D2 SYNTHASE AT 1.95A. 2VCZ ; 1.95 ; COMPLEX STRUCTURE OF PROSTAGLANDIN D2 SYNTHASE AT 1.95A. 2VCX ; 2.1 ; COMPLEX STRUCTURE OF PROSTAGLANDIN D2 SYNTHASE AT 2.1A. 2VD1 ; 2.25 ; COMPLEX STRUCTURE OF PROSTAGLANDIN D2 SYNTHASE AT 2.25A. 2VD0 ; 2.2 ; COMPLEX STRUCTURE OF PROSTAGLANDIN D2 SYNTHASE AT 2.2A. 3T7K ; 2.028 ; Complex structure of Rtt107p and phosphorylated histone H2A 2Z9J ; 1.95 ; Complex structure of SARS-CoV 3C-like protease with EPDTC 2Z9L ; 2.1 ; complex structure of SARS-CoV 3C-like protease with JMF1586 2Z9K ; 1.85 ; Complex structure of SARS-CoV 3C-like protease with JMF1600 2Z9G ; 1.86 ; Complex structure of SARS-CoV 3C-like protease with PMA 2Z94 ; 1.78 ; Complex structure of SARS-CoV 3C-like protease with TDT 2ZU4 ; 1.93 ; Complex structure of SARS-CoV 3CL protease with TG-0204998 2ZU5 ; 1.65 ; complex structure of SARS-CoV 3CL protease with TG-0205486 3MP6 ; 1.48 ; Complex Structure of Sgf29 and dimethylated H3K4 3MP1 ; 2.6 ; Complex structure of Sgf29 and trimethylated H3K4 3L0I ; 2.85 ; Complex structure of SidM/DrrA with the wild type Rab1 2R66 ; 2.8 ; Complex Structure of Sucrose Phosphate Synthase (SPS)-F6P of Halothermothrix orenii 2R68 ; 2.4 ; Complex Structure of Sucrose Phosphate Synthase (SPS)-S6P of Halothermothrix orenii 2V9W ; 3 ; COMPLEX STRUCTURE OF SULFOLOBUS SOLFATARICUS DPO4 AND DNA DUPLEX CONTAINING A HYDROPHOBIC THYMINE ISOSTERE 2,4-DIFLUOROTOLUENE NUCLEOTIDE IN THE TEMPLATE STRAND 2VA2 ; 2.8 ; COMPLEX STRUCTURE OF SULFOLOBUS SOLFATARICUS DPO4 AND DNA DUPLEX CONTAINING A HYDROPHOBIC THYMINE ISOSTERE 2,4-DIFLUOROTOLUENE NUCLEOTIDE IN THE TEMPLATE STRAND 2VA3 ; 2.98 ; COMPLEX STRUCTURE OF SULFOLOBUS SOLFATARICUS DPO4 AND DNA DUPLEX CONTAINING A HYDROPHOBIC THYMINE ISOSTERE 2,4-DIFLUOROTOLUENE NUCLEOTIDE IN THE TEMPLATE STRAND 1G9Q ; 2.3 ; COMPLEX STRUCTURE OF THE ADPR-ASE AND ITS SUBSTRATE ADP-RIBOSE 1WTB ; ; Complex structure of the C-terminal RNA-binding domain of hnRNP D (AUF1) with telomere DNA 1X0F ; ; Complex structure of the C-terminal RNA-binding domain of hnRNP D(AUF1) with telomeric DNA 2K2Q ; ; complex structure of the external thioesterase of the Surfactin-synthetase with a carrier domain 2W5O ; 2.05 ; COMPLEX STRUCTURE OF THE GH93 ALPHA-L-ARABINOFURANOSIDASE OF FUSARIUM GRAMINEARUM WITH ARABINOBIOSE 2XFM ; ; COMPLEX STRUCTURE OF THE MIWI PAZ DOMAIN BOUND TO METHYLATED SINGLE STRANDED RNA 2RR4 ; ; Complex structure of the zf-CW domain and the H3K4me3 peptide 2EJU ; 1.95 ; Complex structure of Trm1 from Pyrococcus horikoshii with S-adenosyl-L-Homocystein 2YTZ ; 2.65 ; Complex structure of Trm1 from Pyrococcus horikoshii with S-adenosyl-L-Homocystein in the orthorhombic crystal-lattice 2EJT ; 2.2 ; Complex structure of Trm1 from Pyrococcus horikoshii with S-adenosyl-L-Methionine 3AXT ; 2.491 ; Complex structure of tRNA methyltransferase Trm1 from Aquifex aeolicus with S-adenosyl-L-Methionine 3AXS ; 2.162 ; Complex structure of tRNA methyltransferase Trm1 from Aquifex aeolicus with sinefungin 4FWT ; 3.2 ; Complex structure of viral RNA polymerase form III 3VNU ; 3.2 ; Complex structure of viral RNA polymerase I 3VNV ; 2.604 ; Complex structure of viral RNA polymerase II 2X0E ; 2.81 ; COMPLEX STRUCTURE OF WSAF WITH DTDP 2RSF ; ; Complex structure of WWE in RNF146 with ATP 1XL3 ; 2.2 ; Complex structure of Y.pestis virulence Factors YopN and TyeA 2RNY ; ; Complex Structures of CBP Bromodomain with H4 ack20 Peptide 2Z59 ; ; Complex Structures of Mouse Rpn13 (22-130aa) and ubiquitin 1FGH ; 2.05 ; COMPLEX WITH 4-HYDROXY-TRANS-ACONITATE 2UXR ; 2.3 ; COMPLEX WITH ISOCITRATE AND THE PROTEIN ISOCITRATE DEHYDROGENASE FROM THE PSYCHROPHILIC BACTERIUM DESULFOTALEA PSYCHROPHILA 1GT5 ; 2.08 ; COMPLEXE OF BOVINE ODORANT BINDING PROTEIN WITH BENZOPHENONE 2CC6 ; 1.27 ; COMPLEXES OF DODECIN WITH FLAVIN AND FLAVIN-LIKE LIGANDS 2CC7 ; 1.8 ; COMPLEXES OF DODECIN WITH FLAVIN AND FLAVIN-LIKE LIGANDS 2CC8 ; 1.9 ; COMPLEXES OF DODECIN WITH FLAVIN AND FLAVIN-LIKE LIGANDS 2CC9 ; 1.55 ; COMPLEXES OF DODECIN WITH FLAVIN AND FLAVIN-LIKE LIGANDS 2CCB ; 1.65 ; COMPLEXES OF DODECIN WITH FLAVIN AND FLAVIN-LIKE LIGANDS 2CCC ; 1.7 ; COMPLEXES OF DODECIN WITH FLAVIN AND FLAVIN-LIKE LIGANDS 2CIE ; 1.8 ; COMPLEXES OF DODECIN WITH FLAVIN AND FLAVIN-LIKE LIGANDS 2CIF ; 2.8 ; COMPLEXES OF DODECIN WITH FLAVIN AND FLAVIN-LIKE LIGANDS 2CJC ; 1.85 ; COMPLEXES OF DODECIN WITH FLAVIN AND FLAVIN-LIKE LIGANDS 2VKF ; 1.7 ; COMPLEXES OF DODECIN WITH FLAVIN AND FLAVIN-LIKE LIGANDS 2VKG ; 1.8 ; COMPLEXES OF DODECIN WITH FLAVIN AND FLAVIN-LIKE LIGANDS 4B2M ; 2 ; COMPLEXES OF DODECIN WITH FLAVIN AND FLAVIN-LIKE LIGANDS 4B2H ; 1.6 ; COMPLEXES OF DODECIN WITH FLAVIN AND FLAVIN-LIKE LIGANDS 4ANW ; 2.31 ; Complexes of PI3Kgamma with isoform selective inhibitors. 4ANX ; 2.73 ; Complexes of PI3Kgamma with isoform selective inhibitors. 4ANU ; 2.81 ; Complexes of PI3Kgamma with isoform selective inhibitors. 4ANV ; 2.13 ; Complexes of PI3Kgamma with isoform selective inhibitors. 1WQZ ; 3 ; Complicated water orientations in the minor groove of B-DNA decamer D(CCATTAATGG)2 observed by neutron diffraction measurements 1HQI ; ; COMPONENT P2 FROM THE MULTICOMPONENT PHENOL HYDROXYLASE, NMR, 11 STRUCTURES 1T1O ; 12 ; Components of the control 70S ribosome to provide reference for the RRF binding site 4HLE ; 2.78 ; Compound 21 (1-alkyl-substituted 1,2,4-triazoles) 1MQF ; 2.5 ; Compound I from Proteus mirabilis catalase 1GWF ; 1.96 ; COMPOUND II STRUCTURE OF MICROCOCCUS LYSODEIKTICUS CATALASE 1A1P ; ; COMPSTATIN, NMR, 21 STRUCTURES 2HP4 ; 2.1 ; Computational design and crystal structure of an enhanced affinity mutant human CD8-alpha-alpha co-receptor 3V86 ; 2.91 ; Computational Design of a Protein Crystal 2LLE ; ; Computational design of an eight-stranded (beta/alpha)-barrel from fragments of different folds 3E0L ; 2.37 ; Computationally Designed Ammelide Deaminase 3MFC ; 1.7 ; Computationally designed end0-1,4-beta,xylanase 3MF6 ; 1.28 ; Computationally designed endo-1,4-beta-xylanase 3MF9 ; 1.7 ; Computationally designed endo-1,4-beta-xylanase 3MFA ; 1.63 ; Computationally designed endo-1,4-beta-xylanase 1PSV ; ; COMPUTATIONALLY DESIGNED PEPTIDE WITH A BETA-BETA-ALPHA FOLD SELECTION, NMR, 32 STRUCTURES 4DDF ; 3.15 ; Computationally Designed Self-assembling Octahedral Cage protein, O333, Crystallized in space group P4 3VCD ; 2.35 ; Computationally Designed Self-assembling Octahedral Cage protein, O333, Crystallized in space group R32 4DCL ; 3.35 ; Computationally Designed Self-assembling tetrahedron protein, T308, Crystallized in space group F23 4EGG ; 2.21 ; Computationally Designed Self-assembling tetrahedron protein, T310 3TDM ; 2.4 ; Computationally designed TIM-barrel protein, HalfFLR 3TDN ; 1.4 ; Computationally designed two-fold symmetric Tim-barrel protein, FLR 1JBC ; 1.15 ; CONCANAVALIN A 1NLS ; 0.94 ; CONCANAVALIN A AND ITS BOUND SOLVENT AT 0.94A RESOLUTION 1CJP ; 2.78 ; CONCANAVALIN A COMPLEX WITH 4'-METHYLUMBELLIFERYL-ALPHA-D-GLUCOPYRANOSIDE 1VAL ; 3 ; CONCANAVALIN A COMPLEX WITH 4'-NITROPHENYL-ALPHA-D-GLUCOPYRANOSIDE 1VAM ; 2.75 ; CONCANAVALIN A COMPLEX WITH 4'-NITROPHENYL-ALPHA-D-MANNOPYRANOSIDE 3D4K ; 1.8 ; Concanavalin A Complexed to a Synthetic Analog of the Trimannoside 1BXH ; 2.75 ; CONCANAVALIN A COMPLEXED TO METHYL ALPHA1-2 MANNOBIOSIDE 1CVN ; 2.3 ; CONCANAVALIN A COMPLEXED TO TRIMANNOSIDE 1GIC ; 2 ; CONCANAVALIN A COMPLEXED WITH METHYL ALPHA-D-GLUCOPYRANOSIDE 1GKB ; 1.56 ; CONCANAVALIN A, NEW CRYSTAL FORM 1JUI ; 2.75 ; CONCANAVALIN A-CARBOHYDRATE MIMICKING 10-MER PEPTIDE COMPLEX 1I3H ; 1.2 ; CONCANAVALIN A-DIMANNOSE STRUCTURE 1JOJ ; 3 ; CONCANAVALIN A-HEXAPEPTIDE COMPLEX 1JYI ; 2.75 ; CONCANAVALIN A/12-MER PEPTIDE COMPLEX 1JYC ; 2.75 ; CONCANAVALIN A/15-mer PEPTIDE COMPLEX 1AZD ; 3 ; CONCANAVALIN FROM CANAVALIA BRASILIENSIS 2K10 ; ; Confirmational analysis of the broad-spectrum antibacterial peptide, rantuerin-2csa: identification of a full length helix-turn-helix motif 2C7U ; 2.38 ; CONFLICTING SELECTIVE FORCES AFFECT CD8 T-CELL RECEPTOR CONTACT SITES IN AN HLA-A2 IMMUNODOMINANT HIV EPITOPE. 1ZNA ; 1.5 ; CONFORMATION AND DYNAMICS IN A Z-DNA TETRAMER 1CAP ; 3 ; CONFORMATION AND MOLECULAR ORGANIZATION IN FIBERS OF THE CAPSULAR POLYSACCHARIDE FROM ESCHERICHIA COLI M41 MUTANT 1D6V ; 2 ; CONFORMATION EFFECTS IN BIOLOGICAL CATALYSIS INTRODUCED BY OXY-COPE ANTIBODY MATURATION 2LBR ; ; Conformation Effects of Base Modification on the Anticodon Stem-loop of Bacillus subtilis tRNATYR 1EFS ; ; CONFORMATION OF A DNA-RNA HYBRID 1KAJ ; ; CONFORMATION OF AN RNA PSEUDOKNOT FROM MOUSE MAMMARY TUMOR VIRUS, NMR, 1 STRUCTURE 1MRT ; ; CONFORMATION OF CD-7 METALLOTHIONEIN-2 FROM RAT LIVER IN AQUEOUS SOLUTION DETERMINED BY NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY 2MRT ; ; CONFORMATION OF CD-7 METALLOTHIONEIN-2 FROM RAT LIVER IN AQUEOUS SOLUTION DETERMINED BY NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY 2JQS ; ; Conformation of DIP-AST5 from 2D NMR data 2JQU ; ; Conformation of DIP-AST8 from 2D NMR data 3IZP ; ; Conformation of EF-G during translocation 1KES ; 3 ; CONFORMATION OF KERATAN SULPHATE 2HQC ; 3.56 ; Conformation of the AcrB Multidrug Efflux Pump in Mutants of the Putative Proton Relay Pathway 2HQD ; 3.65 ; Conformation of the AcrB Multidrug Efflux Pump in Mutants of the Putative Proton Relay Pathway 2HQF ; 3.38 ; Conformation of the AcrB Multidrug Efflux Pump in Mutants of the Putative Proton Relay Pathway 2HQG ; 3.38 ; Conformation of the AcrB Multidrug Efflux Pump in Mutants of the Putative Proton Relay Pathway 1D75 ; 2.8 ; CONFORMATION OF THE GUANINE.8-OXOADENINE BASE PAIRS IN THE CRYSTAL STRUCTURE OF D(CGCGAATT(O8A)GCG) 1ALE ; ; CONFORMATION OF TWO PEPTIDES CORRESPONDING TO HUMAN APOLIPOPROTEIN C-I RESIDUES 7-24 AND 35-53 IN THE PRESENCE OF SODIUM DODECYLSULFATE BY CD AND NMR SPECTROSCOPY 1ALF ; ; CONFORMATION OF TWO PEPTIDES CORRESPONDING TO HUMAN APOLIPOPROTEIN C-I RESIDUES 7-24 AND 35-53 IN THE PRESENCE OF SODIUM DODECYLSULFATE BY CD AND NMR SPECTROSCOPY 1Y4S ; 2.9 ; Conformation rearrangement of heat shock protein 90 upon ADP binding 1Y4U ; 2.9 ; Conformation rearrangement of heat shock protein 90 upon ADP binding 2LTJ ; ; Conformational analysis of StrH, the surface-attached exo- beta-D-N-acetylglucosaminidase from Streptococcus pneumoniae 2L5R ; ; Conformational and membrane interactins studies of antimicrobial peptide Alyteserin-1C 1ZE1 ; 2.9 ; Conformational Change of Pseudouridine 55 Synthase upon Its Association with RNA Substrate 1ZE2 ; 3 ; Conformational change of pseudouridine 55 synthase upon its association with RNA substrate 1APH ; 2 ; CONFORMATIONAL CHANGES IN CUBIC INSULIN CRYSTALS IN THE PH RANGE 7-11 1BPH ; 2 ; CONFORMATIONAL CHANGES IN CUBIC INSULIN CRYSTALS IN THE PH RANGE 7-11 1CPH ; 1.9 ; CONFORMATIONAL CHANGES IN CUBIC INSULIN CRYSTALS IN THE PH RANGE 7-11 1DPH ; 1.9 ; CONFORMATIONAL CHANGES IN CUBIC INSULIN CRYSTALS IN THE PH RANGE 7-11 2TUN ; 3.1 ; CONFORMATIONAL CHANGES IN THE (ALA-84-VAL) MUTANT OF TUMOR NECROSIS FACTOR 2YJ3 ; 2.2 ; Conformational changes in the catalytic domain of the CPx-ATPase CopB- B upon nucleotide binding 2YJ4 ; 2.4 ; Conformational changes in the catalytic domain of the CPx-ATPase CopB- B upon nucleotide binding 2YJ5 ; 2.4 ; Conformational changes in the catalytic domain of the CPx-ATPase CopB- B upon nucleotide binding 2YJ6 ; 2.2 ; Conformational changes in the catalytic domain of the CPx-ATPase CopB- B upon nucleotide binding 1NNO ; 2.65 ; CONFORMATIONAL CHANGES OCCURRING UPON NO BINDING IN NITRITE REDUCTASE FROM PSEUDOMONAS AERUGINOSA 1BL9 ; 2.9 ; CONFORMATIONAL CHANGES OCCURRING UPON REDUCTION IN NITRITE REDUCTASE FROM PSEUDOMONAS AERUGINOSA 3BCG ; 2.48 ; Conformational changes of the AcrR regulator reveal a mechanism of induction 3F6Y ; 1.45 ; Conformational Closure of the Catalytic Site of Human CD38 Induced by Calcium 4AOK ; 1.5 ; Conformational dynamics of aspartate alpha-decarboxylase active site revealed by protein-ligand complexes: 1-methyl-L-aspartate complex 4AON ; 1.5 ; Conformational dynamics of aspartate alpha-decarboxylase active site revealed by protein-ligand complexes: 1-methyl-L-aspartate complex 4F7Z ; 2.6 ; Conformational dynamics of exchange protein directly activated by cAMP 2L0R ; ; Conformational Dynamics of the Anthrax Lethal Factor Catalytic Center 2LWA ; ; Conformational ensemble for the G8A mutant of the influenza hemagglutinin fusion peptide 2F1M ; 2.71 ; Conformational flexibility in the multidrug efflux system protein AcrA 2CEK ; 2.2 ; CONFORMATIONAL FLEXIBILITY IN THE PERIPHERAL SITE OF TORPEDO CALIFORNICA ACETYLCHOLINESTERASE REVEALED BY THE COMPLEX STRUCTURE WITH A BIFUNCTIONAL INHIBITOR 1W28 ; 2.3 ; CONFORMATIONAL FLEXIBILITY OF THE C-TERMINUS WITH IMPLICATIONS FOR SUBSTRATE BINDING AND CATALYSIS IN A NEW CRYSTAL FORM OF DEACETOXYCEPHALOSPORIN C SYNTHASE 2BKE ; 3.2 ; CONFORMATIONAL FLEXIBILITY REVEALED BY THE CRYSTAL STRUCTURE OF A CRENARCHAEAL RADA 1ND7 ; 2.1 ; Conformational Flexibility Underlies Ubiquitin Ligation Mediated by the WWP1 HECT domain E3 Ligase 1D87 ; 2.25 ; CONFORMATIONAL INFLUENCE OF THE RIBOSE 2'-HYDROXYL GROUP: CRYSTAL STRUCTURES OF DNA-RNA CHIMERIC DUPLEXES 1D88 ; 2 ; CONFORMATIONAL INFLUENCE OF THE RIBOSE 2'-HYDROXYL GROUP: CRYSTAL STRUCTURES OF DNA-RNA CHIMERIC DUPLEXES 1EDP ; ; CONFORMATIONAL ISOMERISM OF ENDOTHELIN IN ACIDIC AQUEOUS MEDIA: A QUANTITATIVE NOESY ANALYSIS 1TIB ; 1.84 ; CONFORMATIONAL LABILITY OF LIPASES OBSERVED IN THE ABSENCE OF AN OIL-WATER INTERFACE: CRYSTALLOGRAPHIC STUDIES OF ENZYMES FROM THE FUNGI HUMICOLA LANUGINOSA AND RHIZOPUS DELEMAR 1TIC ; 2.6 ; CONFORMATIONAL LABILITY OF LIPASES OBSERVED IN THE ABSENCE OF AN OIL-WATER INTERFACE: CRYSTALLOGRAPHIC STUDIES OF ENZYMES FROM THE FUNGI HUMICOLA LANUGINOSA AND RHIZOPUS DELEMAR 1SSZ ; ; Conformational mapping of mini-b: an n-terminal/c-terminal construct of surfactant protein b using 13c-enhanced fourier transform infrared (FTIR) spectroscopy 1ERF ; ; CONFORMATIONAL MAPPING OF THE N-TERMINAL FUSION PEPTIDE OF HIV-1 GP41 USING 13C-ENHANCED FOURIER TRANSFORM INFRARED SPECTROSCOPY (FTIR) 1P5A ; ; Conformational Mapping of the N-terminal Peptide of HIV-1 GP41 in lipid detergent and aqueous environments using 13C-enhanced Fourier Transform Infrared Spectroscopy 1DFW ; ; CONFORMATIONAL MAPPING OF THE N-TERMINAL SEGMENT OF SURFACTANT PROTEIN B IN LIPID USING 13C-ENHANCED FOURIER TRANSFORM INFRARED SPECTROSCOPY (FTIR) 2GHC ; 1.25 ; Conformational mobility in the active site of a heme peroxidase 2GHD ; 1.4 ; Conformational mobility in the active site of a heme peroxidase 2GHE ; 1.75 ; Conformational mobility in the active site of a heme peroxidase 2GHH ; 2.013 ; Conformational mobility in the active site of a heme peroxidase 2GHK ; 1.999 ; Conformational mobility in the active site of a heme peroxidase 2GGN ; 1.35 ; Conformational mobility in the active site of a heme peroxidase 5CA2 ; 2.1 ; CONFORMATIONAL MOBILITY OF HIS-64 IN THE THR-200 (RIGHT ARROW) SER MUTANT OF HUMAN CARBONIC ANHYDRASE II 1CE4 ; ; CONFORMATIONAL MODEL FOR THE CONSENSUS V3 LOOP OF THE ENVELOPE PROTEIN GP120 OF HIV-1 3MPA ; 2.1 ; Conformational plasticity of p38 MAP kinase DFG motif mutants in response to inhibitor binding 3O8P ; 2.1 ; Conformational plasticity of p38 MAP kinase DFG motif mutants in response to inhibitor binding 3O8U ; 2.1 ; Conformational plasticity of p38 MAP kinase DFG motif mutants in response to inhibitor binding 3OC1 ; 2.59 ; Conformational plasticity of p38 MAP kinase DFG motif mutants in response to inhibitor binding 3OBG ; 2.8 ; Conformational plasticity of p38 MAP kinase DFG mutants in response to inhibitor binding 3OBJ ; 2.4 ; Conformational plasticity of p38 MAP kinase DFG mutants in response to inhibitor binding 3O8T ; 2 ; Conformational plasticity of p38 MAP kinase DFG-motif mutants in response to inhibitor binding 3IAO ; 2.8 ; Conformational plasticity of the coiled coil domain of BmrR is required for bmr promoter binding-the unliganded structure of BmrR 1XH3 ; 1.48 ; Conformational Restraints and Flexibility of 14-Meric Peptides in Complex with HLA-B*3501 1QX3 ; 1.9 ; Conformational restrictions in the active site of unliganded human caspase-3 1SRB ; ; CONFORMATIONAL STUDIES ON SRTB, A NON-SELECTIVE ENDOTHELIN RECEPTOR AGONIST, AND ON IRL 1620, AN ETB RECEPTOR SPECIFIC AGONIST 1T0M ; 2 ; Conformational switch in polymorphic H-2K molecules containing an HSV peptide 1T0N ; 1.8 ; Conformational switch in polymorphic H-2K molecules containing an HSV peptide 2GUS ; 1.75 ; Conformational Transition between Four- and Five-stranded Phenylalanine Zippers Determined by a Local Packing Interaction 2GUV ; 1.4 ; Conformational Transition between Four- and Five-stranded Phenylalanine Zippers Determined by a Local Packing Interaction 4FBP ; 2.5 ; CONFORMATIONAL TRANSITION OF FRUCTOSE-1,6-BISPHOSPHATASE: STRUCTURE COMPARISON BETWEEN THE AMP COMPLEX (T FORM) AND THE FRUCTOSE 6-PHOSPHATE COMPLEX (R FORM) 1OEL ; 2.8 ; CONFORMATIONAL VARIABILITY IN THE REFINED STRUCTURE OF THE CHAPERONIN GROEL AT 2.8 ANGSTROM RESOLUTION 1MEC ; 3.2 ; CONFORMATIONAL VARIABILITY OF A PICORNAVIRUS CAPSID: PH-DEPENDENT STRUCTURAL CHANGES OF MENGO VIRUS RELATED TO ITS HOST RECEPTOR ATTACHMENT SITE AND DISASSEMBLY 4EBE ; 2.1 ; Conformationally Restrained North-methanocarba-2'-deoxyadenosine Corrects the Error-Prone Nature of Human DNA Polymerase Iota 4EBD ; 2.571 ; Conformationally Restrained North-methanocarba-2'-deoxyadenosine Corrects the Error-Prone Nature of Human DNA Polymerase Iota 4EBC ; 2.901 ; Conformationally Restrained North-methanocarba-2'-deoxyadenosine Corrects the Error-Prone Nature of Human DNA Polymerase Iota 1CCJ ; 2.1 ; CONFORMER SELECTION BY LIGAND BINDING OBSERVED WITH PROTEIN CRYSTALLOGRAPHY 1WLD ; 1.6 ; Congerin II T88I single mutant 1WLW ; 1.8 ; Congerin II Y16S single mutant 1WLC ; 2 ; Congerin II Y16S/T88I double mutant 1ZM5 ; 2.5 ; Conjugative Relaxase TRWC in complex with ORIT dna, cooper-bound structure 1QX0 ; 2.26 ; CONJUGATIVE RELAXASE TRWC IN COMPLEX WITH ORIT DNA. METAL-BOUND STRUCTURE 1S6M ; 2.28 ; Conjugative Relaxase Trwc In Complex With Orit DNA. Metal-Bound Structure 1OMH ; 1.95 ; Conjugative Relaxase TrwC in complex with OriT Dna. Metal-free structure. 1OSB ; 2.65 ; Conjugative Relaxase TrwC in complex with OriT Dna. Metal-free structure. 2CA7 ; ; CONKUNITZIN-S1 IS THE FIRST MEMBER OF A NEW KUNITZ-TYPE NEUROTOXIN FAMILY- STRUCTURAL AND FUNCTIONAL CHARACTERIZATION 2J6D ; ; CONKUNITZIN-S2 - CONE SNAIL NEUROTOXIN - DENOVO STRUCTURE 1FOU ; 3.2 ; CONNECTOR PROTEIN FROM BACTERIOPHAGE PHI29 1JNB ; 3.2 ; CONNECTOR PROTEIN FROM BACTERIOPHAGE PHI29 1R5S ; ; Connexin 43 Carboxyl Terminal Domain 2LOC ; ; Conotoxin analogue [D-Ala2]BuIIIB 1AG7 ; ; CONOTOXIN GS, NMR, 20 STRUCTURES 2LER ; ; Conotoxin pc16a 2XKM ; 3.3 ; Consensus structure of Pf1 filamentous bacteriophage from X-ray fibre diffraction and solid-state NMR 149L ; 2.6 ; CONSERVATION OF SOLVENT-BINDING SITES IN 10 CRYSTAL FORMS OF T4 LYSOZYME 150L ; 2.2 ; CONSERVATION OF SOLVENT-BINDING SITES IN 10 CRYSTAL FORMS OF T4 LYSOZYME 151L ; 2.2 ; CONSERVATION OF SOLVENT-BINDING SITES IN 10 CRYSTAL FORMS OF T4 LYSOZYME 152L ; 2 ; CONSERVATION OF SOLVENT-BINDING SITES IN 10 CRYSTAL FORMS OF T4 LYSOZYME 16VP ; 2.1 ; CONSERVED CORE OF THE HERPES SIMPLEX VIRUS TRANSCRIPTIONAL REGULATORY PROTEIN VP16 2G7Z ; 2.05 ; Conserved DegV-like Protein of Unknown Function from Streptococcus pyogenes M1 GAS Binds Long-chain Fatty Acids 2FPE ; 1.75 ; Conserved dimerization of the ib1 src-homology 3 domain 1EO0 ; ; CONSERVED DOMAIN COMMON TO TRANSCRIPTION FACTORS TFIIS, ELONGIN A, CRSP70 2I7R ; 2.2 ; conserved domain protein 3HVP ; 2.8 ; CONSERVED FOLDING IN RETROVIRAL PROTEASES. CRYSTAL STRUCTURE OF A SYNTHETIC HIV-1 PROTEASE 2XET ; 1.6 ; CONSERVED HYDROPHOBIC CLUSTERS ON THE SURFACE OF THE CAF1A USHER C-TERMINAL DOMAIN ARE IMPORTANT FOR F1 ANTIGEN ASSEMBLY 2EHW ; 2.22 ; Conserved hypothetical proteim (TTHB059) from Thermo thermophilus HB8 2EJQ ; 2.08 ; Conserved hypothetical protein (TTHA0227) from Thermo thermophilus HB8 1YBX ; 1.8 ; Conserved hypothetical protein Cth-383 from Clostridium thermocellum 1YBY ; 1.95 ; Conserved hypothetical protein Cth-95 from Clostridium thermocellum 1XRG ; 2.2 ; Conserved hypothetical protein from Clostridium thermocellum Cth-2968 1YBZ ; 1.82 ; Conserved hypothetical protein from Pyrococcus furiosus Pfu-1581948-001 1VK1 ; 1.2 ; Conserved hypothetical protein from Pyrococcus furiosus Pfu-392566-001 1XX7 ; 2.261 ; Conserved hypothetical protein from Pyrococcus furiosus Pfu-403030-001 1YD7 ; 2.3 ; Conserved hypothetical protein Pfu-1647980-001 from Pyrococcus furiosus 1YB3 ; 1.6 ; Conserved hypothetical protein Pfu-178653-001 from Pyrococcus furiosus 1YCY ; 2.8 ; Conserved hypothetical protein Pfu-1806301-001 from Pyrococcus furiosus 1Y82 ; 2.3 ; Conserved hypothetical protein Pfu-367848-001 from Pyrococcus furiosus 1Y81 ; 1.701 ; Conserved hypothetical protein Pfu-723267-001 from Pyrococcus furiosus 1YEM ; 2.3 ; Conserved hypothetical protein Pfu-838710-001 from Pyrococcus furiosus 1XG7 ; 1.88 ; Conserved hypothetical protein Pfu-877259-001 from Pyrococcus furiosus 1WCJ ; ; CONSERVED HYPOTHETICAL PROTEIN TM0487 FROM THERMOTOGA MARITIMA 2ESR ; 1.8 ; conserved hypothetical protein- streptococcus pyogenes 2YGV ; 2.94 ; Conserved N-terminal domain of the yeast Histone Chaperone Asf1 in complex with the C-terminal fragment of Rad53 1VOP ; ; CONSERVED RNA COMPONENT OF THE PEPTIDYL TRANSFERASE CENTER, NMR, 33 STRUCTURES 1KP7 ; ; Conserved RNA Structure within the HCV IRES eIF3 Binding Site 2R27 ; 2 ; Constitutively zinc-deficient mutant of human superoxide dismutase (SOD), C6A, H80S, H83S, C111S 1CCE ; 2.3 ; CONSTRUCTION OF A BIS-AQUO HEME ENZYME AND REPLACEMENT WITH EXOGENOUS LIGAND 1CCG ; 2.1 ; CONSTRUCTION OF A BIS-AQUO HEME ENZYME AND REPLACEMENT WITH EXOGENOUS LIGAND 1X18 ; 13.5 ; Contact sites of ERA GTPase on the THERMUS THERMOPHILUS 30S SUBUNIT 1CIS ; ; CONTEXT DEPENDENCE OF PROTEIN SECONDARY STRUCTURE FORMATION. THE THREE-DIMENSIONAL STRUCTURE AND STABILITY OF A HYBRID BETWEEN CHYMOTRYPSIN INHIBITOR 2 AND HELIX E FROM SUBTILISIN CARLSBERG 1F23 ; 2.3 ; CONTRIBUTION OF A BURIED HYDROGEN BOND TO HIV-1 ENVELOPE GLYCOPROTEIN STRUCTURE AND FUNCTION 3C8Q ; 1.64 ; Contribution of all 20 amino acids at site 96 to the stability and structure of T4 lysozyme 1FFA ; 1.69 ; CONTRIBUTION OF CUTINASE SERINE 42 SIDE CHAIN TO THE STABILIZATION OF THE OXYANION TRANSITION STATE 1FFB ; 1.75 ; CONTRIBUTION OF CUTINASE SERINE 42 SIDE CHAIN TO THE STABILIZATION OF THE OXYANION TRANSITION STATE 1FFC ; 1.75 ; CONTRIBUTION OF CUTINASE SERINE 42 SIDE CHAIN TO THE STABILIZATION OF THE OXYANION TRANSITION STATE 1FFD ; 1.69 ; CONTRIBUTION OF CUTINASE SERINE 42 SIDE CHAIN TO THE STABILIZATION OF THE OXYANION TRANSITION STATE 1FFE ; 1.69 ; CONTRIBUTION OF CUTINASE SERINE 42 SIDE CHAIN TO THE STABILIZATION OF THE OXYANION TRANSITION STATE 4DM1 ; 1.75 ; Contribution of disulfide bond toward thermostability in hyperthermostable endocellulase 4DM2 ; 1.95 ; Contribution of disulfide bond toward thermostability in hyperthermostable endocellulase 3W6M ; 1.948 ; Contribution of disulfide bond toward thermostability in hyperthermostable endocellulase 3W6L ; 1.751 ; Contribution of disulfide bond toward thermostability in hyperthermostable endocellulase 1WQM ; 1.8 ; CONTRIBUTION OF HYDROGEN BONDS TO THE CONFORMATIONAL STABILITY OF HUMAN LYSOZYME 1WQN ; 1.8 ; CONTRIBUTION OF HYDROGEN BONDS TO THE CONFORMATIONAL STABILITY OF HUMAN LYSOZYME 1WQO ; 1.8 ; CONTRIBUTION OF HYDROGEN BONDS TO THE CONFORMATIONAL STABILITY OF HUMAN LYSOZYME 1WQP ; 1.8 ; CONTRIBUTION OF HYDROGEN BONDS TO THE CONFORMATIONAL STABILITY OF HUMAN LYSOZYME 1WQQ ; 1.8 ; CONTRIBUTION OF HYDROGEN BONDS TO THE CONFORMATIONAL STABILITY OF HUMAN LYSOZYME 1WQR ; 1.8 ; CONTRIBUTION OF HYDROGEN BONDS TO THE CONFORMATIONAL STABILITY OF HUMAN LYSOZYME 1B5U ; 1.8 ; CONTRIBUTION OF HYDROGEN BONDS TO THE CONFORMATIONAL STABILITY OF HUMAN LYSOZYME: CALORIMETRY AND X-RAY ANALYSIS OF SIX SER->ALA MUTANT 1B5V ; 2.17 ; CONTRIBUTION OF HYDROGEN BONDS TO THE CONFORMATIONAL STABILITY OF HUMAN LYSOZYME: CALORIMETRY AND X-RAY ANALYSIS OF SIX SER->ALA MUTANTS 1B5W ; 2.17 ; CONTRIBUTION OF HYDROGEN BONDS TO THE CONFORMATIONAL STABILITY OF HUMAN LYSOZYME: CALORIMETRY AND X-RAY ANALYSIS OF SIX SER->ALA MUTANTS 1B5X ; 2 ; Contribution of hydrogen bonds to the conformational stability of human lysozyme: calorimetry and x-ray analysis of six ser->ala mutants 1B5Y ; 2.2 ; CONTRIBUTION OF HYDROGEN BONDS TO THE CONFORMATIONAL STABILITY OF HUMAN LYSOZYME: CALORIMETRY AND X-RAY ANALYSIS OF SIX SER->ALA MUTANTS 1B5Z ; 2.2 ; CONTRIBUTION OF HYDROGEN BONDS TO THE CONFORMATIONAL STABILITY OF HUMAN LYSOZYME: CALORIMETRY AND X-RAY ANALYSIS OF SIX SER->ALA MUTANTS 2BQA ; 1.8 ; CONTRIBUTION OF HYDROPHOBIC EFFECT TO THE CONFORMATIONAL STABILITY OF HUMAN LYSOZYME 2BQB ; 1.8 ; CONTRIBUTION OF HYDROPHOBIC EFFECT TO THE CONFORMATIONAL STABILITY OF HUMAN LYSOZYME 2BQC ; 1.8 ; CONTRIBUTION OF HYDROPHOBIC EFFECT TO THE CONFORMATIONAL STABILITY OF HUMAN LYSOZYME 2BQD ; 1.8 ; CONTRIBUTION OF HYDROPHOBIC EFFECT TO THE CONFORMATIONAL STABILITY OF HUMAN LYSOZYME 2BQE ; 1.8 ; CONTRIBUTION OF HYDROPHOBIC EFFECT TO THE CONFORMATIONAL STABILITY OF HUMAN LYSOZYME 2BQF ; 1.8 ; CONTRIBUTION OF HYDROPHOBIC EFFECT TO THE CONFORMATIONAL STABILITY OF HUMAN LYSOZYME 2BQG ; 1.8 ; CONTRIBUTION OF HYDROPHOBIC EFFECT TO THE CONFORMATIONAL STABILITY OF HUMAN LYSOZYME 2BQH ; 1.8 ; CONTRIBUTION OF HYDROPHOBIC EFFECT TO THE CONFORMATIONAL STABILITY OF HUMAN LYSOZYME 2BQI ; 1.8 ; CONTRIBUTION OF HYDROPHOBIC EFFECT TO THE CONFORMATIONAL STABILITY OF HUMAN LYSOZYME 2BQJ ; 1.8 ; CONTRIBUTION OF HYDROPHOBIC EFFECT TO THE CONFORMATIONAL STABILITY OF HUMAN LYSOZYME 2BQK ; 1.8 ; CONTRIBUTION OF HYDROPHOBIC EFFECT TO THE CONFORMATIONAL STABILITY OF HUMAN LYSOZYME 2BQL ; 1.8 ; CONTRIBUTION OF HYDROPHOBIC EFFECT TO THE CONFORMATIONAL STABILITY OF HUMAN LYSOZYME 2BQM ; 1.8 ; CONTRIBUTION OF HYDROPHOBIC EFFECT TO THE CONFORMATIONAL STABILITY OF HUMAN LYSOZYME 2BQN ; 1.8 ; CONTRIBUTION OF HYDROPHOBIC EFFECT TO THE CONFORMATIONAL STABILITY OF HUMAN LYSOZYME 2BQO ; 1.8 ; CONTRIBUTION OF HYDROPHOBIC EFFECT TO THE CONFORMATIONAL STABILITY OF HUMAN LYSOZYME 2MED ; 1.8 ; CONTRIBUTION OF HYDROPHOBIC EFFECT TO THE CONFORMATIONAL STABILITY OF HUMAN LYSOZYME 2MEE ; 1.8 ; CONTRIBUTION OF HYDROPHOBIC EFFECT TO THE CONFORMATIONAL STABILITY OF HUMAN LYSOZYME 2MEF ; 1.8 ; CONTRIBUTION OF HYDROPHOBIC EFFECT TO THE CONFORMATIONAL STABILITY OF HUMAN LYSOZYME 2MEH ; 1.8 ; CONTRIBUTION OF HYDROPHOBIC EFFECT TO THE CONFORMATIONAL STABILITY OF HUMAN LYSOZYME 2MEI ; 1.8 ; CONTRIBUTION OF HYDROPHOBIC EFFECT TO THE CONFORMATIONAL STABILITY OF HUMAN LYSOZYME 1YAM ; 1.8 ; CONTRIBUTION OF HYDROPHOBIC RESIDUES TO THE STABILITY OF HUMAN LYSOZYME: CALORIMETRIC STUDIES AND X-RAY STRUCTURAL ANALYSIS OF THE FIVE ISOLEUCINE TO VALINE MUTANTS 1YAN ; 1.8 ; CONTRIBUTION OF HYDROPHOBIC RESIDUES TO THE STABILITY OF HUMAN LYSOZYME: CALORIMETRIC STUDIES AND X-RAY STRUCTURAL ANALYSIS OF THE FIVE ISOLEUCINE TO VALINE MUTANTS 1YAO ; 1.8 ; CONTRIBUTION OF HYDROPHOBIC RESIDUES TO THE STABILITY OF HUMAN LYSOZYME: CALORIMETRIC STUDIES AND X-RAY STRUCTURAL ANALYSIS OF THE FIVE ISOLEUCINE TO VALINE MUTANTS 1YAP ; 1.8 ; CONTRIBUTION OF HYDROPHOBIC RESIDUES TO THE STABILITY OF HUMAN LYSOZYME: CALORIMETRIC STUDIES AND X-RAY STRUCTURAL ANALYSIS OF THE FIVE ISOLEUCINE TO VALINE MUTANTS 1YAQ ; 1.8 ; CONTRIBUTION OF HYDROPHOBIC RESIDUES TO THE STABILITY OF HUMAN LYSOZYME: CALORIMETRIC STUDIES AND X-RAY STRUCTURAL ANALYSIS OF THE FIVE ISOLEUCINE TO VALINE MUTANTS 1OUA ; 1.8 ; CONTRIBUTION OF HYDROPHOBIC RESIDUES TO THE STABILITY OF HUMAN LYSOZYME: X-RAY STRUCTURE OF THE I56T MUTANT 1OUB ; 1.8 ; CONTRIBUTION OF HYDROPHOBIC RESIDUES TO THE STABILITY OF HUMAN LYSOZYME: X-RAY STRUCTURE OF THE V100A MUTANT 1OUC ; 1.8 ; CONTRIBUTION OF HYDROPHOBIC RESIDUES TO THE STABILITY OF HUMAN LYSOZYME: X-RAY STRUCTURE OF THE V110A MUTANT 1OUD ; 1.8 ; CONTRIBUTION OF HYDROPHOBIC RESIDUES TO THE STABILITY OF HUMAN LYSOZYME: X-RAY STRUCTURE OF THE V121A MUTANT 1OUE ; 1.8 ; CONTRIBUTION OF HYDROPHOBIC RESIDUES TO THE STABILITY OF HUMAN LYSOZYME: X-RAY STRUCTURE OF THE V125A MUTANT 1OUF ; 1.8 ; CONTRIBUTION OF HYDROPHOBIC RESIDUES TO THE STABILITY OF HUMAN LYSOZYME: X-RAY STRUCTURE OF THE V130A MUTANT 1OUG ; 1.8 ; CONTRIBUTION OF HYDROPHOBIC RESIDUES TO THE STABILITY OF HUMAN LYSOZYME: X-RAY STRUCTURE OF THE V2A MUTANT 1OUH ; 1.8 ; CONTRIBUTION OF HYDROPHOBIC RESIDUES TO THE STABILITY OF HUMAN LYSOZYME: X-RAY STRUCTURE OF THE V74A MUTANT 1OUI ; 1.8 ; CONTRIBUTION OF HYDROPHOBIC RESIDUES TO THE STABILITY OF HUMAN LYSOZYME: X-RAY STRUCTURE OF THE V93A MUTANT 1OUJ ; 1.8 ; CONTRIBUTION OF HYDROPHOBIC RESIDUES TO THE STABILITY OF HUMAN LYSOZYME: X-RAY STRUCTURE OF THE V99A MUTANT 2NVB ; 2.8 ; Contribution of Pro275 to the Thermostability of the Alcohol Dehydrogenases (ADHs) 1W8O ; 1.7 ; CONTRIBUTION OF THE ACTIVE SITE ASPARTIC ACID TO CATALYSIS IN THE BACTERIAL NEURAMINIDASE FROM MICROMONOSPORA VIRIDIFACIENS 1W8N ; 2.1 ; CONTRIBUTION OF THE ACTIVE SITE ASPARTIC ACID TO CATALYSIS IN THE BACTERIAL NEURAMINIDASE FROM MICROMONOSPORA VIRIDIFACIENS. 3VKE ; 1.77 ; Contribution of the first K-homology domain of poly(C)-binding protein 1 to its affinity and specificity for C-rich oligonucleotides 2HEA ; 1.8 ; CONTRIBUTION OF WATER MOLECULES IN THE INTERIOR OF A PROTEIN TO THE CONFORMATIONAL STABILITY 2HEB ; 2.2 ; CONTRIBUTION OF WATER MOLECULES IN THE INTERIOR OF A PROTEIN TO THE CONFORMATIONAL STABILITY 2HEC ; 1.8 ; CONTRIBUTION OF WATER MOLECULES IN THE INTERIOR OF A PROTEIN TO THE CONFORMATIONAL STABILITY 2HED ; 1.8 ; CONTRIBUTION OF WATER MOLECULES IN THE INTERIOR OF A PROTEIN TO THE CONFORMATIONAL STABILITY 2HEE ; 1.8 ; CONTRIBUTION OF WATER MOLECULES IN THE INTERIOR OF A PROTEIN TO THE CONFORMATIONAL STABILITY 2HEF ; 1.8 ; CONTRIBUTION OF WATER MOLECULES IN THE INTERIOR OF A PROTEIN TO THE CONFORMATIONAL STABILITY 1ZTE ; 1.85 ; Contribution to Structure and Catalysis of Tyrosine 34 in Human Manganese Suerpoxide Dismutase 1ZUQ ; 2 ; Contribution to Structure and Catalysis of Tyrosine 34 in Human Manganese Superoxide Dismutase 2P4K ; 1.48 ; Contribution to Structure and Catalysis of Tyrosine 34 in Human Manganese Superoxide Dismutase 1ZSP ; 1.9 ; Contribution to Structure and Catalysis of Tyrosine 34 in Human Manganese Superoxide Dismutase 3C8R ; 1.8 ; Contributions of all 20 amino acids at site 96 to stability and structure of T4 lysozyme 3C7W ; 1.77 ; Contributions of all 20 amino acids at site 96 to the stability and structure of T4 lysozyme 3C8S ; 1.68 ; Contributions of all 20 amino acids at site 96 to the stability and structure of T4 lysozyme 3CDQ ; 1.68 ; Contributions of all 20 amino acids at site 96 to the stability and structure of T4 lysozyme 3CDT ; 1.63 ; Contributions of all 20 amino acids at site 96 to the stability and structure of T4 lysozyme 3CDV ; 1.73 ; Contributions of all 20 amino acids at site 96 to the stability and structure of T4 lysozyme 1L37 ; 1.85 ; CONTRIBUTIONS OF ENGINEERED SURFACE SALT BRIDGES TO THE STABILITY OF T4 LYSOZYME DETERMINED BY DIRECTED MUTAGENESIS 1L38 ; 1.8 ; CONTRIBUTIONS OF ENGINEERED SURFACE SALT BRIDGES TO THE STABILITY OF T4 LYSOZYME DETERMINED BY DIRECTED MUTAGENESIS 1L39 ; 1.85 ; CONTRIBUTIONS OF ENGINEERED SURFACE SALT BRIDGES TO THE STABILITY OF T4 LYSOZYME DETERMINED BY DIRECTED MUTAGENESIS 1L40 ; 1.85 ; CONTRIBUTIONS OF ENGINEERED SURFACE SALT BRIDGES TO THE STABILITY OF T4 LYSOZYME DETERMINED BY DIRECTED MUTAGENESIS 1L41 ; 1.75 ; CONTRIBUTIONS OF ENGINEERED SURFACE SALT BRIDGES TO THE STABILITY OF T4 LYSOZYME DETERMINED BY DIRECTED MUTAGENESIS 1L02 ; 1.7 ; CONTRIBUTIONS OF HYDROGEN BONDS OF THR 157 TO THE THERMODYNAMIC STABILITY OF PHAGE T4 LYSOZYME 1L03 ; 1.7 ; CONTRIBUTIONS OF HYDROGEN BONDS OF THR 157 TO THE THERMODYNAMIC STABILITY OF PHAGE T4 LYSOZYME 1L04 ; 1.7 ; CONTRIBUTIONS OF HYDROGEN BONDS OF THR 157 TO THE THERMODYNAMIC STABILITY OF PHAGE T4 LYSOZYME 1L05 ; 1.7 ; CONTRIBUTIONS OF HYDROGEN BONDS OF THR 157 TO THE THERMODYNAMIC STABILITY OF PHAGE T4 LYSOZYME 1L06 ; 1.7 ; CONTRIBUTIONS OF HYDROGEN BONDS OF THR 157 TO THE THERMODYNAMIC STABILITY OF PHAGE T4 LYSOZYME 1L07 ; 1.7 ; CONTRIBUTIONS OF HYDROGEN BONDS OF THR 157 TO THE THERMODYNAMIC STABILITY OF PHAGE T4 LYSOZYME 1L08 ; 1.7 ; CONTRIBUTIONS OF HYDROGEN BONDS OF THR 157 TO THE THERMODYNAMIC STABILITY OF PHAGE T4 LYSOZYME 1L09 ; 1.7 ; CONTRIBUTIONS OF HYDROGEN BONDS OF THR 157 TO THE THERMODYNAMIC STABILITY OF PHAGE T4 LYSOZYME 1L11 ; 1.7 ; CONTRIBUTIONS OF HYDROGEN BONDS OF THR 157 TO THE THERMODYNAMIC STABILITY OF PHAGE T4 LYSOZYME 1L12 ; 1.7 ; CONTRIBUTIONS OF HYDROGEN BONDS OF THR 157 TO THE THERMODYNAMIC STABILITY OF PHAGE T4 LYSOZYME 1L13 ; 1.7 ; CONTRIBUTIONS OF HYDROGEN BONDS OF THR 157 TO THE THERMODYNAMIC STABILITY OF PHAGE T4 LYSOZYME 1L14 ; 1.7 ; CONTRIBUTIONS OF HYDROGEN BONDS OF THR 157 TO THE THERMODYNAMIC STABILITY OF PHAGE T4 LYSOZYME 1L15 ; 1.7 ; CONTRIBUTIONS OF HYDROGEN BONDS OF THR 157 TO THE THERMODYNAMIC STABILITY OF PHAGE T4 LYSOZYME 1L21 ; 1.85 ; CONTRIBUTIONS OF LEFT-HANDED HELICAL RESIDUES TO THE STRUCTURE AND STABILITY OF BACTERIOPHAGE T4 LYSOZYME 1L22 ; 1.7 ; CONTRIBUTIONS OF LEFT-HANDED HELICAL RESIDUES TO THE STRUCTURE AND STABILITY OF BACTERIOPHAGE T4 LYSOZYME 1L33 ; 1.7 ; CONTRIBUTIONS OF LEFT-HANDED HELICAL RESIDUES TO THE STRUCTURE AND STABILITY OF BACTERIOPHAGE T4 LYSOZYME 1JMF ; 2.5 ; CONTRIBUTIONS OF ORIENTATION AND HYDROGEN BONDING TO CATALYSIS IN ASN-229 MUTANTS OF THYMIDYLATE SYNTHASE 1JMG ; 2.2 ; CONTRIBUTIONS OF ORIENTATION AND HYDROGEN BONDING TO CATALYSIS IN ASN-229 MUTANTS OF THYMIDYLATE SYNTHASE 1JMH ; 2.5 ; CONTRIBUTIONS OF ORIENTATION AND HYDROGEN BONDING TO CATALYSIS IN ASN-229 MUTANTS OF THYMIDYLATE SYNTHASE 1JMI ; 2.5 ; CONTRIBUTIONS OF ORIENTATION AND HYDROGEN BONDING TO CATALYSIS IN ASN-229 MUTANTS OF THYMIDYLATE SYNTHASE 1TVU ; 2.5 ; CONTRIBUTIONS OF ORIENTATION AND HYDROGEN BONDING TO CATALYSIS IN ASN-229 MUTANTS OF THYMIDYLATE SYNTHASE 1TVV ; 2.3 ; CONTRIBUTIONS OF ORIENTATION AND HYDROGEN BONDING TO CATALYSIS IN ASN-229 MUTANTS OF THYMIDYLATE SYNTHASE 1TVW ; 2.5 ; CONTRIBUTIONS OF ORIENTATION AND HYDROGEN BONDING TO CATALYSIS IN ASN-229 MUTANTS OF THYMIDYLATE SYNTHASE 155L ; 1.85 ; CONTROL OF ENZYME ACTIVITY BY AN ENGINEERED DISULFIDE BOND 156L ; 1.8 ; CONTROL OF ENZYME ACTIVITY BY AN ENGINEERED DISULFIDE BOND 157L ; 1.85 ; CONTROL OF ENZYME ACTIVITY BY AN ENGINEERED DISULFIDE BOND 158L ; 1.8 ; CONTROL OF ENZYME ACTIVITY BY AN ENGINEERED DISULFIDE BOND 159L ; 1.8 ; CONTROL OF ENZYME ACTIVITY BY AN ENGINEERED DISULFIDE BOND 160L ; 1.8 ; CONTROL OF ENZYME ACTIVITY BY AN ENGINEERED DISULFIDE BOND 161L ; 1.7 ; CONTROL OF ENZYME ACTIVITY BY AN ENGINEERED DISULFIDE BOND 162L ; 1.8 ; CONTROL OF ENZYME ACTIVITY BY AN ENGINEERED DISULFIDE BOND 163L ; 1.8 ; CONTROL OF ENZYME ACTIVITY BY AN ENGINEERED DISULFIDE BOND 164L ; 1.8 ; CONTROL OF ENZYME ACTIVITY BY AN ENGINEERED DISULFIDE BOND 165L ; 1.75 ; CONTROL OF ENZYME ACTIVITY BY AN ENGINEERED DISULFIDE BOND 166L ; 1.75 ; CONTROL OF ENZYME ACTIVITY BY AN ENGINEERED DISULFIDE BOND 1B4G ; ; CONTROL OF K+ CHANNEL GATING BY PROTEIN PHOSPHORYLATION: STRUCTURAL SWITCHES OF THE INACTIVATION GATE, NMR, 22 STRUCTURES 1B4I ; ; Control of K+ Channel Gating by protein phosphorylation: structural switches of the inactivation gate, NMR, 22 structures 1ABB ; 2.8 ; CONTROL OF PHOSPHORYLASE B CONFORMATION BY A MODIFIED COFACTOR: CRYSTALLOGRAPHIC STUDIES ON R-STATE GLYCOGEN PHOSPHORYLASE RECONSTITUTED WITH PYRIDOXAL 5'-DIPHOSPHATE 2V5H ; 2.75 ; CONTROLLING THE STORAGE OF NITROGEN AS ARGININE: THE COMPLEX OF PII AND ACETYLGLUTAMATE KINASE FROM SYNECHOCOCCUS ELONGATUS PCC 7942 1CF8 ; 2.7 ; Convergence of catalytic antibody and terpene cyclase mechanisms: polyene cyclization directed by carbocation-pi interactions 1TRB ; 2 ; CONVERGENT EVOLUTION OF SIMILAR FUNCTION IN TWO STRUCTURALLY DIVERGENT ENZYMES 1SHM ; 1.9 ; Convergent solutions to VHH domain stabilization from natural and in vitro evolution 1JML ; 1.9 ; Conversion of Monomeric Protein L to an Obligate Dimer by Computational Protein Design 4F4J ; 2.45 ; Conversion of the enzyme guanylate kinase into a mitotic spindle orienting protein by a single mutation that inhibits gmp- induced closing 1RWB ; 2 ; Cooperative Effect of Two Surface Amino Acid Mutations (Q252L and E170K) of Glucose Dehydrogenase from Bacillus megaterium IWG3 for the stabilization of Oligomeric State 1GOA ; 1.9 ; COOPERATIVE STABILIZATION OF ESCHERICHIA COLI RIBONUCLEASE HI BY INSERTION OF GLY-80B AND GLY-77-> ALA SUBSTITUTION 1GOB ; 2 ; COOPERATIVE STABILIZATION OF ESCHERICHIA COLI RIBONUCLEASE HI BY INSERTION OF GLY-80B AND GLY-77-> ALA SUBSTITUTION 1GOC ; 2 ; COOPERATIVE STABILIZATION OF ESCHERICHIA COLI RIBONUCLEASE HI BY INSERTION OF GLY-80B AND GLY-77-> ALA SUBSTITUTION 1AXR ; 2.3 ; COOPERATIVITY BETWEEN HYDROGEN-BONDING AND CHARGE-DIPOLE INTERACTIONS IN THE INHIBITION OF BETA-GLYCOSIDASES BY AZOLOPYRIDINES: EVIDENCE FROM A STUDY WITH GLYCOGEN PHOSPHORYLASE B 1D1O ; ; COOPERATIVITY IN EF-HAND CA2+-BINDING PROTEINS: EVIDENCE OF SITE-SITE COMMUNICATION FROM BINDING-INDUCED CHANGES IN STRUCTURE AND DYNAMICS OF N56A CALBINDIN D9K 2JYP ; ; Coordinates for lowest energy structure of Aragonite protein-7, C-terminal domain 3DG2 ; 10 ; Coordinates of 16S and 23S rRNAs fitted into the cryo-EM map of a pretranslocation complex 3DG0 ; 10.8 ; Coordinates of 16S and 23S rRNAs fitted into the cryo-EM map of EF-G-bound translocation complex 3DG4 ; 12.8 ; Coordinates of 16S and 23S rRNAs fitted into the cryo-EM map of RF1-bound termination complex 3DG5 ; 15.5 ; Coordinates of 16S and 23S rRNAs fitted into the cryo-EM map of RF3-bound termination complex 1R2X ; 9 ; Coordinates of L11 with 58nts of 23S rRNA fitted into the cryo-EM map of EF-Tu ternary complex (GDP.Kirromycin) bound 70S ribosome 1R2W ; 9 ; Coordinates of L11 with 58nts of 23S rRNA fitted into the cryo-EM map of the 70S ribosome 1GOL ; 2.8 ; COORDINATES OF RAT MAP KINASE ERK2 WITH AN ARGININE MUTATION AT POSITION 52 1ZN0 ; 15.5 ; Coordinates of RRF and EF-G fitted into Cryo-EM map of the 50S subunit bound with both EF-G (GDPNP) and RRF 1ZN1 ; 14.1 ; Coordinates of RRF fitted into Cryo-EM map of the 70S post-termination complex 1PN8 ; 10.8 ; Coordinates of S12, L11 proteins and E-site tRNA from 70S crystal structure separately fitted into the Cryo-EM map of E.coli 70S.EF-G.GDPNP complex. The atomic coordinates originally from the E-site tRNA were fitted in the position of the hybrid P/E-site tRNA. 1PN7 ; 10.8 ; Coordinates of S12, L11 proteins and P-tRNA, from the 70S X-ray structure aligned to the 70S Cryo-EM map of E.coli ribosome 1QZC ; 9 ; Coordinates of S12, SH44, LH69 and SRL separately fitted into the cryo-EM map of EF-Tu ternary complex (GDP.Kirromycin) bound 70S ribosome 1QZB ; 9 ; Coordinates of the A-site tRNA model fitted into the cryo-EM map of 70S ribosome in the pre-translocational state 1QZA ; 10 ; Coordinates of the A/T site tRNA model fitted into the cryo-EM map of EF-Tu ternary complex (GDP.Kirromycin) bound 70S ribosome 3IYX ; 9 ; Coordinates of the b1b bridge-forming protein structures fitted into the Cryo-EM map of E.coli 70S ribosome (EMD-1056) 3IYY ; 10.9 ; Coordinates of the b1b bridge-forming protein structures fitted into the Cryo-EM map of EFG.GDPNP-bound E.coli 70S ribosome(EMD-1363) 2BCW ; 11.2 ; Coordinates of the N-terminal domain of ribosomal protein L11,C-terminal domain of ribosomal protein L7/L12 and a portion of the G' domain of elongation factor G, as fitted into cryo-em map of an Escherichia coli 70S*EF-G*GDP*fusidic acid complex 2R1G ; 12.5 ; Coordinates of the thermus thermophilus 30S components neighboring RbfA as obtained by fitting into the CRYO-EM map of A 30S-RBFA complex 2R1C ; 12.5 ; Coordinates of the thermus thermophilus ribosome binding factor A (RbfA) homology model as fitted into the CRYO-EM map of a 30S-RBFA complex 1ZC8 ; 13 ; Coordinates of tmRNA, SmpB, EF-Tu and h44 fitted into Cryo-EM map of the 70S ribosome and tmRNA complex 2B8E ; 2.3 ; CopA ATP Binding Domain 3RE7 ; 2.82 ; Copper (II) loaded Bullfrog Ferritin M chain 1A2V ; 2.4 ; COPPER AMINE OXIDASE FROM HANSENULA POLYMORPHA 1N68 ; 1.7 ; Copper bound to the Multicopper Oxidase CueO 2XMT ; 1.5 ; COPPER CHAPERONE ATX1 FROM SYNECHOCYSTIS PCC6803 (CU1 FORM) 2XMV ; 1.8 ; Copper chaperone Atx1 from Synechocystis PCC6803 (Cu1, trimeric form, His61Tyr mutant) 2XMU ; 1.75 ; COPPER CHAPERONE ATX1 FROM SYNECHOCYSTIS PCC6803 (CU2 FORM) 1CPZ ; ; COPPER CHAPERONE OF ENTEROCOCCUS HIRAE (APO-FORM) 1K0V ; ; Copper trafficking: the solution structure of Bacillus subtilis CopZ 2RSQ ; ; Copper(I) loaded form of the first domain of the human copper chaperone for SOD1, CCS 3BKT ; 1.5 ; Copper-bound C-terminal Domain of NikR 3S0P ; 3 ; Copper-reconstituted Tomato Chloroplast Superoxide Dismutase 2K4B ; ; CopR Repressor Structure 1OLT ; 2.07 ; COPROPORPHYRINOGEN III OXIDASE (HEMN) FROM ESCHERICHIA COLI IS A RADICAL SAM ENZYME. 3EJO ; 2.3 ; Coproporphyrinogen III oxidase from Leishmania donovani 1VJU ; 1.401 ; Coproporphyrinogen III oxidase from Leishmania major 2QT8 ; 1.75 ; Coproporphyrinogen III oxidase from Leishmania major 3E8J ; 2.27 ; Coproporphyrinogen III oxidase from Leishmania naiffi 3DPT ; 2.9 ; COR domain of Rab family protein (Roco) 4EEB ; 3.8 ; CorA coiled-coil mutant under Mg2+ absence 4EED ; 3.92 ; CorA coiled-coil mutant under Mg2+ presence 1SFK ; 3.2 ; Core (C) protein from West Nile Virus, subtype Kunjin 2JHB ; ; CORE BINDING FACTOR BETA 1QS4 ; 2.1 ; Core domain of HIV-1 integrase complexed with Mg++ and 1-(5-chloroindol-3-yl)-3-hydroxy-3-(2H-tetrazol-5-yl)-propenone 1GPC ; 2.2 ; CORE GP32, DNA-BINDING PROTEIN 3J0P ; 10.6 ; Core of mammalian 80S pre-ribosome in complex with tRNAs fitted to a 10.6A cryo-em map: rotated PRE state 1 3J0Q ; 10.6 ; Core of mammalian 80S pre-ribosome in complex with tRNAs fitted to a 10.6A cryo-em map: rotated PRE state 2 3J0L ; 9.8 ; Core of mammalian 80S pre-ribosome in complex with tRNAs fitted to a 9.8A cryo-EM map: classic PRE state 1 3J0O ; 9 ; Core of mammalian 80S pre-ribosome in complex with tRNAs fitted to a 9A cryo-EM map: classic PRE state 2 1E8O ; 3.2 ; CORE OF THE ALU DOMAIN OF THE MAMMALIAN SRP 1P3N ; 1.55 ; CORE REDESIGN BACK-REVERTANT I103V/CORE10 1KFM ; 2 ; Core side-chain packing and backbone conformation in Lpp-56 coiled-coil mutants 1KFN ; 1.65 ; Core side-chain packing and backbone conformation in Lpp-56 coiled-coil mutants 1I9H ; 2.4 ; CORE STREPTAVIDIN-BNA COMPLEX 2EBO ; 1.9 ; CORE STRUCTURE OF GP2 FROM EBOLA VIRUS 2IEQ ; 1.747 ; Core Structure of S2 from the Human Coronavirus NL63 Spike Glycoprotein 1EQ7 ; 1.9 ; CORE STRUCTURE OF THE OUTER MEMBRANE LIPOPROTEIN FROM ESCHERICHIA COLI AT 1.9 ANGSTROM RESOLUTION 4DFC ; 2.803 ; Core UvrA/TRCF complex 1SWS ; 2 ; CORE-STREPTAVIDIN MUTANT D128A AT PH 4.5 1SWT ; 2 ; CORE-STREPTAVIDIN MUTANT D128A IN COMPLEX WITH BIOTIN AT PH 4.5 3MG5 ; 1.3 ; Core-streptavidin mutant F130L in complex with biotin 1SWL ; 1.8 ; CORE-STREPTAVIDIN MUTANT W108F AT PH 7.0 1SWN ; 2.2 ; CORE-STREPTAVIDIN MUTANT W108F IN COMPLEX WITH BIOTIN AT PH 7.0 1SWQ ; 1.9 ; CORE-STREPTAVIDIN MUTANT W120A AT PH 7.5 1SWR ; 1.9 ; CORE-STREPTAVIDIN MUTANT W120A IN COMPLEX WITH BIOTIN AT PH 7.5 1SWO ; 1.95 ; CORE-STREPTAVIDIN MUTANT W120F AT PH 7.5 1SWP ; 2 ; CORE-STREPTAVIDIN MUTANT W120F IN COMPLEX WITH BIOTIN AT PH 7.5 1SWH ; 1.7 ; CORE-STREPTAVIDIN MUTANT W79F AT PH 4.5 1SWJ ; 2 ; CORE-STREPTAVIDIN MUTANT W79F AT PH 4.5 1SWK ; 2 ; CORE-STREPTAVIDIN MUTANT W79F IN COMPLEX WITH BIOTIN AT PH 4.5 4A2F ; 1.9 ; Coriolopsis gallica laccase collected at 12.65 keV 4A2G ; 1.8 ; Coriolopsis gallica laccase collected at 8.98 keV 4A2D ; 2.3 ; CORIOLOPSIS GALLICA LACCASE T2 COPPER DEPLETED AT PH 4.5 1P9S ; 2.54 ; Coronavirus Main Proteinase (3CLpro) Structure: Basis for Design of anti-SARS Drugs 1P9U ; 2.37 ; Coronavirus Main Proteinase (3CLpro) Structure: Basis for Design of anti-SARS Drugs 1YYF ; 4.16 ; Correction of X-ray Intensities from an HslV-HslU co-crystal containing lattice translocation defects 1CNR ; 1.05 ; CORRELATED DISORDER OF THE PURE PRO22(SLASH)LEU25 FORM OF CRAMBIN AT 150K REFINED TO 1.05 ANGSTROMS RESOLUTION 2TMD ; 2.4 ; CORRELATION OF X-RAY DEDUCED AND EXPERIMENTAL AMINO ACID SEQUENCES OF TRIMETHYLAMINE DEHYDROGENASE 3F8Y ; 1.45 ; Correlations of Human Dihydrofolate Reductase with Structural Data for Human Active Site Mutant Enzyme Complexes 3FS6 ; 1.23 ; Correlations of Inhibitor Kinetics for Pneumocystis jirovecii and Human Dihydrofolate Reductase with Structural Data for Human Active Site Mutant Enzyme Complexes 2H9A ; 1.9 ; Corrinoid Iron-Sulfur Protein 1M9H ; 2 ; Corynebacterium 2,5-DKGR A and Phe 22 replaced with Tyr (F22Y), Lys 232 replaced with Gly (K232G), Arg 238 replaced with His (R238H)and Ala 272 replaced with Gly (A272G)in presence of NADH cofactor 4AC6 ; 2.54 ; Corynebacterium glutamicum AcnR AU derivative structure 3RH0 ; 1.724 ; Corynebacterium glutamicum mycothiol/mycoredoxin1-dependent arsenate reductase Cg_ArsC2 3T38 ; 2.2 ; Corynebacterium glutamicum thioredoxin-dependent arsenate reductase Cg_ArsC1' 3F8E ; 2 ; Coumarins are a novel class of suicide carbonic anhydrase inhibitors 1BV7 ; 2 ; COUNTERACTING HIV-1 PROTEASE DRUG RESISTANCE: STRUCTURAL ANALYSIS OF MUTANT PROTEASES COMPLEXED WITH XV638 AND SD146, CYCLIC UREA AMIDES WITH BROAD SPECIFICITIES 1ZL3 ; 2.8 ; Coupling of active site motions and RNA binding 1FN7 ; 2.6 ; COUPLING OF DAMAGE RECOGNITION AND CATALYSIS BY A HUMAN BASE-EXCISION DNA REPAIR PROTEIN 1N3H ; ; Coupling of Folding and Binding in the PTB Domain of the Signaling Protein Shc 1OY2 ; ; Coupling of Folding and Binding in the PTB Domain of the Signaling Protein Shc 1PW8 ; 1.3 ; Covalent Acyl Enzyme Complex Of The R61 DD-Peptidase with A Highly Specific Cephalosporin 1PWD ; 1.2 ; Covalent acyl enzyme complex of the Streptomyces R61 DD-peptidase with cephalosporin C 1H84 ; 2 ; COVALENT ADDUCT BETWEEN POLYAMINE OXIDASE AND N1ETHYLN11 ((CYCLOHEPTYL)METHYL)4,8DIAZAUNDECANE AT PH 4.6 1H86 ; 2 ; COVALENT ADDUCT BETWEEN POLYAMINE OXIDASE AND N1ethylN11((cycloheptyl)methyl)4,8diazaundecane at pH 7.0 1DAO ; 3.2 ; COVALENT ADDUCT OF D-AMINO ACID OXIDASE FROM PIG KIDNEY WITH 3-METHYL-2-OXO-VALERIC ACID 1GJM ; 2.2 ; COVALENT ATTACHMENT OF AN ELECTROACTIVE SULPHYDRYL REAGENT IN THE ACTIVE SITE OF CYTOCHROME P450CAM 3U9X ; 1.8 ; Covalent attachment of pyridoxal-phosphate derivatives to 14-3-3 proteins 2E6Y ; 1.6 ; Covalent complex of orotidine 5'-monophosphate decarboxylase (ODCase) with 6-Iodo-UMP 2ZZ3 ; 1.8 ; Covalent complex of orotidine monophosphate decarboxylase D70A mutant from M. thermoautotrophicus with 6-cyano-UMP 2ZZ4 ; 1.67 ; Covalent complex of orotidine monophosphate decarboxylase D75N mutant from M. thermoautotrophicum with 6-cyano-UMP 2ZZ6 ; 1.66 ; Covalent complex of orotidine monophosphate decarboxylase from M. thermoautotrophicum with 6-azido-UMP 2QCN ; 1.85 ; Covalent complex of the orotidine-5'-monophosphate decarboxylase domain of human UMP synthase with 6-iodo-UMP 2RG3 ; 1.8 ; Covalent complex structure of elastase 1H6M ; 1.64 ; COVALENT GLYCOSYL-ENZYME INTERMEDIATE OF HEN EGG WHITE LYSOZYME 2OWW ; 2.2 ; Covalent intermediate in amylomaltase in complex with the acceptor analog 4-deoxyglucose 1S46 ; 2.2 ; Covalent intermediate of the E328Q amylosucrase mutant 1D39 ; 1.2 ; COVALENT MODIFICATION OF GUANINE BASES IN DOUBLE STRANDED DNA: THE 1.2 ANGSTROMS Z-DNA STRUCTURE OF D(CGCGCG) IN THE PRESENCE OF CUCL2 1PWG ; 1.074 ; Covalent Penicilloyl Acyl Enzyme Complex Of The Streptomyces R61 DD-Peptidase With A Highly Specific Penicillin 1TQH ; 1.63 ; Covalent Reaction intermediate Revealed in Crystal Structure of the Geobacillus stearothermophilus Carboxylesterase Est30 1MHT ; 2.6 ; COVALENT TERNARY STRUCTURE OF HHAI METHYLTRANSFERASE, DNA AND S-ADENOSYL-L-HOMOCYSTEINE 2IBI ; 2.2 ; Covalent Ubiquitin-USP2 Complex 3IHP ; 2.8 ; Covalent Ubiquitin-Usp5 Complex 1NY7 ; 3 ; COWPEA MOSAIC VIRUS (CPMV) 4AGY ; 6.09 ; Coxsackievirus A7 (CAV7) empty capsid reconstruction at 6.09 angstrom resolution. 4AGX ; 8.23 ; Coxsackievirus A7 (CAV7) full capsid reconstruction at 8.23 angstrom resolution. 3DDK ; 2.25 ; Coxsackievirus B3 3Dpol RNA Dependent RNA Polymerase 1COV ; 3.5 ; COXSACKIEVIRUS B3 COAT PROTEIN 4K4Y ; 2.72 ; Coxsackievirus B3 polymerase elongation complex (r2+1_form) 4K4X ; 2.37 ; Coxsackievirus B3 polymerase elongation complex (r2_form), rna 4K4Z ; 2.17 ; Coxsackievirus B3 polymerase elongation complex (r2_Mg_form) 2GG4 ; 2.1 ; CP4 EPSP synthase (unliganded) 2GGD ; 1.7 ; CP4 EPSP synthase Ala100Gly liganded with S3P and Glyphosate 2GG6 ; 1.64 ; CP4 EPSP synthase liganded with S3P 2GGA ; 1.7 ; CP4 EPSP synthase liganded with S3P and Glyphosate 2PQB ; 1.8 ; CP4 EPSPS liganded with (R)-difluoromethyl tetrahedral intermediate analog 2PQC ; 1.6 ; CP4 EPSPS liganded with (R)-phosphonate tetrahedral reaction intermediate analog 2JA5 ; 3.8 ; CPD lesion containing RNA Polymerase II elongation complex A 2JA6 ; 4 ; CPD LESION CONTAINING RNA POLYMERASE II ELONGATION COMPLEX B 2JA7 ; 3.8 ; CPD lesion containing RNA Polymerase II elongation complex C 2JA8 ; 3.8 ; CPD LESION CONTAINING RNA POLYMERASE II ELONGATION COMPLEX D 3REN ; 2 ; CPF_2247, a novel alpha-amylase from Clostridium perfringens 4DKJ ; 2.15 ; CpG specific methyltransferase in complex with target DNA 4A4A ; 1.9 ; CpGH89 (E483Q, E601Q), from Clostridium perfringens, in complex with its substrate GlcNAc-alpha-1,4-galactose 4A3Z ; 1.55 ; CpGH89CBM32-4 (seleno-methionine labeled) produced by Clostridium perfringens 4A6O ; 2.8 ; CpGH89CBM32-4, produced by Clostridium perfringens, in complex with glcNAc-alpha-1,4-galactose 4A41 ; 1.55 ; CpGH89CBM32-5, from Clostridium perfringens, in complex with galactose 4A45 ; 1.75 ; CpGH89CBM32-5, from Clostridium perfringens, in complex with GalNAc- beta-1,3-galactose 4AAX ; 1.9 ; CpGH89CBM32-5, from Clostridium perfringens, in complex with N- acetylgalactosamine 4A44 ; 1.7 ; CpGH89CBM32-5, from Clostridium perfringens, in complex with the Tn Antigen 4A42 ; 1.55 ; CpGH89CBM32-6 produced by Clostridium perfringens 1K5O ; ; CPI-17(35-120) deletion mutant 3N26 ; 2.1 ; Cpn0482 : the arginine binding protein from the periplasm of chlamydia Pneumoniae 2YDQ ; 2.6 ; CpOGA D298N in complex with hOGA-derived O-GlcNAc peptide 2YDR ; 2.75 ; CpOGA D298N in complex with p53-derived O-GlcNAc peptide 2YDS ; 2.55 ; CpOGA D298N in complex with TAB1-derived O-GlcNAc peptide 3E6C ; 1.8 ; CprK OCPA DNA Complex 4B4N ; 1.813 ; CPSF6 defines a conserved capsid interface that modulates HIV-1 replication 1IJS ; 3.25 ; CPV (STRAIN D) mutant A300D, complex (VIRAL COAT/DNA), VP2, PH=7.5, T=4 DEGREES C 1GHQ ; 2.04 ; CR2-C3D COMPLEX STRUCTURE 1EJG ; 0.54 ; CRAMBIN AT ULTRA-HIGH RESOLUTION: VALENCE ELECTRON DENSITY. 1JXT ; 0.89 ; CRAMBIN MIXED SEQUENCE FORM AT 160 K. PROTEIN/WATER SUBSTATES 1JXW ; 0.89 ; CRAMBIN MIXED SEQUENCE FORM AT 180 K. PROTEIN/WATER SUBSTATES 1JXX ; 0.89 ; CRAMBIN MIXED SEQUENCE FORM AT 200 K. PROTEIN/WATER SUBSTATES 1JXY ; 0.89 ; CRAMBIN MIXED SEQUENCE FORM AT 220 K. PROTEIN/WATER SUBSTATES 1JXU ; 0.99 ; CRAMBIN MIXED SEQUENCE FORM AT 240 K. PROTEIN/WATER SUBSTATES 2D3P ; 2.8 ; Cratylia Floribunda seed lectin crystallized at basic pH 2D3R ; 2.9 ; Cratylia folibunda seed lectin at acidic pH 1MVQ ; 1.77 ; Cratylia mollis lectin (isoform 1) in complex with methyl-alpha-D-mannose 1KBU ; 2.2 ; CRE RECOMBINASE BOUND TO A LOXP HOLLIDAY JUNCTION 3MGV ; 2.29 ; Cre recombinase-DNA transition state 3CRX ; 2.5 ; CRE RECOMBINASE/DNA COMPLEX INTERMEDIATE I 1CRX ; 2.4 ; CRE RECOMBINASE/DNA COMPLEX REACTION INTERMEDIATE I 3C29 ; 2.2 ; Cre-loxP Synaptic structure 3A6D ; 1.9 ; Creatininase complexed with 1-methylguanidine 1J2T ; 1.8 ; Creatininase Mn 1J2U ; 1.85 ; Creatininase Zn 1V7Z ; 1.6 ; creatininase-product complex 1BTI ; 2.2 ; CREVICE-FORMING MUTANTS IN THE RIGID CORE OF BOVINE PANCREATIC TRYPSIN INHIBITOR: CRYSTAL STRUCTURES OF F22A, Y23A, N43G, AND F45A 1FAN ; 2 ; CREVICE-FORMING MUTANTS IN THE RIGID CORE OF BOVINE PANCREATIC TRYPSIN INHIBITOR: CRYSTAL STRUCTURES OF F22A, Y23A, N43G, AND F45A 1NAG ; 1.9 ; CREVICE-FORMING MUTANTS IN THE RIGID CORE OF BOVINE PANCREATIC TRYPSIN INHIBITOR: CRYSTAL STRUCTURES OF F22A, Y23A, N43G, AND F45A 1BPT ; 2 ; CREVICE-FORMING MUTANTS OF BPTI: CRYSTAL STRUCTURES OF F22A, Y23A, N43G, AND F45A 1B35 ; 2.4 ; CRICKET PARALYSIS VIRUS (CRPV) 3MJ3 ; 3.1 ; Cricket Paralysis Virus IGR IRES Domain 3 RNA bound to selenate 3MJA ; 2.8 ; Cricket Paralysis Virus IGR IRES Domain 3 RNA bound to selenate, structure #2 3MJB ; 2.8 ; Cricket Paralysis Virus IGR IRES Domain 3 RNA bound to sulfate 2ICF ; 4.1 ; CRIg bound to C3b 2ICE ; 3.1 ; CRIg bound to C3c 2L7X ; ; Crimean Congo Hemorrhagic Fever Gn zinc finger 3ZNH ; 2.3 ; Crimean Congo Hemorrhagic Fever Virus OTU domain in complex with ubiquitin-propargyl. 4ILM ; 3.068 ; CRISPR RNA Processing endoribonuclease 2YK3 ; 1.55 ; CRITHIDIA FASCICULATA CYTOCHROME C 2VRW ; 1.85 ; CRITICAL STRUCTURAL ROLE FOR THE PH AND C1 DOMAINS OF THE VAV1 EXCHANGE FACTOR 1B07 ; 2.5 ; CRK SH3 DOMAIN COMPLEXED WITH PEPTOID INHIBITOR 1ORC ; 1.54 ; CRO REPRESSOR INSERTION MUTANT K56-[DGEVK] 2ORC ; ; CRO REPRESSOR INSERTION MUTANT K56-[DGEVK], NMR, 32 STRUCTURES 1ZEI ; 1.9 ; CROSS-LINKED B28 ASP INSULIN 2F5W ; 2.001 ; Cross-linked barnase soaked in 3 M thiourea 2F5M ; 1.95 ; Cross-linked barnase soaked in bromo-ethanol 2LYO ; 1.93 ; CROSS-LINKED CHICKEN LYSOZYME CRYSTAL IN 90% ACETONITRILE-WATER 3LYO ; 1.93 ; CROSS-LINKED CHICKEN LYSOZYME CRYSTAL IN 95% ACETONITRILE-WATER 4LYO ; 2.05 ; CROSS-LINKED CHICKEN LYSOZYME CRYSTAL IN NEAT ACETONITRILE, THEN BACK-SOAKED IN WATER 1CLS ; 1.9 ; CROSS-LINKED HUMAN HEMOGLOBIN DEOXY 1LYO ; 1.93 ; CROSS-LINKED LYSOZYME CRYSTAL IN NEAT WATER 1SDK ; 1.8 ; CROSS-LINKED, CARBONMONOXY HEMOGLOBIN A 1SDL ; 1.8 ; CROSS-LINKED, CARBONMONOXY HEMOGLOBIN A 2J23 ; 1.41 ; CROSS-REACTIVITY AND CRYSTAL STRUCTURE OF MALASSEZIA SYMPODIALIS THIOREDOXIN (MALA S 13), A MEMBER OF A NEW PAN-ALLERGEN FAMILY 4IML ; 2.931 ; CrossFab binding to human Angiopoietin 2 3M1F ; 2.89 ; Crosslinked complex of actin with first W domain of Vibrio parahaemolyticus VopL 1HAB ; 2.3 ; CROSSLINKED HAEMOGLOBIN 1HAC ; 2.6 ; CROSSLINKED HAEMOGLOBIN 1NYI ; 2.85 ; Crosslinked Hammerhead Ribozyme Initial State 1BIJ ; 2.3 ; CROSSLINKED, DEOXY HUMAN HEMOGLOBIN A 2GJB ; 2.2 ; Crosslinking of DNA duplexes: X-ray crystal structure of an unsubstituted bisacridine with the oligonucleotide d(CGTACG) 1E4W ; 1.95 ; CROSSREACTIVE BINDING OF A CIRCULARIZED PEPTIDE TO AN ANTI-TGFALPHA ANTIBODY FAB-FRAGMENT 1E4X ; 1.9 ; CROSSREACTIVE BINDING OF A CIRCULARIZED PEPTIDE TO AN ANTI-TGFALPHA ANTIBODY FAB-FRAGMENT 1V11 ; 1.95 ; CROSSTALK BETWEEN COFACTOR BINDING AND THE PHOSPHORYLATION LOOP CONFORMATION IN THE BCKD MACHINE 1V16 ; 1.9 ; CROSSTALK BETWEEN COFACTOR BINDING AND THE PHOSPHORYLATION LOOP CONFORMATION IN THE BCKD MACHINE 1V1M ; 2 ; CROSSTALK BETWEEN COFACTOR BINDING AND THE PHOSPHORYLATION LOOP CONFORMATION IN THE BCKD MACHINE 1V1R ; 1.8 ; CROSSTALK BETWEEN COFACTOR BINDING AND THE PHOSPHORYLATION LOOP CONFORMATION IN THE BCKD MACHINE 4A4J ; 1.25 ; Crosstalk between Cu(I) and Zn(II) homeostasis 4A46 ; 1.85 ; Crosstalk between Cu(I) and Zn(II) homeostasis 4A47 ; 1.9 ; Crosstalk between Cu(I) and Zn(II) homeostasis 4A48 ; 1.4 ; Crosstalk between Cu(I) and Zn(II) homeostasis 2QOG ; 2.28 ; Crotoxin B, the basic PLA2 from Crotalus durissus terrificus. 4A2U ; 2.63 ; CRP(CAP) from Myco. Tuberculosis, with cAMP 3K9Q ; 2.5 ; Crsytal strcuture of C151G mutant of Glyceraldehyde 3-phosphate dehydrogenase 1 from Methicillin resistant Staphylococcus aureus (MRSA252) at 2.5 angstrom resolution 3D8K ; 2.71 ; Crsytal structure of a phosphatase from a toxoplasma gondii 1XD7 ; 2.3 ; Crsytal structure of a putative DNA binding protein 1WVN ; 2.1 ; Crsytal Structure of domain 3 of human alpha polyC binding protein 1ZNQ ; 2.5 ; Crsytal Structure of Human Liver GAPDH 2G3T ; 1.8 ; Crsytal structure of human spermidine/spermine N1-acetyltransferase (hSSAT) 3QD2 ; 2.81 ; Crsytal structure of mouse PERK kinase domain 2D7I ; 2.5 ; Crsytal structure of pp-GalNAc-T10 with UDP, GalNAc and Mn2+ 3AO9 ; 2.1 ; Crsytal structure of the C-terminal domain of sequence-specific ribonuclease 1EWP ; 1.75 ; CRUZAIN BOUND TO MOR-LEU-HPQ 3KKU ; 1.28 ; Cruzain in complex with a non-covalent ligand 1AIM ; 2 ; CRUZAIN INHIBITED BY BENZOYL-TYROSINE-ALANINE-FLUOROMETHYLKETONE 2AIM ; 2.2 ; CRUZAIN INHIBITED WITH BENZOYL-ARGININE-ALANINE-FLUOROMETHYLKETONE 1GEG ; 1.7 ; CRYATAL STRUCTURE ANALYSIS OF MESO-2,3-BUTANEDIOL DEHYDROGENASE 3N9T ; 2 ; Cryatal structure of Hydroxyquinol 1,2-dioxygenase from Pseudomonas putida DLL-E4 2B6B ; 25 ; Cryo EM structure of Dengue complexed with CRD of DC-SIGN 1A5B ; 2 ; CRYO-CRYSTALLOGRAPHY OF A TRUE SUBSTRATE, INDOLE-3-GLYCEROL PHOSPHATE, BOUND TO A MUTANT (ALPHA D60N) TRYPTOPHAN SYNTHASE ALPHA2BETA2 COMPLEX REVEALS THE CORRECT ORIENTATION OF ACTIVE SITE ALPHA GLU 49 1A5A ; 1.9 ; CRYO-CRYSTALLOGRAPHY OF A TRUE SUBSTRATE, INDOLE-3-GLYCEROL PHOSPHATE, BOUND TO A MUTANT (ALPHAD60N) TRYPTOPHAN SYNTHASE ALPHA2BETA2 COMPLEX REVEALS THE CORRECT ORIENTATION OF ACTIVE SITE ALPHA GLU 49 4BBL ; 18 ; Cryo-electron microscopy reconstruction of the helical part of influenza A virus ribonucleoprotein isolated from virions. 4A2I ; 16.5 ; CRYO-ELECTRON MICROSCOPY STRUCTURE OF THE 30S SUBUNIT IN COMPLEX WITH THE YJEQ BIOGENESIS FACTOR 3ZEX ; 5.57 ; cryo-electron microscopy structure of the Trypanosoma brucei 80S ribosome 2X8Q ; 18.3 ; CRYO-EM 3D MODEL OF THE ICOSAHEDRAL PARTICLE COMPOSED OF ROUS SARCOMA VIRUS CAPSID PROTEIN PENTAMERS 2I68 ; ; Cryo-EM based theoretical model structure of transmembrane domain of the multidrug-resistance antiporter from E. coli EmrE 3J1O ; 16 ; Cryo-EM map of a yeast minimal preinitiation complex interacting with the Mediator Head module 3J1N ; 16 ; Cryo-EM map of a yeast minimal preinitiation complex interacting with the Mediator Head module 3IYO ; 10.5 ; Cryo-EM model of virion-sized HEV virion-sized capsid 3J35 ; 35 ; Cryo-EM reconstruction of Dengue virus at 37 C 3ZX8 ; 11.5 ; Cryo-EM reconstruction of native and expanded Turnip Crinkle virus 3ZX9 ; 17 ; Cryo-EM reconstruction of native and expanded Turnip Crinkle virus 3J0B ; 10.3 ; cryo-EM reconstruction of West Nile virus 3G37 ; 6 ; Cryo-EM structure of actin filament in the presence of phosphate 1SJJ ; 20 ; Cryo-EM Structure of Chicken Gizzard Smooth Muscle alpha-Actinin 1JEW ; 22 ; CRYO-EM STRUCTURE OF COXSACKIEVIRUS B3(M STRAIN) WITH ITS CELLULAR RECEPTOR, COXSACKIEVIRUS AND ADENOVIRUS RECEPTOR (CAR). 2ZLE ; 28 ; Cryo-EM structure of DegP12/OMP 2YN9 ; 8 ; Cryo-EM structure of gastric H+,K+-ATPase with bound rubidium 1Z7Z ; 8 ; Cryo-em structure of human coxsackievirus A21 complexed with five domain icam-1kilifi 1DGI ; 22 ; Cryo-EM structure of human poliovirus(serotype 1)complexed with three domain CD155 1D3I ; 26 ; CRYO-EM STRUCTURE OF HUMAN RHINOVIRUS 14 (HRV14) COMPLEXED WITH A TWO-DOMAIN FRAGMENT OF ITS CELLULAR RECEPTOR, INTERCELLULAR ADHESION MOLECULE-1 (D1D2-ICAM-1). IMPLICATIONS FOR VIRUS-RECEPTOR INTERACTIONS. ALPHA CARBONS ONLY 1D3E ; 28 ; CRYO-EM STRUCTURE OF HUMAN RHINOVIRUS 16 (HRV16) COMPLEXED WITH A TWO-DOMAIN FRAGMENT OF ITS CELLULAR RECEPTOR, INTERCELLULAR ADHESION MOLECULE-1 (D1D2-ICAM-1). IMPLICATIONS FOR VIRUS-RECEPTOR INTERACTIONS. ALPHA CARBONS ONLY 2WWA ; 8.9 ; CRYO-EM STRUCTURE OF IDLE YEAST SSH1 COMPLEX BOUND TO THE YEAST 80S RIBOSOME 4B6B ; 8.1 ; Cryo-EM Structure of the 60S Ribosomal Subunit in Complex with Arx1 and Rei1 4B6A ; 8.1 ; Cryo-EM Structure of the 60S Ribosomal Subunit in Complex with Arx1 and Rei1 2WW9 ; 8.6 ; CRYO-EM STRUCTURE OF THE ACTIVE YEAST SSH1 COMPLEX BOUND TO THE YEAST 80S RIBOSOME 3ZFS ; 4 ; Cryo-EM structure of the F420-reducing NiFe-hydrogenase from a methanogenic archaeon with bound substrate 1I84 ; 20 ; CRYO-EM STRUCTURE OF THE HEAVY MEROMYOSIN SUBFRAGMENT OF CHICKEN GIZZARD SMOOTH MUSCLE MYOSIN WITH REGULATORY LIGHT CHAIN IN THE DEPHOSPHORYLATED STATE. ONLY C ALPHAS PROVIDED FOR REGULATORY LIGHT CHAIN. ONLY BACKBONE ATOMS PROVIDED FOR S2 FRAGMENT. 3J2K ; 17 ; Cryo-EM structure of the mammalian eRF1-eRF3-associated termination complex 2WWB ; 6.48 ; CRYO-EM STRUCTURE OF THE MAMMALIAN SEC61 COMPLEX BOUND TO THE ACTIVELY TRANSLATING WHEAT GERM 80S RIBOSOME 3ZEN ; 7.5 ; Cryo-EM Structure of the Mycobacterial Fatty Acid Synthase 4B3Y ; 7.5 ; Cryo-EM Structure of the Mycobacterial Fatty Acid Synthase 2WVW ; 9 ; Cryo-EM structure of the RbcL-RbcX complex 1QLE ; 3 ; CRYO-STRUCTURE OF THE PARACOCCUS DENITRIFICANS FOUR-SUBUNIT CYTOCHROME C OXIDASE IN THE COMPLETELY OXIDIZED STATE COMPLEXED WITH AN ANTIBODY FV FRAGMENT 3U4L ; 2.4 ; Cryocooled bovine profilin:actin crystal structure to 2.4 A 3J06 ; 3.3 ; CryoEM Helical Reconstruction of TMV 2VOY ; 18 ; CryoEM model of CopA, the copper transporting ATPase from Archaeoglobus fulgidus 2WYY ; 10 ; CRYOEM MODEL OF THE VESICULAR STOMATITIS VIRUS 3J24 ; 9 ; CryoEM reconstruction of complement decay-accelerating factor 3IZ3 ; 3.9 ; CryoEM structure of cytoplasmic polyhedrosis virus 3J27 ; 3.6 ; CryoEM structure of Dengue virus 3J2P ; 3.6 ; CryoEM structure of Dengue virus capsid protein heterotetramer 1NN8 ; 15 ; CryoEM structure of poliovirus receptor bound to poliovirus 3EPC ; 8 ; CryoEM structure of poliovirus receptor bound to poliovirus type 1 3EPF ; 9 ; CryoEM structure of poliovirus receptor bound to poliovirus type 2 3EPD ; 9 ; CryoEM structure of poliovirus receptor bound to poliovirus type 3 1CXP ; 1.8 ; CRYOGENIC CRYSTAL STRUCTURE OF HUMAN MYELOPEROXIDASE ISOFORM C 2OEO ; 2 ; Cryogenic crystal structure of Staphylococcal Nuclease variant truncated Delta+PHS I92D 1TQO ; 2 ; Cryogenic Crystal Structure of Staphylococcal Nuclease Variant truncated Delta+PHS I92E 1TT2 ; 1.85 ; Cryogenic crystal structure of Staphylococcal nuclease variant truncated Delta+PHS I92K 2OF1 ; 1.92 ; Cryogenic crystal structure of the Staphylococcal Nuclease variant truncated Delta+PHS I92W 3K0M ; 1.25 ; Cryogenic structure of CypA 3K0R ; 2.424 ; Cryogenic structure of CypA mutant Arg55Lys 3K0P ; 1.649 ; Cryogenic structure of CypA mutant Ser99Thr 3K0Q ; 2.317 ; Cryogenic structure of CypA mutant Ser99Thr (2) 1BU7 ; 1.65 ; CRYOGENIC STRUCTURE OF CYTOCHROME P450BM-3 HEME DOMAIN 5CP4 ; 1.75 ; CRYOGENIC STRUCTURE OF P450CAM 3QOJ ; 1.6 ; Cryogenic structure of Staphylococcal nuclease variant D+PHS/V23K 1OT6 ; 0.95 ; CRYOTRAPPED CRYSTAL STRUCTURE OF THE E46Q MUTANT OF PHOTOACTIVE YELLOW PROTEIN UNDER CONTINUOUS ILLUMINATION AT 110K 1OT9 ; 1 ; CRYOTRAPPED STATE IN WILD TYPE PHOTOACTIVE YELLOW PROTEIN, INDUCED WITH CONTINUOUS ILLUMINATION AT 110K 2J4D ; 1.9 ; CRYPTOCHROME 3 FROM ARABIDOPSIS THALIANA 3ZXS ; 2.7 ; Cryptochrome B from Rhodobacter sphaeroides 3Q79 ; 2.506 ; Cryptococcus neoformans protein farnesyltransferase in complex with farnesyl-DDPTASACNIQ product 3Q7F ; 2.2 ; Cryptococcus neoformans protein farnesyltransferase in complex with FPP and ethylenediamine inhibitor 1 3Q7A ; 2 ; Cryptococcus neoformans protein farnesyltransferase in complex with FPP and L-778,123 3SFY ; 2.1 ; Cryptococcus neoformans protein farnesyltransferase in complex with FPT-II and ethylenediamine inhibitor 2 3SFX ; 2 ; Cryptococcus neoformans protein farnesyltransferase in complex with FPT-II and tipifarnib 3Q75 ; 2.14 ; Cryptococcus neoformans protein farnesyltransferase in complex with FPT-II and TKCVVM peptide 3Q78 ; 2.2 ; Cryptococcus neoformans protein farnesyltransferase in complex with FSPP and DDPTASACNIQ peptide 3Q73 ; 2.3 ; Cryptococcus neoformans protein farnesyltransferase, apo enzyme 2AAZ ; 2.08 ; Cryptococcus neoformans thymidylate synthase complexed with substrate and an antifolate 2QG5 ; 2.3 ; Cryptosporidium parvum calcium dependent protein kinase cgd7_1840 3NIZ ; 2.4 ; Cryptosporidium parvum cyclin-dependent kinase cgd5_2510 with ADP bound. 2QKR ; 2.6 ; Cryptosporidium parvum cyclin-dependent kinase cgd5_2510 with indirubin 3'-monoxime bound 2POY ; 1.8 ; Cryptosporidium parvum cyclophilin type peptidyl-prolyl cis-trans isomerase cgd2_4120 in complex with cyclosporin A 2O1O ; 2.42 ; Cryptosporidium parvum putative polyprenyl pyrophosphate synthase (cgd4_2550) in complex with risedronate. 2Q58 ; 2.37 ; Cryptosporidium parvum putative polyprenyl pyrophosphate synthase (cgd4_2550) in complex with zoledronate 3TD7 ; 2.21 ; Crysal structure of the mimivirus sulfhydryl oxidase R596 2ZBI ; 2 ; Crysatl structure of a bacterial cell-surface flagellin 3K8V ; 2.1 ; Crysatl structure of a bacterial cell-surface flagellin N20C20 3K8W ; 1.7 ; Crysatl structure of a bacterial cell-surface flagellin N20C45 3B8G ; 2.6 ; Crysta structure of N-acetylglutamate synthase from Neisseria gonorrhoeae complexed with coenzyme A and N-acetyl-glutamate 2BJK ; 1.4 ; CRYSTAL ANALYSIS OF 1-PYRROLINE-5-CARBOXYLATE DEHYDROGENASE FROM THERMUS WITH BOUND NAD AND CITRATE. 2EHU ; 1.8 ; Crystal analysis of 1-pyrroline-5-carboxylate dehydrogenase from thermus with bound NAD and Inhibitor L-serine 2BHP ; 1.8 ; CRYSTAL ANALYSIS OF 1-PYRROLINE-5-CARBOXYLATE DEHYDROGENASE FROM THERMUS WITH BOUND NAD. 2BJA ; 1.9 ; CRYSTAL ANALYSIS OF 1-PYRROLINE-5-CARBOXYLATE DEHYDROGENASE FROM THERMUS WITH BOUND NADH 2EHQ ; 1.55 ; Crystal analysis of 1-pyrroline-5-carboxylate dehydrogenase from thermus with bound NADP 2BHQ ; 1.4 ; CRYSTAL ANALYSIS OF 1-PYRROLINE-5-CARBOXYLATE DEHYDROGENASE FROM THERMUS WITH BOUND PRODUCT GLUTAMATE. 1UFY ; 0.96 ; Crystal analysis of chorismate mutase from thermus thermophilus 1UI9 ; 1.65 ; Crystal analysis of chorismate mutase from thermus thermophilus 1ODE ; 1.65 ; CRYSTAL ANALYSIS OF CHORISMATE MUTASE FROM THERMUS THERMOPHILUS. 2EJ6 ; 2.06 ; Crystal analysis of delta1-pyrroline-5-carboxylate dehydrogenase from Thermus thermophilus with bound D-proline 2EJD ; 1.85 ; Crystal analysis of delta1-pyrroline-5-carboxylate dehydrogenase from Thermus thermophilus with bound L-alanine 2EIT ; 1.65 ; Crystal analysis of delta1-pyrroline-5-carboxylate dehydrogenase from Thermus thermophilus with bound L-alanine and NAD 2EIW ; 1.9 ; Crystal analysis of delta1-pyrroline-5-carboxylate dehydrogenase from Thermus thermophilus with bound L-proline 2EJL ; 1.5 ; Crystal analysis of delta1-pyrroline-5-carboxylate dehydrogenase from Thermus thermophilus with bound L-serine 2EII ; 1.88 ; Crystal analysis of delta1-pyrroline-5-carboxylate dehydrogenase from Thermus thermophilus with bound L-valine and NAD. 1V9C ; 2.2 ; Crystal Analysis of Precorrin-8x Methyl Mutase from Thermus Thermophilus 3QHN ; 1.99 ; Crystal analysis of the complex structure, E201A-cellotetraose, of endocellulase from pyrococcus horikoshii 3QHM ; 2.01 ; Crystal analysis of the complex structure, E342A-cellotetraose, of endocellulase from pyrococcus horikoshii 3QHO ; 1.65 ; Crystal analysis of the complex structure, Y299F-cellotetraose, of endocellulase from pyrococcus horikoshii 3CSQ ; 1.8 ; Crystal and cryoEM structural studies of a cell wall degrading enzyme in the bacteriophage phi29 tail 3CSR ; 1.8 ; Crystal and cryoEM structural studies of a cell wall degrading enzyme in the bacteriophage phi29 tail 3CSZ ; 1.8 ; Crystal and cryoEM structural studies of a cell wall degrading enzyme in the bacteriophage phi29 tail 3CT0 ; 1.77 ; Crystal and cryoEM structural studies of a cell wall degrading enzyme in the bacteriophage phi29 tail 3CT1 ; 1.51 ; Crystal and cryoEM structural studies of a cell wall degrading enzyme in the bacteriophage phi29 tail 3CT5 ; 1.37 ; Crystal and cryoEM structural studies of a cell wall degrading enzyme in the bacteriophage phi29 tail 2AYH ; 1.6 ; CRYSTAL AND MOLECULAR STRUCTURE AT 1.6 ANGSTROMS RESOLUTION OF THE HYBRID BACILLUS ENDO-1,3-1,4-BETA-D-GLUCAN 4-GLUCANOHYDROLASE H(A16-M) 1CAG ; 1.85 ; CRYSTAL AND MOLECULAR STRUCTURE OF A COLLAGEN-LIKE PEPTIDE AT 1.9 ANGSTROM RESOLUTION 1D24 ; 1.9 ; CRYSTAL AND MOLECULAR STRUCTURE OF A DNA DUPLEX CONTAINING THE CARCINOGENIC LESION O6-METHYLGUANINE 1D76 ; 1.3 ; CRYSTAL AND MOLECULAR STRUCTURE OF A DNA FRAGMENT CONTAINING A 2-AMINO ADENINE MODIFICATION: THE RELATIONSHIP BETWEEN CONFORMATION, PACKING, AND HYDRATION IN Z-DNA HEXAMERS 1D28 ; 2.7 ; CRYSTAL AND MOLECULAR STRUCTURE OF A DNA FRAGMENT: D(CGTGAATTCACG) 210D ; 1.35 ; CRYSTAL AND MOLECULAR STRUCTURE OF A NEW Z-DNA CRYSTAL FORM: D[CGT(2-NH2-A)CG] AND ITS PLATINATED DERIVATIVE 1AMY ; 2.8 ; CRYSTAL AND MOLECULAR STRUCTURE OF BARLEY ALPHA-AMYLASE 1TYT ; 2.6 ; CRYSTAL AND MOLECULAR STRUCTURE OF CRITHIDIA FASCICULATA TRYPANOTHIONE REDUCTASE AT 2.6 ANGSTROMS RESOLUTION 119D ; 2.25 ; CRYSTAL AND MOLECULAR STRUCTURE OF D(CGTAGATCTACG) AT 2.25 ANGSTROMS RESOLUTION 1D82 ; 2.5 ; CRYSTAL AND MOLECULAR STRUCTURE OF D(GTCTAGAC) 118D ; 1.64 ; CRYSTAL AND MOLECULAR STRUCTURE OF D(GTGCGCAC): INVESTIGATION OF THE EFFECTS OF BASE SEQUENCE ON THE CONFORMATION OF OCTAMER DUPLEXES 1AVH ; 2.3 ; CRYSTAL AND MOLECULAR STRUCTURE OF HUMAN ANNEXIN V AFTER REFINEMENT. IMPLICATIONS FOR STRUCTURE, MEMBRANE BINDING AND ION CHANNEL FORMATION OF THE ANNEXIN FAMILY OF PROTEINS 1AVR ; 2.3 ; CRYSTAL AND MOLECULAR STRUCTURE OF HUMAN ANNEXIN V AFTER REFINEMENT. IMPLICATIONS FOR STRUCTURE, MEMBRANE BINDING AND ION CHANNEL FORMATION OF THE ANNEXIN FAMILY OF PROTEINS 1PK4 ; 1.9 ; CRYSTAL AND MOLECULAR STRUCTURE OF HUMAN PLASMINOGEN KRINGLE 4 REFINED AT 1.9-ANGSTROMS RESOLUTION 157D ; 1.8 ; CRYSTAL AND MOLECULAR STRUCTURE OF R(CGCGAAUUAGCG): AN RNA DUPLEX CONTAINING TWO G(ANTI).A(ANTI) BASE-PAIRS 116D ; 2.5 ; CRYSTAL AND MOLECULAR STRUCTURE OF THE A-DNA DODECAMER D(CCGTACGTACGG): CHOICE OF FRAGMENT HELICAL AXIS 117D ; 2.55 ; CRYSTAL AND MOLECULAR STRUCTURE OF THE ALTERNATING DODECAMER D(GCGTACGTACGC) IN THE A-DNA FORM: COMPARISON WITH THE ISOMORPHOUS NON-ALTERNATING DODECAMER D(CCGTACGTACGG) 1ACB ; 2 ; CRYSTAL AND MOLECULAR STRUCTURE OF THE BOVINE ALPHA-CHYMOTRYPSIN-EGLIN C COMPLEX AT 2.0 ANGSTROMS RESOLUTION 2CI2 ; 2 ; CRYSTAL AND MOLECULAR STRUCTURE OF THE SERINE PROTEINASE INHIBITOR CI-2 FROM BARLEY SEEDS 1HTR ; 1.62 ; CRYSTAL AND MOLECULAR STRUCTURES OF HUMAN PROGASTRICSIN AT 1.62 ANGSTROMS RESOLUTION 2ATC ; 3 ; CRYSTAL AND MOLECULAR STRUCTURES OF NATIVE AND CTP-LIGANDED ASPARTATE CARBAMOYLTRANSFERASE FROM ESCHERICHIA COLI 1CHO ; 1.8 ; CRYSTAL AND MOLECULAR STRUCTURES OF THE COMPLEX OF ALPHA-*CHYMOTRYPSIN WITH ITS INHIBITOR TURKEY OVOMUCOID THIRD DOMAIN AT 1.8 ANGSTROMS RESOLUTION 295D ; 1.5 ; CRYSTAL AND SOLUTION STRUCTURES OF THE OLIGONUCLEOTIDE D(ATGCGCAT)2: A COMBINED X-RAY AND NMR STUDY 1IHO ; 1.7 ; CRYSTAL APO-STRUCTURE OF PANTOTHENATE SYNTHETASE FROM E. COLI 2CMY ; 2.25 ; CRYSTAL COMPLEX BETWEEN BOVINE TRYPSIN AND VERONICA HEDERIFOLIA TRYPSIN INHIBITOR 3L4T ; 1.9 ; Crystal complex of N-terminal Human Maltase-Glucoamylase with BJ2661 3CTT ; 2.1 ; Crystal complex of N-terminal Human Maltase-Glucoamylase with Casuarine 3L4U ; 1.9 ; Crystal complex of N-terminal Human Maltase-Glucoamylase with de-O-sulfonated kotalanol 3L4V ; 2.1 ; Crystal complex of N-terminal Human Maltase-Glucoamylase with kotalanol 3L4W ; 2 ; Crystal complex of N-terminal Human Maltase-Glucoamylase with miglitol 3L4X ; 1.9 ; Crystal complex of N-terminal Human Maltase-Glucoamylase with NR4-8 3L4Y ; 1.8 ; Crystal complex of N-terminal Human Maltase-Glucoamylase with NR4-8II 3L4Z ; 2 ; Crystal complex of N-terminal Human Maltase-Glucoamylase with Salacinol 3LPP ; 2.15 ; Crystal complex of N-terminal sucrase-isomaltase with kotalanol 3C2G ; 2.5 ; Crystal complex of SYS-1/POP-1 at 2.5A resolution 1QA7 ; 1.9 ; CRYSTAL COMPLEX OF THE 3C PROTEINASE FROM HEPATITIS A VIRUS WITH ITS INHIBITOR AND IMPLICATIONS FOR THE POLYPROTEIN PROCESSING IN HAV 3HMS ; 1.7 ; Crystal Crystal structure of the N-terminal fragment (28-126) of the human hepatocyte growth factor/scatter factor, orthorhombic crystal form 3S80 ; 1.92 ; Crystal form 2 of a chiral ruthenium complex bound to DNA 2R6D ; 3.7 ; Crystal Form B1 2R6E ; 5.019 ; Crystal Form B2 2R6A ; 2.9 ; Crystal Form BH1 2R6C ; 4 ; Crystal Form BH2 2FKC ; 2.39 ; Crystal Form I of Pre-Reactive Complex of Restriction Endonuclease HinP1I with Cognate DNA and Calcium Ion 4ANC ; 2.8 ; CRYSTAL FORM I OF THE D93N MUTANT OF NUCLEOSIDE DIPHOSPHATE KINASE FROM MYCOBACTERIUM TUBERCULOSIS 1M3J ; 3 ; CRYSTAL form II of perfringolysin O 2FKH ; 3.09 ; Crystal Form II of Pre-Reactive Complex of Restriction Endonuclease HinP1I with Cognate DNA and Calcium Ions 4AND ; 2.808 ; CRYSTAL FORM II OF THE D93N MUTANT OF NUCLEOSIDE DIPHOSPHATE KINASE FROM MYCOBACTERIUM TUBERCULOSIS 2DQU ; 1.7 ; Crystal form II: high resolution crystal structure of the complex of the hydrolytic antibody Fab 6D9 and a transition-state analog 1BDN ; 2.6 ; CRYSTAL LATTICE PACKING IS IMPORTANT IN DETERMINING THE BEND OF A DNA DODECAMER CONTAINING AN ADENINE TRACT 3HGL ; 1.9 ; crystal of AvrPtoB 121-205 3GMZ ; 1.43 ; Crystal of human arginase in complex with L-ornithine. Resolution 1.43 A. 3VGJ ; 2.212 ; Crystal of Plasmodium falciparum tyrosyl-tRNA synthetase (PfTyrRS)in complex with adenylate analog 3RZ2 ; 2.8 ; Crystal of Prl-1 complexed with peptide 2H14 ; 1.48 ; Crystal of WDR5 (apo-form) 2QMT ; 1.05 ; Crystal Polymorphism of Protein GB1 Examined by Solid-state NMR and X-ray Diffraction 2NVW ; 2.1 ; Crystal sctucture of transcriptional regulator Gal80p from kluyveromymes lactis 2PVG ; 2.4 ; Crystal srtucture of the binary complex between ferredoxin and ferredoxin:thioredoxin reductase 2PU9 ; 1.65 ; Crystal srtucture of the binary complex between ferredoxin: thioredoxin reductase and thioredoxin f 2PUK ; 3 ; Crystal srtucture of the binary complex between ferredoxin: thioredoxin reductase and thioredoxin m 2PUO ; 1.7 ; Crystal srtucture of the NEM modified ferredoxin:thioredoxin reductase 2PVD ; 1.95 ; Crystal srtucture of the reduced ferredoxin:thioredoxin reductase 2PVO ; 3.4 ; Crystal srtucture of the ternary complex between thioredoxin f, ferredoxin, and ferredoxin: thioredoxin reductase 2RKT ; 1.99 ; Crystal Sructure of apo F. graminearum TRI101 3B2S ; 1.92 ; Crystal Sructure of F. graminearum TRI101 complexed with Coenzyme A and Deoxynivalenol 2RKV ; 1.6 ; Crystal Sructure of F. graminearum TRI101 complexed with Coenzyme A and T-2 mycotoxin 3B30 ; 1.97 ; Crystal Sructure of F. graminearum TRI101 complexed with Ethyl Coenzyme A 2ZBA ; 2 ; Crystal Sructure of F. sporotrichioides TRI101 complexed with Coenzyme A and T-2 2R0T ; 1.9 ; Crystal sructure of GDP-4-keto-6-deoxymannose-3-dehydratase with a trapped PLP-glutamate geminal diamine 3A43 ; 2.3 ; Crystal sructure of HypA 1YS9 ; 2.56 ; Crystal sructure of phosphatase SPy1043 from Streptococcus pyogenes 3RY7 ; 2.15 ; Crystal Sructure of Sa239 1RD8 ; 3 ; Crystal Sructure of the 1918 Human H1 Hemagglutinin Precursor (HA0) 1Y1L ; 2.8 ; crystal stracture of arsenate reductase from Archaeoglobus fulgidus DSM 4304, structural genomics 3K1I ; 2.7 ; Crystal strcture of FliS-HP1076 complex in H. pylori 3GUS ; 1.53 ; Crystal strcture of human Pi class glutathione S-transferase GSTP1-1 in complex with 6-(7-Nitro-2,1,3-benzoxadiazol-4-ylthio)hexanol (NBDHEX) 2OKN ; 2.45 ; Crystal Strcture of Human Prolidase 3VIR ; 2.7 ; Crystal strcture of Swi5 from fission yeast 2OVS ; 1.9 ; Crystal strcuture of a Type Three secretion System protein 3UQH ; 3 ; Crystal strcuture of aba receptor pyl10 (apo) 2I5G ; 2.6 ; Crystal strcuture of amidohydrolase from Pseudomonas aeruginosa 1RVG ; 2 ; crystal strcuture of class II fructose-bisphosphate aldolase from Thermus aquaticus in complex with Y 3M3W ; 2.6 ; Crystal strcuture of mouse PACSIN3 BAR domain mutant 3FHU ; 2.1 ; Crystal strcuture of type IV b pilin from Salmonella typhi 3N12 ; 1.2 ; Crystal stricture of chitinase in complex with zinc atoms from Bacillus cereus NCTU2 3N13 ; 1.7 ; Crystal stricture of D143A chitinase in complex with NAG from Bacillus cereus NCTU2 3N1A ; 2 ; Crystal stricture of E145G/Y227F chitinase in complex with cyclo-(L-His-L-Pro) from Bacillus cereus NCTU2 3N18 ; 1.6 ; Crystal stricture of E145G/Y227F chitinase in complex with NAG from Bacillus cereus NCTU2 3N15 ; 1.94 ; Crystal stricture of E145Q chitinase in complex with NAG from Bacillus cereus NCTU2 3N17 ; 1.2 ; Crystal stricture of E145Q/Y227F chitinase in complex with NAG from Bacillus cereus NCTU2 3N11 ; 1.35 ; Crystal stricture of wild-type chitinase from Bacillus cereus NCTU2 3RIR ; 2.6 ; Crystal Strucrture of Biotin Protein Ligase from S. aureus 3S4E ; 1.26 ; Crystal Structrue of a Novel Mitogen-activated Protein Kinase Phosphatase, SKRP1 2PEZ ; 1.4 ; Crystal structrue of deletion mutant of APS-kinase domain of human PAPS-synthetase 1 in complex with cyclic PAPS and dADP 1XWO ; 2.8 ; crystal structrue of goose delta crystallin 3A1V ; 2.4 ; Crystal structue of the cytosolic domain of T. maritima FeoB iron iransporter in apo form 3A1S ; 1.5 ; Crystal structue of the cytosolic domain of T. maritima FeoB iron iransporter in GDP form I 3A1T ; 1.8 ; Crystal structue of the cytosolic domain of T. maritima FeoB iron iransporter in GDP form II 3A1U ; 1.8 ; Crystal structue of the cytosolic domain of T. maritima FeoB iron iransporter in GMPPNP form 3A1W ; 1.9001 ; Crystal structue of the G domain of T. maritima FeoB iron iransporter 1SL3 ; 1.81 ; crystal structue of Thrombin in complex with a potent P1 heterocycle-Aryl based inhibitor 1W2I ; 1.5 ; CRYSTAL STRUCTUORE OF ACYLPHOSPHATASE FROM PYROCOCCUS HORIKOSHII COMPLEXED WITH FORMATE 3KM8 ; 2 ; Crystal structuore of adenosine deaminase from mus musculus complexed with 9-deazainosine 1SS9 ; 2.6 ; Crystal Structural Analysis of Active Site Mutant Q189E of LgtC 2ZA4 ; 1.58 ; Crystal Structural Analysis of Barnase-barstar Complex 3ECY ; 1.88 ; Crystal structural analysis of Drosophila melanogaster dUTPase 3A4K ; 2.17 ; Crystal structural analysis of HindIII restriction endonuclease in complex with cognate DNA and divalent cations at 2.17 angstrom resolution 2E52 ; 2 ; Crystal structural analysis of HindIII restriction endonuclease in complex with cognate DNA at 2.0 angstrom resolution 1BSA ; 2 ; CRYSTAL STRUCTURAL ANALYSIS OF MUTATIONS IN THE HYDROPHOBIC CORES OF BARNASE 1BSB ; 2 ; CRYSTAL STRUCTURAL ANALYSIS OF MUTATIONS IN THE HYDROPHOBIC CORES OF BARNASE 1BSC ; 2 ; CRYSTAL STRUCTURAL ANALYSIS OF MUTATIONS IN THE HYDROPHOBIC CORES OF BARNASE 1BSD ; 2.3 ; CRYSTAL STRUCTURAL ANALYSIS OF MUTATIONS IN THE HYDROPHOBIC CORES OF BARNASE 1BSE ; 2 ; CRYSTAL STRUCTURAL ANALYSIS OF MUTATIONS IN THE HYDROPHOBIC CORES OF BARNASE 1EJJ ; 1.9 ; CRYSTAL STRUCTURAL ANALYSIS OF PHOSPHOGLYCERATE MUTASE COCRYSTALLIZED WITH 3-PHOSPHOGLYCERATE 3DUW ; 1.2 ; Crystal Structural Analysis of the O-methyltransferase from Bacillus cereus in complex SAH 1TNV ; 5 ; CRYSTAL STRUCTURAL ANALYSIS OF TOBACCO NECROSIS VIRUS (TNV) AT 5 ANGSTROMS RESOLUTION 2GX0 ; 1.9 ; Crystal structural and functional analysis of GFP-like fluorescent protein 2GX2 ; 1.8 ; Crystal structural and functional analysis of GFP-like fluorescent protein Dronpa 3I3C ; 2.48 ; Crystal Structural of CBX5 Chromo Shadow Domain 3D3I ; 1.78 ; Crystal structural of Escherichia coli K12 YgjK, a glucosidase belonging to glycoside hydrolase family 63 2ZJG ; 3 ; Crystal structural of mouse kynurenine aminotransferase III 3PDX ; 2.91 ; Crystal structural of mouse tyrosine aminotransferase 3N9H ; 2.5 ; Crystal Structural of mutant Y305A in the copper amine oxidase from hansenula polymorpha 3BZL ; 1.71 ; Crystal structural of native EscU C-terminal domain 3BZO ; 1.5 ; Crystal structural of native EscU C-terminal domain 3C01 ; 2.6 ; Crystal structural of native SpaS C-terminal domain 3ULX ; 2.6 ; Crystal structural of the conserved domain of Rice Stress-responsive NAC1 3C00 ; 1.41 ; Crystal structural of the mutated G247T EscU/SpaS C-terminal domain 3BZP ; 1.499 ; Crystal structural of the mutated N262A EscU C-terminal domain 3BZT ; 1.5 ; Crystal structural of the mutated P263A EscU C-terminal domain 3BZZ ; 1.407 ; Crystal structural of the mutated R313T EscU/SpaS C-terminal domain 3BZV ; 1.94 ; Crystal structural of the mutated T264A EscU C-terminal domain 4EUK ; 1.95 ; Crystal structure 1RU9 ; 2.5 ; Crystal Structure (A) of u.v.-irradiated cationic cyclization antibody 4C6 Fab at pH 4.6 with a data set collected in-house. 1RUA ; 1.75 ; Crystal structure (B) of u.v.-irradiated cationic cyclization antibody 4C6 fab at pH 4.6 with a data set collected at SSRL beamline 11-1. 1RUK ; 1.4 ; Crystal structure (C) of native cationic cyclization antibody 4C6 fab at pH 4.6 with a data set collected at SSRL beamline 9-1 1RUL ; 1.88 ; Crystal Structure (D) of u.v.-irradiated cationic cyclization antibody 4C6 Fab at pH 5.6 with a data set collected at SSRL beamline 11-1. 1RUM ; 1.48 ; Crystal structure (F) of H2O2-soaked cationic cyclization antibody 4C6 fab at pH 8.5 with a data set collected at SSRL beamline 9-1. 1RUP ; 1.4 ; Crystal structure (G) of native cationic cyclization antibody 4C6 fab at pH 8.5 with a data set collected at APS beamline 19-ID 1RUQ ; 1.86 ; Crystal Structure (H) of u.v.-irradiated Diels-Alder antibody 13G5 Fab at pH 8.0 with a data set collected in house. 1RUR ; 1.5 ; Crystal Structure (I) of native Diels-Alder antibody 13G5 Fab at pH 8.0 with a data set collected at SSRL beamline 9-1. 2ANN ; 2.3 ; Crystal structure (I) of Nova-1 KH1/KH2 domain tandem with 25 nt RNA hairpin 2ANR ; 1.94 ; Crystal structure (II) of Nova-1 KH1/KH2 domain tandem with 25nt RNA hairpin 1FCQ ; 1.6 ; CRYSTAL STRUCTURE (MONOCLINIC) OF BEE VENOM HYALURONIDASE 1FCU ; 2.1 ; CRYSTAL STRUCTURE (TRIGONAL) OF BEE VENOM HYALURONIDASE 3U54 ; 2.35 ; Crystal structure (Type-1) of SAICAR synthetase from Pyrococcus horikoshii OT3 3U55 ; 1.9 ; Crystal structure (Type-2) of SAICAR synthetase from Pyrococcus horikoshii OT3 479D ; 1.9 ; CRYSTAL STRUCTURE A DNA:RNA HYBRID DUPLEX, A DYNAMIC MODEL FOR RNASE H RECOGNITION 3UV1 ; 2 ; Crystal structure a major allergen from dust mite 3DYJ ; 1.85 ; Crystal structure a talin rod fragment 3DCY ; 1.748 ; Crystal Structure a TP53-induced glycolysis and apoptosis regulator protein from Homo sapiens. 2J0M ; 2.8 ; CRYSTAL STRUCTURE A TWO-CHAIN COMPLEX BETWEEN THE FERM AND KINASE DOMAINS OF FOCAL ADHESION KINASE. 2ZGU ; 2.4 ; Crystal structure Agrocybe aegerita lectin AAL mutant I144G 2X2Z ; 2 ; Crystal structure AMA1 from Toxoplasma gondii 3S3Y ; 2 ; Crystal Structure an Tandem Cyanovirin-N Dimer, CVN2L0 3S3Z ; 1.75 ; Crystal Structure an Tandem Cyanovirin-N Dimer, CVN2L10 2EBS ; 2.4 ; Crystal Structure Anaalysis of Oligoxyloglucan reducing-end-specific cellobiohydrolase (OXG-RCBH) D465N Mutant Complexed with a Xyloglucan Heptasaccharide 1V8S ; 2.2 ; Crystal structure analusis of the ADP-ribose pyrophosphatase complexed with AMP and Mg 1R4X ; 1.9 ; Crystal Structure Analys of the Gamma-COPI Appendage domain 4PCY ; 2.15 ; CRYSTAL STRUCTURE ANALYSES OF REDUCED (CUI) POPLAR PLASTOCYANIN AT SIX PH VALUES 5PCY ; 1.8 ; CRYSTAL STRUCTURE ANALYSES OF REDUCED (CUI) POPLAR PLASTOCYANIN AT SIX PH VALUES 6PCY ; 1.9 ; CRYSTAL STRUCTURE ANALYSES OF REDUCED (CUI) POPLAR PLASTOCYANIN AT SIX PH VALUES 2OI0 ; 2 ; Crystal structure analysis 0f the TNF-a Coverting Enzyme (TACE) in complexed with Aryl-sulfonamide 4CTS ; 2.9 ; CRYSTAL STRUCTURE ANALYSIS AND MOLECULAR MODEL OF A COMPLEX OF CITRATE SYNTHASE WITH OXALOACETATE AND S-ACETONYL-COENZYME A 2Z6B ; 3.11 ; Crystal Structure Analysis of (gp27-gp5)3 conjugated with Fe(III) protoporphyrin 3BFJ ; 2.7 ; Crystal structure analysis of 1,3-propanediol oxidoreductase 3D61 ; 1.95 ; Crystal Structure Analysis of 1,5-alpha-arabinanase catalytic mutant (AbnBD147A) complexed to arabinobiose 3D5Z ; 1.9 ; Crystal Structure Analysis of 1,5-alpha-arabinanase catalytic mutant (AbnBE201A) complexed to arabinotriose 3D60 ; 1.9 ; Crystal Structure Analysis of 1,5-alpha-arabinanase catalytic mutant (D27A) 4GWG ; 1.3907 ; Crystal Structure Analysis of 6-phosphogluconate dehydrogenase apo-form 2QJ6 ; 2.5 ; Crystal structure analysis of a 14 repeat C-terminal fragment of toxin TcdA in Clostridium difficile 3BSE ; 1.6 ; Crystal structure analysis of a 16-base-pair B-DNA 1MLX ; 1.25 ; Crystal Structure Analysis of a 2'-O-[2-(Methylthio)-ethyl]-Modified Oligodeoxynucleotide Duplex 2AXB ; 1.61 ; Crystal Structure Analysis Of A 2-O-[2-(methoxy)ethyl]-2-thiothymidine Modified Oligodeoxynucleotide Duplex 1MHK ; 2.5 ; Crystal Structure Analysis of a 26mer RNA molecule, representing a new RNA motif, the hook-turn 3UA8 ; 1.9 ; Crystal Structure Analysis of a 6-Amino Quinazolinedione Sulfonamide bound to human GluR2 1WIY ; 2 ; Crystal Structure Analysis of a 6-coordinated Cytochorome P450 from Thermus thermophilus HB8 4H0S ; 1.55 ; Crystal structure analysis of a basic phospholipase A2 from Trimeresurus stejnegeri venom 3K83 ; 2.251 ; Crystal Structure Analysis of a Biphenyl/Oxazole/Carboxypyridine alpha-ketoheterocycle Inhibitor Bound to a Humanized Variant of Fatty Acid Amide Hydrolase 2NO4 ; 1.93 ; Crystal Structure analysis of a Dehalogenase 2NO5 ; 2.6 ; Crystal Structure analysis of a Dehalogenase with intermediate complex 1JBZ ; 1.5 ; CRYSTAL STRUCTURE ANALYSIS OF A DUAL-WAVELENGTH EMISSION GREEN FLUORESCENT PROTEIN VARIANT AT HIGH PH 1JBY ; 1.8 ; CRYSTAL STRUCTURE ANALYSIS OF A DUAL-WAVELENGTH EMISSION GREEN FLUORESCENT PROTEIN VARIANT AT LOW PH 2CE2 ; 1 ; CRYSTAL STRUCTURE ANALYSIS OF A FLUORESCENT FORM OF H-RAS P21 IN COMPLEX WITH GDP 2CLD ; 1.22 ; CRYSTAL STRUCTURE ANALYSIS OF A FLUORESCENT FORM OF H-RAS P21 IN COMPLEX WITH GDP (2) 2CL0 ; 1.8 ; CRYSTAL STRUCTURE ANALYSIS OF A FLUORESCENT FORM OF H-RAS P21 IN COMPLEX WITH GPPNHP 2CL7 ; 1.25 ; CRYSTAL STRUCTURE ANALYSIS OF A FLUORESCENT FORM OF H-RAS P21 IN COMPLEX WITH GTP 2CLC ; 1.3 ; CRYSTAL STRUCTURE ANALYSIS OF A FLUORESCENT FORM OF H-RAS P21 IN COMPLEX WITH GTP (2) 2EVW ; 1.05 ; Crystal structure analysis of a fluorescent form of H-Ras p21 in complex with R-caged GTP 2CL6 ; 1.24 ; CRYSTAL STRUCTURE ANALYSIS OF A FLUORESCENT FORM OF H-RAS P21 IN COMPLEX WITH S-CAGED GTP 3F8T ; 1.9 ; Crystal structure analysis of a full-length MCM homolog from Methanopyrus kandleri 3I4U ; 2.1 ; Crystal Structure Analysis of a helicase associated domain 1JUC ; 2.35 ; Crystal Structure Analysis of a Holliday Junction Formed by CCGGTACCGG 1QSW ; 1.85 ; CRYSTAL STRUCTURE ANALYSIS OF A HUMAN LYSOZYME MUTANT W64C C65A 1MCV ; 1.8 ; Crystal Structure Analysis of a Hybrid Squash Inhibitor in Complex with Porcine Pancreatic Elastase 2ALM ; 2.6 ; Crystal structure analysis of a mutant beta-ketoacyl-[acyl carrier protein] synthase II from Streptococcus pneumoniae 2TIR ; 2 ; CRYSTAL STRUCTURE ANALYSIS OF A MUTANT ESCHERICHIA COLI THIOREDOXIN IN WHICH LYSINE 36 IS REPLACED BY GLUTAMIC ACID 1S5T ; 2.3 ; Crystal Structure Analysis of a mutant of DIHYDRODIPICOLINATE SYNTHASE--residue thr44 to val44 1S5V ; 2.35 ; Crystal Structure Analysis of a mutant of DIHYDRODIPICOLINATE SYNTHASE--residue Tyr107 to Phe107 1S5W ; 2.32 ; Crystal Structure Analysis of a mutant of DIHYDRODIPICOLINATE SYNTHASE--residue Tyr133 to Phe133 1HR2 ; 2.25 ; CRYSTAL STRUCTURE ANALYSIS OF A MUTANT P4-P6 DOMAIN (DELC209) OF TETRAHYMENA THEMOPHILA GROUP I INTRON. 2D42 ; 2.07 ; Crystal structure analysis of a non-toxic crystal protein from Bacillus thuringiensis 1T4U ; 2 ; Crystal Structure Analysis of a novel Oxyguanidine bound to Thrombin 1T4V ; 2 ; Crystal Structure Analysis of a novel Oxyguanidine bound to Thrombin 3K84 ; 2.25 ; Crystal Structure Analysis of a Oleyl/Oxadiazole/pyridine Inhibitor Bound to a Humanized Variant of Fatty Acid Amide Hydrolase 3K7F ; 1.95 ; Crystal Structure Analysis of a Phenhexyl/Oxazole/Carboxypyridine alpha-Ketoheterocycle Inhibitor Bound to a Humanized Variant of Fatty Acid Amide Hydrolase' 3R7X ; 2.1 ; Crystal Structure Analysis of a Quinazolinedione sulfonamide bound to human GluR2: A Novel Class of Competitive AMPA Receptor Antagonists with Oral Activity 2AHA ; 1.98 ; Crystal structure analysis of a rate-enhanced variant of redox-sensitive green fluorescent protein in the reduced form, roGFP1-R8. 3TKK ; 1.99 ; Crystal Structure Analysis of a recombinant predicted acetamidase/ formamidase from the thermophile thermoanaerobacter tengcongensis 1JC1 ; 1.9 ; CRYSTAL STRUCTURE ANALYSIS OF A REDOX-SENSITIVE GREEN FLUORESCENT PROTEIN VARIANT IN A OXIDIZED FORM 1JC0 ; 2 ; CRYSTAL STRUCTURE ANALYSIS OF A REDOX-SENSITIVE GREEN FLUORESCENT PROTEIN VARIANT IN A REDUCED FORM 1LNI ; 1 ; CRYSTAL STRUCTURE ANALYSIS OF A RIBONUCLEASE FROM STREPTOMYCES AUREOFACIENS AT ATOMIC RESOLUTION (1.0 A) 3LLM ; 2.8 ; Crystal Structure Analysis of a RNA Helicase 2RJT ; 1.75 ; Crystal Structure Analysis of a Surface Entropy Reduction Mutant of S. pneumoniae FabF 1MFQ ; 3.1 ; Crystal Structure Analysis of a Ternary S-Domain Complex of Human Signal Recognition Particle 1I9V ; 2.6 ; CRYSTAL STRUCTURE ANALYSIS OF A TRNA-NEOMYCIN COMPLEX 1QZN ; 1.9 ; Crystal Structure Analysis of a type II cohesin domain from the cellulosome of Acetivibrio cellulolyticus 1ZV9 ; 1.28 ; Crystal structure analysis of a type II cohesin domain from the cellulosome of Acetivibrio cellulolyticus- SeMet derivative 1V8M ; 1.8 ; Crystal structure analysis of ADP-ribose pyrophosphatase complexed with ADP-ribose and Gd 1EV5 ; 1.7 ; CRYSTAL STRUCTURE ANALYSIS OF ALA167 MUTANT OF ESCHERICHIA COLI 1EPX ; 1.8 ; CRYSTAL STRUCTURE ANALYSIS OF ALDOLASE FROM L. MEXICANA 1F2J ; 1.9 ; CRYSTAL STRUCTURE ANALYSIS OF ALDOLASE FROM T. BRUCEI 1UA7 ; 2.21 ; Crystal Structure Analysis of Alpha-Amylase from Bacillus Subtilis complexed with Acarbose 3BT4 ; 2.1 ; Crystal Structure Analysis of AmFPI-1, fungal protease inhibitor from Antheraea mylitta 1AAJ ; 1.8 ; CRYSTAL STRUCTURE ANALYSIS OF AMICYANIN AND APOAMICYANIN FROM PARACOCCUS DENITRIFICANS AT 2.0 ANGSTROMS AND 1.8 ANGSTROMS RESOLUTION 1AAN ; 2 ; CRYSTAL STRUCTURE ANALYSIS OF AMICYANIN AND APOAMICYANIN FROM PARACOCCUS DENITRIFICANS AT 2.0 ANGSTROMS AND 1.8 ANGSTROMS RESOLUTION 28DN ; 2.4 ; CRYSTAL STRUCTURE ANALYSIS OF AN A(DNA) OCTAMER D(GTACGTAC) 9DNA ; 1.8 ; CRYSTAL STRUCTURE ANALYSIS OF AN A-DNA FRAGMENT AT 1.8 ANGSTROMS RESOLUTION. D(GCCCGGGC) 3HKX ; 1.66 ; Crystal structure analysis of an amidase from Nesterenkonia sp. 1P2C ; 2 ; crystal structure analysis of an anti-lysozyme antibody 1XQI ; 2.5 ; Crystal Structure Analysis of an NDP kinase from Pyrobaculum aerophilum 1L3Z ; 2.01 ; Crystal Structure Analysis of an RNA Heptamer 1Q1J ; 2.5 ; Crystal Structure Analysis of anti-HIV-1 Fab 447-52D in complex with V3 peptide 2B0S ; 2.3 ; Crystal structure analysis of anti-HIV-1 V3 Fab 2219 in complex with MN peptide 2B1A ; 2.348 ; Crystal structure analysis of anti-HIV-1 V3 Fab 2219 in complex with UG1033 peptide 2B1H ; 2 ; Crystal structure analysis of anti-HIV-1 V3 Fab 2219 in complex with UG29 peptide 2QSC ; 2.8 ; Crystal structure analysis of anti-HIV-1 V3-Fab F425-B4e8 in complex with a V3-peptide 1K3O ; 1.8 ; Crystal Structure Analysis of apo Glutathione S-Transferase 2FGZ ; 1.75 ; Crystal Structure Analysis of apo pullulanase from Klebsiella pneumoniae 3NYJ ; 3.2 ; Crystal Structure Analysis of APP E2 domain 1I49 ; 2.8 ; CRYSTAL STRUCTURE ANALYSIS OF ARFAPTIN 1G8J ; 2.03 ; CRYSTAL STRUCTURE ANALYSIS OF ARSENITE OXIDASE FROM ALCALIGENES FAECALIS 1G8K ; 1.64 ; CRYSTAL STRUCTURE ANALYSIS OF ARSENITE OXIDASE FROM ALCALIGENES FAECALIS 3LNB ; 2.01 ; Crystal Structure Analysis of Arylamine N-acetyltransferase C from Bacillus anthracis 3FI0 ; 2.7 ; Crystal Structure Analysis of B. stearothermophilus Tryptophanyl-tRNA Synthetase Complexed with Tryptophan, AMP, and Inorganic Phosphate 1VEM ; 1.85 ; Crystal Structure Analysis of Bacillus Cereus Beta-Amylase at the optimum pH (6.5) 2GLX ; 2.2 ; Crystal Structure Analysis of bacterial 1,5-AF Reductase 1HV4 ; 2.8 ; CRYSTAL STRUCTURE ANALYSIS OF BAR-HEAD GOOSE HEMOGLOBIN (DEOXY FORM) 2QJ9 ; 2.44 ; Crystal structure analysis of BMP-2 in complex with BMPR-IA variant B1 2QJA ; 2.6 ; Crystal structure analysis of BMP-2 in complex with BMPR-IA variant B12 2QJB ; 2.5 ; Crystal structure analysis of BMP-2 in complex with BMPR-IA variant IA/IB 2R52 ; 2.5 ; Crystal structure analysis of Bone Morphogenetic Protein-6 (BMP-6) 2R53 ; 2.1 ; Crystal structure analysis of Bone Morphogenetic Protein-6 variant B2 (B2-BMP-6) 1SQB ; 2.69 ; Crystal Structure Analysis of Bovine Bc1 with Azoxystrobin 1SQQ ; 3 ; Crystal Structure Analysis of Bovine Bc1 with Methoxy Acrylate Stilbene (MOAS) 1SQP ; 2.7 ; Crystal Structure Analysis of Bovine Bc1 with Myxothiazol 1SQX ; 2.6 ; Crystal Structure Analysis of Bovine Bc1 with Stigmatellin A 1SQV ; 2.85 ; Crystal Structure Analysis of Bovine Bc1 with UHDBT 1V9E ; 1.95 ; Crystal Structure Analysis of Bovine Carbonic Anhydrase II 1ITO ; 2.286 ; Crystal Structure Analysis of Bovine Spleen Cathepsin B-E64c complex 1ISF ; 2.5 ; Crystal Structure Analysis of BST-1/CD157 1ISI ; 2.1 ; Crystal Structure Analysis of BST-1/CD157 complexed with ethenoNAD 1ISH ; 2.4 ; Crystal Structure Analysis of BST-1/CD157 complexed with ethenoNADP 1ISM ; 3 ; Crystal Structure Analysis of BST-1/CD157 complexed with nicotinamide 1ISJ ; 2.3 ; Crystal Structure Analysis of BST-1/CD157 complexed with NMN 1ISG ; 2.6 ; Crystal Structure Analysis of BST-1/CD157 with ATPgammaS 1KYZ ; 2.2 ; Crystal Structure Analysis of Caffeic acid/5-hydroxyferulic acid 3/5-O-methyltransferase Ferulic Acid Complex 1KYW ; 2.4 ; Crystal Structure Analysis of Caffeic Acid/5-hydroxyferulic acid 3/5-O-methyltransferase in complex with 5-hydroxyconiferaldehyde 2ZIB ; 1.34 ; Crystal structure analysis of calcium-independent type II antifreeze protein 1KRQ ; 2.7 ; CRYSTAL STRUCTURE ANALYSIS OF CAMPYLOBACTER JEJUNI FERRITIN 2NZ7 ; 1.9 ; Crystal Structure Analysis of Caspase-recruitment Domain (CARD) of Nod1 1M7S ; 1.8 ; Crystal Structure Analysis of Catalase CatF of Pseudomonas syringae 2J2M ; 2.4 ; CRYSTAL STRUCTURE ANALYSIS OF CATALASE FROM EXIGUOBACTERIUM OXIDOTOLERANS 3RRS ; 1.7 ; Crystal structure analysis of cellobiose phosphorylase from Cellulomonas uda 1FP1 ; 1.82 ; CRYSTAL STRUCTURE ANALYSIS OF CHALCONE O-METHYLTRANSFERASE 4EQ2 ; 2.502 ; Crystal Structure Analysis of Chicken Interferon Gamma Receptor Alpha Chain 3ARO ; 2.22 ; Crystal Structure Analysis of Chitinase A from Vibrio harveyi with novel inhibitors - apo structure 3ARS ; 2.45 ; Crystal Structure Analysis of Chitinase A from Vibrio harveyi with novel inhibitors - apo structure of mutant W275G 3ARY ; 1.35 ; Crystal Structure Analysis of Chitinase A from Vibrio harveyi with novel inhibitors - complex structure with 2-(imidazolin-2-yl)-5-isothiocyanatobenzofuran 3ARZ ; 1.82 ; Crystal Structure Analysis of Chitinase A from Vibrio harveyi with novel inhibitors - complex structure with 2-(imidazolin-2-yl)-5-isothiocyanatobenzofuran 3ARW ; 1.5 ; Crystal Structure Analysis of Chitinase A from Vibrio harveyi with novel inhibitors - complex structure with chelerythrine 3ARP ; 1.55 ; Crystal Structure Analysis of Chitinase A from Vibrio harveyi with novel inhibitors - complex structure with DEQUALINIUM 3ARQ ; 1.5 ; Crystal Structure Analysis of Chitinase A from Vibrio harveyi with novel inhibitors - complex structure with IDARUBICIN 3ARR ; 1.65 ; Crystal Structure Analysis of Chitinase A from Vibrio harveyi with novel inhibitors - complex structure with PENTOXIFYLLINE 3ARX ; 1.16 ; Crystal Structure Analysis of Chitinase A from Vibrio harveyi with novel inhibitors - complex structure with Propentofylline 3ARV ; 1.5 ; Crystal Structure Analysis of Chitinase A from Vibrio harveyi with novel inhibitors - complex structure with Sanguinarine 3AS3 ; 2.4 ; Crystal Structure Analysis of Chitinase A from Vibrio harveyi with novel inhibitors - W275G mutant complex structure with 2-(imidazolin-2-yl)-5-isothiocyanatobenzofuran 3AS1 ; 2 ; Crystal Structure Analysis of Chitinase A from Vibrio harveyi with novel inhibitors - W275G mutant complex structure with chelerythrine 3ART ; 2.23 ; Crystal Structure Analysis of Chitinase A from Vibrio harveyi with novel inhibitors - W275G mutant complex structure with DEQUALINIUM 3ARU ; 1.9 ; Crystal Structure Analysis of Chitinase A from Vibrio harveyi with novel inhibitors - W275G mutant complex structure with PENTOXIFYLLINE 3AS2 ; 1.8 ; Crystal Structure Analysis of Chitinase A from Vibrio harveyi with novel inhibitors - W275G mutant complex structure with Propentofylline 3AS0 ; 2 ; Crystal Structure Analysis of Chitinase A from Vibrio harveyi with novel inhibitors - W275G mutant complex structure with Sanguinarine 1FNK ; 2 ; CRYSTAL STRUCTURE ANALYSIS OF CHORISMATE MUTASE MUTANT C88K/R90S 1FNJ ; 1.9 ; CRYSTAL STRUCTURE ANALYSIS OF CHORISMATE MUTASE MUTANT C88S/R90K 1U9T ; 2.16 ; Crystal Structure Analysis of ChuS, an E. coli Heme Oxygenase 3RBG ; 2.3 ; Crystal structure analysis of Class-I MHC restricted T-cell associated molecule 1KHO ; 2.4 ; Crystal Structure Analysis of Clostridium perfringens alpha-Toxin Isolated from Avian Strain SWCP 1QVR ; 3 ; Crystal Structure Analysis of ClpB 1MBU ; 2.3 ; Crystal Structure Analysis of ClpSN heterodimer 1MBV ; 3.3 ; CRYSTAL STRUCTURE ANALYSIS OF ClpSN HETERODIMER TETRAGONAL FORM 1MBX ; 2.25 ; CRYSTAL STRUCTURE ANALYSIS OF ClpSN WITH TRANSITION METAL ION BOUND 2R7E ; 3.7 ; Crystal Structure Analysis of Coagulation Factor VIII 2IJH ; 1.8 ; Crystal structure analysis of ColE1 ROM mutant F14W 2IJJ ; 1.9 ; Crystal structure analysis of ColE1 ROM mutant F14Y 4EMS ; 1.7534 ; Crystal Structure Analysis of Coniferyl Alcohol 9-O-Methyltransferase from Linum Nodiflorum 4E70 ; 1.6093 ; Crystal Structure Analysis of Coniferyl Alcohol 9-O-Methyltransferase from Linum Nodiflorum in Complex with Coniferyl Alcohol 4EVI ; 2.015 ; Crystal Structure Analysis of Coniferyl Alcohol 9-O-Methyltransferase from Linum Nodiflorum in Complex with Coniferyl Alcohol 9-Methyl Ether and S -Adenosyl-L-Homocysteine 2RFH ; 1.7 ; Crystal Structure Analysis of CPA-2-benzyl-3-nitropropanoic acid complex 1K7U ; 2.2 ; Crystal Structure Analysis of crosslinked-WGA3/GlcNAcbeta1,4GlcNAc complex 1K7T ; 2.4 ; Crystal Structure Analysis of crosslinked-WGA3/GlcNAcbeta1,6Gal complex 1K7V ; 2.2 ; Crystal Structure Analysis of crosslinked-WGA3/GlcNAcbeta1,6Galbeta1,4Glc 1F29 ; 2.15 ; CRYSTAL STRUCTURE ANALYSIS OF CRUZAIN BOUND TO A VINYL SULFONE DERIVED INHIBITOR (I) 1F2A ; 1.6 ; CRYSTAL STRUCTURE ANALYSIS OF CRUZAIN BOUND TO A VINYL SULFONE DERIVED INHIBITOR (II) 1F2B ; 1.8 ; CRYSTAL STRUCTURE ANALYSIS OF CRUZAIN BOUND TO VINYL SULFONE DERIVED INHIBITOR (III) 2OZ2 ; 1.95 ; Crystal structure analysis of cruzain bound to vinyl sulfone derived inhibitor (K11777) 3LXS ; 1.5 ; Crystal structure analysis of cruzain bound to vinyl sulfone derived inhibitor (WRR483) 1F2C ; 2 ; CRYSTAL STRUCTURE ANALYSIS OF CRYZAIN BOUND TO VINYL SULFONE DERIVED INHIBITOR (IV) 3TT8 ; 1.12 ; Crystal Structure Analysis of Cu Human Insulin Derivative 2COL ; 2.2 ; Crystal structure analysis of CyaA/C-Cam with Pyrophosphate 1EV8 ; 2.6 ; CRYSTAL STRUCTURE ANALYSIS OF CYS167 MUTANT OF ESCHERICHIA COLI 1EVF ; 1.7 ; CRYSTAL STRUCTURE ANALYSIS OF CYS167 MUTANT OF ESCHERICHIA COLI 1EVG ; 2 ; CRYSTAL STRUCTURE ANALYSIS OF CYS167 MUTANT OF ESCHERICHIA COLI WITH UNMODIFIED CATALYTIC CYSTEINE 1EG6 ; 2 ; CRYSTAL STRUCTURE ANALYSIS OF D(CG(5-BRU)ACG) COMPLEXES TO A PHENAZINE 1C0K ; 1.46 ; CRYSTAL STRUCTURE ANALYSIS OF D-AMINO ACID OXIDASE IN COMPLEX WITH L-LACTATE 1GG1 ; 2 ; CRYSTAL STRUCTURE ANALYSIS OF DAHP SYNTHASE IN COMPLEX WITH MN2+ AND 2-PHOSPHOGLYCOLATE 1XY1 ; 1.04 ; CRYSTAL STRUCTURE ANALYSIS OF DEAMINO-OXYTOCIN. CONFORMATIONAL FLEXIBILITY AND RECEPTOR BINDING 1XY2 ; 1.2 ; CRYSTAL STRUCTURE ANALYSIS OF DEAMINO-OXYTOCIN. CONFORMATIONAL FLEXIBILITY AND RECEPTOR BINDING 3B20 ; 2.398 ; Crystal Structure Analysis of Dehydrogenase complexed with NAD 1DLK ; 2.14 ; CRYSTAL STRUCTURE ANALYSIS OF DELTA-CHYMOTRYPSIN BOUND TO A PEPTIDYL CHLOROMETHYL KETONE INHIBITOR 3IRC ; 2.25 ; Crystal structure analysis of dengue-1 envelope protein domain III 1MH9 ; 1.8 ; Crystal Structure Analysis of deoxyribonucleotidase 2PO3 ; 2.1 ; Crystal Structure Analysis of DesI in the presence of its TDP-sugar product 2YXX ; 1.7 ; Crystal structure analysis of Diaminopimelate decarboxylate (lysA) 1JUV ; 1.7 ; Crystal structure analysis of Dihydrofolate reductase from Bacteriophage T4 2E3U ; 2.3 ; Crystal structure analysis of Dim2p from Pyrococcus horikoshii OT3 1YHT ; 2 ; Crystal structure analysis of Dispersin B 2RAL ; 2.8 ; Crystal Structure Analysis of double cysteine mutant of S.epidermidis adhesin SdrG: Evidence for the Dock,Lock and Latch ligand binding mechanism 3EIO ; 2 ; Crystal Structure Analysis of DPPIV Inhibitor 1HO3 ; 2.5 ; CRYSTAL STRUCTURE ANALYSIS OF E. COLI L-ASPARAGINASE II (Y25F MUTANT) 1T43 ; 3.2 ; Crystal Structure Analysis of E.coli Protein (N5)-Glutamine Methyltransferase (HemK) 3A9Q ; 1.896 ; Crystal Structure Analysis of E173A variant of the soybean ferritin SFER4 3UVH ; 1.84 ; Crystal Structure Analysis of E81M mutant of human CLIC1 3JU4 ; 0.98 ; Crystal Structure Analysis of EndosialidaseNF at 0.98 A Resolution 2AL1 ; 1.5 ; Crystal Structure Analysis of Enolase Mg Subunit Complex at pH 8.0 2AL2 ; 1.85 ; Crystal Structure Analysis of Enolase Mg Subunit Complex at pH 8.0 3QTP ; 1.9 ; Crystal Structure Analysis of Entamoeba histolytica Enolase 3E5V ; 2.1 ; Crystal Structure Analysis of eqFP611 Double Mutant T122R, N143S 2OQJ ; 2.8 ; Crystal structure analysis of Fab 2G12 in complex with peptide 2G12.1 1IUE ; 1.7 ; Crystal Structure Analysis of ferredoxin from Plasmodium falciparum 3UD7 ; 2.8 ; Crystal Structure Analysis of FGF1-Disaccharide(NI21) complexes 3UD8 ; 2.37 ; Crystal Structure Analysis of FGF1-Disaccharide(NI22) complex 3UD9 ; 2.34 ; Crystal Structure Analysis of FGF1-Disaccharide(NI23) complex 3UDA ; 2.51 ; Crystal Structure Analysis of FGF1-Disaccharide(NI24) complex 3BZ3 ; 2.2 ; Crystal Structure Analysis of Focal Adhesion Kinase with a Methanesulfonamide Diaminopyrimidine Inhibitor 3Q9T ; 2.24 ; Crystal structure analysis of formate oxidase 3E5T ; 1.1 ; Crystal Structure Analysis of FP611 3E5W ; 1.71 ; Crystal Structure Analysis of FP611 1K9A ; 2.5 ; Crystal structure analysis of full-length carboxyl-terminal Src kinase at 2.5 A resolution 3FJW ; 2.8 ; Crystal Structure Analysis of Fungal Versatile Peroxidase from Pleurotus eryngii 3FKG ; 1.81 ; Crystal Structure Analysis of Fungal Versatile Peroxidase from Pleurotus eryngii 3FM1 ; 1.78 ; Crystal Structure Analysis of Fungal Versatile Peroxidase from Pleurotus eryngii 3FM4 ; 2.11 ; Crystal Structure Analysis of Fungal Versatile Peroxidase from Pleurotus eryngii 3FM6 ; 1.13 ; Crystal Structure Analysis of Fungal Versatile Peroxidase from Pleurotus eryngii 3FMU ; 1.04 ; Crystal Structure Analysis of Fungal Versatile Peroxidase from Pleurotus eryngii 2DWY ; 2.3 ; Crystal Structure Analysis of GGA1-GAE 2D7J ; 1.89 ; Crystal Structure Analysis of Glutamine Amidotransferase from Pyrococcus horikoshii OT3 1XA8 ; 2.4 ; Crystal Structure Analysis of Glutathione-dependent formaldehyde-activating enzyme (Gfa) 2AF9 ; 2 ; Crystal Structure analysis of GM2-Activator protein complexed with phosphatidylcholine 2AG2 ; 2 ; Crystal Structure Analysis of GM2-activator protein complexed with Phosphatidylcholine 2AG4 ; 1.8 ; Crystal Structure Analysis of GM2-activator protein complexed with phosphatidylcholine 2P4Q ; 2.37 ; Crystal Structure Analysis of Gnd1 in Saccharomyces cerevisiae 1K34 ; 1.88 ; Crystal structure analysis of gp41 core mutant 4HJ2 ; 2.1 ; Crystal Structure Analysis of GSTA1-1 in complex with chlorambucil 3A0G ; 2.5 ; Crystal structure analysis of guinea pig oxyhemoglobin at 2.5 angstroms resolution 3QR6 ; 1.78 ; Crystal Structure Analysis of H185F Mutant of Human CLIC1 3P90 ; 2.3 ; Crystal Structure Analysis of H207F Mutant of Human CLIC1 3SWL ; 2.35 ; Crystal Structure Analysis of H74A Mutant of Human CLIC1 1NNF ; 1.1 ; Crystal Structure Analysis of Haemophlius Influenzae Ferric-ion Binding Protein H9Q Mutant Form 1LGD ; 1.9 ; Crystal Structure Analysis of HCA II Mutant T199P in Complex with Bicarbonate 1LG6 ; 2.2 ; Crystal Structure Analysis of HCA II Mutant T199P in Complex with Thiocyanate 3SZS ; 1.95 ; Crystal structure analysis of hellethionin D 2HTX ; 1.56 ; Crystal Structure Analysis of Hen Egg White Lysozyme Crosslinked by Polymerized Glutaraldehyde in Acidic Environment 2EPE ; 2.5 ; Crystal structure analysis of Hen egg white lysozyme grown by capillary method 2HU1 ; 1.63 ; Crystal structure Analysis of Hen Egg White Lyszoyme 1Q9B ; 1.5 ; CRYSTAL STRUCTURE ANALYSIS OF Hev b 6.02 (HEVEIN) AT 1.5 ANGSTROMS RESOLUTION 2FBB ; 1.46 ; Crystal Structure Analysis of Hexagonal Lysozyme 1JOV ; 1.57 ; Crystal Structure Analysis of HI1317 2NNK ; 1.25 ; Crystal structure analysis of HIV-1 protease mutant I84V with a inhibitor saquinavir 2NNP ; 1.2 ; Crystal structure analysis of HIV-1 protease mutant I84V with a inhibitor saquinavir 2IEO ; 1.53 ; Crystal structure analysis of HIV-1 protease mutant I84V with a potent non-peptide inhibitor (UIC-94017) 2AOC ; 1.3 ; Crystal structure analysis of HIV-1 protease mutant I84V with a substrate analog P2-NC 2NMY ; 1.1 ; Crystal structure analysis of HIV-1 protease mutant V82A with a inhibitor saquinavir 2NMZ ; 0.97 ; Crystal structure analysis of HIV-1 protease mutant V82A with a inhibitor saquinavir 2IDW ; 1.1 ; Crystal structure analysis of HIV-1 protease mutant V82A with a potent non-peptide inhibitor (UIC-94017) 2AOE ; 1.54 ; crystal structure analysis of HIV-1 protease mutant V82A with a substrate analog CA-P2 2AOF ; 1.32 ; Crystal structure analysis of HIV-1 Protease mutant V82A with a substrate analog P1-P6 2AOG ; 1.1 ; Crystal structure analysis of HIV-1 protease mutant V82A with a substrate analog P2-NC 2AOH ; 1.42 ; Crystal structure analysis of HIV-1 Protease mutant V82A with a substrate analog P6-PR 2IEN ; 1.3 ; Crystal structure analysis of HIV-1 protease with a potent non-peptide inhibitor (UIC-94017) 2AOI ; 1.4 ; Crystal structure analysis of HIV-1 protease with a substrate analog P1-P6 2AOD ; 1.4 ; Crystal structure analysis of HIV-1 protease with a substrate analog P2-NC 2AOJ ; 1.6 ; Crystal structure analysis of HIV-1 protease with a substrate analog P6-PR 2R5P ; 2.3 ; Crystal Structure Analysis of HIV-1 Subtype C Protease Complexed with Indinavir 2R5Q ; 2.3 ; Crystal Structure Analysis of HIV-1 Subtype C Protease Complexed with Nelfinavir 1IXV ; 2.3 ; Crystal Structure Analysis of homolog of oncoprotein gankyrin, an interactor of Rb and CDK4/6 2PLN ; 1.8 ; Crystal structure analysis of HP1043, an orphan resonse regulator of h. pylori 2HL4 ; 1.55 ; Crystal structure analysis of human carbonic anhydrase II in complex with a benzenesulfonamide derivative 2B2V ; 2.65 ; Crystal structure analysis of human CHD1 chromodomains 1 and 2 bound to histone H3 resi 1-15 MeK4 2O72 ; 2 ; Crystal Structure Analysis of human E-cadherin (1-213) 2EC9 ; 2 ; Crystal structure analysis of human Factor VIIa , Souluble tissue factor complexed with BCX-3607 3MX7 ; 1.76 ; Crystal Structure Analysis of Human FAIM-NTD 1K3Y ; 1.3 ; Crystal Structure Analysis of human Glutathione S-transferase with S-hexyl glutatione and glycerol at 1.3 Angstrom 3F07 ; 3.3 ; Crystal Structure Analysis of Human HDAC8 complexed with APHA in a new monoclinic crystal form 3F0R ; 2.54 ; Crystal Structure Analysis of Human HDAC8 complexed with trichostatin A in a new monoclinic crystal form 3F06 ; 2.55 ; Crystal Structure Analysis of Human HDAC8 D101A Variant. 3EZT ; 2.85 ; Crystal Structure Analysis of Human HDAC8 D101E Variant 3EW8 ; 1.8 ; Crystal Structure Analysis of human HDAC8 D101L variant 3EZP ; 2.65 ; Crystal Structure Analysis of human HDAC8 D101N variant 3EWF ; 2.5 ; Crystal Structure Analysis of human HDAC8 H143A variant complexed with substrate. 2CVD ; 1.45 ; Crystal structure analysis of human hematopoietic prostaglandin D synthase complexed with HQL-79 1JQE ; 1.91 ; Crystal Structure Analysis of Human Histamine Methyltransferase (Ile105 Polymorphic Variant) Complexed with AdoHcy and Antimalarial Drug Quinacrine 1JQD ; 2.28 ; Crystal Structure Analysis of Human Histamine Methyltransferase (Thr105 Polymorphic Variant) Complexed with AdoHcy and Histamine 3LRE ; 2.2 ; Crystal Structure Analysis of Human Kinesin-8 Motor Domain 3PCV ; 1.9 ; Crystal structure analysis of human leukotriene C4 synthase at 1.9 angstrom resolution 3U0V ; 1.72 ; Crystal Structure Analysis of human LYPLAL1 1IWT ; 1.4 ; Crystal Structure Analysis of Human lysozyme at 113K. 1IWU ; 1.4 ; Crystal Structure Analysis of Human lysozyme at 127K. 1IWV ; 1.4 ; Crystal Structure Analysis of Human lysozyme at 147K. 1IWW ; 1.4 ; Crystal Structure Analysis of Human lysozyme at 152K. 1IWX ; 1.4 ; Crystal Structure Analysis of Human lysozyme at 161K. 1IWY ; 1.4 ; Crystal Structure Analysis of Human lysozyme at 170K. 1IWZ ; 1.48 ; Crystal Structure Analysis of Human lysozyme at 178K. 1JIZ ; 2.6 ; Crystal Structure Analysis of human Macrophage Elastase MMP-12 2FV2 ; 2.2 ; Crystal Structure Analysis of human Rcd-1 conserved region 3T0O ; 1.59 ; Crystal Structure Analysis of Human RNase T2 2H2K ; 2 ; Crystal Structure Analysis of Human S100A13 1P5J ; 2.5 ; Crystal Structure Analysis of Human Serine Dehydratase 3A73 ; 2.19 ; Crystal Structure Analysis of Human serum albumin complexed with delta 12-prostaglandin J2 4EMX ; 2.3 ; Crystal structure analysis of Human Serum Albumin in complex with chloride anions at cryogenic temperature 2R83 ; 2.7 ; Crystal structure analysis of human synaptotagmin 1 C2A-C2B 1YWR ; 1.95 ; Crystal Structure Analysis of inactive P38 kinase domain in complex with a Monocyclic Pyrazolone Inhibitor 3SNP ; 2.8 ; Crystal structure analysis of iron regulatory protein 1 in complex with ferritin H IRE RNA 3SN2 ; 2.99 ; Crystal structure analysis of iron regulatory protein 1 in complex with transferrin receptor IRE B RNA 1FP2 ; 1.4 ; CRYSTAL STRUCTURE ANALYSIS OF ISOFLAVONE O-METHYLTRANSFERASE 1CUO ; 1.6 ; CRYSTAL STRUCTURE ANALYSIS OF ISOMER-2 AZURIN FROM METHYLOMONAS J 1R5Q ; 2 ; Crystal Structure Analysis of Kai A from PCC7120 1R5P ; 2.2 ; Crystal Structure Analysis of KaiB from PCC7120 1GG0 ; 3 ; CRYSTAL STRUCTURE ANALYSIS OF KDOP SYNTHASE AT 3.0 A 1FPZ ; 2 ; CRYSTAL STRUCTURE ANALYSIS OF KINASE ASSOCIATED PHOSPHATASE (KAP) WITH A SUBSTITUTION OF THE CATALYTIC SITE CYSTEINE (CYS140) TO A SERINE 3H8N ; 2.5 ; Crystal Structure Analysis of KIR2DS4 2FH6 ; 1.8 ; Crystal Structure Analysis of Klebsiella pneumoniae pullulanase complexed with glucose 2FH8 ; 1.9 ; Crystal Structure Analysis of Klebsiella pneumoniae pullulanase complexed with isomaltose 2FHB ; 1.8 ; Crystal Structure Analysis of Klebsiella pneumoniae pullulanase complexed with maltose 2FHF ; 1.65 ; Crystal Structure Analysis of Klebsiella pneumoniae pullulanase complexed with maltotetraose 2FHC ; 1.85 ; Crystal Structure Analysis of Klebsiella pneumoniae pullulanase complexed with maltotriose 2WNH ; 1.68 ; CRYSTAL STRUCTURE ANALYSIS OF KLEBSIELLA SP ASR1 PHYTASE 2WNI ; 2.57 ; CRYSTAL STRUCTURE ANALYSIS OF KLEBSIELLA SP ASR1 PHYTASE 2WU0 ; 2.57 ; CRYSTAL STRUCTURE ANALYSIS OF KLEBSIELLA SP ASR1 PHYTASE 3U6V ; 2.2 ; Crystal Structure Analysis of L23A mutant of human GST A1-1 2QEI ; 1.85 ; Crystal structure analysis of LeuT complexed with L-alanine, sodium, and clomipramine 2QB4 ; 1.9 ; Crystal Structure Analysis of LeuT complexed with L-leucine, sodium and desipramine 2Q6H ; 1.85 ; Crystal Structure Analysis of LeuT complexed with L-leucine, sodium, and clomipramine 2Q72 ; 1.7 ; Crystal Structure Analysis of LeuT complexed with L-leucine, sodium, and imipramine 4EGS ; 2.3 ; Crystal Structure Analysis of Low Molecular Weight Protein Tyrosine Phosphatase from T. tengcongensis 1HQK ; 1.6 ; CRYSTAL STRUCTURE ANALYSIS OF LUMAZINE SYNTHASE FROM AQUIFEX AEOLICUS 3QE8 ; 1.49 ; Crystal Structure Analysis of Lysozyme-bound fac-[Re(CO)3(H2O)(Im)]+ 3QNG ; 1.55 ; Crystal Structure Analysis of Lysozyme-bound fac-[Re(CO)3(L-serine)] 3O3T ; 1.7 ; Crystal Structure Analysis of M32A mutant of human CLIC1 3LLY ; 2.25 ; Crystal Structure Analysis of Maclura pomifera agglutinin 3LLZ ; 1.55 ; Crystal Structure Analysis of Maclura pomifera agglutinin complex with Gal-beta-1,3-GalNAc 3LM1 ; 2.1 ; Crystal Structure Analysis of Maclura pomifera agglutinin complex with p-nitrophenyl-GalNAc 1IZC ; 1.7 ; Crystal Structure Analysis of Macrophomate synthase 3LZQ ; 1.41 ; Crystal Structure Analysis of Manganese treated P19 protein from Campylobacter jejuni at 1.41 A at pH 9 3LZR ; 2.73 ; Crystal Structure Analysis of Manganese treated P19 protein from Campylobacter jejuni at 2.73 A at pH 9 and Manganese peak wavelength (1.893 A) 1P9E ; 2.4 ; Crystal Structure Analysis of Methyl Parathion Hydrolase from Pseudomonas sp WBC-3 1IXK ; 1.9 ; Crystal Structure Analysis of Methyltransferase Homolog Protein from Pyrococcus Horikoshii 3IF5 ; 2.44 ; Crystal Structure Analysis of Mglu 3IHA ; 2.6 ; Crystal Structure Analysis of Mglu in its glutamate form 3IH8 ; 2.3 ; Crystal Structure Analysis of Mglu in its native form 3IHB ; 2.4 ; Crystal Structure Analysis of Mglu in its tris and glutamate form 3IH9 ; 2.5 ; Crystal Structure Analysis of Mglu in its tris form 3N52 ; 1.9 ; crystal Structure analysis of MIP2 2P2V ; 1.85 ; Crystal structure analysis of monofunctional alpha-2,3-sialyltransferase Cst-I from Campylobacter jejuni 3IKK ; 2.5 ; Crystal structure analysis of msp domain 2QJK ; 3.1 ; Crystal Structure Analysis of mutant rhodobacter sphaeroides bc1 with stigmatellin and antimycin 4DKY ; 2.478 ; Crystal structure Analysis of N terminal region containing the dimerization domain and DNA binding domain of HU protein(Histone like protein-DNA binding) from Mycobacterium tuberculosis [H37Rv] 3C4I ; 2.04 ; Crystal structure Analysis of N terminal region containing the dimerization domain and DNA binding domain of HU protein(Histone like protein-DNA binding) from Mycobacterium tuberculosis [H37Rv] 1F5Z ; 1.88 ; CRYSTAL STRUCTURE ANALYSIS OF N-ACETYLNEURAMINATE LYASE FROM HAEMOPHILUS INFLUENZAE: CRYSTAL FORM I 1F6K ; 1.6 ; CRYSTAL STRUCTURE ANALYSIS OF N-ACETYLNEURAMINATE LYASE FROM HAEMOPHILUS INFLUENZAE: CRYSTAL FORM II 1F74 ; 1.6 ; CRYSTAL STRUCTURE ANALYSIS OF N-ACETYLNEURAMINATE LYASE FROM HAEMOPHILUS INFLUENZAE: CRYSTAL FORM II COMPLEXED WITH 4-DEOXY-SIALIC ACID 1F7B ; 1.8 ; CRYSTAL STRUCTURE ANALYSIS OF N-ACETYLNEURAMINATE LYASE FROM HAEMOPHILUS INFLUENZAE: CRYSTAL FORM II IN COMPLEX WITH 4-OXO-SIALIC ACID 1F6P ; 2.25 ; CRYSTAL STRUCTURE ANALYSIS OF N-ACETYLNEURAMINATE LYASE FROM HAEMOPHILUS INFLUENZAE: CRYSTAL FORM III 1F73 ; 1.95 ; CRYSTAL STRUCTURE ANALYSIS OF N-ACETYLNEURAMINATE LYASE FROM HAEMOPHILUS INFLUENZAE: CRYSTAL FORM III IN COMPLEX WITH SIALIC ACID ALDITOL 1NEG ; 2.3 ; Crystal Structure Analysis of N-and C-terminal labeled SH3-domain of alpha-Chicken Spectrin 1FO6 ; 1.95 ; CRYSTAL STRUCTURE ANALYSIS OF N-CARBAMoYL-D-AMINO-ACID AMIDOHYDROLASE 1JSZ ; 1.93 ; Crystal Structure Analysis of N7,9-dimethylguanine-VP39 complex 1FVF ; 3.2 ; CRYSTAL STRUCTURE ANALYSIS OF NEURONAL SEC1 FROM THE SQUID L. PEALEI 1FVH ; 2.8 ; CRYSTAL STRUCTURE ANALYSIS OF NEURONAL SEC1 FROM THE SQUID L. PEALEI 2ZWS ; 1.4 ; Crystal Structure Analysis of neutral ceramidase from Pseudomonas aeruginosa 1F9A ; 2 ; CRYSTAL STRUCTURE ANALYSIS OF NMN ADENYLYLTRANSFERASE FROM METHANOCOCCUS JANNASCHII 3D9W ; 2.7 ; Crystal Structure Analysis of Nocardia farcinica Arylamine N-acetyltransferase 1IHM ; 3.4 ; CRYSTAL STRUCTURE ANALYSIS OF NORWALK VIRUS CAPSID 2I0W ; 2.5 ; Crystal structure analysis of NP24-I, a thaumatin-like protein 1F8Y ; 2.4 ; CRYSTAL STRUCTURE ANALYSIS OF NUCLEOSIDE 2-DEOXYRIBOSYLTRANSFERASE COMPLEXED WITH 5-METHYL-2'-DEOXYPSEUDOURIDINE 1S9X ; 2.5 ; Crystal Structure Analysis of NY-ESO-1 epitope analogue, SLLMWITQA, in complex with HLA-A2 1S9Y ; 2.3 ; Crystal Structure Analysis of NY-ESO-1 epitope analogue, SLLMWITQS, in complex with HLA-A2 1S9W ; 2.2 ; Crystal Structure Analysis of NY-ESO-1 epitope, SLLMWITQC, in complex with HLA-A2 1FHU ; 1.65 ; CRYSTAL STRUCTURE ANALYSIS OF O-SUCCINYLBENZOATE SYNTHASE FROM E. COLI 1FHV ; 1.77 ; CRYSTAL STRUCTURE ANALYSIS OF O-SUCCINYLBENZOATE SYNTHASE FROM E. COLI COMPLEXED WITH MG AND OSB 1SQJ ; 2.2 ; Crystal Structure Analysis of Oligoxyloglucan reducing-end-specific cellobiohydrolase (OXG-RCBH) 1X7D ; 1.6 ; Crystal Structure Analysis of Ornithine Cyclodeaminase Complexed with NAD and ornithine to 1.6 Angstroms 4G2U ; 1.85 ; Crystal Structure Analysis of Ostertagia ostertagi ASP-1 4AZU ; 1.9 ; CRYSTAL STRUCTURE ANALYSIS OF OXIDIZED PSEUDOMONAS AERUGINOSA AZURIN AT PH 5.5 AND PH 9.0. A PH-INDUCED CONFORMATIONAL TRANSITION INVOLVES A PEPTIDE BOND FLIP 5AZU ; 1.9 ; CRYSTAL STRUCTURE ANALYSIS OF OXIDIZED PSEUDOMONAS AERUGINOSA AZURIN AT PH 5.5 AND PH 9.0. A PH-INDUCED CONFORMATIONAL TRANSITION INVOLVES A PEPTIDE BOND FLIP 2EHD ; 2.4 ; Crystal Structure Analysis of Oxidoreductase 4DQW ; 2.51 ; Crystal Structure Analysis of PA3770 1CVZ ; 1.7 ; CRYSTAL STRUCTURE ANALYSIS OF PAPAIN WITH CLIK148(CATHEPSIN L SPECIFIC INHIBITOR) 3LX2 ; 2.4 ; Crystal Structure analysis of PCNA from Thermococcus kodakaraensis tk0582 3LX1 ; 2 ; Crystal Structure analysis of PCNA1 from Thermococcus kodakaraensis tk0535 2ZPL ; 1.7 ; Crystal structure analysis of PDZ domain A 2ZPM ; 0.98 ; Crystal structure analysis of PDZ domain B 3B4N ; 1.45 ; Crystal Structure Analysis of Pectate Lyase PelI from Erwinia chrysanthemi 1Z15 ; 1.7 ; Crystal structure analysis of periplasmic Leu/Ile/Val-binding protein in superopen form 1Z16 ; 1.72 ; Crystal structure analysis of periplasmic Leu/Ile/Val-binding protein with bound leucine 1Z17 ; 1.96 ; Crystal structure analysis of periplasmic Leu/Ile/Val-binding protein with bound ligand isoleucine 1Z18 ; 2.1 ; Crystal structure analysis of periplasmic Leu/Ile/Val-binding protein with bound valine 1UB0 ; 2.05 ; Crystal Structure Analysis of Phosphomethylpyrimidine Kinase (ThiD) from Thermus Thermophilus Hb8 3KPX ; 1.899 ; Crystal Structure Analysis of photoprotein clytin 3GPE ; 2 ; Crystal Structure Analysis of PKC (alpha)-C2 domain complexed with Ca2+ and PtdIns(4,5)P2 1NHW ; 2.35 ; Crystal Structure Analysis of Plasmodium falciparum enoyl-acyl-carrier-protein reductase 1VRW ; 2.4 ; Crystal structure analysis of plasmodium falciparum enoyl-acyl-carrier-protein reductase with nadh 1NHG ; 2.43 ; CRYSTAL STRUCTURE ANALYSIS OF PLASMODIUM FALCIPARUM ENOYL-ACYL-CARRIER-PROTEIN REDUCTASE WITH TRICLOSAN 1NNU ; 2.5 ; Crystal Structure Analysis of Plasmodium falciparum enoyl-acyl-carrier-protein reductase with Triclosan Analog 3VI2 ; 2.1 ; Crystal Structure Analysis of Plasmodium falciparum OMP Decarboxylase in complex with inhibitor HMOA 3PHZ ; 1.7 ; Crystal Structure Analysis of Polyporus squamosus lectin bound to human-type influenza-binding epitope Neu5Aca2-6Galb1-4GlcNAc 1I1H ; 2.6 ; CRYSTAL STRUCTURE ANALYSIS OF PRECORRIN-8X METHYLMUTASE COMPLEX WITH HYDROGENOBYRINIC ACID 1F2V ; 2.1 ; CRYSTAL STRUCTURE ANALYSIS OF PRECORRIN-8X METHYLMUTASE OF AEROBIC VITAMIN B12 SYNTHESIS 1YJ3 ; 1.6 ; Crystal structure analysis of product bound methionine aminopeptidase Type 1c from Mycobacterium Tuberculosis 2CZW ; 1.9 ; Crystal structure analysis of protein component Ph1496p of P.horikoshii ribonuclease P 1GA1 ; 1.4 ; CRYSTAL STRUCTURE ANALYSIS OF PSCP (PSEUDOMONAS SERINE-CARBOXYL PROTEINASE) COMPLEXED WITH A FRAGMENT OF IODOTYROSTATIN (THIS ENZYME RENAMED ""SEDOLISIN"" IN 2003) 1GA6 ; 1 ; CRYSTAL STRUCTURE ANALYSIS OF PSCP (PSEUDOMONAS SERINE-CARBOXYL PROTEINASE) COMPLEXED WITH A FRAGMENT OF TYROSTATIN (THIS ENZYME RENAMED ""SEDOLISIN"" IN 2003) 1GA4 ; 1.4 ; CRYSTAL STRUCTURE ANALYSIS OF PSCP (PSEUDOMONAS SERINE-CARBOXYL PROTEINASE) COMPLEXED WITH INHIBITOR PSEUDOIODOTYROSTATIN (THIS ENZYME RENAMED ""SEDOLISIN"" IN 2003) 1I2H ; 1.8 ; CRYSTAL STRUCTURE ANALYSIS OF PSD-ZIP45(HOMER1C/VESL-1L)CONSERVED HOMER 1 DOMAIN 1G3Q ; 2 ; CRYSTAL STRUCTURE ANALYSIS OF PYROCOCCUS FURIOSUS CELL DIVISION ATPASE MIND 1G3R ; 2.7 ; CRYSTAL STRUCTURE ANALYSIS OF PYROCOCCUS FURIOSUS CELL DIVISION ATPASE MIND 2E28 ; 2.4 ; Crystal structure analysis of pyruvate kinase from Bacillus stearothermophilus 1SG0 ; 1.5 ; Crystal structure analysis of QR2 in complex with resveratrol 3P8W ; 2 ; Crystal Structure Analysis of R29M/E81M double mutant of human CLIC1 1G98 ; 1.9 ; CRYSTAL STRUCTURE ANALYSIS OF RABBIT PHOSPHOGLUCOSE ISOMERASE COMPLEXED WITH 5-PHOSPHOARABINONATE, A TRANSITION STATE ANALOGUE 1I4D ; 2.5 ; CRYSTAL STRUCTURE ANALYSIS OF RAC1-GDP COMPLEXED WITH ARFAPTIN (P21) 1I4L ; 2.7 ; CRYSTAL STRUCTURE ANALYSIS OF RAC1-GDP IN COMPLEX WITH ARFAPTIN (P41) 1I4T ; 2.6 ; CRYSTAL STRUCTURE ANALYSIS OF RAC1-GMPPNP IN COMPLEX WITH ARFAPTIN 1MJ3 ; 2.1 ; Crystal Structure Analysis of rat enoyl-CoA hydratase in complex with hexadienoyl-CoA 2Z9S ; 2.9 ; Crystal Structure Analysis of rat HBP23/Peroxiredoxin I, Cys52Ser mutant 1U5I ; 2.86 ; Crystal Structure analysis of rat m-calpain mutant Lys10 Thr 1TB3 ; 2.3 ; Crystal Structure Analysis of Recombinant Rat Kidney Long-chain Hydroxy Acid Oxidase 3OOT ; 2.55 ; Crystal Structure Analysis of Renin-indole-piperazin inhibitor complexes 3OQK ; 2.9 ; Crystal Structure Analysis of Renin-indole-piperazin inhibitor complexes 3OQF ; 2.78 ; Crystal Structure Analysis of Renin-indole-piperazine inhibitor complexes 1P2F ; 1.8 ; Crystal Structure Analysis of Response Regulator DrrB, a Thermotoga maritima OmpR/PhoB Homolog 3TVF ; 3.1 ; Crystal structure analysis of ribosomal decoding. This entry contains the 30s ribosomal subunit of the first 70s molecule in the asymmetric unit for the cognate trna-leu complex 3UYF ; 3 ; Crystal structure analysis of ribosomal decoding. this entry contains the 30s ribosomal subunit of the first 70s molecule in the asymmetric unit for the near-cognate trna-leu complex 3UYD ; 3 ; Crystal structure analysis of ribosomal decoding. this entry contains the 30s ribosomal subunit of the first 70s molecule in the asymmetric unit for the near-cognate trna-leu complex 3UZ3 ; 3.3 ; Crystal structure analysis of ribosomal decoding. This entry contains the 30S ribosomal subunit of the first 70S molecule in the asymmetric unit for the near-cognate tRNA-leu complex with paromomycin. 3UZG ; 3.3 ; Crystal structure analysis of ribosomal decoding. This entry contains the 30S ribosomal subunit of the first 70S molecule in the asymmetric unit for the near-cognate tRNA-tyr complex 3UZL ; 3.3 ; Crystal structure analysis of ribosomal decoding. this entry contains the 30s ribosomal subunit of the first 70s molecule in the asymmetric unit for the near-cognate trna-tyr complex with paromomycin 3TVG ; 3.1 ; Crystal structure analysis of ribosomal decoding. This entry contains the 30s ribosomal subunit of the second 70s molecule in the asymmetric unit for the cognate trna-leu complex 3UZ7 ; 3 ; Crystal structure analysis of ribosomal decoding. This entry contains the 30S ribosomal subunit of the second 70S molecule in the asymmetric unit for the cognate tRNA-tyr complex. 3UZ4 ; 3.3 ; Crystal structure analysis of ribosomal decoding. this entry contains the 30S ribosomal subunit of the second 70S molecule in the asymmetric unit for the near-cognate trna-leu complex with paromomycin. 3UZI ; 3.3 ; Crystal structure analysis of ribosomal decoding. this entry contains the 30S ribosomal subunit of the second 70S molecule in the asymmetric unit for the near-cognate tRNA-tyr complex 3UZM ; 3.3 ; Crystal structure analysis of ribosomal decoding. this entry contains the 30s ribosomal subunit of the second 70s molecule in the asymmetric unit for the near-cognate trna-tyr complex with paromomycin 3TVE ; 3.1 ; Crystal structure analysis of ribosomal decoding. this entry contains the 50s ribosomal subunit of the first 70s molecule in the asymmetric unit for the cognate trna-leu complex 3UZ9 ; 3 ; Crystal structure analysis of ribosomal decoding. This entry contains the 50S ribosomal subunit of the first 70S molecule in the asymmetric unit for the cognate tRNA-tyr complex. 3UYG ; 3 ; Crystal structure analysis of ribosomal decoding. this entry contains the 50s ribosomal subunit of the first 70s molecule in the asymmetric unit for the near-cognate trna-leu complex 3UYE ; 3 ; Crystal structure analysis of ribosomal decoding. this entry contains the 50s ribosomal subunit of the first 70s molecule in the asymmetric unit for the near-cognate trna-leu complex 3UZ1 ; 3.3 ; Crystal structure analysis of ribosomal decoding. This entry contains the 50S ribosomal subunit of the first 70S molecule in the asymmetric unit for the near-cognate tRNA-leu complex with paromomycin 3UZF ; 3.3 ; Crystal structure analysis of ribosomal decoding. This entry contains the 50S ribosomal subunit of the first 70S molecule in the asymmetric unit for the near-cognate tRNA-tyr complex 3UZK ; 3.3 ; Crystal structure analysis of ribosomal decoding. this entry contains the 50s ribosomal subunit of the first 70s molecule in the asymmetric unit for the near-cognate trna-tyr complex with paromomycin 3TVH ; 3.1 ; Crystal structure analysis of ribosomal decoding. This entry contains the 50s ribosomal subunit of the second 70s molecule in the asymmetric unit for the cognate trna-leu complex 3UZ8 ; 3 ; Crystal structure analysis of ribosomal decoding. This entry contains the 50S ribosomal subunit of the second 70S molecule in the asymmetric unit for the cognate tRNA-tyr complex. 3UZ2 ; 3.3 ; Crystal structure analysis of ribosomal decoding. This entry contains the 50S ribosomal subunit of the second 70S molecule in the asymmetric unit for the near-cognate tRNA-leu complex with paromomycin. 3UZN ; 3.3 ; Crystal structure analysis of ribosomal decoding. this entry contains the 50s ribosomal subunit of the second 70s molecule in the asymmetric unit for the near-cognate trna-tyr complex with paromomycin 3UZH ; 3.3 ; Crystal structure analysis of ribosomal decoding. This entry contains the 50S ribosomal subunit of the second 70S molecule in the asymmetric unit for the near-cognate tRNA-tyr complex. 3BK1 ; 2.33 ; Crystal Structure Analysis of RNase J 1K3L ; 1.5 ; Crystal Structure Analysis of S-hexyl-glutathione Complex of Glutathione Transferase at 1.5 Angstroms Resolution 2IP1 ; 1.8 ; Crystal Structure Analysis of S. cerevisiae Tryptophanyl tRNA Synthetase 3GVA ; 2 ; Crystal Structure Analysis of S. Pombe ATL 3GYH ; 2.8 ; Crystal Structure Analysis of S. Pombe ATL in complex with damaged DNA containing POB 3GX4 ; 2.7 ; Crystal Structure Analysis of S. Pombe ATL in complex with DNA 1R17 ; 1.86 ; Crystal Structure Analysis of S.epidermidis adhesin SdrG binding to Fibrinogen (adhesin-ligand complex) 1R19 ; 3.51 ; Crystal Structure Analysis of S.epidermidis adhesin SdrG binding to Fibrinogen (Apo structure) 4EQ3 ; 2.001 ; Crystal Structure Analysis of Selenomethionine (Se-Met) Substituted Chicken Interferon Gamma Receptor Alpha Chain 1FPQ ; 2 ; CRYSTAL STRUCTURE ANALYSIS OF SELENOMETHIONINE SUBSTITUTED CHALCONE O-METHYLTRANSFERASE 1FPX ; 1.65 ; CRYSTAL STRUCTURE ANALYSIS OF SELENOMETHIONINE SUBSTITUTED ISOFLAVONE O-METHYLTRANSFERASE 1QQQ ; 1.5 ; CRYSTAL STRUCTURE ANALYSIS OF SER254 MUTANT OF ESCHERICHIA COLI THYMIDYLATE SYNTHASE 3CH2 ; 1.8 ; Crystal Structure Analysis of SERA5E from plasmodium falciparum 3CH3 ; 1.79 ; Crystal Structure Analysis of SERA5E from plasmodium falciparum 2WBF ; 1.6 ; CRYSTAL STRUCTURE ANALYSIS OF SERA5E FROM PLASMODIUM FALCIPARUM WITH LOOP 690-700 ORDERED 1XUZ ; 2.2 ; Crystal structure analysis of sialic acid synthase (NeuB)from Neisseria meningitidis, bound to Mn2+, Phosphoenolpyruvate, and N-acetyl mannosaminitol 1QVC ; 2.2 ; CRYSTAL STRUCTURE ANALYSIS OF SINGLE STRANDED DNA BINDING PROTEIN (SSB) FROM E.COLI 3U71 ; 2.72 ; Crystal Structure Analysis of South African wild type HIV-1 Subtype C Protease 1K30 ; 1.9 ; Crystal Structure Analysis of Squash (Cucurbita moschata) glycerol-3-phosphate (1)-acyltransferase 2QXL ; 2.41 ; Crystal Structure Analysis of Sse1, a yeast Hsp110 3CZE ; 1.9 ; Crystal Structure Analysis of Sucrose hydrolase (SUH)- Tris complex 3CZG ; 1.8 ; Crystal Structure Analysis of Sucrose hydrolase (SUH)-glucose complex 3CZL ; 2 ; Crystal Structure Analysis of Sucrose hydrolase(SUH) E322Q-glucose complex 3CZK ; 2.2 ; Crystal Structure Analysis of Sucrose hydrolase(SUH) E322Q-sucrose complex 3B4X ; 1.94 ; Crystal Structure Analysis of Sulfolobus tokodaii strain7 cytochrom P450 1R5B ; 2.35 ; Crystal structure analysis of sup35 1R5N ; 2.9 ; Crystal Structure Analysis of sup35 complexed with GDP 1R5O ; 3.2 ; crystal structure analysis of sup35 complexed with GMPPNP 1J9J ; 1.9 ; CRYSTAL STRUCTURE ANALYSIS OF SURE PROTEIN FROM T.MARITIMA 2D73 ; 1.6 ; Crystal Structure Analysis of SusB 3FFV ; 2 ; Crystal Structure Analysis of Syd 1NP7 ; 1.9 ; Crystal Structure Analysis of Synechocystis sp. PCC6803 cryptochrome 2FJ1 ; 2.2 ; Crystal Structure Analysis of Tet Repressor (class D) in Complex with 7-Chlortetracycline-Nickel(II) 2O7O ; 1.89 ; Crystal structure analysis of TetR(D) complex with doxycycline 3LZP ; 1.65 ; Crystal Structure Analysis of the 'as-isolated' P19 protein from Campylobacter jejuni at 1.65 A at pH 9.0 2EI2 ; 1.69 ; Crystal Structure Analysis of the 1,2-dihydroxynaphthalene dioxygenase from Pseudomonas sp. stain C18 3HQ0 ; 2 ; Crystal Structure Analysis of the 2,3-dioxygenase LapB from Pseudomonas in complex with a product 3HPY ; 1.94 ; Crystal Structure Analysis of the 2,3-dioxygenase LapB from Pseudomonas in the complex with 4-methylcatechol 3HPV ; 2.3 ; Crystal Structure Analysis of the 2,3-dioxygenase LapB from Pseudomonas sp. KL28 1S9C ; 3 ; Crystal structure analysis of the 2-enoyl-CoA hydratase 2 domain of human peroxisomal multifunctional enzyme type 2 2YW3 ; 1.67 ; Crystal Structure Analysis of the 4-hydroxy-2-oxoglutarate aldolase/2-deydro-3-deoxyphosphogluconate aldolase from TTHB1 2YW4 ; 2.53 ; Crystal Structure Analysis of the 4-hydroxy-2-oxoglutarate aldolase/2-deydro-3-deoxyphosphogluconate aldolase from TTHB1 1SZO ; 1.9 ; Crystal Structure Analysis of the 6-Oxo Camphor Hydrolase His122Ala Mutant Bound to Its Natural Product (2S,4S)-alpha-Campholinic Acid 2FIJ ; 1.19 ; Crystal Structure Analysis of the A-DNA Decamer GCGT-2'OMeA-aU-ACGC, with Incorporated 2'-O-Methylated-Adenosine (2'OMeA) and Arabino-Uridine (aU) 2FIL ; 1.69 ; Crystal Structure Analysis of the A-DNA Decamer GCGT-2'OMeA-faT-ACGC, with Incorporated 2'-O-Methylated-Adenosine (2'OMeA) and 2'-Fluoroarabino-Thymidine (faT) 1JI0 ; 2 ; Crystal Structure Analysis of the ABC transporter from Thermotoga maritima 1J0A ; 2.5 ; Crystal Structure Analysis of the ACC deaminase homologue 1J0B ; 2.7 ; Crystal Structure Analysis of the ACC deaminase homologue complexed with inhiitor 1YRT ; 2.1 ; Crystal Structure analysis of the adenylyl cyclaes catalytic domain of adenylyl cyclase toxin of Bordetella pertussis in presence of c-terminal calmodulin 1YRU ; 2.5 ; Crystal Structure analysis of the adenylyl cyclaes catalytic domain of adenylyl cyclase toxin of Bordetella pertussis in presence of c-terminal calmodulin and 1mM calcium chloride 1V8I ; 1.76 ; Crystal Structure Analysis of the ADP-ribose pyrophosphatase 1V8R ; 1.8 ; Crystal structure analysis of the ADP-ribose pyrophosphatase complexed with ADP-ribose and Zn 1V8T ; 2.6 ; Crystal Structure analysis of the ADP-ribose pyrophosphatase complexed with ribose-5'-phosphate and Zn 1V8N ; 1.74 ; Crystal structure analysis of the ADP-ribose pyrophosphatase complexed with Zn 1V8U ; 1.9 ; Crystal structure analysis of the ADP-ribose pyrophosphatase of E82Q mutant with SO4 and Mg 1V8W ; 1.66 ; Crystal structure analysis of the ADP-ribose pyrophosphatase of E82Q mutant, complexed with SO4 and Zn 1V8V ; 1.97 ; Crystal structure analysis of the ADP-ribose pyrophosphatase of E86Q mutant, complexed with ADP-ribose and Mg 1V8Y ; 1.65 ; Crystal structure analysis of the ADP-ribose pyrophosphatase of E86Q mutant, complexed with ADP-ribose and Zn 1L6B ; 1.5 ; CRYSTAL STRUCTURE ANALYSIS OF THE ALL DNA HOLLIDAY JUNCTION STRUCTURE OF CCGGTACM5CGG 2G91 ; 1.5 ; Crystal Structure Analysis of the an RNA nonamer r(GGUGCGC)d(BrC)r(C) 1KGZ ; 2.4 ; Crystal Structure Analysis of the Anthranilate Phosphoribosyltransferase from Erwinia carotovora (current name, Pectobacterium carotovorum) 1KHD ; 1.86 ; Crystal Structure Analysis of the anthranilate phosphoribosyltransferase from Erwinia carotovora at 1.9 resolution (current name, Pectobacterium carotovorum) 2Y06 ; 2.5 ; CRYSTAL STRUCTURE ANALYSIS OF THE ANTI-(4-HYDROXY-3-NITROPHENYL) - ACETYL MURINE GERMLINE ANTIBODY BBE6.12H3 FAB FRAGMENT IN COMPLEX WITH A PHAGE DISPLAY DERIVED DODECAPEPTIDE GDPRPSYISHLL 2Y07 ; 2.4 ; CRYSTAL STRUCTURE ANALYSIS OF THE ANTI-(4-HYDROXY-3-NITROPHENYL) - ACETYL MURINE GERMLINE MONOCLONAL ANTIBODY BBE6.12H3 FAB FRAGMENT IN COMPLEX WITH A PHAGE DISPLAY DERIVED DODECAPEPTIDE PPYPAWHAPGNI 2Y36 ; 2.7 ; Crystal structure analysis of the anti-(4-hydroxy-3-nitrophenyl)- acetyl murine germline antibody BBE6.12H3 Fab fragment in complex with a phage display derived dodecapeptide DLWTTAIPTIPS 2XZQ ; 2.4 ; CRYSTAL STRUCTURE ANALYSIS OF THE ANTI-(4-HYDROXY-3-NITROPHENYL)- ACETYL MURINE GERMLINE MONOCLONAL ANTIBODY BBE6.12H3 FAB FRAGMENT IN COMPLEX WITH A PHAGE DISPLAY DERIVED DODECAPEPTIDE YQLRPNAETLRF 2A6J ; 2.7 ; Crystal structure analysis of the anti-arsonate germline antibody 36-65 2A6I ; 2.5 ; Crystal structure analysis of the anti-arsonate germline antibody 36-65 in complex with a phage display derived dodecapeptide KLASIPTHTSPL 2A6D ; 2.9 ; Crystal structure analysis of the anti-arsonate germline antibody 36-65 in complex with a phage display derived dodecapeptide RLLIADPPSPRE 1L7T ; 2.1 ; Crystal Structure Analysis of the anti-testosterone Fab fragment 1VPO ; 2.15 ; Crystal Structure Analysis of the Anti-testosterone Fab in Complex with Testosterone 3LZN ; 1.59 ; Crystal Structure Analysis of the apo P19 protein from Campylobacter jejuni at 1.59 A at pH 9 1IQV ; 2.1 ; Crystal Structure Analysis of the archaebacterial ribosomal protein S7 4DCN ; 3.01 ; Crystal Structure Analysis of the Arfaptin2 BAR domain in Complex with ARL1 3VLH ; 1.73 ; Crystal Structure Analysis of the Arg409Leu Variants of KatG from HALOARCULA MARISMORTUI 1ULY ; 2.5 ; Crystal structure analysis of the ArsR homologue DNA-binding protein from P. horikoshii OT3 3LZL ; 1.45 ; Crystal Structure Analysis of the as-solated P19 protein from Campylobacter jejuni at 1.45 A at pH 9.0 1S23 ; 1.6 ; Crystal Structure Analysis of the B-DNA Decamer CGCAATTGCG 2FIH ; 1.13 ; Crystal Structure Analysis of the B-DNA Dodecamer CGCGAA-aU-TCGCG, with Incorporated Arabino-Uridine (aU) 2FII ; 1.24 ; Crystal Structure Analysis of the B-DNA Dodecamer CGCGAAT-aU-CGCG, with Incorporated Arabino-Uridin (aU) 1N5C ; 1.79 ; Crystal Structure Analysis of the B-DNA Dodecamer CGCGAATT(ethenoC)GCG 1JGR ; 1.2 ; Crystal Structure Analysis of the B-DNA Dodecamer CGCGAATTCGCG with Thallium Ions. 1D29 ; 2.5 ; CRYSTAL STRUCTURE ANALYSIS OF THE B-DNA DODECAMER CGTGAATTCACG 1S9B ; 2.81 ; Crystal Structure Analysis of the B-DNA GAATTCG 1C9O ; 1.17 ; CRYSTAL STRUCTURE ANALYSIS OF THE BACILLUS CALDOLYTICUS COLD SHOCK PROTEIN BC-CSP 2ES2 ; 1.78 ; Crystal Structure Analysis of the Bacillus Subtilis Cold Shock Protein Bs-CspB in Complex with Hexathymidine 2QXT ; 2 ; Crystal Structure Analysis of the Bacillus subtilis lipase crystallized at pH 4.5 2QXU ; 1.9 ; Crystal Structure Analysis of the Bacillus subtilis lipase crystallized at pH 5.0 4HYX ; 1.99 ; Crystal Structure Analysis of the Bacteriorhodopsin in Facial Amphiphile-4 DMPC Bicelle 4HWL ; 2 ; Crystal Structure Analysis of the Bacteriorhodopsin in Facial Amphiphile-7 DMPC Bicelle 1RRK ; 2 ; Crystal Structure Analysis of the Bb segment of Factor B 1RTK ; 2.3 ; Crystal Structure Analysis of the Bb segment of Factor B complexed with 4-guanidinobenzoic acid 1RS0 ; 2.6 ; Crystal Structure Analysis of the Bb segment of Factor B complexed with Di-isopropyl-phosphate (DIP) 1S4U ; 2.1 ; Crystal Structure analysis of the beta-propeller protein Ski8p 1NEP ; 1.7 ; Crystal Structure Analysis of the Bovine NPC2 (Niemann-Pick C2) Protein 1I7N ; 1.9 ; CRYSTAL STRUCTURE ANALYSIS OF THE C DOMAIN OF SYNAPSIN II FROM RAT BRAIN 1U13 ; 2.01 ; Crystal structure analysis of the C37L/C151T/C442A-triple mutant of CYP51 from Mycobacterium tuberculosis 1Q42 ; 1.75 ; Crystal structure analysis of the Candida albicans Mtr2 3CN7 ; 2.99 ; Crystal Structure Analysis of the Carboxylesterase PA3859 from Pseudomonas aeruginosa PAO1- MONOCLINIC CRYSTAL FORM 3CN9 ; 2.09 ; Crystal Structure Analysis of the Carboxylesterase PA3859 from Pseudomonas aeruginosa PAO1- orthorhombic crystal form 3N5N ; 2.3 ; Crystal structure analysis of the catalytic domain and interdomain connector of human MutY homologue 1KWI ; 2.19 ; Crystal Structure Analysis of the Cathelicidin Motif of Protegrins 3QIL ; 3.92 ; Crystal structure analysis of the clathrin trimerization domain 2E46 ; 2.3 ; Crystal Structure Analysis of the clock protein EA4 2E47 ; 2.11 ; Crystal Structure Analysis of the clock protein EA4 (glycosylation form) 3VOR ; 0.9 ; Crystal Structure Analysis of the CofA 3A1H ; 1.08 ; Crystal Structure Analysis of the Collagen-like Peptide, (PPG)4-OTG-(PPG)4 2EFF ; 1.8 ; Crystal structure analysis of the complex between CyaY and Co(II) 2P1X ; 1.42 ; Crystal structure analysis of the complex between CyaY and Eu(III) 1L0P ; 2.1 ; CRYSTAL STRUCTURE ANALYSIS OF THE COMPLEX BETWEEN PSYCHROPHILIC ALPHA AMYLASE FROM PSEUDOALTEROMONAS HALOPLANCTIS AND NITRATE 1CQP ; 2.6 ; CRYSTAL STRUCTURE ANALYSIS OF THE COMPLEX LFA-1 (CD11A) I-DOMAIN / LOVASTATIN AT 2.6 A RESOLUTION 1I7L ; 2.35 ; CRYSTAL STRUCTURE ANALYSIS OF THE COMPLEX OF THE C DOMAIN OF SYNAPSIN II FROM RAT WITH ATP 3LZO ; 1.65 ; Crystal Structure Analysis of the copper-reconstituted P19 protein from Campylobacter jejuni at 1.65 A at pH 10.0 1ZOT ; 2.2 ; crystal structure analysis of the CyaA/C-Cam with PMEAPP 3VLJ ; 1.7 ; Crystal Structure Analysis of the Cyanide Arg409Leu Variant Complexes with o-Dianisidine in KatG from HALOARCULA MARISMORTUI 3VLI ; 1.7 ; Crystal Structure Analysis of the Cyanide Arg409Leu Variant KatG from HALOARCULA MARISMORTUI 1MJ4 ; 1.2 ; Crystal Structure Analysis of the cytochrome b5 domain of human sulfite oxidase 1PTJ ; 2.61 ; Crystal structure analysis of the DI and DIII complex of transhydrogenase with a thio-nicotinamide nucleotide analogue 1ZI6 ; 1.7 ; Crystal Structure Analysis of the dienelactone hydrolase (C123S) mutant- 1.7 A 1ZIC ; 1.7 ; Crystal Structure Analysis of the dienelactone hydrolase (C123S, R206A) mutant- 1.7 A 1ZI9 ; 1.5 ; Crystal Structure Analysis of the dienelactone hydrolase (E36D, C123S) mutant- 1.5 A 1ZIY ; 1.9 ; Crystal Structure Analysis of the dienelactone hydrolase mutant (C123S) bound with the PMS moiety of the protease inhibitor, Phenylmethylsulfonyl fluoride (PMSF)- 1.9 A 1ZJ4 ; 1.7 ; Crystal Structure Analysis of the dienelactone hydrolase mutant (E36D, C123S) bound with the PMS moiety of the protease inhibitor, Phenylmethylsulfonyl fluoride (PMSF)- 1.7 A 1ZJ5 ; 1.7 ; Crystal Structure Analysis of the dienelactone hydrolase mutant (E36D, C123S, A134S, S208G, A229V, K234R) bound with the PMS moiety of the protease inhibitor, Phenylmethylsulfonyl fluoride (PMSF)- 1.7 A 1ZIX ; 1.8 ; Crystal Structure Analysis of the dienelactone hydrolase mutant (E36D, R105H, C123S, G211D, K234N)- 1.8 A 1ZI8 ; 1.4 ; Crystal Structure Analysis of the dienelactone hydrolase mutant(E36D, C123S, A134S, S208G, A229V, K234R)- 1.4 A 2CZS ; 1.5 ; Crystal Structure Analysis of the Diheme c-type Cytochrome DHC2 1PT9 ; 2.42 ; Crystal Structure Analysis of the DIII Component of Transhydrogenase with a Thio-Nicotinamide Nucleotide Analogue 2OYA ; 1.77 ; Crystal structure analysis of the dimeric form of the SRCR domain of mouse MARCO 1S45 ; 2.2 ; Crystal structure analysis of the DNA quadruplex d(TGGGGT) S1 1S47 ; 2.5 ; Crystal structure analysis of the DNA quadruplex d(TGGGGT)S2 1J0W ; 2.5 ; Crystal Structure Analysis of the Dok-5 PTB Domain 2FYN ; 3.2 ; Crystal Structure Analysis of the double mutant Rhodobacter Sphaeroides bc1 complex 3GLX ; 1.85 ; Crystal Structure Analysis of the DtxR(E175K) complexed with Ni(II) 1EN4 ; 2 ; CRYSTAL STRUCTURE ANALYSIS OF THE E. COLI MANGANESE SUPEROXIDE DISMUTASE Q146H MUTANT 1EN6 ; 2 ; CRYSTAL STRUCTURE ANALYSIS OF THE E. COLI MANGANESE SUPEROXIDE DISMUTASE Q146L MUTANT 1EN5 ; 2.3 ; CRYSTAL STRUCTURE ANALYSIS OF THE E. COLI MANGANESE SUPEROXIDE DISMUTASE Y34F MUTANT 1JLL ; 2.69 ; Crystal Structure Analysis of the E197betaA Mutant of E. coli SCS 4IQA ; 2.49 ; Crystal Structure Analysis of the E228L Mutant of Human CLIC1 3EMR ; 1.85 ; Crystal Structure Analysis of the ectoine hydroxylase ECTD from Salibacillus salexigens 3M8L ; 3.4 ; Crystal Structure Analysis of the Feline Calicivirus Capsid Protein 1GAW ; 2.2 ; CRYSTAL STRUCTURE ANALYSIS OF THE FERREDOXIN-NADP+ REDUCTASE FROM MAIZE LEAF 1SM4 ; 2.5 ; Crystal Structure Analysis of the Ferredoxin-NADP+ Reductase from Paprika 1NUN ; 2.9 ; Crystal Structure Analysis of the FGF10-FGFR2b Complex 1J4H ; 1.8 ; crystal structure analysis of the FKBP12 complexed with 000107 small molecule 1J4I ; 1.8 ; crystal structure analysis of the FKBP12 complexed with 000308 small molecule 3A8S ; 2.9 ; Crystal structure analysis of the fluorescent protein KillerRed 2HM7 ; 2 ; Crystal Structure Analysis of the G84S EST2 mutant 1C16 ; 3.1 ; CRYSTAL STRUCTURE ANALYSIS OF THE GAMMA/DELTA T CELL LIGAND T22 2A6K ; 3 ; Crystal Structure Analysis of the germline antibody 36-65 Fab in complex with the dodecapeptide SLGDNLTNHNLR 1K33 ; 1.75 ; Crystal structure analysis of the gp41 core mutant 1I08 ; 2.2 ; CRYSTAL STRUCTURE ANALYSIS OF THE H30A MUTANT OF MANGANESE SUPEROXIDE DISMUTASE FROM E. COLI 1LG5 ; 1.75 ; Crystal Structure Analysis of the HCA II Mutant T199P in complex with beta-mercaptoethanol 2ZZQ ; 3.81 ; Crystal structure analysis of the HEV capsid protein, PORF2 2GD8 ; 1.46 ; Crystal structure analysis of the human carbonic anhydrase II in complex with a 2-substituted estradiol bis-sulfamate 2AAQ ; 2.6 ; Crystal Structure Analysis of the human Glutahione Reductase, complexed with GoPI 1FP5 ; 2.3 ; CRYSTAL STRUCTURE ANALYSIS OF THE HUMAN IGE-FC CEPSILON3-CEPSILON4 FRAGMENT. 1S31 ; 2.704 ; Crystal Structure Analysis of the human Tub protein (isoform a) spanning residues 289 through 561 1MWO ; 2.2 ; Crystal Structure Analysis of the Hyperthermostable Pyrocoocus woesei alpha-amylase 1N64 ; 2.34 ; Crystal structure analysis of the immunodominant antigenic site on Hepatitis C virus protein bound to mAb 19D9D6 3F2L ; 1.85 ; Crystal structure analysis of the K171A mutation of N-terminal type II cohesin 1 from the cellulosomal ScaB subunit of Acetivibrio cellulolyticus 3KM5 ; 1.4 ; Crystal Structure Analysis of the K2 Cleaved Adhesin Domain of Lys-gingipain (Kgp) 3M1H ; 1.56 ; Crystal Structure Analysis of the K3 Cleaved Adhesin Domain of Lys-gingipain (Kgp) from Porphyromonas gingivalis w83 2DU2 ; 2.1 ; Crystal Structure Analysis of the L-Lactate Oxidase 3Q74 ; 1.79 ; Crystal Structure Analysis of the L7A Mutant of the Apo Form of Human Alpha Class Glutathione Transferase 1U4N ; 2.1 ; Crystal Structure Analysis of the M211S/R215L EST2 mutant 1QWR ; 1.8 ; Crystal Structure Analysis of the Mannose 6-Phosphate Isomerase from Bacillus subtilis 3VLM ; 2.33 ; Crystal Structure Analysis of the Met244Ala Variant of KatG from Haloarcula marismortui 3JWH ; 2.2 ; Crystal structure analysis of the methyltransferase domain of bacterial-AvHen1-C 3JWJ ; 2.5 ; Crystal structure analysis of the methyltransferase domain of bacterial-AvHen1-CN 3JWG ; 1.9 ; Crystal structure analysis of the methyltransferase domain of bacterial-CtHen1-C 3JWI ; 2.2 ; Crystal structure analysis of the methyltransferase domain of bacterial-CtHen1-CN 1IU4 ; 2.4 ; Crystal Structure Analysis of the Microbial Transglutaminase 3FCG ; 2.85 ; Crystal Structure Analysis of the Middle Domain of the Caf1A Usher 1ZPI ; 1.6 ; Crystal structure analysis of the minor groove binding quinolinium quaternary salt SN 8224 complexed with CGCGAATTCGCG 1ZPH ; 1.8 ; Crystal structure analysis of the minor groove binding quinolinium quaternary salt SN 8315 complexed with CGCGAATTCGCG 2OW9 ; 1.74 ; Crystal structure analysis of the MMP13 catalytic domain in complex with specific inhibitor 2OY3 ; 1.78 ; Crystal structure analysis of the monomeric SRCR domain of mouse MARCO 1N1X ; 1.45 ; Crystal Structure Analysis of the monomeric [S-carboxyamidomethyl-Cys31, S-carboxyamidomethyl-Cys32] Bovine seminal ribonuclease 3AA9 ; 2.3 ; Crystal Structure Analysis of the Mutant CutA1 (E61V) from E. coli 3AA8 ; 2.3 ; Crystal Structure Analysis of the Mutant CutA1 (S11V/E61V) from E. coli 1JD9 ; 2.5 ; CRYSTAL STRUCTURE ANALYSIS OF THE MUTANT K300Q OF PSEUDOALTEROMONAS HALOPLANCTIS ALPHA-AMYLASE 1JD7 ; 2.25 ; CRYSTAL STRUCTURE ANALYSIS OF THE MUTANT K300R OF PSEUDOALTEROMONAS HALOPLANCTIS ALPHA-AMYLASE 1FNQ ; 2.6 ; CRYSTAL STRUCTURE ANALYSIS OF THE MUTANT REACTION CENTER PRO L209-> GLU FROM THE PHOTOSYNTHETIC PURPLE BACTERIUM RHODOBACTER SPHAEROIDES 1FNP ; 2.6 ; CRYSTAL STRUCTURE ANALYSIS OF THE MUTANT REACTION CENTER PRO L209-> PHE FROM THE PHOTOSYNTHETIC PURPLE BACTERIUM RHODOBACTER SPHAEROIDES 1F6N ; 2.8 ; CRYSTAL STRUCTURE ANALYSIS OF THE MUTANT REACTION CENTER PRO L209-> TYR FROM THE PHOTOSYNTHETIC PURPLE BACTERIUM RHODOBACTER SPHAEROIDES 1KDQ ; 2.55 ; Crystal Structure Analysis of the Mutant S189D Rat Chymotrypsin 1X0J ; 1.8 ; Crystal structure analysis of the N-terminal bromodomain of human Brd2 2DVQ ; 2.04 ; Crystal structure analysis of the N-terminal bromodomain of human BRD2 complexed with acetylated histone H4 peptide 2DVR ; 2.3 ; Crystal structure analysis of the N-terminal bromodomain of human BRD2 complexed with acetylated histone H4 peptide 2DVS ; 2.04 ; Crystal structure analysis of the N-terminal bromodomain of human BRD2 complexed with acetylated histone H4 peptide 1LV1 ; 2.1 ; Crystal Structure Analysis of the non-active site mutant of tethered HIV-1 protease to 2.1A resolution 1T6V ; 1.7 ; Crystal structure analysis of the nurse shark new antigen receptor (NAR) variable domain in complex with lysozyme 1SQ2 ; 1.45 ; Crystal Structure Analysis of the Nurse Shark New Antigen Receptor (NAR) Variable Domain in Complex With Lyxozyme 2I27 ; 1.92 ; Crystal Structure Analysis of the Nurse Shark New Antigen Receptor Ancestral variable domain 2I26 ; 2.5 ; Crystal structure analysis of the nurse shark new antigen receptor ancestral variable domain in complex with lysozyme 2I24 ; 1.35 ; Crystal structure analysis of the nurse shark New Antigen Receptor PBLA8 variable domain 2I25 ; 1.8 ; Crystal structure analysis of the nurse shark New antigen Receptor PBLA8 variable domain in complex with lysozyme 3DUL ; 1.8 ; Crystal Structure Analysis of the O-methyltransferase from Bacillus cereus 1YI9 ; 1.7 ; Crystal Structure Analysis of the oxidized form of the M314I mutant of Peptidylglycine alpha-Hydroxylating Monooxygenase 3VJJ ; 3 ; Crystal Structure Analysis of the P9-1 3VQF ; 1.199 ; Crystal Structure Analysis of the PDZ Domain Derived from the Tight Junction Regulating Protein 3VQG ; 1.35 ; Crystal Structure Analysis of the PDZ Domain Derived from the Tight Junction Regulating Protein 1M21 ; 1.8 ; Crystal structure analysis of the peptide amidase PAM in complex with the competitive inhibitor chymostatin 2DX8 ; 2.7 ; Crystal Structure Analysis of the PHD domain of the Transcription Coactivator Pygophus 1FU0 ; 1.9 ; CRYSTAL STRUCTURE ANALYSIS OF THE PHOSPHO-SERINE 46 HPR FROM ENTEROCOCCUS FAECALIS 3QO6 ; 2.5 ; Crystal structure analysis of the plant protease Deg1 1FQ2 ; 1.2 ; CRYSTAL STRUCTURE ANALYSIS OF THE POTASSIUM FORM OF B-DNA DODECAMER CGCGAATTCGCG 1QTR ; 2.32 ; CRYSTAL STRUCTURE ANALYSIS OF THE PROLYL AMINOPEPTIDASE FROM SERRATIA MARCESCENS 1VB5 ; 2.2 ; Crystal Structure Analysis of the Pyrococcus horikoshii OT3 translation initiation factor eIF-2B 1HM5 ; 1.8 ; CRYSTAL STRUCTURE ANALYSIS OF THE RABBIT D-GLUCOSE 6-PHOSPHATE ISOMERASE (NO LIGAND BOUND) 2EMS ; 2.9 ; Crystal Structure Analysis of the radixin FERM domain complexed with adhesion molecule CD43 2EMT ; 2.8 ; Crystal Structure Analysis of the radixin FERM domain complexed with adhesion molecule PSGL-1 3LOA ; 2.299 ; Crystal Structure Analysis of the RNA construct with two adjacent ligand binding sites of helix h44 in 16S ribosomal RNA 2G92 ; 1.61 ; Crystal Structure Analysis of the RNA Dodecamer CGC-(NF2)-AAUUAGCG, with an Incorporated 2,4-Difluorotoluyl Residue (NF2) 2Q1O ; 1.1 ; Crystal Structure Analysis of the RNA Dodecamer CGC-NF2-AAUUGGCG, with an Incorporated 2,4-Difluorotoluyl Residue (NF2) 2Q1R ; 1.12 ; Crystal Structure Analysis of the RNA Dodecamer CGCGAAUUAGCG, with a G-A mismatch. 3BK2 ; 2.1 ; Crystal Structure Analysis of the RNase J/UMP complex 1KS2 ; 1.5 ; Crystal Structure Analysis of the rpiA, Structural Genomics, protein EC1268. 1S4D ; 2.7 ; Crystal Structure Analysis of the S-adenosyl-L-methionine dependent uroporphyrinogen-III C-methyltransferase SUMT 1NTE ; 1.24 ; CRYSTAL STRUCTURE ANALYSIS OF THE SECOND PDZ DOMAIN OF SYNTENIN 1PN2 ; 1.95 ; Crystal structure analysis of the selenomethionine labelled 2-enoyl-CoA hydratase 2 domain of Candida tropicalis multifunctional enzyme type 2 1EW0 ; 1.4 ; CRYSTAL STRUCTURE ANALYSIS OF THE SENSOR DOMAIN OF RMFIXL(FERROUS FORM) 3VLK ; 2 ; Crystal Structure Analysis of the Ser305Ala variant of KatG from Haloarcula marismortui 3VLL ; 2 ; Crystal Structure Analysis of the Ser305Ala variant of KatG from HALOARCULA MARISMORTUI Complexes with Inhibitor SHA 3UW8 ; 2.35 ; Crystal Structure Analysis of the Ser305Thr Variants of KatG from Haloarcula marismortui 1JWO ; 2.5 ; Crystal Structure Analysis of the SH2 Domain of the Csk Homologous Kinase CHK 1PL5 ; 2.5 ; Crystal Structure Analysis of the Sir4p C-terminal Coiled Coil 1V9I ; 2.95 ; Crystal Structure Analysis of the site specific mutant (Q253C) of bovine carbonic anhydrase II 2Z41 ; 3.51 ; Crystal Structure Analysis of the Ski2-type RNA helicase 1DD1 ; 2.62 ; CRYSTAL STRUCTURE ANALYSIS OF THE SMAD4 ACTIVE FRAGMENT 2ZHJ ; 1.35 ; Crystal Structure Analysis of the Sodium-Bound Annexin A4 at 1.34 A resolution 2ZHI ; 1.58 ; Crystal Structure Analysis of the Sodium-Bound Annexin A4 at 1.58 A resolution 3CX3 ; 2.4 ; Crystal structure Analysis of the Streptococcus pneumoniae AdcAII protein 3TJT ; 1.801 ; Crystal Structure Analysis of the superoxide dismutase from Clostridium difficile 1G94 ; 1.74 ; CRYSTAL STRUCTURE ANALYSIS OF THE TERNARY COMPLEX BETWEEN PSYCHROPHILIC ALPHA AMYLASE FROM PSEUDOALTEROMONAS HALOPLANCTIS IN COMPLEX WITH A HEPTA-SACCHARIDE AND A TRIS MOLECULE 1ZZI ; 1.8 ; Crystal Structure Analysis of the third KH domain of hnRNP K in complex with ssDNA 1ILV ; 2 ; Crystal Structure Analysis of the TM107 3VQT ; 1.8 ; Crystal structure analysis of the translation factor RF3 3VR1 ; 3 ; Crystal structure analysis of the translation factor RF3 1J4G ; 2 ; crystal structure analysis of the trichosanthin delta C7 2HDZ ; 2 ; Crystal Structure Analysis of the UBF HMG box5 2P5P ; 2.8 ; Crystal Structure Analysis of the West Nile virus envelope (E) protein domain III 1LNS ; 2.2 ; Crystal Structure Analysis of the X-Prolyl Dipeptidyl Aminopeptidase From Lactococcus lactis 1Q32 ; 2.03 ; Crystal Structure Analysis of the Yeast Tyrosyl-DNA Phosphodiesterase 3SQ8 ; 2.1 ; Crystal Structure Analysis of the Yeast Tyrosyl-DNA Phosphodiesterase 1 H432R Mutant (SCAN1 Mutant) 3SQ3 ; 2.5 ; Crystal Structure Analysis of the Yeast Tyrosyl-DNA Phosphodiesterase H182A Mutant 3SQ5 ; 2.3 ; Crystal Structure Analysis of the Yeast Tyrosyl-DNA Phosphodiesterase H432N Mutant 3SQ7 ; 2 ; Crystal Structure Analysis of the Yeast Tyrosyl-DNA Phosphodiesterase H432N_Glu Mutant 1JI1 ; 1.6 ; Crystal Structure Analysis of Thermoactinomyces vulgaris R-47 alpha-Amylase 1 1Z9G ; 1.7 ; Crystal Structure Analysis of Thermolysin Complexed with the Inhibitor (R)-retro-thiorphan 1ZDP ; 1.7 ; Crystal Structure Analysis of Thermolysin Complexed with the Inhibitor (S)-thiorphan 1V98 ; 1.82 ; Crystal Structure Analysis of Thioredoxin from Thermus thermophilus 1M6Y ; 1.9 ; Crystal Structure Analysis of TM0872, a Putative SAM-dependent Methyltransferase, Complexed with SAH 1N2X ; 1.9 ; Crystal Structure Analysis of TM0872, a Putative SAM-dependent Methyltransferase, Complexed with SAM 3SJM ; 1.35 ; Crystal Structure Analysis of TRF2-Dbd-DNA complex 3C2J ; 1.78 ; Crystal structure analysis of trioxacarcin A covalently bound to d(AACCGGTT) 3EE6 ; 2.35 ; Crystal Structure Analysis of Tripeptidyl peptidase -I 1VEP ; 2.06 ; Crystal Structure Analysis of Triple (T47M/Y164E/T328N)/maltose of Bacillus cereus Beta-Amylase at pH 6.5 2QAE ; 1.9 ; Crystal Structure Analysis of Trypanosoma cruzi Lipoamide dehydrogenase 2DST ; 2 ; Crystal Structure Analysis of TT1977 1TYJ ; 1.6 ; Crystal Structure Analysis of type II Cohesin A11 from Bacteroides cellulosolvens 1FX5 ; 2.2 ; CRYSTAL STRUCTURE ANALYSIS OF ULEX EUROPAEUS LECTIN I 1YBD ; 2.6 ; Crystal structure analysis of uridylate kinase from Neisseria meningitidis 3VE6 ; 2.829 ; Crystal Structure Analysis of Venezuelan Equine Encephalitis Virus Capsid Protein NLS and Importin Alpha 1CW0 ; 2.3 ; CRYSTAL STRUCTURE ANALYSIS OF VERY SHORT PATCH REPAIR (VSR) ENDONUCLEASE IN COMPLEX WITH A DUPLEX DNA 3AZ1 ; 1.5 ; Crystal Structure Analysis of Vitamin D receptor 3AZ2 ; 1.69 ; Crystal Structure Analysis of Vitamin D receptor 3AZ3 ; 1.36 ; Crystal Structure Analysis of Vitamin D receptor 1JTE ; 2 ; Crystal Structure Analysis of VP39 F180W mutant 1JTF ; 2.6 ; Crystal Structure Analysis of VP39-F180W mutant and m7GpppG complex 3L0H ; 2.13 ; Crystal Structure Analysis of W21A mutant of human GSTA1-1 in complex with S-hexylglutathione 3TGZ ; 2.3 ; Crystal Structure Analysis of W35F/H207W Mutant of Human CLIC1 3LU1 ; 2.5 ; Crystal Structure Analysis of WbgU: a UDP-GalNAc 4-epimerase 1VEN ; 2.02 ; Crystal Structure Analysis of Y164E/maltose of Bacilus cereus Beta-amylase at pH 4.6 1VEO ; 2.12 ; Crystal Structure Analysis of Y164F/maltose of Bacillus cereus Beta-Amylase at pH 4.6 1PV1 ; 2.3 ; Crystal Structure Analysis of Yeast Hypothetical Protein: YJG8_YEAST 2DZN ; 2.2 ; Crystal structure analysis of yeast Nas6p complexed with the proteasome subunit, rpt3 2DZO ; 3 ; Crystal structure analysis of yeast Nas6p complexed with the proteasome subunit, rpt3 3PR6 ; 1.8 ; Crystal structure analysis of yeast TRAPP associate protein Tca17 3C8E ; 1.5 ; Crystal Structure Analysis of yghU from E. Coli 3R2Q ; 1.05 ; Crystal Structure Analysis of yibF from E. Coli 1NBA ; 2 ; CRYSTAL STRUCTURE ANALYSIS, REFINEMENT AND ENZYMATIC REACTION MECHANISM OF N-CARBAMOYLSARCOSINE AMIDOHYDROLASE FROM ARTHROBACTER SP. AT 2.0 ANGSTROMS RESOLUTION 1NZJ ; 1.5 ; Crystal Structure and Activity Studies of Escherichia Coli Yadb ORF 3PFQ ; 4 ; Crystal Structure and Allosteric Activation of Protein Kinase C beta II 2HIM ; 1.82 ; Crystal Structure and Allosteric Regulation of the Cytoplasmic Escherichia coli L-Asparaginase I 2P2D ; 1.89 ; Crystal Structure and Allosteric Regulation of the Cytoplasmic Escherichia coli L-Asparaginase I 2P2N ; 1.9 ; Crystal Structure and Allosteric Regulation of the Cytoplasmic Escherichia coli L-Asparaginase I 3F3H ; 2.1 ; Crystal structure and anti-tumor activity of LZ-8 from the fungus Ganoderma lucidium 1GME ; 2.7 ; CRYSTAL STRUCTURE AND ASSEMBLY OF AN EUKARYOTIC SMALL HEAT SHOCK PROTEIN 2BOL ; 2.5 ; CRYSTAL STRUCTURE AND ASSEMBLY OF TSP36, A METAZOAN SMALL HEAT SHOCK PROTEIN 2O8T ; 1.45 ; Crystal Structure and Binding Epitopes of Urokinase-type Plasminogen Activator (C122A/N145Q) in complex with Inhibitors 2O8U ; 1.7 ; Crystal Structure and Binding Epitopes of Urokinase-type Plasminogen Activator (C122A/N145Q/S195A) in complex with Inhibitors 2O8W ; 1.86 ; Crystal Structure and Binding Epitopes of Urokinase-type Plasminogen Activator (C122A/N145Q/S195A) in complex with Inhibitors 2DRU ; 2.6 ; Crystal structure and binding properties of the CD2 and CD244 (2B4) binding protein, CD48 3BU7 ; 2.8 ; Crystal Structure and Biochemical Characterization of GDOsp, a Gentisate 1,2-Dioxygenase from Silicibacter Pomeroyi 3E3R ; 2.65 ; Crystal structure and biochemical characterization of recombinant human calcyphosine delineates a novel EF-hand-containing protein family 1JTH ; 2 ; Crystal structure and biophysical properties of a complex between the N-terminal region of SNAP25 and the SNARE region of syntaxin 1a 2BTN ; 2 ; CRYSTAL STRUCTURE AND CATALYTIC MECHANISM OF THE QUORUM-QUENCHING N-ACYL HOMOSERINE LACTONE HYDROLASE 4GKF ; 2.1 ; Crystal structure and characterization of Cmr5 protein from Pyrococcus furiosus 3HWP ; 2 ; Crystal structure and computational analyses provide insights into the catalytic mechanism of 2, 4-diacetylphloroglucinol hydrolase PhlG from Pseudomonas fluorescens 4H20 ; 1.9 ; Crystal Structure and Computational Modeling of the Fab Fragment from the Protective anti-Ricin Monoclonal Antibody RAC18 3ZX3 ; 1.7 ; Crystal Structure and Domain Rotation of NTPDase1 CD39 2CJL ; 1.5 ; CRYSTAL STRUCTURE AND ENZYMATIC PROPERTIES OF A BACTERIAL FAMILY 19 CHITINASE REVEAL DIFFERENCES WITH PLANT ENZYMES 2F0X ; 2.3 ; Crystal structure and function of human thioesterase superfamily member 2(THEM2) 1ENY ; 2.2 ; CRYSTAL STRUCTURE AND FUNCTION OF THE ISONIAZID TARGET OF MYCOBACTERIUM TUBERCULOSIS 1ENZ ; 2.7 ; CRYSTAL STRUCTURE AND FUNCTION OF THE ISONIAZID TARGET OF MYCOBACTERIUM TUBERCULOSIS 1OVN ; 1.9 ; Crystal Structure and Functional Analysis of Drosophila Wind-- a PDI-Related Protein 3E5R ; 2.3 ; Crystal structure and Functional Analysis of Glyceraldehyde-3-phosphate Dehydrogenase from Oryza Sativa 3E6A ; 3.77 ; Crystal structure and Functional Analysis of Glyceraldehyde-3-phosphate Dehydrogenase from Oryza Sativa 3LUO ; 2.55 ; Crystal Structure and functional characterization of the thermophilic prolyl isomerase and chaperone SlyD 4HVK ; 1.43 ; Crystal structure and functional studies of an unusual L-cysteine desulfurase from Archaeoglobus fulgidus. 2B8I ; 1.8 ; Crystal Structure and Functional Studies Reveal that PAS Factor from Vibrio vulnificus is a Novel Member of the Saposin-Fold Family 2QN5 ; 3 ; Crystal Structure and Functional Study of the Bowman-Birk Inhibitor from Rice Bran in Complex with Bovine Trypsin 3RON ; 2.19 ; Crystal Structure and Hemolytic Activity of the Cyt1Aa Toxin from Bacillus thuringiensis subsp. israelensis 471D ; 2.7 ; CRYSTAL STRUCTURE AND IMPROVED ANTISENSE PROPERTIES OF 2'-O-(2-METHOXYETHYL)-RNA 468D ; 1.8 ; CRYSTAL STRUCTURE AND IMPROVED ANTISENSE PROPERTIES OF 2'-O-(2-METHOXYETHYL)-RNA 470D ; 1.95 ; CRYSTAL STRUCTURE AND IMPROVED ANTISENSE PROPERTIES OF 2'-O-(2-METHOXYETHYL)-RNA 469D ; 1.7 ; CRYSTAL STRUCTURE AND IMPROVED ANTISENSE PROPERTIES OF 2'-O-(2-METHOXYETHYL)-RNA 1PTS ; 2 ; CRYSTAL STRUCTURE AND LIGAND BINDING STUDIES OF A SCREENED PEPTIDE COMPLEXED WITH STREPTAVIDIN 1RQP ; 1.8 ; Crystal structure and mechanism of a bacterial fluorinating enzyme 1RQR ; 2.67 ; Crystal structure and mechanism of a bacterial fluorinating enzyme, product complex 4IW0 ; 4 ; Crystal structure and mechanism of activation of TBK1 4IWO ; 2.61 ; Crystal structure and mechanism of activation of TBK1 4IWP ; 3.065 ; Crystal structure and mechanism of activation of TBK1 4IWQ ; 3 ; Crystal structure and mechanism of activation of TBK1 2H94 ; 2.9 ; Crystal Structure and Mechanism of human Lysine-Specific Demethylase-1 1JDW ; 1.9 ; CRYSTAL STRUCTURE AND MECHANISM OF L-ARGININE: GLYCINE AMIDINOTRANSFERASE: A MITOCHONDRIAL ENZYME INVOLVED IN CREATINE BIOSYNTHESIS 2JDW ; 2.1 ; CRYSTAL STRUCTURE AND MECHANISM OF L-ARGININE: GLYCINE AMIDINOTRANSFERASE: A MITOCHONDRIAL ENZYME INVOLVED IN CREATINE BIOSYNTHESIS 3JDW ; 2.4 ; CRYSTAL STRUCTURE AND MECHANISM OF L-ARGININE: GLYCINE AMIDINOTRANSFERASE: A MITOCHONDRIAL ENZYME INVOLVED IN CREATINE BIOSYNTHESIS 4JDW ; 2.5 ; CRYSTAL STRUCTURE AND MECHANISM OF L-ARGININE: GLYCINE AMIDINOTRANSFERASE: A MITOCHONDRIAL ENZYME INVOLVED IN CREATINE BIOSYNTHESIS 3HH8 ; 1.87 ; Crystal Structure and metal binding properties of the lipoprotein MtsA 3NV0 ; 1.84 ; Crystal structure and mutational analysis of the NXF2/NXT1 heterodimeric complex from caenorhabditis elegans at 1.84 A resolution 2V1C ; 3.8 ; CRYSTAL STRUCTURE AND MUTATIONAL STUDY OF RECOR PROVIDE INSIGHT INTO ITS ROLE IN DNA REPAIR 2GER ; 3.1 ; Crystal Structure and Oxidative Mechanism of Human Pyrroline-5-carboxylate Reductase 2ADF ; 1.9 ; Crystal Structure and Paratope Determination of 82D6A3, an Antithrombotic Antibody Directed Against the von Willebrand factor A3-Domain 3CGL ; 2.09 ; Crystal Structure and Raman Studies of dsFP483, a Cyan Fluorescent Protein from Discosoma striata 1U08 ; 2.35 ; Crystal Structure and Reactivity of YbdL from Escherichia coli Identify a Methionine Aminotransferase Function. 1CPT ; 2.3 ; CRYSTAL STRUCTURE AND REFINEMENT OF CYTOCHROME P450-TERP AT 2.3 ANGSTROMS RESOLUTION 3THP ; 3.2 ; Crystal structure and RNA binding properties of the RRM/AlkB domains in human ABH8, an enzyme catalyzing tRNA hypermodification, Northeast Structural Genomics Consortium Target HR5601B 3THT ; 3.01 ; Crystal structure and RNA binding properties of the RRM/AlkB domains in human ABH8, an enzyme catalyzing tRNA hypermodification, Northeast Structural Genomics Consortium Target HR5601B 1DNM ; 2.5 ; CRYSTAL STRUCTURE AND SEQUENCE-DEPENDENT CONFORMATION OF THE A.G MIS-PAIRED OLIGONUCLEOTIDE D(CGCAAGCTGGCG) 1MAC ; 2.3 ; CRYSTAL STRUCTURE AND SITE-DIRECTED MUTAGENESIS OF BACILLUS MACERANS ENDO-1,3-1,4-BETA-GLUCANASE 2O6V ; 2.2 ; Crystal structure and solution NMR studies of Lys48-linked tetraubiquitin at neutral pH 3TKA ; 2.25 ; crystal structure and solution saxs of methyltransferase rsmh from E.coli 111D ; 2.25 ; CRYSTAL STRUCTURE AND STABILITY OF A DNA DUPLEX CONTAINING A(ANTI).G(SYN) BASE-PAIRS 1J93 ; 2.3 ; Crystal Structure and Substrate Binding Modeling of the Uroporphyrinogen-III Decarboxylase from Nicotiana tabacum: Implications for the Catalytic Mechanism 3ZRR ; 1.99 ; Crystal structure and substrate specificity of a thermophilic archaeal serine : pyruvate aminotransferase from Sulfolobus solfataricus 3ZRP ; 1.75 ; Crystal structure and substrate specificity of a thermophilic archaeal serine : pyruvate aminotransferase from Sulfolobus solfataricus 3ZRQ ; 1.8 ; Crystal structure and substrate specificity of a thermophilic archaeal serine : pyruvate aminotransferase from Sulfolobus solfataricus 1LYN ; 2.75 ; CRYSTAL STRUCTURE AND SUBUNIT DYNAMICS OF THE LYSIN DIMER: EGG ENVELOPES DISSOCIATE DIMERS, THE MONOMER IS THE ACTIVE SPECIES 3E8U ; 2.1 ; Crystal structure and thermodynamic analysis of diagnostic Fab 106.3 complexed with BNP 5-13 (C10A) reveal basis of selective molecular recognition 2BBA ; 1.65 ; Crystal Structure and Thermodynamic Characterization of the EphB4 Receptor in Complex with an ephrin-B2 Antagonist Peptide Reveals the Determinants for Receptor Specificity. 3LI6 ; 2.502 ; Crystal structure and trimer-monomer transition of N-terminal domain of EhCaBP1 from Entamoeba histolytica 3QAX ; 2 ; Crystal structure anlysis of the cpb0502 2CWS ; 1 ; Crystal structure at 1.0 A of alginate lyase A1-II', a member of polysaccharide lyase family-7 1M2D ; 1.05 ; Crystal structure at 1.05 Angstroms resolution of the Cys59Ser variant of the thioredoxin-like [2Fe-2S] ferredoxin from Aquifex aeolicus 1M2B ; 1.25 ; Crystal structure at 1.25 Angstroms resolution of the Cys55Ser variant of the thioredoxin-like [2Fe-2S] ferredoxin from Aquifex aeolicus 2CYG ; 1.45 ; Crystal structure at 1.45- resolution of the major allergen endo-beta-1,3-glucanase of banana as a molecular basis for the latex-fruit syndrome 3RGW ; 1.5 ; Crystal structure at 1.5 A resolution of an H2-reduced, O2-tolerant hydrogenase from Ralstonia eutropha unmasks a novel iron-sulfur cluster 1D53 ; 1.5 ; CRYSTAL STRUCTURE AT 1.5 ANGSTROMS RESOLUTION OF D(CGCICICG), AN OCTANUCLEOTIDE CONTAINING INOSINE, AND ITS COMPARISON WITH D(CGCG) AND D(CGCGCG) STRUCTURES 1M2A ; 1.5 ; Crystal structure at 1.5 Angstroms resolution of the wild type thioredoxin-like [2Fe-2S] ferredoxin from Aquifex aeolicus 1KGS ; 1.5 ; Crystal Structure at 1.50 A of an OmpR/PhoB Homolog from Thermotoga maritima 1HT6 ; 1.5 ; CRYSTAL STRUCTURE AT 1.5A RESOLUTION OF THE BARLEY ALPHA-AMYLASE ISOZYME 1 2BOP ; 1.7 ; CRYSTAL STRUCTURE AT 1.7 ANGSTROMS OF THE BOVINE PAPILLOMAVIRUS-1 E2 DNA-BINDING DOMAIN BOUND TO ITS DNA TARGET 1IQ9 ; 1.8 ; crystal structure at 1.8 A of toxin a from Naja nigricollis venom 1RKX ; 1.8 ; Crystal Structure at 1.8 Angstrom of CDP-D-glucose 4,6-dehydratase from Yersinia pseudotuberculosis 1MO1 ; 1.8 ; CRYSTAL STRUCTURE AT 1.8 ANGSTROMS OF SELENO METHIONYLED CRH, THE BACILLUS SUBTILIS CATABOLITE REPRESSION CONTAINING PROTEIN CRH REVEALS AN UNEXPECTED SWAPPING DOMAIN AS AN UNTERTWINNED DIMER 1MU4 ; 1.8 ; CRYSTAL STRUCTURE AT 1.8 ANGSTROMS OF THE BACILLUS SUBTILIS CATABOLITE REPRESSION HISTIDINE CONTAINING PROTEIN (CRH) 1MZN ; 1.9 ; CRYSTAL STRUCTURE at 1.9 ANGSTROEMS RESOLUTION OF THE HOMODIMER OF HUMAN RXR ALPHA LIGAND BINDING DOMAIN BOUND TO THE SYNTHETIC AGONIST COMPOUND BMS 649 AND A COACTIVATOR PEPTIDE 1HSG ; 2 ; CRYSTAL STRUCTURE AT 1.9 ANGSTROMS RESOLUTION OF HUMAN IMMUNODEFICIENCY VIRUS (HIV) II PROTEASE COMPLEXED WITH L-735,524, AN ORALLY BIOAVAILABLE INHIBITOR OF THE HIV PROTEASES 1HSH ; 1.9 ; CRYSTAL STRUCTURE AT 1.9 ANGSTROMS RESOLUTION OF HUMAN IMMUNODEFICIENCY VIRUS (HIV) II PROTEASE COMPLEXED WITH L-735,524, AN ORALLY BIOAVAILABLE INHIBITOR OF THE HIV PROTEASES 1HSI ; 2.5 ; CRYSTAL STRUCTURE AT 1.9 ANGSTROMS RESOLUTION OF HUMAN IMMUNODEFICIENCY VIRUS (HIV) II PROTEASE COMPLEXED WITH L-735,524, AN ORALLY BIOAVAILABLE INHIBITOR OF THE HIV PROTEASES 3C2E ; 1.9 ; Crystal structure at 1.9A of the apo quinolinate phosphoribosyl transferase (BNA6) from Saccharomyces cerevisiae 3RLB ; 2 ; Crystal structure at 2.0 A of the S-component for thiamin from an ECF-type ABC transporter 4DVE ; 2.09 ; Crystal structure at 2.1 A of the S-component for biotin from an ECF-type ABC transporter 3K6K ; 2.2 ; Crystal structure at 2.2 angstrom of HSL-homolog EstE7 from a metagenome library 1DYN ; 2.2 ; CRYSTAL STRUCTURE AT 2.2 ANGSTROMS RESOLUTION OF THE PLECKSTRIN HOMOLOGY DOMAIN FROM HUMAN DYNAMIN 1DFO ; 2.4 ; CRYSTAL STRUCTURE AT 2.4 ANGSTROM RESOLUTION OF E. COLI SERINE HYDROXYMETHYLTRANSFERASE IN COMPLEX WITH GLYCINE AND 5-FORMYL TETRAHYDROFOLATE 1EKM ; 2.5 ; CRYSTAL STRUCTURE AT 2.5 A RESOLUTION OF ZINC-SUBSTITUTED COPPER AMINE OXIDASE OF HANSENULA POLYMORPHA EXPRESSED IN ESCHERICHIA COLI 1JVQ ; 2.6 ; Crystal structure at 2.6A of the ternary complex between antithrombin, a P14-P8 reactive loop peptide, and an exogenous tetrapeptide 1JJC ; 2.6 ; Crystal structure at 2.6A resolution of phenylalanyl-tRNA synthetase complexed with phenylalanyl-adenylate in the presence of manganese 1DEE ; 2.7 ; CRYSTAL STRUCTURE AT 2.7A RESOLUTION OF A COMPLEX BETWEEN A STAPHYLOCOCCUS AUREUS DOMAIN AND A FAB FRAGMENT OF A HUMAN IGM ANTIBODY 1HNG ; 2.8 ; CRYSTAL STRUCTURE AT 2.8 ANGSTROMS RESOLUTION OF A SOLUBLE FORM OF THE CELL ADHESION MOLECULE CD2 2F83 ; 2.87 ; Crystal structure at 2.9 Angstroms resolution of human plasma coagulation factor XI zymogen 3GQG ; 1.73 ; Crystal structure at acidic pH of the ferric form of the Root effect hemoglobin from Trematomus bernacchii. 3U9Z ; 2.09 ; Crystal structure between actin and a protein construct containing the first beta-thymosin domain of drosophila ciboulot (residues 2-58) with the three mutations N26D/Q27K/D28S 2RL7 ; 2 ; Crystal Structure cation-dependent mannose 6-phosphate receptor at pH 4.8 2RL8 ; 1.45 ; Crystal Structure cation-dependent mannose 6-phosphate receptor at pH 6.5 bound to M6P 2RLB ; 1.75 ; Crystal Structure cation-dependent mannose 6-phosphate receptor at pH 6.5 bound to M6P in absence of Mn 2RL9 ; 2.4 ; Crystal Structure cation-dependent mannose 6-phosphate receptor at pH 6.5 bound to trimannoside 3CY4 ; 1.51 ; Crystal Structure cation-dependent mannose 6-phosphate receptor at pH 7.4 1TDZ ; 1.8 ; Crystal Structure Complex Between the Lactococcus Lactis FPG (Mutm) and a FAPY-dG Containing DNA 1NNJ ; 1.9 ; Crystal structure Complex between the Lactococcus lactis Fpg and an abasic site containing DNA 1XC8 ; 1.95 ; CRYSTAL STRUCTURE COMPLEX BETWEEN THE WILD-TYPE LACTOCOCCUS LACTIS FPG (MUTM) AND A FAPY-DG CONTAINING DNA 2O3B ; 2.3 ; Crystal structure complex of Nuclease A (NucA) with intra-cellular inhibitor NuiA 2LAL ; 1.8 ; CRYSTAL STRUCTURE DETERMINATION AND REFINEMENT AT 2.3 ANGSTROMS RESOLUTION OF THE LENTIL LECTIN 1THC ; 2.3 ; CRYSTAL STRUCTURE DETERMINATION AT 2.3A OF HUMAN TRANSTHYRETIN-3',5'-DIBROMO-2',4,4',6-TETRA-HYDROXYAURONE COMPLEX 1GYC ; 1.9 ; CRYSTAL STRUCTURE DETERMINATION AT ROOM TEMPERATURE OF A LACCASE FROM TRAMETES VERSICOLOR IN ITS OXIDISED FORM CONTAINING A FULL COMPLEMENT OF COPPER IONS 2QT6 ; 1.5 ; Crystal Structure Determination of a Blue Laccase from Lentinus Tigrinus 1RTT ; 1.28 ; Crystal structure determination of a putative NADH-dependent reductase using sulfur anomalous signal 2PHD ; 2.9 ; Crystal Structure Determination of a Salicylate 1,2-Dioxygenase from Pseudaminobacter salicylatoxidans 3FG5 ; 2.5 ; Crystal structure determination of a ternary complex of phospholipase A2 with a pentapeptide FLSYK and Ajmaline at 2.5 A resolution 1JFL ; 1.9 ; CRYSTAL STRUCTURE DETERMINATION OF ASPARTATE RACEMASE FROM AN ARCHAEA 3CY5 ; 2 ; Crystal structure determination of buffalo (Bubalus bubalis) hemoglobin at 2 angstrom resolution 3GDJ ; 2 ; Crystal structure determination of camel(Camelus dromedarius)hemoglobin at 2 angstrom resolution 3GQP ; 2 ; Crystal structure determination of cat (Felis silvestris catus) hemoglobin at 2.0 angstrom resolution 3D4X ; 2.2 ; Crystal structure determination of cat (Felis silvestris catus) hemoglobin at 2.2 angstrom resolution 3GQR ; 2.4 ; Crystal structure determination of cat (Felis silvestris catus) hemoglobin at 2.4 angstrom resolution 3GYS ; 2.9 ; Crystal structure determination of cat (Felis silvestris catus) hemoglobin at 2.9 angstrom resolution 3I4Y ; 1.85 ; Crystal structure determination of Catechol 1,2-Dioxygenase from Rhodococcus opacus 1CP in complex with 3,5-dichlorocatechol 3I4V ; 2 ; Crystal structure determination of catechol 1,2-dioxygenase from rhodococcus opacus 1CP in complex with 3-chlorocatechol 3I51 ; 1.8 ; Crystal structure determination of Catechol 1,2-Dioxygenase from Rhodococcus opacus 1CP in complex with 4,5-dichlorocatechol 3HJ8 ; 2.4 ; Crystal structure determination of catechol 1,2-dioxygenase from rhodococcus opacus 1CP in complex with 4-chlorocatechol 3HHY ; 1.55 ; Crystal structure determination of Catechol 1,2-Dioxygenase from Rhodococcus opacus 1CP in complex with catechol 3HKP ; 1.85 ; Crystal structure determination of Catechol 1,2-Dioxygenase from Rhodococcus opacus 1CP in complex with protocatechuate 3HHX ; 2 ; Crystal structure determination of Catechol 1,2-Dioxygenase from Rhodococcus opacus 1CP in complex with pyrogallol 3EOK ; 2.1 ; Crystal structure determination of duck (Anas platyrhynchos) hemoglobin at 2.1 Angstrom resolution 2FX3 ; 3.4 ; Crystal Structure Determination of E. coli Elongation Factor, Tu using a Twinned Data Set 3EU1 ; 3 ; Crystal Structure determination of goat hemoglobin (Capra hircus) at 3 angstrom resolution 3D1A ; 2.61 ; Crystal Structure Determination of Goat Hemoglobin at 2.61 Angstrom Resolution 2RI4 ; 2.7 ; Crystal Structure determination of Goat Methemoglobin at 2.7 Angstrom 1EEY ; 2.25 ; Crystal Structure Determination Of HLA A2 Complexed to Peptide GP2 with the substitution (I2L/V5L/L9V) 1EEZ ; 2.3 ; Crystal Structure Determination of HLA-A2.1 Complexed to GP2 Peptide Variant(I2L/V5L) 3FH9 ; 1.62 ; Crystal structure determination of indian flying fox (Pteropus giganteus) at 1.62 A resolution 3MJP ; 2.76 ; Crystal structure determination of Japanese quail (Coturnix coturnix japonica) hemoglobin at 2.76 Angstrom resolution 3LQD ; 2.8 ; Crystal structure determination of Lepus europaeus 2.8 A resolution 3DHR ; 2 ; Crystal Structure Determination of Methemoglobin from Pigeon at 2 Angstrom Resolution (Columba livia) 3FS4 ; 2.22 ; Crystal structure determination of Ostrich hemoglobin at 2.2 Angstrom resolution 3MJU ; 3.5 ; Crystal structure determination of pigeon (columba livia) haemoglobin at 3.5 angstrom resolution 1QPW ; 1.8 ; CRYSTAL STRUCTURE DETERMINATION OF PORCINE HEMOGLOBIN AT 1.8A RESOLUTION 2QU0 ; 2.7 ; Crystal structure determination of sheep methemoglobin at 2.7 Angstrom resolution 3MKB ; 1.9 ; Crystal structure determination of Shortfin Mako (Isurus oxyrinchus) hemoglobin at 1.9 Angstrom resolution 1NJJ ; 2.45 ; Crystal structure determination of T. brucei ornithine decarboxylase bound to D-ornithine and to G418 4EMR ; 1.75 ; Crystal Structure determination of type1 ribosome inactivating protein complexed with 7-methylguanosine-triphosphate at 1.75A 1HOE ; 2 ; CRYSTAL STRUCTURE DETERMINATION, REFINEMENT AND THE MOLECULAR MODEL OF THE ALPHA-AMYLASE INHIBITOR HOE-467A 3RS6 ; 1.8 ; Crystal structure Dioclea virgata lectin in complexed with X-mannose 1RTA ; 2.5 ; CRYSTAL STRUCTURE DISPOSITION OF THYMIDYLIC ACID TETRAMER IN COMPLEX WITH RIBONUCLEASE A 1RTB ; 2.5 ; CRYSTAL STRUCTURE DISPOSITION OF THYMIDYLIC ACID TETRAMER IN COMPLEX WITH RIBONUCLEASE A 3ETJ ; 1.6 ; Crystal structure E. coli Purk in complex with Mg, ADP, and Pi 2X5I ; 3.1 ; CRYSTAL STRUCTURE ECHOVIRUS 7 3P85 ; 1.9 ; Crystal structure enoyl-coa hydratase from mycobacterium avium 3QSE ; 1.75 ; Crystal structure for the complex of substrate-reduced msox with sarcosine 3QSM ; 1.9 ; Crystal structure for the MSOX.chloride binary complex 3QSS ; 1.85 ; Crystal structure for the MSOX.chloride.MTA ternary complex 2AZJ ; 2.4 ; Crystal structure for the mutant D81C of Sulfolobus solfataricus hexaprenyl pyrophosphate synthase 2AZL ; 2.8 ; Crystal structure for the mutant F117E of Thermotoga maritima octaprenyl pyrophosphate synthase 2AZK ; 2.7 ; Crystal structure for the mutant W136E of Sulfolobus solfataricus hexaprenyl pyrophosphate synthase 2VJZ ; 1.8 ; CRYSTAL STRUCTURE FORM ULTALENTE INSULIN MICROCRYSTALS 2VK0 ; 2.2 ; CRYSTAL STRUCTURE FORM ULTALENTE INSULIN MICROCRYSTALS 3IT1 ; 1.691 ; Crystal Structure Francisella tularensis histidine acid phosphatase complexed with L(+)-tartrate 3IT0 ; 1.692 ; Crystal Structure Francisella tularensis histidine acid phosphatase complexed with phosphate 4E3W ; 1.75 ; Crystal Structure Francisella tularensis histidine acid phosphatase cryoprotected with proline 3IT3 ; 1.5 ; Crystal Structure Francisella tularensis histidine acid phosphatase D261A mutant complexed with substrate 3'-AMP 2WKC ; 2.6 ; CRYSTAL STRUCTURE FROM A SINGLE-STRANDED DNA BINDING PROTEIN FROM THE LACTOCOCCAL PHAGE P2 3FYN ; 1.449 ; Crystal structure from the mobile metagenome of Cole Harbour Salt Marsh: Integron Cassette Protein HFX_CASS3 3FXH ; 1.837 ; Crystal structure from the mobile metagenome of Halifax Harbour Sewage Outfall: Integron Cassette Protein HFX_CASS2 3GHJ ; 1.471 ; Crystal structure from the mobile metagenome of Halifax Harbour Sewage Outfall: Integron Cassette Protein HFX_CASS4 3GK6 ; 1.8 ; Crystal structure from the mobile metagenome of Vibrio cholerae. Integron cassette protein VCH_CASS2. 2XZ9 ; 1.677 ; CRYSTAL STRUCTURE FROM THE PHOSPHOENOLPYRUVATE-BINDING DOMAIN OF ENZYME I IN COMPLEX WITH PYRUVATE FROM THE THERMOANAEROBACTER TENGCONGENSIS PEP-SUGAR PHOSPHOTRANSFERASE SYSTEM (PTS) 4ANO ; 1.7 ; Crystal Structure Geobacillus thermodenitrificans EssB cytoplasmic fragment 3G9D ; 2.5 ; Crystal structure glycohydrolase 3DNM ; 2.8 ; Crystal Structure Hormone-Sensitive Lipase from a Metagenome Library 4EVD ; 2.2 ; Crystal Structure HP-NAP from strain YS29 cadmium loaded (Cocrystallization 50mM) 4EVE ; 2.1 ; Crystal Structure HP-NAP from strain YS29 in apo form 4EVC ; 2.4 ; Crystal Structure HP-NAP from strain YS39 cadmium loaded (Cocrystallization 50mM) 3T9J ; 2.2 ; Crystal structure HP-NAP from strain YS39 in apo form 3TA8 ; 2.5 ; Crystal structure HP-NAP from strain YS39 iron loaded (cocrystallization 5mM) 4EVB ; 2.5 ; Crystal Structure HP-NAP from strain YS39 zinc soaked (20mM) 2ITF ; 1.9 ; Crystal structure IsdA NEAT domain from Staphylococcus aureus with heme bound 3E9G ; 2.5 ; Crystal structure long-form (residue1-124) of Eaf3 chromo domain 4EB2 ; 1.94 ; Crystal structure Mistletoe Lectin I from Viscum album in complex with n-acetyl-d-glucosamine at 1.94 A resolution. 4ITM ; 2.1994 ; Crystal structure of ""apo"" form LpxK from Aquifex aeolicus in complex with ATP at 2.2 angstrom resolution 4ITN ; 2.1912 ; Crystal structure of ""compact P-loop"" LpxK from Aquifex aeolicus in complex with chloride at 2.2 angstrom resolution 3O3Q ; 1.6 ; Crystal structure of ""L44F/M67I/L73V/A103G/deletion 104-106/F108Y/V109L/L111I/C117V/R119G/deletion 120-122"" mutant form of Human acidic fibroblast growth factor 1S61 ; 2.1 ; Crystal Structure of ""Truncated"" Hemoglobin N (HbN) from Mycobacterium tuberculosis, Soaked with Butyl-isocyanide 1S56 ; 2.43 ; Crystal Structure of ""Truncated"" Hemoglobin N (HbN) from Mycobacterium tuberculosis, Soaked with Xe Atoms 3NRP ; 1.6 ; Crystal structure of 'as isolated' uropathogenic E. coli strain F11 FetP recombinantly expressed in the periplasm of E. coli BL21(DE3) 2JEW ; 1.4 ; CRYSTAL STRUCTURE OF ((2S)-5-AMINO-2-((1-N-PROPYL-1H-IMIDAZOL-4-YL)METHYL)PENTANOIC ACID) UK396,082 A TAFIA INHIBITOR, BOUND TO ACTIVATED PORCINE PANCREATIC CARBOXYPEPTIDASEB 3G4F ; 2.651 ; Crystal Structure of (+)- -Cadinene Synthase from Gossypium arboreum in complex with 2-fluorofarnesyl diphosphate 3JRS ; 2.05 ; Crystal structure of (+)-ABA-bound PYL1 3JRQ ; 2.1 ; Crystal structure of (+)-ABA-bound PYL1 in complex with ABI1 1N1B ; 2 ; Crystal Structure of (+)-Bornyl Diphosphate Synthase from Sage 3G4D ; 2.403 ; Crystal Structure of (+)-delta-Cadinene Synthase from Gossypium arboreum and Evolutionary Divergence of Metal Binding Motifs for Catalysis 3IDC ; 2.7 ; Crystal structure of (102-265)RIIb:C holoenzyme of cAMP-dependent protein kinase 3IDB ; 1.62 ; Crystal structure of (108-268)RIIb:C holoenzyme of cAMP-dependent protein kinase 3CF9 ; 2.6 ; Crystal structure of (3R)-Hydroxyacyl-Acyl Carrier Protein Dehydratase (FabZ) from Helicobacter pylori in complex with apigenin 3DOY ; 2.4 ; Crystal structure of (3R)-Hydroxyacyl-Acyl Carrier Protein Dehydratase (FabZ) from Helicobacter pylori in complex with compound 3i 3DP2 ; 2.4 ; Crystal structure of (3R)-Hydroxyacyl-Acyl Carrier Protein Dehydratase (FabZ) from Helicobacter pylori in complex with compound 3j 3DOZ ; 2.5 ; Crystal structure of (3R)-Hydroxyacyl-Acyl Carrier Protein Dehydratase (FabZ) from Helicobacter pylori in complex with compound 3k 3DP0 ; 2.5 ; Crystal structure of (3R)-Hydroxyacyl-Acyl Carrier Protein Dehydratase (FabZ) from Helicobacter pylori in complex with compound 3m 3DP1 ; 2.3 ; Crystal structure of (3R)-Hydroxyacyl-Acyl Carrier Protein Dehydratase (FabZ) from Helicobacter pylori in complex with compound 3n 3DP3 ; 2.3 ; Crystal structure of (3R)-Hydroxyacyl-Acyl Carrier Protein Dehydratase (FabZ) from Helicobacter pylori in complex with compound 3q 3ED0 ; 2.3 ; Crystal structure of (3R)-Hydroxyacyl-Acyl Carrier Protein Dehydratase (FabZ) from Helicobacter pylori in complex with emodin 3CF8 ; 2.4 ; Crystal structure of (3R)-Hydroxyacyl-Acyl Carrier Protein Dehydratase (FabZ) from Helicobacter pylori in complex with quercetin 3D04 ; 2.4 ; Crystal structure of (3R)-Hydroxyacyl-Acyl Carrier Protein Dehydratase (FabZ) from Helicobacter pylori in complex with sakuranetin 2GLL ; 2.2 ; Crystal structure of (3R)-Hydroxyacyl-Acyl Carrier Protein Dehydratase(FabZ) from Helicobacter pylori 2GLP ; 2.42 ; Crystal structure of (3R)-Hydroxyacyl-Acyl Carrier Protein Dehydratase(FabZ) from Helicobacter pylori complexed with compound 1 2GLM ; 2.6 ; Crystal structure of (3R)-Hydroxyacyl-Acyl Carrier Protein Dehydratase(FabZ) from Helicobacter pylori complexed with Compound 2 3B7J ; 2.4 ; Crystal structure of (3R)-Hydroxyacyl-Acyl Carrier Protein Dehydratase(FabZ) from Helicobacter pylori complexed with juglone 2GLV ; 2.5 ; Crystal structure of (3R)-Hydroxyacyl-Acyl Carrier Protein Dehydratase(FabZ) mutant(Y100A) from Helicobacter pylori 4I83 ; 2.6 ; Crystal Structure of (3R)-Hydroxymyristoyl-ACP Dehydratase from Neisseria meningitidis FAM18 4H4G ; 2.65 ; Crystal Structure of (3R)-hydroxymyristoyl-[acyl-carrier-protein] dehydratase from Burkholderia thailandensis E264 3PVB ; 3.3 ; Crystal structure of (73-244)RIa:C holoenzyme of cAMP-dependent Protein kinase 2PKR ; 2.4 ; Crystal structure of (A+CTE)4 chimeric form of photosyntetic glyceraldehyde-3-phosphate dehydrogenase, complexed with NADP 3NQJ ; 2.1 ; Crystal structure of (CENP-A/H4)2 heterotetramer 4DQF ; 1.9 ; Crystal Structure of (G16A/L38A) HIV-1 Protease in Complex with DRV 4DQC ; 1.94 ; Crystal Structure of (G16C/L38C) HIV-1 Protease in Complex with DRV 4DQE ; 1.3 ; Crystal Structure of (G16C/L38C) HIV-1 Protease in Complex with DRV 3B0S ; 1.45 ; Crystal Structure of (Gly-Pro-Hyp)9 1P92 ; 2.1 ; Crystal Structure of (H79A)DtxR 1XCV ; 2.1 ; Crystal Structure Of (H79AC102D)Dtxr complexed with Nickel(II) 2WJZ ; 2.601 ; Crystal structure of (HisH) K181A Y138A mutant of imidazoleglycerolphosphate synthase (HisH HisF) which displays constitutive glutaminase activity 3ABN ; 1.02 ; Crystal structure of (Pro-Pro-Gly)4-Hyp-Asp-Gly-(Pro-Pro-Gly)4 at 1.02 A 3ADM ; 1.18 ; Crystal structure of (Pro-Pro-Gly)4-Hyp-Ser-Gly-(Pro-Pro-Gly)4 3AH9 ; 1.08 ; Crystal structure of (Pro-Pro-Gly)9 at 1.1 A resolution 1ZG8 ; 2 ; Crystal Structure of (R)-2-(3-{[amino(imino)methyl]amino}phenyl)-3-sulfanylpropanoic acid Bound to Activated Porcine Pancreatic Carboxypeptidase B 3MF7 ; 1.65 ; Crystal Structure of (R)-oxirane-2-carboxylate inhibited cis-CaaD 4DQH ; 1.79 ; Crystal Structure of (R14C/E65C) HIV-1 Protease in complex with DRV 2F6U ; 1.55 ; Crystal Structure of (S)-3-O-Geranylgeranylglyceryl Phosphate Synthase complexed with citrate 2F6X ; 2 ; Crystal Structure of (S)-3-O-Geranylgeranylglyceryl Phosphate Synthase complexed with sn-G1P and MPD 4E2Q ; 2.5 ; Crystal Structure of (S)-Ureidoglycine Aminohydrolase from Arabidopsis thaliana 4E2S ; 2.59 ; Crystal structure of (S)-Ureidoglycine Aminohydrolase from Arabidopsis thaliana in complex with its substrate, (S)-Ureidoglycine 2C8L ; 3.1 ; CRYSTAL STRUCTURE OF (SR) CALCIUM-ATPASE E2(TG) FORM 2C8K ; 2.8 ; CRYSTAL STRUCTURE OF (SR) CALCIUM-ATPASE E2(TG) WITH PARTIALLY OCCUPIED AMPPCP SITE 2C88 ; 3.1 ; CRYSTAL STRUCTURE OF (SR) CALCIUM-ATPASE E2(TG):AMPPCP FORM 2PD2 ; 2.06 ; Crystal structure of (ST0148) conserved hypothetical from Sulfolobus Tokodaii Strain7 3VFZ ; 1.901 ; Crystal structure of -35 promoter binding domain of SigD of Mycobacterium tuberculosis 2EAB ; 1.12 ; Crystal structure of 1,2-a-L-fucosidase from Bifidobacterium bifidum (apo form) 2EAC ; 2.1 ; Crystal structure of 1,2-a-L-fucosidase from Bifidobacterium bifidum in complex with deoxyfuconojirimycin 2EAD ; 1.89 ; Crystal structure of 1,2-a-L-fucosidase from Bifidobacterium bifidum in complex with substrate 2EAE ; 1.8 ; Crystal structure of 1,2-a-L-fucosidase from Bifidobacterium bifidum in complexes with products 1JA9 ; 1.5 ; Crystal structure of 1,3,6,8-tetrahydroxynaphthalene reductase in complex with NADPH and pyroquilon 1U0M ; 2.22 ; Crystal Structure of 1,3,6,8-Tetrahydroxynaphthalene Synthase (THNS) from Streptomyces coelicolor A3(2): a Bacterial Type III Polyketide Synthase (PKS) Provides Insights into Enzymatic Control of Reactive Polyketide Intermediates 1FGG ; 2.3 ; CRYSTAL STRUCTURE OF 1,3-GLUCURONYLTRANSFERASE I (GLCAT-I) COMPLEXED WITH GAL-GAL-XYL, UDP, AND MN2+ 3VSF ; 2.757 ; Crystal structure of 1,3Gal43A, an exo-beta-1,3-Galactanase from Clostridium thermocellum 1W91 ; 2.2 ; CRYSTAL STRUCTURE OF 1,4-BETA-D-XYLAN XYLOHYDROLASE SOLVE USING ANOMALOUS SIGNAL FROM SELENIOMETHIONINE 3VSJ ; 2.3 ; Crystal structure of 1,6-APD (2-ANIMOPHENOL-1,6-DIOXYGENASE) complexed with intermediate products 1M2P ; 2 ; Crystal structure of 1,8-di-hydroxy-4-nitro-anthraquinone/CK2 kinase complex 1M2Q ; 1.79 ; Crystal structure of 1,8-di-hydroxy-4-nitro-xanten-9-one/CK2 kinase complex 2XX9 ; 1.97 ; CRYSTAL STRUCTURE OF 1-((2-FLUORO-4-(3-(TRIFLUOROMETHYL)-4,5,6,7-TETRAHYDRO-1H-INDAZOL-1-YL)PHENYL)METHYL)-2-PYRROLIDINONE IN COMPLEX WITH THE LIGAND BINDING DOMAIN OF THE RAT GLUA2 RECEPTOR AND GLUTAMATE AT 2.2A RESOLUTION. 2XXI ; 1.6 ; CRYSTAL STRUCTURE OF 1-((4-(3-(TRIFLUOROMETHYL)-6,7-DIHYDROPYRANO(4,3 -C(PYRAZOL-1(4H)-YL)PHENYL)METHYL)-2-PYRROLIDINONE IN COMPLEX WITH THE LIGAND BINDING DOMAIN OF THE RAT GLUA2 RECEPTOR AND GLUTAMATE AT 1.6A RESOLUTION. 2XX7 ; 2.2 ; CRYSTAL STRUCTURE OF 1-(4-(1-PYRROLIDINYLCARBONYL)PHENYL)-3-(TRIFLUOROMETHYL)-4,5,6,7-TETRAHYDRO-1H-INDAZOLE IN COMPLEX WITH THE LIGAND BINDING DOMAIN OF THE RAT GLUA2 RECEPTOR AND GLUTAMATE AT 2.2A RESOLUTION. 2XXH ; 1.5 ; CRYSTAL STRUCTURE OF 1-(4-(2-OXO-2-(1-PYRROLIDINYL)ETHYL)PHENYL)-3-(TRIFLUOROMETHYL)-4,5,6,7-TETRAHYDRO-1H-INDAZOLE IN COMPLEX WITH THE LIGAND BINDING DOMAIN OF THE RAT GLUA2 RECEPTOR AND GLUTAMATE AT 1.5A RESOLUTION. 4GJ1 ; 2.152 ; Crystal structure of 1-(5-phosphoribosyl)-5-[(5-phosphoribosylamino)methylideneamino] imidazole-4-carboxamide isomerase (hisA). 3G2I ; 2 ; Crystal structure of 1-(beta-D-glucopyranosyl)-4-substituted-1,2,3-triazole 3G2K ; 2 ; Crystal structure of 1-(beta-D-glucopyranosyl)-4-substituted-1,2,3-triazole 3G2H ; 2.03 ; Crystal structure of 1-(beta-D-glucopyranosyl)-4-substituted-1,2,3-triazoles in complex with glycogen phosphorylase 3G2J ; 2.14 ; Crystal structure of 1-(beta-D-glucopyranosyl)-4-substituted-1,2,3-triazoles in complex with glycogen phosphorylase 3G2L ; 2.3 ; Crystal structure of 1-(beta-D-glucopyranosyl)-4-substituted-1,2,3-triazoles in complex with glycogen phosphorylase 1TZJ ; 1.99 ; Crystal Structure of 1-aminocyclopropane-1-carboxylate deaminase complexed with d-vinyl glycine 1TZK ; 2 ; Crystal structure of 1-aminocyclopropane-1-carboxylate-deaminase complexed with alpha-keto-butyrate 1TZ2 ; 2.1 ; Crystal structure of 1-aminocyclopropane-1-carboyxlate deaminase complexed with ACC 1TYZ ; 2 ; Crystal structure of 1-Aminocyclopropane-1-carboyxlate Deaminase from Pseudomonas 3ANM ; 2 ; Crystal structure of 1-deoxy-D-xylulose 5-phosphate reductoisomerase (DXR) complexed with 5-phenylpyridin-2-ylmethylphosphonic acid 3RAS ; 2.55 ; Crystal structure of 1-deoxy-D-xylulose 5-phosphate reductoisomerase (DXR) complexed with a lipophilic phosphonate inhibitor 3ANL ; 2.1 ; Crystal structure of 1-deoxy-D-xylulose 5-phosphate reductoisomerase (DXR) complexed with pyridin-2-ylmethylphosphonic acid 3ANN ; 2 ; Crystal structure of 1-deoxy-D-xylulose 5-phosphate reductoisomerase (DXR) complexed with quinolin-2-ylmethylphosphonic acid 2EGH ; 2.2 ; Crystal structure of 1-deoxy-D-xylulose 5-phosphate reductoisomerase complexed with a magnesium ion, NADPH and fosmidomycin 1R0K ; 1.91 ; Crystal structure of 1-deoxy-D-xylulose 5-phosphate reductoisomerase from Zymomonas mobilis 1JVS ; 2.2 ; Crystal structure of 1-deoxy-D-xylulose 5-phosphate reductoisomerase; a target enzyme for antimalarial drugs 3QAN ; 1.95 ; Crystal structure of 1-pyrroline-5-carboxylate dehydrogenase from bacillus halodurans 3RJL ; 2.2 ; Crystal structure of 1-pyrroline-5-carboxylate dehydrogenase from Bacillus licheniformis (Target NYSGRC-000337) 2AMF ; 2.2 ; Crystal structure of 1-Pyrroline-5-Carboxylate Reductase from Human Pathogen Streptococcus Pyogenes 3CQZ ; 2.8 ; Crystal structure of 10 subunit RNA polymerase II in complex with the inhibitor alpha-amanitin 4FQ2 ; 1.9 ; Crystal Structure of 10-1074 Fab 3O41 ; 1.95 ; Crystal Structure of 101F Fab Bound to 15-mer Peptide Epitope 3O45 ; 2.872 ; Crystal Structure of 101F Fab Bound to 17-mer Peptide Epitope 4G6F ; 2.1 ; Crystal Structure of 10E8 Fab in Complex with an HIV-1 gp41 Peptide 4HX5 ; 2.19 ; Crystal structure of 11 beta-HSD1 in complex with SAR184841 3A1L ; 2.5 ; Crystal Structure of 11,11'-Dichlorochromopyrrolic Acid Bound Cytochrome P450 StaP (CYP245A1) 3TFQ ; 1.8 ; Crystal structure of 11b-hsd1 double mutant (l262r, f278e) complexed with 8-{[(2-CYANOPYRIDIN-3-YL)METHYL]SULFANYL}-6-HYDROXY-3,4-DIHYDRO-1H-PYRANO[3,4-C]PYRIDINE-5-CARBONITRILE 3D5Q ; 2.55 ; Crystal Structure of 11b-HSD1 in Complex with Triazole Inhibitor 3FRJ ; 2.3 ; Crystal Structure of 11b-Hydroxysteroid Dehydrogenase-1 (11b-HSD1) in Complex with Piperidyl Benzamide Inhibitor 3CH6 ; 2.35 ; Crystal Structure of 11beta-HSD1 Double Mutant (L262R, F278E) Complexed with (3,3-dimethylpiperidin-1-yl)(6-(3-fluoro-4-methylphenyl)pyridin-2-yl)methanone 3FCO ; 2.65 ; Crystal Structure of 11beta-Hydroxysteroid Dehydrogenase 1 (11b-HSD1) in Complex with Benzamide Inhibitor 3QQP ; 2.72 ; Crystal Structure of 11beta-Hydroxysteroid Dehydrogenase 1 (11b-HSD1) in Complex with Urea Inhibitor 3OQ1 ; 2.6 ; Crystal Structure of 11beta-Hydroxysteroid Dehydrogenase-1 (11b-HSD1) in Complex with Diarylsulfone Inhibitor 1ICS ; 2.3 ; CRYSTAL STRUCTURE OF 12-OXOPHYTODIENOATE REDUCTASE 1 FROM TOMATO 1ICQ ; 2 ; CRYSTAL STRUCTURE OF 12-OXOPHYTODIENOATE REDUCTASE 1 FROM TOMATO COMPLEXED WITH 9R,13R-OPDA 1ICP ; 1.9 ; CRYSTAL STRUCTURE OF 12-OXOPHYTODIENOATE REDUCTASE 1 FROM TOMATO COMPLEXED WITH PEG400 2HSA ; 1.5 ; Crystal structure of 12-oxophytodienoate reductase 3 (OPR3) from tomato 2OV3 ; 2.4 ; Crystal structure of 138-173 ZnuA deletion mutant plus zinc bound 3UAL ; 1.8 ; Crystal Structure of 14-3-3 epsilon with Mlf1 peptide 3UZD ; 1.86 ; Crystal structure of 14-3-3 GAMMA 2B05 ; 2.55 ; Crystal Structure of 14-3-3 gamma in complex with a phosphoserine peptide 4F7R ; 3.2 ; Crystal structure of 14-3-3 protein from Giardia intestinalis 2GDZ ; 1.65 ; Crystal structure of 15-hydroxyprostaglandin dehydrogenase type1, complexed with NAD+ 1Z7F ; 2.1 ; Crystal structure of 16 base pair RNA duplex containing a C-A mismatch 4J3C ; 2 ; Crystal structure of 16S ribosomal RNA methyltransferase RsmE 2DYI ; 2 ; Crystal structure of 16S ribosomal RNA processing protein RimM from Thermus thermophilus HB8 3MTE ; 1.805 ; Crystal Structure of 16S rRNA Methyltranferase 3MQ2 ; 1.69 ; Crystal Structure of 16S rRNA Methyltranferase KamB 2PJD ; 2.1 ; Crystal structure of 16S rRNA methyltransferase RsmC 4E8B ; 2.249 ; Crystal structure of 16S rRNA Methyltransferase RsmE from E.coli 2HE5 ; 2.9 ; Crystal structure of 17alpha-hydroxysteroid dehydrogenase in binary complex with NADP(H) in an open conformation 2HEJ ; 1.35 ; Crystal structure of 17alpha-hydroxysteroid dehydrogenase in complex with NADP(H) in a closed conformation 2IPF ; 1.85 ; Crystal structure of 17alpha-hydroxysteroid dehydrogenase in complex with NADP+ and epi-testosterone 2HE8 ; 1.9 ; Crystal structure of 17alpha-hydroxysteroid dehydrogenase in its apo-form 2IPG ; 1.9 ; Crystal structure of 17alpha-hydroxysteroid dehydrogenase mutant K31A in complex with NADP+ and epi-testosterone 3DEY ; 1.7 ; Crystal structure of 17beta-HSD1 with DHT in normal and reverse orientation. 3IS3 ; 1.48 ; Crystal structure of 17beta-Hydroxysteroid dehydrogenase (Apo form) from fungus Cochliobolus lunatus 1JTV ; 1.54 ; Crystal structure of 17beta-Hydroxysteroid Dehydrogenase Type 1 complexed with Testosterone 4JUG ; 2.7 ; Crystal structure of 1918 pandemic influenza virus hemagglutinin mutant D225G 4JUH ; 2.805 ; Crystal structure of 1918 pandemic influenza virus hemagglutinin mutant D225G complexed with avian receptor analogue LSTa 4JUJ ; 3.013 ; Crystal structure of 1918 pandemic influenza virus hemagglutinin mutnat D225G complexed with human receptor analogue LSTc 3TIA ; 1.8 ; Crystal structure of 1957 pandemic H2N2 neuraminidase complexed with laninamivir 3TIB ; 2.201 ; Crystal structure of 1957 pandemic H2N2 neuraminidase complexed with laninamivir octanoate 3TIC ; 1.89 ; Crystal structure of 1957 pandemic H2N2 neuraminidase complexed with zanamivir 3W6I ; 2.693 ; Crystal structure of 19F probe-labeled hCAI 3W6H ; 2.964 ; Crystal structure of 19F probe-labeled hCAI in complex with acetazolamide 4E5C ; 1.7 ; Crystal Structure of 19mer double-helical RNA containing CUG/CGG-repeats 1C0G ; 2 ; CRYSTAL STRUCTURE OF 1:1 COMPLEX BETWEEN GELSOLIN SEGMENT 1 AND A DICTYOSTELIUM/TETRAHYMENA CHIMERA ACTIN (MUTANT 228: Q228K/T229A/A230Y/E360H) 2O5X ; 2.05 ; Crystal structure of 1E9 LeuH47Trp/ArgH100Trp, an engineered Diels-Alderase Fab with nM steroid-binding affinity 3O2V ; 2.3 ; Crystal structure of 1E9 PheL89Ser/LeuH47Trp/MetH100bPhe, an engineered Diels-Alderase Fab with modified specificity and catalytic activity 3MKP ; 2.81 ; Crystal structure of 1K1 mutant of Hepatocyte Growth Factor/Scatter Factor fragment NK1 in complex with heparin 1VGJ ; 1.94 ; Crystal structure of 2'-5' RNA ligase from Pyrococcus horikoshii 3H5X ; 1.77 ; Crystal Structure of 2'-amino-2'-deoxy-cytidine-5'-triphosphate bound to Norovirus GII RNA polymerase 2R9Q ; 2.2 ; Crystal structure of 2'-deoxycytidine 5'-triphosphate deaminase from Agrobacterium tumefaciens 1I7J ; 1.19 ; CRYSTAL STRUCTURE OF 2'-O-ME(CGCGCG)2: AN RNA DUPLEX AT 1.19 A RESOLUTION. 2-METHYL-2,4-PENTANEDIOL AND MAGNESIUM BINDING. 310D ; 1.3 ; Crystal structure of 2'-O-Me(CGCGCG)2: an RNA duplex at 1.3 A resolution. Hydration pattern of 2'-O-methylated RNA 3VB0 ; 2.1 ; Crystal structure of 2,2',3-trihydroxybiphenyl 1,2-dioxygenase from dibenzofuran-degrading Sphingomonas wittichii strain RW1 3EG4 ; 1.87 ; Crystal structure of 2,3,4,5-Tetrahydropyridine-2-carboxylate N-Succinyltransferase from Brucella melitensis biovar abortus 2308 3CJ8 ; 1.95 ; Crystal structure of 2,3,4,5-tetrahydropyridine-2-carboxylate N-succinyltransferase from Enterococcus faecalis V583 3LM4 ; 1.8 ; Crystal Structure of 2,3-Dihydroxy Biphenyl dioxygenase from Rhodococcus sp. (strain RHA1) 1KW3 ; 1.45 ; Crystal structure of 2,3-dihydroxybiphenyal dioxygenase (BphC) at 1.45 A resolution 1LKD ; 1.7 ; CRYSTAL STRUCTURE OF 2,3-DIHYDROXYBIPHENYL 1,2-DIOXYGENASE (DHBD) COMPLEXED WITH 2',6'-DICL DIHYDROXYBIPHENYL (DHB) 1LGT ; 1.7 ; CRYSTAL STRUCTURE OF 2,3-DIHYDROXYBIPHENYL 1,2-DIOXYGENASE (DHBD) COMPLEXED WITH 2'-Cl DIHYDROXYBIPHENYL (DHB) 1KMY ; 2 ; Crystal Structure of 2,3-dihydroxybiphenyl 1,2-dioxygenase Complexed with 2,3-dihydroxybiphenyl under Anaerobic Condition 1KNF ; 1.9 ; Crystal Structure of 2,3-dihydroxybiphenyl 1,2-dioxygenase Complexed with 3-methyl Catechol under Anaerobic Condition 1KND ; 1.9 ; Crystal Structure of 2,3-dihydroxybiphenyl 1,2-dioxygenase Complexed with Catechol under Anaerobic Condition 1KW6 ; 1.45 ; Crystal structure of 2,3-dihydroxybiphenyl dioxygenase (BphC) in complex with 2,3-dihydroxybiphenyl at 1.45 A resolution 1KW9 ; 1.95 ; Crystal structure of 2,3-dihydroxybiphenyl dioxygenase (BphC) in complex with 2,3-dihydroxybiphenyl at 2.0A resolution 2ZVI ; 2.3 ; Crystal structure of 2,3-diketo-5-methylthiopentyl-1-phosphate enolase from Bacillus subtilis 3FA4 ; 2.18 ; Crystal structure of 2,3-dimethylmalate lyase, a PEP mutase/isocitrate lyase superfamily member, triclinic crystal form 3FA3 ; 2.6 ; Crystal structure of 2,3-dimethylmalate lyase, a PEP mutase/isocitrate lyase superfamily member, trigonal crystal form 1VP5 ; 2.4 ; Crystal structure of 2,5-diketo-D-gluconic acid reductase (TM1009) from Thermotoga maritima at 2.40 A resolution 2DVU ; 1.9 ; Crystal Structure of 2,6-Dihydroxybenzoate Decarboxylase Complexed with 2,6-Dihydroxybenzoate 2DVX ; 1.7 ; Crystal Structure of 2,6-Dihydroxybenzoate Decarboxylase Complexed with inhibitor 2,3-dihydroxybenzaldehyde 2DVT ; 1.7 ; Crystal Structure of 2,6-Dihydroxybenzoate Decarboxylase from Rhizobium 1ZG7 ; 1.75 ; Crystal Structure of 2-(5-{[amino(imino)methyl]amino}-2-chlorophenyl)-3-sulfanylpropanoic acid Bound to Activated Porcine Pancreatic Carboxypeptidase B 3R74 ; 2.9 ; Crystal structure of 2-amino-2-desoxyisochorismate synthase (ADIC) synthase PhzE from Burkholderia lata 383 3R76 ; 2.6 ; Crystal structure of 2-amino-2-desoxyisochorismate synthase (ADIC) synthase PhzE from Burkholderia lata 383 in complex with benzoate, pyruvate and glutamine 3R75 ; 2.1 ; Crystal structure of 2-amino-2-desoxyisochorismate synthase (ADIC) synthase PhzE from Burkholderia lata 383 in complex with benzoate, pyruvate, glutamine and contaminating Zn2+ 1M32 ; 2.2 ; Crystal Structure of 2-aminoethylphosphonate Transaminase 1T0D ; 2.2 ; Crystal Structure of 2-aminopurine labelled bacterial decoding site RNA 1T0E ; 1.7 ; Crystal Structure of 2-aminopurine labelled bacterial decoding site RNA 1KNK ; 2.8 ; Crystal Structure of 2-C-methyl-D-erythritol 2,4-cyclodiphosphate Synthase (ispF) from E. coli involved in Mevalonate-Independent Isoprenoid Biosynthesis 3QHD ; 1.7 ; Crystal structure of 2-C-METHYL-D-ERYTHRITOL 2,4-CYCLODIPHOSPHATE Synthase from BURKHOLDERIA PSEUDOMALLEI bound to CYTIDINE, FOL795 and FOL955 3P10 ; 1.7 ; Crystal structure of 2-C-methyl-D-erythritol 2,4-cyclodiphosphate synthase from Burkholderia pseudomallei with cytidine and FOL694, 2-(thiophen-2-yl)phenyl methanol 3P0Z ; 1.95 ; Crystal structure of 2-C-methyl-D-erythritol 2,4-cyclodiphosphate synthase from Burkholderia pseudomallei with cytidine and FOL955, 4-(1H-imidazol)-1-yl)phenol 3RE3 ; 2.645 ; Crystal Structure of 2-C-Methyl-D-Erythritol 2,4-Cyclodiphosphate Synthase from Francisella tularensis 3T80 ; 2.5 ; Crystal structure of 2-C-methyl-D-erythritol 2,4-cyclodiphosphate synthase from Salmonella typhimurium bound to cytidine 3FPI ; 2.8 ; Crystal Structure of 2-C-Methyl-D-Erythritol 2,4-Cyclodiphosphate Synthase IspF complexed with Cytidine Triphosphate 3F6M ; 2.96 ; Crystal Structure of 2-C-methyl-D-erythritol 2,4-cyclodiphosphate synthase IspF from Yersinia pestis 3N9W ; 1.9 ; Crystal structure of 2-C-methyl-D-erythritol 4-phosphate cytidylyltransferase (IspD) in complex with 1,2-Propanediol 1VPA ; 2.67 ; Crystal structure of 2-C-methyl-D-erythritol 4-phosphate cytidylyltransferase (TM1393) from Thermotoga maritima at 2.67 A resolution 3F1C ; 2.3 ; CRYSTAL STRUCTURE OF 2-C-methyl-D-erythritol 4-phosphate cytidylyltransferase from Listeria monocytogenes 2PX7 ; 2.2 ; Crystal structure of 2-C-methyl-D-erythritol 4-phosphate cytidylyltransferase from Thermus thermophilus HB8 1M5A ; 1.2 ; Crystal Structure of 2-Co(2+)-Insulin at 1.2A Resolution 2AFB ; 2.05 ; Crystal structure of 2-dehydro-3- deoxygluconokinase (EC 2.7.1.45) (tm0067) from THERMOTOGA MARITIMA at 2.05 A resolution 3NZR ; 1.9 ; Crystal structure of 2-dehydro-3-deoxyphosphogluconate aldolase from Vibrio fischeri ES114 1VLW ; 2.3 ; Crystal structure of 2-dehydro-3-deoxyphosphogluconate aldolase/4-hydroxy-2-oxoglutarate aldolase (TM0066) from Thermotoga maritima at 2.30 A resolution 3FS2 ; 1.85 ; Crystal structure of 2-Dehydro-3-Deoxyphosphooctonate aldolase from Bruciella melitensis at 1.85A resolution 3T4C ; 1.95 ; Crystal structure of 2-dehydro-3-deoxyphosphooctonate aldolase from Burkholderia ambifaria 3TML ; 1.9 ; Crystal structure of 2-dehydro-3-deoxyphosphooctonate aldolase from Burkholderia cenocepacia 3SZ8 ; 2.05 ; Crystal structure of 2-dehydro-3-deoxyphosphooctonate aldolase from Burkholderia pseudomallei 3E9A ; 1.8 ; Crystal structure of 2-dehydro-3-deoxyphosphooctonate aldolase from Vibrio cholerae O1 biovar eltor str. N16961 3HN2 ; 2.5 ; Crystal structure of 2-dehydropantoate 2-reductase FROM Geobacter metallireducens GS-15 3I83 ; 1.9 ; Crystal structure of 2-dehydropantoate 2-reductase from Methylococcus capsulatus 2QYT ; 2.15 ; Crystal structure of 2-dehydropantoate 2-reductase from Porphyromonas gingivalis W83 2D2X ; 2.3 ; Crystal structure of 2-deoxy-scyllo-inosose synthase 2GRU ; 2.15 ; Crystal structure of 2-deoxy-scyllo-inosose synthase complexed with carbaglucose-6-phosphate, NAD+ and Co2+ 2VCY ; 2.41 ; CRYSTAL STRUCTURE OF 2-ENOYL THIOESTER REDUCTASE OF HUMAN FAS II 1PN4 ; 2.35 ; Crystal structure of 2-enoyl-CoA hydratase 2 domain of Candida tropicalis multifunctional enzyme type 2 complexed with (3R)-hydroxydecanoyl-CoA. 3Q8F ; 2.1 ; Crystal structure of 2-Fluorohistine labeled Protective Antigen (pH 5.8) 3VAY ; 1.979 ; Crystal structure of 2-Haloacid Dehalogenase from Pseudomonas syringae pv. Tomato DC3000 1WLY ; 1.3 ; Crystal Structure of 2-Haloacrylate Reductase 3QDF ; 2.05 ; Crystal structure of 2-hydroxyhepta-2,4-diene-1,7-dioate isomerase from Mycobacterium marinum 1SV6 ; 2.9 ; Crystal structure of 2-hydroxypentadienoic acid hydratase from Escherichia Coli 1MXS ; 2.2 ; Crystal structure of 2-keto-3-deoxy-6-phosphogluconate (KDPG) aldolase from Pseudomonas putida. 1WYE ; 2.8 ; Crystal structure of 2-keto-3-deoxygluconate kinase (form 1) from Sulfolobus Tokodaii 2DCN ; 2.25 ; Crystal structure of 2-keto-3-deoxygluconate kinase from Sulfolobus tokodaii complexed with 2-keto-6-phosphogluconate (alpha-furanose form) 3GMB ; 2.1 ; Crystal Structure of 2-Methyl-3-hydroxypyridine-5-carboxylic acid Oxygenase 3GMC ; 2.1 ; Crystal Structure of 2-Methyl-3-hydroxypyridine-5-carboxylic acid Oxygenase with substrate bound 3ALI ; 1.77 ; Crystal structure of 2-methyl-3-hydroxypyridine-5-carboxylic acid oxygenase, 5-pyridoxic acid bound form 3ALM ; 1.77 ; Crystal structure of 2-methyl-3-hydroxypyridine-5-carboxylic acid oxygenase, mutant C294A 3ALL ; 1.78 ; Crystal structure of 2-methyl-3-hydroxypyridine-5-carboxylic acid oxygenase, mutant Y270A 3ALK ; 2.3 ; Crystal structure of 2-methyl-3-hydroxypyridine-5-carboxylic acid oxygenase, mutant Y270F 3ALJ ; 1.48 ; Crystal structure of 2-methyl-3-hydroxypyridine-5-carboxylic acid oxygenase, reduced form 1SZQ ; 2.7 ; Crystal Structure of 2-methylcitrate dehydratase 3O8J ; 2.41 ; Crystal structure of 2-methylcitrate synthase (PrpC) from Salmonella typhimurium 3V1X ; 1.955 ; Crystal structure of 2-methylisoborneol synthase from Streptomyces coelicolor A3(2) in complex with Mg2+ and 2-fluorogeranyl diphosphate 3V1V ; 1.8 ; Crystal structure of 2-methylisoborneol synthase from Streptomyces coelicolor A3(2) in complex with Mg2+ and geranyl-S-thiolodiphosphate 1UJQ ; 2.1 ; Crystal structure of 2-methylisocitrate lyase (PrpB) from Salmonella enterica serovar typhimurium 2GJL ; 2 ; Crystal Structure of 2-nitropropane dioxygenase 2GJN ; 2.3 ; crystal structure of 2-nitropropane dioxygenase complexed with FMN and substrate 3R1X ; 2.093 ; Crystal structure of 2-oxo-3-deoxygalactonate kinase from Klebsiella pneumoniae 3O7H ; 1.79 ; Crystal structure of 2-oxo-4-hydroxy-4-carboxy-5-ureidoimidazoline decarboxylase from Klebsiella pneumoniae 3O7I ; 1.5 ; Crystal structure of 2-oxo-4-hydroxy-4-carboxy-5-ureidoimidazoline decarboxylase from Klebsiella pneumoniae 3O7J ; 2 ; Crystal structure of 2-oxo-4-hydroxy-4-carboxy-5-ureidoimidazoline decarboxylase from Klebsiella pneumoniae 3O7K ; 1.98 ; Crystal structure of 2-oxo-4-hydroxy-4-carboxy-5-ureidoimidazoline decarboxylase from Klebsiella pneumoniae 3C3E ; 3 ; Crystal structure of 2-phospho-(S)-lactate transferase from Methanosarcina mazei in complex with Fo and GDP. Northeast Structural Genomics Consortium target MaR46 3C3D ; 2.5 ; Crystal structure of 2-phospho-(S)-lactate transferase from Methanosarcina mazei in complex with Fo and phosphate. Northeast Structural Genomics Consortium target MaR46 3CGW ; 3.1 ; Crystal structure of 2-phospho-(S)-lactate transferase from Methanosarcina mazei. Northeast Structural Genomics Consortium target MaR46 3HGD ; 1.57 ; Crystal Structure of 2-Se-Thymidine Derivatized DNA 4F4N ; 1.3 ; Crystal structure of 2-se-thymidine derivatized dna 8mer 3LQ1 ; 2.6 ; Crystal structure of 2-succinyl-6-hydroxy-2,4-cyclohexadiene 1-carboxylic acid synthase/2-oxoglutarate decarboxylase FROM Listeria monocytogenes str. 4b F2365 3TI3 ; 1.8 ; Crystal structure of 2009 pandemic H1N1 neuraminidase complexed with laninamivir 3TI4 ; 1.602 ; Crystal structure of 2009 pandemic H1N1 neuraminidase complexed with laninamivir octanoate 3TI6 ; 1.69 ; Crystal structure of 2009 pandemic H1N1 neuraminidase complexed with oseltamivir 3TI5 ; 1.9 ; Crystal structure of 2009 pandemic H1N1 neuraminidase complexed with Zanamivir 4JTV ; 2.997 ; Crystal structure of 2009 pandemic influenza virus hemagglutinin complexed with human receptor analogue LSTc 4JTX ; 2.997 ; Crystal structure of 2009 pandemic influenza virus hemagglutinin mutant D225E 4JU0 ; 2.908 ; Crystal structure of 2009 pandemic influenza virus hemagglutinin mutant D225E complexed with human receptor analogue LSTc 2R40 ; 2.402 ; Crystal structure of 20E bound EcR/USP 3HYE ; 2.5 ; Crystal structure of 20S proteasome in complex with hydroxylated salinosporamide 4EU2 ; 2.509 ; Crystal structure of 20s proteasome with novel inhibitor K-7174 2Z6X ; 2.3 ; Crystal structure of 22G, the wild-type protein of the photoswitchable GFP-like protein Dronpa 3IF1 ; 2.39 ; Crystal structure of 237mAb in complex with a GalNAc 3IET ; 2.2 ; Crystal Structure of 237mAb with antigen 4DUH ; 1.5 ; Crystal structure of 24 kDa domain of E. coli DNA gyrase B in complex with small molecule inhibitor 3AF7 ; 1.58 ; Crystal Structure of 25Pd(allyl)/apo-Fr 3ISO ; 1.9 ; Crystal structure of 26 kDa GST of Clonorchis sinensis in P3221 symmetry 4ADY ; 2.7 ; Crystal structure of 26S proteasome subunit Rpn2 3CU1 ; 2.6 ; Crystal Structure of 2:2:2 FGFR2D2:FGF1:SOS complex 3ERN ; 2.1 ; Crystal structure of 2C-methyl-D-erythritol 2,4-clycodiphosphate synthase complexed with AraCMP 3ELC ; 2.5 ; Crystal structure of 2C-methyl-D-erythritol 2,4-clycodiphosphate synthase complexed with ligand 3EOR ; 2.9 ; Crystal structure of 2C-methyl-D-erythritol 2,4-clycodiphosphate synthase complexed with ligand 3ESJ ; 2.7 ; Crystal structure of 2C-methyl-D-erythritol 2,4-clycodiphosphate synthase complexed with ligand 3FBA ; 3.1 ; Crystal structure of 2C-methyl-D-erythritol 2,4-clycodiphosphate synthase complexed with ligand 1VHA ; 2.35 ; Crystal structure of 2C-methyl-D-erythritol 2,4-cyclodiphosphate synthase 3F0E ; 2.05 ; Crystal structure of 2C-methyl-D-erythritol 2,4-cyclodiphosphate synthase from Burkholderia pseudomallei 3K2X ; 1.85 ; Crystal structure of 2C-methyl-D-erythritol 2,4-cyclodiphosphate synthase from Burkholderia pseudomallei in complex with 5'-iodo-cytosine 3KE1 ; 2.05 ; Crystal structure of 2C-methyl-D-erythritol 2,4-cyclodiphosphate synthase from Burkholderia pseudomallei in complex with a fragment-nucleoside fusion D000161829 3Q8H ; 1.75 ; Crystal structure of 2c-methyl-d-erythritol 2,4-cyclodiphosphate synthase from burkholderia pseudomallei in complex with cytidine derivative EBSI01028 3IEW ; 2.1 ; Crystal structure of 2C-methyl-D-erythritol 2,4-cyclodiphosphate synthase from Burkholderia pseudomallei with bound CTP and CDP 3IEQ ; 2.1 ; Crystal structure of 2C-methyl-D-erythritol 2,4-cyclodiphosphate synthase from Burkholderia pseudomallei with cytidine 3IKE ; 2.3 ; Crystal structure of 2C-methyl-D-erythritol 2,4-cyclodiphosphate synthase from Burkholderia pseudomallei with cytosine 3MBM ; 1.8 ; Crystal structure of 2C-methyl-D-erythritol 2,4-cyclodiphosphate synthase from Burkholderia pseudomallei with cytosine and FoL fragment 717, imidazo[2,1-b][1,3]thiazol-6-ylmethanol 3IKF ; 2.07 ; Crystal structure of 2C-methyl-D-erythritol 2,4-cyclodiphosphate synthase from Burkholderia pseudomallei with FOL fragment 717, imidazo[2,,1-b][1,3]thiazol-6-ylmethanol 3B6N ; 2.26 ; Crystal structure of 2C-methyl-D-erythritol 2,4-cyclodiphosphate synthase PV003920 from Plasmodium vivax 3JVH ; 1.69 ; Crystal structure of 2C-methyl-D-erythritol-2,4-cyclodiphosphate synthase from Burkholderia pseudomallei with FOL fragment 8395 1T0A ; 1.6 ; Crystal Structure of 2C-Methyl-D-Erythritol-2,4-cyclodiphosphate Synthase from Shewanella Oneidensis 1RFK ; 1.25 ; Crystal Structure of 2Fe2S Ferredoxin from Thermophilic Cyanobacterium Mastigocladus Laminosus 2JIL ; 1.5 ; CRYSTAL STRUCTURE OF 2ND PDZ DOMAIN OF GLUTAMATE RECEPTOR INTERACTING PROTEIN-1 (GRIP1) 2IS5 ; 1.85 ; Crystal structure of 3 residues truncated version of protein NMB1012 from Neisseria meningitides 1J7L ; 2.2 ; Crystal Structure of 3',5""-Aminoglycoside Phosphotransferase Type IIIa ADP Complex 1L8T ; 2.4 ; Crystal Structure Of 3',5""-Aminoglycoside Phosphotransferase Type IIIa ADP Kanamycin A Complex 2B0Q ; 2.7 ; Crystal Structure Of 3',5""-Aminoglycoside Phosphotransferase Type IIIa ADP Neomycin B Complex 3TM0 ; 2.1 ; Crystal Structure of 3',5""-Aminoglycoside Phosphotransferase Type IIIa AMPPNP Butirosin A Complex 1J7U ; 2.4 ; Crystal Structure of 3',5""-Aminoglycoside Phosphotransferase Type IIIa AMPPNP Complex 1J7I ; 3.2 ; Crystal Structure of 3',5""-Aminoglycoside Phosphotransferase Type IIIa Apoenzyme 3Q2J ; 2.1501 ; Crystal Structure of 3',5""-Aminoglycoside Phosphotransferase Type IIIa Protein Kinase Inhibitor CKI-7 Complex 1G57 ; 1.4 ; CRYSTAL STRUCTURE OF 3,4-DIHYDROXY-2-BUTANONE 4-PHOSPHATE SYNTHASE 1K49 ; 1.5 ; Crystal Structure of 3,4-dihydroxy-2-butanone 4-phosphate synthase (cation free form) 3LQU ; 2.522 ; Crystal structure of 3,4-Dihydroxy-2-butanone 4-phosphate synthase complexed with Ribulose-5 phosphate 3MIO ; 1.8 ; Crystal structure of 3,4-dihydroxy-2-butanone 4-phosphate synthase domain from Mycobacterium tuberculosis at pH 6.00 3MK5 ; 2.06 ; Crystal structure of 3,4-dihydroxy-2-butanone 4-phosphate synthase domain from Mycobacterium tuberculosis with sulfate and zinc at pH 4.00 3H07 ; 1.95 ; Crystal structure of 3,4-dihydroxy-2-butanone 4-phosphate synthase from Yersinia pestis CO92 1G58 ; 1.55 ; CRYSTAL STRUCTURE OF 3,4-DIHYDROXY-2-BUTANONE 4-PHOSPHATE SYNTHASE GOLD DERIVATIVE 1K4O ; 1.1 ; Crystal Structure of 3,4-dihydroxy-2-butanone 4-phosphate synthase in complex with one Manganese, and a glycerol 3LS6 ; 1.86 ; Crystal structure of 3,4-Dihydroxy-2-butanone 4-phosphate synthase in complex with sulfate and zinc 3LRJ ; 2.803 ; Crystal structure of 3,4-Dihydroxy-2-butanone 4-phosphate synthase in complex with sulfate ion. 1K4I ; 0.98 ; Crystal Structure of 3,4-dihydroxy-2-butanone 4-phosphate synthase in complex with two Magnesium ions 1K4L ; 1.6 ; Crystal Structure of 3,4-dihydroxy-2-butanone 4-phosphate synthase in complex with two Manganese ions 1K4P ; 1 ; Crystal Structure of 3,4-dihydroxy-2-butanone 4-phosphate synthase in complex with zinc ions 1TKS ; 1.6 ; Crystal structure of 3,4-Dihydroxy-2-butanone 4-phosphate Synthase of Candida albicans 1TKU ; 1.66 ; Crystal Structure of 3,4-Dihydroxy-2-butanone 4-phosphate Synthase of Candida albicans in complex with Ribulose-5-phosphate 2RIS ; 1.6 ; Crystal structure of 3,4-dihydroxy-2-butanone 4-phosphate synthase of candida albicans- alternate interpretation 1B9H ; 2 ; CRYSTAL STRUCTURE OF 3-AMINO-5-HYDROXYBENZOIC ACID (AHBA) SYNTHASE 1B9I ; 2 ; CRYSTAL STRUCTURE OF 3-AMINO-5-HYDROXYBENZOIC ACID (AHBA) SYNTHASE 1F8M ; 1.8 ; CRYSTAL STRUCTURE OF 3-BROMOPYRUVATE MODIFIED ISOCITRATE LYASE (ICL) FROM MYCOBACTERIUM TUBERCULOSIS 1RE5 ; 2.6 ; Crystal structure of 3-carboxy-cis,cis-muconate lactonizing enzyme from Pseudomonas putida 1MQ5 ; 2.1 ; Crystal Structure of 3-chloro-N-[4-chloro-2-[[(4-chlorophenyl)amino]carbonyl]phenyl]-4-[(4-methyl-1-piperazinyl)methyl]-2-thiophenecarboxamide Complexed with Human Factor Xa 1MQ6 ; 2.1 ; Crystal Structure of 3-chloro-N-[4-chloro-2-[[(5-chloro-2-pyridinyl)amino]carbonyl]-6-methoxyphenyl]-4-[[(4,5-dihydro-2-oxazolyl)methylamino]methyl]-2-thiophenecarboxamide Complexed with Human Factor Xa 2BOY ; 1.9 ; CRYSTAL STRUCTURE OF 3-CHLOROCATECHOL 1,2-DIOXYGENASE FROM RHODOCOCCUS OPACUS 1CP 1L9W ; 2.1 ; CRYSTAL STRUCTURE OF 3-DEHYDROQUINASE FROM SALMONELLA TYPHI COMPLEXED WITH REACTION PRODUCT 2YR1 ; 2 ; Crystal Structure of 3-dehydroquinate dehydratase from Geobacillus kaustophilus HTA426 3N76 ; 1.9 ; Crystal structure of 3-dehydroquinate dehydratase from Mycobacterium tuberculosis in complex with compound 5 3N7A ; 2 ; Crystal structure of 3-dehydroquinate dehydratase from Mycobacterium tuberculosis in complex with inhibitor 2 3N87 ; 2.4 ; Crystal structure of 3-dehydroquinate dehydratase from Mycobacterium tuberculosis in complex with inhibitor 3 3N86 ; 1.9 ; Crystal structure of 3-dehydroquinate dehydratase from Mycobacterium tuberculosis in complex with inhibitor 4 3N8N ; 2.5 ; Crystal structure of 3-dehydroquinate dehydratase from Mycobacterium tuberculosis in complex with inhibitor 6 1NUA ; 2.85 ; Crystal structure of 3-dehydroquinate synthase (DHQS) in complex with ZN2+ 1NVA ; 2.62 ; Crystal structure of 3-dehydroquinate synthase (DHQS) in complex with ZN2+ and ADP 1NVB ; 2.7 ; Crystal structure of 3-dehydroquinate synthase (DHQS) in complex with ZN2+ and carbaphosphonate 1NVD ; 2.51 ; Crystal structure of 3-dehydroquinate synthase (DHQS) in complex with ZN2+ and carbaphosphonate 1NRX ; 2.9 ; Crystal structure of 3-dehydroquinate synthase (DHQS) in complex with ZN2+ and NAD 1NVE ; 2.58 ; Crystal structure of 3-dehydroquinate synthase (DHQS) in complex with ZN2+ and NAD 1NVF ; 2.8 ; Crystal structure of 3-dehydroquinate synthase (DHQS) in complex with ZN2+, ADP and carbaphosphonate 1NR5 ; 2.1 ; Crystal structure of 3-dehydroquinate synthase (DHQS) in complex with ZN2+, NAD and carbaphosphonate 3CLH ; 2.4 ; Crystal structure of 3-dehydroquinate synthase (DHQS)from Helicobacter pylori 1VS1 ; 2.3 ; Crystal structure of 3-deoxy-D-arabino-heptulosonate-7-phosphate synthase (DAHP synthase) from Aeropyrum pernix in complex with Mn2+ and PEP 1RZM ; 2.2 ; Crystal structure of 3-deoxy-D-arabino-heptulosonate-7-phosphate synthase (DAHPS) from Thermotoga maritima complexed with Cd2+, PEP and E4P 2QKF ; 1.75 ; Crystal structure of 3-deoxy-d-manno-octulosonate 8-phosphate synthase (KDO8PS) from Neisseria meningitidis 3DUV ; 2.3 ; Crystal structure of 3-deoxy-manno-octulosonate cytidylyltransferase from Haemophilus influenzae complexed with the substrate 3-deoxy-manno-octulosonate in the-configuration 3AJX ; 1.6 ; Crystal Structure of 3-Hexulose-6-Phosphate Synthase 2RFQ ; 1.65 ; Crystal structure of 3-HSA hydroxylase from Rhodococcus sp. RHA1 1TVZ ; 2 ; Crystal structure of 3-hydroxy-3-methylglutaryl-coenzyme A synthase from Staphylococcus aureus 1ZCJ ; 1.9 ; Crystal structure of 3-hydroxyacyl-CoA dehydrogenase 3PPI ; 2 ; Crystal structure of 3-hydroxyacyl-CoA dehydrogenase type-2 from Mycobacterium avium 3FE5 ; 2.51 ; Crystal structure of 3-hydroxyanthranilate 3,4-dioxygenase from bovine kidney 1YFU ; 1.9 ; Crystal structure of 3-hydroxyanthranilate-3,4-dioxygenase from Ralstonia metallidurans 1YFY ; 3.2 ; Crystal structure of 3-hydroxyanthranilate-3,4-dioxygenase from Ralstonia metallidurans complexed with 3-hydroxyanthranilic acid 1YFX ; 2 ; Crystal structure of 3-hydroxyanthranilate-3,4-dioxygenase from Ralstonia metallidurans complexed with 4-chloro-3-hydroxyanthranilic acid and NO 1YFW ; 2 ; Crystal structure of 3-hydroxyanthranilate-3,4-dioxygenase from Ralstonia metallidurans complexed with 4-chloro-3-hydroxyanthranilic acid and O2 2DKH ; 1.8 ; Crystal structure of 3-hydroxybenzoate hydroxylase from Comamonas testosteroni, in complex with the substrate 2DKI ; 2.5 ; Crystal structure of 3-hydroxybenzoate hydroxylase from Comamonas testosteroni, under pressure of xenon gas (12 atm) 3MOG ; 2.2 ; Crystal structure of 3-hydroxybutyryl-CoA dehydrogenase from Escherichia coli K12 substr. MG1655 3Q62 ; 1.4 ; Crystal Structure of 3-hydroxydecanoyl-(acyl carrier protein) dehydratase from Yersinia pestis 4FQ9 ; 2.02 ; Crystal Structure of 3-hydroxydecanoyl-Acyl Carrier Protein Dehydratase (FabA) from Pseudomonas aeruginosa 4B0C ; 2.7 ; Crystal Structure of 3-hydroxydecanoyl-Acyl Carrier Protein Dehydratase (FabA) from Pseudomonas aeruginosa in complex with 3-(pentylthio)-4H-1,2,4-triazole 4B0B ; 1.9 ; Crystal Structure of 3-hydroxydecanoyl-Acyl Carrier Protein Dehydratase (FabA) from Pseudomonas aeruginosa in complex with 3-(pyridin-2-yloxy)aniline 4B0J ; 2.5 ; Crystal Structure of 3-hydroxydecanoyl-Acyl Carrier Protein Dehydratase (FabA) from Pseudomonas aeruginosa in complex with 5-(2- thienyl)-3-isoxazolyl methanol 4B8U ; 2.76 ; Crystal Structure of 3-hydroxydecanoyl-Acyl Carrier Protein Dehydratase (FabA) from Pseudomonas aeruginosa in complex with N- isobutyl-2-(5-(2-thienyl)-1,2-oxazol-3-yl-)methoxy)acetamide 4B0I ; 2.03 ; Crystal Structure of 3-hydroxydecanoyl-Acyl Carrier Protein Dehydratase (FabA) mutant (H70N) from Pseudomonas aeruginosa in complex with 3-hydroxydecanoyl-N-acetyl cysteamine 3G0O ; 1.8 ; Crystal structure of 3-hydroxyisobutyrate dehydrogenase (ygbJ) from Salmonella typhimurium 2PKP ; 2.1 ; Crystal structure of 3-isopropylmalate dehydratase (leuD)from Methhanocaldococcus Jannaschii DSM2661 (MJ1271) 1VLC ; 1.9 ; Crystal structure of 3-isopropylmalate dehydrogenase (TM0556) from Thermotoga maritima at 1.90 A resolution 1KV8 ; 1.62 ; Crystal Structure of 3-Keto-L-Gulonate 6-Phosphate Decarboxylase 1XBZ ; 1.8 ; Crystal structure of 3-keto-L-gulonate 6-phosphate decarboxylase E112D/R139V/T169A mutant with bound L-xylulose 5-phosphate 1XBV ; 1.66 ; Crystal structure of 3-keto-L-gulonate 6-phosphate decarboxylase with bound D-ribulose 5-phosphate 1KW1 ; 2.2 ; Crystal Structure of 3-Keto-L-Gulonate 6-Phosphate Decarboxylase with bound L-gulonate 6-phosphate 3IEB ; 2.1 ; Crystal structure of 3-keto-L-gulonate-6-phosphate decarboxylase from Vibrio cholerae O1 biovar El Tor str. N16961 4AFN ; 2.3 ; Crystal structure of 3-ketoacyl-(acyl-carrier-protein) reductase (FabG) from Pseudomonas aeruginosa at 2.3A resolution 4AG3 ; 1.8 ; Crystal structure of 3-ketoacyl-(acyl-carrier-protein) reductase (FabG) from Pseudomonas aeruginosa in complex with NADPH at 1.8A resolution 3RRO ; 2 ; Crystal structure of 3-ketoacyl-(acyl-carrier-protein) reductase (FabG) from Vibrio cholerae 3TZH ; 2.1 ; Crystal structure of 3-ketoacyl-(acyl-carrier-protein) reductase (FabG)(F187A) from Vibrio cholerae 3TZK ; 1.8 ; Crystal structure of 3-ketoacyl-(acyl-carrier-protein) reductase (FabG)(G92A) from Vibrio cholerae 3U09 ; 1.75 ; Crystal structure of 3-ketoacyl-(acyl-carrier-protein) reductase (FabG)(G92D) from Vibrio cholerae 3TZC ; 2.45 ; Crystal structure of 3-ketoacyl-(acyl-carrier-protein) reductase (FabG)(Y155F) from Vibrio cholerae 3N74 ; 2.2 ; Crystal structure of 3-ketoacyl-(acyl-carrier-protein) reductase from Brucella melitensis 3FTP ; 2.05 ; Crystal structure of 3-Ketoacyl-(acyl-carrier-protein) reductase from Burkholderia pseudomallei at 2.05 A resolution 3LLS ; 2.4 ; Crystal structure of 3-ketoacyl-(acyl-carrier-protein) reductase from Mycobacterium tuberculosis 3F9I ; 2.25 ; Crystal structure of 3-ketoacyl-(acyl-carrier-protein) reductase Rickettsia prowazekii 2ZYL ; 2.3 ; Crystal structure of 3-ketosteroid-9-alpha-hydroxylase (KshA) from M. tuberculosis 1OZ3 ; 1.85 ; Crystal Structure of 3-MBT repeats of lethal (3) malignant Brain Tumor (Native-I) at 1.85 angstrom 1OZ2 ; 1.55 ; CRYSTAL STRUCTURE OF 3-MBT REPEATS OF LETHAL (3) MALIGNANT BRAIN TUMOR (NATIVE-II) AT 1.55 ANGSTROM 1OYX ; 1.85 ; CRYSTAL STRUCTURE OF 3-MBT REPEATS OF LETHAL (3) MALIGNANT BRAIN TUMOR (SELENO-MET) AT 1.85 ANGSTROM 1O66 ; 1.75 ; Crystal structure of 3-methyl-2-oxobutanoate hydroxymethyltransferase 1O68 ; 2.1 ; Crystal structure of 3-methyl-2-oxobutanoate hydroxymethyltransferase 3EZ4 ; 2.1 ; Crystal structure of 3-methyl-2-oxobutanoate hydroxymethyltransferase from Burkholderia pseudomallei 3VAV ; 1.8 ; Crystal structure of 3-methyl-2-oxobutanoate hydroxymethyltransferase from Burkholderia thailandensis 2OFK ; 1.5 ; Crystal Structure of 3-methyladenine DNA glycosylase I (TAG) 2OFI ; 1.85 ; Crystal Structure of 3-methyladenine DNA Glycosylase I (TAG) bound to DNA/3mA 3UAN ; 1.844 ; Crystal structure of 3-O-sulfotransferase (3-OST-1) with bound PAP and heptasaccharide substrate 2IDB ; 2.9 ; Crystal Structure of 3-octaprenyl-4-hydroxybenzoate decarboxylase (UbiD) from Escherichia coli, Northeast Structural Genomics Target ER459. 4IMR ; 1.96 ; Crystal structure of 3-oxoacyl (acyl-carrier-protein) reductase (target EFI-506442) from agrobacterium tumefaciens C58 with NADP bound 1O5I ; 2.5 ; Crystal structure of 3-oxoacyl-(acyl carrier protein) reductase (TM1169) from Thermotoga maritima at 2.50 A resolution 3E60 ; 1.95 ; Crystal structure of 3-oxoacyl-(acyl carrier protein) synthase II from Bartonella henselae 3KZU ; 1.75 ; Crystal structure of 3-oxoacyl-(acyl carrier protein) synthase II from Brucella melitensis 3LED ; 1.45 ; Crystal structure of 3-oxoacyl-(acyl carrier protein) synthase III from Rhodopseudomonas palustris CGA009 3FK5 ; 2.05 ; Crystal structure of 3-oxoacyl-(acyl carrier protein) synthase III, FabH (Xoo4209) from Xanthomonas oryzae pv. oryzae KACC10331 2X3E ; 1.81 ; CRYSTAL STRUCTURE OF 3-OXOACYL-(ACYL CARRIER PROTEIN) SYNTHASE III, FABH FROM PSEUDOMONAS AERUGINOSA PAO1 4EFI ; 1.35 ; Crystal Structure of 3-oxoacyl-(Acyl-carrier protein) Synthase from Burkholderia Xenovorans LB400 1J3N ; 2 ; Crystal Structure of 3-oxoacyl-(acyl-carrier protein) Synthase II from Thermus thermophilus HB8 2PH3 ; 1.91 ; Crystal structure of 3-oxoacyl-[acyl carrier protein] reductase TTHA0415 from Thermus thermophilus 4JRO ; 1.92 ; Crystal structure of 3-oxoacyl-[acyl-carrier protein]reductase (FabG)from Listeria monocytogenes in complex with NADP+ 4DDO ; 1.9 ; Crystal structure of 3-oxoacyl-[acyl-carrier-protein] synthase ii from burkholderia vietnamiensis 4F32 ; 1.9 ; Crystal structure of 3-oxoacyl-[acyl-carrier-protein] synthase II from Burkholderia vietnamiensis in complex with platencin 2EBD ; 2.1 ; Crystal structure of 3-oxoacyl-[acyl-carrier-protein] synthase III from Aquifex aeolicus VF5 4DFE ; 2.35 ; Crystal structure of 3-oxoacyl-[acyl-carrier-protein] synthase III from Burkholderia xenovorans 3OZ7 ; 2.7 ; Crystal Structure of 3-Phosphopglycerate Kinase of Plasmodium falciparum 3R3T ; 2.302 ; Crystal Structure of 30S Ribosomal Protein S from Bacillus anthracis 1VMB ; 1.7 ; Crystal structure of 30S ribosomal protein S6 (TM0603) from Thermotoga maritima at 1.70 A resolution 3RF2 ; 2.16 ; Crystal Structure of 30S Ribosomal Protein S8 from Aquifex Aeolicus 1VQ0 ; 2.2 ; Crystal structure of 33 kDa chaperonin (Heat shock protein 33 homolog) (HSP33) (TM1394) from Thermotoga maritima at 2.20 A resolution 1ZGL ; 2.8 ; Crystal structure of 3A6 TCR bound to MBP/HLA-DR2a 3S96 ; 1.9 ; Crystal structure of 3B5H10 4GW4 ; 2.65 ; Crystal structure of 3BNC60 Fab with P61A mutation 2ZTY ; 1.72 ; crystal structure of 3C protease from CVB3 in space group C2 2ZTZ ; 2 ; crystal structure of 3C protease from CVB3 in space group P21 3ZZ3 ; 1.89 ; Crystal structure of 3C protease mutant (N126Y) of coxsackievirus B3 3ZZ4 ; 2.1 ; Crystal structure of 3C protease mutant (T68A and N126Y) of coxsackievirus B3 3ZZC ; 2.1 ; Crystal structure of 3C protease mutant (T68A and N126Y) of coxsackievirus B3 complexed with alpha, beta-unsaturated ethyl ester inhibitor 83 3ZZD ; 2.1 ; Crystal structure of 3C protease mutant (T68A and N126Y) of coxsackievirus B3 complexed with alpha, beta-unsaturated ethyl ester inhibitor 85 3ZYE ; 1.85 ; Crystal structure of 3C protease mutant (T68A) of coxsackievirus B3 3ZYD ; 1.7 ; Crystal structure of 3C protease of coxsackievirus B3 3ZZ5 ; 2.2 ; Crystal structure of 3C protease of coxsackievirus B3 complexed with alpha, beta-unsaturated ethyl ester inhibitor 74 3ZZ7 ; 1.8 ; Crystal structure of 3C protease of coxsackievirus B3 complexed with alpha, beta-unsaturated ethyl ester inhibitor 81 3ZZ8 ; 1.85 ; Crystal structure of 3C protease of coxsackievirus B3 complexed with alpha, beta-unsaturated ethyl ester inhibitor 82 3ZZ9 ; 1.9 ; Crystal structure of 3C protease of coxsackievirus B3 complexed with alpha, beta-unsaturated ethyl ester inhibitor 83 3ZZA ; 1.8 ; Crystal structure of 3C protease of coxsackievirus B3 complexed with alpha, beta-unsaturated ethyl ester inhibitor 84 3ZZB ; 2.1 ; Crystal structure of 3C protease of coxsackievirus B3 complexed with alpha, beta-unsaturated ethyl ester inhibitor 85 3ZZ6 ; 2.05 ; Crystal structure of 3C protease of coxsackievirus B3 complexed with Michael receptor inhibitor 75 3ZV8 ; 2.4 ; Crystal structure of 3C protease of Enterovirus 68 1JS0 ; 2.2 ; Crystal Structure of 3D Domain-swapped RNase A Minor Trimer 4HDI ; 2.449 ; Crystal Structure of 3E5 IgG3 FAB from mus musculus 3FJG ; 2.2 ; Crystal structure of 3PG bound PEB3 1QE1 ; 2.85 ; CRYSTAL STRUCTURE OF 3TC-RESISTANT M184I MUTANT OF HIV-1 REVERSE TRANSCRIPTASE 3QMN ; 1.85 ; Crystal Structure of 4'-Phosphopantetheinyl Transferase AcpS from Vibrio cholerae O1 biovar eltor 1UEK ; 1.7 ; Crystal structure of 4-(cytidine 5'-diphospho)-2C-methyl-D-erythritol kinase 3D6U ; 2.2 ; Crystal structure of 4-(trifluoromethyldiazirinyl)phenylalanyl-tRNA synthetase 3D6V ; 2.2 ; Crystal structure of 4-(trifluoromethyldiazirinyl)phenylalanyl-tRNA synthetase 1K1W ; 2.8 ; Crystal structure of 4-alpha-glucanotransferase from thermococcus litoralis 1K1X ; 2.4 ; Crystal structure of 4-alpha-glucanotransferase from thermococcus litoralis 2Y4R ; 1.75 ; CRYSTAL STRUCTURE OF 4-AMINO-4-DEOXYCHORISMATE LYASE FROM PSEUDOMONAS AERUGINOSA 2EO5 ; 1.9 ; Crystal structure of 4-aminobutyrate aminotransferase from Sulfolobus tokodaii strain7 3R4T ; 2.5 ; Crystal structure of 4-aminobutyrate aminotransferase GabT from Mycobacterium marinum covalently bound to pyridoxal phosphate 3OKS ; 1.8 ; Crystal structure of 4-aminobutyrate transaminase from mycobacterium smegmatis 3Q8N ; 2.05 ; Crystal structure of 4-aminobutyrate transaminase from Mycobacterium smegmatis 1S9A ; 2.47 ; Crystal Structure of 4-Chlorocatechol 1,2-dioxygenase from Rhodococcus opacus 1CP 3O32 ; 2.85 ; Crystal Structure of 4-Chlorocatechol Dioxygenase from Rhodococcus opacus 1CP in complex with 3,5-dichlorocatechol 3O6J ; 2.9 ; Crystal Structure of 4-Chlorocatechol Dioxygenase from Rhodococcus opacus 1CP in complex with hydroxyquinol 3O5U ; 2.35 ; Crystal Structure of 4-Chlorocatechol Dioxygenase from Rhodococcus opacus 1CP in complex with protocatechuate 3O6R ; 2.6 ; Crystal Structure of 4-Chlorocatechol Dioxygenase from Rhodococcus opacus 1CP in complex with pyrogallol 1YWK ; 2.95 ; Crystal structure of 4-deoxy-1-threo-5-hexosulose-uronate ketol-isomerase from Enterococcus faecalis 3PYD ; 2.101 ; crystal structure of 4-diphosphocytidyl-2-C-methyl-D-erythritol kinase (IspE) from Mycobacterium tuberculosis 1I52 ; 1.5 ; CRYSTAL STRUCTURE OF 4-DIPHOSPHOCYTIDYL-2-C-METHYLERYTHRITOL (CDP-ME) SYNTHASE (YGBP) INVOLVED IN MEVALONATE INDEPENDENT ISOPRENOID BIOSYNTHESIS 1INI ; 1.82 ; CRYSTAL STRUCTURE OF 4-DIPHOSPHOCYTIDYL-2-C-METHYLERYTHRITOL (CDP-ME) SYNTHETASE (YGBP) INVOLVED IN MEVALONATE INDEPENDENT ISOPRENOID BIOSYNTHESIS, COMPLEXED WITH CDP-ME AND MG2+ 1VGT ; 1.8 ; Crystal structure of 4-diphosphocytidyl-2C-methyl-D-erythritol synthase 1VGU ; 2.8 ; Crystal structure of 4-diphosphocytidyl-2C-methyl-D-erythritol synthase 1VGW ; 2.35 ; Crystal structure of 4-diphosphocytidyl-2C-methyl-D-erythritol synthase 1VGZ ; 3 ; Crystal structure of 4-diphosphocytidyl-2C-methyl-D-erythritol synthase 1Q4U ; 1.6 ; Crystal structure of 4-hydroxybenzoyl CoA thioesterase from arthrobacter sp. strain SU complexed with 4-hydroxybenzyl CoA 1Q4T ; 1.6 ; crystal structure of 4-hydroxybenzoyl CoA thioesterase from Arthrobacter sp. strain SU complexed with 4-hydroxyphenyl CoA 3D3U ; 2.8 ; Crystal structure of 4-hydroxybutyrate CoA-transferase (abfT-2) from Porphyromonas gingivalis. Northeast Structural Genomics Consortium target PgR26 3GK7 ; 1.85 ; Crystal structure of 4-hydroxybutyrate CoA-Transferase from Clostridium aminobutyricum 2OAS ; 2.4 ; Crystal Structure of 4-hydroxybutyrate coenzyme A transferase (AtoA) in complex with CoA from Shewanella oneidensis, Northeast Structural Genomics Target SoR119. 1U8V ; 1.6 ; Crystal Structure of 4-Hydroxybutyryl-CoA Dehydratase from Clostridium aminobutyricum: Radical catalysis involving a [4Fe-4S] cluster and flavin 3LXY ; 1.7 ; Crystal structure of 4-hydroxythreonine-4-phosphate dehydrogenase from Yersinia pestis CO92 3DZV ; 2.57 ; Crystal structure of 4-methyl-5-(beta-hydroxyethyl)thiazole kinase (NP_816404.1) from ENTEROCOCCUS FAECALIS V583 at 2.57 A resolution 3HFK ; 1.9 ; Crystal structure of 4-methylmuconolactone methylisomerase (H52A) in complex with 4-methylmuconolactone 3HF5 ; 1.4 ; Crystal structure of 4-methylmuconolactone methylisomerase in complex with 3-methylmuconolactone 3HDS ; 1.45 ; Crystal structure of 4-methylmuconolactone methylisomerase in complex with MES 1VJR ; 2.4 ; Crystal structure of 4-nitrophenylphosphatase (TM1742) from Thermotoga maritima at 2.40 A resolution 1BJP ; 2.4 ; CRYSTAL STRUCTURE OF 4-OXALOCROTONATE TAUTOMERASE INACTIVATED BY 2-OXO-3-PENTYNOATE AT 2.4 ANGSTROMS RESOLUTION 2GWG ; 1.8 ; Crystal Structure of 4-Oxalomesaconate Hydratase, LigJ, from Rhodopseudomonas palustris, Northeast Structural Genomics Target RpR66. 2D0T ; 2.3 ; Crystal structure of 4-phenylimidazole bound form of human indoleamine 2,3-dioxygenase 3AJ0 ; 1.89 ; Crystal structure of 4-pyridoxolactonase from Mesorhizobium loti 3HGA ; 1.3 ; Crystal Structure of 4-Se-Uridine Derivatized RNA 1D59 ; 2.3 ; CRYSTAL STRUCTURE OF 4-STRANDED OXYTRICHA TELOMERIC DNA 1WTA ; 1.78 ; Crystal Structure of 5'-Deoxy-5'-methylthioadenosine from Aeropyrum pernix (R32 form) 1JDU ; 2.5 ; CRYSTAL STRUCTURE OF 5'-DEOXY-5'-METHYLTHIOADENOSINE PHOSPHORYLASE 1JP7 ; 1.8 ; Crystal Structure of 5'-deoxy-5'-methylthioadenosine phosphorylase 3T94 ; 1.452 ; Crystal structure of 5'-deoxy-5'-methylthioadenosine phosphorylase (MTAP) II complexed with 5'-deoxy-5'-methylthioadenosine and sulfate 1JDV ; 2 ; CRYSTAL STRUCTURE OF 5'-DEOXY-5'-METHYLTHIOADENOSINE PHOSPHORYLASE COMPLEXED WITH ADENOSINE AND SULFATE ION 1JDT ; 2 ; CRYSTAL STRUCTURE OF 5'-DEOXY-5'-METHYLTHIOADENOSINE PHOSPHORYLASE COMPLEXED WITH MTA AND SULFATE ION 1JE0 ; 1.6 ; CRYSTAL STRUCTURE OF 5'-DEOXY-5'-METHYLTHIOADENOSINE PHOSPHORYLASE COMPLEXED WITH PHOSPHATE AND TRIS MOLECULE 1JPV ; 1.8 ; Crystal Structure of 5'-deoxy-5'-methylthioadenosine phosphorylase complexed with SO4 1K27 ; 1.95 ; Crystal Structure of 5'-Deoxy-5'-Methylthioadenosine Phosphorylase in Complex with a Transition State Analogue 1JDZ ; 2 ; CRYSTAL STRUCTURE OF 5'-DEOXY-5'-METHYLTHIOADENOSINE PHOSPHORYLASE WITH FORMYCIN B AND SULFATE ION 2A8Y ; 1.45 ; Crystal structure of 5'-deoxy-5'methylthioadenosine phosphorylase complexed with 5'-deoxy-5'methylthioadenosine and sulfate 4FFS ; 1.9 ; Crystal structure of 5'-methylthioadenosine/S-adenosylhomocysteine nucleosidase from Helicobacter pylori with butyl-thio-DADMe-Immucillin-A 3EEI ; 1.78 ; Crystal structure of 5'-methylthioadenosine/S-adenosylhomocysteine nucleosidase from neisseria meningitidis in complex with methylthio-immucillin-A 4F1W ; 1.36 ; Crystal structure of 5'-methylthioadenosine/S-adenosylhomocysteine nucleosidase from Salmonella enterica with Adenine 4F3C ; 1.93 ; Crystal structure of 5'-methylthioadenosine/S-adenosylhomocysteine nucleosidase from Salmonella enterica with butyl-thio-DADMe-Immucillin-A 4F2P ; 1.64 ; Crystal structure of 5'-methylthioadenosine/S-adenosylhomocysteine nucleosidase from Salmonella enterica with diEtglycol-thio-DADMe-Immucillin-A 4F3K ; 1.85 ; Crystal structure of 5'-methylthioadenosine/S-adenosylhomocysteine nucleosidase from Salmonella enterica with homocysteine-DADMe-Immucillin-A 4F2W ; 2 ; Crystal structure of 5'-methylthioadenosine/S-adenosylhomocysteine nucleosidase from Salmonella enterica with methyl-thio-DADMe-Immucillin-A 3OZB ; 2.8 ; Crystal Structure of 5'-methylthioinosine phosphorylase from Psedomonas aeruginosa in complex with hypoxanthine 3C9F ; 1.9 ; Crystal structure of 5'-nucleotidase from Candida albicans SC5314 2Z1A ; 1.75 ; Crystal structure of 5'-nucleotidase precursor from Thermus thermophilus HB8 3ONN ; 1.87 ; Crystal structure of 5'-nucleotidase SDT1 from saccharomyces cerevisiae 1M2R ; 1.7 ; Crystal structure of 5,8-di-amino-1,4-di-hydroxy-anthraquinone/CK2 kinase complex 1OHP ; 1.53 ; CRYSTAL STRUCTURE OF 5-3-KETOSTEROID ISOMERASE MUTANT D38N FROM PSEUDOMONAS TESTOSTERONI COMPLEXED WITH 5ALPHA-ESTRAN-3,17-DIONE 1OHS ; 1.7 ; CRYSTAL STRUCTURE OF 5-3-KETOSTEROID ISOMERASE MUTANT Y14F/ D38N FROM PSEUDOMONAS TESTOSTERONI COMPLEXED WITH ANDROSTANEDIONE 1OGZ ; 2.3 ; CRYSTAL STRUCTURE OF 5-3-KETOSTEROID ISOMERASE MUTANTS P39A COMPLEXED WITH EQUILENIN FROM PSEUDOMONAS TESTOSTERONI 2Z1B ; 3.3 ; Crystal Structure of 5-aminolevulinic acid dehydratase (ALAD) from Mus musculs 2Z0I ; 3.2 ; Crystal Structure of 5-aminolevulinic acid dehydratase (ALAD) from Mus musculus 4JJ9 ; 1.76 ; Crystal Structure of 5-carboxymethyl-2-hydroxymuconate delta-isomerase 4FPI ; 2.2 ; Crystal Structure of 5-chloromuconolactone isomerase from Rhodococcus opacus 1CP 3M00 ; 2.1 ; Crystal Structure of 5-epi-aristolochene synthase M4 mutant complexed with (2-cis,6-trans)-2-fluorofarnesyl diphosphate 1DL8 ; 1.55 ; CRYSTAL STRUCTURE OF 5-F-9-AMINO-(N-(2-DIMETHYLAMINO)ETHYL)ACRIDINE-4-CARBOXAMIDE BOUND TO D(CGTACG)2 2H1X ; 1.98 ; Crystal structure of 5-hydroxyisourate Hydrolase (formerly known as TRP, Transthyretin Related Protein) 2H6U ; 1.7 ; Crystal structure of 5-hydroxyisourate hydrolase (formerly known as TRP, transthyretin related protein) 1XRU ; 1.94 ; Crystal Structure of 5-keto-4-deoxyuronate Isomerase from Eschericia coli 2YRF ; 2.7 ; Crystal structure of 5-methylthioribose 1-phosphate isomerase from Bacillus subtilis complexed with sulfate ion 2YVK ; 2.4 ; Crystal structure of 5-methylthioribose 1-phosphate isomerase product complex from Bacillus subtilis 2OLC ; 2 ; Crystal structure of 5-methylthioribose kinase in complex with ADP-2Ho 3RSR ; 2.3 ; Crystal Structure of 5-NITP Inhibition of Yeast Ribonucleotide Reductase 3HG8 ; 1.38 ; Crystal Structure of 5-SMe Derivatized DNA 1ZG9 ; 2 ; Crystal Structure of 5-{[amino(imino)methyl]amino}-2-(sulfanylmethyl)pentanoic acid Bound to Activated Porcine Pancreatic Carboxypeptidase B 2QIH ; 1.897 ; Crystal structure of 527-665 fragment of UspA1 protein from Moraxella catarrhalis 2G3R ; 1.25 ; Crystal Structure of 53BP1 tandem tudor domains at 1.2 A resolution 3UZW ; 1.892 ; Crystal structure of 5beta-reductase (AKR1D1) E120H mutant in complex with NADP+ 3UZY ; 1.832 ; Crystal structure of 5beta-reductase (AKR1D1) E120H mutant in complex with NADP+ and 5beta-dihydrotestosterone 3UZZ ; 1.82 ; Crystal structure of 5beta-reductase (AKR1D1) E120H mutant in complex with NADP+ and delta4-androstenedione 3UZX ; 1.637 ; Crystal structure of 5beta-reductase (AKR1D1) E120H mutant in complex with NADP+ and epiandrosterone 3CAS ; 2 ; Crystal structure of 5beta-reductase (AKR1D1) in complex with NADP+ and 4-androstenedione 3DOP ; 2 ; Crystal structure of 5beta-reductase (AKR1D1) in complex with NADP+ and 5beta-dihydrotestosterone, Resolution 2.00A 3CAV ; 1.9 ; Crystal structure of 5beta-reductase (AKR1D1) in complex with NADP+ and 5beta-pregnan-3,20-dione 3CAQ ; 2.2 ; Crystal structure of 5beta-reductase (AKR1D1) in complex with NADPH 3A5E ; 1.6 ; Crystal structure of 5K RNase Sa 2DCF ; 1.4 ; Crystal structure of 6-aminohexanoate-dimer hydrolase S112A/G181D/H266N mutant with substrate 3A65 ; 1.7 ; Crystal structure of 6-aminohexanoate-dimer hydrolase S112A/G181D/H266N mutant with substrate 2ZMA ; 1.51 ; Crystal Structure of 6-Aminohexanoate-dimer Hydrolase S112A/G181D/H266N/D370Y Mutant with Substrate 3A66 ; 1.6 ; Crystal structure of 6-aminohexanoate-dimer hydrolase S112A/G181D/H266N/D370Y mutant with substrate 3VPK ; 1.94 ; Crystal Structure of 6-Guanidinohexanoyl Trypsin 2BVG ; 3.18 ; CRYSTAL STRUCTURE OF 6-HYDOXY-D-NICOTINE OXIDASE FROM ARTHROBACTER NICOTINOVORANS. CRYSTAL FORM 1 (P21) 2BVH ; 2.9 ; CRYSTAL STRUCTURE OF 6-HYDOXY-D-NICOTINE OXIDASE FROM ARTHROBACTER NICOTINOVORANS. CRYSTAL FORM 2 (P21) 2BVF ; 1.92 ; CRYSTAL STRUCTURE OF 6-HYDOXY-D-NICOTINE OXIDASE FROM ARTHROBACTER NICOTINOVORANS. CRYSTAL FORM 3 (P1) 3K7M ; 1.95 ; Crystal structure of 6-hydroxy-L-nicotine oxidase from Arthrobacter nicotinovorans 1EX8 ; 1.85 ; CRYSTAL STRUCTURE OF 6-HYDROXYMETHYL-7,8-DIHYDROPTERIN PYROPHOSPHOKINASE COMPLEXED WITH HP4A, THE TWO-SUBSTRATE-MIMICKING INHIBITOR 3QOM ; 1.498 ; Crystal structure of 6-phospho-beta-glucosidase from Lactobacillus plantarum 4GZE ; 2.31 ; Crystal structure of 6-phospho-beta-glucosidase from Lactobacillus plantarum (apo form) 4GWK ; 1.534 ; Crystal structure of 6-phosphogluconate dehydrogenase complexed with 3-phosphoglyceric acid 1VL1 ; 1.55 ; Crystal structure of 6-phosphogluconolactonase (TM1154) from Thermotoga maritima at 1.70A resolution 3CH7 ; 2.29 ; Crystal structure of 6-phosphogluconolactonase from Leishmania braziliensis 3CSS ; 1.7 ; Crystal structure of 6-phosphogluconolactonase from Leishmania guyanensis 3OC6 ; 2.1 ; Crystal structure of 6-phosphogluconolactonase from mycobacterium smegmatis, apo form 3ICO ; 2.15 ; Crystal structure of 6-phosphogluconolactonase from Mycobacterium tuberculosis 3E7F ; 2.2 ; Crystal structure of 6-phosphogluconolactonase from Trypanosoma brucei complexed with 6-phosphogluconic acid 3EB9 ; 2 ; Crystal structure of 6-phosphogluconolactonase from trypanosoma brucei complexed with citrate 2DJ6 ; 2.1 ; Crystal structure of 6-pyruvoyl tetrahydrobiopterin synthase from Pyrococcus horikoshii OT3 2DTT ; 2.2 ; Crystal structure of 6-pyruvoyl tetrahydrobiopterin synthase from Pyrococcus horikoshii OT3 complexed with (1'R,2'S)-biopterin 2A0S ; 2.2 ; Crystal structure of 6-pyruvoyl tetrahydropterin synthase (PTPS) from Plasmodium vivax at 2.2 A resolution 3PQY ; 3.192 ; Crystal Structure of 6218 TCR in complex with the H2Db-PA224 3OGP ; 1.7 ; Crystal Structure of 6s-98S FIV Protease with Darunavir bound 3OGQ ; 1.8 ; Crystal Structure of 6s-98S FIV Protease with Lopinavir bound 3DRD ; 2.17 ; Crystal Structure of 7,8 Diaminopelargonic Acid Synthase Apoenzyme in Bacillus subtilis 1QJ5 ; 1.8 ; CRYSTAL STRUCTURE OF 7,8-DIAMINOPELARGONIC ACID SYNTHASE 3TFU ; 1.94 ; Crystal structure of 7,8-diaminopelargonic acid synthase (BioA) from Mycobacterium tuberculosis, post-reaction complex with a 3,6-dihydropyrid-2-one heterocycle inhibitor 3TFT ; 1.95 ; Crystal structure of 7,8-diaminopelargonic acid synthase (BioA) from Mycobacterium tuberculosis, pre-reaction complex with a 3,6-dihydropyrid-2-one heterocycle inhibitor 1QJ3 ; 2.7 ; CRYSTAL STRUCTURE OF 7,8-DIAMINOPELARGONIC ACID SYNTHASE IN COMPLEX WITH 7-KETO-8-AMINOPELARGONIC ACID 1MLY ; 1.81 ; Crystal Structure of 7,8-Diaminopelargonic Acid Synthase in complex with the cis isomer of amiclenomycin 1MLZ ; 2.15 ; Crystal Structure of 7,8-Diaminopelargonic Acid Synthase in complex with the trans-isomer of amiclenomycin. 1SQL ; 2.2 ; Crystal structure of 7,8-dihydroneopterin aldolase in complex with guanine 1UNM ; 2 ; Crystal structure of 7-Aminoactinomycin D with non-complementary DNA 3RJ4 ; 1.75 ; Crystal Structure of 7-cyano-7-deazaguanine Reductase, QueF from Vibrio cholerae 3UXV ; 1.56 ; Crystal Structure of 7-cyano-7-deazaguanine reductase, QueF from Vibrio cholerae complexed with NADP and PreQ 3UXJ ; 1.401 ; Crystal Structure of 7-cyano-7-deazaguanine reductase, QueF from Vibrio cholerae complexed with NADP and PreQ0 4IQI ; 1.5 ; Crystal Structure of 7-cyano-7-deazaguanine Reductase, QueF from Vibrio cholerae O1 biovar El Tor complexed with cytosine 3DU4 ; 2.2 ; Crystal structure of 7-keto-8-aminopelargonic acid bound 7,8-diaminopelargonic acid synthase in bacillus subtilis 4B8F ; 3.7 ; Crystal Structure of 70S Ribosome with Both Cognate tRNAs in the E and P Sites Representing an Authentic Elongation Complex. 4B8G ; 3.7 ; Crystal Structure of 70S Ribosome with Both Cognate tRNAs in the E and P Sites Representing an Authentic Elongation Complex. 4B8I ; 3.7 ; Crystal Structure of 70S Ribosome with Both Cognate tRNAs in the E and P Sites Representing an Authentic Elongation Complex. 1YL4 ; 5.5 ; Crystal structure of 70S ribosome with thrS operator and tRNAs. 30S subunit. The coordinates for the 50S subunit are in the pdb entry 1YL3 1YL3 ; 5.5 ; Crystal structure of 70S ribosome with thrS operator and tRNAs. Large subunit. The coordinates for the small subunit are in the pdb entry 1YL4. 1SGF ; 3.15 ; CRYSTAL STRUCTURE OF 7S NGF: A COMPLEX OF NERVE GROWTH FACTOR WITH FOUR BINDING PROTEINS (SERINE PROTEINASES) 1Z43 ; 2.6 ; Crystal structure of 7S.S SRP RNA of M. jannaschii 1DJ9 ; 2 ; CRYSTAL STRUCTURE OF 8-AMINO-7-OXONANOATE SYNTHASE (OR 7-KETO-8AMINIPELARGONATE OR KAPA SYNTHASE) COMPLEXED WITH PLP AND THE PRODUCT 8(S)-AMINO-7-OXONANONOATE (OR KAPA). THE ENZYME OF BIOTIN BIOSYNTHETIC PATHWAY. 4IW7 ; 2.25 ; Crystal structure of 8-amino-7-oxononanoate synthase (bioF) from Francisella tularensis. 1XQP ; 1.69 ; Crystal structure of 8-oxoguanosine complexed Pa-AGOG, 8-oxoguanine DNA glycosylase from Pyrobaculum aerophilum 3RDT ; 2.7 ; Crystal Structure of 809.B5 TCR complexed with MHC Class II I-Ab/3k peptide 3MBS ; 1.27 ; Crystal structure of 8mer PNA 2CV6 ; 2.65 ; Crystal Structure of 8Salpha Globulin, the Major Seed Storage Protein of Mungbean 1FN1 ; 1.6 ; CRYSTAL STRUCTURE OF 9-AMINO-(N-(2-DIMETHYLAMINO)BUTYL)ACRIDINE-4-CARBOXAMIDE BOUND TO D(CG(5BR)UACG)2 1KCI ; 1.8 ; Crystal Structure of 9-amino-N-[2-(4-morpholinyl)ethyl]-4-acridinecarboxamide Bound to d(CGTACG)2 3EDC ; 2.1 ; Crystal Structure of a 1.6-hexanediol Bound Tetrameric Form of Escherichia coli Lac-repressor Refined to 2.1 Resolution 433D ; 2.1 ; CRYSTAL STRUCTURE OF A 14 BASE PAIR RNA DUPLEX WITH NONSYMMETRICAL TANDEM G.U WOBBLE BASE PAIRS 3EFZ ; 2.08 ; Crystal Structure of a 14-3-3 protein from cryptosporidium parvum (cgd1_2980) 1FUF ; 1.7 ; CRYSTAL STRUCTURE OF A 14BP RNA OLIGONUCLEOTIDE CONTAINING DOUBLE UU BULGES: A NOVEL INTRAMOLECULAR U*(AU) BASE TRIPLE 1IK5 ; 1.8 ; Crystal Structure of a 14mer RNA Containing Double UU Bulges in Two Crystal Forms: A Novel U*(AU) Intramolecular Base Triple 2QLA ; 2.9 ; Crystal Structure of a 16-Helix Bundle Architecture Produced by the Zinc-Mediated Self Assembly of Four Cytochrome cb562 Molecules 420D ; 1.9 ; CRYSTAL STRUCTURE OF A 16-MER RNA DUPLEX WITH NON-ADJACENT A(ANTI).G(SYN) MISMATCHES 3QWI ; 2.5 ; Crystal structure of a 17beta-hydroxysteroid dehydrogenase (holo form) from fungus Cochliobolus lunatus in complex with NADPH and coumestrol 1QC0 ; 1.55 ; CRYSTAL STRUCTURE OF A 19 BASE PAIR COPY CONTROL RELATED RNA DUPLEX 3S7C ; 1.1 ; Crystal structure of a 2'-azido-uridine-modified RNA 3S8U ; 1.2 ; Crystal structure of a 2-azido-adenine-modified RNA 3TMQ ; 2.1 ; Crystal structure of a 2-dehydro-3-deoxyphosphooctonate aldolase from Burkholderia pseudomallei in complex with D-arabinose-5-phosphate 3VPL ; 1.2 ; Crystal structure of a 2-fluoroxylotriosyl complex of the Vibrio sp. AX-4 Beta-1,3-xylanase 4DLL ; 2.11 ; Crystal structure of a 2-hydroxy-3-oxopropionate reductase from Polaromonas sp. JS666 3EEG ; 2.78 ; Crystal structure of a 2-isopropylmalate synthase from Cytophaga hutchinsonii 3LZG ; 2.6 ; Crystal structure of a 2009 H1N1 influenza virus hemagglutinin 2D4X ; 1.9 ; Crystal structure of a 26K fragment of HAP3 (FlgL) 4DI3 ; 3.05 ; Crystal structure of a 2:1 complex of Treponema pallidum TatP(T) (Tp0957) bound to TatT (Tp0956) 1VH8 ; 2.35 ; Crystal structure of a 2C-methyl-D-erythritol 2,4-cyclodiphosphate synthase 2R64 ; 2.3 ; Crystal structure of a 3-aminoindazole compound with CDK2 4K7G ; 2 ; Crystal structure of a 3-hydroxyproline dehydratse from agrobacterium vitis, target efi-506470, with bound pyrrole 2-carboxylate, ordered active site 4IWH ; 1.75 ; Crystal structure of a 3-isopropylmalate dehydrogenase from Burkholderia pseudomallei 3V8B ; 2.7 ; Crystal Structure of a 3-ketoacyl-ACP reductase from Sinorhizobium meliloti 1021 2JG6 ; 1.7 ; CRYSTAL STRUCTURE OF A 3-METHYLADENINE DNA GLYCOSYLASE I FROM STAPHYLOCOCCUS AUREUS 3E4Y ; 2.6 ; Crystal structure of a 33kDa catalase-related protein from Mycobacterium avium subsp. paratuberculosis. I2(1)2(1)2(1) crystal form 3E4W ; 1.8 ; Crystal structure of a 33kDa catalase-related protein from Mycobacterium avium subsp. paratuberculosis. P2(1)2(1)2(1) crystal form. 4DI4 ; 2.714 ; Crystal structure of a 3:1 complex of Treponema pallidum TatP(T) (Tp0957) bound to TatT (Tp0956) 4IS3 ; 2 ; Crystal structure of a 3alpha-hydroxysteroid dehydrogenase (BaiA2) associated with secondary bile acid synthesis from Clostridium scindens VPI12708 in complex with a putative NAD(+)-OH- adduct at 2.0 A resolution 3JUY ; 2.5 ; Crystal Structure of a 3B3 Variant, a Broadly Neutralizing HIV-1 scFv Antibody 1A2W ; 2.1 ; CRYSTAL STRUCTURE OF A 3D DOMAIN-SWAPPED DIMER OF BOVINE PANCREATIC RIBONUCLEASE A 2HJ1 ; 2.1 ; Crystal structure of a 3D domain-swapped dimer of protein HI0395 from Haemophilus influenzae 4FFC ; 1.8 ; Crystal structure of a 4-aminobutyrate aminotransferase (GabT) from Mycobacterium abscessus 4G9Q ; 1.77 ; Crystal structure of a 4-carboxymuconolactone decarboxylase 4K7X ; 1.75 ; Crystal structure of a 4-hydroxyproline epimerase from burkholderia multivorans, target efi-506479, with bound phosphate, closed domains 3ABF ; 1.94 ; Crystal Structure of a 4-Oxalocrotonate Tautomerase Homologue (TTHB242) 2ESC ; 2.1 ; Crystal structure of a 40 KDa protective signalling protein from Bovine (SPC-40) at 2.1 A resolution 1OWQ ; 2 ; Crystal structure of a 40 kDa signalling protein (SPC-40) secreted during involution 1XHG ; 2.9 ; Crystal structure of a 40 kDa signalling protein from Porcine (SPP-40) at 2.89A resolution 2D4Y ; 2.1 ; Crystal structure of a 49K fragment of HAP1 (FlgK) 4JCU ; 2.4 ; Crystal structure of a 5-carboxymethyl-2-hydroxymuconate isomerase from Deinococcus radiodurans R1 1WKC ; 1.7 ; Crystal structure of a 5-formyltetrahydrofolate cycloligase-related protein from Thermus thermophilus HB8 3PL2 ; 1.89 ; Crystal structure of a 5-keto-2-deoxygluconokinase (NCgl0155, Cgl0158) from Corynebacterium glutamicum ATCC 13032 KITASATO at 1.89 A resolution 2INR ; 2.8 ; Crystal structure of a 59 kDa fragment of topoisomerase IV subunit A (GrlA) from Staphylococcus aureus 3R47 ; 2.5002 ; Crystal structure of a 6-helix coiled coil CC-hex-H24 3NWP ; 1.4 ; Crystal structure of a 6-phosphogluconolactonase (Sbal_2240) from Shewanella baltica OS155 at 1.40 A resolution 3QN9 ; 2.93 ; Crystal structure of a 6-pyruvoyltetrahydropterin synthase homologue from Esherichia coli 3QNA ; 2.5 ; Crystal structure of a 6-pyruvoyltetrahydropterin synthase homologue from Esherichia coli complexed sepiapterin 3UGF ; 1.7 ; Crystal structure of a 6-SST/6-SFT from Pachysandra terminalis 3UGG ; 2.9 ; Crystal structure of a 6-SST/6-SFT from Pachysandra terminalis in complex with 1-kestose 3UGH ; 2.9 ; Crystal structure of a 6-SST/6-SFT from Pachysandra terminalis in complex with 6-kestose 1UNJ ; 2.5 ; Crystal structure of a 7-Aminoactinomycin D complex with non-complementary DNA 1VSA ; 3.71 ; Crystal Structure of a 70S Ribosome-tRNA Complex Reveals Functional Interactions and Rearrangements. This file, 1VSA, contains the 50S ribosome subunit. 30S ribosome subunit is in the file 2OW8 2OW8 ; 3.71 ; Crystal Structure of a 70S Ribosome-tRNA Complex Reveals Functional Interactions and Rearrangements. This file, 2OW8, contains the 30S ribosome subunit, two tRNA, and mRNA molecules. 50S ribosome subunit is in the file 1VSA. 2PGC ; 2.53 ; Crystal structure of a a marine metagenome protein (jcvi_pep_1096685590403) from uncultured marine organism at 2.53 A resolution 3SBT ; 1.799 ; Crystal structure of a Aar2-Prp8 complex 4H0Q ; 1.6 ; Crystal structure of a acidic PLA2 from Trimeresurus stejnegeri venom 1VHE ; 1.9 ; Crystal structure of a aminopeptidase/glucanase homolog 1VGX ; 1.9 ; Crystal structure of a autoinducer-2 synthesis protein 1VH2 ; 2 ; Crystal structure of a autoinducer-2 synthesis protein 1VJE ; 1.64 ; Crystal structure of a autoinducer-2 synthesis protein with bound selenomethionine 1D77 ; 2.4 ; CRYSTAL STRUCTURE OF A B-DNA DODECAMER CONTAINING INOSINE, D(CGCIAATTCGCG), AT 2.4 ANGSTROMS RESOLUTION AND ITS COMPARISON WITH OTHER B-DNA DODECAMERS 1N1O ; 1.2 ; Crystal Structure of a B-form DNA Duplex Containing (L)-alpha-threofuranosyl (3'-2') Nucleosides: A Four-Carbon Sugar is Easily Accommodated into the Backbone of DNA 2FNJ ; 1.8 ; Crystal structure of a B30.2/SPRY domain-containing protein GUSTAVUS in complex with Elongin B and Elongin C 3H16 ; 2.5 ; Crystal structure of a bacteria TIR domain, PdTIR from Paracoccus denitrificans 3ELQ ; 2 ; Crystal structure of a bacterial arylsulfate sulfotransferase 3ETS ; 2.4 ; Crystal structure of a bacterial arylsulfate sulfotransferase catalytic intermediate with 4-methylumbelliferone bound in the active site 3ETT ; 2.1 ; Crystal structure of a bacterial arylsulfate sulfotransferase catalytic intermediate with 4-nitrophenol bound in the active site 1CTN ; 2.3 ; CRYSTAL STRUCTURE OF A BACTERIAL CHITINASE AT 2.3 ANGSTROMS RESOLUTION 4F35 ; 3.196 ; Crystal Structure of a bacterial dicarboxylate/sodium symporter 2ETS ; 2.25 ; CRYSTAL STRUCTURE OF A BACTERIAL DOMAIN OF UNKNOWN FUNCTION FROM DUF1798 FAMILY (MW1337) FROM STAPHYLOCOCCUS AUREUS SUBSP. AUREUS AT 2.25 A RESOLUTION 2GDR ; 2.1 ; Crystal structure of a bacterial glutathione transferase 1N2A ; 1.9 ; Crystal Structure of a Bacterial Glutathione Transferase from Escherichia coli with Glutathione Sulfonate in the Active Site 3ZUX ; 2.2 ; CRYSTAL STRUCTURE OF A BACTERIAL HOMOLOGUE OF THE BILE ACID SODIUM SYMPORTER ASBT. 3ZUY ; 2.2 ; CRYSTAL STRUCTURE OF A BACTERIAL HOMOLOGUE OF THE BILE ACID SODIUM SYMPORTER ASBT. 1QWD ; 1.75 ; CRYSTAL STRUCTURE OF A BACTERIAL LIPOCALIN, THE BLC GENE PRODUCT FROM E. COLI 3GF6 ; 1.69 ; Crystal structure of a bacterial lipoprotein (bt_1233) from bacteroides thetaiotaomicron vpi-5482 at 1.69 A resolution 1XBN ; 2.5 ; Crystal structure of a bacterial nitric oxide sensor: an ortholog of mammalian soluble guanylate cyclase heme domain 1MMO ; 2.2 ; CRYSTAL STRUCTURE OF A BACTERIAL NON-HAEM IRON HYDROXYLASE THAT CATALYSES THE BIOLOGICAL OXIDATION OF METHANE 3OLP ; 1.95 ; Crystal structure of a bacterial phosphoglucomutase, an enzyme important in the virulence of multiple human pathogens 3NA5 ; 1.7 ; Crystal structure of a bacterial phosphoglucomutase, an enzyme important in the virulence of several human pathogens. 1L3L ; 1.66 ; Crystal structure of a bacterial quorum-sensing transcription factor complexed with pheromone and DNA 3Q1R ; 4.21 ; Crystal structure of a bacterial RNase P holoenzyme in complex with TRNA and in the presence of 5' leader 1KN9 ; 2.4 ; CRYSTAL STRUCTURE OF A BACTERIAL SIGNAL PEPTIDASE APO-ENZYME, IMPLICATIONS FOR SIGNAL PEPTIDE BINDING AND THE SER-LYS DYAD MECHANISM. 3M4A ; 1.65 ; Crystal structure of a bacterial topoisomerase IB in complex with DNA reveals a secondary DNA binding site 2CX3 ; 2.64 ; Crystal structure of a bacterioferritin comigratory protein peroxiredoxin from the Aeropyrum pernix K1 (form-1 crystal) 2CX4 ; 2.3 ; Crystal structure of a bacterioferritin comigratory protein peroxiredoxin from the Aeropyrum pernix K1 (form-2 crystal) 1HX1 ; 1.9 ; CRYSTAL STRUCTURE OF A BAG DOMAIN IN COMPLEX WITH THE HSC70 ATPASE DOMAIN 3CAZ ; 3.344 ; Crystal structure of a BAR protein from Galdieria sulphuraria 1RNB ; 1.9 ; CRYSTAL STRUCTURE OF A BARNASE-D(*GP*C) COMPLEX AT 1.9 ANGSTROMS RESOLUTION 3HNW ; 2.196 ; Crystal Structure of a Basic Coiled-Coil Protein of Unknown Function from Eubacterium eligens ATCC 27750 3S99 ; 2.05 ; Crystal structure of a basic membrane lipoprotein from brucella melitensis, iodide soak 3JTY ; 2.58 ; Crystal structure of a BenF-like porin from Pseudomonas fluorescens Pf-5 4EAT ; 1.798 ; Crystal structure of a benzoate coenzyme A ligase 2P8O ; 1.5 ; Crystal Structure of a Benzohydroxamic Acid/Vanadate complex bound to chymotrypsin A 1S0M ; 2.7 ; Crystal structure of a Benzo[a]pyrene Diol Epoxide adduct in a ternary complex with a DNA polymerase 3FZ1 ; 1.9 ; Crystal structure of a benzthiophene inhibitor bound to human Cyclin-dependent Kinase-2 (CDK-2) 3FYK ; 3.5 ; Crystal structure of a benzthiophene lead bound to MAPKAP Kinase-2 (MK-2) 1D63 ; 2 ; CRYSTAL STRUCTURE OF A BERENIL-D(CGCAAATTTGCG) COMPLEX; AN EXAMPLE OF DRUG-DNA RECOGNITION BASED ON SEQUENCE-DEPENDENT STRUCTURAL FEATURES 2DBE ; 2.5 ; CRYSTAL STRUCTURE OF A BERENIL-DODECANUCLEOTIDE COMPLEX: THE ROLE OF WATER IN SEQUENCE-SPECIFIC LIGAND BINDING 1J18 ; 2 ; Crystal Structure of a Beta-Amylase from Bacillus cereus var. mycoides Cocrystallized with Maltose 2GL7 ; 2.6 ; Crystal Structure of a beta-catenin/BCL9/Tcf4 complex 3D3A ; 2.15 ; Crystal structure of a beta-galactosidase from Bacteroides thetaiotaomicron 3GM8 ; 2.4 ; Crystal structure of a beta-glycosidase from Bacteroides vulgatus 3V1U ; 2.5 ; Crystal structure of a beta-ketoacyl reductase FabG4 from Mycobacterium tuberculosis H37Rv complexed with NAD+ and Hexanoyl-CoA at 2.5 Angstrom resolution 4EWG ; 2.25 ; Crystal structure of a Beta-ketoacyl synthase from Burkholderia phymatum STM815 3I7J ; 2.2 ; Crystal Structure of a beta-lactamase (Mb2281c) from Mycobacterium bovis, Northeast Structural Genomics Consortium Target MbR246 3QH8 ; 1.6 ; Crystal structure of a beta-lactamase-like protein bound to AMP from brucella melitensis, long wavelength synchrotron data 3MD7 ; 1.27 ; Crystal structure of a beta-lactamase-like protein bound to GMP from brucella melitensis 3PY5 ; 1.7 ; Crystal structure of a beta-lactamase-like protein from brucella melitensis bound to AMP 3PY6 ; 1.7 ; Crystal Structure of a Beta-Lactamase-Like Protein from Brucella Melitensis bound to GMP 3I9H ; 2 ; Crystal structure of a betagamma-crystallin domain from Clostridium beijerinckii 3IAJ ; 2.1 ; Crystal structure of a betagamma-crystallin domain from Clostridium beijerinckii-in alternate space group I422 3HZB ; 1.74 ; Crystal structure of a betagamma-crystallin domain from Flavobacterium johnsoniae 3HZ2 ; 1.86 ; Crystal structure of a betagamma-crystallin from an Archaea 3NYW ; 2.16 ; Crystal Structure of a betaketoacyl-[ACP] reductase (FabG) from Bacteroides thetaiotaomicron 2V6Q ; 2.7 ; CRYSTAL STRUCTURE OF A BHRF-1 : BIM BH3 COMPLEX 1NVM ; 1.7 ; Crystal structure of a bifunctional aldolase-dehydrogenase : sequestering a reactive and volatile intermediate 2B3Z ; 2.41 ; Crystal structure of a bifunctional deaminase and reductase involved in riboflavin biosynthesis 2D5N ; 2.97 ; Crystal structure of a bifunctional deaminase and reductase involved in riboflavin biosynthesis 3LN7 ; 3.2 ; Crystal structure of a bifunctional glutathione synthetase from Pasteurella multocida 3LN6 ; 2.95 ; Crystal structure of a bifunctional glutathione synthetase from Streptococcus agalactiae 2W3X ; 1.75 ; CRYSTAL STRUCTURE OF A BIFUNCTIONAL HOTDOG FOLD THIOESTERASE IN ENEDIYNE BIOSYNTHESIS, CALE7 2QJO ; 2.6 ; crystal structure of a bifunctional NMN adenylyltransferase/ADP ribose pyrophosphatase (NadM) complexed with ADPRP and NAD from Synechocystis sp. 2QJT ; 2.3 ; Crystal structure of a bifunctional NMN adenylyltransferase/ADP ribose pyrophosphatase complexed with AMP and MN ion from Francisella tularensis 2R5W ; 2.3 ; Crystal structure of a bifunctional NMN adenylyltransferase/ADP ribose pyrophosphatase from Francisella tularensis 1GD7 ; 2 ; CRYSTAL STRUCTURE OF A BIFUNCTIONAL PROTEIN (CSAA) WITH EXPORT-RELATED CHAPERONE AND TRNA-BINDING ACTIVITIES. 1LC3 ; 1.5 ; Crystal Structure of a Biliverdin Reductase Enzyme-Cofactor Complex 2QYI ; 2.6 ; Crystal structure of a binary complex between an engineered trypsin inhibitor and Bovine trypsin 3I29 ; 2.4 ; Crystal structure of a binary complex between an mutant trypsin inhibitor with bovine trypsin 1AJ2 ; 2 ; CRYSTAL STRUCTURE OF A BINARY COMPLEX OF E. COLI DIHYDROPTEROATE SYNTHASE 1RB0 ; 1.35 ; CRYSTAL STRUCTURE OF A BINARY COMPLEX OF E. COLI HPPK WITH 6-HYDROXYMETHYLPTERIN-DIPHOSPHATE AT 1.35 ANGSTROM RESOLUTION 1DAW ; 2.2 ; CRYSTAL STRUCTURE OF A BINARY COMPLEX OF PROTEIN KINASE CK2 (ALPHA-SUBUNIT) AND MG-AMPPNP 1DAY ; 2.2 ; CRYSTAL STRUCTURE OF A BINARY COMPLEX OF PROTEIN KINASE CK2 (ALPHA-SUBUNIT) AND MG-GMPPNP 1LP4 ; 1.86 ; Crystal structure of a binary complex of the catalytic subunit of protein kinase CK2 with Mg-AMPPNP 3N5L ; 1.97 ; Crystal structure of a binding protein component of ABC phosphonate transporter (PA3383) from Pseudomonas aeruginosa at 1.97 A resolution 1EKU ; 2.9 ; CRYSTAL STRUCTURE OF A BIOLOGICALLY ACTIVE SINGLE CHAIN MUTANT OF HUMAN IFN-GAMMA 3BFM ; 1.7 ; Crystal structure of a biotin protein ligase-like protein of unknown function (tm1040_0394) from silicibacter sp. tm1040 at 1.70 A resolution 1F27 ; 1.3 ; CRYSTAL STRUCTURE OF A BIOTIN-BINDING RNA PSEUDOKNOT 2PXH ; 1.97 ; Crystal structure of a bipyridylalanyl-tRNA synthetase 2PGG ; 2.5 ; Crystal Structure of a Birnavirus (IBDV) RNA-dependent RNA Polymerase VP1 1TR0 ; 1.8 ; Crystal Structure of a boiling stable protein SP1 3O2E ; 1.95 ; Crystal structure of a bol-like protein from babesia bovis 2VE7 ; 2.88 ; CRYSTAL STRUCTURE OF A BONSAI VERSION OF THE HUMAN NDC80 COMPLEX 2FID ; 2.8 ; Crystal Structure of a Bovine Rabex-5 fragment complexed with ubiquitin 2FIF ; 2.49 ; Crystal Structure of a Bovine Rabex-5 fragment complexed with ubiquitin 1PBI ; 2.7 ; CRYSTAL STRUCTURE OF A BOWMAN-BIRK INHIBITOR FROM PEA SEEDS 2R33 ; 2.5 ; Crystal structure of a Bowman-Birk inhibitor from Vigna unguiculata seeds 2FI4 ; 1.58 ; Crystal structure of a BPTI variant (Cys14->Ser) in complex with trypsin 2FI3 ; 1.58 ; Crystal structure of a BPTI variant (Cys14->Ser, Cys38->Ser) in complex with trypsin 2FI5 ; 1.58 ; Crystal structure of a BPTI variant (Cys38->Ser) in complex with trypsin 3LKB ; 2.4 ; Crystal structure of a branched chain amino acid ABC transporter from Thermus thermophilus with bound valine 3N0W ; 1.88 ; Crystal structure of a branched chain amino acid ABC transporter periplasmic ligand-binding protein (Bxe_C0949) from BURKHOLDERIA XENOVORANS LB400 at 1.88 A resolution 1YCO ; 2.4 ; Crystal structure of a branched-chain phosphotransacylase from Enterococcus faecalis V583 4DYJ ; 2.45 ; Crystal structure of a broad specificity amino acid racemase (Bar) within internal aldimine linkage 1N0X ; 1.8 ; Crystal Structure of a Broadly Neutralizing Anti-HIV-1 Antibody in Complex with a Peptide Mimotope 1QBP ; 2.1 ; CRYSTAL STRUCTURE OF A BROMINATED RNA HELIX WITH FOUR MISMATCHED BASE PAIRS 3PL0 ; 1.91 ; Crystal structure of a bsmA homolog (Mpe_A2762) from Methylobium petroleophilum PM1 at 1.91 A resolution 1TFV ; 2.9 ; CRYSTAL STRUCTURE OF A BUFFALO SIGNALING GLYCOPROTEIN (SPB-40) SECRETED DURING INVOLUTION 1JZV ; 1.7 ; Crystal structure of a bulged RNA from the SL2 stem-loop of the HIV-1 psi-RNA 1P79 ; 1.1 ; Crystal structure of a bulged RNA tetraplex: implications for a novel binding site in RNA tetraplex 2PU5 ; 2.3 ; Crystal Structure of a C-C bond hydrolase, BphD, from Burkholderia xenovorans LB400 3HRN ; 1.9 ; crystal structure of a C-terminal coiled coil domain of Transient receptor potential (TRP) channel subfamily P member 2 (TRPP2, polycystic kidney disease 2) 3HRO ; 1.9 ; Crystal structure of a C-terminal coiled coil domain of Transient receptor potential (TRP) channel subfamily P member 2 (TRPP2, polycystic kidney disease 2) 1PJK ; 2.5 ; Crystal Structure of a C-terminal deletion mutant of human protein kinase CK2 catalytic subunit 3AQJ ; 1.27 ; Crystal Structure of a C-terminal domain of the bacteriophage P2 tail spike protein, gpV 1LVA ; 2.12 ; Crystal structure of a C-terminal fragment of Moorella thermoacetica elongation factor SelB 1O6A ; 1.85 ; CRYSTAL STRUCTURE OF A C-TERMINAL FRAGMENT OF THE PUTATIVE FLAGELLAR MOTOR SWITCH PROTEIN FLIN (TM0680) FROM THERMOTOGA MARITIMA AT 1.85 A RESOLUTION 4EW8 ; 2.5 ; Crystal structure of a C-terminal part of tyrosine kinase (DivL) from Caulobacter crescentus CB15 at 2.50 A resolution (PSI Community Target, Shapiro L.) 2NV5 ; 2 ; Crystal structure of a C-terminal phosphatase domain of Rattus norvegicus ortholog of human protein tyrosine phosphatase, receptor type, D (PTPRD) 1YZ7 ; 2.26 ; Crystal structure of a C-terminal segment of the alpha subunit of aIF2 from Pyrococcus abyssi 4JHS ; 3 ; Crystal structure of a C-terminal two domain fragment of human beta-2-glycoprotein 1 1Y42 ; 1.95 ; Crystal structure of a C-terminally truncated CYT-18 protein 1KTG ; 1.8 ; Crystal Structure of a C. elegans Ap4A Hydrolase Binary Complex 2R4H ; 2.05 ; Crystal structure of a C1190S mutant of the 6th PDZ domain of human membrane associated guanylate kinase 3FDW ; 2.2 ; Crystal structure of a C2 domain from human synaptotagmin-like protein 4 4DNL ; 1.9 ; Crystal structure of a C2 domain of a protein kinase C alpha (PRKCA) from Homo sapiens at 1.90 A resolution 1OWS ; 2.3 ; Crystal structure of a C49 Phospholipase A2 from Indian cobra reveals carbohydrate binding in the hydrophobic channel 1SJ4 ; 2.7 ; Crystal structure of a C75U mutant Hepatitis Delta Virus ribozyme precursor, in Cu2+ solution 1S36 ; 1.96 ; Crystal structure of a Ca2+-discharged photoprotein: Implications for the mechanisms of the calcium trigger and the bioluminescence 3B5O ; 1.35 ; CRYSTAL STRUCTURE OF A CADD-LIKE PROTEIN OF UNKNOWN FUNCTION (NPUN_F6505) FROM NOSTOC PUNCTIFORME PCC 73102 AT 1.35 A RESOLUTION 3B5P ; 2 ; Crystal structure of a cadd-like protein of unknown function (npun_f6505) from nostoc punctiforme pcc 73102 at 2.00 A resolution 4ED9 ; 1.95 ; Crystal structure of a CAIB/BAIF family protein from Brucella suis 2GHS ; 1.55 ; CRYSTAL STRUCTURE OF A CALCIUM-BINDING PROTEIN, REGUCALCIN (AGR_C_1268) FROM AGROBACTERIUM TUMEFACIENS STR. C58 AT 1.55 A RESOLUTION 1MH7 ; 2 ; Crystal Structure of a Calcium-Free Isoform of Phospholipase A2 from Naja naja sagittifera at 2.0 A Resolution 1CLP ; 2.8 ; CRYSTAL STRUCTURE OF A CALCIUM-INDEPENDENT PHOSPHOLIPASELIKE MYOTOXIC PROTEIN FROM BOTHROPS ASPER VENOM 1MEL ; 2.5 ; CRYSTAL STRUCTURE OF A CAMEL SINGLE-DOMAIN VH ANTIBODY FRAGMENT IN COMPLEX WITH LYSOZYME 2XXC ; 1.67 ; CRYSTAL STRUCTURE OF A CAMELID VHH RAISED AGAINST THE HIV-1 CAPSID PROTEIN C-TERMINAL DOMAIN. 1OL0 ; 1.8 ; CRYSTAL STRUCTURE OF A CAMELISED HUMAN VH 1U4J ; 2.18 ; Crystal structure of a carbohydrate induced dimer of group I phospholipase A2 from Bungarus caeruleus at 2.1 A resolution 3K5W ; 2.6 ; Crystal structure of a Carbohydrate kinase (YjeF family)from Helicobacter pylori 3R1W ; 1.73 ; Crystal structure of a carbonic anhydrase from a crude oil degrading psychrophilic library 3CTM ; 2.69 ; Crystal Structure of a Carbonyl Reductase from Candida Parapsilosis with anti-Prelog Stereo-specificity 4FHZ ; 2.01 ; Crystal structure of a carboxyl esterase at 2.0 angstrom resolution 4FTW ; 2.3 ; Crystal structure of a carboxyl esterase N110C/L145H at 2.3 angstrom resolution 1MEG ; 2 ; CRYSTAL STRUCTURE OF A CARICAIN D158E MUTANT IN COMPLEX WITH E-64 4HDT ; 1.6 ; Crystal structure of a Carnitinyl-CoA dehydratase from Mycobacterium thermoresistibile 1EAP ; 2.4 ; CRYSTAL STRUCTURE OF A CATALYTIC ANTIBODY WITH A SERINE PROTEASE ACTIVE SITE 2GFB ; 3 ; CRYSTAL STRUCTURE OF A CATALYTIC FAB HAVING ESTERASE-LIKE ACTIVITY 1ZCP ; 2.3 ; Crystal Structure of a catalytic site mutant E. coli TrxA (CACA) 1P14 ; 1.9 ; Crystal structure of a catalytic-loop mutant of the insulin receptor tyrosine kinase 3PLA ; 3.15 ; Crystal structure of a catalytically active substrate-bound box C/D RNP from Sulfolobus solfataricus 2W2D ; 2.59 ; Crystal Structure of a Catalytically Active, Non-toxic Endopeptidase Derivative of Clostridium botulinum Toxin A 2W8S ; 2.4 ; CRYSTAL STRUCTURE OF A CATALYTICALLY PROMISCUOUS PHOSPHONATE MONOESTER HYDROLASE FROM BURKHOLDERIA CARYOPHYLLI 2EY4 ; 2.11 ; Crystal Structure of a Cbf5-Nop10-Gar1 Complex 3U28 ; 1.9 ; Crystal structure of a Cbf5-Nop10-Gar1 complex from Saccharomyces cerevisiae 2UV4 ; 1.33 ; CRYSTAL STRUCTURE OF A CBS DOMAIN PAIR FROM THE REGULATORY GAMMA1 SUBUNIT OF HUMAN AMPK IN COMPLEX WITH AMP 2UV5 ; 1.69 ; CRYSTAL STRUCTURE OF A CBS DOMAIN PAIR FROM THE REGULATORY GAMMA1 SUBUNIT OF HUMAN AMPK IN COMPLEX WITH AMP 2UV6 ; 2 ; CRYSTAL STRUCTURE OF A CBS DOMAIN PAIR FROM THE REGULATORY GAMMA1 SUBUNIT OF HUMAN AMPK IN COMPLEX WITH AMP 2UV7 ; 2 ; CRYSTAL STRUCTURE OF A CBS DOMAIN PAIR FROM THE REGULATORY GAMMA1 SUBUNIT OF HUMAN AMPK IN COMPLEX WITH AMP 1VR9 ; 1.7 ; CRYSTAL STRUCTURE OF A CBS DOMAIN PAIR/ACT DOMAIN PROTEIN (TM0892) FROM THERMOTOGA MARITIMA AT 1.70 A RESOLUTION 1O50 ; 1.87 ; Crystal structure of a cbs domain-containing protein (tm0935) from thermotoga maritima at 1.87 A resolution 3DDJ ; 1.8 ; Crystal structure of a cbs domain-containing protein in complex with amp (sso3205) from sulfolobus solfataricus at 1.80 A resolution 1ZVV ; 2.98 ; Crystal structure of a ccpa-crh-dna complex 3TYF ; 2.806 ; Crystal structure of a CD1d-lysophosphatidylcholine reactive iNKT TCR 2ATP ; 2.4 ; Crystal structure of a CD8ab heterodimer 3HKO ; 1.8 ; Crystal structure of a cdpk kinase domain from cryptosporidium Parvum, cgd7_40 1TY4 ; 2.2 ; Crystal structure of a CED-9/EGL-1 complex 1N0E ; 2.7 ; CRYSTAL STRUCTURE OF A CELL DIVISION AND CELL WALL BIOSYNTHESIS PROTEIN UPF0040 FROM MYCOPLASMA PNEUMONIAE: INDICATION OF A NOVEL FOLD WITH A POSSIBLE NEW CONSERVED SEQUENCE MOTIF 1N0F ; 2.8 ; CRYSTAL STRUCTURE OF A CELL DIVISION AND CELL WALL BIOSYNTHESIS PROTEIN UPF0040 FROM MYCOPLASMA PNEUMONIAE: INDICATION OF A NOVEL FOLD WITH A POSSIBLE NEW CONSERVED SEQUENCE MOTIF 1N0G ; 2.8 ; Crystal Structure of A Cell Division and Cell Wall Biosynthesis Protein UPF0040 from Mycoplasma pneumoniae: Indication of A Novel Fold with A Possible New Conserved Sequence Motif 1RJ1 ; 1.87 ; Crystal Structure of a Cell Wall Invertase Inhibitor from Tobacco 2CJ5 ; 1.84 ; CRYSTAL STRUCTURE OF A CELL WALL INVERTASE INHIBITOR FROM TOBACCO (PH 5.0) 2CJ6 ; 2 ; CRYSTAL STRUCTURE OF A CELL WALL INVERTASE INHIBITOR FROM TOBACCO (PH 7.5) 2CJ7 ; 1.8 ; CRYSTAL STRUCTURE OF A CELL WALL INVERTASE INHIBITOR FROM TOBACCO (PH 9.0) 2CJ8 ; 2.38 ; CRYSTAL STRUCTURE OF A CELL WALL INVERTASE INHIBITOR FROM TOBACCO (PH 9.5) 2CJ4 ; 1.63 ; CRYSTAL STRUCTURE OF A CELL WALL INVERTASE INHIBITOR FROM TOBACCO AT PH 4.6 2QQU ; 2.84 ; Crystal structure of a cell-wall invertase (D239A) from Arabidopsis thaliana in complex with sucrose 2QQW ; 2.8 ; Crystal structure of a cell-wall invertase (D23A) from Arabidopsis thaliana in complex with sucrose 2QQV ; 3.01 ; Crystal structure of a cell-wall invertase (E203A) from Arabidopsis thaliana in complex with sucrose 2OXB ; 2.6 ; Crystal structure of a cell-wall invertase (E203Q) from Arabidopsis thaliana in complex with sucrose 2AC1 ; 2.15 ; Crystal structure of a cell-wall invertase from Arabidopsis thaliana 4JON ; 2.15 ; Crystal structure of a centrosomal protein 170kDa, transcript variant beta (CEP170) from Homo sapiens at 2.15 A resolution (PSI Community Target, Sundstrom) 3RG6 ; 3.2 ; Crystal structure of a chaperone-bound assembly intermediate of form I Rubisco 3LN2 ; 2.037 ; Crystal Structure of a Charge Engineered Human Lysozyme Variant 2O40 ; 1.65 ; Crystal Structure of a Chemically Synthesized 203 Amino Acid 'Covalent Dimer' HIV-1 Protease Molecule 3HZC ; 1.45 ; Crystal structure of a chemically synthesized 203 amino acid 'covalent dimer' [Gly51;Aib51']HIV-1 protease molecule complexed with MVT-101 reduced isostere inhibitor 3IAW ; 1.61 ; Crystal structure of a chemically synthesized 203 amino acid 'covalent dimer' [Gly51;Aib51']HIV-1 protease molecule complexed with MVT-101 reduced isostere inhibitor at 1.6 A resolution 3FSM ; 1.6 ; CRYSTAL STRUCTURE OF A CHEMICALLY SYNTHESIZED 203 AMINO ACID 'COVALENT DIMER' [L-Ala51,D-Ala51'] HIV-1 PROTEASE MOLECULE 3GI0 ; 1.8 ; Crystal structure of a chemically synthesized 203 amino acid 'covalent dimer' [l-ala51,d-ala51'] hiv-1 protease molecule complexed with jg-365 inhibitor 3I2L ; 1.5 ; Crystal structure of a chemically synthesized [allo-Ile50/50']HIV-1 protease molecule complexed with MVT-101 reduced isostere inhibitor 3IA9 ; 1.3 ; Crystal structure of a chemically synthesized [D25N]HIV-1 protease molecule complexed with MVT-101 reduced isostere inhibitor 3H2D ; 1.86 ; Crystal structure of a chemotactic chec-like protein (so_3915) from shewanella oneidensis mr-1 at 1.86 A resolution 3HM4 ; 1.3 ; CRYSTAL STRUCTURE OF A CHEMOTAXIS PROTEIN CHEX (DDE_0281) FROM DESULFOVIBRIO DESULFURICANS SUBSP. AT 1.30 A RESOLUTION 3U9D ; 2.5 ; Crystal Structure of a chimera containing the N-terminal domain (residues 8-24) of drosophila Ciboulot and the C-terminal domain (residues 13-44) of bovine Thymosin-beta4, bound to G-actin-ATP 3U8X ; 2 ; Crystal Structure of a chimera containing the N-terminal domain (residues 8-29) of drosophila Ciboulot and the C-terminal domain (residues 18-44) of bovine Thymosin-beta4, bound to G-actin-ATP 3SJH ; 1.75 ; Crystal Structure of a chimera containing the N-terminal domain (residues 8-29) of drosophila Ciboulot and the C-terminal domain (residues 18-44) of bovine Thymosin-beta4, bound to G-actin-ATP-Latrunculin A 1DOW ; 1.8 ; CRYSTAL STRUCTURE OF A CHIMERA OF BETA-CATENIN AND ALPHA-CATENIN 2VFA ; 2.8 ; Crystal structure of a chimera of Plasmodium falciparum and human hypoxanthine-guanine phosphoribosyl transferases 1MHP ; 2.8 ; Crystal structure of a chimeric alpha1 integrin I-domain in complex with the Fab fragment of a humanized neutralizing antibody 4GRS ; 3 ; Crystal structure of a chimeric DAH7PS 1BBJ ; 3.1 ; CRYSTAL STRUCTURE OF A CHIMERIC FAB' FRAGMENT OF AN ANTIBODY BINDING TUMOUR CELLS 3D8M ; 3.35 ; Crystal structure of a chimeric receptor binding protein from lactococcal phages subspecies TP901-1 and p2 3I2X ; 2.85 ; Crystal structure of a chimeric trypsin inhibitor having reactive site loop of ETI on the scaffold of WCI 3I2A ; 2.3 ; Crystal structure of a chimeric trypsin inhibitor protein STI(L)-WCI(S) 3UAM ; 2 ; Crystal structure of a chitin binding domain from Burkholderia pseudomallei 3G6M ; 1.65 ; crystal structure of a chitinase CrChi1 from the nematophagous fungus Clonostachys rosea in complex with a potent inhibitor caffeine 3CO4 ; 1.92 ; Crystal structure of a chitinase from Bacteroides thetaiotaomicron 3FND ; 1.9 ; Crystal structure of a chitinase from Bacteroides thetaiotaomicron 3IAN ; 1.75 ; Crystal structure of a chitinase from Lactococcus lactis subsp. lactis 4DWS ; 1.8 ; Crystal Structure of a chitinase from the Yersinia entomophaga toxin complex 3FBT ; 2.1 ; Crystal structure of a chorismate mutase/shikimate 5-dehydrogenase fusion protein from Clostridium acetobutylicum 4FMT ; 2.3 ; Crystal structure of a ChpT protein (CC_3470) from Caulobacter crescentus CB15 at 2.30 A resolution 3S2Y ; 2.244 ; Crystal structure of a chromate/uranium reductase from Gluconacetobacter hansenii 3R4I ; 2.24 ; Crystal structure of a Citrate lyase (Bxe_B2899) from BURKHOLDERIA XENOVORANS LB400 at 2.24 A resolution 3FT2 ; 1.8 ; Crystal Structure of a citrulline peptide variant of the minor histocompatibility peptide HA-1 in complex with HLA-A2 3RLH ; 1.72 ; Crystal structure of a class II phospholipase D from Loxosceles intermedia venom 3HMU ; 2.1 ; Crystal structure of a class III aminotransferase from Silicibacter pomeroyi 4HSR ; 2.13 ; Crystal Structure of a class III engineered cephalosporin acylase 3AQU ; 2.01 ; Crystal structure of a class V chitinase from Arabidopsis thaliana 3LVG ; 7.94 ; Crystal structure of a clathrin heavy chain and clathrin light chain complex 3LVH ; 9 ; Crystal structure of a clathrin heavy chain and clathrin light chain complex 3DA0 ; 1.65 ; Crystal structure of a cleaved form of a chimeric receptor binding protein from Lactococcal phages subspecies TP901-1 and p2 1DO8 ; 2.2 ; CRYSTAL STRUCTURE OF A CLOSED FORM OF HUMAN MITOCHONDRIAL NAD(P)+-DEPENDENT MALIC ENZYME 4G67 ; 1.8 ; Crystal structure of a COG1565 superfamily member and likely methyl transferase from Burkholderia thailandensis bound to S-adenosyl-homocysteine 4GXW ; 1.3 ; Crystal structure of a cog1816 amidohydrolase (target EFI-505188) from Burkhoderia ambifaria, with bound Zn 3O0Z ; 2.33 ; Crystal structure of a coiled-coil domain from human ROCK I 2OVC ; 2.07 ; Crystal structure of a coiled-coil tetramerization domain from Kv7.4 channels 1O0Q ; 2.2 ; Crystal structure of a cold adapted alkaline protease from Pseudomonas TAC II 18, co-crystallized with 1 mM EDTA 1O0T ; 2.5 ; CRYSTAL STRUCTURE OF A COLD ADAPTED ALKALINE PROTEASE FROM PSEUDOMONAS TAC II 18, CO-CRYSTALLIZED WITH 5 mM EDTA (5 DAYS) 1OM6 ; 2 ; CRYSTAL STRUCTURE OF A COLD ADAPTED ALKALINE PROTEASE FROM PSEUDOMONAS TAC II 18, CO-CRYSTALLIZED WITH 5mM EDTA (2 MONTHS) 1OM8 ; 2 ; CRYSTAL STRUCTURE OF A COLD ADAPTED ALKALINE PROTEASE FROM PSEUDOMONAS TAC II 18, CO-CRYSTALLYZED WITH 10 mM EDTA 1OM7 ; 2.8 ; CRYSTAL STRUCTURE OF A COLD ADAPTED ALKALINE PROTEASE FROM PSEUDOMONAS TAC II 18, SOAKED IN 85 mM EDTA 1SH7 ; 1.84 ; Crystal structure of a cold adapted subtilisin-like serine proteinase 1O91 ; 1.9 ; CRYSTAL STRUCTURE OF A COLLAGEN VIII NC1 DOMAIN TRIMER 2G66 ; 1.8 ; Crystal structure of a collagen-like peptide with 3(S)Hyp in the Xaa position 1G44 ; 2.6 ; CRYSTAL STRUCTURE OF A COMPLEMENT CONTROL PROTEIN THAT REGULATES BOTH PATHWAYS OF COMPLEMENT ACTIVATION AND BINDS HEPARAN SULFATE PROTEOGLYCANS 1G40 ; 2.2 ; CRYSTAL STRUCTURE OF A COMPLEMENT PROTEIN THAT REGULATES BOTH PATHWAYS OF COMPLEMENT ACTIVATION AND BINDS HEPARAN SULFATE PROTEOGLYCANS 2QF7 ; 2 ; Crystal structure of a complete multifunctional pyruvate carboxylase from Rhizobium etli 2ICW ; 2.41 ; Crystal structure of a complete ternary complex between TCR, superantigen, and peptide-MHC class II molecule 3T0E ; 4 ; Crystal structure of a complete ternary complex of T cell receptor, peptide-MHC and CD4 1LBZ ; 2.2 ; Crystal Structure of a complex (P32 crystal form) of dual activity FBPase/IMPase (AF2372) from Archaeoglobus fulgidus with 3 Calcium ions and Fructose-1,6 bisphosphate 1LBY ; 2.25 ; Crystal Structure of a complex (P32 crystal form) of dual activity FBPase/IMPase (AF2372) from Archaeoglobus fulgidus with 3 Manganese ions, Fructose-6-Phosphate, and Phosphate ion 2XDM ; 2.4 ; CRYSTAL STRUCTURE OF A COMPLEX BETWEEN ACTINOMADURA R39 DD PEPTIDASE AND A PEPTIDOGLYCAN MIMETIC BORONATE INHIBITOR 2XK1 ; 2.8 ; Crystal structure of a complex between Actinomadura R39 DD-peptidase and a boronate inhibitor 2XLN ; 2.4 ; Crystal structure of a complex between Actinomadura R39 DD-peptidase and a boronate inhibitor 3ZCZ ; 2.6 ; Crystal structure of a complex between Actinomadura R39 DD-peptidase and a trifluoroketone inhibitor 1N8O ; 2 ; Crystal structure of a complex between bovine chymotrypsin and ecotin 3ML4 ; 2.6 ; Crystal structure of a complex between Dok7 PH-PTB and the MuSK juxtamembrane region 1G9S ; 2.8 ; CRYSTAL STRUCTURE OF A COMPLEX BETWEEN E.COLI HPRT AND IMP 2PCB ; 2.8 ; CRYSTAL STRUCTURE OF A COMPLEX BETWEEN ELECTRON TRANSFER PARTNERS, CYTOCHROME C PEROXIDASE AND CYTOCHROME C 2PCC ; 2.3 ; CRYSTAL STRUCTURE OF A COMPLEX BETWEEN ELECTRON TRANSFER PARTNERS, CYTOCHROME C PEROXIDASE AND CYTOCHROME C 1MW8 ; 1.9 ; Crystal Structure of a Complex between H365R mutant of 67 kDA N-terminal fragment of E. coli DNA Topoisomerase I and 5'-ACTTCGGGATG-3' 1FQ4 ; 2.7 ; CRYSTAL STRUCTURE OF A COMPLEX BETWEEN HYDROXYETHYLENE INHIBITOR CP-108,420 AND YEAST ASPARTIC PROTEINASE A 3F7P ; 2.75 ; Crystal structure of a complex between integrin beta4 and plectin 3HVQ ; 2.2 ; Crystal structure of a complex between Protein Phosphatase 1 alpha (PP1) and the PP1 binding and PDZ domains of Neurabin 3EGG ; 1.85 ; Crystal structure of a complex between Protein Phosphatase 1 alpha (PP1) and the PP1 binding and PDZ domains of Spinophilin 3EGH ; 2 ; Crystal structure of a complex between Protein Phosphatase 1 alpha (PP1), the PP1 binding and PDZ domains of Spinophilin and the small natural molecular toxin Nodularin-R 2B4S ; 2.3 ; Crystal structure of a complex between PTP1B and the insulin receptor tyrosine kinase 1SMP ; 2.3 ; CRYSTAL STRUCTURE OF A COMPLEX BETWEEN SERRATIA MARCESCENS METALLO-PROTEASE AND AN INHIBITOR FROM ERWINIA CHRYSANTHEMI 3FHI ; 2 ; Crystal structure of a complex between the catalytic and regulatory (RI{alpha}) subunits of PKA 4G7X ; 1.44 ; Crystal structure of a complex between the CTXphi pIII N-terminal domain and the Vibrio cholerae TolA C-terminal domain 1F93 ; 2.6 ; CRYSTAL STRUCTURE OF A COMPLEX BETWEEN THE DIMERIZATION DOMAIN OF HNF-1 ALPHA AND THE COACTIVATOR DCOH 4E5X ; 1.95 ; Crystal structure of a complex between the human adenovirus type 2 E3-19K protein and MHC class I molecule HLA-A2/Tax 3C58 ; 1.9 ; Crystal structure of a complex between the wild-type lactococcus lactis Fpg (MutM) and a N7-Benzyl-Fapy-dG containing DNA 2XZF ; 1.799 ; CRYSTAL STRUCTURE OF A COMPLEX BETWEEN THE WILD-TYPE LACTOCOCCUS LACTIS FPG (MUTM) AND AN OXIDIZED PYRIMIDINE CONTAINING DNA AT 293K 2XZU ; 1.82 ; CRYSTAL STRUCTURE OF A COMPLEX BETWEEN THE WILD-TYPE LACTOCOCCUS LACTIS FPG (MUTM) AND AN OXIDIZED PYRIMIDINE CONTAINING DNA AT 310K 1F6M ; 2.95 ; CRYSTAL STRUCTURE OF A COMPLEX BETWEEN THIOREDOXIN REDUCTASE, THIOREDOXIN, AND THE NADP+ ANALOG, AADP+ 1Z5S ; 3.01 ; Crystal structure of a complex between UBC9, SUMO-1, RANGAP1 and NUP358/RANBP2 1T0J ; 2 ; Crystal structure of a complex between voltage-gated calcium channel beta2a subunit and a peptide of the alpha1c subunit 1U1Y ; 2.85 ; Crystal structure of a complex between WT bacteriophage MS2 coat protein and an F5 aptamer RNA stemloop with 2aminopurine substituted at the-10 position 3PYN ; 3.5 ; Crystal structure of a complex containing domain 3 from the PSIV IGR IRES RNA bound to the 70S ribosome. This file contains the 30S subunit of the first 70S ribosome. 3PYQ ; 3.5 ; Crystal structure of a complex containing domain 3 from the PSIV IGR IRES RNA bound to the 70S ribosome. This file contains the 30S subunit of the second 70S ribosome. 3PYO ; 3.5 ; Crystal structure of a complex containing domain 3 from the PSIV IGR IRES RNA bound to the 70S ribosome. This file contains the 50S subunit of the first 70S ribosome. 3PYR ; 3.5 ; Crystal structure of a complex containing domain 3 from the PSIV IGR IRES RNA bound to the 70S ribosome. This file contains the 50S subunit of the second 70S ribosome. 3PYS ; 3.4 ; Crystal structure of a complex containing domain 3 of CrPV IGR IRES RNA bound to the 70S ribosome. This file contains the 30S subunit of the first 70S ribosome. 3PYU ; 3.4 ; Crystal structure of a complex containing domain 3 of CrPV IGR IRES RNA bound to the 70S ribosome. This file contains the 30S subunit of the second 70S ribosome. 3PYT ; 3.4 ; Crystal structure of a complex containing domain 3 of CrPV IGR IRES RNA bound to the 70S ribosome. This file contains the 50S subunit of the first 70S ribosome. 3PYV ; 3.4 ; Crystal structure of a complex containing domain 3 of CrPV IGR IRES RNA bound to the 70S ribosome. This file contains the 50S subunit of the second 70S ribosome. 1TGM ; 1.86 ; Crystal structure of a complex formed between group II phospholipase A2 and aspirin at 1.86 A resolution 1PO8 ; 2.71 ; Crystal structure of a complex formed between krait venom phospholipase A2 and heptanoic acid at 2.7 A resolution. 1OXG ; 2.2 ; Crystal structure of a complex formed between organic solvent treated bovine alpha-chymotrypsin and its autocatalytically produced highly potent 14-residue peptide at 2.2 resolution 1SXK ; 1.21 ; Crystal Structure of a complex formed between phospholipase A2 and a non-specific anti-inflammatory amino salicylic acid at 1.2 A resolution 1JQ9 ; 1.8 ; Crystal structure of a complex formed between phospholipase A2 from Daboia russelli pulchella and a designed pentapeptide Phe-Leu-Ser-Tyr-Lys at 1.8 resolution 2GWA ; 1.75 ; Crystal Structure of a Complex Formed Between the DNA Holliday Junction and a Bis-Acridine Molecule. 1FYT ; 2.6 ; CRYSTAL STRUCTURE OF A COMPLEX OF A HUMAN ALPHA/BETA-T CELL RECEPTOR, INFLUENZA HA ANTIGEN PEPTIDE, AND MHC CLASS II MOLECULE, HLA-DR1 1J8H ; 2.4 ; Crystal Structure of a Complex of a Human alpha/beta-T cell Receptor, Influenza HA Antigen Peptide, and MHC Class II Molecule, HLA-DR4 3C84 ; 1.94 ; Crystal structure of a complex of AChBP from aplysia californica and the neonicotinoid thiacloprid 2NU5 ; 1.564 ; Crystal structure of a complex of griffithsin cocrystallized with N-acetylglucosamine 2HYQ ; 2 ; Crystal structure of a complex of griffithsin with 6alpha-mannobiose 2NUO ; 1.5 ; Crystal structure of a complex of griffithsin with glucose 2HYR ; 1.51 ; Crystal structure of a complex of griffithsin with maltose 2GUD ; 0.94 ; Crystal structure of a complex of griffithsin with mannose at 0.94 A resolution 2GUC ; 1.79 ; Crystal structure of a complex of griffithsin with mannose at 1.78 A resolution. 2GUE ; 2.02 ; Crystal structure of a complex of griffithsin with N-acetylglucosamine 1HIV ; 2 ; CRYSTAL STRUCTURE OF A COMPLEX OF HIV-1 PROTEASE WITH A DIHYDROETHYLENE-CONTAINING INHIBITOR: COMPARISONS WITH MOLECULAR MODELING 1G4C ; 1.65 ; CRYSTAL STRUCTURE OF A COMPLEX OF HPPK(R92A) FROM E.COLI WITH MG2+ AT 1.65 ANGSTROM RESOLUTION 1JOW ; 3.1 ; Crystal structure of a complex of human CDK6 and a viral cyclin 1GG5 ; 2.5 ; CRYSTAL STRUCTURE OF A COMPLEX OF HUMAN NAD[P]H-QUINONE OXIDOREDUCTASE AND A CHEMOTHERAPEUTIC DRUG (E09) AT 2.5 A RESOLUTION 1QJM ; 3.4 ; CRYSTAL STRUCTURE OF A COMPLEX OF LACTOFERRIN WITH A LANTHANIDE ION (SM3+) AT 3.4 ANSTROM RESOLUTION 1ZLF ; 2.3 ; Crystal structure of a complex of mutant HIV-1 protease (A71V, V82T, I84V) with a hydroxyethylamine peptidomimetic inhibitor 1ZBG ; 1.995 ; Crystal structure of a complex of mutant hiv-1 protease (A71V, V82T, I84V) with a hydroxyethylamine peptidomimetic inhibitor BOC-PHE-PSI[R-CH(OH)CH2NH]-PHE-GLU-PHE-NH2 1ZJ7 ; 1.93 ; Crystal structure of a complex of mutant HIV-1 protease (A71V, V82T, I84V) with a hydroxyethylamine peptidomimetic inhibitor BOC-PHE-PSI[S-CH(OH)CH2NH]-PHE-GLU-PHE-NH2 2G58 ; 0.98 ; Crystal structure of a complex of phospholipase A2 with a designed peptide inhibitor Dehydro-Ile-Ala-Arg-Ser at 0.98 A resolution 2QHW ; 2.21 ; Crystal structure of a complex of phospholipase A2 with a gramine derivative at 2.2 resolution 2O1N ; 2.8 ; Crystal structure of a complex of phospholipase A2 with a peptide Ala-Ile-Ala-Ser at 2.8 A resolution 2V6T ; 3.1 ; CRYSTAL STRUCTURE OF A COMPLEX OF PTERIN-4A-CARBINOLAMINE DEHYDRATASE FROM TOXOPLASMA GONDII WITH 7,8-DIHYDROBIOPTERIN 3D2F ; 2.3 ; Crystal structure of a complex of Sse1p and Hsp70 3D2E ; 2.35 ; Crystal structure of a complex of Sse1p and Hsp70, Selenomethionine-labeled crystals 1JPZ ; 1.65 ; Crystal structure of a complex of the heme domain of P450BM-3 with N-Palmitoylglycine 3D3H ; 2.31 ; Crystal structure of a complex of the peptidoglycan glycosyltransferase domain from Aquifex aeolicus and neryl moenomycin A 1Z58 ; 3.8 ; Crystal structure of a complex of the ribosome large subunit with rapamycin 1IS0 ; 1.9 ; Crystal Structure of a Complex of the Src SH2 Domain with Conformationally Constrained Peptide Inhibitor 1C9S ; 1.9 ; CRYSTAL STRUCTURE OF A COMPLEX OF TRP RNA-BINDING ATTENUATION PROTEIN WITH A 53-BASE SINGLE STRANDED RNA CONTAINING ELEVEN GAG TRIPLETS SEPARATED BY AU DINUCLEOTIDES 1V5V ; 1.5 ; Crystal Structure of a Component of Glycine Cleavage System: T-protein from Pyrococcus horikoshii OT3 at 1.5 A Resolution 1ZSZ ; 2 ; Crystal structure of a computationally designed SspB heterodimer 3TIJ ; 2.436 ; Crystal structure of a concentrative nucleoside transporter from Vibrio cholerae 4HBC ; 1.54 ; Crystal structure of a conformation-dependent rabbit IgG Fab specific for amyloid prefibrillar oligomers 1PVM ; 1.5 ; Crystal Structure of a Conserved CBS Domain Protein TA0289 of Unknown Function from Thermoplasma acidophilum 4IAJ ; 1.91 ; Crystal structure of a conserved domain protein (SP_1775) from Streptococcus pneumoniae TIGR4 at 1.91 A resolution 1LFP ; 1.72 ; Crystal Structure of a Conserved Hypothetical Protein Aq1575 from Aquifex Aeolicus 1T6S ; 1.95 ; Crystal structure of a conserved hypothetical protein from Chlorobium tepidum 2CW5 ; 1.94 ; Crystal structure of a conserved hypothetical protein from Thermus thermophilus HB8 2CVE ; 1.6 ; Crystal structure of a conserved hypothetical protein TT1547 from thermus thermophilus HB8 2IB0 ; 2 ; Crystal structure of a conserved hypothetical protein, rv2844, from Mycobacterium tuberculosis 3D19 ; 2.3 ; Crystal structure of a conserved metalloprotein from Bacillus cereus 3RCO ; 1.8 ; Crystal structure of a conserved motif in human TDRD7 3CBN ; 1.63 ; Crystal structure of a conserved protein (MTH639) from Methanobacterium thermoautotrophicum 3B4Q ; 1.55 ; Crystal structure of a conserved protein domain (unknown function) from Corynebacterium diphtheriae 3D3Y ; 1.95 ; Crystal structure of a conserved protein from Enterococcus faecalis V583 2P0O ; 2.15 ; Crystal structure of a conserved protein from locus EF_2437 in Enterococcus faecalis with an unknown function 4DPO ; 2.73 ; Crystal structure of a conserved protein MM_1583 from Methanosarcina mazei Go1 3CLQ ; 2.5 ; Crystal structure of a conserved protein of unknown function from Enterococcus faecalis V583 3BRC ; 1.6 ; Crystal structure of a conserved protein of unknown function from Methanobacterium thermoautotrophicum 3BZ6 ; 2.21 ; Crystal structure of a conserved protein of unknown function from Pseudomonas syringae pv. tomato str. DC3000 2FYW ; 2.4 ; Crystal Structure of a Conserved Protein of Unknown Function from Streptococcus pneumoniae 2I71 ; 1.7 ; Crystal structure of a Conserved Protein of Unknown Function from Sulfolobus solfataricus P2 2IAZ ; 2.4 ; Crystal structure of a Conserved Protein of Unknown Function SP1372 from Streptococcus pneumoniae 1HC8 ; 2.8 ; CRYSTAL STRUCTURE OF A CONSERVED RIBOSOMAL PROTEIN-RNA COMPLEX 1QA6 ; 2.8 ; CRYSTAL STRUCTURE OF A CONSERVED RIBOSOMAL PROTEIN-RNA COMPLEX 1KMQ ; 1.55 ; Crystal Structure of a Constitutively Activated RhoA Mutant (Q63L) 1P1Y ; 2.1 ; Crystal structure of a continuous three-dimensional DNA lattice from d(GGACAGATGGGAG) 1JT0 ; 2.9 ; Crystal structure of a cooperative QacR-DNA complex 3DXS ; 1.7 ; Crystal structure of a copper binding domain from HMA7, a P-type ATPase 1NPN ; 1.8 ; Crystal structure of a copper reconstituted H145A mutant of nitrite reductase from Alcaligenes faecalis 3LOY ; 2 ; Crystal structure of a Copper-containing benzylamine oxidase from Hansenula Polymorpha 1JES ; 1.5 ; Crystal Structure of a Copper-Mediated Base Pair in DNA 3RFU ; 3.2 ; Crystal structure of a copper-transporting PIB-type ATPase 2HN1 ; 2.9 ; Crystal structure of a CorA soluble domain from A. fulgidus in complex with Co2+ 2P4P ; 1.8 ; Crystal structure of a CorC_HlyC domain from Haemophilus ducreyi 3BK6 ; 3.2 ; Crystal structure of a core domain of stomatin from Pyrococcus horikoshii 3OKQ ; 2.044 ; Crystal structure of a core domain of yeast actin nucleation cofactor Bud6 4A2E ; 1.8 ; CRYSTAL STRUCTURE OF A CORIOLOPSIS GALLICA LACCASE AT 1.7 A RESOLUTION PH 5.5 2C0U ; 2.2 ; CRYSTAL STRUCTURE OF A COVALENT COMPLEX OF NITROALKANE OXIDASE TRAPPED DURING SUBSTRATE TURNOVER 274D ; 2.3 ; CRYSTAL STRUCTURE OF A COVALENT DNA-DRUG ADDUCT: ANTHRAMYCIN BOUND TO C-C-A-A-C-G-T-T-G-G, AND A MOLECULAR EXPLANATION OF SPECIFICITY 1N2K ; 2.75 ; Crystal structure of a covalent intermediate of endogenous human arylsulfatase A 1N2L ; 3.2 ; Crystal structure of a covalent intermediate of endogenous human arylsulfatase A 3PR0 ; 2.2 ; Crystal Structure of a Covalently Bound alpha-Ketoheterocycle Inhibitor (Phenhexyl/Oxadiazole/Pyridine) to a Humanized Variant of Fatty Acid Amide Hydrolase 4J5P ; 2.3 ; Crystal Structure of a Covalently Bound alpha-Ketoheterocycle Inhibitor (Phenhexyl/Oxadiazole/Pyridine) to a Humanized Variant of Fatty Acid Amide Hydrolase 4FBK ; 2.379 ; Crystal structure of a covalently fused Nbs1-Mre11 complex with one manganese ion per active site 4FBQ ; 2.5 ; Crystal structure of a covalently fused Nbs1-Mre11 complex with two manganese ions per active site 3NO4 ; 2 ; Crystal structure of a creatinine amidohydrolase (Npun_F1913) from Nostoc punctiforme PCC 73102 at 2.00 A resolution 1DH3 ; 3 ; CRYSTAL STRUCTURE OF A CREB BZIP-CRE COMPLEX REVEALS THE BASIS FOR CREB FAIMLY SELECTIVE DIMERIZATION AND DNA BINDING 1WVR ; 2.4 ; Crystal Structure of a CRISP family Ca-channel blocker derived from snake venom 4EJ3 ; 2.52 ; Crystal structure of a CRISPR associated protein from Thermus thermophilus HB8 1WJ9 ; 1.9 ; Crystal structure of a CRISPR-associated protein from thermus thermophilus 2A5X ; 2.49 ; Crystal Structure of a Cross-linked Actin Dimer 1FBI ; 3 ; CRYSTAL STRUCTURE OF A CROSS-REACTION COMPLEX BETWEEN FAB F9.13.7 AND GUINEA-FOWL LYSOZYME 2AJ3 ; 2.03 ; Crystal Structure of a Cross-Reactive HIV-1 Neutralizing CD4-Binding Site Antibody Fab m18 1KYR ; 1.5 ; Crystal Structure of a Cu-bound Green Fluorescent Protein Zn Biosensor 1PZS ; 1.63 ; Crystal Structure of a Cu-Zn Superoxide Dismutase from Mycobacterium tuberculosis at 1.63 resolution 2IHW ; 2.7 ; Crystal structure of a cubic core of the dihydrolipoamide acyltransferase (E2b) component in the branched-chain alpha-ketoacid dehydrogenase complex (BCKDC), apo form 2II4 ; 2.59 ; Crystal structure of a cubic core of the dihydrolipoamide acyltransferase (E2b) component in the branched-chain alpha-ketoacid dehydrogenase complex (BCKDC), Coenzyme A-bound form 2II5 ; 2.5 ; Crystal structure of a cubic core of the dihydrolipoamide acyltransferase (E2b) component in the branched-chain alpha-ketoacid dehydrogenase complex (BCKDC), Isobutyryl-Coenzyme A-bound form 2II3 ; 2.17 ; Crystal structure of a cubic core of the dihydrolipoamide acyltransferase (E2b) component in the branched-chain alpha-ketoacid dehydrogenase complex (BCKDC), Oxidized Coenzyme A-bound form 3KGZ ; 1.85 ; Crystal structure of a cupin 2 conserved barrel domain protein from Rhodopseudomonas palustris 2FQP ; 1.8 ; Crystal structure of a cupin domain (bp2299) from bordetella pertussis tohama i at 1.80 A resolution 3CEW ; 2.31 ; Crystal structure of a cupin protein (BF4112) from Bacteroides fragilis. Northeast Structural Genomics Consortium target BfR205 2OZJ ; 1.6 ; CRYSTAL STRUCTURE OF A CUPIN SUPERFAMILY PROTEIN (DSY2733) FROM DESULFITOBACTERIUM HAFNIENSE DCB-2 AT 1.60 A RESOLUTION 3D82 ; 2.05 ; Crystal structure of a cupin-2 domain containing protein (sfri_3543) from shewanella frigidimarina ncimb 400 at 2.05 A resolution 2F4P ; 1.9 ; Crystal structure of a cupin-like protein (tm1010) from thermotoga maritima msb8 at 1.90 A resolution 1VH7 ; 1.9 ; Crystal structure of a cyclase subunit of imidazolglycerolphosphate synthase 3GYD ; 1.79 ; Crystal structure of a cyclic nucleotide-binding domain (mfla_1926) from methylobacillus flagellatus kt at 1.79 A resolution 2QU1 ; 1.7 ; Crystal Structure of a Cyclized GFP Variant 2DFY ; 1.65 ; Crystal structure of a cyclized protein fusion of LMO4 LIM domains 1 and 2 with the LIM interacting domain of LDB1 1XS7 ; 2.8 ; Crystal Structure of a cycloamide-urethane-derived novel inhibitor bound to human brain memapsin 2 (beta-secretase). 3GHD ; 1.81 ; Crystal structure of a cystathionine beta-synthase domain protein fused to a Zn-ribbon-like domain 2OWP ; 2 ; Crystal structure of a cystatin-like fold protein (bxe_b1374) from burkholderia xenovorans lb400 at 2.00 A resolution 3EJV ; 1.4 ; Crystal structure of a cystatin-like protein (saro_2766) from novosphingobium aromaticivorans dsm at 1.40 A resolution 3PW3 ; 2.23 ; Crystal structure of a cysteine protease (BDI_2249) from Parabacteroides distasonis ATCC 8503 at 2.23 A resolution 1CJL ; 2.2 ; CRYSTAL STRUCTURE OF A CYSTEINE PROTEASE PROFORM 3VUD ; 3.5 ; Crystal structure of a cysteine-deficient mutant M1 in MAP kinase JNK1 3VUL ; 2.81 ; Crystal structure of a cysteine-deficient mutant M1 in MAP kinase JNK1 3VUG ; 3.24 ; Crystal structure of a cysteine-deficient mutant M2 in MAP kinase JNK1 3VUI ; 2.8 ; Crystal structure of a cysteine-deficient mutant M2 in MAP kinase JNK1 3VUH ; 2.7 ; Crystal structure of a cysteine-deficient mutant M3 in MAP kinase JNK1 3VUK ; 2.95 ; Crystal structure of a cysteine-deficient mutant M5 in MAP kinase JNK1 3VUM ; 2.69 ; Crystal structure of a cysteine-deficient mutant M7 in MAP kinase JNK1 4DIE ; 2.65 ; Crystal structure of a cytidylate kinase CmK from Mycobacterium abscessus bound to cytidine-5'-monophosphate 3IBD ; 2 ; Crystal structure of a cytochrome P450 2B6 genetic variant in complex with the inhibitor 4-(4-chlorophenyl)imidazole 2RFB ; 2.5 ; Crystal Structure of a Cytochrome P450 from the Thermoacidophilic Archaeon Picrophilus Torridus 1I1R ; 2.4 ; CRYSTAL STRUCTURE OF A CYTOKINE/RECEPTOR COMPLEX 4E6R ; 2.2 ; Crystal structure of a Cytoplasmic protein NCK2 (NCK2) from Homo sapiens at 2.20 A resolution 1ST6 ; 3.1 ; Crystal structure of a cytoskeletal protein 1UNO ; 1.4 ; CRYSTAL STRUCTURE OF A D,L-ALTERNATING PEPTIDE 1KO0 ; 2.2 ; Crystal Structure of a D,L-lysine complex of diaminopimelate decarboxylase 1EI5 ; 1.9 ; CRYSTAL STRUCTURE OF A D-AMINOPEPTIDASE FROM OCHROBACTRUM ANTHROPI 3K85 ; 2.28 ; Crystal structure of a D-glycero-D-manno-heptose 1-phosphate kinase from Bacteriodes thetaiotaomicron 3QC3 ; 2.2 ; Crystal structure of a D-ribulose-5-phosphate-3-epimerase (NP_954699) from HOMO SAPIENS at 2.20 A resolution 2ZVR ; 2.2 ; Crystal structure of a D-tagatose 3-epimerase-related protein from Thermotoga maritima 2XO7 ; 2.85 ; CRYSTAL STRUCTURE OF A DA:O-ALLYLHYDROXYLAMINE-DC BASEPAIR IN COMPLEX WITH FRAGMENT DNA POLYMERASE I FROM BACILLUS STEAROTHERMOPHILUS 3BDE ; 1.79 ; Crystal structure of a dabb family protein with a ferredoxin-like fold (mll5499) from mesorhizobium loti maff303099 at 1.79 A resolution 2XUU ; 1.8 ; CRYSTAL STRUCTURE OF A DAP-KINASE 1 MUTANT 3HG0 ; 2.1 ; Crystal structure of a DARPin in complex with ORF49 from Lactococcal phage TP901-1 2I5A ; 1.65 ; Crystal structure of a DB1055-D(CGCGAATTCGCG)2 complex 4AG4 ; 2.8 ; Crystal structure of a DDR1-Fab complex 1HQJ ; 1.2 ; CRYSTAL STRUCTURE OF A DE NOVO DESIGNED TRIMERIC COILED-COIL PEPTIDE 1KYC ; 1.45 ; CRYSTAL STRUCTURE OF A DE NOVO DESIGNED TRIMERIC COILED-COIL PEPTIDE STABLIZED BY IONIC INTERACTIONS 1NJ4 ; 1.9 ; Crystal structure of a deacylation-defective mutant of penicillin-binding protein 5 at 1.9 A resolution 1HD8 ; 2.3 ; CRYSTAL STRUCTURE OF A DEACYLATION-DEFECTIVE MUTANT OF PENICILLIN-BINDING PROTEIN 5 AT 2.3 A RESOLUTION 1SDN ; 2.5 ; CRYSTAL STRUCTURE OF A DEACYLATION-DEFECTIVE MUTANT OF PENICILLIN-BINDING PROTEIN 5 MODIFIED BY MERCURY 1HV8 ; 3 ; CRYSTAL STRUCTURE OF A DEAD BOX PROTEIN FROM THE HYPERTHERMOPHILE METHANOCOCCUS JANNASCHII 2YVI ; 1.92 ; Crystal structure of a death domain of human ankryn protein 2BJ6 ; 2.6 ; CRYSTAL STRUCTURE OF A DECAMERIC HNA-RNA HYBRID 3MZV ; 1.9 ; Crystal structure of a decaprenyl diphosphate synthase from Rhodobacter capsulatus 2D3Q ; 2.8 ; Crystal Structure of a Decolorizing Peroxidase (DyP) That Catalyses the Biological Oxidation of Anthraquinone Derivatives 1VPV ; 2.45 ; Crystal structure of a degv lipid binding protein (tm1468) from thermotoga maritima at 2.45 A resolution 3V2G ; 2.3 ; Crystal structure of a dehydrogenase/reductase from Sinorhizobium meliloti 1021 3QQ0 ; 1.9 ; Crystal structure of a deletion mutant (N59) of 3-deoxy-D-manno-octulosonate 8-phosphate synthase (KDO8PS) from Neisseria meningitidis 4TS1 ; 2.5 ; CRYSTAL STRUCTURE OF A DELETION MUTANT OF A TYROSYL-T/RNA SYNTHETASE COMPLEXED WITH TYROSINE 4AD8 ; 3.998 ; Crystal structure of a deletion mutant of Deinococcus radiodurans RecN 3N00 ; 2.6 ; Crystal Structure of a deletion mutant of human Reverba ligand binding domain bound with an NCoR ID1 peptide determined to 2.60A 1CX4 ; 2.45 ; CRYSTAL STRUCTURE OF A DELETION MUTANT OF THE TYPE II BETA REGULATORY SUBUNIT OF CAMP-DEPENDENT PROTEIN KINASE 3Q4O ; 1.34 ; Crystal Structure of a deletion mutant(11-185) of hypothetical protein MJ0754 determined to 1.34A 3Q4Q ; 1.75 ; Crystal Structure of a deletion mutant(11-185) of hypothetical protein MJ0754 with Mn2+ 3Q4R ; 1.6 ; Crystal Structure of a deletion mutant(11-185) of hypothetical protein MJ0754 with Zn2+ 3F63 ; 1.8 ; Crystal structure of a Delta class GST (adGSTD4-4) from Anopheles dirus, in complex with S-hexyl glutathione 3G7I ; 2.05 ; Crystal structure of a Delta class GST (adGSTD4-4) from Anopheles dirus, with glutathione complexed in one subunit 4DHK ; 2.05 ; Crystal structure of a deoxycytidine triphosphate deaminase (dCTP deaminase) from Burkholderia thailandensis 3R12 ; 1.75 ; Crystal structure of a Deoxyribose-phosphate aldolase (TM_1559) from THERMOTOGA MARITIMA at 1.75 A resolution 3R13 ; 1.83 ; Crystal structure of a Deoxyribose-phosphate aldolase (TM_1559) from THERMOTOGA MARITIMA at 1.83 A resolution 4I1V ; 2.6 ; Crystal structure of a dephospho-CoA kinase from Burkholderia vietnamiensis bound to ADP 3HNU ; 1.56 ; Crystal structure of a designed Cyanovirin-N homolog lectin; LKAMG in P21 space group 3HNX ; 1.37 ; Crystal structure of a designed Cyanovirin-N homolog lectin; LKAMG in P212121 space group 3HP8 ; 2 ; Crystal structure of a designed Cyanovirin-N homolog lectin; LKAMG, bound to sucrose 2QYJ ; 2.05 ; Crystal structure of a designed full consensus ankyrin 2XGE ; 2.14 ; CRYSTAL STRUCTURE OF A DESIGNED HETERODIMERIC VARIANT T-A(A) B OF THE TETRACYCLINE REPRESSOR 2XGC ; 2.15 ; CRYSTAL STRUCTURE OF A DESIGNED HETERODIMERIC VARIANT T-A(I) B OF THE TETRACYCLINE REPRESSOR 2XGD ; 2.25 ; CRYSTAL STRUCTURE OF A DESIGNED HOMODIMERIC VARIANT T-A(L)A(L) OF THE TETRACYCLINE REPRESSOR 1SVX ; 2.24 ; Crystal structure of a designed selected Ankyrin Repeat protein in complex with the Maltose Binding Protein 3ZU7 ; 1.97 ; Crystal structure of a designed selected Ankyrin Repeat protein in complex with the MAP kinase ERK2 3ZUV ; 2.72 ; Crystal structure of a designed selected Ankyrin Repeat protein in complex with the phosphorylated MAP kinase ERK2 1MEY ; 2.2 ; CRYSTAL STRUCTURE OF A DESIGNED ZINC FINGER PROTEIN BOUND TO DNA 1BB1 ; 1.8 ; CRYSTAL STRUCTURE OF A DESIGNED, THERMOSTABLE HETEROTRIMERIC COILED COIL 3OF5 ; 1.52 ; Crystal Structure of a Dethiobiotin Synthetase from Francisella tularensis subsp. tularensis SCHU S4 2HXV ; 1.8 ; Crystal structure of a diaminohydroxyphosphoribosylaminopyrimidine deaminase/ 5-amino-6-(5-phosphoribosylamino)uracil reductase (tm1828) from thermotoga maritima at 1.80 A resolution 1Q4Q ; 2.1 ; Crystal structure of a DIAP1-Dronc complex 3A5N ; 2.36 ; Crystal Structure of a Dictyostelium P109A Ca2+-Actin in Complex with Human Gelsolin Segment 1 3A5L ; 2.4 ; Crystal Structure of a Dictyostelium P109A Mg2+-Actin in Complex with Human Gelsolin Segment 1 3A5O ; 2.4 ; Crystal Structure of a Dictyostelium P109I Ca2+-Actin in Complex with Human Gelsolin Segment 1 3A5M ; 2.4 ; Crystal Structure of a Dictyostelium P109I Mg2+-Actin in Complex with Human Gelsolin Segment 1 1DEJ ; 2.4 ; CRYSTAL STRUCTURE OF A DICTYOSTELIUM/TETRAHYMENA CHIMERA ACTIN (MUTANT 646: Q228K/T229A/A230Y/A231K/S232E/E360H) IN COMPLEX WITH HUMAN GELSOLIN SEGMENT 1 1C1E ; 1.9 ; CRYSTAL STRUCTURE OF A DIELS-ALDERASE CATALYTIC ANTIBODY 1E9 IN COMPLEX WITH ITS HAPTEN 3FNI ; 2.3 ; Crystal structure of a diflavin flavoprotein A3 (all3895) from Nostoc sp., Northeast Structural Genomics Consortium Target NsR431A 3URH ; 1.9 ; Crystal structure of a dihydrolipoamide dehydrogenase from Sinorhizobium meliloti 1021 3L8K ; 2.5 ; Crystal structure of a dihydrolipoyl dehydrogenase from Sulfolobus solfataricus 2OGJ ; 2.62 ; Crystal structure of a dihydroorotase 1M2Z ; 2.5 ; Crystal structure of a dimer complex of the human glucocorticoid receptor ligand-binding domain bound to dexamethasone and a TIF2 coactivator motif 2P5L ; 2.85 ; Crystal structure of a dimer of N-terminal domains of AhrC in complex with an 18bp DNA operator site 3NBN ; 3.45 ; Crystal structure of a dimer of Notch Transcription Complex trimers on HES1 DNA 1U73 ; 1.9 ; Crystal structure of a Dimeric Acidic Platelet Aggregation Inhibitor and Hypotensive Phospholipase A2 from Bothrops jararacussu 1RLV ; 3 ; Crystal structure of a dimeric Archaeal Splicing Endonuclease 2AR9 ; 2.8 ; Crystal structure of a dimeric caspase-9 3DE8 ; 1.72 ; Crystal Structure of a Dimeric Cytochrome cb562 Assembly Induced by Copper Coordination 2QYC ; 1.9 ; Crystal structure of a dimeric ferredoxin-like protein (bb1511) from bordetella bronchiseptica rb50 at 1.90 A resolution 3BN7 ; 1.64 ; CRYSTAL STRUCTURE OF A DIMERIC FERREDOXIN-LIKE PROTEIN (CC_2267) FROM CAULOBACTER CRESCENTUS CB15 AT 1.64 A RESOLUTION 2OD4 ; 1.7 ; Crystal structure of a dimeric ferredoxin-like protein (jcvi_pep_1096665735785) from uncultured marine organism at 1.70 A resolution 2OP5 ; 2.2 ; CRYSTAL STRUCTURE OF A DIMERIC FERREDOXIN-LIKE PROTEIN (JCVI_PEP_1096672785533) FROM UNCULTURED MARINE ORGANISM AT 2.20 A RESOLUTION 2OD6 ; 1.85 ; Crystal structure of a dimeric ferredoxin-like protein (jcvi_pep_1096682647733) from uncultured marine organism at 1.85 A resolution 3BB5 ; 2.3 ; CRYSTAL STRUCTURE OF A DIMERIC FERREDOXIN-LIKE PROTEIN OF UNKNOWN FUNCTION (JANN_3925) FROM JANNASCHIA SP. CCS1 AT 2.30 A RESOLUTION 3BGU ; 1.5 ; Crystal structure of a dimeric ferredoxin-like protein of unknown function (tfu_0763) from thermobifida fusca yx at 1.50 A resolution 1CVS ; 2.8 ; CRYSTAL STRUCTURE OF A DIMERIC FGF2-FGFR1 COMPLEX 1UUP ; 2.6 ; CRYSTAL STRUCTURE OF A DIMERIC FORM OF STREPTOCOCCAL PYROGENIC EXOTOXIN A (SPEA1). 3IO5 ; 2.4 ; Crystal Structure of a dimeric form of the uvsX Recombinase core domain from Enterobacteria Phage T4 3UX7 ; 2.97 ; Crystal structure of a dimeric myotoxic component of the Vipera ammodytes meridionalis venom reveals determinants of myotoxicity and membrane damaging activity 4G2E ; 1.4 ; Crystal structure of a dimeric PrxQ from Sulfolobus tokodaii 2NXF ; 1.7 ; Crystal Structure of a dimetal phosphatase from Danio rerio LOC 393393 2H1R ; 1.89 ; Crystal structure of a dimethyladenosine transferase from Plasmodium falciparum 1K1Q ; 2.8 ; Crystal Structure of a DinB Family Error Prone DNA Polymerase from Sulfolobus solfataricus 2OQM ; 1.83 ; Crystal structure of a dinb family member protein (sden_0562) from shewanella denitrificans at 1.83 A resolution 1IM4 ; 2.3 ; Crystal Structure of a DinB Homolog (DBH) Lesion Bypass DNA Polymerase Catalytic Fragment from Sulfolobus solfataricus 3DI5 ; 2.009 ; Crystal structure of a dinb-like protein (bce_4655) from bacillus cereus atcc 10987 at 2.01 A resolution 3DKA ; 2.3 ; Crystal structure of a dinb-like protein (yjoa, bsu12410) from bacillus subtilis at 2.30 A resolution 2NP9 ; 2.45 ; Crystal structure of a dioxygenase in the Crotonase superfamily 2HNU ; 2 ; Crystal Structure of a Dipeptide Complex of Bovine Neurophysin-I 2HNV ; 2.5 ; Crystal Structure of a Dipeptide Complex of the Q58V Mutant of Bovine Neurophysin-I 4EOW ; 1.97 ; Crystal structure of a disease-associated anti-human GM-CSF autoantibody MB007 1TEJ ; 1.9 ; Crystal structure of a disintegrin heterodimer at 1.9 A resolution. 1FCS ; 1.6 ; CRYSTAL STRUCTURE OF A DISTAL SITE DOUBLE MUTANT OF SPERM WHALE MYOGLOBIN AT 1.6 ANGSTROMS RESOLUTION 2IPL ; 1.2 ; Crystal structure of a disulfide mutant glucose binding protein 2IPM ; 1.12 ; Crystal structure of a disulfide mutant glucose binding protein 2IPN ; 1.15 ; Crystal structure of a disulfide mutant glucose binding protein 2QRT ; 1.8 ; Crystal Structure of a disulfide trapped single chain trimer composed of the MHC I heavy chain H-2Kb Y84C, beta-2microglobulin, and ovalbumin-derived peptide. 2IUB ; 2.9 ; CRYSTAL STRUCTURE OF A DIVALENT METAL ION TRANSPORTER CORA AT 2.9 A RESOLUTION. 3BHN ; 1.76 ; Crystal structure of a dj-1/pfpi-like protein (shew_2856) from shewanella loihica pv-4 at 1.76 A resolution 1NH9 ; 2 ; Crystal Structure of a DNA Binding Protein Mja10b from the hyperthermophile Methanococcus jannaschii 3OT0 ; 1.7004 ; Crystal structure of a DNA containing the rigid nitroxide spin-labeled nucleotide C-spin 1N4E ; 2.5 ; Crystal Structure of a DNA Decamer Containing a Thymine-dimer 1SM5 ; 2 ; Crystal Structure of a DNA Decamer Containing a Thymine-dimer 1T4I ; 2.5 ; Crystal Structure of a DNA Decamer Containing a Thymine-dimer 237D ; 2.5 ; CRYSTAL STRUCTURE OF A DNA DECAMER SHOWING A NOVEL PSEUDO FOUR-WAY HELIX-HELIX JUNCTION 3GJH ; 2.9 ; Crystal structure of a DNA duplex containing 7,8-dihydropyridol[2,3-d]pyrimidin-2-one 3GJJ ; 2.9 ; crystal structure of a DNA duplex containing 7,8-dihydropyridol[2,3-d]pyrimidin-2-one 3GJK ; 2.2 ; crystal structure of a DNA duplex containing 7,8-dihydropyridol[2,3-d]pyrimidin-2-one 3GJL ; 1.92 ; crystal structure of a DNA duplex containing 7,8-dihydropyridol[2,3-d]pyrimidin-2-one 178D ; 2.5 ; CRYSTAL STRUCTURE OF A DNA DUPLEX CONTAINING 8-HYDROXYDEOXYGUANINE.ADENINE BASE-PAIRS 4IEJ ; 1.45 ; Crystal structure of a DNA methyltransferase 1 associated protein 1 (DMAP1) from Homo sapiens at 1.45 A resolution 4GX8 ; 1.7 ; Crystal structure of a DNA polymerase III alpha-epsilon chimera 4GX9 ; 2.15 ; Crystal structure of a DNA polymerase III alpha-epsilon chimera 2GNO ; 2 ; Crystal structure of a dna polymerase iii, gamma subunit-related protein (tm0771) from thermotoga maritima msb8 at 2.00 A resolution 1XRX ; 2.15 ; Crystal structure of a DNA-binding protein 3TEJ ; 1.9 ; Crystal structure of a domain fragment involved in peptide natural product biosynthesis 4DCZ ; 2.9 ; Crystal structure of a domain from a mycoplasma genitalium terminal organelle protein 3MVN ; 1.9 ; Crystal structure of a domain from a putative UDP-N-acetylmuramate:L-alanyl-gamma-D-glutamyl-medo-diaminopimelate ligase from Haemophilus ducreyi 35000HP 3KW6 ; 2.1 ; Crystal Structure of a domain of 26S proteasome regulatory subunit 8 from homo sapiens. Northeast Structural Genomics Consortium target id HR3102A 3ONX ; 2.904 ; Crystal structure of a domain of a protein involved in formation of actin cytoskeleton 3CNI ; 2.3 ; Crystal structure of a domain of a putative ABC type-2 transporter from Thermotoga maritima MSB8 3DM3 ; 2.4 ; Crystal structure of a domain of a Replication factor A protein, from Methanocaldococcus jannaschii. NorthEast Structural Genomics target MjR118E 3SWV ; 3 ; Crystal Structure of a domain of Brefeldin A-inhibited guanine nucleotide-exchange protein 2 (Brefeldin A-inhibited GEP 2) from Homo sapiens (Human), Northeast Structural Genomics Consortium target id HR5562A 3L8N ; 2.86 ; Crystal Structure of a domain of Brefeldin A-inhibited guanine nucleotide-exchange protein 2 (BrefeldinA-inhibited GEP 2) from Homo sapiens (Human). Northeast Structural Genomics Consortium target id HR5562A 3IX7 ; 2.15 ; Crystal structure of a domain of functionally unknown protein from Thermus thermophilus HB8 3GX1 ; 2.3 ; Crystal structure of a domain of lin1832 from Listeria innocua 3CAN ; 1.8 ; Crystal structure of a domain of pyruvate-formate lyase-activating enzyme from Bacteroides vulgatus ATCC 8482 3E0E ; 1.6 ; Crystal structure of a domain of replication protein A from Methanococcus maripaludis. NorthEast Structural Genomics targe MrR110B 3LYV ; 2.7 ; Crystal structure of a domain of ribosome-associated factor Y from streptococcus pyogenes serotype M6. Northeast Structural Genomics Consortium target id DR64A 2R2C ; 1.8 ; Crystal structure of a domain of the outer membrane lipoprotein Omp28 from Porphyromonas gingivalis 2RK5 ; 1.5 ; Crystal structure of a domain of the putative hemolysin from Streptococcus mutans UA159 2R78 ; 1.6 ; Crystal structure of a domain of the sensory box sensor histidine kinase/response regulator from Geobacter sulfurreducens 3PAM ; 2.31 ; Crystal structure of a domain of transmembrane protein of ABC-type oligopeptide transport system from Bartonella henselae str. Houston-1 3CU3 ; 2 ; Crystal structure of a domain of unknown function with a cystatin-like fold (npun_r1993) from nostoc punctiforme pcc 73102 at 2.00 A resolution 3DDE ; 2.3 ; Crystal structure of a domain of unknown function with a heme oxygenase-like fold (sden_3740) from shewanella denitrificans os217 at 2.30 A resolution 3U6G ; 1.35 ; Crystal structure of a domain of unknown function, DUF4425 (BVU_3708) from Bacteroides vulgatus ATCC 8482 at 1.35 A resolution 1G6U ; 1.48 ; CRYSTAL STRUCTURE OF A DOMAIN SWAPPED DIMER 1L5T ; 3 ; Crystal Structure of a Domain-Opened Mutant (R121D) of the Human Lactoferrin N-lobe Refined From a Merohedrally-Twinned Crystal Form. 2ZNH ; 2.8 ; Crystal Structure of a Domain-Swapped Serpin Dimer 2WKD ; 2.1 ; CRYSTAL STRUCTURE OF A DOUBLE ILE-TO-MET MUTANT OF PROTEIN ORF34 FROM LACTOCOCCUS PHAGE P2 2YC8 ; 2.7 ; CRYSTAL STRUCTURE OF A DOUBLE MUTANT (C202A AND C222N) OF TRIOSEPHOSPHATE ISOMERASE FROM GIARDIA LAMBLIA. 2DP3 ; 2.1 ; Crystal structure of a double mutant (C202A/A198V) of Triosephosphate isomerase from giardia lamblia 4HST ; 1.571 ; Crystal structure of a double mutant of a class III engineered cephalosporin acylase 3SO1 ; 1.85 ; Crystal structure of a double mutant T41S T82S of a betagamma-crystallin domain from Clostridium beijerinckii 3QQ1 ; 2.7 ; Crystal structure of a double mutant [A58P, DEL(N59)] of 3-deoxy-D-manno-octulosonate 8-phosphate synthase (KDO8PS) from Neisseria meningitidis 1JYJ ; 2 ; Crystal Structure of a Double Variant (W67L/W91H) of Recombinant Human Serum Retinol-binding Protein at 2.0 A Resolution 1AIO ; 2.6 ; CRYSTAL STRUCTURE OF A DOUBLE-STRANDED DNA CONTAINING THE MAJOR ADDUCT OF THE ANTICANCER DRUG CISPLATIN 1A2E ; 1.63 ; CRYSTAL STRUCTURE OF A DOUBLE-STRANDED DNA DECAMER CONTAINING A CISPLATIN INTERSTRAND CROSS-LINK ADDUCT 1N1Q ; 2.2 ; Crystal structure of a Dps protein from Bacillus brevis 3V8I ; 1.802 ; Crystal Structure of a Drosophila melanogaster Dopamine N-Acetyltransferase 2FNT ; 1.44 ; Crystal structure of a drug-resistant (V82A) inactive (D25N) HIV-1 protease complexed with AP2V variant of HIV-1 NC-p1 substrate. 1DI2 ; 1.9 ; CRYSTAL STRUCTURE OF A DSRNA-BINDING DOMAIN COMPLEXED WITH DSRNA: MOLECULAR BASIS OF DOUBLE-STRANDED RNA-PROTEIN INTERACTIONS 1VL0 ; 2.05 ; CRYSTAL STRUCTURE OF A DTDP-4-DEHYDRORHAMNOSE REDUCTASE, RFBD ORTHOLOG (CA_C2315) FROM CLOSTRIDIUM ACETOBUTYLICUM ATCC 824 AT 2.05 A RESOLUTION 1U15 ; 2.5 ; Crystal structure of a duck-delta-crystallin-1 double loop mutant (DLM) 1U16 ; 2.2 ; Crystal structure of a duck-delta-crystallin-1 double loop mutant (DLM) in complex with sulfate 2O3L ; 2.05 ; Crystal structure of a duf1048 protein with a left-handed superhelix fold (bce_3448) from bacillus cereus atcc 10987 at 2.05 A resolution 2H1T ; 1.8 ; Crystal structure of a duf1089 family protein (pa1994) from pseudomonas aeruginosa at 1.80 A resolution 3BYQ ; 1.7 ; Crystal structure of a duf1185 family protein (bb2672) from bordetella bronchiseptica rb50 at 1.70 A resolution 2QTP ; 2.1 ; Crystal structure of a duf1185 family protein (spo0826) from silicibacter pomeroyi dss-3 at 2.10 A resolution 2RA9 ; 1.4 ; Crystal structure of a duf1285 family protein (sbal_2486) from shewanella baltica os155 at 1.40 A resolution 2RE3 ; 2.5 ; CRYSTAL STRUCTURE OF a DUF1285 family protein (SPO_0140) FROM SILICIBACTER POMEROYI DSS-3 AT 2.50 A RESOLUTION 3GI7 ; 1.85 ; Crystal structure of a duf1311 family protein (pp0307) from pseudomonas putida kt2440 at 1.85 A resolution 3H0N ; 1.45 ; Crystal structure of a duf1470 family protein (jann_2411) from jannaschia sp. ccs1 at 1.45 A resolution 1VJL ; 1.9 ; Crystal structure of a duf151 family protein (tm0160) from thermotoga maritima at 1.90 A resolution 1SJ5 ; 2.8 ; Crystal structure of a duf151 family protein (tm0160) from thermotoga maritima at 2.8 A resolution 2OBN ; 2.3 ; Crystal structure of a duf1611 family protein (ava_3511) from anabaena variabilis atcc 29413 at 2.30 A resolution 2G40 ; 1.7 ; Crystal structure of a duf162 family protein (dr_1909) from deinococcus radiodurans at 1.70 A resolution 3DCX ; 2 ; Crystal structure of a duf1696 family protein with a pleckstrin-homology domain (shew_0819) from shewanella loihica pv-4 at 2.00 A resolution 2IAY ; 1.2 ; Crystal structure of a duf1831 family protein (lp2179) from lactobacillus plantarum at 1.20 A resolution 1VK9 ; 2.7 ; CRYSTAL STRUCTURE OF A DUF1893 family protein (TM1506) FROM THERMOTOGA MARITIMA AT 2.70 A RESOLUTION 3DI4 ; 1.6 ; Crystal structure of a duf1989 family protein (spo0365) from silicibacter pomeroyi dss-3 at 1.60 A resolution 3ORU ; 1.11 ; Crystal structure of a DUF1989 family protein (TM1040_0329) from SILICIBACTER SP. TM1040 at 1.11 A resolution 3SIY ; 1.35 ; Crystal structure of a DUF1989 family protein (TM1040_0329) from SILICIBACTER SP. TM1040 at 1.35 A resolution 2HUH ; 1.54 ; Crystal structure of a duf2027 family protein (bt_2179) from bacteroides thetaiotaomicron at 1.54 A resolution 3D4R ; 2.2 ; CRYSTAL STRUCTURE OF a DUF2118 family protein (MMP0046) FROM METHANOCOCCUS MARIPALUDIS AT 2.20 A RESOLUTION 3KE2 ; 2.5 ; CRYSTAL STRUCTURE OF a DUF2131 family protein (SAMA_2911) FROM SHEWANELLA AMAZONENSIS SB2B AT 2.50 A RESOLUTION 2PYQ ; 1.5 ; Crystal structure of a duf2853 member protein (jann_4075) from jannaschia sp. ccs1 at 1.500 A resolution 3CE8 ; 2.4 ; Crystal structure of a duf3240 family protein (sbal_0098) from shewanella baltica os155 at 2.40 A resolution 3D33 ; 1.7 ; Crystal structure of a duf3244 family protein with an immunoglobulin-like beta-sandwich fold (bvu_0276) from bacteroides vulgatus atcc 8482 at 1.70 A resolution 3F7C ; 2 ; Crystal structure of a duf416 family protein (maqu_0942) from marinobacter aquaeolei vt8 at 2.00 A resolution 2Q9R ; 1.91 ; CRYSTAL STRUCTURE OF a DUF416 family protein (SBAL_3149) FROM SHEWANELLA BALTICA OS155 AT 1.91 A RESOLUTION 2GA1 ; 2 ; Crystal structure of a duf433 member protein (ava_0674) from anabaena variabilis atcc 29413 at 2.00 A resolution 3GIW ; 1.45 ; CRYSTAL STRUCTURE OF a DUF574 family protein (SAV_2177) FROM STREPTOMYCES AVERMITILIS MA-4680 AT 1.45 A RESOLUTION 3GO4 ; 1.8 ; Crystal structure of a duf574 family protein (sav_2177) from streptomyces avermitilis ma-4680 at 1.80 A resolution 3BWW ; 2.2 ; Crystal structure of a duf692 family protein (hs_1138) from haemophilus somnus 129pt at 2.20 A resolution 1VPY ; 2.52 ; CRYSTAL STRUCTURE OF a DUF72 family protein (EF0366) FROM ENTEROCOCCUS FAECALIS V583 AT 2.52 A RESOLUTION 1ZTV ; 3.1 ; Crystal structure of a duf72 family protein (ef0366) from enterococcus faecalis v583 at 3.10 A resolution 1VPQ ; 2.2 ; CRYSTAL STRUCTURE OF a DUF72 family protein (TM1631) FROM THERMOTOGA MARITIMA MSB8 AT 2.20 A RESOLUTION 3E02 ; 1.9 ; Crystal structure of a duf849 family protein (bxe_c0271) from burkholderia xenovorans lb400 at 1.90 A resolution 3FA5 ; 1.9 ; CRYSTAL STRUCTURE OF a DUF849 family protein (PDEN_3495) FROM PARACOCCUS DENITRIFICANS PD1222 AT 1.90 A RESOLUTION 1O5U ; 1.83 ; Crystal structure of a duf861 family protein (tm1112) from thermotoga maritima at 1.83 A resolution 3BCW ; 1.6 ; Crystal structure of a duf861 family protein with a rmlc-like cupin fold (bb1179) from bordetella bronchiseptica rb50 at 1.60 A resolution 2FFJ ; 2.45 ; CRYSTAL STRUCTURE OF a DUF89 family protein (AF1104) FROM ARCHAEOGLOBUS FULGIDUS DSM 4304 AT 2.45 A RESOLUTION 2G8L ; 2.04 ; Crystal structure of a duf89 family protein (ph1575) from pyrococcus horikoshii at 2.04 A resolution 2GVK ; 1.6 ; Crystal structure of a dye-decolorizing peroxidase (DyP) from Bacteroides thetaiotaomicron VPI-5482 at 1.6 A resolution 2J4Q ; 2.6 ; CRYSTAL STRUCTURE OF A E138A ESCHERICHIA COLI DCTP DEAMINASE MUTANT ENZYME IN COMPLEX WITH DTTP 3K92 ; 2.3 ; Crystal structure of a E93K mutant of the majour Bacillus subtilis glutamate dehydrogenase RocG 3PFM ; 2.908 ; Crystal structure of a EAL domain of GGDEF domain protein from Pseudomonas fluorescens Pf 2EXW ; 3.2 ; Crystal structure of a EcClC-Fab complex in the absence of bound ions 4JFC ; 2.25 ; Crystal structure of a enoyl-CoA hydratase from Polaromonas sp. JS666 4KPK ; 2.09 ; Crystal structure of a enoyl-CoA hydratase from Shewanella pealeana ATCC 700345 1KSI ; 2.2 ; CRYSTAL STRUCTURE OF A EUKARYOTIC (PEA SEEDLING) COPPER-CONTAINING AMINE OXIDASE AT 2.2A RESOLUTION 3ORG ; 3.5 ; Crystal Structure of a eukaryotic CLC transporter 4J05 ; 2.9 ; Crystal structure of a eukaryotic phosphate transporter 3G3Q ; 2.64 ; Crystal structure of a eukaryotic polyphosphate polymerase in complex with a phosphate polymer 3G3R ; 2 ; Crystal structure of a eukaryotic polyphosphate polymerase in complex with AppNHp-Mn2+ 3G3T ; 1.85 ; Crystal structure of a eukaryotic polyphosphate polymerase in complex with orthophosphate 3G3U ; 2.07 ; Crystal structure of a eukaryotic polyphosphate polymerase in complex with pyrophosphate 2BCF ; 2.3 ; Crystal structure of a evolved putative penicillin-binding protein homolog, Rv2911, from Mycobacterium Tuberculosis. 3CQO ; 2.32 ; Crystal structure of a f-lectin (fucolectin) from morone saxatilis (striped bass) serum 2YIF ; 3.298 ; CRYSTAL STRUCTURE OF A F. NUCLEATUM FMN RIBOSWITCH - FREE STATE 2YIE ; 2.941 ; CRYSTAL STRUCTURE OF A F. NUCLEATUM FMN RIBOSWITCH BOUND TO FMN 1OB1 ; 2.9 ; CRYSTAL STRUCTURE OF A FAB COMPLEX WHITH PLASMODIUM FALCIPARUM MSP1-19 2I0Z ; 1.84 ; Crystal structure of a FAD binding protein from Bacillus cereus, a putative NAD(FAD)-utilizing dehydrogenases 2HQ9 ; 1.95 ; Crystal structure of a fad-binding protein (mll6688) from mesorhizobium loti at 1.95 A resolution 3IWA ; 2.3 ; Crystal structure of a FAD-dependent pyridine nucleotide-disulphide oxidoreductase from Desulfovibrio vulgaris 1PZ3 ; 1.75 ; Crystal structure of a family 51 (GH51) alpha-L-arabinofuranosidase from Geobacillus stearothermophilus T6 1QW9 ; 1.2 ; Crystal structure of a family 51 alpha-L-arabinofuranosidase in complex with 4-nitrophenyl-Ara 1QW8 ; 1.8 ; Crystal structure of a family 51 alpha-L-arabinofuranosidase in complex with Ara-alpha(1,3)-Xyl 2V4V ; 1.5 ; CRYSTAL STRUCTURE OF A FAMILY 6 CARBOHYDRATE-BINDING MODULE FROM CLOSTRIDIUM CELLULOLYTICUM IN COMPLEX WITH XYLOSE 4DWX ; 1.8 ; Crystal Structure of a Family GH-19 Chitinase from rye seeds 4DYG ; 1.7 ; Crystal Structure of a Family GH-19 Chitinase from rye seeds in complex with (GlcNAc)4 2JJM ; 3.1 ; CRYSTAL STRUCTURE OF A FAMILY GT4 GLYCOSYLTRANSFERASE FROM BACILLUS ANTHRACIS ORF BA1558. 1G43 ; 2.2 ; CRYSTAL STRUCTURE OF A FAMILY IIIA CBD FROM CLOSTRIDIUM CELLULOLYTICUM 3FFA ; 2.3 ; Crystal Structure of a fast activating G protein mutant 1VI1 ; 2.95 ; Crystal structure of a fatty acid/phospholipid synthesis protein 2OKF ; 1.6 ; CRYSTAL STRUCTURE OF A FDXN ELEMENT EXCISION CONTROLLING FACTOR PROTEIN (AVA_3312) FROM ANABAENA VARIABILIS AT 1.60 A RESOLUTION 1MIX ; 1.75 ; Crystal structure of a FERM domain of Talin 3HL1 ; 1.95 ; CRYSTAL STRUCTURE OF A FERRITIN LIKE PROTEIN (CC_0557) FROM CAULOBACTER VIBRIOIDES AT 1.95 A RESOLUTION 2OC5 ; 1.68 ; Crystal structure of a ferritin-like protein (pmt1231) from prochlorococcus marinus str. mit 9313 at 1.68 A resolution 4H87 ; 1.55 ; Crystal structure of a FHA domain of kanadaptin (SLC4A1AP) from Homo sapiens at 1.55 A resolution 1FBN ; 1.6 ; CRYSTAL STRUCTURE OF A FIBRILLARIN HOMOLOGUE FROM METHANOCOCCUS JANNASCHII, A HYPERTHERMOPHILE, AT 1.6 A 3CUC ; 2.71 ; CRYSTAL STRUCTURE OF A FIC DOMAIN CONTAINING SIGNALING PROTEIN (BT_2513) FROM BACTEROIDES THETAIOTAOMICRON VPI-5482 AT 2.71 A RESOLUTION 3EQX ; 1.6 ; CRYSTAL STRUCTURE OF A FIC FAMILY PROTEIN (SO_4266) FROM SHEWANELLA ONEIDENSIS AT 1.6 A RESOLUTION 3TDQ ; 2.1 ; Crystal structure of a fimbrial biogenesis protein PilY2 (PilY2_PA4555) from Pseudomonas aeruginosa PAO1 at 2.10 A resolution 3SY6 ; 1.9 ; Crystal structure of a fimbrial protein BF1861 [Bacteroides fragilis NCTC 9343] (BF1861) from Bacteroides fragilis NCTC 9343 at 1.90 A resolution 2Z21 ; 1.8 ; Crystal Structure of a five site mutated Cyanovirin-N 2PYS ; 1.8 ; Crystal Structure of a Five Site Mutated Cyanovirin-N with a Mannose Dimer Bound at 1.8 A Resolution 1QX8 ; 2.02 ; Crystal structure of a five-residue deletion mutant of the Rop protein 1VH6 ; 2.5 ; Crystal structure of a flagellar protein 1MRZ ; 1.9 ; Crystal structure of a flavin binding protein from Thermotoga Maritima, TM379 2HTI ; 2.5 ; CRYSTAL STRUCTURE OF A FLAVIN-NUCLEOTIDE-BINDING PROTEIN (BH_0577) FROM BACILLUS HALODURANS AT 2.50 A RESOLUTION 1RAR ; 1.9 ; CRYSTAL STRUCTURE OF A FLUORESCENT DERIVATIVE OF RNASE A 1RAS ; 1.7 ; CRYSTAL STRUCTURE OF A FLUORESCENT DERIVATIVE OF RNASE A 3HMZ ; 1.5 ; CRYSTAL STRUCTURE OF A FMN-BINDING DOMAIN OF FLAVIN REDUCTASES-LIKE ENZYME (SBAL_0626) FROM SHEWANELLA BALTICA OS155 AT 1.50 A RESOLUTION 3IN6 ; 2.12 ; Crystal structure of a fmn-binding protein (swol_0183) from syntrophomonas wolfei subsp. wolfei at 2.12 A resolution 3OF4 ; 1.9 ; Crystal structure of a FMN/FAD- and NAD(P)H-dependent nitroreductase (nfnB, IL2077) from Idiomarina loihiensis L2TR at 1.90 A resolution 2GLZ ; 1.45 ; Crystal structure of a formylmethanofuran dehydrogenase subunit e-like protein (dhaf_2992) from desulfitobacterium hafniense dcb-2 at 1.45 A resolution 3OBI ; 1.95 ; Crystal structure of a formyltetrahydrofolate deformylase (NP_949368) from RHODOPSEUDOMONAS PALUSTRIS CGA009 at 1.95 A resolution 3N0V ; 2.25 ; Crystal structure of a formyltetrahydrofolate deformylase (PP_0327) from PSEUDOMONAS PUTIDA KT2440 at 2.25 A resolution 3O1L ; 2.2 ; Crystal structure of a formyltetrahydrofolate deformylase (PSPTO_4314) from Pseudomonas syringae pv. tomato str. DC3000 at 2.20 A resolution 3NRB ; 2.05 ; Crystal structure of a formyltetrahydrofolate deformylase (purU, PP_1943) from PSEUDOMONAS PUTIDA KT2440 at 2.05 A resolution 190D ; 1.8 ; Crystal structure of a four-stranded intercalated DNA: d(C4) 4KKM ; 1.9 ; Crystal structure of a FPP/GFPP synthase (Target EFI-501952) from Zymomonas mobilis, apo structure 2IAF ; 2.05 ; Crystal structure of a fragment (residues 11 to 161) of L-serine dehydratase from Legionella pneumophila 3TZX ; 2.3 ; Crystal structure of a fragment containing the acyltransferase domain of Pks13 from Mycobacterium tuberculosis in tetragonal apo form at 2.3 A 3TZZ ; 2.49 ; Crystal structure of a fragment containing the acyltransferase domain of Pks13 from Mycobacterium tuberculosis in the carboxypalmitoylated form at 2.5 A 3TZW ; 2.6 ; Crystal structure of a fragment containing the acyltransferase domain of Pks13 from Mycobacterium tuberculosis in the orthorhombic apoform at 2.6 A 3TZY ; 2.2 ; Crystal structure of a fragment containing the acyltransferase domain of Pks13 from Mycobacterium tuberculosis in the palmitoylated form at 2.2 A 3EVY ; 1.95 ; Crystal structure of a fragment of a putative type I restriction enzyme R protein from Bacteroides fragilis 1SL6 ; 2.25 ; Crystal Structure of a fragment of DC-SIGNR (containg the carbohydrate recognition domain and two repeats of the neck) complexed with Lewis-x. 1XAR ; 2.25 ; Crystal Structure of a fragment of DC-SIGNR (containing the carbohydrate recognition domain and two repeats of the neck). 3O5D ; 4 ; Crystal structure of a fragment of FKBP51 comprising the Fk1 and Fk2 domains 2J0J ; 2.8 ; CRYSTAL STRUCTURE OF A FRAGMENT OF FOCAL ADHESION KINASE CONTAINING THE FERM AND KINASE DOMAINS. 2J0K ; 3 ; CRYSTAL STRUCTURE OF A FRAGMENT OF FOCAL ADHESION KINASE CONTAINING THE FERM AND KINASE DOMAINS. 3U21 ; 2.18 ; Crystal structure of a Fragment of Nuclear factor related to kappa-B-binding protein (residues 370-495) (NFRKB) from Homo sapiens at 2.18 A resolution 2ODU ; 2.3 ; Crystal structure of a fragment of the plakin domain of plectin 2ODV ; 2.05 ; Crystal structure of a fragment of the plakin domain of plectin, Cys to Ala mutant. 1SGS ; 1.6 ; Crystal structure of a free kB DNA 3C8L ; 1.22 ; Crystal structure of a ftsz-like protein of unknown function (npun_r1471) from nostoc punctiforme pcc 73102 at 1.22 A resolution 2Z6G ; 3.4 ; Crystal Structure of a Full-Length Zebrafish Beta-Catenin 2XYB ; 1.75 ; CRYSTAL STRUCTURE OF A FULLY FUNCTIONAL LACCASE FROM THE LIGNINOLYTIC FUNGUS PYCNOPORUS CINNABARINUS 4HGV ; 2.09 ; Crystal structure of a fumarate hydratase 3HGC ; 3 ; Crystal structure of a functional acid sensing ion channel in the desensitized state 1J7X ; 1.8 ; CRYSTAL STRUCTURE OF A FUNCTIONAL UNIT OF INTERPHOTORECEPTOR RETINOID-BINDING PROTEIN (IRBP) 3KDQ ; 3 ; Crystal structure of a functionally unknown conserved protein from Corynebacterium diphtheriae. 3CQY ; 2.3 ; Crystal structure of a functionally unknown protein (SO_1313) from Shewanella oneidensis MR-1 3G74 ; 2.43 ; Crystal structure of a functionally unknown protein from Eubacterium ventriosum ATCC 27560 4I5U ; 1.22 ; Crystal structure of a fungal chimeric cellobiohydrolase Cel6A 4I5R ; 1.5 ; Crystal structure of a fungal chimeric cellobiohydrolase